sentence	label
Stavudine and @DRUG$ @DRUG$ can antagonize in activity of stavudine and HIV	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
or eliminated increases produced by intermediate doses either @DRUG$ FI or doses PCP or either	DDI-false
Flupenthixol may some like @DRUG$ ( MAOI MAOI could flupenthixol pharmacodynamics Arecoline - Eproxindine - Ethanol and cause additive - Tricyclic @DRUG$ the effect of Tricyclic antidepressants	DDI-false
The anesthetic @DRUG$ or to @DRUG$ tricyclic may severe , prolonged hypertension	DDI-effect
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
@DRUG$ @DRUG$ , increased .	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
concentrations of SN38 active of @DRUG$ 33 % receiving combination with @DRUG$ compared .	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Bacteriostatic Antibiotics: @DRUG$, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
In studies Fondaparinux concomitant use oral @DRUG$ ) , platelet inhibitors @DRUG$ ) , ( affect the of fondaparinux sodium	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-mechanism
: @DRUG$ and have been concomitantly with beta agents calcium-blocking , hydralazine @DRUG$ evidence of clinically significant interactions	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, @DRUG$ and nifedipine.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Although studies performed coadministration with mainly CYP3A4 channel dapsone , , quinine , @DRUG$ , quinidine @DRUG$ cyclosporine derivatives , , , alprazolam and triazolam ) have plasma concentrations coadministered with saquinavir	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Nephrotoxic : administration of VISTIDE and with , @DRUG$ , gentamicin and amikacin ) , @DRUG$ intravenous pentamidine , and non-steroidal agents is contraindicated .	DDI-false
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of @DRUG$ with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ administration of @DRUG$ may of diflunisal .	DDI-false
These drugs include the thiazides and , phenothiazines products oral phenytoin , @DRUG$ @DRUG$ , and	DDI-false
In vitro inhibition the cytochrome 2C9 substrates/inhibitors @DRUG$ @DRUG$.	DDI-false
ACE Inhibitors II Receptor Antagonists Congestive Failure In , 3020 ( % ) patients @DRUG$ 50 received inhibitors or receptor ( ) .	DDI-false
This may with alcohol may potentiate the CNS of either medications or @DRUG$ ) other anticholinergic anticholinergic potentiated with antihistamines ) , and monoamine oxidase ( ) use may and intensify and depressant @DRUG$ .	DDI-false
Imidazoles e. ketoconazole , miconazole , , fluconazole etc . ): in and animal studies with the @DRUG$ and imidazoles that imidazoles may induce resistance	DDI-false
which may the blocking action nondepolarizing agents as NUROMAX antibiotics aminoglycosides , @DRUG$ , bacitracin , , colistin , magnesium , lithium , @DRUG$ , , and	DDI-false
which CYP 3A4 @DRUG$ , macrolide antibiotics ) have potential to result increased concentrations of @DRUG$.	DDI-mechanism
A increase lopinavir/@DRUG$ to 533/133 twice with isrecommended in with	DDI-advise
In a in the @DRUG$ was administered and without ( with multiple on GI ) to healthy volunteers AUC % the Cmax @DRUG$ was when the disintegrating tablet was given with propantheline compared to it alone	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Nalfon @DRUG$ concomitantly in steroid gradual to the complications of @DRUG$ withdrawal .	DDI-false
@DRUG$ apparently through an effect on enzyme , has reported reduce the of anticoagulants , @DRUG$ , , , tricyclic antidepressants , lidocaine , metronidazole thereby delaying of these drugs	DDI-mechanism
prothrombin time monitored in patients receiving @DRUG$ and drugs simultaneously .	DDI-advise
5HT3 Antagonists : Based on reports of hypotension of consciousness @DRUG$ was the concomitant use apomorphine @DRUG$ including , example , ) contraindicated	DDI-false
inhibition was observed during of @DRUG$ @DRUG$ and glutethimide	DDI-false
Non-selective MAO tranylcypromine @DRUG$ @DRUG$ : of L-tyrosine cause .	DDI-false
whether @DRUG$ a of @DRUG$ , the distribution was studied five lacking function and one with a impaired renal presence probenecid	DDI-false
Erythromycin Co-administration of @DRUG$ (PLENDIL) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
Specific studies have these effects @DRUG$ , @DRUG$ midazolam .	DDI-false
Although specific have been , coadministration that are eg , calcium quinine amiodarone , @DRUG$ warfarin , tacrolimus , derivatives pimozide , carbamazepine , fentanyl , alfentanyl alprazolam may coadministered @DRUG$ ;	DDI-mechanism
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Anticholinesterases: Concomitant use of @DRUG$ and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-effect
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to @DRUG$.	DDI-effect
@DRUG$, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
Antihypertensives be in   -receptor ( , , @DRUG$ ) or calcium channel ( , verapamil a @DRUG$ substrate , and a because of the possible arrest , and block	DDI-false
INOmax has been administered with @DRUG$, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
, effect certain microsomal been reported reduce the hepatic of warfarin-type anticoagulants , phenytoin propranolol , , @DRUG$ certain tricyclic antidepressants lidocaine , theophylline and @DRUG$ , delaying elimination .	DDI-false
Important Date important interactions with captopril , @DRUG$ , warfarin , @DRUG$ , ethanol or itraconazole	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Ingestion of @DRUG$ may increase serum concentrations of @DRUG$ and methotrexate and increase cyclosporine s nephrotoxicity.	DDI-mechanism
@DRUG$ a potent inhibitor CYP2D6 was co-administered @DRUG$ at , either was not altered	DDI-false
@DRUG$ : Amphetamines enhance the of @DRUG$ sympathomimetic agents	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
I trial using escalating of ( 110 - 200 mg/m2 ( 50 or given as infusions , myelosuppression was profound TAXOL was than ( ie , @DRUG$ before @DRUG$	DDI-false
Short-term demonstrated that administration and Lodine ( @DRUG$ ) reduced protein of , there was no change clearance of @DRUG$.	DDI-false
@DRUG$ ( @DRUG$ ) or	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Other : In small of patients ( ) concomitant administration of azathioprine gold , @DRUG$ , @DRUG$ or digitoxin not and values of diclofenac .	DDI-false
and ( @DRUG$ , @DRUG$ , , phenytoin primidone and valproate ) were assessed by the serum placebo-controlled .	DDI-false
Drugs Demonstrated CYP Inhibitors of Basis Clinical Involving Alprazolam caution recommended coadministration with Coadministration of @DRUG$ with @DRUG$ the concentration of alprazolam by % , decreased clearance by 21 , half-life by 17 % and decreased	DDI-mechanism
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	DDI-effect
This relevant interaction with , although , known to alter cardiac conduction , anti-arrhythmic or blocking , @DRUG$ @DRUG$ H1-blocking antidepressants and might contribute a prolongation the QTc interval	DDI-false
That Should Not VIRACEPT Antiarrhythmics : amiodarone @DRUG$ Antihistamines astemizole terfenadine Antimigraine @DRUG$ Antimycobacterial agents rifampin midazolam motility	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and @DRUG$.	DDI-false
interactions were assessed clinical pharmacokinetic studies @DRUG$ oral , digoxin @DRUG$ and through screening in studies patients	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
interactions are @DRUG$ , such as @DRUG$ , which hepatic microsomal systems .	DDI-false
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of @DRUG$ on the availability of digoxin and @DRUG$.	DDI-mechanism
@DRUG$/prednisolone not have important the pharmacokinetics of @DRUG$.	DDI-false
Amiodarone may suppress enzymes @DRUG$ , , CYP2D6 , and	DDI-false
@DRUG$s and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
The risk of myopathy treatment with drugs of this is with concurrent , derivatives , @DRUG$ ( @DRUG$ erythromycin , antifungals .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
example @DRUG$ ( e.g. @DRUG$ ) the renin-angiotensin-aldosterone	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Interactions : Flupenthixol may with drugs , @DRUG$ @DRUG$ ): MAOI could affect pharmacodynamics - Arecoline - Ethanol Flupenthixol and additive depression - Tricyclic antidepressants : increases effect of antidepressants	DDI-false
play important role in hemostasis @DRUG$ platelet therapy with all @DRUG$ diclofenac warfarin monitoring of patients to certain that no change is required .	DDI-false
Coadministration experimental soft-gelatin @DRUG$ @DRUG$ resulted in an % increase and a 4-fold increase saquinavir plasma	DDI-false
@DRUG$	DDI-mechanism
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
@DRUG$ : In , concomitant administration of @DRUG$ in an in plasma levels acetaminophen .	DDI-false
the therapeutic @DRUG$ is theophylline serum levels be closely and appropriate adjustments @DRUG$ should be made .	DDI-false
inhibitors : Reports @DRUG$ the effect of @DRUG$.	DDI-effect
@DRUG$ 400 mg . ) no @DRUG$ ( AUC maximum Cmax ) vardenafil when co-administered mg Vardenafil in healthy	DDI-false
@DRUG$ or @DRUG$ ( hepatotoxic ) together with Bezalip Bezalip retard .	DDI-false
@DRUG$ on ( Phenytoin : Tiagabine had no effect on of @DRUG$ patients with epilepsy .	DDI-false
@DRUG$/theophylline , , , acid , , theophylline/acetaminophen , and acid/phenobarbital	DDI-false
of valdecoxib 40 BID 1 ) and mg days - 7 ) ) @DRUG$ @DRUG$ resulted 21 increase in glyburide AUC0 - and a in Cmax leading to glucose AUC0 -	DDI-false
Concurrent @DRUG$ @DRUG$ severe orthostatic . an of microsomal drug , toxicity in .	DDI-effect
clinical received or the with ORENCIA : corticosteroids , blocking gold , hydroxychloroquine , @DRUG$ ,	DDI-false
Although the magnitude of changes in diazepam plasma exposure when coadministered with @DRUG$ were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ under this circumstance.	DDI-effect
Because of the reactions patients have taking on , important or their carefully @DRUG$ as part of the to any procedure which use of @DRUG$	DDI-false
Potential interactions between Keppra other ( @DRUG$ gabapentin , lamotrigine phenobarbital , phenytoin @DRUG$ valproate ) by the concentrations these during .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drug/Laboratory Test Interaction with @DRUG$ , a false-positive for glucose the occur @DRUG$ tests Benedicts , Fehlings solution , or Clinitest not with Clinistix and Glucose Test .	DDI-false
Other therapy specific studies , more used in studies with @DRUG$ @DRUG$ a-blockers , enzyme ( ACE ) inhibitors , anticonvulsants benzodiazepines , beta blockers calcium-channel blockers , nitrates , diuretics , antagonists reductase inhibitors , prostaglandin ( referred to ) and quinolone anti-infectives of significant interactions	DDI-false
@DRUG$: There is no significant pharmacokinetic interaction between @DRUG$ and zalcitabine which has been confirmed clinically.	DDI-false
Central Nervous Depressants : concomitant ( with other nervous including but not limited , sedatives hypnotics tranquilizers ( , , phenothiazines @DRUG$ , and @DRUG$ may respiratory , hypotension and sedation , potentially result in coma or death .	DDI-false
contraceptives Co-administration @DRUG$ with an contraceptive has been shown influence the plasma the hormonal components , ethinylestradiol EE and @DRUG$ ( LNG	DDI-false
Drugs that have been peripheral analogues @DRUG$ cisplatin , @DRUG$ , ethionamide , hydralazine , , metronidazole , nitrofurantoin , , ribavirin and vincristine	DDI-false
Lithium generally should not be given with @DRUG$ because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	DDI-false
Drug Interactions may with like oxidase inhibitors ( @DRUG$ could theoretically affect Arecoline Eproxindine - : @DRUG$ cause additive CNS antidepressants Flupenthixol increases the	DDI-false
WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
: In a clinical coadministration ( aluminum hydroxide magnesium hydroxide and ) fosinopril serum and fosinoprilat as compared with , suggesting @DRUG$ impair of @DRUG$.	DDI-mechanism
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, @DRUG$, metoclopramide, pimozide.	DDI-effect
: use of DURAGESIC ( @DRUG$ system ) central , but not to other opioids , sedatives tranquilizers e.g. , benzodiazepines anesthetics , @DRUG$ skeletal muscle , , may respiratory depression and , or potentially result or .	DDI-effect
Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with chlorpropamide, @DRUG$ should be employed with caution.	DDI-false
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
@DRUG$ The , , and @DRUG$ been .	DDI-false
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Patients treated @DRUG$ be effects of	DDI-effect
Interactions may with drugs , Monoamine inhibitors @DRUG$ ): could theoretically @DRUG$ pharmacodynamics - - : and additive CNS increases the Tricyclic antidepressants	DDI-false
that been with include nucleoside analogues cisplatin , dapsone disulfiram , @DRUG$ , gold , @DRUG$ iodoquinol , , nitrofurantoin phenytoin ribavirin vincristine	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
- Indomethacin: @DRUG$ blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-mechanism
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Physiological oral @DRUG$ load constitutes the best tool for diagnosis of @DRUG$ deficiency and the first step of its treatment.	DDI-false
Anticoagulants : of warfarin-type CYP2C9 @DRUG$ substrate ) @DRUG$ always seen patients and serious or	DDI-false
It is recommended that serum @DRUG$ levels be monitored frequently if @DRUG$ is administered concomitantly with lithium.	DDI-false
150 ranitidine for increased the @DRUG$ max by 23 % @DRUG$ .	DDI-false
@DRUG$ @DRUG$	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$    @DRUG$ antagonism	DDI-false
Interactions occur @DRUG$ aspirin and other @DRUG$ sativum ) ( Ginkgo biloba .	DDI-int
of diclofenac increase concentrations @DRUG$ @DRUG$ cyclosporine s nephrotoxicity	DDI-false
May interact ( effect , @DRUG$ , rifampin and hepatic system effect corticosteroids ( effect @DRUG$ )	DDI-false
Probenecid : @DRUG$ renal tubular ciprofloxacin and increase in the level of @DRUG$ serum	DDI-mechanism
Since the therapeutic range of @DRUG$ is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.	DDI-false
Should Not Coadministered VIRACEPT Antiarrhythmics : , quinidine : astemizole terfenadine Antimigraine @DRUG$ rifampin @DRUG$ , triazolam agents	DDI-false
@DRUG$ : concomitant use of @DRUG$ long- and short-acting has safely patients stable angina	DDI-false
Co-medications that e.g. , @DRUG$ @DRUG$ or	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-false
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
drugs may enhance the neuromuscular action agents such as @DRUG$ certain g. , , polymyxins lincomycin , clindamycin , @DRUG$ , sodium colistimethate ) magnesium salts , lithium , quinidine	DDI-effect
Drug @DRUG$ @DRUG$   mg twice did not influence the pharmacokinetics an oral containing 0.03 and 0.15 levonorgestrel or and progesterone levels impairment of is unlikely .	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
@DRUG$ (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
Although specific not been that are calcium channel blockers dapsone , , , , warfarin @DRUG$ pimozide carbamazepine , fentanyl @DRUG$ , , and may concentrations coadministered with ;	DDI-false
@DRUG$ increased blood @DRUG$ different times the overload .	DDI-false
: report of resulting from concomitant of @DRUG$	DDI-false
When in subcutaneous infusion pumps for insulin @DRUG$ not mixed any @DRUG$ diluent .	DDI-false
that @DRUG$ and possibly @DRUG$ and retinoids , regulate the of prostate epithelium a modification of activity of and EGF	DDI-false
Other specific studies were not finasteride doses 1 or more were in studies with @DRUG$ , analgesics angiotensin-converting ( ACE ) inhibitors benzodiazepines beta blockers , calcium-channel blockers cardiac nitrates , reductase prostaglandin inhibitors referred as @DRUG$ of clinically adverse	DDI-false
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
@DRUG$ Coadministration of @DRUG$ VIRACEPT resulted % increase in nelfinavir plasma AUC and ritonavir plasma	DDI-false
in @DRUG$ concomitant AVONEX 30 mcg once @DRUG$ to the need for dose adjustment of or .	DDI-false
In , drugs that have or more pharmacologic similar to @DRUG$ , including @DRUG$ such as quinidine procainamide cardiac and anti-depressants	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
@DRUG$ or @DRUG$ excess the effect of Carbimazole , and can increase the effect .	DDI-false
Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium.	DDI-false
have associated include antiretroviral nucleoside , chloramphenicol cisplatin , dapsone , , @DRUG$ gold , @DRUG$ metronidazole nitrofurantoin , , .	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of @DRUG$ given as a single dose.	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Cation-Containing of quinolone , @DRUG$ , with products as antacids @DRUG$ tablets or , or products containing calcium , the absorption , in serum and urine considerably than desired .	DDI-mechanism
( 5 mg/kg ) , @DRUG$ ( mg/kg , 0.25 mg/kg ) 20 mg/kg @DRUG$ ( 30 mg/kg ) or	DDI-false
Example azole , , , doxycycline imatinib , isoniazid , nefazodone @DRUG$ , , @DRUG$ , quinidine , .	DDI-false
action sulfonylureas may potentiated certain drugs including nonsteroidal drugs that highly @DRUG$ , sulfonamides @DRUG$ coumarins , , adrenergic agents	DDI-false
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either @DRUG$ or @DRUG$ when the two agents were administered together.	DDI-false
including indandione derivatives , and inhibitors such nonsteroidal drugs NSAIDs @DRUG$ increase risk of when administered concomitantly @DRUG$.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Coadministration of @DRUG$ did of @DRUG$.	DDI-false
not recommended.@DRUG$ no effect plasma concentrations , valproate , @DRUG$ , lamotrigine .	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ as potent @DRUG$ of glucocorticoid-induced mouse mammary tumor virus gene expression.	DDI-false
ACE Inhibitors and @DRUG$ ( Congestive Infarction)- In 3020 91 patients receiving INSPRA to 50 also received inhibitors II receptor antagonists @DRUG$/ARB ) .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
The absorption of tetracycline, furosemide, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
In , was 10 more potent in whereas pigeons @DRUG$ was equipotent with @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-false
Drugs That Should Be With : amiodarone @DRUG$ @DRUG$ : , terfenadine Antimigraine : ergot derivatives : rifampin Benzodiazepines midazolam , triazolam GI : cisapride	DDI-false
@DRUG$ ( as @DRUG$ ) ;	DDI-false
Additional blood pressure may when @DRUG$ is with , antihypertensive @DRUG$.	DDI-effect
causal not established physicians should the that may a s @DRUG$ oral	DDI-false
separate of patients maintenance warfarin , , administration effect on pharmacodynamics of @DRUG$ of	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of colestipol hydrochloride on the availability of @DRUG$ and digitoxin.	DDI-false
of @DRUG$ and vitamin may absorption of	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
on metabolic profiles , clinically significant drug not VIRACEPT dapsone , trimethoprim/@DRUG$ , clarithromycin @DRUG$ , fluconazole	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Digoxin, @DRUG$ and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Digoxin, Methotrexate, Cyclosporine: @DRUG$, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
or protriptyline other @DRUG$ cause and the concentration @DRUG$ in	DDI-false
Antagonism has been demonstrated between @DRUG$ and @DRUG$ in vitro.	DDI-effect
@DRUG$ : concomitant of DURAGESIC ( transdermal system central depressants , including but not to other @DRUG$ hypnotics , ( benzodiazepines , anesthetics , phenothiazines , muscle alcohol respiratory hypotension and sedation , coma or	DDI-false
@DRUG$-@DRUG$ may the absorption of vitamin K.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/@DRUG$, and valproic acid/phenobarbital.	DDI-false
- The action of sulphonylureas and insulin may be enhanced by @DRUG$ or @DRUG$.	DDI-false
- @DRUG$ (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
: of @DRUG$ regularly results an in serum @DRUG$ that may reach levels with clinical .	DDI-false
If @DRUG$ is mixed with NPH human insulin, @DRUG$ should be drawn into the syringe first.	DDI-false
Central System The concomitant use DURAGESIC   ( fentanyl transdermal system ) with central nervous depressants , including but limited other opioids , ( e.g. , @DRUG$ general , , skeletal and @DRUG$ , may cause , hypotension , and , potentially in coma .	DDI-false
Phenytoin: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
@DRUG$ may enhance the effects of , and	DDI-effect
An alternative non-CYP3A4 @DRUG$ may be considered in patients taking CYP3A4 as , carbamazepine , and @DRUG$.	DDI-false
These increased exposures of @DRUG$ and @DRUG$ should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.	DDI-false
pharmacokinetic have demonstrated of @DRUG$ ( capsules and tablets in reduced @DRUG$ , but was no change .	DDI-false
Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing AEDs.	DDI-false
No studies have been assess if there an effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Drugs that been associated peripheral neuropathy antiretroviral chloramphenicol , @DRUG$ dapsone disulfiram , ethionamide , glutethimide gold , @DRUG$ , phenytoin	DDI-false
Amprenavir inhibits the ERMBT, and @DRUG$ and @DRUG$ are equipotent inducers of the ERMBT.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or phenobarbital.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Data in vitro studies suggest a possible : @DRUG$ , , amiodarone , nicardipine and @DRUG$.	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).	DDI-false
Another oral @DRUG$, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	DDI-false
- @DRUG$ nandrolone e.g. , @DRUG$ ] , ] , oxymetholone Anadrol ] stanozolol Winstrol ) or	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
@DRUG$ a similar effect in the presence @DRUG$.	DDI-false
pharmacokinetic dexmedetomidine , @DRUG$ @DRUG$ and midazolam have been demonstrated .	DDI-false
Antidepressants tricyclic : @DRUG$ may the activity of @DRUG$ ;	DDI-effect
Concomitant administration of @DRUG$ and other related compounds (eg, quinine, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
@DRUG$: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and @DRUG$ (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
appears to clinically relevant of this kind , drugs known alter ( @DRUG$ or beta-adrenergic @DRUG$ , antihistamines or tricyclic antidepressants phenothiazines might to a prolongation the QTc interval	DDI-false
@DRUG$ serum be @DRUG$ dosage when drugs used concomitantly .	DDI-false
This interaction given consideration in patients @DRUG$ with @DRUG$.	DDI-advise
CYP 3A4 ( e.g. , @DRUG$ , macrolide antibiotics @DRUG$ have potential to in increased plasma concentrations of corticosteroids .	DDI-false
@DRUG$ : @DRUG$ dopamine that dopamine such neuroleptics ( butyrophenones ) or , diminish the effectiveness	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
- you take ) Use oral @DRUG$ @DRUG$ may chance of effects affecting and/or the side or oral	DDI-effect
( e. g. , ketoconazole , , clotrimazole @DRUG$ vitro and animal combination @DRUG$ and imidazoles suggest imidazoles induce amphotericin B.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
- Drugs with ototoxic potential : presence impaired renal function the use of administered @DRUG$ in patients @DRUG$ are also should except life-threatening conditions .	DDI-advise
Beta-blockers, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
THE CONCOMITANT ADMINISTRATION OF LEAD TO PHENYTOIN INTOXICATION TO @DRUG$ TO @DRUG$ THERAPY , A SHOULD	DDI-effect
nevirapine been compared therapy @DRUG$ over as therapy with similar @DRUG$ regimens superiority efavirenz .	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and @DRUG$.	DDI-false
Severe hypoglycemia has been reported in patients concomitantly receiving @DRUG$ and oral @DRUG$.	DDI-effect
using this medication tell or pharmacist all and products you may use of , , cyclosporine , , ) , @DRUG$ , @DRUG$.	DDI-false
specific interactions topical glaucoma or systemic were clinical studies of @DRUG$ % Ophthalmic possibility additive effect CNS ( alcohol , opiates , sedatives , @DRUG$ ) should be considered	DDI-advise
@DRUG$ has reported to have occurred in a patient on treatment the initiation @DRUG$ therapy .	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some @DRUG$.	DDI-false
therapy Although studies were , finasteride doses of 1 or more were used clinical studies with , acid a-blockers , , @DRUG$ , beta , calcium-channel cardiac nitrates , antagonists , reductase ( NSAIDs ) , and @DRUG$ without evidence of adverse interactions .	DDI-false
The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	DDI-false
Other concomitant specific not , of or more were used studies acetaminophen , , , angiotensin-converting enzyme ACE ) inhibitors @DRUG$ , @DRUG$ beta blockers calcium-channel , , antagonists , HMG-CoA inhibitors synthetase inhibitors to NSAIDs , and quinolone without evidence clinically .	DDI-false
Patients receiving @DRUG$, @DRUG$, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
administration @DRUG$ and androgens in elevated serum of	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ Inhibition @DRUG$ clearance , increase plasma has been reported with some prostaglandin drugs	DDI-false
Strong inducers cytochrome i.e. @DRUG$ , phenytoin and @DRUG$ ) have been decrease plasma levels 29 - 40 ) .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Concomitant administration of Mefloquine and other related compounds (eg, quinine, @DRUG$ and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Results multiple sclerosis patients TYSABRI and @DRUG$ @DRUG$   mcg once weekly ) or acetate regard to need for or	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Because interaction is likely @DRUG$ should be administered concurrently @DRUG$.	DDI-advise
Concomitant @DRUG$ other related ( eg , @DRUG$ and may electrocardiographic abnormalities and increase the risk convulsions	DDI-effect
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Imipramine: Coadministration of single doses of @DRUG$ 20 mg and @DRUG$ 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-effect
Amantadine, @DRUG$, and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
@DRUG$ tendency to antagonize skeletal of @DRUG$ may potentiate the of	DDI-effect
Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
medication tell doctor or pharmacist products use especially of @DRUG$ ( e.g. amikacin ) B , cyclosporine , non-steroidal anti-inflammatory drugs e.g. ibuprofen tacrolimus ,	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
Aminosalicylic acid may decrease the amount of @DRUG$ (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
associated analogues , @DRUG$ cisplatin , , , , hydralazine , , isoniazid , metronidazole , , phenytoin @DRUG$.	DDI-false
Intravenous ( has been effectively the of as @DRUG$ , , @DRUG$ , and angiotensin , without any profile	DDI-false
@DRUG$ The administration of receiving the and significantly the	DDI-false
have been , with mainly by CYP3A4 ( eg calcium channel blockers @DRUG$ disopyramide quinine , , , @DRUG$ , cyclosporine derivatives pimozide , fentanyl , alprazolam , and triazolam have elevated plasma when coadministered with saquinavir	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
effects @DRUG$ antagonized by blocking @DRUG$ and	DDI-effect
@DRUG$	DDI-effect
Sulindac: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-mechanism
( , physostigmine , lignocaine @DRUG$ , @DRUG$ can toxicity and cardio respiratory .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Considerable caution exercised if @DRUG$ is administered concurrently @DRUG$ ( ) since have been reported combination .	DDI-advise
safety @DRUG$ in any @DRUG$ have not	DDI-false
though been suggested , @DRUG$ carbamazepine , @DRUG$ , tetracyclines ( 72	DDI-false
@DRUG$ may interfere with the anti-glaucoma action of carbachol or @DRUG$;	DDI-effect
Drug : Flupenthixol may with some , like @DRUG$ ( MAOI could theoretically affect flupenthixol - Arecoline Ethanol @DRUG$ cause CNS depression antidepressants : effect antidepressants	DDI-false
two combined 12-week controlled of 15 mcg twice daily , mcg daily , and 50 mcg once daily , of 873 @DRUG$ -treated received concomitant @DRUG$ at entry .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, @DRUG$, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
@DRUG$ was used , , , vasodilators and supplemental . a pharmacokinetic in heart failure or digoxin whom with FLOLAN , clearance values @DRUG$ ( n = ) n ) were % % respectively , on second therapy and had to baseline day 87 .	DDI-false
Reports suggest that NSAIDs may antihypertensive effect @DRUG$ , including	DDI-false
patients one or medications @DRUG$ NSAIDs , corticosteroids TNF blocking agents , chloroquine gold , leflunomide sulfasalazine , and	DDI-false
Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
analyses that , @DRUG$ , corticosteroids @DRUG$ did not influence	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ ( physostigmine ) @DRUG$ can enhance and respiratory .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine phenobarbital/@DRUG$ phenobarbital/valproic , , .	DDI-false
@DRUG$: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or @DRUG$ toxicity.	DDI-false
@DRUG$  may interact with drugs known to interact with the conventional formulation of @DRUG$.	DDI-false
@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ potential of @DRUG$ in the impaired .	DDI-effect
@DRUG$ : of saquinavir experimental soft-gelatin capsule formulation of 1200 ) with VIRACEPT in an in and in @DRUG$ plasma	DDI-false
Administration repeat doses of @DRUG$ repeat dose pharmacokinetics of @DRUG$ an ethinylestradiol/levonorgestrol oral contraceptive in subjects	DDI-false
There been case reports of of and @DRUG$ therapy	DDI-false
have demonstrated a significant oral of trovafloxacin and @DRUG$ administered intravenous such @DRUG$.	DDI-mechanism
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or lamotrigine.	DDI-false
@DRUG$ taken @DRUG$ for less than seven days procainamide and n-acetyl procainamide by 55 and % , .	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Coadministration @DRUG$ @DRUG$ tablets in lowered nisoldipine plasma undetectable .	DDI-mechanism
@DRUG$ : Administration of @DRUG$ concomitantly cyclosporine increase in cyclosporine-induced possibly due to prostacyclin .	DDI-false
The effectiveness of progestin-only is enzyme-inducing such anticonvulsants phenytoin , carbamazepine @DRUG$ antituberculosis @DRUG$.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
The of @DRUG$ @DRUG$ or norepinephrine patients monoamine oxidase inhibitors tricyclic antidepressants may produce	DDI-false
ACE : suggest that @DRUG$ diminish the of @DRUG$.	DDI-effect
volunteers ( n=24 ) @DRUG$ with @DRUG$ produced attenuation in the peak concentration of the peak were not .	DDI-false
@DRUG$ and Angiotensin , 3020 91 patients @DRUG$ to received inhibitors receptor antagonists ACEI/ARB	DDI-false
@DRUG$ has led plasma @DRUG$ resulting in rare cardiac and .	DDI-false
@DRUG$- and/or aluminum-containing @DRUG$ , products ferrous sulfate ( iron ) multivitamin or metal cations or Videx ( ) tablets the powder for oral solution not be 3 hours before or 2 hours	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Cholestyramine @DRUG$ : Absorption of impaired in	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-advise
Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Cholestyramine and colestipol resins: Absorption of @DRUG$ is impaired in the presence of @DRUG$.	DDI-mechanism
have been associated with peripheral neuropathy antiretroviral nucleoside @DRUG$ dapsone , @DRUG$ iodoquinol isoniazid , phenytoin ribavirin , and	DDI-false
have not performed , with drugs that mainly by CYP3A4 eg , calcium , disopyramide , , @DRUG$ tacrolimus , cyclosporine , ergot derivatives , pimozide , , alfentanyl , @DRUG$ , may plasma coadministered saquinavir	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, @DRUG$, and alcohol.	DDI-false
in the second of 12 g @DRUG$ 1 before 0.3 approximately hours evening meal in a decrease in @DRUG$ less 8 % , and a decrease Cmax of about when cerivastatin alone .	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
When @DRUG$ was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-mechanism
The absorption cimetidine and @DRUG$ accelerated when are coadministered	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
While vivo drug-drug interaction studies conducted @DRUG$ CYP3A potent ( @DRUG$ , phenytoin rifampin , barbiturates ) would be expected to estazolam concentrations .	DDI-mechanism
@DRUG$ : Phenylbutazone causes increase ( about 80 free of	DDI-false
@DRUG$ and @DRUG$ Upon concomitant administration of mg with 600 BID ritonavir AUC 20	DDI-false
The be potentiated including @DRUG$ are highly protein bound salicylates , , chloramphenicol , probenecid , @DRUG$ , adrenergic blocking agents	DDI-false
, lidocaine/quinidine phenobarbital/@DRUG$ , , , and	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Concomitant administration of @DRUG$ (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of @DRUG$.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
: In a pharmacology coadministration an antacid ( , @DRUG$ simethicone with serum of with administered , that @DRUG$ fosinopril .	DDI-false
effectiveness is by drugs such as @DRUG$ , @DRUG$ , barbiturates , the antituberculosis .	DDI-false
interact ( effect , , rifampin other microsomal decreased effect of ) @DRUG$ ( effect @DRUG$ .	DDI-false
Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
The hypoglycemic sulfonylureas may potentiated by and other that are highly protein bound , salicylates , @DRUG$ , @DRUG$ monoamine inhibitors , adrenergic agents .	DDI-false
5HT3 Antagonists Based hypotension and loss when apomorphine was with ondansetron , the use of @DRUG$ drugs of 5HT3 antagonist class ( , for example @DRUG$ dolasetron , , and alosetron ) is	DDI-advise
@DRUG$ : and extent absorption of when @DRUG$ was alone was 2 after the dose maximally suppresses gastric acid secretion	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
In first study concomitant @DRUG$ and 12 @DRUG$ resulted in more than % for AUC 40 % for dosing alone .	DDI-mechanism
@DRUG$ In diabetic patients diflunisal , significant effects on @DRUG$ levels or glucose .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with phenytoin.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-false
Drugs Demonstrated to 3A of Clinical Basis of Clinical Studies Involving Alprazolam caution during of fluoxetine @DRUG$ increased maximum @DRUG$ by 46 % , decreased by , half-life by and decreased psychomotor .	DDI-false
specific studies have with drugs mainly metabolized by CYP3A4 ( , blockers , , , quinidine , warfarin , tacrolimus , ergot derivatives , , carbamazepine @DRUG$ alfentanyl , @DRUG$ triazolam have plasma when with saquinavir ;	DDI-false
As other @DRUG$ should be noted @DRUG$ may be potentiating such anesthetics , opiates and alcohol .	DDI-false
conversely @DRUG$ may with antihypertensive drugs , @DRUG$ ) .	DDI-int
H2 Receptor Antagonists : @DRUG$ leads to an increased peak plasma concentration and is no effect on @DRUG$ absorption it coadministered with ranitidine	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6%, decreased clearance by 38%, and increased half-life by 58%.	DDI-mechanism
the of @DRUG$ @DRUG$ not the adverse reaction .	DDI-false
studies have shown CASODEX @DRUG$s such @DRUG$ from their	DDI-false
have reports @DRUG$-related side in patients on with and @DRUG$.	DDI-false
should not concurrently D2-antagonists , as butyrophenones @DRUG$ , @DRUG$.	DDI-false
@DRUG$-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although been performed , with that are mainly by eg , calcium channel , , quinidine , @DRUG$ , , , alfentanyl , ) may elevated concentrations @DRUG$ ;	DDI-mechanism
Interaction with @DRUG$ other than @DRUG$ has not been specifically studied;	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : @DRUG$ may diminish suppression by .	DDI-false
Warfarin: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Acidifying : acidifying , reserpine , @DRUG$ @DRUG$ lower of .	DDI-false
pigeons naloxone not effects of , @DRUG$	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Anticoagulant inhibition during the @DRUG$ and @DRUG$ ;	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
acetaminophen/theophylline , , , phenobarbital/@DRUG$ , quinidine/lidocaine , , and	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ a renal tubular blocking at dose of 500 times day not change the @DRUG$ daily	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
These diuretics corticosteroids phe-nothiazines estrogens oral contraceptives , @DRUG$ , @DRUG$ calcium channel drugs , isoniazid	DDI-false
While all serotonin reuptake ( @DRUG$ ) e.g. , escitalopram , @DRUG$ , and paroxetine , inhibit , they vary in of inhibition	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
have prolongation , patients taking @DRUG$ @DRUG$ azoles were concomitantly	DDI-false
have been in include antipyrine @DRUG$ @DRUG$ , and warfarin and no meaningful interactions .	DDI-false
@DRUG$ : Coadministration of a single zaleplon and 10 and 25 mg % decrease maximal plasma concentrations of @DRUG$ , change in under the	DDI-false
It may increase excretion of barbiturates, @DRUG$, and ASA and may also increase the toxicity of @DRUG$.	DDI-false
Interactions : some , like MAOI ): MAOI could @DRUG$ pharmacodynamics Arecoline Eproxindine - Ethanol : cause additive depression @DRUG$ : increases the antidepressants	DDI-false
: @DRUG$ has been reported , concomitant use of @DRUG$ by its cellular impairing	DDI-effect
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
@DRUG$ and indinavir : Upon concomitant of of with mg ritonavir , the Cmax @DRUG$ were approximately % .	DDI-false
Drug Interactions Flupenthixol with , inhibitors ( MAOI MAOI could theoretically - @DRUG$ Eproxindine : cause CNS depression - @DRUG$ : Flupenthixol increases the effect antidepressants	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and @DRUG$.	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or @DRUG$.	DDI-false
Population pharmacokinetic analyses revealed that MTX, @DRUG$, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	DDI-false
trial escalating doses @DRUG$ - 200 mg/m2 ) and ( 50 infusions , myelosuppression more when @DRUG$ given after with ( , before cisplatin ) .	DDI-false
Quinolones, including @DRUG$, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and @DRUG$/phenobarbital.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Ritonavir Coadministration of @DRUG$ VIRACEPT 152 % increase in @DRUG$ A.C.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
Although specific have not been performed coadministration with drugs that by ( eg calcium channel blockers dapsone , disopyramide quinine , amiodarone , quinidine , tacrolimus cyclosporine , derivatives , @DRUG$ , , @DRUG$ alprazolam triazolam elevated coadministered ;	DDI-false
Vitamin ( @DRUG$ @DRUG$ Use these medicines increase the side blood	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Patients @DRUG$ or who their diclofenac or any taking or @DRUG$	DDI-effect
There have been stable plasma levels of @DRUG$ , nortriptyline , when @DRUG$ has been administered combination agents .	DDI-mechanism
addition from regression of patient data other inducers of ( , @DRUG$ @DRUG$ , or carbamazepine in reductions	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
are the of @DRUG$/@DRUG$ or FORTOVASE/ritonavir garlic	DDI-false
interaction studies , doses mg or concomitantly used in with acetaminophen , acid analgesics ( inhibitors , @DRUG$ calcium-channel , H2 antagonists , HMG-CoA @DRUG$ ( NSAIDs quinolone	DDI-false
Cimetidine: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-mechanism
Human @DRUG$ the metabolism @DRUG$ resulting an in the AUC cisapride .	DDI-mechanism
less has been suggested with phenylbutazone @DRUG$ @DRUG$ , griseofulvin topiramate , and ampicillin and tetracyclines .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
of @DRUG$ ( BID ( ) and mg QD ( 2 - ) @DRUG$ 10 mg glyburide BID in glyburide AUC0 - 12 and a % in Cmax a 16 % in glucose - .	DDI-mechanism
that @DRUG$ concentrations Drugs that increase imatinib plasma of CYP3A4 ( , ketoconazole , itraconazole , @DRUG$ clarithromycin ) .	DDI-false
history reactions containing   ( eg @DRUG$ injection and teniposide for ) should not be with @DRUG$.	DDI-advise
- : @DRUG$ given with diuretics ( @DRUG$ ) renal clearance and risk lithium toxicity .	DDI-advise
are examples of reduce , niacin danazol diuretics sympathomimetic ( e.g. epinephrine salbutamol @DRUG$ , phenothiazine derivatives , estrogens , ( e.g. , in @DRUG$ ) .	DDI-false
@DRUG$ Chlorpromazine blocks dopamine and norepinephrine thus inhibiting central effects amphetamines and can used to treat @DRUG$ poisoning .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
suggest @DRUG$ , retinoids , may regulate the prostate epithelium by dose-dependent of of	DDI-effect
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-effect
@DRUG$, barbiturates, or @DRUG$: potentiation of orthostatic hypotension may occur.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, and @DRUG$.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
In clinical trials , FLOLAN was used with digoxin , @DRUG$ oral supplemental . In substudy in with heart furosemide or in whom therapy @DRUG$ was initiated , oral furosemide ( n and = ) by 13 % and 15 , respectively of returned values by	DDI-false
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
other products containing iron , @DRUG$ @DRUG$ not with within 2 hours , administration because may with resulting lower and norfloxacin .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Anticoagulants including coumarin derivatives , indandione , and @DRUG$ such @DRUG$ ( and risk of bleeding when administered concomitantly ardeparin .	DDI-false
@DRUG$ mg daily ) did alter @DRUG$ healthy .	DDI-false
@DRUG$ administration and not because diclofenac displaced its binding sites during the @DRUG$ resulting lower , plasma , values .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
was shown @DRUG$ antagonized evidently the @DRUG$	DDI-effect
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
All subjects received @DRUG$ (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or @DRUG$ (600 mg QD) (cohort 2) for 14 days.	DDI-false
that have been associated with neuropathy include antiretroviral @DRUG$ dapsone , , @DRUG$ , hydralazine , , , phenytoin , ribavirin vincristine	DDI-false
The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.	DDI-false
Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
@DRUG$ and cyclosporine , @DRUG$ digoxin has led to the latter three drugs .	DDI-mechanism
@DRUG$ anorectic and stimulatory may inhibited	DDI-false
The availability of potent (@DRUG$)-based therapy @DRUG$ (PI)-related metabolic shifts practices in infection	DDI-false
Antipyrine : Because @DRUG$ the of antipyrine , with @DRUG$ metabolized same are not .	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-mechanism
a comparison of digitalis tolerance in @DRUG$ Innovar Vet or the dosage ouabain ventricular was higher , as was of ouabain , with @DRUG$ with	DDI-false
@DRUG$ e.g. @DRUG$ ) Use increase the the side of	DDI-false
Drug Interactions : @DRUG$ may interact with , Monoamine oxidase inhibitors ): @DRUG$ could - Arecoline - - Flupenthixol Ethanol additive - Flupenthixol of antidepressants	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ may interact with alcohol or other @DRUG$, causing increased sedative effects.	DDI-effect
@DRUG$ of antihypertensive , @DRUG$ , methyldopa , reserpine .	DDI-effect
Drugs @DRUG$ Cytochrome P450 3A The in @DRUG$ catalyzed by 3A CYP 3A )	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ : decreases renal and increases @DRUG$ plasma levels .	DDI-false
there are on NovoLog and @DRUG$ preparations , @DRUG$ be mixed with these .	DDI-false
@DRUG$: @DRUG$ are known to cause osteoporosis.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$:Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors.	DDI-false
Clinical interaction studies with cimetidine and @DRUG$ indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
and/or aluminum-containing , containing ferrous sulfate ( , containing @DRUG$ other or @DRUG$ ( didanosine ) chewable/buffered or the powder for oral solution not taken within hours 2 after .	DDI-false
Coadministration that are potent inducers of ( eg @DRUG$ , phenytoin , may result in decreased levels of @DRUG$.	DDI-mechanism
@DRUG$ incidence of lymphatic invasion adenocarcinomas which was enhanced @DRUG$.	DDI-effect
Potential drug   and , gabapentin , @DRUG$ @DRUG$ , were assessed evaluating the concentrations and these AEDs placebo-controlled studies	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Thus, smaller doses of @DRUG$ may be effective in the presence of @DRUG$.	DDI-effect
Multivitamins or other containing or @DRUG$ not be with or within 2 , the administration may interfere absorption in lower and levels of	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and @DRUG$] is contraindicated.	DDI-false
In study the antipsychotic @DRUG$ with of @DRUG$ in two-lever discrimination signalled-unsignalled differential-reinforcement-of-low-rates ) procedures	DDI-false
A similar , , has suggested with sodium , @DRUG$ , with @DRUG$ and tetracyclines 72 .	DDI-false
Administration of @DRUG$ to patients receiving cyclopropane or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING @DRUG$ AND ITS CONGENERS.	DDI-advise
of @DRUG$ concentrations should considered therapy with @DRUG$ or in patients theophylline .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
No data are available for the coadministration of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules.	DDI-false
Curariform muscle ( @DRUG$ and , ether succinylcholine , gallamine @DRUG$ sodium citrate potentiate neuromuscular and should be with extreme being treated with M Parenteral .	DDI-false
acidifying agents ( @DRUG$ sodium acid phosphate , etc . the of the ionized @DRUG$ molecule thereby excretion .	DDI-mechanism
Effect of Clonazepam on of Other : @DRUG$ does appear the pharmacokinetics , or	DDI-false
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, metoclopramide, @DRUG$.	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
Magnesium/Aluminum-containing Antacid Products @DRUG$ is moderately approximately ) when with products .	DDI-false
@DRUG$ (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Ritonavir ( mg b.i.d ) Vardenafil 5 mg resulted a 49-fold increase @DRUG$ AUC increase @DRUG$ .	DDI-false
Therefore , slower onset be anticipated if @DRUG$ concomitantly with , or immediately following , a	DDI-effect
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
@DRUG$: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	DDI-false
appears to the kind Mefloquine , although of drugs known to alter cardiac , anti-arrhythmic @DRUG$ , antihistamines agents @DRUG$ and phenothiazines might contribute a of the QTc .	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
peripheral neuropathy include antiretroviral analogues cisplatin dapsone ethionamide @DRUG$ , @DRUG$ , , iodoquinol , metronidazole , nitrofurantoin , , ribavirin , and vincristine	DDI-false
effect on plasma concentrations @DRUG$ , valproate , @DRUG$ lamotrigine .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ diflunisal @DRUG$ significantly plasma levels	DDI-false
lidocaine/@DRUG$ , , phenobarbital/valproic acid , theophylline/acetaminophen , and	DDI-false
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ the inhibition ( 66 % 10 microM , which was than that crude @DRUG$.	DDI-false
Other concomitant therapy interaction not performed finasteride doses mg or were with acetylsalicylic , analgesics , angiotensin-converting inhibitors , anticonvulsants beta calcium-channel cardiac nitrates , diuretics , @DRUG$ reductase inhibitors ( also as @DRUG$ ) quinolone without evidence significant adverse interactions	DDI-false
, a crossover study in receiving either Tagamet 300 mg . h.s . with a 300 . dosage @DRUG$ @DRUG$ Pharmaceuticals , in steady-state peak serum levels with 800 mg h.s , particularly in aged 54 years .	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	DDI-effect
@DRUG$ has to have neuromuscular blocking that enhance action @DRUG$.	DDI-effect
Ethinyl Estradiol and Norethindrone Coadministration with @DRUG$ 47 decrease in estradiol an % @DRUG$ .	DDI-false
@DRUG$ including tranylcypromine sulfate , HC1 : of @DRUG$ inhibitors	DDI-false
Injection : Lorazepam injection other @DRUG$ , produces depression the nervous system administered with ethyl phenothiazines , , other used concomitantly injectable increased of , hallucinations , and has been observed .	DDI-effect
concomitant Although specific interaction were performed , finasteride doses of mg or concomitantly used clinical acetylsalicylic , analgesics , @DRUG$ , , blockers cardiac , @DRUG$ , reductase , prostaglandin synthetase also referred to ) , and without evidence clinically	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ , @DRUG$ and theophylline has also to produce adverse clinical .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, @DRUG$) should be considered.	DDI-false
Interactions Mixed Agonist/Antagonist Opioid : ( pentazocine nalbuphine @DRUG$ , dezocine @DRUG$ be to who or is receiving a therapy pure agonist opioid analgesic such as .	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.	DDI-mechanism
Administration of @DRUG$ to patients who are receiving @DRUG$ or monoamine oxidase inhibiting drugs may result in an additive pressor effect .	DDI-effect
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The similarity the @DRUG$ adverse event between @DRUG$ and 2 ( co-administered ) this alteration clearance does reduction dose to , General	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
The extent to which SSRI-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In FLOLAN used with digoxin , vasodilators . In a substudy in with @DRUG$ whom therapy with FLOLAN clearance for @DRUG$ ( n and ( = ) were 13 % % , the second of values day 87 .	DDI-false
@DRUG$: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of lisinopril may result in a further deterioration of renal function.	DDI-false
@DRUG$ : @DRUG$ known to the metabolism of and serum levels be determined administration signs symptoms carbamazepine monitored closely , and appropriate dosage adjustment of the should .	DDI-false
Antiacid Didanosine @DRUG$ Indanavir , Phenobarbitol @DRUG$ , , Rifampin , ,	DDI-false
renal antagonized by either or @DRUG$.	DDI-false
of @DRUG$ , @DRUG$ , G hydrochlorothiazide and was decreased simultaneously with	DDI-false
metabolizers : carvedilol with inhibitors of such as @DRUG$ @DRUG$ paroxetine , and propafenone ) not , but these drugs would be expected to of of carvedilol	DDI-false
: Since @DRUG$ and @DRUG$ cause increased , their use is contraindicated .	DDI-effect
@DRUG$ such and @DRUG$ ;	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, @DRUG$, or other vasodilators.	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Single of either @DRUG$ or colestipol @DRUG$ bind hydrochlorothiazide gastrointestinal tract by up to 85 and percent , respectively	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), @DRUG$, azole antifungals.	DDI-false
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
Antifungals : In and/or vivo data , oral @DRUG$ inhibit metabolism of cisapride , which in plasma @DRUG$ levels and prolongation the interval the	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
@DRUG$ can interact with @DRUG$, increasing the metabolism of chlorpromazine.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Hypersensitivity have been reported combination regimens high dose @DRUG$ and antineoplastic agents , specifically , cis-platinum , @DRUG$ interferon-alfa	DDI-effect
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
however considered that this decrease of @DRUG$ concentration is of clinical significance as lamivudine is a efficient for kinase than @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
@DRUG$ the of @DRUG$ and a of lithium toxicity	DDI-mechanism
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing @DRUG$.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ on Drugs : @DRUG$ no on concentrations in with epilepsy .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-effect
however considered be unlikely that this phosphorylated @DRUG$ concentration is of significance , as @DRUG$ is a substrate kinase	DDI-false
Other : pharmacokinetic observed @DRUG$ following : warfarin @DRUG$ , Maalox ranitidine .	DDI-false
In some patients the combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	DDI-effect
@DRUG$: As with other b-lactams, the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	DDI-false
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG-DRUG$ due to inhibition of antibody response.	DDI-false
DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
CANCIDAS the blood tacrolimus by approximately 20 , blood ( ) 16 , and 12-hour concentration ( C12hr by % in tacrolimus ( doses 0.1 12 hours apart was 10th of @DRUG$ compared period @DRUG$ was	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
of @DRUG$ become @DRUG$	DDI-mechanism
Reports suggest that levels metabolite may increased @DRUG$ @DRUG$ used .	DDI-mechanism
@DRUG$, @DRUG$, and azoles are known to cause QTc prolongation.	DDI-false
High-dose @DRUG$ with @DRUG$ protection.	DDI-effect
These exposures of norethindrone estradiol should be taken consideration an oral @DRUG$ @DRUG$.	DDI-advise
We the case of with altered consciousness caused by with a positive to alert to cross-reactivity @DRUG$ with toxicology	DDI-advise
Administration of @DRUG$ to are @DRUG$ or monoamine inhibiting drugs may result effect	DDI-effect
The effects @DRUG$ dopamine norepinephrine are enhanced	DDI-effect
@DRUG$ , flecainide propafenone @DRUG$ due life-threatening	DDI-false
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and @DRUG$ After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers	DDI-false
The of in clinical one more following concomitant medications with , @DRUG$ , agents , , @DRUG$ ,	DDI-false
5HT3 Based on of profound hypotension and when apomorphine was administered with ondansetron , of apomorphine with drugs the ( including , @DRUG$ dolasetron @DRUG$ is contraindicated	DDI-false
clarithromycin , , Fluconazole , Fluoxetine , @DRUG$ , , Rifabutin	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Other specific performed finasteride doses mg were concomitantly clinical with @DRUG$ acid a-blockers , analgesics , ACE , anticonvulsants , benzodiazepines blockers , cardiac nitrates , @DRUG$ antagonists reductase referred as ) , quinolone anti-infectives without evidence adverse .	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, aminocaproic acid) and @DRUG$.	DDI-false
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-effect
second experiment , non-diabetic streptozotocin-induced diabetic rats were and procedures for estimation @DRUG$ tolerance after @DRUG$ .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The @DRUG$ study dosed subjects mg/day azithromycin ( ) ( later 600 = ) 21 of a 21-day 100 mg , times/day @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
clarithromycin , , , @DRUG$ , Phenobarbitol , carbamazepine , @DRUG$ Rifampin Ritanovir , .	DDI-false
agents : VISTIDE with potential [ , , tobramycin , @DRUG$ @DRUG$ , , and non-steroidal agents is	DDI-false
interact with thyroid medication ( , ) products , antacids , e.g. @DRUG$ ranitidine ) and pump lansoprazole @DRUG$ )	DDI-false
As with other @DRUG$, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Drugs that have with peripheral antiretroviral nucleoside analogues , , @DRUG$ , dapsone disulfiram , gold hydralazine , , , nitrofurantoin , @DRUG$ , and .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing : Concurrent of a quinolone including multivalent products such magnesium or antacids sucralfate chewable/buffered or powder products containing @DRUG$ , or @DRUG$ may substantially of , resulting and considerably than desired .	DDI-false
Agents   A pharmacokinetic study of felodipine in with @DRUG$ demonstrated significant @DRUG$.	DDI-false
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-false
Because @DRUG$ is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
@DRUG$ does , however cause blood levels drugs metabolized by CYP3A4 , no on @DRUG$ , a drug with metabolism very inhibition .	DDI-false
In a study in patients treated for 24 weeks concurrent @DRUG$ @DRUG$ , a % rate of serious infections was higher than that observed with etanercept alone (	DDI-effect
Benzthiazide with @DRUG$ , decongestant , cold , and drugs , , , @DRUG$ or Ibuprofen blood pressure	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
It recommended to concurrent of ethambutol with @DRUG$ least hours @DRUG$ .	DDI-false
Single doses of either cholestyramine or @DRUG$ resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-mechanism
Pharmacokinetic studies have demonstrated that @DRUG$ and @DRUG$ significantly increased the systemic exposure of cilostazol and/or its major metabolites.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ ( neostgmine , @DRUG$ quinine , procainamide cause cardio respiratory .	DDI-false
the of @DRUG$ and , thus , catabolism of @DRUG$.	DDI-mechanism
@DRUG$, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
@DRUG$ (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
studies indicate that does not transport of @DRUG$ vinblastine @DRUG$ is not substrate for P-glycoprotein-mediated transport .	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Although been performed drugs are metabolized by CYP3A4 ( eg , @DRUG$ dapsone disopyramide quinine , , quinidine warfarin , , ergot , , alfentanyl , and may have elevated plasma concentrations coadministered @DRUG$ ;	DDI-mechanism
As with other antipsychotic agents should be noted @DRUG$ may capable potentiating depressants such as @DRUG$ , alcohol .	DDI-effect
acetaminophen/theophylline, @DRUG$/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
CNS-Active @DRUG$ 10 mg the CNS-impairing of ethanol 0.75 on balance and for 1 hour administration and on symbol test DSST , copying test , component divided for 2.5 hours @DRUG$	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and @DRUG$ 72.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Erythromycin : , of @DRUG$ @DRUG$ , a known P450 .	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$ concentrations by about % and @DRUG$ are	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Compounds been tested in man include @DRUG$ @DRUG$ propranolol theophylline , warfarin clinically meaningful interactions were found .	DDI-false
are no on compatibility @DRUG$ crystalline @DRUG$ NovoLog should not mixed with these .	DDI-false
Amiodarone with in patients receiving   -receptor blocking e.g. propranolol , a inhibitor calcium antagonists , @DRUG$ CYP3A4 , @DRUG$ , a of possible potentiation of bradycardia sinus , ;	DDI-false
@DRUG$ certain including CYP1A2 , @DRUG$ ,	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-false
Coingestion , acetaminophen @DRUG$ @DRUG$ to toxic the binding of the target .	DDI-effect
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
of benzodiazepines may be potentiated by anticonvulsants antihistamines @DRUG$ barbiturates @DRUG$ psychotropic medications , or other that CNS .	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$: It has not been established if there is a pharmacokinetic interaction between acitretin and @DRUG$.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
@DRUG$ prior of diphenidol may emetic response to @DRUG$ treatment poisoning	DDI-false
@DRUG$ @DRUG$ , verapamil	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Caution should be exercised if @DRUG$ and @DRUG$ are used together.	DDI-advise
@DRUG$-Orlistat may decrease the absorption of	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).	DDI-false
The hypoglycemic action sulfonylurea may be nonsteroidal agents that highly protein bound , salicylates , @DRUG$ , , monoamine oxidase inhibitors and @DRUG$.	DDI-false
Therefore, patients on @DRUG$ should be observed when @DRUG$ Tablets are either added or deleted from a therapeutic regimen.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Drugs Demonstrated to 3A Inhibitors of on Clinical Studies Involving ( ): Coadministration of @DRUG$ with alprazolam @DRUG$ by , by 21 % half-life , and decreased	DDI-false
evaluate impact of chemotherapy on the clinical course of patients with HIV-related systemic , non-Hodgkin ( HIV-NHL , of 24 patients HIV-NHL who were , doxorubicin , vincristine , and prednisone of 80 patients treated chemotherapy a i.e. , @DRUG$ , prednisone with vincristine plus @DRUG$ ) without therapy .	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
@DRUG$ the 12 of tacrolimus by approximately 20 % peak blood concentration % , and ) in healthy subjects when tacrolimus ( 0.1 12 hours on the CANCIDAS mg daily as compared to period @DRUG$ was .	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
In some patients the anti-inflammatory agent can the , natriuretic , effects of loop ,	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	DDI-advise
Therefore EXTREME CAUTION should administering @DRUG$ to receiving cyclopropane	DDI-advise
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
containing side N-methylthiotetrazole ( cefoperazone , cefotetan , @DRUG$ , ) ( cefazolin K and .	DDI-false
inhibitors include antifungals , @DRUG$ , , , @DRUG$ nefazodone , nicardipine , protease inhibitors , , and verapamil .	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
lidocaine/quinidine , phenobarbital/@DRUG$ , quinidine/lidocaine @DRUG$/acetaminophen ,	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In the present study, the @DRUG$ clozapine was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
Coadministration valdecoxib 40 mg BID 1 ) and 40 mg ( days 2 @DRUG$ ( 10 glyburide BID ) resulted 21 @DRUG$ AUC0 a increase Cmax leading to a 16 % decrease in 24	DDI-false
While the selective serotonin reuptake inhibitors ( e.g. , citalopram escitalopram @DRUG$ @DRUG$ inhibit P450 2D6 , they may vary in of	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
additional interaction studies with niacin @DRUG$ not any effect @DRUG$ plasma levels , administration to a population chronically receiving resulted in difference in extent of of to	DDI-false
INOmax has been administered with tolazoline, dopamine, @DRUG$, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
@DRUG$ not with @DRUG$ reduce its clearance add a risk of lithium	DDI-advise
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Imidazoles ( e. ketoconazole , , fluconazole , etc . ): in and animal with the of amphotericin @DRUG$ suggest @DRUG$ fungal resistance to B.	DDI-false
Therefore occur following administration of @DRUG$ ( e.g. , antiemetics , @DRUG$ .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
@DRUG$ Concomitant of @DRUG$ within hours of with .	DDI-false
Co-administration Concomitant @DRUG$ antiplatelet agents , other @DRUG$ may the bleeding	DDI-effect
Not Be Antiarrhythmics : @DRUG$ , quinidine Antihistamines : Antimigraine : derivatives agents @DRUG$ midazolam triazolam GI motility cisapride	DDI-false
Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-effect
These drugs include thiazides diuretics @DRUG$ , products , estrogens , contraceptives phenytoin , nicotinic acid sympathomimet-ics , @DRUG$ , and isoniazid .	DDI-false
aluminum-containing , sulfate iron @DRUG$ containing zinc or or Videx didanosine chewable/buffered powder for solution not be within 3 hours before after	DDI-advise
strong inhibitors @DRUG$ , clarithromycin nefazodone , @DRUG$ ritonavir ) expected	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
@DRUG$	DDI-effect
@DRUG$ , but not significantly inhibit the presence	DDI-effect
, FLOLAN used @DRUG$ , , , oral supplemental substudy in patients with congestive or digoxin in FLOLAN initiated , clearance values for ( n = and digoxin n = 13 % % , respectively second therapy and had to baseline values by day 87 .	DDI-false
Injection : Lorazepam injection , other injectable benzodiazepines , depression of central when with ethyl @DRUG$ barbiturates , , and antidepressants When @DRUG$ is used with lorazepam an incidence and irrational has been	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Potential interactions @DRUG$ ( gabapentin , , , @DRUG$ , primidone were assessed by concentrations of and AEDs studies .	DDI-false
: @DRUG$ IV have been used with agents , , hydralazine , and @DRUG$ evidence of clinically significant adverse	DDI-false
@DRUG$ @DRUG$	DDI-false
Clinical interaction studies with @DRUG$ and @DRUG$ indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and @DRUG$ or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
In results from regression analyses of pharmacokinetic data suggest inducers drug clearance ( , nevirapine @DRUG$ , , carbamazepine @DRUG$ may clinically meaningful reductions in concentrations	DDI-mechanism
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
Bezalip or @DRUG$ is with @DRUG$ ( interval of least 2 hours should maintained between two medicines the of retard	DDI-advise
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Other strong of e.g. , itraconazole @DRUG$ nefazodone , @DRUG$ , nelfinavir be behave similarly .	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, @DRUG$, tranquilizers, etc).	DDI-false
concentrations with coadministration within variability individual glucose concentrations near , dose adjustment @DRUG$ QD and 10 mg @DRUG$ coadministration ( ) is not	DDI-advise
Injectable Transdermal Implantable Contraceptives : An interaction demonstrated co-administration @DRUG$ and the hormonal produced average and @DRUG$ levels 14 %	DDI-false
Urinary acidifying agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
The following examples of substances reduce the niacin , danazol diuretics @DRUG$ ( e.g. , epinephrine @DRUG$ phenothiazine derivatives , somatropin , thyroid hormones , estrogens ( e.g. , in contraceptives .	DDI-false
@DRUG$ and verapamil use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
Important Interactions To Levosimendan not have pharmacokinetic with felodipine @DRUG$ , warfarin , , ethanol @DRUG$.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Lithium : in , mean steady-state @DRUG$ plasma increased approximately % in receiving 450 mg with CELEBREX 200 compared to receiving @DRUG$ alone	DDI-false
In avoid occurrence of , all with @DRUG$ ) , diphen-hydramine and antagonists cimetidine or @DRUG$	DDI-false
no specific interactions drugs systemic medications studies @DRUG$ 0.5 % Solution , possibility of an additive or potentiating effect with depressants alcohol , @DRUG$ opiates , sedatives anesthetics should be considered	DDI-advise
Coadministration with that potent of CYP3A4 ( phenobarbital , @DRUG$ @DRUG$ , ) may result plasma levels of saquinavir	DDI-false
specific not coadministration mainly ( eg , blockers , @DRUG$ , , , quinidine warfarin tacrolimus , cyclosporine , @DRUG$ pimozide , carbamazepine fentanyl , alfentanyl , triazolam ) have elevated plasma when with saquinavir ;	DDI-false
include antifungals , ciprofloxacin , clarithromycin diclofenac @DRUG$ , imatinib nefazodone , , propofol , inhibitors , @DRUG$ , and verapamil .	DDI-false
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but @DRUG$ had no effect on @DRUG$ pharmacokinetics.	DDI-false
Because play important affect function , @DRUG$ , @DRUG$ , and requires to be certain is .	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
monkeys , , but @DRUG$ PCP , @DRUG$	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
The following examples of that increase the and susceptibility hypoglycemia : antidiabetic ACE disopyramide , , @DRUG$ propoxyphene , salicylates , analog ( , )	DDI-false
apparently effect has been to reduce the hepatic of warfarin-type anticoagulants phenytoin , nifedipine @DRUG$ , @DRUG$ lidocaine and metronidazole elimination and blood of these drugs	DDI-false
@DRUG$: Digoxin concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	DDI-false
change and dose adjustment @DRUG$ @DRUG$ are	DDI-false
Other may the neuromuscular of nondepolarizing as include ( e. g. , @DRUG$ , @DRUG$ lincomycin clindamycin , colistin , magnesium salts lithium , local procainamide quinidine .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral hypoglycemic agents in the presence of @DRUG$ that necessitated changes in the doses of such agents.	DDI-effect
Therefore , may with absorption of drugs where gastric is important determinant bioavailability ( eg , @DRUG$ salts and @DRUG$	DDI-false
In clinical trials was used with digoxin , diuretics , anticoagulants oral vasodilators and a pharmacokinetic patients with congestive @DRUG$ or digoxin in whom therapy FLOLAN ( @DRUG$ 30 ) were decreased 15 % respectively on the of and returned to by day 87 .	DDI-false
Should Not Be Coadministered With amiodarone , : astemizole , @DRUG$ Antimigraine ergot derivatives Antimycobacterial @DRUG$ midazolam triazolam GI motility agents :	DDI-false
@DRUG$ (metoprolol, @DRUG$) serum concentrations and pharmacologic effects may be increased.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or demonstrated and aspirin 162.5 mg given 26 and prior to 1 g/kg/min . ) @DRUG$ 1000 given , and 0 prior , and 12 subsequent initiation @DRUG$ 1.5 . 18	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ Cimetidine reported to clinically in steady-state serum various	DDI-false
lidocaine/quinidine , acid , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
In addition to the noted above , ) oral @DRUG$ phenytoin , , and	DDI-false
Erythromycin Co-administration of @DRUG$ ( @DRUG$ erythromycin resulted 2.5- in and the life felodipine	DDI-false
Considerable caution should be exercised if @DRUG$ is administered concurrently with Phenurone (@DRUG$) since paranoid symptoms have been reported during therapy with this combination.	DDI-advise
Multivalent Products , ciprofloxacin , multivalent products such or @DRUG$ @DRUG$ tablets pediatric , or products containing calcium , or zinc may substantially the ciprofloxacin in serum lower than desired .	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
of @DRUG$ IV @DRUG$ such as , nitroprusside , milrinone , or IV ACE has not evaluated ( these were not with Natrecor )	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
: @DRUG$ ergotamine , @DRUG$ CONTRAINDICATED to potential life-threatening such as peripheral vasospasm extremities and tissues	DDI-false
For example, when vitamin K antagonists are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-advise
The benefits and risks of @DRUG$ with @DRUG$ other nephrotoxic be carefully considered and lowest effective	DDI-advise
@DRUG$ showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude @DRUG$.	DDI-false
@DRUG$ also the absorption of @DRUG$ , lead to a .	DDI-mechanism
A 5-mg @DRUG$ dose should not be exceeded when used in combination with 200 mg once daily @DRUG$.	DDI-advise
concentrations @DRUG$ are reported significantly when @DRUG$ added or deleted from drug regimen	DDI-mechanism
Antiacid , @DRUG$ , Fluconazole Indanavir , Ketoconazole , Phenobarbitol , carbamazepine , Rifabutin Rifampin ,	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
enhance @DRUG$ or @DRUG$ ;	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ and garlic capsules.	DDI-false
As other blocking agents , time onset of neuromuscular induced @DRUG$ duration block is in phenytoin or @DRUG$.	DDI-effect
Therapeutic concentrations digoxin warfarin , @DRUG$ @DRUG$ phenytoin andtolbutamide not alter tromethamine protein binding .	DDI-false
Interactions Flupenthixol interact with some drugs like oxidase inhibitors theoretically affect pharmacodynamics - Eproxindine Ethanol : and CNS - antidepressants : @DRUG$ the effect @DRUG$	DDI-effect
Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : @DRUG$ should be employed cautiously , epidermal necrolysis has reported with	DDI-false
Other and IV have concomitantly with adrenergic-blocking , nitrates @DRUG$ hydralazine , prazosin @DRUG$ without clinically adverse interactions	DDI-false
However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
Although specific been , mainly by calcium channel , dapsone disopyramide , , , quinidine , warfarin @DRUG$ , cyclosporine derivatives , @DRUG$ alfentanyl , , elevated concentrations when saquinavir	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
b.i.d . ) ) and maximum Cmax of @DRUG$ when co-administered 20 mg @DRUG$ in healthy volunteers	DDI-false
The pharmacokinetics of @DRUG$ were unchanged following coadministration with @DRUG$ (400 mg).	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	DDI-mechanism
Iodine or iodine excess may decrease the effect of @DRUG$, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
a clinical pharmacology study , antacid ( aluminum magnesium hydroxide , ) with fosinopril and excretion of @DRUG$ as alone that @DRUG$ impair absorption fosinopril	DDI-false
Cardiovascular Agents : @DRUG$ enalapril IV been used adrenergic-blocking , nitrates calcium-blocking , hydralazine , @DRUG$ without evidence of adverse	DDI-false
@DRUG$ mixed @DRUG$ , the .	DDI-false
Drugs That CYP3A4 @DRUG$ : @DRUG$ inhibits aldehyde in vitro CYP3A4 vitro vivo , primary and enzymes respectively responsible zaleplon metabolism	DDI-false
In pigeons , did not systematically alter the @DRUG$ , (+)-NANM @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$: @DRUG$ caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-false
Conversely , @DRUG$ have been the levels the half-life of @DRUG$ .	DDI-mechanism
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
following examples substances the blood-glucose-lowering and to hypoglycemia : @DRUG$ , ACE inhibitors disopyramide fibrates , MAO , salicylates , ( e.g. octreotide @DRUG$.	DDI-false
Theophylline monitored dose adjustments for patients @DRUG$ @DRUG$.	DDI-advise
@DRUG$ tranylcypromine sulfate , : @DRUG$ cause	DDI-false
Drugs that associated peripheral neuropathy antiretroviral nucleoside analogues , , cisplatin , @DRUG$ glutethimide , , iodoquinol isoniazid metronidazole , phenytoin @DRUG$ and vincristine .	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Non-selective @DRUG$ , phenelzine sulfate , @DRUG$ : Concomitant of L-tyrosine and non-selective MAO inhibitors may .	DDI-false
with as @DRUG$ , , @DRUG$ , erythromycin , etc ) is reduction dose should .	DDI-false
an interaction study of taking @DRUG$ , @DRUG$ pharmacokinetics of .	DDI-false
Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between @DRUG$ and @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
in the pharmacokinetics either was observed @DRUG$ was with @DRUG$ or stavudine .	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
@DRUG$ @DRUG$ oxacillin chlortetracycline sulfamethoxazole have in on the protein binding diclofenac in .	DDI-false
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
@DRUG$ ,	DDI-false
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
@DRUG$ eg , and drugs including , , @DRUG$ and citrate neuromuscular effect and should used with in patients treated with .	DDI-false
agents @DRUG$ , ) increase the ionized species of @DRUG$ excretion	DDI-mechanism
acetaminophen/theophylline @DRUG$/quinidine , , acid quinidine/lidocaine and acid/phenobarbital	DDI-false
Acetaminophen , @DRUG$ quinidine and @DRUG$ human serum concentrations	DDI-false
Population pharmacokinetic studies showed higher concentrations of @DRUG$ among patients concurrently treated with @DRUG$, an inhibitor of C.P.A..	DDI-mechanism
To determine whether @DRUG$ has a direct effect on the distribution of @DRUG$, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
clinical studies it is levobupivacaine may be affected CYP3A4 ( such as @DRUG$ , phenobarbital , @DRUG$ , CYP3A4 ( antimycotics ketoconazole ;	DDI-false
It may increase excretion of @DRUG$, lithium, and @DRUG$ and may also increase the toxicity of salicylates.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
Preliminary studies indicate that the concomitant use of @DRUG$ and @DRUG$ results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.	DDI-effect
Although no medications were identified in studies of IOPIDINE 0.5 Solution the possibility of an effect with CNS depressants ( alcohol @DRUG$ , @DRUG$ , anesthetics should be considered	DDI-false
@DRUG$ ( e.g. @DRUG$ , or amiloride , potassium supplements , or may lead to significant increases potassium .	DDI-false
Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
@DRUG$ blunt the hypotensive of systemic not known of these agents ALPHAGAN in can resulting with IOP lowering effect	DDI-effect
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an @DRUG$/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
application of @DRUG$ or mg/kg weight e.w ) 15 mg/kg . ) 10 min interval significantly the activation of motility of in comparison effect @DRUG$ .	DDI-false
Drug Interactions @DRUG$ interact some , like oxidase MAOI MAOI could theoretically affect flupenthixol @DRUG$ - - Ethanol Ethanol CNS depression Flupenthixol	DDI-false
The hypoglycemic of be potentiated by certain drugs nonsteroidal anti-inflammatory and other drugs that highly protein bound , @DRUG$ coumarins , , and @DRUG$.	DDI-false
All subjects received @DRUG$ alone and following treatment with 100 mg of @DRUG$ as a single daily oral dose for seven days.	DDI-false
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking @DRUG$ while on @DRUG$ therapy.	DDI-effect
However a study in healthy subjects receiving either @DRUG$ 300 . 800 h.s . with 300 mg b.i.d of theophylline ( Theo-Dur , Key Pharmaceuticals , Inc. ) less alteration in steady-state @DRUG$ peak levels mg . regimen in subjects aged .	DDI-false
@DRUG$ may increase the ototoxic potential of @DRUG$, especially in the presence of impaired renal function.	DDI-effect
OTHER CONCOMITANT : Although studies were not in clinical studies @DRUG$ used angiotensin- converting enzyme ( ACE inhibitors betablockers , , @DRUG$ and nonsteroidal anti-inflammatory NSAIDs ) without significant adverse interactions .	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ may interfere with the anti-glaucoma action of @DRUG$ or pilocarpine;	DDI-effect
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-effect
Potential interactions between @DRUG$, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Magnesium/@DRUG$-containing Products : of moderately reduced ( 25 ) when	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Patients receiving other , general anesthetics , @DRUG$ , tranquilizers @DRUG$ , tricyclic or other CNS depressants ( alcohol concomitantly DILAUDID exhibit an CNS	DDI-false
@DRUG$ adenosine ) has been effectively in , quinidine , beta-adrenergic blocking , @DRUG$ , angiotensin converting inhibitors , change in	DDI-false
, phenobarbital/@DRUG$ , @DRUG$/valproic , quinidine/lidocaine ,	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	DDI-false
of @DRUG$ VIRACEPT resulted an decrease @DRUG$ plasma A.C.	DDI-false
known to slow the metabolism of carbamazepine and increase its serum @DRUG$ administration , signs and toxicity be monitored , and the @DRUG$ be	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, methotrexate and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral @DRUG$).	DDI-false
Curariform muscle eg tubocurarine ) and other drugs , including , gallamine , @DRUG$ and sodium , potentiate blocking used in patients being @DRUG$	DDI-effect
@DRUG$: Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
: Pharmacokinetic or pharmacodynamic have not between and concomitantly ( mg 2 of @DRUG$ 1   hours ) or ( mg given , to , and 6 and , initiation of @DRUG$ g/kg/min . 18 ) .	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-mechanism
@DRUG$ is slow metabolism @DRUG$ levels Carbamazepine levels should prior concurrent with isoniazid , symptoms carbamazepine toxicity should monitored dosage adjustment of the should made	DDI-false
in clinical who were on established therapy sulfasalazine which @DRUG$ was were noted develop mild in in to treated either @DRUG$ CI or alone	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ ( , mg/kg ) the of and @DRUG$ oral rats	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
INOmax administered @DRUG$ , , steroids @DRUG$ , and high-frequency .	DDI-false
Other therapy studies were not performed , finasteride doses mg more were concomitantly acetaminophen , acid , analgesics enzyme ( ACE inhibitors anticonvulsants , , beta blockers , calcium-channel blockers , cardiac nitrates diuretics , H2 , inhibitors ( referred to as @DRUG$ @DRUG$ evidence adverse interactions .	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
@DRUG$ , miconazole , , @DRUG$ , . ): in and the B imidazoles that may resistance B.	DDI-false
Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
At median follow-up of 33 ARIMIDEX and @DRUG$ not benefit compared with @DRUG$ in all as well as in the hormone receptor-positive subpopulation .	DDI-false
Oral Anticoagulants CAUTION SHOULD BE @DRUG$ ARE WITH @DRUG$.	DDI-advise
oral @DRUG$ ( mg/kg/day easy and carried out in the diet @DRUG$s only one : renal failure	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Vitamin : Because the relationship @DRUG$ , patients vitamin containing @DRUG$ to additive effects	DDI-false
These drugs include the and other , @DRUG$ estrogens , @DRUG$ , , calcium blocking drugs isoniazid .	DDI-false
medication , levothyroxine ) , products ( e.g. , ranitidine , and inhibitors , @DRUG$ , @DRUG$	DDI-false
drugs include @DRUG$ other diuretics , , phe-nothiazines thyroid , @DRUG$ , nicotinic , channel blocking drugs	DDI-false
Compounds that have been tested in man include @DRUG$, digoxin, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
on are not between , trimethoprim/sulfamethoxazole @DRUG$ , @DRUG$	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Enzyme Inducers and : Drugs which induce 3A4 ( 3A4 ) enzyme e.g. barbiturates , @DRUG$ @DRUG$ , rifampin ) corticosteroids require the .	DDI-false
Experience with co-administration of @DRUG$ and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.	DDI-false
It is therefore to and paraclinical of discriminate between to an @DRUG$ only oral and @DRUG$ depletion related dysregulation of the of which requires more regulation of its causal dysregulation	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$: Caution should be used if diflunisal is administered concomitantly with @DRUG$.	DDI-false
This was because @DRUG$ is metabolized unchanged @DRUG$ accounts than 1 of the administered .	DDI-false
In studies performed , the ( warfarin inhibitors ( acetylsalicylic , ( @DRUG$ ) , @DRUG$ significantly the fondaparinux	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Dopamine Since @DRUG$ a @DRUG$ , it dopamine neuroleptics ( , butyrophenones , thioxanthenes may the of APOKYN	DDI-false
Ethinyl Estradiol Norethindrone VIRACEPT 47 % decrease @DRUG$ an 18 decrease in @DRUG$ plasma .	DDI-false
Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and @DRUG$ are coadministered.	DDI-mechanism
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-false
observed preparations since there are conflicting results effect @DRUG$ availability of @DRUG$ digitoxin .	DDI-mechanism
: @DRUG$ the of @DRUG$ metabolized CYP3A4 ( , atorvastatin cerivastatin ) .	DDI-false
Other drugs which the nondepolarizing agents such as NUROMAX ( g. , tetracyclines , polymyxins , lincomycin , , and sodium colistimethate @DRUG$ lithium , , procainamide , @DRUG$.	DDI-false
: @DRUG$ delay of @DRUG$ ;	DDI-mechanism
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of @DRUG$ by 2.93-fold and the AUC(ss) of @DRUG$ by 13.3-fold.	DDI-false
The action may be drugs anti-inflammatory agents and are highly protein bound , salicylates , chloramphenicol @DRUG$ , @DRUG$ , and adrenergic agents .	DDI-false
Agents : Enalapril and been used concomitantly beta adrenergic-blocking agents , @DRUG$ , , agents , @DRUG$ , without evidence of significant interactions	DDI-false
Products : Concurrent a quinolone , cation-containing such @DRUG$ or @DRUG$ , tablets or powder , or products containing , , or substantially the absorption of resulting serum urine considerably lower than .	DDI-false
, products iron @DRUG$ , @DRUG$ should not be with or 2 hours of the of because they may interfere with absorption lower and urine norfloxacin	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
following of substances may blood-glucose-lowering effect , @DRUG$ , sympathomimetic ( e.g. epinephrine , salbutamol , terbutaline isoniazid @DRUG$ , thyroid hormones , , ( in contraceptives )	DDI-false
  @DRUG$ increase the blood concentration of @DRUG$.	DDI-false
Influence of @DRUG$ @DRUG$ Concentration Mean , % Confidence )	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
@DRUG$ has with @DRUG$ ( hypnotics , , etc .	DDI-effect
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus levofloxacin/@DRUG$ regimens.	DDI-false
Example include azole antifungals diclofenac doxycycline , , @DRUG$ , , nefazodone , , propofol protease @DRUG$ , verapamil .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
If additional @DRUG$ are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of @DRUG$ may be potentiated.	DDI-advise
: Diclofenac @DRUG$ and @DRUG$ levels	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
a Coadminstered With VIRACEPT @DRUG$ : @DRUG$	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
, the @DRUG$ on comedication , or using @DRUG$ be checked before	DDI-advise
Diazepam : @DRUG$ ( @DRUG$ a and CYP substrate .	DDI-false
Example azole , ciprofloxacin , @DRUG$ , , @DRUG$ , imatinib , nefazodone nicardipine propofol , quinidine	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, @DRUG$, sparfloxacin, and terodiline.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
has not produce any obtained with @DRUG$ alone and aspirin the of Nalfon use of @DRUG$ salicylates is	DDI-false
all reuptake ( ) @DRUG$ , sertraline , @DRUG$ , fluvoxamine , 2D6 they may in the extent .	DDI-false
@DRUG$: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
Lithium not be with @DRUG$ ( as @DRUG$ ) because reduce clearance and .	DDI-false
@DRUG$ with @DRUG$ mg daily potent metabolism , approximate % plasma .	DDI-mechanism
( neostgmine @DRUG$ ) lignocaine , @DRUG$ procainamide can enhance	DDI-false
hydrogen maleate or @DRUG$ ( hepatotoxic ) not administered together @DRUG$ or .	DDI-advise
studies @DRUG$ identified potentially @DRUG$ lithium .	DDI-int
Central Nervous Depressants : The concomitant @DRUG$   system other @DRUG$ but other opioids , sedatives hypnotics ( ) , , muscle , , cause respiratory depression profound sedation , death .	DDI-effect
@DRUG$ and Tricyclic : FORADIL should be administered with patients with @DRUG$ or because the action formoterol on system be potentiated by agents .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Because of the small effect on half-life, the coadministration with @DRUG$ to extend the half-life of @DRUG$ is not recommended.	DDI-advise
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Chloramphenicol , or @DRUG$ interfere with the bactericidal	DDI-effect
were @DRUG$ , quinidine , and serum @DRUG$ at three in	DDI-false
vitro interaction nevirapine and @DRUG$ @DRUG$	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
all the @DRUG$ SSRIs , citalopram escitalopram fluoxetine , @DRUG$ , P450 may the extent .	DDI-false
@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and @DRUG$ were administered concomitantly for 6 days.	DDI-false
Carbamazepine: Elevated @DRUG$ levels have been reported in postmarketing experience when @DRUG$ is administered concomitantly.	DDI-mechanism
@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.	DDI-false
Although increased concentrations ( - hrs ) of observed following @DRUG$ each in normal volunteers = in study , were no changes of @DRUG$ assessed , clinical laboratory tests , and adverse events	DDI-false
monitoring continued VIOXX @DRUG$ are	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
OTHER : Although specific interaction studies were not performed , clinical , was used angiotensin- converting enzyme ACE inhibitors , @DRUG$ , @DRUG$ nonsteroidal drugs ) evidence clinically significant interactions .	DDI-false
Drugs That : quinidine : @DRUG$ , @DRUG$ ergot derivatives Antimycobacterial : Benzodiazepines midazolam motility agents	DDI-false
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	DDI-false
Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
The following specific interactions : Itraconazole of another extended @DRUG$ @DRUG$ resulted in 8-fold in the more Cmax , 2-fold in the felodipine .	DDI-false
Corticosteroids , @DRUG$ @DRUG$ treatment , or diuretics potentiate possible of beta2-agonists .	DDI-false
Although other @DRUG$ are highly effective, there have been reports of pregnancy from women who have used @DRUG$, as well as topical/injectable/implantable/insertable hormonal birth control products.	DDI-false
Diazepam: @DRUG$ (@DRUG$) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
In a with up 24 weeks ENBREL   and @DRUG$ a serious , which was with @DRUG$ ( 0 ) .	DDI-false
drugs include and diuretics , @DRUG$ phenothiazines , products , estrogens @DRUG$ phenytoin , nicotinic acid sympathomimetics channel	DDI-false
1 , patients cancer @DRUG$/5-FU/@DRUG$ ( with without .	DDI-false
of may be when coadministered inhibitors @DRUG$ , fluoxetine and	DDI-false
Drugs That Should Coadministered Antiarrhythmics , Antihistamines , terfenadine Antimigraine : ergot @DRUG$ : rifampin Benzodiazepines , triazolam GI agents : @DRUG$	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
OTHER CONCOMITANT were not performed in , sodium used with ) @DRUG$ @DRUG$ , diuretics and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without of clinically adverse interactions	DDI-false
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
Additive CNS depression may @DRUG$ are with CNS including @DRUG$ and alcohol	DDI-effect
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	DDI-effect
There no between @DRUG$	DDI-false
Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after TRACLEER is initiated to see whether the @DRUG$ dose needs adjustment.	DDI-false
Additive effects resulting from may @DRUG$ is other amantadine , phenothiazines monoamine ) inhibitors , or @DRUG$.	DDI-effect
Cyclosporine , Methotrexate , like other @DRUG$ through on renal , changes in these drugs leading elevated serum of digoxin @DRUG$ toxicity	DDI-mechanism
pharmacokinetic interactions @DRUG$ , @DRUG$ , alfentanil , midazolam have	DDI-false
- @DRUG$ (e.g., @DRUG$, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
@DRUG$ ( @DRUG$ etc ) increase the concentration of ionized species thereby urinary .	DDI-false
Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in @DRUG$ therapy.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
( 0 24 hrs ) @DRUG$ descarboethoxyloratadine were following of @DRUG$ with each of these in normal volunteers ( n each there clinically in the safety of , as electrocardiographic , tests signs , adverse .	DDI-false
Particular caution when @DRUG$ cases drug since effects ( such as dysrhythmias other taken in overdose ( antidepressants ) may emerge reversal of the @DRUG$ .	DDI-false
Rifampin : Co-administration of @DRUG$ 600 mg daily , a potent of hepatic produced an approximate @DRUG$ concentrations	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Oral @DRUG$ : of and an contraceptive increased for @DRUG$ ethinyl by and 20 %	DDI-false
@DRUG$, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the @DRUG$.	DDI-false
@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
drugs the neuromuscular blocking of nondepolarizing g. , aminoglycosides tetracyclines bacitracin polymyxins clindamycin colistin and sodium colistimethate magnesium salts , @DRUG$ @DRUG$ ,	DDI-false
In clinical studies with , of ( @DRUG$ ) , inhibitors ( acetylsalicylic acid ) , ( ) and @DRUG$ did	DDI-false
@DRUG$ Steady-state concentrations of 56 % higher 8 @DRUG$ was coadministered with each dose ( 15 ) neurocysticercosis	DDI-false
@DRUG$: @DRUG$ may diminish adrenal suppression by corticosteroids.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Co-medications that ( dexamethasone , , @DRUG$ , @DRUG$ or St.	DDI-false
In a study in which patients active up to concurrent @DRUG$ and therapy , % rate serious observed which was that with @DRUG$ alone 0 ) .	DDI-false
@DRUG$ In healthy given doses and , @DRUG$ mean cmax AUC increased by an % % , respectively and mean decreased 14 % .	DDI-false
@DRUG$ with theophylline , acetaminophen , acid with @DRUG$ toxic concentrations	DDI-false
apomorphine - of @DRUG$ decrease the @DRUG$ apomorphine the	DDI-false
The action of by drugs nonsteroidal anti-inflammatory and other that are highly , @DRUG$ , , chloramphenicol , probenecid @DRUG$ , .	DDI-false
Concomitant use @DRUG$s may in the reduced absorption	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
interactions Keppra and other ( , , lamotrigine , @DRUG$ phenytoin @DRUG$ and the concentrations and these AEDs placebo-controlled clinical studies .	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	DDI-false
@DRUG$ drug interaction an @DRUG$ has not	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
1 hour starting the @DRUG$ @DRUG$ p.o .	DDI-false
include thiazides other , corticosteroids @DRUG$ , , estrogens , contraceptives phenytoin , @DRUG$	DDI-false
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as @DRUG$.	DDI-false
In with @DRUG$ , the concomitant use of oral anticoagulants ( , platelet ( acid , piroxicam and @DRUG$ did significantly affect pharmacokinetics/pharmacodynamics sodium .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
To of HAART course of with , non-Hodgkin HIV-NHL retrospectively group 24 with HIV-NHL who treated the cyclophosphamide doxorubicin , vincristine , and prednisone ( chemotherapy plus HAART a group were treated with CHOP a CHOP-like regimen i.e. , and @DRUG$ bleomycin ) without @DRUG$	DDI-false
drug may interact with @DRUG$ or depressants ( potentiate the effects these @DRUG$ anticholinergics other medications with anticholinergic activity ( may when these are used concurrently antihistamines monoamine ) with antihistamines intensify the anticholinergic antihistamines	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
While @DRUG$ ibogaine for and receptors , @DRUG$ has much affinities and sigma-2 receptors channels , the 5-HT .	DDI-false
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ , , @DRUG$ terodiline .	DDI-false
These include the thiazides and diuretics , , phenothiazines thyroid products @DRUG$ , phenytoin , nicotinic acid sympathomimetics channel drugs , and	DDI-false
@DRUG$ ( @DRUG$ also have this .	DDI-false
@DRUG$ renal and @DRUG$ plasma .	DDI-mechanism
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Antiarrhythmics antiarrhythmic , as quinidine , procainamide , @DRUG$ , used concurrently @DRUG$.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
INOmax has been administered with @DRUG$, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
@DRUG$ @DRUG$-induced increases	DDI-effect
Hormonal contraceptives Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
Antacid @DRUG$ is approximately 25 when magnesium/aluminum-containing antacid products	DDI-false
Nephrotoxic Concomitant administration of @DRUG$ and agents potential e.g. , intravenous e.g. , @DRUG$ , , amphotericin , , intravenous vancomycin , agents contraindicated .	DDI-advise
Corticosteroids , Methylxanthines Diuretics : treatment , @DRUG$ or @DRUG$ may a possible hypokalemic effect   beta2-agonists	DDI-false
Fenfluramine may slightly the @DRUG$ e.g. @DRUG$ , methyldopa , .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-false
between , a of CYP3A4 , and @DRUG$ @DRUG$ indinavir , and ) substrates of CYP3A4 have evaluated in clinical trials	DDI-false
@DRUG$ The anorectic of @DRUG$ may by carbonate	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.	DDI-false
glucocorticoids have been shown reduce PROLEUKIN-induced side fever , insufficiency , , dyspnea , concomitant administration with reduce the antitumor of @DRUG$ thus avoided . @DRUG$ antihypertensives may hypotension .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Antacids clinical pharmacology coadministration of @DRUG$ aluminum hydroxide , magnesium hydroxide , and ) with reduced levels urinary of @DRUG$ fosinopril alone , may fosinopril .	DDI-false
Lithium Increased serum and have been reported @DRUG$ and @DRUG$ therapy .	DDI-effect
@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
When @DRUG$ was coadministered with phenytoin , , or H2antagonists , plasma of @DRUG$ were	DDI-false
Benzthiazide interact alcohol , thinners decongestant drugs ( allergy , and medicines , diabetic @DRUG$ @DRUG$ NSAIDs like Ibuprofen , high medications .	DDI-false
However crossover healthy subjects @DRUG$ . or mg a b.i.d . dosage of theophylline @DRUG$ , Key , ) alteration theophylline 800 mg h.s . regimen particularly aged years and older .	DDI-mechanism
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
, such @DRUG$ and , clonazepam , plasma @DRUG$ levels	DDI-false
@DRUG$ be discontinued at least prior cautious initiation of with @DRUG$.	DDI-advise
@DRUG$ should be with caution   -receptor blocking agents ( a or antagonists @DRUG$ , substrate , CYP3A4 inhibitor of the possible potentiation bradycardia , arrest , and AV	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Caution should be an HMG-CoA reductase is administered concomitantly with that may decrease the endogenous hormones @DRUG$ and	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-mechanism
In @DRUG$ tolerance in dogs with , Innovar , or pentobarbital , dosage of @DRUG$ needed to ventricular tachycardia as the LD50 of with Innovar with pentobarbital .	DDI-false
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating @DRUG$ and @DRUG$, respectively.	DDI-false
@DRUG$ lower @DRUG$ levels , by	DDI-mechanism
Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, @DRUG$ and antipyrine.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Prostatic in a medium consisting basal @DRUG$ 1 @DRUG$ ( ng/ml ) and 3.7 micrograms/ml or .	DDI-false
, lidocaine/quinidine phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/@DRUG$ .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other may enhance blocking action of nondepolarizing NUROMAX include certain antibiotics ( e. g. , @DRUG$ , bacitracin @DRUG$ clindamycin colistin , and sodium ) , magnesium , anesthetics , procainamide , quinidine	DDI-false
Antiacid @DRUG$ , @DRUG$ Phenytoin , Phenobarbitol , carbamazepine , Rifampin Saquinavir .	DDI-false
@DRUG$-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
@DRUG$ @DRUG$ ( using experimental capsule formulation 1200 mg ) with VIRACEPT resulted an 18 % AUC in plasma	DDI-false
Other concomitant Although interaction studies were not , mg or were used studies acetylsalicylic a-blockers , analgesics inhibitors , benzodiazepines blockers @DRUG$ @DRUG$ antagonists reductase ( also referred and clinically .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	DDI-false
@DRUG$ : @DRUG$ may given , TRICOR hours after bile acid binding to impeding absorption	DDI-false
Dopamine Since @DRUG$ dopamine agonist , is dopamine antagonists such the @DRUG$ , thioxanthenes ) or , may diminish the effectiveness of	DDI-false
@DRUG$ and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)	DDI-advise
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of @DRUG$.	DDI-false
drugs other diuretics @DRUG$ , thyroid @DRUG$ , oral contraceptives , phenytoin , acid calcium channel blocking , and isoniazid	DDI-false
serum @DRUG$ have been reported use cyclosporine	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
- steroids ( nandrolone @DRUG$ [ , ] oxymetholone , , @DRUG$ e.g. Winstrol or	DDI-false
@DRUG$: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ may with @DRUG$ causing increased	DDI-effect
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
necessary using ROMAZICON in cases of drug overdosage the ( cardiac dysrhythmias of drugs taken in overdose ( antidepressants ) may emerge the reversal @DRUG$	DDI-false
Example antifungals @DRUG$ , clarithromycin , , , , imatinib , isoniazid nefazodone nicardipine propofol , @DRUG$.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
@DRUG$ , @DRUG$ , Diclofenac like other NSAIDs , affect prostaglandins the of certain .	DDI-false
which CYP 3A4 e.g. , @DRUG$ , @DRUG$ erythromycin the potential plasma concentrations of corticosteroids	DDI-false
@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-false
Additionally @DRUG$ @DRUG$ reflecting the absence role CYP2D6 in s metabolism .	DDI-false
Sedatives/@DRUG$ @DRUG$ , midazolam CONTRAINDICATED due for serious life-threatening or sedation respiratory	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing @DRUG$.	DDI-false
The possibility of effects with @DRUG$ by either discontinuing the @DRUG$ the intake prior initiation of	DDI-effect
Therefore , @DRUG$ agents concomitantly , patient should be observed closely to if the desired effect the @DRUG$ .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
in studies benzodiazepines other suggest a drug interaction the following @DRUG$ , cyclosporine amiodarone @DRUG$ and nifedipine	DDI-false
The examples the blood-glucose-lowering effect corticosteroids niacin , danazol , , sympathomimetic , @DRUG$ @DRUG$ ) , phenothiazine , , hormones progestogens e.g. , in contraceptives )	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of @DRUG$ with @DRUG$ resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.	DDI-false
of @DRUG$ agents neuromuscular transmission @DRUG$ should only with caution toxin may	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine.	DDI-false
For , @DRUG$ are with @DRUG$ prothrombin time should be carefully and if dosage of vitamin antagonists should	DDI-advise
@DRUG$ @DRUG$ may blood concentrations , dosage may be required .	DDI-false
that have been associated peripheral neuropathy antiretroviral nucleoside , cisplatin dapsone , disulfiram , , glutethimide , gold isoniazid @DRUG$ @DRUG$	DDI-false
performed with the use of oral warfarin ) @DRUG$ ) , NSAIDs ( piroxicam , and @DRUG$ the pharmacokinetics/pharmacodynamics	DDI-false
@DRUG$/@DRUG$ : Pharmacokinetic drug-drug interactions have not demonstrated Argatroban concomitantly administered given 26 2 hours prior initiation Argatroban 1 g/kg/min hours or ( 6 0 prior to and 6 and 12 to , 1.5 g/kg/min . over 18 hours .	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	DDI-false
Drugs with peripheral include antiretroviral nucleoside analogues chloramphenicol @DRUG$ , , gold @DRUG$ , iodoquinol , phenytoin and .	DDI-false
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
of @DRUG$ ( mg BID ( day 1 ) 40 ( 7 ) ) with glyburide ( 10 mg BID in % increase @DRUG$ 12 a 16 glyburide Cmax % decrease in glucose -	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Consequently should receiving @DRUG$ and @DRUG$ are very .	DDI-false
Therapeutic , @DRUG$ , @DRUG$ , phenytoin andtolbutamide alter ketorolac tromethamine protein	DDI-false
concomitant therapies clinical trials , the profile with @DRUG$ anxiolytics , @DRUG$ and ( benzodiazepines , or non-opioid was similar to that of taking placebo with these medications	DDI-false
Coadministration @DRUG$ ( 40 mg BID 1 ) 40 mg 7 ) with glyburide ( mg QD ) affect either the pharmacokinetics ( exposure ) or ( glucose and levels of @DRUG$.	DDI-false
@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and @DRUG$.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ and many are substrates for P450 2D6 ( @DRUG$ , phenothiazines 1C antiarrhythmics .	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ products containing or or be administered or , the of @DRUG$ , in urine of .	DDI-advise
These suggest that @DRUG$ retinyl and retinoids , of epithelium by of the of insulin @DRUG$.	DDI-effect
are of substances may blood-glucose-lowering : oral products , @DRUG$ , fibrates oxidase ( MAO , , salicylates , @DRUG$ sulfonamide antibiotics .	DDI-false
An additive hypotensive has been reported with combination of systemic @DRUG$ @DRUG$ therapy .	DDI-effect
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ had on the AUC zidovudine it significantly decreased @DRUG$ tmax and phosphorylated by 110 % .	DDI-mechanism
@DRUG$s and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
The extent to which SSRI-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
@DRUG$ : @DRUG$ had effect plasma concentrations of metabolite .	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg QD @DRUG$ has not been studied.	DDI-false
begin taking diclofenac or @DRUG$ other NSAID while @DRUG$ , or develop toxicity these drugs .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
concomitant Although specific not performed finasteride 1 or more in with acetaminophen acetylsalicylic analgesics enzyme ACE ) , , benzodiazepines @DRUG$ @DRUG$ , diuretics , antagonists inhibitors prostaglandin inhibitors ( also referred as NSAIDs , without evidence of .	DDI-false
on between neurotensin @DRUG$	DDI-false
Drug Interactions may interact some , ( @DRUG$ - Eproxindine @DRUG$ and additive antidepressants effect Tricyclic antidepressants	DDI-false
No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, @DRUG$, and midazolam have been demonstrated.	DDI-false
@DRUG$ a dopamine agonist it is possible , neuroleptics ( phenothiazines thioxanthenes , diminish the effectiveness	DDI-false
Therefore , administration of TRACLEER and @DRUG$ is contraindicated alternative @DRUG$ .	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
Results of sclerosis TYSABRI   @DRUG$ ( mcg IM weekly ) @DRUG$ were for of acetate	DDI-false
Epinephrine also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
While all the selective serotonin @DRUG$ ) , e.g. , citalopram escitalopram @DRUG$ , 2D6 may the extent inhibition .	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	DDI-false
Although studies have been , that mainly by CYP3A4 , channel blockers dapsone quinine , , , tacrolimus , cyclosporine , derivatives carbamazepine , @DRUG$ , @DRUG$ and ) have when coadministered with	DDI-false
Mixed Agonist/Antagonist Agonist/antagonist , , nalbuphine @DRUG$ buprenorphine ) should a who has received or course therapy a @DRUG$ such as .	DDI-false
, absolute @DRUG$-related number or @DRUG$ .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing antacids for at least 4 hours following @DRUG$ administration.	DDI-false
Tagamet , apparently effect microsomal has to of anticoagulants @DRUG$ propranolol , @DRUG$ certain , delaying elimination and increasing blood of these drugs .	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
concomitant therapy specific studies , @DRUG$ doses of 1 mg or more concomitantly in clinical with , acetylsalicylic , a-blockers , analgesics angiotensin-converting ( ACE ) inhibitors , @DRUG$ , benzodiazepines , blockers , cardiac , , H2 , prostaglandin ( referred to NSAIDs , of	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with @DRUG$ immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
@DRUG$ : serum @DRUG$ symptoms of toxicity been reported concomitant lithium ACE .	DDI-false
@DRUG$ inhibits the ERMBT, and rifampin and @DRUG$ are equipotent inducers of the ERMBT.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, @DRUG$ (10% decrease in binding), or warfarin.	DDI-false
that have been man include , propranolol @DRUG$ , @DRUG$ and no clinically meaningful .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The intravenously orally methylxanthines ( , @DRUG$ , @DRUG$ by patients receiving has not been completely	DDI-false
May interact with the following: cholestyramine, colestipol (use with @DRUG$ may prevent the @DRUG$ from working properly;	DDI-false
Potential interactions @DRUG$ , substrate CYP3A4 ( , @DRUG$ , , substrates and/or been evaluated .	DDI-false
@DRUG$ mg b.i.d co-administered with @DRUG$ resulted in vardenafil AUC 13-fold increase in vardenafil Cmax	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ slightly the effect of @DRUG$ guanethidine	DDI-effect
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of @DRUG$ (300 mg QID).	DDI-false
Other interactions: Vardenafil had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	DDI-false
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.	DDI-mechanism
Other @DRUG$ had no effect on @DRUG$.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or @DRUG$) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
@DRUG$: TORADOLIV/IM has been administered concurrently with @DRUG$ in several clinical trials of postoperative pain without evidence of adverse interactions.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
non-CYP3A4 substrate agent considered patients CYP3A4 inducers such as @DRUG$ , , @DRUG$ and phenobarbital	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, @DRUG$, @DRUG$) would be expected to behave similarly.	DDI-false
Benzylpenicillin , ampicillin , doxycycline , @DRUG$ , and @DRUG$ no in the protein binding diclofenac serum .	DDI-false
Indinavir : Coadministration of indinavir @DRUG$ resulted % increase nelfinavir and % increase in @DRUG$	DDI-false
@DRUG$ have blunt the hypotensive of clonidine . It the concurrent of these @DRUG$ in lead to interference the lowering effect	DDI-false
Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Slow-channel calcium blockers, such as @DRUG$, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Specific studies confirmed these with sevoflurane @DRUG$ , @DRUG$ alfentanil	DDI-false
Drug-Drug Between   @DRUG$ ( ) Phenytoin @DRUG$ mg effect on phenytoin with	DDI-false
These include and other phenothiazines thyroid products , @DRUG$ oral @DRUG$ phenytoin , , , channel .	DDI-false
containing chains of N-methylthiotetrazole , cefoperazone , @DRUG$ ) or methylthiadiazole cefazolin cause vitamin deficiency .	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ alcohol blood thinners decongestant ( allergy cold , and sinus medicines ) , drugs , @DRUG$ NSAIDs like or Ibuprofen , blood pressure .	DDI-int
After dosing interferon beta-1a @DRUG$   IM once ) @DRUG$   clearance approximately 30 % .	DDI-mechanism
The majority of in clinical received one or more of the concomitant with ORENCIA : MTX , NSAIDs corticosteroids , azathioprine @DRUG$ , @DRUG$ , , sulfasalazine , and anakinra .	DDI-false
of @DRUG$ the plasma concentrations @DRUG$ by 40 % .	DDI-mechanism
This might be explained by a blockade by @DRUG$ of the elimination of @DRUG$ by the liver.	DDI-mechanism
@DRUG$ or other containing iron or zinc , sucralfate not be administered of administration of norfloxacin , because they may with absorption resulting and of	DDI-false
@DRUG$: concurrent use may blunt the response to @DRUG$.	DDI-false
@DRUG$ interactions Trileptal other @DRUG$ were in .	DDI-false
@DRUG$ : @DRUG$ to cause osteoporosis .	DDI-false
do not indicate significant interaction TORADOL and @DRUG$ or @DRUG$ , of TORADOL taking anticoagulants be extremely should be closely .	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
the between @DRUG$ other potent inhibitors ( e.g. , itraconazole , ) has not been , to almotriptan may be expected @DRUG$ used concomitantly medications	DDI-false
@DRUG$ Oral Transdermal , and Contraceptives interaction study demonstrated that co-administration of hormonal produced average @DRUG$ 14 % ,	DDI-false
thiazides and @DRUG$ , phenothiazines products , contraceptives @DRUG$ channel drugs , .	DDI-false
@DRUG$ daily ) a increase in @DRUG$ and a 4-fold in co-administered with 5	DDI-mechanism
Other Drug No pharmacokinetic observed between and following , @DRUG$ , digoxin @DRUG$ , .	DDI-false
Contraceptives Oral Injectable , Transdermal @DRUG$ : study demonstrated that co-administration bosentan the @DRUG$ average decreases ethinyl estradiol and % respectively .	DDI-false
Multivalent Cation-Containing Products administration quinolone , ciprofloxacin , multivalent cation-containing products such as @DRUG$ or sucralfate VIDEX chewable/buffered tablets or containing , , @DRUG$ substantially decrease absorption ciprofloxacin resulting serum .	DDI-false
Other Drug Interactions : warfarin , digoxin @DRUG$ , and	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, @DRUG$, and phenobarbital.	DDI-false
acetaminophen/@DRUG$ lidocaine/quinidine , , phenobarbital/valproic acid , , , valproic acid/phenobarbital	DDI-false
reported interactions with @DRUG$ : @DRUG$ ( CYP3A4 in combination with amiodarone hypotension , bradycardia , cardiac output .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
In 12-week endoscopy study conducted patients there was difference in cumulative incidence of gastroduodenal ulcers low-dose ( enteric @DRUG$ VIOXX 25 daily , as compared @DRUG$ daily alone	DDI-false
A similar association less marked been suggested , @DRUG$ , phenytoin sodium , carbamazepine , @DRUG$ , with ampicillin tetracyclines	DDI-false
Non-selective inhibitors sulfate phenelzine and pargyline HC1 Concomitant use @DRUG$ and @DRUG$ may .	DDI-effect
of digoxin warfarin ibuprofen @DRUG$ , phenytoin andtolbutamide did not @DRUG$	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
- be with @DRUG$ ( such because reduce its clearance and a high risk @DRUG$ toxicity	DDI-false
Tagamet apparently an effect on microsomal , been reported reduce warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , @DRUG$ @DRUG$ , , lidocaine , , delaying blood levels of these drugs .	DDI-false
Warfarin: The effect of @DRUG$ on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ e.g. Antiminth ) @DRUG$ and together may effects	DDI-false
clinical study in healthy male volunteers ( ) human insulin before produced some attenuation in the concentration @DRUG$ time to peak and total @DRUG$ not significantly affected	DDI-false
In , @DRUG$ neither the @DRUG$ acid piroxicam , and digoxin nor the state	DDI-false
effect probenecid on @DRUG$ natriuresis due to a sodium but is probably to effect renal @DRUG$.	DDI-false
THE CONCOMITANT DRUGS CAN LEAD TO @DRUG$ INTOXICATION PRIOR A PATIENT @DRUG$ , BASELINE SERUM LEVEL SHOULD BE	DDI-false
@DRUG$: @DRUG$ are inhibited by amphetamines.	DDI-false
@DRUG$ plus @DRUG$ tolerated .	DDI-false
therapy specific studies were performed of 1 mg or concomitantly used in studies with acetaminophen , acetylsalicylic acid , @DRUG$ ( ACE , benzodiazepines blockers , calcium-channel blockers , nitrates H2 , HMG-CoA @DRUG$ also to ) , and quinolone anti-infectives without clinically significant interactions	DDI-false
@DRUG$ ( , @DRUG$ ( 30 mg/kg ) clonazepam , fluoxetine 20 mg/kg sertraline ) or vehicle .	DDI-false
Intermediate doses of @DRUG$ or @DRUG$ produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
Antacids In pharmacology , coadministration of ( hydroxide , and with @DRUG$ reduced excretion as compared with @DRUG$ administered alone that antacids impair absorption of	DDI-false
In pigeons, @DRUG$ did not systematically alter the effects of @DRUG$, (+)-NANM or PCP.	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with @DRUG$	DDI-advise
, @DRUG$ 10 and mg selective inhibitor produced a increase in maximal and a % in the under the plasma	DDI-false
trials used with @DRUG$ , @DRUG$ and oxygen . in patients with heart receiving furosemide or digoxin in whom therapy with initiated , oral for furosemide ( n = 23 ) = ) were % , on day therapy and had to baseline by 87	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ , @DRUG$ : significant digoxin , no significant effect plasma .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and @DRUG$.	DDI-false
Although specific , coadministration with drugs that are mainly by ( eg , calcium channel , disopyramide , , warfarin , tacrolimus , cyclosporine @DRUG$ , @DRUG$ , carbamazepine fentanyl alprazolam triazolam ) have elevated concentrations with saquinavir ;	DDI-false
a Phase trial doses @DRUG$ ( 110 mg/m2 ) cisplatin ( 50 mg/m2 ) given as infusions , when TAXOL with the alternate sequence ( @DRUG$ cisplatin	DDI-false
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
may with @DRUG$ , allergy , cold sinus medicines , , lithium norepinephrine like or , and high blood pressure	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , , quinidine/lidocaine , and	DDI-false
These drugs include the and other , , phenothiazines products , estrogens , oral @DRUG$ , @DRUG$ nicotinic calcium channel blocking , and isoniazid .	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with @DRUG$ or stavudine.	DDI-false
In a pharmacology study an @DRUG$ ( @DRUG$ , magnesium hydroxide simethicone ) serum levels urinary of compared fosinopril administered alone , that antacids may absorption	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
drug interactions Keppra   and other @DRUG$ ( , lamotrigine , @DRUG$ valproate also by the of during placebo-controlled .	DDI-false
are of that the blood-glucose-lowering niacin , agents e.g. , salbutamol , ) derivatives somatropin , thyroid @DRUG$ , @DRUG$ ( e.g. , oral )	DDI-false
Multivitamins or containing iron or @DRUG$ @DRUG$ sucralfate should not , hours of the administration of they may with absorption resulting and urine levels of .	DDI-false
@DRUG$ Patients @DRUG$ a diminished and live inhibition	DDI-false
possibility of hypotensive @DRUG$ minimized by discontinuing the or intake initiation of enalapril or @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
specific studies have not been , coadministration drugs are metabolized by CYP3A4 ( , blockers disopyramide quinine @DRUG$ , quinidine , warfarin , ergot , alfentanyl , and @DRUG$ may have concentrations	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, @DRUG$ salts and digoxin).	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
therapies In concomitantly and @DRUG$ including @DRUG$ , or was similar to of with concomitant	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
inhibitors , , @DRUG$ , , troleandomycin @DRUG$ ) be to behave	DDI-false
Zidovudine: There is no significant pharmacokinetic interaction between @DRUG$ and @DRUG$ which has been confirmed clinically.	DDI-false
Coadministration of @DRUG$ and drugs primarily metabolized by CYP3A (e.g., @DRUG$) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.	DDI-false
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-effect
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
@DRUG$ @DRUG$ beadministered nevirapine may the efficacy ofthe drug	DDI-advise
@DRUG$ 10 potentiated CNS-impairing effects of g/kg balance and reaction time after administration on digit test ( DSST ) , symbol copying test , and the variability of the divided attention test for 2.5 @DRUG$ .	DDI-false
Drugs Be With @DRUG$ , quinidine Antihistamines , terfenadine : ergot derivatives Antimycobacterial agents : midazolam @DRUG$ GI :	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
A similar association less marked been with @DRUG$ , phenylbutazone , phenytoin sodium , @DRUG$ , , with ampicillin tetracyclines .	DDI-false
in that the absorption of @DRUG$ as excretion is markedly even one hour	DDI-mechanism
addition under of sympatholytic medicinal products @DRUG$ , guanethidine and @DRUG$ the hypoglycemia be or	DDI-false
and/or antacids products containing ferrous ( @DRUG$ ) , preparations other cations Videx ( didanosine chewable/buffered pediatric powder oral be taken within or 2 hours .	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
Anticholinesterases (neostgmine, physostigmine), lignocaine, @DRUG$, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
Multivalent Concurrent of including , with as magnesium or aluminum , @DRUG$ tablets or pediatric powder , or @DRUG$ , , zinc substantially absorption , resulting urine levels considerably lower than desired .	DDI-false
@DRUG$ with blood , , ) , diabetic drugs , , NSAIDs like or @DRUG$ high blood pressure	DDI-int
The coadministration of @DRUG$ decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.	DDI-mechanism
following are examples of known to the metabolism of other related , presumably @DRUG$ , , @DRUG$ , isoniazide and some macrolide .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
clinically drug are expected and @DRUG$ trimethoprim/@DRUG$ , erythromycin , or	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$ stimulate @DRUG$- or insulin-induced prostatic epithelium	DDI-effect
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-effect
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
drugs which may enhance neuromuscular action nondepolarizing agents such include @DRUG$ ( , tetracyclines , @DRUG$ polymyxins lincomycin clindamycin , colistin sodium colistimethate , lithium , local anesthetics , , and .	DDI-false
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral @DRUG$ in the presence of @DRUG$ that necessitated changes in the doses of such agents.	DDI-effect
Potential differences in @DRUG$ and pharmacokinetics different @DRUG$ ANOVA .	DDI-false
The are examples of may reduce the blood-glucose-lowering effect : @DRUG$ , diuretics , sympathomimetic ( @DRUG$ , terbutaline phenothiazine somatropin thyroid hormones progestogens ( e.g. in oral contraceptives ) .	DDI-false
@DRUG$/@DRUG$	DDI-false
@DRUG$ may , blood thinners drugs allergy cold , sinus medicines , diabetic drugs , , norepinephrine , NSAIDs @DRUG$ Ibuprofen , blood .	DDI-int
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$ @DRUG$ a 3A4 substrate	DDI-false
possibility of with @DRUG$ minimized by either discontinuing or the intake initiation treatment with	DDI-false
, a @DRUG$ and has to cause decreased serum of @DRUG$ increased prothrombin-proconvertin concentrations	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ effects with depressants hypnotics , @DRUG$ tranquilizers etc )	DDI-effect
interactions occur concomitant use Antizol and that increase cytochrome P450 system ( , @DRUG$ @DRUG$ , though this has	DDI-false
Aspirin: Concomitant administration of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
dosing is required efficacy @DRUG$ future on investigation chronic in combination with	DDI-false
Nervous System Depressants concomitant use of fentanyl transdermal , but to other @DRUG$ , sedatives , hypnotics , e.g. , benzodiazepines ) , general , muscle @DRUG$ , respiratory depression , result coma death .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
of be by nonsteroidal agents and drugs that are protein bound , salicylates , @DRUG$ @DRUG$ , and agents .	DDI-false
however , affected duration suggesting that @DRUG$ with HEXALEN	DDI-advise
Although interaction were not performed , finasteride mg or more were concomitantly in clinical with acetaminophen acetylsalicylic acid a-blockers , @DRUG$ , ACE , anticonvulsants , beta blockers , blockers nitrates , @DRUG$ antagonists , reductase prostaglandin inhibitors ( also to as NSAIDs ) , quinolone evidence significant interactions .	DDI-false
Coingestion of @DRUG$ with theophylline, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
indinavir : Upon administration of 5 of @DRUG$ 600 @DRUG$ , the and AUC of were reduced by 20	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
, , oxacillin , , and @DRUG$ have on the @DRUG$ human serum	DDI-false
injection of @DRUG$ ( @DRUG$ ) observed by locomotor activity behavior	DDI-false
Drugs Should Be Coadministered VIRACEPT : amiodarone , @DRUG$ Antihistamines : : ergot Antimycobacterial : @DRUG$ , agents	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and @DRUG$.	DDI-effect
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Reports @DRUG$ diminish the @DRUG$ ,	DDI-effect
Concurrent administration of @DRUG$ for of to @DRUG$ cause , persistent hypertension cerebrovascular	DDI-effect
@DRUG$ overdose a @DRUG$ assay	DDI-false
Patients receiving high doses of salicylates concomitantly with @DRUG$, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	DDI-false
Plasma valproate concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ and Losartan Bosentan has interactions with digoxin @DRUG$ , losartan significant effect on of .	DDI-false
Magnesium- and/or antacids , products containing ferrous sulfate iron @DRUG$ containing or metal , or Videx ( didanosine ) chewable/buffered tablets for solution should not be taken within before or 2 hours after FACTIVE .	DDI-false
When was coadministered @DRUG$ , or H2antagonists , concentrations @DRUG$ reported .	DDI-false
Although studies , with drugs that by , calcium channel blockers @DRUG$ , quinidine @DRUG$ , cyclosporine , ergot pimozide , carbamazepine , fentanyl alprazolam and elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Since animal action @DRUG$ be prolonged by therapy chlorpropamide , @DRUG$ should be .	DDI-false
In single and multiple dose studies in healthy subjects receiving both @DRUG$ and @DRUG$, prothrombin time (measured as INR) was increased by approximately 8% to 11%.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
the of to the effects @DRUG$ 100 than required antagonize the effects @DRUG$.	DDI-false
include the thiazides diuretics , , products , @DRUG$ , contraceptives @DRUG$ isoniazid	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion.	DDI-effect
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Ketoconazole (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	DDI-false
@DRUG$ : reduced the @DRUG$ response to furosemide in normovolemic healthy by approximately 20 % mean urinary output decreased 17 % .	DDI-false
In a comparison @DRUG$ tolerance with ketamine , pentobarbital , ouabain to tachycardia significantly higher , as was LD50 ouabain Innovar	DDI-false
@DRUG$ containing magnesium trisilicate, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	DDI-false
Although specific studies been performed , coadministration with drugs metabolized by ( channel blockers , dapsone disopyramide , tacrolimus , @DRUG$ derivatives , pimozide , @DRUG$ , and elevated plasma saquinavir ;	DDI-false
Urinary alkalinizing agents acetazolamide @DRUG$ ) increase the species of the @DRUG$ molecule decreasing urinary excretion	DDI-mechanism
@DRUG$: Coadministration of eszopiclone 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	DDI-false
@DRUG$: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
CNS-Active Drugs @DRUG$: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and @DRUG$.	DDI-false
CYP3A4 ( e.g. , @DRUG$ , @DRUG$ or St.	DDI-false
@DRUG$ ( ) @DRUG$ InsP(3))-induced studied in rat megakaryocytes with the technique combination .	DDI-false
@DRUG$ : When @DRUG$ 10 or 20 mg either simultaneously or 6 hours a 10 mg dose , significant in a substantial number of	DDI-false
Therefore may need a @DRUG$ while @DRUG$.	DDI-advise
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Magnesium- and/or antacids , ferrous ( @DRUG$ , @DRUG$ zinc cations , didanosine ) chewable/buffered tablets the powder for oral solution should within hours 2	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including nortriptyline, when @DRUG$ has been administered in combination with these agents.	DDI-mechanism
Inhibitors SSRIs @DRUG$ ( e.g. fluoxetine , fluvoxamine sertraline rarely reported to weakness , , and incoordination coadministered @DRUG$.	DDI-effect
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ (0.375 mg q24h for 8 days).	DDI-false
Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
Hormonal contraceptives with @DRUG$ been shown the plasma concentrations the hormonal , @DRUG$ EE ) and	DDI-false
has tolazoline @DRUG$ @DRUG$ , surfactant , and high-frequency .	DDI-false
of @DRUG$ mg/kg egg e.w . ) @DRUG$ ( mg/kg . ) a 10 min significantly increased activation 17-day-old chick with .	DDI-effect
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Population revealed that @DRUG$ , , corticosteroids , and @DRUG$ not clearance	DDI-false
unlike @DRUG$ , @DRUG$ does affect for nondrug .	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
Antidepressants, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-effect
phenobarbital/acetaminophen , quinidine/lidocaine , and valproic	DDI-false
@DRUG$: Doxorubicin caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-false
In addition , results regression pharmacokinetic other clearance ( , , dexamethasone @DRUG$ with may result clinically reductions in @DRUG$ concentrations .	DDI-false
Before this tell your doctor or pharmacist of and nonprescription you use , of aminoglycosides ( e.g. , , B cyclosporine anti-inflammatory ( @DRUG$ , @DRUG$.	DDI-false
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, @DRUG$, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
Antiepileptic drugs: Potential interactions between @DRUG$ and other @DRUG$ were assessed in clinical studies.	DDI-false
Benzthiazide interact @DRUG$s , @DRUG$ ( allergy medicines ) , , norepinephrine , like or , high pressure	DDI-false
concomitant therapy interaction not , @DRUG$ mg or more concomitantly used in clinical acetaminophen acid a-blockers , ACE inhibitors anticonvulsants , beta blockers @DRUG$ diuretics , , reductase synthetase inhibitors and anti-infectives evidence of clinically significant interactions	DDI-false
The co-administration of @DRUG$ with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
should be caution patients @DRUG$ @DRUG$ , Wyeth-Ayerst Laboratories ) .	DDI-false
Although there is no documentation of such, a similar interaction between @DRUG$ and the @DRUG$ may occur.	DDI-false
Cardiovascular : Enalapril @DRUG$ adrenergic-blocking , , calcium-blocking , , @DRUG$ and evidence of significant interactions .	DDI-false
@DRUG$ has alcohol other CNS depressants @DRUG$ , tranquilizers etc ) .	DDI-effect
If intravenous @DRUG$ is required to treat Pneumocystis carinii pneumonia, treatment with @DRUG$ should be interrupted.	DDI-advise
When a @DRUG$ is added to the therapy of a patient receiving @DRUG$, an additional antihypertensive effect is usually observed.	DDI-effect
It has been reported studies indicate @DRUG$-induced anesthesia can be reversed @DRUG$.	DDI-effect
, interaction @DRUG$ propranolol have demonstrated fluvastatin plasma , and to patient chronically receiving @DRUG$ resulted no extent of digoxin to control .	DDI-false
@DRUG$: @DRUG$ decreases lithium renal clearance and increases lithium plasma levels.	DDI-false
nephrotoxic medications : aminoglycosides , @DRUG$ , @DRUG$ may for toxicity and should be with great	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Preliminary animal studies have shown that small quantities administered @DRUG$ enter primarily as , 1 to of magnitude than the usual @DRUG$ following	DDI-false
Patients receiving other narcotic anesthetics , , tranquilizers sedative-hypnotics @DRUG$ ( including @DRUG$ ) concomitantly with DILAUDID may exhibit additive	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
A two-way between hydantoin , @DRUG$ the has .	DDI-false
Although the pressor activity of @DRUG$ is very low compared to its antidiuretic activity, large doses of @DRUG$ Tablets should be used with other pressor agents only with careful patient monitoring.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	DDI-advise
Drug-Drug @DRUG$ And Other Antiepileptic ) Phenytoin   ( mg effect the pharmacokinetic of @DRUG$ refractory .	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
Co-administration of @DRUG$ with @DRUG$ has been shown to increase the mean half-life and the area under the concentration-time curve.	DDI-mechanism
@DRUG$ : Simvastatin ( @DRUG$ substrate ) amiodarone has been with of .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
The hypoglycemic sulfonylurea be by other drugs that protein bound , salicylates @DRUG$ inhibitors , @DRUG$.	DDI-false
acetaminophen/theophylline , , phenobarbital/acetaminophen phenobarbital/@DRUG$ , quinidine/lidocaine , @DRUG$/acetaminophen	DDI-false
: of , including @DRUG$ multivalent cation-containing such as magnesium or , chewable/buffered , products containing calcium , , or @DRUG$ may substantially of ciprofloxacin urine levels lower desired	DDI-mechanism
Results multiple @DRUG$ and concomitant beta-1a AVONEX   30 IM or inconclusive regard the need for dose the @DRUG$	DDI-false
with @DRUG$ , blood thinners drugs ( allergy , cold and medicines ) , diabetic , @DRUG$ , norepinephrine NSAIDs like Aleve or , and blood medications .	DDI-false
results that @DRUG$ retinyl , and possibly other glucocorticoids and retinoids , may the of prostate epithelium dose-dependent modification of @DRUG$ .	DDI-effect
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with @DRUG$ resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of @DRUG$.	DDI-false
of @DRUG$ is in the of	DDI-mechanism
Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide;	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Interactions may , @DRUG$ ( ): @DRUG$ could flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol : Flupenthixol cause CNS Tricyclic Tricyclic	DDI-false
@DRUG$-type and ) @DRUG$ response always in patients can serious or bleeding .	DDI-false
Cyclosporine @DRUG$ like NSAIDs , through effects renal cause changes in the of levels cyclosporine , , @DRUG$ .	DDI-mechanism
@DRUG$: The concomitant administration of ciprofloxacin with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
The are of may the blood-glucose-lowering , danazol @DRUG$ , @DRUG$ ( epinephrine , terbutaline , isoniazid , somatropin thyroid , estrogens ( , in oral .	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational @DRUG$, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
Valdecoxib 40 mg 7 days significant decreases in @DRUG$ serum clearance ( clearance higher serum exposure to @DRUG$ alone	DDI-false
Concomitant @DRUG$ with other @DRUG$ recommended	DDI-advise
The effect of orally ingested @DRUG$ @DRUG$ from milk the infant has not evaluated .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
of small effect half-life the @DRUG$ to extend half-life @DRUG$ not recommended	DDI-advise
Antacids clinical pharmacology study , coadministration an @DRUG$ aluminum hydroxide , @DRUG$ ) fosinopril reduced levels urinary as compared fosinopril administered alone suggesting that may impair fosinopril .	DDI-false
Nervous System : The concomitant use of   transdermal system with nervous system depressants , including but not limited to other opioids sedatives , @DRUG$ , tranquilizers ( e.g. benzodiazepines ) @DRUG$ , , and cause depression hypotension and profound sedation , or potentially death .	DDI-false
Serum @DRUG$ levels should be monitored frequently if INSPRA is administered concomitantly with @DRUG$.	DDI-false
To Levosimendan does interactions with @DRUG$ felodipine @DRUG$ , warfarin , isosorbide mononitrate carvedilol or itraconazole .	DDI-false
@DRUG$ : @DRUG$ the of veratrum alkaloids .	DDI-false
Benzthiazide interact with @DRUG$ , blood thinners , @DRUG$ ( allergy , cold , medicines ) , norepinephrine NSAIDs Ibuprofen and	DDI-false
Antacids a clinical pharmacology study , coadministration ( aluminum , magnesium and @DRUG$ ) @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as fosinopril , suggesting that antacids may impair fosinopril .	DDI-mechanism
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
@DRUG$ interfere the of a of @DRUG$.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Cyclopropane or @DRUG$ increase autonomic irritability may sensitize of @DRUG$ , such .	DDI-effect
treatment class is increased concurrent administration of @DRUG$ @DRUG$ , acid ) azole antifungals .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Magnesium- antacids , ferrous ( @DRUG$ or other metal , didanosine ) chewable/buffered tablets the pediatric powder for solution should not be taken within 3 hours before 2 @DRUG$.	DDI-advise
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-mechanism
Although neither @DRUG$ @DRUG$ the prostatic in containing transferrin they the effect of EGF and insulin	DDI-false
Hypersensitivity have been reported receiving combination sequential high dose PROLEUKIN and agents , dacarbazine , @DRUG$ , tamoxifen @DRUG$.	DDI-false
Depressants concomitant use ( transdermal system ) other nervous depressants but @DRUG$ sedatives , tranquilizers ( @DRUG$ general anesthetics , relaxants and , cause depression , sedation , potentially in coma or death .	DDI-false
Potential interactions between a substrate of CYP3A4 protease ( @DRUG$ @DRUG$ and , are of not evaluated in clinical trials .	DDI-false
the clinical of therapies , @DRUG$ , @DRUG$ and	DDI-false
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	DDI-effect
In case that @DRUG$ @DRUG$ higher doses of digoxin may be	DDI-advise
Indinavir : Coadministration with in an % increase in @DRUG$ 51 % in @DRUG$ plasma	DDI-false
@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
A increase @DRUG$/ritonavir 533/133 twice with isrecommended combination @DRUG$.	DDI-advise
In addition, @DRUG$ does not affect the in vitro glucuronidation of @DRUG$.	DDI-false
The the benzodiazepines may be by anticonvulsants antihistamines @DRUG$ @DRUG$ , monoamine oxidase inhibitors narcotics , phenothiazines psychotropic medications , produce depression .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Clonazepam Pharmacokinetics Other Clonazepam not appear @DRUG$ , carbamazepine , or	DDI-false
Metoclopramide is reduced ( approximately ) when @DRUG$ @DRUG$ are	DDI-mechanism
Use with @DRUG$: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and 5-fluorouracil.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
No Important Date does clinically important interactions captopril beta-blockers , felodipine , , warfarin @DRUG$ @DRUG$ ethanol or itraconazole	DDI-false
Other Although were not finasteride doses 1 mg or in clinical studies , angiotensin-converting enzyme ) inhibitors , , blockers , @DRUG$ , nitrates @DRUG$ , antagonists , reductase , prostaglandin inhibitors also and quinolone anti-infectives evidence of clinically adverse interactions	DDI-false
@DRUG$ warfarin @DRUG$ ,	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other Drugs : Drugs such as , @DRUG$ , , phenothiazines @DRUG$ tricyclic may be with QT-interval prolongation an risk .	DDI-false
1 received plus @DRUG$ days , cohort received @DRUG$ for days .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
of @DRUG$ @DRUG$ can result in of on	DDI-effect
other agents , it should be noted potentiating @DRUG$ such @DRUG$ , and	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The of benzodiazepines may by anticonvulsants , antihistamines @DRUG$ , narcotics , phenothiazines , @DRUG$ , that	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ : on of profound hypotension loss consciousness when @DRUG$ was administered ondansetron the use with of the 5HT3 antagonist ( including for example , dolasetron palonosetron and alosetron ) is contraindicated	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, @DRUG$, or other vasodilators.	DDI-effect
1 hour after starting the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
Certain endocrine tests be @DRUG$-containing	DDI-false
ECG changes and/or result administration of @DRUG$ as diuretics acutely @DRUG$ especially recommended dose the is exceeded .	DDI-effect
BACKGROUND : effects administration of and @DRUG$ ) @DRUG$ , on incidence intestinal adenocarcinomas induced azoxymethane ( AOM ) and the labeling cancers investigated in male Wistar .	DDI-false
Oral : @DRUG$ ( 40 mg BID induce the contraceptive norethindrone/@DRUG$ 1 mg /35 mcg .	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Other Drug Interactions : No interactions observed vardenafil : @DRUG$ , warfarin , digoxin	DDI-false
drugs which the blocking of as NUROMAX include antibiotics ( e. , aminoglycosides , polymyxins , , @DRUG$ colistin , and @DRUG$ , magnesium salts ,	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-advise
depressant drugs ( @DRUG$ , @DRUG$ , opioids and anesthetics have or effects with .	DDI-false
Interaction of @DRUG$ with Highly Protein Bound Drugs: In vitro data showed that @DRUG$ is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.	DDI-false
majority in clinical received or more of following with : @DRUG$ corticosteroids , TNF blocking , azathioprine chloroquine gold , @DRUG$ , and anakinra .	DDI-false
Dopamine dopamine agonist it is antagonists , such as ( phenothiazines , @DRUG$ @DRUG$ ) or , the effectiveness APOKYN	DDI-false
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
this , tell your of prescription you use of @DRUG$ , gentamicin ) , @DRUG$ cyclosporine anti-inflammatory drugs ( ibuprofen , vancomycin	DDI-false
have been peripheral neuropathy nucleoside analogues chloramphenicol dapsone , disulfiram , , glutethimide , @DRUG$ , iodoquinol @DRUG$ , nitrofurantoin , , , and vincristine	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
with Analgesics : analgesics eg pentazocine nalbuphine butorphanol , @DRUG$ ) NOT to a who has or is receiving @DRUG$ .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
@DRUG$ Etodolac has apparent when administered @DRUG$.	DDI-false
Diuretic agents reduce the renal clearance of @DRUG$ and add a high risk of @DRUG$ toxicity.	DDI-false
following substances that may the effect and susceptibility hypoglycemia oral products inhibitors disopyramide , @DRUG$ , , ( MAO , @DRUG$ e.g. octreotide	DDI-false
@DRUG$ addition patients taking valproate chronically had effect on , but significantly decreased @DRUG$ in from 96.3 to which in an of approximately in free .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	DDI-mechanism
Drug have shown that does have interactions @DRUG$ , @DRUG$ or .	DDI-false
@DRUG$ : is to slow of increase its serum levels @DRUG$ levels should be determined administration and of monitored and dosage adjustment the be	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
that been associated peripheral include antiretroviral , chloramphenicol , cisplatin dapsone , ethionamide gold hydralazine iodoquinol @DRUG$ , nitrofurantoin , @DRUG$ and vincristine .	DDI-false
interact with thyroid @DRUG$ , H2-antagonists , famotidine ranitidine , pump inhibitors ( e.g. ,	DDI-false
between almotriptan and other , ritonavir and @DRUG$ ) not studied , increased to almotriptan be when @DRUG$ is concomitantly with these .	DDI-advise
Drugs cause in gastric pH ( H2-receptor antagonists such as @DRUG$ or @DRUG$ ) may concentrations IRESSA therefore may efficacy .	DDI-false
However, caution should be used when administering @DRUG$ with @DRUG$ since these patients are at increased risk of bleeding complications.	DDI-advise
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Acidifying agents: @DRUG$ (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-mechanism
In studies performed with , the concomitant ( platelet inhibitors @DRUG$ ( ) and digoxin not significantly	DDI-false
changes may the administration of sparing as @DRUG$ can be acutely , when dose the @DRUG$ exceeded .	DDI-false
Drugs that associated with include , chloramphenicol , cisplatin , @DRUG$ , disulfiram , , gold @DRUG$ , iodoquinol isoniazid metronidazole , phenytoin , ribavirin , and vincristine .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
include , ciprofloxacin , diclofenac doxycycline , @DRUG$ isoniazid , @DRUG$ , nicardipine , protease inhibitors quinidine ,	DDI-false
@DRUG$ : administration of @DRUG$ may result an of GI ulceration or other compared of alone .	DDI-false
To the chemotherapy course of with , systemic , ( authors compared retrospectively group 24 were treated with , and prednisone ( chemotherapy regimen plus HAART a 80 who were treated with chemotherapy a ( @DRUG$ , prednisone vincristine plus @DRUG$ ) without antiretroviral .	DDI-false
- When @DRUG$ or @DRUG$ is used concurrently with resins ) , an of at least 2 should be the two , since the of Bezalip retard	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
@DRUG$ , , @DRUG$ , and valproic to human at therapeutic	DDI-false
clinical trials , with , diuretics , @DRUG$ , oral oxygen . in congestive heart failure receiving @DRUG$ whom therapy with , oral clearance values n = and ( = 30 ) decreased % 15 , respectively on second day therapy had	DDI-false
@DRUG$ The pharmacokinetics theophylline aminophylline mg/kg 20 minutes were @DRUG$ mg in subjects	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ @DRUG$ ' ) introduced demonstrated in treatment positive negative schizophrenia .	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to insulin or oral @DRUG$.	DDI-effect
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG-DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.	DDI-false
@DRUG$ Concurrent of @DRUG$ may meclofenamate sodium plasma levels possibly protein-binding	DDI-false
@DRUG$ : sulfoxide and cystic fluid increased about 2-fold ) in hydatid cyst treated with cimetidine ( mg/kg/day compared @DRUG$ ( mg/kg/day alone .	DDI-false
Lithium : Increased @DRUG$ levels of have been in receiving @DRUG$ and inhibitor .	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Interactions may between @DRUG$ and @DRUG$ non-steroidal anti-inflammatory as Allium and Ginkgo	DDI-int
Although plasma - of loratadine and/or @DRUG$ were @DRUG$ these in n study were no clinically in safety loratadine , as clinical , events	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, simvastatin).	DDI-mechanism
Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of @DRUG$ with itraconazole is contraindicated.	DDI-false
acetaminophen/theophylline phenobarbital/valproic acid , @DRUG$/lidocaine , @DRUG$/acetaminophen acid/phenobarbital .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
are examples of drugs metabolism of @DRUG$ of CYP3A : nefazodone , fluvoxamine , , @DRUG$ , some macrolide .	DDI-mechanism
@DRUG$ and Norethindrone Coadministration of VIRACEPT with OVCON-35 resulted in 47 decrease @DRUG$ and 18 %	DDI-false
: A study has administration of @DRUG$ and @DRUG$ may cause elevated of , and in instances a slight elimination of isoniazid	DDI-mechanism
In order to occurrence of severe hypersensitivity reactions , patients treated be premedicated @DRUG$ such as ) diphen-hydramine ( such cimetidine @DRUG$	DDI-false
@DRUG$: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine @DRUG$/acetaminophen , phenobarbital/valproic acid , theophylline/acetaminophen ,	DDI-false
In isolated a reversible , by a the serum creatinine level ) has been transplant patients receiving @DRUG$ therapy concomitant @DRUG$.	DDI-effect
astemizole, @DRUG$, @DRUG$, and terodiline.	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of @DRUG$ and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-mechanism
Antidepressants, @DRUG$: Amphetamines may enhance the activity of tricyclic or @DRUG$;	DDI-false
In studies indicate that ertapenem inhibit transport @DRUG$ or @DRUG$ and that ertapenem substrate for P-glycoprotein-mediated transport .	DDI-false
pharmacology , an antacid aluminum hydroxide , simethicone ) with fosinopril reduced serum and urinary excretion of @DRUG$ with administered alone , suggesting antacids of @DRUG$.	DDI-false
and/or aluminum-containing antacids containing sulfate ) , multivitamin containing other or ( ) chewable/buffered tablets or for should be taken 3 hours or hours after	DDI-advise
that been tested in include , @DRUG$ @DRUG$ warfarin clinically found	DDI-false
Numerous drug interactions are possible with some @DRUG$, such as @DRUG$ and phenytoin, which affect hepatic microsomal enzyme systems.	DDI-false
difference in the alone @DRUG$ @DRUG$ as measured	DDI-false
: Quinolones have enhance of the oral @DRUG$ @DRUG$	DDI-false
@DRUG$ may the effects of @DRUG$ , , other CNS depressants .	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
clinical trials , @DRUG$ used , @DRUG$ anticoagulants oral vasodilators , and supplemental oxygen a congestive heart failure or in whom therapy with FLOLAN apparent oral furosemide n 23 and = 30 ) were 13 % % , the of and had to baseline values day 87 .	DDI-false
known profiles significant drug expected between @DRUG$ , trimethoprim/sulfamethoxazole , clarithromycin erythromycin itraconazole or	DDI-false
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$.	DDI-mechanism
@DRUG$ a clinical , coadministration an @DRUG$ aluminum magnesium , simethicone ) fosinopril reduced excretion fosinoprilat as with fosinopril , suggesting antacids may impair absorption fosinopril .	DDI-false
Hypotension - on Therapy on @DRUG$ especially in whom was recently may occasionally experience an excessive after therapy with @DRUG$.	DDI-effect
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
drugs and diuretics , @DRUG$ products @DRUG$ , , nicotinic , sympathomimetics blocking , isoniazid .	DDI-false
In pharmacokinetics @DRUG$ coadministration with	DDI-false
Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
An interaction study @DRUG$ no clinically of @DRUG$ pharmacokinetics or anticoagulant	DDI-false
vivo drug-drug studies were @DRUG$ and inducers , that are ( as carbamazepine , phenytoin , rifampin , and @DRUG$ would decrease concentrations	DDI-mechanism
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	DDI-effect
effectiveness is reduced by drugs such as the anticonvulsants @DRUG$ carbamazepine , and barbiturates and @DRUG$ .	DDI-false
using this , tell your doctor pharmacist of and you may use : e.g. @DRUG$ , , , cyclosporine ( e.g. @DRUG$ ) , tacrolimus vancomycin	DDI-false
receiving of @DRUG$ blood and appropriate @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
have been performed with drugs that are mainly by CYP3A4 ( eg calcium dapsone , amiodarone , , warfarin @DRUG$ cyclosporine ergot pimozide , , fentanyl , , and @DRUG$ ) may have elevated plasma concentrations coadministered saquinavir	DDI-false
The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or @DRUG$ concentrations when compared to placebo.	DDI-false
@DRUG$ @DRUG$ : FORADIL should administered with extreme caution patients being treated oxidase because action the cardiovascular by these agents .	DDI-false
@DRUG$ (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, aminopyrine and @DRUG$.	DDI-false
It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing @DRUG$ for at least 4 hours following ethambutol administration.	DDI-false
the impact chemotherapy HAART on clinical course of , systemic HIV-NHL , authors compared retrospectively a of 24 patients with the doxorubicin @DRUG$ , prednisone ( CHOP regimen HAART with group of who were with CHOP chemotherapy or a regimen i.e. , , @DRUG$ teniposide , and with plus bleomycin receiving .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and @DRUG$.	DDI-false
Lithium : @DRUG$ been reported in @DRUG$ concomitantly drugs which elimination of sodium , inhibitors .	DDI-false
@DRUG$ increase of drugs e.g. , , methyldopa , @DRUG$.	DDI-effect
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ an study of rheumatoid patients did not effect @DRUG$.	DDI-false
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Verapamil: Coadministration of @DRUG$ and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-mechanism
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Additive adverse effects from blockade may when with other , @DRUG$ , , phenothiazines @DRUG$ antidepressants	DDI-false
, and @DRUG$ : has pharmacokinetic interactions with digoxin and @DRUG$ , and significant effect on of bosentan .	DDI-false
@DRUG$, such as verapamil, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
@DRUG$ may decrease vascular response to pressor drugs such as @DRUG$.	DDI-effect
In a Phase I trial using escalating TAXOL 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound TAXOL after @DRUG$ with the ie , TAXOL before @DRUG$ ) .	DDI-false
May interact with the following: @DRUG$, colestipol (use with thiazide diuretics may prevent the @DRUG$ from working properly;	DDI-false
Patients been @DRUG$ within to three prior to the administration @DRUG$ should receive dopamine HCl than ( 1/10 ) of the usual	DDI-advise
These include the other , , thyroid estrogens oral @DRUG$ phenytoin acid @DRUG$ , calcium channel blocking drugs	DDI-false
observed vardenafil the following drugs @DRUG$ warfarin , digoxin , @DRUG$ ranitidine	DDI-false
@DRUG$ antihypertensive action of @DRUG$ and similarly acting compounds	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although been coadministration are metabolized by ( eg , @DRUG$ , dapsone disopyramide , @DRUG$ , , , tacrolimus cyclosporine , , , alprazolam and ) have elevated concentrations saquinavir	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
@DRUG$ : Potential interactions @DRUG$ other in clinical studies	DDI-false
@DRUG$: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
Important Interactions To Date @DRUG$ not interactions captopril , beta-blockers , digoxin warfarin , isosorbide , carvedilol @DRUG$ or itraconazole .	DDI-false
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A: The initial step in @DRUG$ metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	DDI-false
Tagamet , apparently certain microsomal systems , has been to the metabolism @DRUG$ , phenytoin , @DRUG$ chlordiazepoxide diazepam , certain , delaying and increasing levels of these drugs	DDI-false
Test @DRUG$ may cause a serum the Digi-   RIA Kit for @DRUG$.	DDI-false
In clinical trials , was used digoxin , @DRUG$ , oral and a pharmacokinetic substudy congestive receiving furosemide therapy with FLOLAN was initiated , clearance values for ( n = digoxin ( n decreased 13 and % , on the day of therapy baseline by 87	DDI-false
antacids , containing @DRUG$ ( iron , preparations containing zinc or cations , didanosine tablets or pediatric powder oral solution within 3 before	DDI-advise
While the selective serotonin inhibitors ) e.g. , @DRUG$ @DRUG$ , and inhibit P450 2D6 vary the extent inhibition .	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
acetaminophen/@DRUG$ phenobarbital/valproic acid quinidine/lidocaine , valproic .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Corticosteroids and @DRUG$ Concomitant treatment with , @DRUG$ or diuretics may potentiate a possible hypokalemic of beta2-agonists	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
These thiazides diuretics , , phe-nothiazines , products estrogens , , @DRUG$ @DRUG$ , and	DDI-false
In addition, there was no pharmacodynamic interaction as a result of coadministration of @DRUG$ and @DRUG$ ER.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, @DRUG$, and @DRUG$.	DDI-false
A though less marked , suggested with , , @DRUG$ @DRUG$ and tetracyclines	DDI-false
of children prescribed @DRUG$ should alerted the concern asthma therapy , especially and overuse of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
who begin or who increase their dose or any NSAID @DRUG$ , @DRUG$ or may develop characteristics for these drugs	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
( e.g. Taking @DRUG$ and the	DDI-false
@DRUG$ Antidepressants administered with extreme caution with oxidase antidepressants because action @DRUG$ on the may be potentiated by these agents	DDI-false
@DRUG$ eg tubocurarine ) other drugs @DRUG$ decamethonium citrate blocking effect should with caution patients being M	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%.	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, @DRUG$ and antipyrine.	DDI-false
drugs which may neuromuscular blocking action nondepolarizing agents such antibiotics e. g. , aminoglycosides @DRUG$ , , polymyxins lincomycin , @DRUG$ colistin sodium , , local , procainamide .	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	DDI-false
Although there are no study data to evaluate the possibility, @DRUG$, including @DRUG$ and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other nephrotoxic medications: agents such as @DRUG$, cyclosporine, and @DRUG$ may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
@DRUG$ iodine excess may @DRUG$ and an of Carbimazole .	DDI-effect
concentrations @DRUG$ , , naproxen piroxicam @DRUG$ did alter ketorolac tromethamine .	DDI-false
: In groups of patients - study ) the concomitant @DRUG$ @DRUG$ , , prednisolone , digitoxin not the values diclofenac .	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, and nifedipine.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, @DRUG$, itraconazole or fluconazole.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : The use   fentanyl system ) with other central including but not limited to other , benzodiazepines ) anesthetics , phenothiazines , @DRUG$ , may cause , hypotension , profound coma or .	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, @DRUG$, carbamazepine, and phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.	DDI-false
@DRUG$ and Corticotropin (ACTH): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
The effects of @DRUG$ are antagonized by @DRUG$ such as caffeine and theophylline.	DDI-effect
Antidepressants, @DRUG$: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
@DRUG$, an inhibitor of P450 2C9, decreased active metabolite concentration and increased @DRUG$ concentration.	DDI-mechanism
healthy the pharmacokinetics of a 1-mg @DRUG$ administered NS were not by the coadministration a single 6-mg dose @DRUG$.	DDI-false
Concurrent of ( aminoglycosides myelotoxic , chemotherapy ) , cardiotoxic , @DRUG$ ) ( e.g. , @DRUG$ may increase toxicity in these organ .	DDI-effect
Other Agents: PRINIVIL has been used concomitantly with @DRUG$ and/or @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Isoflurane the muscle effect @DRUG$ notably @DRUG$ , MAC ( minimum concentration is reduced by concomitant N 2O .	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
@DRUG$ indinavir with in 83 @DRUG$ plasma AUC and 51 in indinavir plasma A.C.	DDI-false
Agents the coadministration of @DRUG$ in @DRUG$ concentrations of saquinavir .	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
, on @DRUG$ may @DRUG$ concentrations initiation of with FLOLAN , which may be significant patients to digoxin .	DDI-false
d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
effects dopamine are by beta-adrenergic , such as @DRUG$ and @DRUG$.	DDI-false
Dopamine apomorphine a @DRUG$ , it dopamine antagonists , as the neuroleptics phenothiazines , butyrophenones , ) or diminish effectiveness @DRUG$.	DDI-false
Concomitant use of @DRUG$ supplements and L-lysine may increase @DRUG$ absorption	DDI-false
- @DRUG$ ( e.g. @DRUG$ )	DDI-false
@DRUG$ Urinary excretion amphetamines , efficacy reduced by in @DRUG$ .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
antiarrhythmic , as @DRUG$ , procainamide , , @DRUG$ have concurrently with amiodarone	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Digoxin and @DRUG$ Bosentan has significant pharmacokinetic with and and @DRUG$ effect on plasma levels bosentan	DDI-false
@DRUG$ Receptor Infarction)- EPHESUS 3020 ( % ) 25 to 50 also received inhibitors or angiotensin receptor )	DDI-false
Drugs @DRUG$ effects @DRUG$ g/kg balance 1 ethanol and on the digit symbol ) symbol copying test and the component the test 2.5 hours after .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Serotonin Inhibitors ( @DRUG$ ): ( fluoxetine @DRUG$ ) rarely reported , , and 5-HT1	DDI-false
Drugs have associated with peripheral neuropathy include nucleoside , @DRUG$ , disulfiram , , gold , iodoquinol , phenytoin , @DRUG$ , and	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Drugs that have been peripheral neuropathy include nucleoside , @DRUG$ glutethimide gold , @DRUG$ iodoquinol , , metronidazole , nitrofurantoin , , ribavirin and .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
Additionally, @DRUG$ did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in @DRUG$ s metabolism.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, @DRUG$) should be considered.	DDI-false
Other Drugs groups of 7 - 10/interaction study , the of azathioprine gold , , @DRUG$ , doxycycline or digitoxin did affect the levels and	DDI-false
A similar association , though less marked has suggested with phenylbutazone , , @DRUG$ topiramate with @DRUG$ 72	DDI-false
@DRUG$: The effect of valdecoxib on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
Antidepressants, @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
Metformin : healthy of cephalexin and @DRUG$ metformin mean and increased of 34 % and % , respectively , @DRUG$ renal clearance by 14 % .	DDI-false
- @DRUG$ or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.	DDI-false
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
) and many that are for P450 ( many , phenothiazines , and the @DRUG$ @DRUG$ and flecainide )	DDI-false
No adjustment @DRUG$ , of @DRUG$ should .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
It is not whether @DRUG$ , such implants injectables , are adequate of @DRUG$ therapy	DDI-false
Effects GABITRIL on Antiepilepsy Drugs ( @DRUG$ ) : Phenytoin : @DRUG$ effect the steady-state plasma with	DDI-false
However , because quinolones have reported to enhance anticoagulant effects of @DRUG$ in the coagulation should closely a quinolone is @DRUG$ its derivatives	DDI-false
Coadministration of single, oral doses of @DRUG$ with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in @DRUG$s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-false
clinically important pharmacokinetic interactions when @DRUG$ with @DRUG$	DDI-false
@DRUG$ @DRUG$ : with b-blocking properties may the effect insulin and oral hypoglycemics	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-effect
@DRUG$ Lithium has been reported in patients receiving lithium sodium @DRUG$.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Analysis of the @DRUG$ following is rapid of @DRUG$ between Survanta and aqueous phase	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, @DRUG$, cimetidine, ketoconazole), though this has not been studied	DDI-false
In addition to interactions noted above ) oral impairs of phenytoin , @DRUG$ and @DRUG$.	DDI-false
INOmax has been administered with tolazoline, dopamine, dobutamine, @DRUG$, @DRUG$, and high-frequency ventilation.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Important To Levosimendan does have interactions with captopril beta-blockers , felodipine , @DRUG$ warfarin , @DRUG$ ethanol	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or @DRUG$.	DDI-false
A single dose of liquid @DRUG$ did not affect the C max or AUC of @DRUG$;	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
When Itraconazole was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
nor @DRUG$ affected the of prostatic epithelium in containing alone , they modify mitogenic @DRUG$ and .	DDI-effect
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
The AUC and Cmax of both ) ) isomers @DRUG$ by dosing of mg @DRUG$.	DDI-false
@DRUG$ , an effect certain microsomal enzyme systems been reported to of warfarin-type nifedipine , @DRUG$ diazepam certain tricyclic and metronidazole delaying elimination and increasing blood of these drugs	DDI-mechanism
@DRUG$: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
hypoglycemic of sulfonylureas may potentiated drugs including nonsteroidal and drugs are highly bound salicylates , sulfonamides , chloramphenicol probenecid , @DRUG$ and @DRUG$.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
When is with of drug , such efavirenz , phenytoin , @DRUG$ , or , use mg of @DRUG$ should considered	DDI-false
that may reduce effect : corticosteroids , , danazol , diuretics , @DRUG$ , epinephrine salbutamol isoniazid , , , estrogens @DRUG$ ( ,	DDI-false
Additive effects resulting cholinergic blockade when @DRUG$ is administered @DRUG$ , haloperidol , , oxidase ( MAO inhibitors , antidepressants or antihistamines	DDI-effect
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ : @DRUG$ may delay intestinal ethosuximide	DDI-false
Results of multiple patients taking @DRUG$   and concomitant @DRUG$ AVONEX   mcg once ) inconclusive dose adjustment the .	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
effects @DRUG$ @DRUG$ phencyclidine locomotion and in mice .	DDI-false
The effects of adenosine are antagonized by @DRUG$ such as caffeine and @DRUG$.	DDI-false
To determine effect on the distribution @DRUG$ the elimination and distribution cloxacillin in patients , kidney one with a partially renal , presence or @DRUG$.	DDI-false
studies indicate CYP3A4 isoform CYP1A2 isoform metabolism levobupivacaine to @DRUG$ and @DRUG$ , .	DDI-false
enhance of nondepolarizing as NUROMAX antibiotics ( e. , , bacitracin , @DRUG$ , , and ) , salts , local anesthetics @DRUG$ , .	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Expected changes in laboratory assessments of PT and INR were observed after @DRUG$ administration, but these changes were not affected by concomitant @DRUG$ administration.	DDI-false
These drugs the thiazides other , @DRUG$ thyroid products estrogens oral contraceptives , @DRUG$ , nicotinic sympathomimetics drugs , and isoniazid	DDI-false
Patients treated with @DRUG$ and @DRUG$ may monitored increases in INR and prothrombin time	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Other therapy specific not , of mg more used in clinical with acetaminophen , acetylsalicylic @DRUG$ anticonvulsants benzodiazepines , , calcium-channel blockers , diuretics , @DRUG$ HMG-CoA prostaglandin also as ) and clinically adverse .	DDI-false
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
adjustment @DRUG$ may be when with inhibitors , e.g. , paroxetine , fluoxetine and	DDI-advise
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
@DRUG$ ( e.g. , spironolactone triamterene , amiloride ) , @DRUG$ supplements substitutes lead serum .	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Therapeutic digoxin , , @DRUG$ , , piroxicam , @DRUG$ , phenytoin alter binding .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
This appears to be interaction this kind @DRUG$ , although coadministration of other drugs known to alter cardiac conduction , or beta-adrenergic blocking channel blockers H1-blocking agents @DRUG$ and phenothiazines ) might a prolongation of the QTc .	DDI-effect
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of @DRUG$ or @DRUG$ and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , @DRUG$ doxycycline , erythromycin , , nefazodone , , , protease quinidine , and verapamil	DDI-false
Although specific studies have not performed , coadministration with are calcium blockers , dapsone , , @DRUG$ , warfarin cyclosporine , derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam and triazolam may have coadministered ;	DDI-false
Haloperidol: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, @DRUG$, quinidine, clarithromycin or amoxicillin.	DDI-false
Adrenergic blockers @DRUG$ are inhibited by @DRUG$.	DDI-effect
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Sinus been with @DRUG$ ( CYP3A4 substrate ) @DRUG$.	DDI-false
Drugs CYP3A4 @DRUG$ is a of @DRUG$.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ : @DRUG$ ( guanethidine reserpine acid acid juices . ) of amphetamines .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
Potassium-sparing diuretics spironolactone , or @DRUG$ , or @DRUG$-containing salt substitutes serum potassium .	DDI-false
drug other gabapentin lamotrigine @DRUG$ , phenytoin , and ) were also assessed concentrations of levetiracetam and @DRUG$ during placebo-controlled .	DDI-false
@DRUG$ does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on @DRUG$, a drug with metabolism very sensitive to C.P.A. inhibition.	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
drug-drug interaction study the effect of ACZONE Gel combination with ( @DRUG$/@DRUG$ ( ) .	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	DDI-false
Data from in studies @DRUG$ than a possible drug interaction the : ergotamine , amiodarone , @DRUG$ , nifedipine .	DDI-int
Aminosalicylic acid may decrease the amount of digoxin (@DRUG$, @DRUG$) that gets absorbed into your body.	DDI-false
In patients ( 10/interaction study , the of azathioprine chloroquine , @DRUG$ , prednisolone , , @DRUG$ did the values of diclofenac	DDI-false
reports of hypotension and loss administered ondansetron of apomorphine with drugs 5HT3 antagonist class ( , example @DRUG$ , granisetron , palonosetron , and @DRUG$ is .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
who have @DRUG$ , doxapram may temporarily the effects	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with @DRUG$ or hydrochlorothiazide.	DDI-false
Although specific studies have been with drugs that are mainly by eg calcium blockers , @DRUG$ , quinine , , warfarin , ergot , pimozide , @DRUG$ , fentanyl alfentanyl , ) may elevated with	DDI-false
Contraceptives : @DRUG$ ( mg BID ) induce the of combination norethindrone/ethinyl 1 /35 , @DRUG$ )	DDI-false
Drugs that have peripheral antiretroviral nucleoside analogues , , ethionamide , glutethimide , hydralazine iodoquinol , , @DRUG$ nitrofurantoin , ribavirin , and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In clinical studies with @DRUG$ (@DRUG$, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
The concentrations of @DRUG$, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone.	DDI-false
- @DRUG$ : Indomethacin blunts the increases in urine volume sodium seen during treatment and inhibits in renin activity .	DDI-false
Urinary alkalinizing agents (acetazolamide, some @DRUG$) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	DDI-mechanism
Phenylbutazone : @DRUG$ causes increase about in free fraction	DDI-mechanism
No Important Interactions To Levosimendan does pharmacokinetic interactions @DRUG$ @DRUG$ , digoxin , isosorbide , carvedilol or itraconazole .	DDI-false
concomitant specific interaction studies were performed , finasteride doses mg or more concomitantly clinical studies acetaminophen , acid , a-blockers angiotensin-converting ( ACE ) inhibitors beta blockers @DRUG$ , nitrates , diuretics , H2 HMG-CoA reductase inhibitors prostaglandin ( also referred to as @DRUG$ ) , and anti-infectives of significant adverse interactions .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
It is advisable to check coagulation time within the first few days after the start and discontinuation of @DRUG$ therapy, with an appropriate adjustment of the @DRUG$ dose, if necessary.	DDI-advise
To chemotherapy plus HAART the clinical of patients with HIV-related , lymphoma ) authors compared retrospectively of 24 patients with treated , @DRUG$ , prednisone ( plus HAART a of 80 who with CHOP a ( cyclophosphamide , , @DRUG$ plus bleomycin without receiving antiretroviral	DDI-false
Quinolones, including norfloxacin, may enhance the effects of oral @DRUG$, including @DRUG$ or its derivatives or similar agents.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Drug @DRUG$ may with drugs , like oxidase inhibitors ( theoretically affect flupenthixol - Eproxindine Ethanol : CNS depression - Flupenthixol effect @DRUG$	DDI-false
@DRUG$ @DRUG$ can vitro antiviral of stavudine and zidovudine HIV	DDI-false
The are examples may blood-glucose-lowering : , niacin danazol diuretics , sympathomimetic epinephrine , salbutamol , isoniazid @DRUG$ , , @DRUG$ , progestogens e.g. ) .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
- @DRUG$ , @DRUG$ ) or	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
A possible interaction between glyburide and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
@DRUG$: Elevated carbamazepine levels have been reported in postmarketing experience when @DRUG$ is administered concomitantly.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
of @DRUG$ ( @DRUG$ InsP(3))-induced responses in rat bone marrow megakaryocytes patch-clamp whole-cell recording technique in combination fura-2 microfluorometry	DDI-false
, on certain microsomal enzyme systems , has been reported to reduce hepatic warfarin-type anticoagulants , phenytoin , propranolol chlordiazepoxide @DRUG$ , lidocaine , @DRUG$ and , thereby delaying elimination and increasing blood these .	DDI-false
Potential interactions and ( @DRUG$ , gabapentin lamotrigine , phenobarbital primidone and @DRUG$ also evaluating levetiracetam AEDs placebo-controlled	DDI-false
A similar association marked , been suggested with , @DRUG$ , @DRUG$ , carbamazepine , griseofulvin , possibly with ampicillin tetracyclines 72 .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Serum lithium levels should be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
pharmacokinetics @DRUG$ administered @DRUG$ were not affected the cimetidine QID	DDI-false
, would that a given at bedtime and @DRUG$ before the a decrease the @DRUG$.	DDI-false
Rifabutin: Coadministration of @DRUG$ and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-mechanism
have was patients taking @DRUG$ thiothixene @DRUG$ ) .	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to @DRUG$ alone.	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	DDI-mechanism
Pharmacokinetic studies have demonstrated that @DRUG$ and erythromycin significantly increased the systemic exposure of @DRUG$ and/or its major metabolites.	DDI-mechanism
@DRUG$ : Co-administration @DRUG$ 600 , a inducer of hepatic metabolism approximate 50 decrease in plasma .	DDI-false
Other Drug pharmacokinetic vardenafil and following drugs @DRUG$ @DRUG$ digoxin Maalox ,	DDI-false
Hypotension   Patients on @DRUG$ Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
levels related tricyclic have be the of hepatic inhibitors , @DRUG$ , fluoxetine by concomitant hepatic enzyme inducers ( e.g. , @DRUG$ , , and an may be anticipated	DDI-false
Other concomitant therapy specific were not , finasteride 1 mg more were used clinical studies with acetylsalicylic acid , a-blockers , analgesics ( ) inhibitors , @DRUG$ , , nitrates , @DRUG$ , H2 antagonists HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to NSAIDs and quinolone significant .	DDI-false
in vitro studies than @DRUG$ a possible drug for following @DRUG$ , , and nifedipine	DDI-int
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
aBased narcotic in treated with nevirapine and @DRUG$ and evidence decreased @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
May interact thyroid e.g. ) , products @DRUG$ , ( , , ) @DRUG$ ( , lansoprazole ) .	DDI-false
@DRUG$, such as @DRUG$, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Digoxin: @DRUG$ concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	DDI-false
In performed @DRUG$ , concomitant @DRUG$ warfarin platelet inhibitors ( acetylsalicylic ) , ( piroxicam and digoxin did affect pharmacokinetics/pharmacodynamics fondaparinux	DDI-false
: The combined administration bombesin @DRUG$ ) calcium channel blocker , on the of adenocarcinomas by @DRUG$ ) the intestinal investigated male Wistar rats	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Patients begin diclofenac who increase @DRUG$ dose other @DRUG$ taking digoxin cyclosporine may develop toxicity for these drugs	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
@DRUG$ eliminated FI produced intermediate doses @DRUG$ in pigeons but did the in FR responding produced doses of of NANM	DDI-effect
Antacids a pharmacology coadministration of an aluminum @DRUG$ , simethicone reduced and of @DRUG$ as compared with fosinopril administered alone , suggesting antacids may impair absorption .	DDI-false
Antidepressants (tricyclic), atropine or other @DRUG$, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Cardiac effects of dopamine are antagonized by @DRUG$, such as propranolol and @DRUG$.	DDI-false
terfenadine @DRUG$ in the unchanged @DRUG$ plasma ;	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, @DRUG$), though this has not been studied	DDI-false
Coadministration of the @DRUG$ q.d 3 resulted in approximately % increase the under the curve and maximal plasma	DDI-false
: clinical coadministration antacid ( aluminum hydroxide @DRUG$ and simethicone ) @DRUG$ reduced levels and of as with that impair of fosinopril	DDI-mechanism
action of be by certain drugs including @DRUG$ and that protein @DRUG$ , , , probenecid coumarins , inhibitors and adrenergic blocking agents	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
doses @DRUG$ ( mg result higher increases single 2.5 mg @DRUG$ not a 24-hour period when used combination ketoconazole mg	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ : The effect celecoxib anti-coagulant effect @DRUG$ studied a group of healthy receiving doses - mg of warfarin .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or @DRUG$ is impaired	DDI-false
The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.	DDI-false
Drug/Laboratory Test Interaction After treatment with @DRUG$, a false-positive reaction for glucose in the urine may occur with @DRUG$ tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.	DDI-false
therefore , @DRUG$ other used management of ) or vasodilator if discontinued starting	DDI-advise
drugs include @DRUG$ and other @DRUG$ , corticosteroids , , thyroid contraceptives , phenytoin , , drugs and	DDI-false
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either @DRUG$.	DDI-false
@DRUG$-Concomitant intake of and vitamin K may the of	DDI-false
Fondaparinux influenced the , @DRUG$ and @DRUG$ , nor the pharmacokinetics of digoxin	DDI-false
Antiacid , , Fluconazole , Fluoxetine Indanavir @DRUG$ Phenytoin Phenobarbitol Rifabutin , @DRUG$ ,	DDI-false
Conversely, the administration of @DRUG$ (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.	DDI-false
clarithromycin , @DRUG$ , , Indanavir , Phenytoin , Phenobarbitol , @DRUG$ , Rifampin Ritanovir	DDI-false
Concurrent of a @DRUG$ with @DRUG$ has been with increased of significant additional efficacy over antagonists .	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ may interfere with @DRUG$ ( i.e. , guanethidine )	DDI-int
Since @DRUG$ does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and @DRUG$.	DDI-false
Antihistamines: @DRUG$*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Chlorpromazine @DRUG$ blocks dopamine and norepinephrine thus inhibiting the of and can be used to @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
( @DRUG$ ): exposure of mg for 12 was by % when co-administered with mg for days ) of @DRUG$ ( CYP 3A4 inducer ) .	DDI-false
: @DRUG$ mg not affect of@DRUG$n , were any changes in profile ( prothrombin ) a 25 oral of	DDI-false
these results indicate a interaction between TORADOL and warfarin @DRUG$ , the of @DRUG$ to patients taking be done extremely , should closely .	DDI-false
There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.	DDI-false
@DRUG$ containing epinephrine or to patients receiving @DRUG$ or tricyclic antidepressants may produce prolonged .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
both dexamethasone retinyl acetate and possibly glucocorticoids , the of prostate modification the of @DRUG$ and @DRUG$.	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-mechanism
association marked been , @DRUG$ phenytoin , griseofulvin topiramate possibly with @DRUG$	DDI-false
Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with @DRUG$ demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
@DRUG$/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
@DRUG$/prednisolone : @DRUG$ not have any important the prednisolone prednisone .	DDI-false
Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	DDI-false
@DRUG$ and/or in indicate @DRUG$ , itraconazole , the of cisapride , can in in the QT interval on the ECG .	DDI-false
@DRUG$ reported a @DRUG$ clearance	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH @DRUG$.	DDI-false
ACE Inhibitors and @DRUG$ ( Congestive Post-Myocardial Infarction)- In EPHESUS , ( ) patients receiving @DRUG$ or angiotensin antagonists ( ACEI/ARB	DDI-false
Naproxen @DRUG$ naproxen in no effect on plasma levels @DRUG$ decreased the of	DDI-false
Administration of @DRUG$ concomitantly with shown decreases serum concentrations of @DRUG$ and .	DDI-false
@DRUG$ SHOULD BE EXERCISED WHEN @DRUG$ IN CONJUNCTION WITH TRICOR	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
interaction studies @DRUG$ have not demonstrated any on @DRUG$ plasma levels , administration to population chronically resulted difference extent bioavailability to control .	DDI-false
of several related tricyclic been reported be the of hepatic ( e.g. @DRUG$ , @DRUG$ ) decreased by the concomitant administration of hepatic enzyme , , and such an may anticipated with CMI as .	DDI-false
Acetaminophen , , @DRUG$ , @DRUG$ valproic acid were to at .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Tagamet on microsomal , has been reported metabolism @DRUG$ @DRUG$ propranolol , nifedipine , , diazepam , , lidocaine , blood these	DDI-false
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
@DRUG$ : In , @DRUG$ Cmax increased approximately % % respectively after co-administration of erythromycin , a known of cytochrome 3A4 .	DDI-false
this the @DRUG$ should reduced by 30 start of treatment with @DRUG$ or retard then according to clotting parameters	DDI-advise
of the @DRUG$ 600 mg 24 , for 14 days ) , reduced @DRUG$ and AUC 80 % .	DDI-mechanism
@DRUG$: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
Anticoagulants : warfarin-type ( @DRUG$ @DRUG$ substrate response almost in patients receiving amiodarone and result in serious	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
other @DRUG$ be noted be @DRUG$ and alcohol .	DDI-effect
FACTIVE had no significant on of @DRUG$ in on @DRUG$ .	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
of metabotropic mGluR ) , DCG-IV @DRUG$ on the behavioral by @DRUG$ were	DDI-false
The oral @DRUG$ significantly reduced by the administration @DRUG$ magnesium	DDI-mechanism
azole antifungals ciprofloxacin , @DRUG$ erythromycin imatinib , isoniazid , nicardipine @DRUG$ , protease , verapamil	DDI-false
Drugs With A Narrow Therapeutic Index Digoxin A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
Other Drugs : In small of patients ( ) of azathioprine , chloroquine , doxycycline , or @DRUG$ did not the levels and AUC	DDI-false
@DRUG$ @DRUG$ Diuretics : Concomitant with xanthine derivatives , , diuretics possible effect   .	DDI-false
action of benzodiazepines be potentiated by , antihistamines , @DRUG$ , barbiturates , monoamine oxidase inhibitors , narcotics , @DRUG$ , psychotropic or other drugs that produce depression	DDI-false
Tagamet systems been reported to reduce the hepatic metabolism , phenytoin , @DRUG$ diazepam tricyclic , lidocaine @DRUG$ , and increasing blood levels of .	DDI-false
Other concomitant Although interaction studies were not of mg with acetaminophen acetylsalicylic acid , angiotensin-converting enzyme ACE ) inhibitors , , @DRUG$ blockers nitrates H2 antagonists , reductase prostaglandin synthetase inhibitors ( also referred to @DRUG$ ) and evidence of clinically interactions .	DDI-false
- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	DDI-advise
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
Therefore affecting sympathetic , @DRUG$ or @DRUG$ ) should caution	DDI-false
Hypersensitivity reactions been reported in patients receiving containing high dose @DRUG$ antineoplastic , , dacarbazine , cis-platinum , and	DDI-effect
addition @DRUG$ @DRUG$ induce a subgroup the ( CYP3A5 responsible for dihydropyridine calcium and , resulting a lower these drugs .	DDI-false
Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of @DRUG$.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Digoxin : When multiple @DRUG$ @DRUG$ coadministered plasma digoxin approximately 20 % .	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/@DRUG$-containing antacid products.	DDI-false
acetaminophen/theophylline phenobarbital/valproic , @DRUG$/lidocaine , and valproic	DDI-false
Anabolic [ , oxandrolone e.g. , Anavar ] oxymetholone e.g. , @DRUG$ stanozolol e.g. , @DRUG$ ) or	DDI-false
inhibitors include azole antifungals , @DRUG$ , erythromycin , imatinib nefazodone nicardipine @DRUG$ ,	DDI-false
@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
treatment inhibitors ( such ketoconazole , @DRUG$ , @DRUG$ , , , etc . ) is reduction of budesonide dose should be considered .	DDI-false
These the @DRUG$ , corticosteroids , phenothiazines , , , @DRUG$ , acid , , blocking drugs isoniazid .	DDI-false
@DRUG$ potentiates relaxant of all muscle notably @DRUG$ , MAC minimum concentration is administration of N 2O	DDI-effect
Drugs : such as quinidine , @DRUG$ , procainamide @DRUG$ , and associated with prolongation and risk of ventricular arrhythmia .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
To evaluate the clinical of patients with HIV-related , non-Hodgkin HIV-NHL , compared HIV-NHL who were treated cyclophosphamide , and prednisone ( CHOP ) chemotherapy plus HAART a group 80 who regimen ( , @DRUG$ @DRUG$ teniposide vincristine plus bleomycin ) antiretroviral .	DDI-false
, clarithromycin Fluconazole , , Indanavir , , Phenobarbitol , @DRUG$ Rifabutin @DRUG$ Ritanovir	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Interactions Mixed Agonist/Antagonist Opioid @DRUG$ eg pentazocine nalbuphine butorphanol , @DRUG$ be patient who or is a course of therapy with a pure agonist opioid analgesic Levo-Dromoran	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: @DRUG$ inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for @DRUG$ metabolism.	DDI-mechanism
The which @DRUG$-@DRUG$ interactions may on degree of and the the	DDI-int
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Enzyme , and Substrates : Drugs which ( CYP enzyme ( e.g. , phenytoin , @DRUG$ , rifampin ) may metabolism of @DRUG$ and that the the corticosteroid increased	DDI-mechanism
@DRUG$ be with drugs ( e.g. , @DRUG$ glycosides that the drugs .	DDI-advise
- Methotrexate (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
trials FLOLAN was used digoxin diuretics , oral vasodilators , supplemental In a in patients with congestive heart receiving @DRUG$ or digoxin @DRUG$ was initiated , oral for furosemide n 23 ) digoxin n decreased by % 15 % , respectively the of therapy had to values day	DDI-mechanism
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, carbamazepine, and @DRUG$.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
of @DRUG$ with Other Drugs : @DRUG$ ( 800 to patients tiagabine chronically had tiagabine pharmacokinetics	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, @DRUG$) should be considered.	DDI-false
@DRUG$ : concomitant naproxen in normal effect the of @DRUG$ , but significantly decreased of glucuronide metabolite	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with @DRUG$ or @DRUG$.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-false
In both species, (-)-NANM, but not @DRUG$, antagonized the rate-decreasing effects of @DRUG$ on FI and FR responding.	DDI-false
@DRUG$ should not taken hours @DRUG$.	DDI-advise
, lidocaine/quinidine , @DRUG$/valproic , , and valproic	DDI-false
@DRUG$ : The administration of diflunisal @DRUG$ renal clearance and significantly plasma levels of indomethacin	DDI-false
Antihypertensives @DRUG$ antagonize hypotensive	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Drug Interactions : with Monoamine oxidase MAOI @DRUG$ pharmacodynamics - Arecoline Eproxindine Ethanol : Flupenthixol and Ethanol cause CNS depression @DRUG$ the effect antidepressants	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
: The adverse were experienced more commonly patients concomitant @DRUG$ or @DRUG$ ( n 94 ) compared to not these ( n = ): 10 % 4 % , % 1 % , serious pneumonia 5 serious falls 9 3 and 6 % 2 % .	DDI-effect
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
@DRUG$ Ribavirin antagonize the in antiviral activity @DRUG$ zidovudine	DDI-false
@DRUG$ reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-mechanism
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
intensity , time anticoagulant @DRUG$ @DRUG$ , , chloral methaqualone were investigated in 16 .	DDI-false
of during treatment with this class increased with administration @DRUG$ , fibric acid ( @DRUG$ ) azole antifungals	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
concomitant specific were not performed , finasteride or more were used in studies with @DRUG$ , acetylsalicylic a-blockers @DRUG$ , angiotensin-converting enzyme ) inhibitors , anticonvulsants benzodiazepines , beta blockers cardiac nitrates , antagonists , reductase to as NSAIDs quinolone anti-infectives without evidence of clinically significant adverse .	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
interactions could concomitant administration @DRUG$ ( narcotics , @DRUG$ , , sedatives tranquilizers .	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as @DRUG$, opiates, and alcohol.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of CYP3A4 (enzyme induction).	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
In a digitalis with ketamine Innovar Vet was higher , as the @DRUG$ or @DRUG$ with .	DDI-false
Cohort 1 then received @DRUG$ plus @DRUG$ for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.	DDI-false
Other @DRUG$ (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
The similarity the TYSABRI -associated adverse between Study 1 ( co-administered @DRUG$ 2 ( AVONEX this alteration in clearance of @DRUG$ to , ) .	DDI-false
@DRUG$: @DRUG$*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
In pigeons, @DRUG$ did not systematically alter the effects of (-)-NANM, (+)-NANM or @DRUG$.	DDI-false
5HT3 Antagonists : reports of profound hypotension loss consciousness administered , concomitant of the @DRUG$ , @DRUG$ , , and alosetron ) is	DDI-false
Multivalent Products Concurrent administration a quinolone ciprofloxacin cation-containing such as @DRUG$ aluminum , chewable/buffered tablets , products , iron the absorption @DRUG$ , in serum and urine levels lower than	DDI-false
@DRUG$ @DRUG$ toxicity has been in lithium with drugs cause ,	DDI-false
@DRUG$ : , concomitant @DRUG$ hydrochlorothiazide increased levels of	DDI-false
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH @DRUG$.	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/@DRUG$.	DDI-false
These drugs and diuretics phenothiazines , , estrogens , @DRUG$ @DRUG$ , isoniazid .	DDI-false
acid decrease of digoxin ( @DRUG$ @DRUG$ ) gets into your body .	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ is co-administered with inducers , such as efavirenz nevirapine @DRUG$ , dexamethasone , , of a daily 70 mg CANCIDAS should be considered	DDI-advise
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
, drugs with a therapeutic margin such as K , @DRUG$ @DRUG$ , have delayed elimination and their leading to toxic level	DDI-false
Digoxin , @DRUG$ : has no pharmacokinetic digoxin and nimodipine losartan no of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
@DRUG$: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
DISCUSSION: @DRUG$ is a potent inhibitor of CYP3A4, the major enzyme responsible for @DRUG$ metabolism.	DDI-mechanism
Particular caution should be observed @DRUG$ since there are results for the effect colestipol hydrochloride on the digoxin and	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Data from vitro studies @DRUG$ suggest possible drug @DRUG$ for the following : .	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
The risk of a potential interaction between @DRUG$ and @DRUG$ concentrates has not been adequately evaluated in preclinical or clinical studies.	DDI-false
Although clinical studies have been cytochrome 3A family in @DRUG$ inhibitors of this enzyme system oral antifungal agents , should be used cautiously in receiving @DRUG$.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
While all the @DRUG$ (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis.	DDI-mechanism
Dopamine Since apomorphine is a @DRUG$ it is possible antagonists , phenothiazines , @DRUG$ , diminish APOKYN	DDI-false
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other Drugs In of patients ( 10/interaction study ) , concomitant administration azathioprine @DRUG$ @DRUG$ D-penicillamine , , or significantly affect the AUC values of	DDI-false
- @DRUG$ , oral diabetes of with @DRUG$ may the of the effects oral antidiabetics	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
: is moderately reduced ( ) when magnesium/@DRUG$-containing antacid products .	DDI-false
Drugs Inhibit or Induce Cytochrome 3A4 @DRUG$ extensive concomitant administration of of alter @DRUG$ concentrations	DDI-false
and/or antacids , @DRUG$ ) , preparations @DRUG$ other metal or Videx ( ) chewable/buffered tablets or should not taken 3 before or hours FACTIVE .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
That Alter Renal Excretion @DRUG$ : @DRUG$ is known to affect function alter the excretion other .	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
not that are mainly metabolized by ( eg , calcium @DRUG$ , disopyramide @DRUG$ , quinidine tacrolimus cyclosporine ergot carbamazepine , fentanyl , , and triazolam ) have elevated concentrations with saquinavir	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Thioridazine : Coadministration of single @DRUG$ 20 mg and @DRUG$ effects on impaired psychomotor performance for 2 .	DDI-effect
Glyburide with the @DRUG$ @DRUG$ has rare , resulted in severe	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antacid : Absorption zalcitabine ( approximately 25 % coadministered with @DRUG$/@DRUG$-containing antacid .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
MAO inhibitors MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	DDI-mechanism
agents of agents with e.g. intravenous aminoglycosides ( e.g. tobramycin , and @DRUG$ amphotericin foscarnet , intravenous vancomycin , @DRUG$ ]	DDI-false
, , @DRUG$ @DRUG$ doxycycline , cephalothin , and sulfamethoxazole have on the binding of diclofenac in serum .	DDI-false
If it is necessary to @DRUG$ initiate therapy with @DRUG$ a dose mg , close after the initial dose until pressure has .	DDI-advise
Plasma ( AUC 0 24 ) @DRUG$ decreased 15 coadministration @DRUG$ relative to observed with erythromycin .	DDI-mechanism
have not performed , drugs that are metabolized CYP3A4 eg calcium channel blockers , dapsone , , @DRUG$ , , , warfarin , derivatives , pimozide , @DRUG$ , alfentanyl and have elevated plasma when coadministered with ;	DDI-false
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
Effect Clonazepam the of Other Drugs : @DRUG$ does not appear to the pharmacokinetics of phenytoin , @DRUG$ ,	DDI-false
drugs include the and other @DRUG$ , corticosteroids phe-nothiazines @DRUG$ estrogens oral contraceptives , phenytoin nicotinic acid , , calcium drugs , and isoniazid	DDI-false
Therefore, patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ therapy is indicated.	DDI-advise
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Ketoconazole ( once daily ) produced a 10-fold increase @DRUG$ a 4-fold increase @DRUG$ ( 5 mg ) healthy .	DDI-false
No Interactions To Date @DRUG$ have clinically interactions , @DRUG$ , felodipine , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
That Should Not Be Coadministered Antiarrhythmics : , Antihistamines : terfenadine @DRUG$ @DRUG$ : rifampin , GI agents :	DDI-false
@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2.	DDI-false
been performed , coadministration drugs that are CYP3A4 ( calcium blockers , dapsone quinine , @DRUG$ , tacrolimus cyclosporine , ergot , , carbamazepine , @DRUG$ alfentanyl , and plasma concentrations when coadministered with saquinavir ;	DDI-false
This interact with alcohol or other @DRUG$ ( may CNS depressant these or ) , anticholinergics other medications with anticholinergic activity be these medications used concurrently with antihistamines ) , and @DRUG$ concurrent antihistamines may prolong depressant effects of antihistamines	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	DDI-false
studies confirmed these with @DRUG$ , @DRUG$ , , alfentanil , and midazolam .	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, @DRUG$, thioxanthines, or metoclopramide.	DDI-false
Other such as , procainamide @DRUG$ @DRUG$ may associated with an increased .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
The following of drugs benzodiazepines , presumably inhibition of CYP3A : nefazodone @DRUG$ @DRUG$ diltiazem , and some antibiotics .	DDI-false
convulsions reported @DRUG$ is administered with @DRUG$ care should be the regimen these drugs	DDI-effect
- Methotrexate (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
general these drugs that or pharmacologic hydrochloride including agents as quinidine and @DRUG$ @DRUG$.	DDI-false
: @DRUG$ is agonist possible that dopamine such as @DRUG$ , ) APOKYN .	DDI-false
Omeprazole : @DRUG$ was when @DRUG$ given when Proquin XR was hours omeprazole the that gastric .	DDI-false
Pharmacokinetic Interaction between amprenavir and @DRUG$ or @DRUG$ in healthy males.	DDI-false
@DRUG$-based regimens may have several advantages over @DRUG$-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including @DRUG$, when @DRUG$ has been administered in combination with these agents.	DDI-mechanism
Digoxin Losartan : interactions @DRUG$ , and @DRUG$ has no on	DDI-false
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, @DRUG$ and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
vitro differently and does @DRUG$ or @DRUG$.	DDI-false
the thiazides @DRUG$ , corticosteroids , thyroid , estrogens oral phenytoin , nicotinic acid sympathomimetics	DDI-false
steroids nandrolone Anabolin ] , [ Anavar oxymetholone [ e.g. , @DRUG$ , @DRUG$ [ e.g. , Winstrol ) or	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or @DRUG$.	DDI-false
Patients receiving other @DRUG$s, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ : no pharmacokinetic with @DRUG$.	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with @DRUG$, PEGASYS treatment did not affect ribavirin distribution or clearance.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
@DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-effect
Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	DDI-false
@DRUG$ serum monitored closely or therapy with @DRUG$ lithium	DDI-false
Since suggest that the @DRUG$ may be therapy @DRUG$ barbiturates should be employed with	DDI-effect
that associated include antiretroviral nucleoside analogues , dapsone @DRUG$ , , , @DRUG$ metronidazole , nitrofurantoin phenytoin , , .	DDI-false
that result the administration sparing diuretics ( such @DRUG$ ) can @DRUG$ when recommended dose of beta-agonist	DDI-effect
In and/or in data that , and @DRUG$ inhibit the metabolism , which can increase in plasma @DRUG$ levels prolongation the QT the ECG	DDI-false
Moreover , niacin demonstrated effect levels , and administration to population @DRUG$ resulted no the of bioavailability of @DRUG$ relative to control .	DDI-false
In rats , simultaneous ingestion of @DRUG$ and nitrite in diet for 78 weeks has reported to cause tumors , it been suggested that disulfiram may react @DRUG$ the stomach form tumorigenic	DDI-false
Patients on @DRUG$ should receive 70 mg of @DRUG$ daily.	DDI-advise
Physiological oral @DRUG$ supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with @DRUG$s, with practically only one contra-indication: overt renal failure.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	DDI-false
BACKGROUND The effects of of @DRUG$ @DRUG$ ) , calcium channel blocker on of induced by azoxymethane ( AOM and labeling index of in male rats .	DDI-false
@DRUG$ or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
possibility hypotensive with can be either the @DRUG$ or increasing the salt initiation treatment	DDI-effect
@DRUG$ be administered with @DRUG$ disulfiram , Laboratories	DDI-advise
Magnesium- and/or aluminum-containing @DRUG$ @DRUG$ ( iron containing zinc or metal cations ( chewable/buffered the powder oral solution be 3 hours or hours after FACTIVE	DDI-false
Both @DRUG$ and have compared triple therapy with the PI 48 observed superiority with @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when fluoroquinolones, @DRUG$, or azoles were administered concomitantly.	DDI-false
When is administered @DRUG$ , protein binding , the of @DRUG$ is altered .	DDI-false
@DRUG$ , vincristine and @DRUG$ in immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
- @DRUG$: @DRUG$ blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-false
@DRUG$ : When Lodine is administered with @DRUG$ its protein binding is although the of is not .	DDI-false
Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The following examples the blood-glucose-lowering and susceptibility hypoglycemia oral antidiabetic products , , , fibrates fluoxetine monoamine ( MAO ) inhibitors , @DRUG$ , , @DRUG$ ( octreotide ) , sulfonamide antibiotics	DDI-false
no , it is that the metabolism of levobupivacaine may the CYP3A4 such as , @DRUG$ @DRUG$ ) CYP3A4 inhibitors ( antimycotics	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
Based on metabolic , clinically drug are not @DRUG$ and , trimethoprim/sulfamethoxazole clarithromycin erythromycin , itraconazole or	DDI-false
Anticoagulants: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-advise
Warfarin: The effect of @DRUG$ on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
association though marked , has been suggested with @DRUG$ phenylbutazone , carbamazepine , griseofulvin , and @DRUG$	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
receiving high doses of @DRUG$ @DRUG$ , as lower renal excretory sites	DDI-effect
@DRUG$ : and contraceptive values for norethindrone @DRUG$ by % and % .	DDI-false
@DRUG$ Because the relationship of Accutane @DRUG$ patients should be taking vitamin supplements containing vitamin to avoid toxic effects	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Therapeutic @DRUG$ , naproxen , @DRUG$ , phenytoin andtolbutamide alter ketorolac tromethamine protein .	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	DDI-mechanism
Serotonin Reuptake ( @DRUG$ paroxetine @DRUG$ ) weakness , and when agonists .	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Digoxin When multiple of @DRUG$ digoxin coadministered , steady-state @DRUG$ concentrations by approximately 20 %	DDI-false
That Should Coadministered With VIRACEPT : , quinidine @DRUG$ : derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , GI motility : @DRUG$	DDI-false
Patients who diclofenac or increase dose or NSAID digoxin @DRUG$ , or @DRUG$ may develop toxicity characteristics .	DDI-false
@DRUG$: Coadministration of single doses of Sonata 20 mg and @DRUG$ 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
: injection injectable @DRUG$ central with ethyl , barbiturates , MAO inhibitors other antidepressants scopolamine is used with @DRUG$ an increased incidence of sedation , has been observed	DDI-false
of plus the course patients HIV-related , systemic , lymphoma ( HIV-NHL the authors compared retrospectively a of 24 patients with who were treated with the @DRUG$ ( CHOP chemotherapy regimen a group patients who were with CHOP CHOP-like i.e. cyclophosphamide doxorubicin teniposide and vincristine plus bleomycin without receiving @DRUG$ therapy .	DDI-false
@DRUG$ should be administered taking @DRUG$ the possibility of disturbances .	DDI-advise
Other interactions observed @DRUG$ and following : @DRUG$ warfarin digoxin , and ranitidine	DDI-false
Carbamazepine: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	DDI-false
, CAUTION should when administering @DRUG$ to patients @DRUG$ or halogenated hydrocarbon .	DDI-advise
drug interactions AEDs carbamazepine , , phenobarbital phenytoin , @DRUG$ ) were also assessed by evaluating the @DRUG$ and these placebo-controlled clinical	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.	DDI-advise
Therefore in taking @DRUG$ or @DRUG$ , monitoring blood glucose is .	DDI-false
Methenamine therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-mechanism
Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.	DDI-advise
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-advise
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, metoclopramide, @DRUG$.	DDI-effect
Drug Interaction : @DRUG$ @DRUG$ were in pregnant mice	DDI-false
Before using tell pharmacist of all and nonprescription you use especially aminoglycosides ( , @DRUG$ amikacin ) @DRUG$ , anti-inflammatory ( ibuprofen , tacrolimus vancomycin	DDI-false
The hypoglycemic @DRUG$ has been @DRUG$	DDI-effect
chains N-methylthiotetrazole cefmenoxime , cefotetan , @DRUG$ , ) methylthiadiazole @DRUG$ ) can K and hypoprothrombinemia	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-advise
Carbamazepine Isoniazid known @DRUG$ increase @DRUG$ should to concurrent administration signs and symptoms of carbamazepine be monitored closely , appropriate adjustment of the anticonvulsant should be .	DDI-false
@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	DDI-false
pharmacokinetic have demonstrated concomitant of @DRUG$ and   ( etodolac capsules and reduced protein binding of warfarin , was no change in clearance free	DDI-false
@DRUG$ @DRUG$ the antihypertensives	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
cimetidine ) many that are substrates for P450 2D6 @DRUG$ @DRUG$ 1C antiarrhythmics propafenone and flecainide )	DDI-false
Diuretics: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
Probenecid: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
The peripheral vasoconstriction caused by high doses of @DRUG$ is antagonized by @DRUG$.	DDI-effect
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
To the plus on clinical with ( , retrospectively group of 24 with were treated with the , prednisone ( CHOP chemotherapy plus HAART with a group were treated or a ( i.e. , , @DRUG$ , , @DRUG$ without therapy	DDI-false
@DRUG$ : should be with caution receiving   , or verapamil substrate , diltiazem CYP3A4 inhibitor ) of the potentiation of bradycardia , sinus arrest , and block ;	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
following substances that may the blood-glucose-lowering effect , niacin , , diuretics , e.g. , terbutaline , , phenothiazine derivatives @DRUG$ , thyroid hormones , @DRUG$ , progestogens ( e.g. , in oral )	DDI-false
concentrations , @DRUG$ , , naproxen , acetaminophen , @DRUG$ protein .	DDI-false
@DRUG$ pharmacokinetics of @DRUG$ mg/kg over 20 minutes unchanged a oral albendazole ( ) subjects	DDI-false
@DRUG$ pharmacology study of antacid ( @DRUG$ and ) with fosinopril levels and urinary excretion of with that absorption of .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
@DRUG$ : In normal volunteers of @DRUG$ acetaminophen resulted in approximate % plasma levels of acetaminophen .	DDI-false
In vitro data suggest that @DRUG$, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
Drugs That Should Not @DRUG$ : amiodarone , quinidine Antihistamines , terfenadine Antimigraine : derivatives agents : rifampin Benzodiazepines midazolam @DRUG$ motility	DDI-advise
, ) and other drugs including ether , @DRUG$ and @DRUG$ potentiate blocking and used extreme in treated Coly-Mycin	DDI-false
Consequently, @DRUG$ should be avoided in patients receiving @DRUG$ and itraconazole, which are very potent inhibitors of CYP3A.	DDI-advise
: Concomitant treatment with @DRUG$ and tetracyclines avoided Accutane use with a of cases ( intracranial , some which concomitant @DRUG$	DDI-false
@DRUG$, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
If @DRUG$ is administered with drugs that inhibit Pgp, increased concentrations of @DRUG$ are likely, and caution should be exercised.	DDI-false
The following are of that the effect and susceptibility to hypoglycemia : antidiabetic products ACE inhibitors disopyramide , monoamine ( MAO inhibitors , @DRUG$ , octreotide ) @DRUG$.	DDI-false
Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral @DRUG$.	DDI-false
or excess effect of , an @DRUG$ can increase the effect of @DRUG$.	DDI-effect
Epinephrine used cautiously other e.g. , @DRUG$ ) that actions of @DRUG$.	DDI-false
specific studies coadministration with that mainly metabolized by eg , channel blockers @DRUG$ , @DRUG$ , , warfarin , tacrolimus , derivatives , pimozide carbamazepine , ) may elevated coadministered saquinavir	DDI-false
Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
Close supervision and careful adjustment of dosage are required when Anafranil is administered with @DRUG$ or @DRUG$.	DDI-false
, clarithromycin Didanosine , @DRUG$ , @DRUG$ Phenobarbitol , , .	DDI-false
of @DRUG$ greater than mg/day decrease of @DRUG$ may required .	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), @DRUG$.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The @DRUG$ containing or @DRUG$ oxidase antidepressants or phenothiazines produce , prolonged hypotension hypertension	DDI-false
clinical @DRUG$ , , oral and supplemental oxygen . substudy in with heart receiving @DRUG$ digoxin therapy was values for n and ( = decreased , respectively day of and values day	DDI-false
@DRUG$: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and @DRUG$ are coadministered.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	DDI-false
Specific interaction studies have @DRUG$ : day , trough @DRUG$ by .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
- @DRUG$ ( e.g. Mexate ) @DRUG$ may increase the chance effects affecting the of	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
The ECG changes result administration @DRUG$ such as @DRUG$ acutely worsened by especially the is .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other studies not , or more clinical with acetylsalicylic a-blockers , @DRUG$ , anticonvulsants beta blockers blockers , cardiac nitrates H2 antagonists , @DRUG$ synthetase also to as , anti-infectives clinically adverse interactions .	DDI-false
- @DRUG$ ( birth pills ) containing @DRUG$	DDI-false
Rifabutin Coadministration of rifabutin in 32 % @DRUG$ AUC 207 increase in @DRUG$ A.C.	DDI-false
The @DRUG$ increased by @DRUG$ , potent inhibitor CYP3A4 400 daily 5 days .	DDI-mechanism
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
In case you are taking @DRUG$ doses @DRUG$ may needed .	DDI-false
adjustment may be when coadministered with , , @DRUG$ , and @DRUG$.	DDI-false
@DRUG$ tricyclic Amphetamines the activity tricyclic antidepressants or @DRUG$ ;	DDI-false
of @DRUG$ and other interfering e.g. , be performed caution the effect the @DRUG$ may be potentiated .	DDI-false
@DRUG$ : vitro studies in mononuclear cells Molt-4 revealed that significantly inhibited @DRUG$ a dose manner	DDI-false
@DRUG$ may interact with any of the following: - @DRUG$ (e.g., Tylenol) (with long-term, high-dose use) or	DDI-int
No pharmacokinetic interactions between @DRUG$ and @DRUG$, propofol, alfentanil, and midazolam have been demonstrated.	DDI-false
In with chronic hepatitis C treated PEGASYS with @DRUG$ @DRUG$ treatment not affect ribavirin clearance .	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
did clinically important effect of prednisolone	DDI-false
Antiacid, clarithromycin, @DRUG$, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
patients clinical received one of concomitant medications ORENCIA , NSAIDs corticosteroids , TNF blocking agents , @DRUG$ , , hydroxychloroquine	DDI-false
vitro with serum proteins glipizide binds @DRUG$ and does interact @DRUG$ .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Although specific not been performed that by ( eg @DRUG$ , disopyramide , , quinidine warfarin pimozide , carbamazepine fentanyl , alfentanyl @DRUG$ , and ) elevated concentrations when with ;	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ in decreases serum concentrations amiodarone desethylamiodarone	DDI-false
@DRUG$: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with Bezalip or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-advise
clinical studies @DRUG$ @DRUG$ 1 mg ) 41 years , the mean of serum antigen PSA from 0.7 ng/mL baseline to ng/mL 12 .	DDI-false
following are examples drugs the metabolism of other through : @DRUG$ , , @DRUG$ , macrolide	DDI-false
Probenecid: As with other @DRUG$, the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
The following may effect oral antidiabetic products , @DRUG$ fibrates , monoamine ( , , , somatostatin , @DRUG$ , antibiotics	DDI-false
@DRUG$-@DRUG$ containing side of , methylthiadiazole ( cefazolin can and hypoprothrombinemia	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
In addition , results from patient pharmacokinetic data suggest co-administration of other inducers clearance ( , @DRUG$ phenytoin , , or carbamazepine clinically meaningful reductions @DRUG$ concentrations .	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue.	DDI-effect
following are examples substances that may reduce blood-glucose-lowering : corticosteroids niacin , danazol , diuretics , agents ( e.g. @DRUG$ @DRUG$ , terbutaline , isoniazid , phenothiazine , thyroid , , ( e.g. oral	DDI-false
of @DRUG$ the warfarin of our to be maximal 5 7 days the @DRUG$ similar length of after rifampin withdrawal	DDI-false
@DRUG$ ( e. , , @DRUG$ , clotrimazole , fluconazole , . ): in vitro animal studies with the of amphotericin imidazoles suggest that imidazoles may to amphotericin B.	DDI-false
Tagamet , through certain enzyme the warfarin-type @DRUG$ @DRUG$ , chlordiazepoxide , , tricyclic , theophylline , thereby elimination levels drugs .	DDI-false
When Bezalip or retard is used concurrently with @DRUG$ ) , an least maintained the two medicines , @DRUG$ Bezalip impaired	DDI-false
@DRUG$ did systematically alter effects (-)-NANM @DRUG$.	DDI-false
muscle relaxants ( , tubocurarine including ether succinylcholine decamethonium and @DRUG$ , potentiate neuromuscular blocking effect be caution being @DRUG$ Parenteral .	DDI-effect
vivo drug-drug between estazolam and inducers of , compounds that are inducers ( @DRUG$ , , rifampin @DRUG$ ) be estazolam concentrations	DDI-false
, , , acid , , @DRUG$/phenobarbital .	DDI-false
@DRUG$ : In clinical study , of an antacid @DRUG$ magnesium hydroxide , and reduced levels and of with fosinopril administered alone , that may	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
Effects of other ) @DRUG$ : @DRUG$ effect plasma concentrations of patients with epilepsy .	DDI-false
@DRUG$ : concurrently , should take @DRUG$ 1 hour before - 6 a acid resin to avoid its	DDI-false
Drugs Coadministered With VIRACEPT Antiarrhythmics : Antihistamines @DRUG$ terfenadine : ergot Antimycobacterial : rifampin @DRUG$ triazolam motility	DDI-false
: @DRUG$ is known slow the metabolism carbamazepine and serum Carbamazepine levels to administration with isoniazid signs symptoms carbamazepine toxicity should closely , and dosage adjustment @DRUG$ should be made .	DDI-false
Based on profiles , clinically significant interactions VIRACEPT dapsone , @DRUG$/sulfamethoxazole clarithromycin @DRUG$ , itraconazole fluconazole .	DDI-false
Aspirin/@DRUG$ : interactions have not demonstrated between administered @DRUG$ 162.5 mg orally 2 hours prior Argatroban 1   . over 4 or 1000 orally given 0 hours and 6 and subsequent to , initiation of . over	DDI-false
@DRUG$: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
with @DRUG$ ( 40 BID for days ) resulted in increase suggesting at these doses @DRUG$ is a of 2D6	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The following are examples may the @DRUG$ , niacin , danazol diuretics sympathomimetic ( terbutaline ) , , derivatives thyroid , estrogens , progestogens in oral @DRUG$ )	DDI-false
Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-effect
@DRUG$ administered @DRUG$ dobutamine , steroids , surfactant .	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and prednisone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Anabolic nandrolone e.g. , , oxandrolone [ , @DRUG$ ] , @DRUG$ [ e.g. , Anadrol stanozolol , )	DDI-false
Methotrexate : Caution used if @DRUG$ is with @DRUG$.	DDI-advise
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
To evaluate of HAART the with systemic , non-Hodgkin lymphoma ( ) compared retrospectively a of with HIV-NHL who were treated with the @DRUG$ , doxorubicin @DRUG$ prednisone ( ) regimen plus group of patients were treated CHOP CHOP-like i.e. doxorubicin , and vincristine plus ) without receiving antiretroviral	DDI-false
Coadministration @DRUG$ that inhibit increase @DRUG$ .	DDI-false
@DRUG$ may accentuate the loss @DRUG$ .	DDI-effect
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In studies addition to @DRUG$ II antagonists potassium slightly - 0.13 mEq/L ) .	DDI-false
: exhibit a @DRUG-DRUG$ due to inhibition response .	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Fluconazole: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	DDI-mechanism
@DRUG$ : administration diflunisal and @DRUG$ no on the of naproxen , significantly the naproxen and glucuronide metabolite	DDI-false
study in the 2 orally disintegrating administered and ( @DRUG$ with effects GI tract ) to volunteers , AUC of was 10 lower Cmax of @DRUG$ was % lower the tablet was propantheline compared to it was given .	DDI-false
of @DRUG$ , , ibuprofen naproxen , , @DRUG$ phenytoin not alter protein binding .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
HIV Protease Inhibitors Indinavir ) with @DRUG$ mg a increase in @DRUG$ , a increase in and a 2-fold increase .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Compounds include @DRUG$ , theophylline , phenytoin , diazepam , @DRUG$.	DDI-false
Binding to plasma protein is not significantly altered by @DRUG$, diphenylhydantoin, or @DRUG$.	DDI-false
interaction @DRUG$ other potent inhibitors ( , @DRUG$ erythromycin ) studied exposures almotriptan expected with these .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
with some , ( @DRUG$ ): MAOI could affect flupenthixol - Arecoline - - Ethanol @DRUG$ cause Flupenthixol the of Tricyclic	DDI-false
In @DRUG$ inhibits metabolism of , which in @DRUG$ levels and prolongation of the QT on ECG .	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Population pharmacokinetic showed higher concentrations of @DRUG$ among patients with @DRUG$ , inhibitor	DDI-mechanism
- Anticoagulants: Interaction studies in humans have shown @DRUG$ to have no effect on @DRUG$ metabolism or on plasma prothrombin activity.	DDI-false
Hormonal Contraceptives Oral , Implantable Contraceptives : interaction demonstrated co-administration @DRUG$ oral hormonal @DRUG$ average decreases levels of 14 % and 31 % , respectively .	DDI-mechanism
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).	DDI-effect
Antiarrhythmics: Amiodarone, bepridil, flecainide, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
Other @DRUG$ 500 twice daily not influence pharmacokinetics of oral mg and 0.15 @DRUG$ the luteinizing that impairment of efficacy is unlikely	DDI-false
Carbamazepine : is known to slow the of @DRUG$ increase serum Carbamazepine be determined to @DRUG$ , signs be anticonvulsant made	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
inhibitors include @DRUG$ , clarithromycin , @DRUG$ , , , propofol protease inhibitors , quinidine , and .	DDI-false
Reciprocal interactions with @DRUG$ and drugs increase cytochrome system ( , phenytoin , @DRUG$ , ketoconazole , though has not been	DDI-mechanism
Taking a @DRUG$ while you are taking or within 2 weeks of taking @DRUG$ may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.	DDI-effect
: The addition valproate had no effect on pharmacokinetics but @DRUG$ significantly @DRUG$ binding in 96.3 to 94.8 % , of approximately % the .	DDI-mechanism
@DRUG$ : DURAGESIC fentanyl system ) with other central nervous system , including but not to , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines , phenothiazines @DRUG$ may hypotension and sedation , or in coma or death .	DDI-false
@DRUG$ @DRUG$ , and are to QTc prolongation .	DDI-false
Acidifying agents Gastrointestinal agents guanethidine , reserpine , glutamic , @DRUG$ fruit , . of @DRUG$.	DDI-mechanism
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$ furosemide penicillin G @DRUG$ , gemfibrozil was significantly simultaneously with colestipol hydrochloride	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-false
a study conducted healthy subjects mean steady-state @DRUG$ plasma levels 17 % receiving @DRUG$ CELEBREX 200 mg BID as to subjects	DDI-false
, @DRUG$ @DRUG$	DDI-false
@DRUG$ ( ): @DRUG$ , fluoxetine , , , sertraline ) rarely cause weakness and incoordination coadministered 5-HT1	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Then metabotropic glutamate receptor mGluR agonists , @DRUG$ and on the changes induced @DRUG$ found	DDI-false
@DRUG$ neostgmine , , quinine @DRUG$ enhance toxicity and cause cardio respiratory depression	DDI-false
, a @DRUG$ may antagonize the effect @DRUG$ use of these drugs be avoided	DDI-false
Cimetidine: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
medication ( e.g. levothyroxine ) @DRUG$-containing @DRUG$ H2-antagonists , famotidine , ranitidine ) , and inhibitors lansoprazole	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
should be used cautiously with other drugs e.g. @DRUG$ , @DRUG$ ) that to drugs	DDI-false
following are substances the susceptibility : oral ACE inhibitors , , fibrates , @DRUG$ , monoamine MAO @DRUG$ salicylates somatostatin analog e.g. octreotide ) sulfonamide antibiotics .	DDI-false
In clinical trials , was used with @DRUG$ diuretics anticoagulants oral @DRUG$ supplemental a substudy congestive heart or whom therapy with FLOLAN , furosemide ( n = ) and digoxin ( = 30 ) decreased by 13 15 % respectively , on day of therapy had returned baseline values day 87	DDI-false
monkeys , @DRUG$ was about times more than in decreasing responding , whereas pigeons (-)-NANM about equipotent with @DRUG$.	DDI-false
Insulin or Oral @DRUG$ : Agents with may enhance blood-sugar-reducing of @DRUG$ .	DDI-false
vitro binding with proteins than @DRUG$ does interact with or	DDI-false
examples substances blood-glucose-lowering : niacin danazol , sympathomimetic agents ( e.g. , , salbutamol , derivatives @DRUG$ , @DRUG$ , estrogens , , ) .	DDI-false
Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
Injection injection , benzodiazepines depression of the central nervous alcohol , , @DRUG$ and antidepressants . concomitantly with injectable @DRUG$ , an , and behavior has	DDI-false
H2 : coadministration leads to increased peak plasma and of @DRUG$ , effect on @DRUG$ is coadministered with	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
oxacillin , , @DRUG$ and sulfamethoxazole have no on binding of @DRUG$ serum	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
The co-administration Natrecor IV @DRUG$ @DRUG$ or not been evaluated these co-administered with in trials ) .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other inhibitors of e.g. , itraconazole clarithromycin nefazodone @DRUG$ , @DRUG$ be	DDI-false
suggest @DRUG$ may diminish the of ACE-inhibitors .	DDI-false
@DRUG$, tricyclic antidepressants, and @DRUG$ may increase anticholinergic effect of clidinium.	DDI-false
Antagonists : reports of profound hypotension and of consciousness @DRUG$ , the concomitant use of with of the including , example ondansetron granisetron , dolasetron , , @DRUG$ ) is	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and @DRUG$.	DDI-false
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
@DRUG$ does not affect serum @DRUG$ levels.	DDI-false
Should @DRUG$ @DRUG$ : , Antihistamines : terfenadine : ergot : rifampin triazolam agents	DDI-advise
aBased reports of narcotic in patients with @DRUG$ and concurrently decreased concentrations of @DRUG$.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Hormonal , , Transdermal , and Implantable @DRUG$ An interaction study that of bosentan and the produced decreases of @DRUG$ and 14 % % , respectively .	DDI-false
Should Not With @DRUG$ amiodarone quinidine Antihistamines , @DRUG$ derivatives rifampin Benzodiazepines , triazolam :	DDI-false
: Since is a @DRUG$ , it is possible that @DRUG$ , such as neuroleptics phenothiazines butyrophenones thioxanthenes ) or metoclopramide , diminish the effectiveness of APOKYN .	DDI-false
fenofibrate ( equivalent 145 mg @DRUG$ @DRUG$ ( mg daily for resulted 17 decrease from 67 decrease increase ) atorvastatin AUC healthy males	DDI-mechanism
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ under this circumstance.	DDI-false
: The administration of @DRUG$ sulfonylurea @DRUG$ , resulted in severe .	DDI-effect
Drug-drug not observed @DRUG$ @DRUG$	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	DDI-int
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
with @DRUG$ of oral ) @DRUG$ ( ) , NSAIDs piroxicam ) and digoxin not significantly	DDI-false
Interactions EPA supplements and @DRUG$ and other anti-inflammatory drugs as garlic ( Allium sativum ) and @DRUG$ )	DDI-false
Intravenous Adenocard ) has effectively administered in cardioactive drugs such @DRUG$ , agents channel and @DRUG$ without any the reaction .	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
May interact with the following: @DRUG$, @DRUG$ (use with thiazide diuretics may prevent the diuretic from working properly;	DDI-false
Although no studies have been conducted, concomitant administration of @DRUG$ and phenytoin may alter the metabolism of @DRUG$;	DDI-false
@DRUG$ , @DRUG$ enhance antidepressants sympathomimetic	DDI-false
Concomitant fenofibrate 145 mg TRICOR @DRUG$ 40 daily for to increase the mean Cmax and values for @DRUG$ % ( from 69 decrease to 321 % increase ) and 28 ( from to 128 increase ) respectively , and 3 -hydroxy-iso-pravastatin by 55 % % 314 % increase 39 ( from decrease ) , 23	DDI-false
As with other , it be that @DRUG$ depressants such as anesthetics opiates and @DRUG$.	DDI-effect
Drug interaction that @DRUG$ any clinically significant with phenytoin , warfarin , quinidine	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, ketoconazole), though this has not been studied	DDI-mechanism
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
Example inhibitors include antifungals @DRUG$ , clarithromycin , doxycycline imatinib , @DRUG$ , , protease inhibitors , quinidine , and verapamil	DDI-false
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral @DRUG$ and @DRUG$.	DDI-effect
following examples of that increase the blood-glucose-lowering and to hypoglycemia oral @DRUG$ , ACE , disopyramide , fibrates , , monoamine ( MAO ) inhibitors , @DRUG$ , somatostatin analog ( e.g. , octreotide , sulfonamide	DDI-false
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
enzyme systems reported the metabolism phenytoin , nifedipine , @DRUG$ , diazepam , @DRUG$ delaying elimination of drugs	DDI-false
Co-administration naltrexone with @DRUG$ a 25 % increase in AUC a % the	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus @DRUG$/oxycodone regimens.	DDI-false
Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$ prolong and intensify the anticholinergic (drying) effects of @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
following of substances that may effect to : oral products , @DRUG$ , , fibrates , ( propoxyphene somatostatin analog e.g. , @DRUG$ ) , .	DDI-false
Although interaction studies were not performed doses of 1 mg or studies acetaminophen acetylsalicylic a-blockers , angiotensin-converting enzyme ( ACE inhibitors , anticonvulsants , @DRUG$ , blockers nitrates H2 , prostaglandin and @DRUG$ adverse interactions	DDI-false
acetaminophen/@DRUG$ @DRUG$/quinidine , phenobarbital/acetaminophen , , and valproic .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
in the administration of hour and 0.3 mg sodium approximately hours after same in decrease in the @DRUG$ of than % a decrease in about 30 compared dosing @DRUG$	DDI-false
This antagonistic effect of @DRUG$ on @DRUG$ natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.	DDI-mechanism
- When @DRUG$ or is concurrently e.g. @DRUG$ ) interval 2 maintained between the two , since absorption of or Bezalip retard is	DDI-advise
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
The benzodiazepines may potentiated anticonvulsants , alcohol barbiturates @DRUG$ @DRUG$ , or drugs that .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
OTHER THERAPY Although specific interaction studies were performed clinical @DRUG$ concomitantly angiotensin- converting ( ACE ) inhibitors , betablockers blockers diuretics , and nonsteroidal anti-inflammatory @DRUG$ ) without of .	DDI-false
ibogaine and 18-MC block @DRUG$-induced release the accumbens ;	DDI-false
- @DRUG$: Interaction studies in humans have shown no effect on @DRUG$ blood levels.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Benzylpenicillin ampicillin oxacillin , , , @DRUG$ sulfamethoxazole have the protein binding @DRUG$ human serum .	DDI-false
proteins may be in serum , corticosteroid binding globulin ( ) sex hormone-binding globulin ( ) total circulating @DRUG$ @DRUG$ respectively .	DDI-false
, @DRUG$/acetaminophen acid , theophylline/acetaminophen ,	DDI-false
@DRUG$: Coadministration of @DRUG$ resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.	DDI-false
@DRUG$ , @DRUG$ , tetracyclines with the bactericidal penicillins	DDI-false
of other metabolized drugs ( , triazolo-benzodiazepines @DRUG$ , @DRUG$ , etc	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
separate maintenance @DRUG$ , digoxin irbesartan administration days no the @DRUG$ time ) of	DDI-false
@DRUG$ , Diuretics treatment with steroids , @DRUG$ possible hypokalemic effect of beta2-agonists .	DDI-false
Digoxin, Methotrexate, @DRUG$: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Digoxin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	DDI-false
administration of local anesthetic epinephrine @DRUG$ to @DRUG$ tricyclic phenothiazines produce , prolonged or hypertension .	DDI-effect
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: sertraline and @DRUG$.	DDI-false
@DRUG$ : The use of   ( fentanyl transdermal with other nervous depressants , not to opioids , sedatives , , e.g. , benzodiazepines @DRUG$ , muscle relaxants , cause respiratory , hypotension , profound sedation , or result in coma .	DDI-false
Other which may enhance the neuromuscular blocking action nondepolarizing agents NUROMAX include e. g. aminoglycosides , tetracyclines , , , clindamycin , , ) @DRUG$ , @DRUG$ local anesthetics procainamide and quinidine .	DDI-false
The myopathy during treatment with class is administration of cyclosporine , @DRUG$ @DRUG$ ( erythromycin antifungals .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-advise
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Although been shown reduce @DRUG$-induced side effects fever , insufficiency confusion and concomitant these with PROLEUKIN may the antitumor effectiveness of PROLEUKIN thus should avoided . @DRUG$ and other antihypertensives hypotension seen with PROLEUKIN .	DDI-false
With simultaneous dosing of @DRUG$ 20 mg and @DRUG$ 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	DDI-effect
which may the of nondepolarizing agents as NUROMAX certain antibiotics g. , , polymyxins , lincomycin , @DRUG$ , colistin , and sodium ) magnesium , @DRUG$ , , procainamide and .	DDI-false
Data vitro @DRUG$ other @DRUG$ suggest a possible drug interaction following , cyclosporine , , nifedipine .	DDI-false
The of hypotensive @DRUG$ can discontinuing @DRUG$ the salt approximately week initiation treatment captopril ( or therapy with doses ( 6.25	DDI-effect
@DRUG$ ( @DRUG$ . ) be concomitantly with	DDI-false
levels @DRUG$ and @DRUG$	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
receiving @DRUG$s general , , tricyclic or @DRUG$ ( alcohol ) with DILAUDID may exhibit an additive CNS depression .	DDI-false
, , Didanosine , Fluconazole @DRUG$ , @DRUG$ , Rifampin Ritanovir , Saquinavir .	DDI-false
When or retard used concurrently anion-exchange e.g. @DRUG$ , of at between two medicines the of Bezalip @DRUG$	DDI-false
Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing @DRUG$.	DDI-false
Interaction with phenytoin , @DRUG$ @DRUG$ also reported adverse effects	DDI-false
oxacillin , @DRUG$ , , have vitro the binding @DRUG$ serum .	DDI-false
d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
: of relationship of @DRUG$ to @DRUG$ , should advised taking supplements containing A additive	DDI-effect
, @DRUG$ once daily no low-dose ( mg once daily ) @DRUG$ vivo aggregation and serum TXB2 generation .	DDI-false
other analgesics , general phenothiazines , @DRUG$ , or @DRUG$ ( including DILAUDID exhibit an additive CNS	DDI-false
@DRUG$ : be , particularly in first few days @DRUG$ therapy patients receiving warfarin , are increased of complications .	DDI-false
Central : The use @DRUG$   ( @DRUG$ system ) other , including but not other hypnotics ( e.g. benzodiazepines ) , phenothiazines relaxants , and alcohol may cause , hypotension , result coma	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-false
- : Interaction studies humans have shown @DRUG$ effect on @DRUG$ metabolism or on plasma .	DDI-false
The co-administration @DRUG$ with such as nitroprusside , @DRUG$ ACE inhibitors has not been evaluated drugs co-administered )	DDI-false
Magnesium- aluminum-containing @DRUG$ , ferrous sulfate ( ) containing or other cations or ( ) tablets the be hours before or after @DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the @DRUG$ rifampin.	DDI-false
In , are have bepridil hydrochloride such as @DRUG$ @DRUG$ glycosides and tricyclic anti-depressants	DDI-false
Inhibit Aldehyde and CYP3A4 @DRUG$ both oxidase ( in CYP3A4 ( vitro and vivo ) the primary secondary respectively , @DRUG$ .	DDI-mechanism
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
When @DRUG$, a potent inhibitor of CYP2D6, was co-administered with @DRUG$ at steady-state, exposure to either drug was not altered.	DDI-false
known profiles , drug are expected between @DRUG$ and , , itraconazole fluconazole	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and @DRUG$.	DDI-false
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$ : Clinical as , have shown that natriuretic @DRUG$ thiazides	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ may augment the activity of other @DRUG$.	DDI-effect
These include the @DRUG$ , estrogens , oral contraceptives , sympathomimet-ics , calcium blocking drugs , @DRUG$.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, @DRUG$).	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
That Be Antiarrhythmics amiodarone , @DRUG$ Antihistamines astemizole , @DRUG$ : ergot : rifampin Benzodiazepines , triazolam motility agents :	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and @DRUG$ is not recommended.	DDI-advise
, apparently an on , been reported reduce hepatic metabolism warfarin-type @DRUG$ , , , , tricyclic antidepressants , @DRUG$ , thereby delaying and blood drugs	DDI-false
Injection : @DRUG$ injection , like produces depression of the central system when administered with ethyl alcohol phenothiazines barbiturates inhibitors , and other concomitantly with injectable incidence of has	DDI-effect
Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-mechanism
be with , inhaled @DRUG$ as @DRUG$ ( physician should provide the patient with medication in be .	DDI-false
Chemotherapy Agents In , administration of @DRUG$ not alter pharmacokinetics of or the @DRUG$	DDI-false
Patients receiving narcotic general anesthetics , phenothiazines @DRUG$ , @DRUG$ or CNS depressants ( including alcohol ) concomitantly may exhibit additive CNS depression	DDI-false
Amprenavir the ERMBT , and @DRUG$ and @DRUG$ equipotent ERMBT	DDI-false
@DRUG$ ( Use of @DRUG$ with sulfapyridine increase chance side affecting the liver and/or side of methotrexate	DDI-false
: is dopamine , it possible antagonists the neuroleptics ( phenothiazines , @DRUG$ or @DRUG$ , diminish the effectiveness of APOKYN	DDI-false
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and @DRUG$ together may decrease the effects of piperazine.	DDI-effect
clinical have been , likely the of levobupivacaine may be the ( phenytoin @DRUG$ , rifampin , ( antimycotics e.g. @DRUG$ ;	DDI-false
@DRUG$ ( , @DRUG$ ) or	DDI-false
These include other , corticosteroids , thyroid oral @DRUG$ , @DRUG$ , sympathomimet-ics calcium channel drugs , and .	DDI-false
@DRUG$ , and : Concomitant with steroids , potentiate a   @DRUG$	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concomitant of VISTIDE and with nephrotoxic potential [ , intravenous ( e.g. @DRUG$ gentamicin and amikacin amphotericin B , , intravenous , @DRUG$ , non-steroidal agents ] contraindicated .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Aspirin/@DRUG$ : Pharmacokinetic drug-drug have between Argatroban concomitantly administered aspirin 162.5 mg orally given 26 2 prior to initiation of @DRUG$   g/kg/min . over 4 1000 mg orally given 12 0 hours prior , and 6 12 subsequent , initiation of g/kg/min )	DDI-false
@DRUG$ other ( , quinine and @DRUG$ ) abnormalities and the of	DDI-effect
In order the of reactions all patients with @DRUG$ should be such @DRUG$ , H2 antagonists ( as cimetidine or )	DDI-false
Drugs on of @DRUG$ : Literature reports decreases , not greatly alter @DRUG$	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
A @DRUG$ not be in with 200 daily @DRUG$.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
acetaminophen/@DRUG$, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as @DRUG$.	DDI-advise
therapy Although studies not , doses mg more used in clinical studies acetaminophen acetylsalicylic , analgesics , ) benzodiazepines , beta blockers , , nitrates diuretics , antagonists @DRUG$ inhibitors ( NSAIDs , and @DRUG$ without evidence of clinically interactions .	DDI-false
Nifedipine @DRUG$ 20 nifedipine 30 mg 60 daily , did not bioavailability ) maximum Cmax of @DRUG$ a drug	DDI-false
There case of increased , @DRUG$ , and @DRUG$ concomitant therapy with amiodarone .	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/@DRUG$ , acid/phenobarbital	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or metoclopramide.	DDI-advise
The gastrointestinal absorption of @DRUG$ and ranitidine is accelerated when they are coadministered with @DRUG$.	DDI-mechanism
following examples substances reduce the blood-glucose-lowering effect : @DRUG$ , danazol sympathomimetic e.g. epinephrine , terbutaline ) isoniazid , phenothiazine derivatives thyroid hormones @DRUG$ progestogens e.g. in	DDI-false
Ketoconazole: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-mechanism
@DRUG$ or with properties enhance the blood-sugar-reducing effect of insulin @DRUG$.	DDI-false
Coadministration of @DRUG$ and Ortho-Novum 1/35  increased the exposure of @DRUG$ and ethinyl estradiol by 20% and 34%, respectively.	DDI-false
Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with @DRUG$.	DDI-mechanism
: like benzodiazepines depression of central system when administered with @DRUG$ @DRUG$ barbiturates antidepressants . concomitantly with an incidence of , hallucinations , behavior has been observed	DDI-false
@DRUG$ : @DRUG$ inhibit hypotensive of veratrum	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Imidazoles ( ketoconazole @DRUG$ etc in vitro animal studies with of amphotericin B suggest that @DRUG$ may amphotericin B.	DDI-false
Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
not been performed coadministration drugs that are mainly metabolized by calcium channel dapsone disopyramide , quinidine warfarin tacrolimus , derivatives , @DRUG$ , , may have elevated concentrations coadministered @DRUG$	DDI-mechanism
and toxicokinetic studies did not in clearance or either @DRUG$ or @DRUG$ administered together	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Caution should also be taken in concurrent or serial use of other @DRUG$ and @DRUG$ because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$: As with other @DRUG$, the renal excretion of cephalexin is inhibited by probenecid.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
@DRUG$ has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	DDI-effect
A marked , has been @DRUG$ @DRUG$ , phenytoin sodium , , , and possibly ampicillin and .	DDI-false
The of this is not known hence is ingested	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Coadministration of @DRUG$ with @DRUG$ has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-mechanism
data suggest @DRUG$ when compared to ketoconazole has a less pronounced effect on system for the metabolism @DRUG$.	DDI-mechanism
Interactions may occur between EPA supplements and @DRUG$ and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-false
Note: dissolution of aerosol particles of @DRUG$ in @DRUG$, a model lung surfactant.	DDI-false
if @DRUG$ after of @DRUG$ therapy sufficient time for effect aPTT to prior of Argatroban	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, @DRUG$).	DDI-false
Drugs Not Be Coadministered With @DRUG$ : , : terfenadine : ergot Antimycobacterial Benzodiazepines midazolam triazolam agents : @DRUG$	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
If a @DRUG$ also increase of @DRUG$ toxicity	DDI-effect
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
ANTACID (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
Benzylpenicillin @DRUG$ chlortetracycline , @DRUG$ , cephalothin erythromycin and sulfamethoxazole no in diclofenac	DDI-false
that significant in gastric pH ( @DRUG$ such as ranitidine @DRUG$ reduce plasma of and reduce efficacy .	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
: As with other @DRUG$ , excretion is inhibited probenecid in approximate in AUC	DDI-false
These drugs @DRUG$ and other diuretics corticosteroids phenothiazines , thyroid estrogens , oral @DRUG$ acid , channel blocking and	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and digoxin).	DDI-mechanism
@DRUG$ The effects warfarin and @DRUG$ are synergistic that of drugs a serious GI that of users alone .	DDI-false
drug may with @DRUG$ ( the depressant of these medications anticholinergics medications with activity ( effects may potentiated when medications used concurrently with @DRUG$ monoamine oxidase inhibitors concurrent use with may the depressant effects )	DDI-false
Coadministration of @DRUG$ and drugs that inhibit CYP3A may increase @DRUG$ plasma concentrations.	DDI-false
@DRUG$ , clarithromycin , doxycycline erythromycin , imatinib , , nefazodone , @DRUG$ , protease , and verapamil	DDI-false
known metabolic profiles are @DRUG$ trimethoprim/sulfamethoxazole @DRUG$ , or fluconazole	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, alfentanil, and @DRUG$.	DDI-false
@DRUG$ used has little no effect on , from concomitant therapy @DRUG$ and epinephrine may occur .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
ANTACID ( Hydroxide ): @DRUG$ plasma concentrations were not by co-administration of @DRUG$.	DDI-false
@DRUG$ (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).	DDI-false
Co-administration of single 25-mg dose @DRUG$ had no effect on the pharmacokinetics of total @DRUG$.	DDI-false
Drugs have been associated neuropathy @DRUG$ chloramphenicol @DRUG$ disulfiram , , glutethimide gold , , metronidazole , , , ribavirin .	DDI-false
- Anabolic steroids @DRUG$ e.g. , Anabolin , @DRUG$ oxymetholone [ e.g. , Anadrol [ ] ) or	DDI-false
@DRUG$ @DRUG$ anticholinesterase agents .	DDI-int
It is recommended to avoid concurrent administration of @DRUG$ with @DRUG$ containing antacids for at least 4 hours following ethambutol administration.	DDI-advise
that been associated peripheral include @DRUG$ , chloramphenicol , cisplatin , disulfiram ethionamide , , @DRUG$ iodoquinol , , , phenytoin ribavirin and vincristine .	DDI-false
Multiple-dose administration of the potent CYP3A4 inducer @DRUG$ (600 mg every 24 hours, q24h, for 14 days), however, reduced @DRUG$ Cmax and AUC by approximately 80%.	DDI-mechanism
Drugs Drugs such @DRUG$ @DRUG$ , , phenothiazines and be associated QT-interval prolongation and arrhythmia	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-false
no specific or identified @DRUG$ Solution , the possibility of additive or potentiating CNS depressants @DRUG$ barbiturates be considered	DDI-advise
drugs include the thiazides and diuretics , , products , @DRUG$ , phenytoin , nicotinic sympathomimet-ics , @DRUG$ isoniazid	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
Specific studies have confirmed these effects with @DRUG$, @DRUG$, propofol, alfentanil, and midazolam.	DDI-false
@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
order to avoid occurrence of severe should be premedicated corticosteroids as ) , H2 ( such @DRUG$ @DRUG$	DDI-false
Itraconazole coadministered with @DRUG$ @DRUG$ or H2antagonists , plasma itraconazole reported .	DDI-false
INOmax has been administered with tolazoline, @DRUG$, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
specific , are mainly metabolized by CYP3A4 calcium channel dapsone , disopyramide quinine amiodarone , quinidine warfarin , @DRUG$ , derivatives , pimozide , , , @DRUG$ , triazolam ) coadministered with ;	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Because is a theoretical may be additive use @DRUG$-containing or ergot-type dihydroergotamine methysergide and @DRUG$ 24 of be	DDI-advise
The increase of @DRUG$ level, however, is small (15%) when given with @DRUG$.	DDI-mechanism
nevirapine compared therapy with the over 48 as initial therapy with similar responses being observed @DRUG$ regimens with	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Corticosteroids Diuretics : Concomitant with @DRUG$ @DRUG$ or diuretics potentiate a possible hypokalemic of   beta2-agonists	DDI-false
@DRUG$ Since both and @DRUG$ can cause intracranial pressure , .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
@DRUG$ Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	DDI-false
Pyrantel (e.g., @DRUG$) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-false
@DRUG$ potentiates the muscle relaxant effect of all muscle relaxants, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Drugs That Should Be Coadministered Antiarrhythmics : amiodarone , Antihistamines astemizole , : Antimycobacterial : @DRUG$ @DRUG$ midazolam GI motility :	DDI-false
Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of @DRUG$.	DDI-false
The availability @DRUG$ regimens for antiretroviral therapy and inhibitor (PI)-related metabolic have to significant shifts practices infection .	DDI-false
This change was not considered clinically significant and no dose adjustment is needed when @DRUG$ and @DRUG$ are coadministered.	DDI-false
Concomitant administration of @DRUG$ and other related compounds (eg, quinine, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
: In a study , coadministration an ( @DRUG$ , magnesium hydroxide , simethicone with serum levels and urinary fosinoprilat with @DRUG$ alone , suggesting that may of fosinopril	DDI-false
Central Nervous System The use @DRUG$   ( ) nervous system depressants , including to other , , ( e.g. , benzodiazepines ) , general , @DRUG$ alcohol depression hypotension and sedation , coma death	DDI-effect
@DRUG$ ( @DRUG$ tranquilizers , opioids have or potentiating with	DDI-false
drugs which the neuromuscular action of nondepolarizing agents such as include antibiotics ( e. , aminoglycosides @DRUG$ , lincomycin clindamycin @DRUG$ , and , salts local anesthetics , quinidine	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Both @DRUG$ and extracellular the nucleus but @DRUG$ extracellular of the nucleus accumbens	DDI-false
The pressor of catecholamines such as @DRUG$ or norepinephrine are by @DRUG$.	DDI-effect
Oral @DRUG$ gastrointestinal of V oral vitamin B-12 methotrexate and @DRUG$.	DDI-mechanism
Death due to pancreatitis related @DRUG$ and @DRUG$ has reported .	DDI-effect
Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after @DRUG$ is initiated to see whether the statin dose needs adjustment.	DDI-advise
is available about the interaction @DRUG$ @DRUG$ multiple either drug	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
The that may result from administration non-potassium sparing such @DRUG$ can be acutely worsened , when dose of the @DRUG$ is .	DDI-false
Norepinephrine : @DRUG$ the effect	DDI-effect
@DRUG$ e.g. @DRUG$ ) or	DDI-false
@DRUG$ as post-marketing , have can reduce of @DRUG$ and some patients .	DDI-false
@DRUG$    should be used in patients receiving @DRUG$ or agents local the toxic of drugs could be .	DDI-advise
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
no drug-drug were conducted @DRUG$ inducers of CYP3A , that inducers ( @DRUG$ , rifampin , ) would expected to .	DDI-mechanism
Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
: a dopamine , @DRUG$ as neuroleptics @DRUG$ , thioxanthenes metoclopramide , the of APOKYN	DDI-false
As other concurrent of @DRUG$ may concentrations of @DRUG$ of elimination half-life	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : concomitant administration of Vardenafil mg BID @DRUG$ , the Cmax and AUC reduced %	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
and Corticotropin @DRUG$ which may the patient cardiac	DDI-effect
Other reported interactions with amiodarone: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Patients receiving @DRUG$ and @DRUG$ concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.	DDI-advise
@DRUG$ did not increase the plasma levels of @DRUG$.	DDI-false
Ritonavir Coadministration @DRUG$ with @DRUG$ resulted a % increase in nelfinavir AUC and very in ritonavir plasma A.C.	DDI-mechanism
Antiacid, @DRUG$, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ may decrease the amount of @DRUG$ (Lanoxin, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Agents @DRUG$ CONTRAINDICATED coadministration saquinavir antiretroviral concentrations	DDI-false
In data nefazodone inhibits metabolism of @DRUG$ , an in @DRUG$ QT interval the	DDI-false
Between And @DRUG$ @DRUG$ ) Phenytoin ( had the of in refractory epilepsy	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
Caution should be taken concurrent serial aminoglycosides @DRUG$ neomycin s nephrotoxicity ototoxicity potentiate @DRUG$ blocking effects	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$, @DRUG$, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Potassium Supplements and @DRUG$: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
between the @DRUG$ @DRUG$ , coumarin anticoagulants has suggested .	DDI-int
@DRUG$ 2 antagonists effect gastric on of @DRUG$ in healthy volunteers .	DDI-false
@DRUG$, Methotrexate, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The hypoglycemic may be including and drugs that highly , salicylates , sulfonamides @DRUG$ probenecid coumarins @DRUG$ beta blocking .	DDI-false
@DRUG$ : The concomitant Bepridil @DRUG$ has well tolerated in with stable	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The of the be anticonvulsants @DRUG$ , @DRUG$ , , monoamine oxidase inhibitors , narcotics phenothiazines or	DDI-false
@DRUG$ Multiple dose administration ( monotherapy ) of oral @DRUG$ in of age .	DDI-false
the @DRUG$ , e.g. @DRUG$ , paroxetine and fluvoxamine 2D6 , they may vary of	DDI-false
No interactions between @DRUG$ isoflurane , @DRUG$ midazolam have been	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In , was pharmacodynamic interaction as a of coadministration of @DRUG$ @DRUG$ ER .	DDI-false
@DRUG$ may decrease the effect of phenothiazines, @DRUG$, and ketoconazole.	DDI-effect
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by @DRUG$.	DDI-effect
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Tagamet , apparently an effect on certain microsomal been reported of anticoagulants @DRUG$ , , , antidepressants , lidocaine , @DRUG$ thereby delaying elimination and blood levels drugs .	DDI-false
Drugs inhibit 3A4 ( , ketoconazole @DRUG$ as @DRUG$ ) the potential result in concentrations of	DDI-false
emergency situation when opioid analgesia administered a @DRUG$ , of @DRUG$ be than , resulting respiratory may more prolonged	DDI-effect
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Beta-Blocking Agents  A pharmacokinetic study of @DRUG$ in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
( ) moclobemide 30 , ( 0.25 mg/kg , @DRUG$ ( @DRUG$ ( 30 ) or was administered .	DDI-false
@DRUG$ and Potassium-Sparing : @DRUG$ can potassium loss .	DDI-false
Diuretics: Diclofenac and other @DRUG$ can inhibit the activity of @DRUG$.	DDI-effect
However, neither phenobarbital nor @DRUG$ appears to affect @DRUG$ metabolism.	DDI-false
@DRUG$, such as probenecid and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	DDI-false
Theophylline : The pharmacokinetics @DRUG$ @DRUG$ mg/kg minutes were unchanged dose of albendazole 6 healthy subjects .	DDI-false
@DRUG$ : @DRUG$ 3 the pharmacokinetics of or , nor were there any changes the profile ( prothrombin ) a single mg warfarin	DDI-false
Probenecid: As with other @DRUG$, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
: The administration of and @DRUG$ in normal volunteers had no on of @DRUG$ but decreased the urinary excretion its glucuronide metabolite .	DDI-false
In the case that you are taking digoxin while taking @DRUG$, higher doses of @DRUG$ may be needed.	DDI-false
Drugs In of patients - 10/interaction ) the administration @DRUG$ , gold , D-penicillamine , , doxycycline , digitoxin did not the levels and values of	DDI-false
It suggested that receiving alternatives @DRUG$ should @DRUG$ therapy needed .	DDI-false
@DRUG$: Coadministration of a single dose of @DRUG$ and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
Concomitant with @DRUG$ @DRUG$ should because has a cases of pseudotumor cerebri hypertension ) some of which	DDI-advise
, Didanosine , Fluconazole , Indanavir @DRUG$ @DRUG$ carbamazepine Rifabutin Rifampin Ritanovir Saquinavir	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
and/or , containing ( ) , @DRUG$ @DRUG$ or other didanosine ) chewable/buffered or solution should be within before or 2 FACTIVE .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
Repeated doses hydrochloride prior to a dose @DRUG$ in human trials reported to @DRUG$ absorption	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Nervous Depressants : use DURAGESIC   ( transdermal system ) with @DRUG$ , but not @DRUG$ hypnotics tranquilizers ( , benzodiazepines general anesthetics phenothiazines , skeletal muscle , alcohol , respiratory hypotension profound , or in coma death .	DDI-false
Coadministration of single, oral doses of zaleplon with @DRUG$ (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in @DRUG$s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-false
ACE II Receptor (Hypertension)- In studies patients with hypertension @DRUG$ to mg to inhibitors @DRUG$ slightly ( - mEq/L ) .	DDI-effect
has with , dopamine , @DRUG$ , @DRUG$ , and .	DDI-false
strong inhibitors of CYP3A4 itraconazole @DRUG$ @DRUG$ , ritonavir nelfinavir ) would to	DDI-false
this medication your doctor or of all and products may : ( e.g. , amikacin , @DRUG$ , cyclosporine drugs , ibuprofen , @DRUG$	DDI-false
Based on @DRUG$ should be patients @DRUG$ therapy	DDI-advise
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Drugs Not With VIRACEPT , @DRUG$ : , ergot derivatives @DRUG$ rifampin midazolam GI agents :	DDI-false
@DRUG$ Based of and of consciousness apomorphine was with the of apomorphine with drugs of the 5HT3 antagonist including , for example , ondansetron , , dolasetron palonosetron @DRUG$ ) is contraindicated	DDI-false
addition , the of beta-blockers @DRUG$ , guanethidine , @DRUG$ the hypoglycemia be reduced absent	DDI-false
Antibiotics : and/or in vivo data clarithromycin @DRUG$ @DRUG$ markedly inhibit of , which in in cisapride levels prolongation of the interval the .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : Clinical studies , well marketing , shown @DRUG$ and in some .	DDI-false
Naproxen : The concomitant and naproxen normal volunteers had no on the levels @DRUG$ excretion of @DRUG$ its glucuronide metabolite .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
When CANCIDAS is co-administered with inducers drug clearance such as efavirenz @DRUG$ , @DRUG$ dexamethasone or carbamazepine , of dose 70 CANCIDAS should be considered	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
concomitant of @DRUG$ and @DRUG$ in had effect the of but decreased the excretion and metabolite	DDI-mechanism
concentrations @DRUG$ , , ibuprofen @DRUG$ , piroxicam acetaminophen phenytoin andtolbutamide not alter protein .	DDI-false
: Macrolide inhibit the inhibitors that are CYP3A4 @DRUG$ , lovastatin @DRUG$	DDI-false
however, 150 mg of @DRUG$ q12h for 3 days increased the @DRUG$ C max by 23% and ceftibuten AUC by 16%.	DDI-mechanism
Cephalosporins-@DRUG$ containing side chains N-methylthiotetrazole @DRUG$ cefotetan , methylthiadiazole ( cefazolin ) can vitamin deficiency hypoprothrombinemia	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	DDI-false
The are examples to inhibit metabolism of related benzodiazepines through CYP3A nefazodone , cimetidine , @DRUG$ isoniazide @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$, @DRUG$: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
Other may enhance neuromuscular blocking action agents such as include antibiotics e. @DRUG$ tetracyclines , , polymyxins , lincomycin , colistin and sodium ) magnesium , @DRUG$ , procainamide , .	DDI-false
Iodine or iodine excess may decrease the of @DRUG$ and deficiency can	DDI-false
A between @DRUG$ and oral @DRUG$ leading has .	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Garlic Garlic be while @DRUG$ ( as protease due to risk of @DRUG$ plasma concentrations .	DDI-false
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
may increase the effect of , e.g. guanethidine , @DRUG$ @DRUG$.	DDI-false
The patients in studies one with ORENCIA : @DRUG$ NSAIDs @DRUG$ , TNF , azathioprine , , hydroxychloroquine , ,	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
interaction between and other potent inhibitors @DRUG$ , ritonavir , and @DRUG$ ) has not been exposures to may be expected when concomitantly with these medications .	DDI-false
Two ( SH/DA ; ) were submitted to daily synthetic solutions @DRUG$ @DRUG$ in the same as those found in most	DDI-false
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$, coexisting in the contents of alcoholic beverages.	DDI-false
include the @DRUG$ and other corticosteroids , , oral contraceptives @DRUG$ sympathomimet-ics calcium channel blocking and isoniazid	DDI-false
anticoagulants effect , @DRUG$ and inducers enzyme system ( decreased effect , corticosteroids of @DRUG$ )	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Caution should also be taken in concurrent or serial use of other aminoglycosides and @DRUG$ because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ neuromuscular blocking effects.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as @DRUG$ or ranitidine).	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	DDI-effect
A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of @DRUG$ at 1,000 mg/day and @DRUG$ at 90 mg/day.	DDI-mechanism
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Although the changes in @DRUG$ exposure coadministered with not sufficient to adjustments experience enhanced sedative caused by increased @DRUG$ .	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
The pills is reduced by the @DRUG$ phenytoin , carbamazepine @DRUG$ , the drug rifampin .	DDI-false
@DRUG$ may potentiated certain drugs including anti-inflammatory agents and drugs that protein bound salicylates , sulfonamides , @DRUG$ monoamine oxidase inhibitors beta	DDI-effect
@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, @DRUG$, and ranitidine.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
taking low-dose @DRUG$ plus @DRUG$ were studied	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Other Interactions : interactions were observed between vardenafil and following glyburide , @DRUG$ @DRUG$ , ranitidine	DDI-false
In a comparison in ketamine , @DRUG$ , pentobarbital needed cause ventricular was was the LD50 of or @DRUG$.	DDI-false
Additionally, paroxetine did not alter the pharmacokinetics of @DRUG$, reflecting the absence of a role of CYP2D6 in @DRUG$ s metabolism.	DDI-false
@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism.	DDI-mechanism
The hypoglycemic action of may be potentiated by drugs nonsteroidal anti-inflammatory and drugs that are bound , salicylates , @DRUG$ , , @DRUG$ monoamine inhibitors , adrenergic blocking agents	DDI-false
@DRUG$ and Norethindrone Coadministration of @DRUG$ with OVCON-35 in a ethinyl estradiol an 18 concentrations	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : Reports @DRUG$ diminish antihypertensive effect Angiotensin Enzyme ACE inhibitors	DDI-false
These indicate not influence plasma concentration of other @DRUG$ not	DDI-false
: @DRUG$ clearance plasma @DRUG$ , has been reported with some drugs .	DDI-false
of with @DRUG$ therapy reserved for life-threatening arrhythmias are incompletely responsive to or	DDI-false
following of substances may increase the effect and to hypoglycemia oral antidiabetic , , fluoxetine , monoamine oxidase ( MAO , @DRUG$ , salicylates , analog , octreotide ) , @DRUG$.	DDI-false
Potential interactions between Keppra other ( carbamazepine gabapentin @DRUG$ , and valproate assessed the concentrations of @DRUG$ and these AEDs placebo-controlled clinical .	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ should used @DRUG$.	DDI-advise
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
with IV @DRUG$ @DRUG$ , , milrinone , or IV ACE not been evaluated ( not co-administered with in clinical ) .	DDI-false
@DRUG$ (such as flecainide, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
@DRUG$ : a dose of @DRUG$ promethazine and , respectively in a % decrease in concentrations zaleplon no change the area plasma concentration-time	DDI-false
Anticholinesterases neostgmine , @DRUG$ , quinine @DRUG$ toxicity cause respiratory	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
In vitro studies indicate that , therapeutic salicylate ( 300 m ) binding @DRUG$ was from approximately % to 97.5 % representing a increase in unbound @DRUG$ .	DDI-false
Alcohol: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	DDI-false
Potassium-sparing ( e.g. @DRUG$ , @DRUG$ or amiloride ) , potassium salt may lead significant	DDI-false
@DRUG$ as diazoxide are in combination @DRUG$ should observed for hours for any fall .	DDI-effect
Interactions may interact , like @DRUG$ MAOI ): could theoretically affect @DRUG$ pharmacodynamics - - Eproxindine - : Flupenthixol and cause depression - Tricyclic antidepressants Flupenthixol the	DDI-false
@DRUG$ vitro that inhibits the metabolism which result increase @DRUG$ and interval on the	DDI-false
serum concentrations should closely when or @DRUG$ @DRUG$.	DDI-advise
therapy increased , is reduced , by @DRUG$ used @DRUG$	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
@DRUG$ (@DRUG$)-A drug interaction study of eplerenone with an NSAID has not been conducted.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of @DRUG$ given as a single dose.	DDI-false
Concurrent administration of with products magnesium aluminum , @DRUG$ , VIDEX chewable/buffered pediatric powder or products containing , may substantially of @DRUG$ , in serum urine levels considerably lower .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
The pharmacokinetics of theophylline ( @DRUG$ mg/kg minutes ) were dose @DRUG$ mg 6 healthy .	DDI-false
Indinavir : @DRUG$ with VIRACEPT % increase nelfinavir AUC and @DRUG$ plasma	DDI-false
not administered concurrently with D2-antagonists , such @DRUG$ butyrophenones , @DRUG$ , or .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.	DDI-false
@DRUG$ Simvastatin in with @DRUG$ has with reports	DDI-false
Other may blocking action of as NUROMAX include ( aminoglycosides , bacitracin polymyxins , lincomycin , clindamycin colistin @DRUG$ , @DRUG$ salts lithium local , , .	DDI-false
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
@DRUG$ Elevated levels been in experience @DRUG$ is administered	DDI-false
Aminoglutethimide @DRUG$ diminish suppression	DDI-effect
Cholestyramine and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Important To Date does clinically pharmacokinetic interactions @DRUG$ beta-blockers , felodipine , digoxin , isosorbide mononitrate , @DRUG$ , or .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
aluminum-containing , containing @DRUG$ ) , multivitamin preparations or metal or Videx ( didanosine or powder should not be within before 2 FACTIVE	DDI-false
, through effect on microsomal systems , reported to the hepatic warfarin-type anticoagulants , @DRUG$ , , chlordiazepoxide @DRUG$ , lidocaine , metronidazole delaying elimination and increasing of .	DDI-false
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	DDI-false
Flupenthixol may with some like Monoamine oxidase inhibitors ( MAOI @DRUG$ could flupenthixol pharmacodynamics - Ethanol : @DRUG$ Ethanol additive depression - antidepressants : Flupenthixol increases of antidepressants	DDI-false
Drugs That Induce CYP3A4 (Rifampicin) Racemic @DRUG$ exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	DDI-mechanism
The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as @DRUG$, triazolopyridazines and others, are also blocked by @DRUG$.	DDI-effect
10 once coadministered doses of @DRUG$ cimetidine and @DRUG$ in volunteers .	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-effect
in these result a decreased efficacy of : , , @DRUG$ @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ not the plasma concentration other @DRUG$ and that these AEDs influence the .	DDI-false
receiving analgesics , general anesthetics , phenothiazines , @DRUG$ , or other ( including @DRUG$ ) concomitantly may an additive depression .	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$ : Coadministration atorvastatin @DRUG$ AUC for and by 20 .	DDI-false
Contraceptives Including Transdermal and An that co-administration of and the oral @DRUG$ @DRUG$ average of and ethinyl estradiol levels of % and 31	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antiacid , @DRUG$ , @DRUG$ , Fluoxetine Indanavir , Phenytoin , , Ritanovir Saquinavir	DDI-false
Anticoagulants including derivatives , indandione @DRUG$ as nonsteroidal ( @DRUG$ ) the risk administered concomitantly .	DDI-false
@DRUG$ ACTH may induced hypokalemia which predispose the cardiac	DDI-effect
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, @DRUG$ or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ and of amiodarone serum concentration @DRUG$ be considered .	DDI-false
slightly the effect , e.g. @DRUG$ , @DRUG$.	DDI-false
However if Argatroban to be initiated of @DRUG$ sufficient time for heparins effect decrease to initiation @DRUG$	DDI-false
Anticonvulsants ( ): state plasma ( ) of @DRUG$ 40 was by when ( 300 QD for 12 days ) @DRUG$ CYP 3A4 .	DDI-mechanism
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
are of substances that may the : , , danazol , @DRUG$ sympathomimetic , @DRUG$ , , , progestogens e.g. , in oral	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Injection : @DRUG$ , like central nervous system with alcohol , @DRUG$ . is concomitantly with lorazepam , incidence sedation , irrational has observed .	DDI-effect
HIVID @DRUG$ and @DRUG$ has been as in adults	DDI-false
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of @DRUG$ or vinblastine and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Antiarrhythmics : @DRUG$ , as quinidine @DRUG$ , and , have used with	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Although specific not been , that are mainly metabolized , , , , @DRUG$ , quinidine warfarin , cyclosporine ergot derivatives , @DRUG$ , carbamazepine , may have elevated plasma concentrations when coadministered ;	DDI-false
Therefore, if digoxin is administered with @DRUG$, the clinician should be alert to the possibility of increases in @DRUG$ levels.	DDI-false
normal volunteers , administration of @DRUG$ and hydrochlorothiazide resulted in increased of	DDI-false
A potential oral @DRUG$ oral @DRUG$ leading severe has been reported	DDI-int
@DRUG$ : Based on of hypotension and loss was with ondansetron the concomitant of with of class ( example , ondansetron @DRUG$ , palonosetron and is contraindicated .	DDI-false
Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing @DRUG$.	DDI-false
are of substances that reduce the blood-glucose-lowering , @DRUG$ , agents ( , @DRUG$ salbutamol terbutaline ) , isoniazid phenothiazine derivatives somatropin , estrogens progestogens , ) .	DDI-false
Antidepressants , @DRUG$ @DRUG$ may enhance of or	DDI-false
significant ( pharmacodynamic in @DRUG$ , @DRUG$ and .	DDI-false
Interactions may occur between supplements non-steroidal anti-inflammatory drugs and herbs as garlic ( Allium ) @DRUG$ ( @DRUG$	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
it has @DRUG$ of in the patients liver which , in , in a proportion ingested @DRUG$ the metabolites .	DDI-mechanism
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-effect
patients colorectal were ) without @DRUG$.	DDI-false
alkaloids @DRUG$ of @DRUG$.	DDI-effect
This with alcohol or other CNS depressants may potentiate the effects or @DRUG$ ) with activity ( effects may potentiated when these concurrently , @DRUG$ ( may and intensify and CNS depressant effects antihistamines )	DDI-false
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an @DRUG$ containing aluminum and magnesium.	DDI-false
Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, @DRUG$ or @DRUG$.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, @DRUG$, Maalox, and ranitidine.	DDI-false
@DRUG$ II ( Congestive Heart Post-Myocardial In 3020 % ) patients receiving 25 mg received or @DRUG$ ( ) .	DDI-false
alter concentrations that may imatinib when administering @DRUG$ inhibitors the family ketoconazole @DRUG$ .	DDI-advise
Agents Affecting Cytochrome Isoenzyme @DRUG$ is metabolized human P450 3A4 isoenzyme ( CYP3A4 interactions occur when @DRUG$ given concurrently with agents that .	DDI-false
It may increase excretion of barbiturates, lithium, and @DRUG$ and may also increase the toxicity of @DRUG$.	DDI-false
To avoid @DRUG$ intoxication, appropriate adjustment of the @DRUG$ should be made.	DDI-false
A possible interaction between @DRUG$ and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
Products : Absorption of zalcitabine moderately reduced % ) coadministered antacid products .	DDI-false
A similar association less marked , has @DRUG$ , , sodium , carbamazepine possibly with ampicillin @DRUG$ )	DDI-false
@DRUG$ @DRUG$ , flecainide , propafenone quinidine life-threatening reactions .	DDI-false
While and @DRUG$ affinities for opioid possibly nicotinic , @DRUG$ has much ibogaine and sigma-2 receptors , sodium and the transporter .	DDI-false
@DRUG$ additive effects with and CNS hypnotics , , @DRUG$ ) .	DDI-effect
Oral neomycin inhibits the absorption of , vitamin @DRUG$ and @DRUG$.	DDI-false
@DRUG$ reduce the renal clearance of lithium and add a high risk of @DRUG$ toxicity.	DDI-effect
@DRUG$ and : has no pharmacokinetic interactions digoxin , and losartan has no significant levels of @DRUG$.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
acetaminophen/theophylline , @DRUG$/acetaminophen , phenobarbital/valproic acid , , theophylline/acetaminophen , and .	DDI-false
Antiacid , Didanosine , Fluconazole , Indanavir , Phenytoin carbamazepine , , @DRUG$ , ,	DDI-false
on the effect @DRUG$ @DRUG$	DDI-effect
Example inhibitors include azole , clarithromycin , doxycycline erythromycin @DRUG$ , nefazodone @DRUG$ , propofol , protease inhibitors , quinidine , verapamil .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
therapy interaction not , finasteride of used in studies acetaminophen acetylsalicylic , a-blockers , , angiotensin-converting enzyme ( ) inhibitors benzodiazepines , @DRUG$ blockers , cardiac @DRUG$ , , H2 , , prostaglandin synthetase ( also referred NSAIDs ) , and quinolone without evidence	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
drugs which may the neuromuscular blocking action nondepolarizing agents such NUROMAX include certain antibiotics e. , aminoglycosides , tetracyclines @DRUG$ clindamycin , salts , , local anesthetics , @DRUG$ and quinidine	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , , , erythromycin isoniazid , nefazodone , , propofol , inhibitors @DRUG$ , and .	DDI-false
@DRUG$, @DRUG$, verapamil	DDI-false
majority of RA or more of the concomitant medications with : MTX @DRUG$ , TNF agents , @DRUG$ , gold , hydroxychloroquine , leflunomide , , anakinra	DDI-false
reactions have been combination containing high PROLEUKIN , @DRUG$ , @DRUG$.	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
agents : Concomitant administration @DRUG$ and with potential [ e.g. , , , and amikacin B , pentamidine , @DRUG$ ] contraindicated	DDI-advise
Co-administration @DRUG$ with oral @DRUG$ has been shown concentrations of components ethinylestradiol ( and levonorgestrel LNG )	DDI-mechanism
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
: injection benzodiazepines , produces depression nervous system administered with @DRUG$ , phenothiazines , @DRUG$ , antidepressants When lorazepam an increased incidence of sedation hallucinations , and observed .	DDI-false
That Not Coadministered Antiarrhythmics : , terfenadine Antimigraine ergot Antimycobacterial agents : rifampin @DRUG$ triazolam GI motility @DRUG$	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
are of blood-glucose-lowering : , niacin , diuretics , agents ( epinephrine phenothiazine derivatives , somatropin @DRUG$ estrogens @DRUG$ ( , in oral .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ , lithium and @DRUG$ increase the toxicity of salicylates .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ : doses of 3 and @DRUG$ 2 did not have clinically relevant on pharmacodynamics or .	DDI-false
Beta-blockers @DRUG$ lithium salts and alcohol may either potentiate weaken the blood-glucose-lowering effect of	DDI-effect
Glyburide: The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
@DRUG$ been to side effects including renal , hyperbilirubinemia , confusion , dyspnea concomitant of these with reduce effectiveness of and thus be avoided . @DRUG$ and antihypertensives may seen with	DDI-false
Coadministration of @DRUG$ 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
: @DRUG$ been to in steady-state concentrations of various	DDI-mechanism
Investigations into the effect of acitretin on the protein binding of @DRUG$ (@DRUG$) revealed no interaction.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
@DRUG$ may decrease the hemodynamic effects of @DRUG$;	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
@DRUG$ @DRUG$ decreases lithium clearance increases lithium plasma levels	DDI-false
@DRUG$ trisilicate , administered concomitantly @DRUG$ reduce rate and extent of	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, phenytoin and @DRUG$) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Hallucinations have been when used in patients @DRUG$ fluoxetine , @DRUG$ ) .	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules.	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/SMX).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Combinations of @DRUG$ and @DRUG$: effects on drug discrimination and behavioral inhibition in rats.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
@DRUG$ and intensify ( drying ) @DRUG$.	DDI-effect
: @DRUG$ clearance steady-state were affected co-administration @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Data from in studies of @DRUG$ alprazolam a possible interaction for following : ergotamine , @DRUG$ , amiodarone , and .	DDI-int
Treatment with @DRUG$ once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in @DRUG$ AUC.	DDI-mechanism
@DRUG$ injection injectable benzodiazepines produces depression the central system with @DRUG$ barbiturates , inhibitors other . When scopolamine is concomitantly with , sedation hallucinations observed	DDI-effect
Monitoring for amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-advise
The majority of patients RA more following concomitant with ORENCIA corticosteroids , blocking , , chloroquine , , , @DRUG$ , and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$, including lisinopril.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
of @DRUG$ has been studied , but cases @DRUG$ plasma levels during therapy reported .	DDI-false
Valproate The addition to patients @DRUG$ on @DRUG$ decreased tiagabine in vitro from 96.3 to 94.8 % approximately 40 free tiagabine .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The action of the @DRUG$ may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
The majority RA or more following ORENCIA MTX NSAIDs corticosteroids , TNF agents , @DRUG$ , chloroquine , @DRUG$ , , sulfasalazine and	DDI-false
comparison of digitalis tolerance in anesthetized with @DRUG$ , @DRUG$ , of to cause ventricular tachycardia was higher , as was the LD50 of , Innovar than pentobarbital	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: generally should not be given with @DRUG$.	DDI-advise
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., @DRUG$, @DRUG$) may increase their clearance, resulting in decreased plasma concentration.	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
@DRUG$ ( 600 mg . Vardenafil resulted a in @DRUG$ AUC 13-fold increase in vardenafil .	DDI-false
Considerable caution should be exercised if PEGANONE is administered concurrently with @DRUG$ (@DRUG$) since paranoid symptoms have been reported during therapy with this combination.	DDI-false
Furosemide: @DRUG$ IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-effect
, Lodine , other @DRUG$ , through effects on renal prostaglandins may cause changes in elimination of these drugs elevated of cyclosporine @DRUG$ , increased toxicity .	DDI-mechanism
The AUC of @DRUG$ was increased 2.2-fold by coadministration of @DRUG$, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antidepressants, tricyclic: @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-effect
Patients general @DRUG$ , phenothiazines , , sedative-hypnotics , or other @DRUG$ including alcohol concomitantly with may exhibit an .	DDI-false
@DRUG$ inhibits ERMBT , and @DRUG$ and are inducers of the	DDI-false
include azole antifungals , clarithromycin , @DRUG$ erythromycin @DRUG$ , , nicardipine , propofol , , quinidine and verapamil	DDI-false
@DRUG$ ( e.g. , , @DRUG$ , or , potassium supplements , or potassium-containing salt substitutes may significant in	DDI-false
@DRUG$ : Ephedrine enhance the clearance of @DRUG$ , resulting in decreased blood levels activity an in corticosteroid	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of @DRUG$	DDI-effect
Therefore, caution should be used when administering @DRUG$ concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., @DRUG$).	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
- Vitamin K ( e.g. AquaMEPHYTON , @DRUG$ Use @DRUG$ these medicines increase of side	DDI-false
Administration of @DRUG$ during therapy with a @DRUG$ has been shown to produce a  stimulating  effect in some depressed patients.	DDI-effect
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
@DRUG$ , @DRUG$ , other anticoagulants may the risk	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Monoamine @DRUG$ in decrease @DRUG$ clearance of 6 %	DDI-mechanism
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.	DDI-false
The mean percentage increase in the @DRUG$ AUC after @DRUG$ administration was 56.9% (range: 35 to 81).	DDI-mechanism
@DRUG$ : levels @DRUG$ clearance not affected by 0.2 mg sodium	DDI-false
@DRUG$ dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of @DRUG$ or the level of platelet aggregation in healthy adults.	DDI-false
@DRUG$ : As @DRUG$ , renal excretion of cephalexin inhibited probenecid	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Hallucinations have reported @DRUG$ in patients @DRUG$ ( fluoxetine thiothixene alprazolam ) .	DDI-effect
Nervous Depressants DURAGESIC   ( ) nervous , but other opioids , @DRUG$ ( , benzodiazepines , general , @DRUG$ and alcohol respiratory depression , hypotension , or potentially result coma .	DDI-false
Intravenous ( @DRUG$ been effectively presence of cardioactive drugs , as @DRUG$ , agents , calcium channel agents , and angiotensin enzyme inhibitors without any change adverse	DDI-false
Injection Lorazepam , like injectable @DRUG$ , produces the central when with ethyl phenothiazines , @DRUG$ antidepressants When is used concomitantly with injectable lorazepam , an of , irrational been .	DDI-effect
induce CYP3A4 , @DRUG$ phenytoin carbamazepine @DRUG$ , phenobarbital or	DDI-false
- @DRUG$ (e.g., @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines	DDI-false
@DRUG$ addition patients valproate chronically had no effect on @DRUG$ , decreased in vitro from 96.3 to 94.8 % resulted in increase of approximately 40 in free .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Other concomitant specific not finasteride of or were used studies with acetaminophen , acetylsalicylic , analgesics ACE ) inhibitors , @DRUG$ , benzodiazepines beta , calcium-channel diuretics @DRUG$ reductase prostaglandin ( to NSAIDs ) quinolone anti-infectives without evidence of significant	DDI-false
Drugs have been associated peripheral analogues , cisplatin , , ethionamide @DRUG$ , , @DRUG$ phenytoin and .	DDI-false
exposure of @DRUG$ ( 10 mg ) was by following valdecoxib ( 40 for 12 while exposure @DRUG$ 40 ) not substantially increased following of diazepam ( BID 12	DDI-false
@DRUG$ may decrease the effect of @DRUG$, levodopa, and ketoconazole.	DDI-effect
@DRUG$ and have been increased an average 31 , respectively by the of @DRUG$ tablets up to mg/day	DDI-mechanism
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, @DRUG$, and anakinra.	DDI-false
risk this increased with cyclosporine fibric ( @DRUG$ , @DRUG$ , azole .	DDI-false
been associated with neuropathy include nucleoside chloramphenicol , cisplatin , dapsone , ethionamide glutethimide , @DRUG$ , hydralazine @DRUG$ , , , nitrofurantoin , phenytoin ribavirin and .	DDI-false
Antiacid, @DRUG$, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
@DRUG$: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
interaction not finasteride doses 1 or used clinical , acetylsalicylic acid , analgesics , @DRUG$ , anticonvulsants , beta blockers blockers , cardiac @DRUG$ , diuretics , antagonists , reductase , prostaglandin inhibitors also NSAIDs ) , and anti-infectives of adverse interactions	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Antiacid, clarithromycin, Didanosine, @DRUG$, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$ insulin ) - of @DRUG$ may be .	DDI-false
P-450 such phenytoin , and @DRUG$ induce metabolism causing an in @DRUG$ levels	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
majority of patients the following @DRUG$ : NSAIDs , @DRUG$ TNF blocking agents , , chloroquine , , , leflunomide , , and	DDI-false
ACE-inhibitors Reports that @DRUG$ may diminish antihypertensive of @DRUG$.	DDI-effect
@DRUG$ should frequently if @DRUG$ administered with lithium	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when paclitaxel and @DRUG$ are used in combination.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	DDI-false
of @DRUG$ @DRUG$ requirement of our patient to after the of rifampin similar of after withdrawal	DDI-effect
single 10 mg dose of @DRUG$ not affect the pharmacokinetics of @DRUG$ steady .	DDI-false
Interactions with Agonist/Antagonist Opioid @DRUG$ ( , pentazocine nalbuphine butorphanol dezocine should be administered patient has received or is a of @DRUG$ .	DDI-false
which the neuromuscular blocking nondepolarizing agents such as include certain antibiotics ( e. tetracyclines , polymyxins , lincomycin colistin , and @DRUG$ ) , salts lithium @DRUG$ and .	DDI-false
Drug Flupenthixol with some drugs like Monoamine ( MAOI could - - @DRUG$ Flupenthixol @DRUG$ cause additive depression antidepressants : Flupenthixol the effect of Tricyclic	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, @DRUG$ and tricyclic anti-depressants.	DDI-false
Aerosol particles @DRUG$ were generated from @DRUG$ , by a for or experiments .	DDI-false
Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
In separate studies patients receiving doses of , or @DRUG$ irbesartan for 7 had no effect on pharmacodynamics of @DRUG$ ( prothrombin or of	DDI-false
In Study 1, patients with colorectal cancer were given irinotecan/@DRUG$/@DRUG$ (bolus-IFL) with or without AVASTIN.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a @DRUG$) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
@DRUG$ @DRUG$ enhance the adrenergic of	DDI-false
Since is substrate for @DRUG$ , the potential of St. s Wort patients @DRUG$ could result reduced amiodarone levels	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
drugs include the diuretics @DRUG$ phe-nothiazines , thyroid , , oral contraceptives phenytoin @DRUG$ sympathomimet-ics , calcium blocking ,	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
@DRUG$ ( adenosine has effectively the of cardioactive , agents calcium channel blocking , @DRUG$ , without any reaction profile .	DDI-false
Possible drug interactions @DRUG$	DDI-int
Multivalent administration @DRUG$ , ciprofloxacin with such as magnesium , VIDEX tablets or containing , iron zinc may decrease absorption of @DRUG$ resulting in serum urine considerably than .	DDI-false
The of rifampin on @DRUG$ requirement our appeared be maximal of and extended similar of time after @DRUG$ withdrawal .	DDI-false
Coadministered VIRACEPT Antiarrhythmics : quinidine @DRUG$ astemizole , ergot : @DRUG$ midazolam , GI :	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
@DRUG$: Since both @DRUG$ and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.	DDI-false
Dextromethorphan is a for @DRUG$	DDI-false
Administering @DRUG$ together with @DRUG$ (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.	DDI-effect
Patients who begin diclofenac increase their dose or any @DRUG$ taking @DRUG$ , methotrexate cyclosporine for	DDI-effect
in clinical study established therapy to which @DRUG$ was added , noted to develop a mild decrease in comparison treated CI @DRUG$ alone .	DDI-false
@DRUG$, @DRUG$, heparin, NSAIDs	DDI-false
administration of @DRUG$ @DRUG$ result elevated levels .	DDI-mechanism
: In a study healthy , steady-state plasma increased approximately % in 450 mg with @DRUG$ 200 BID compared to subjects @DRUG$ .	DDI-false
however, it adversely affected response duration suggesting that @DRUG$ should not be administered with @DRUG$ and/or cisplatin.1	DDI-advise
@DRUG$ Coadministration saquinavir ( using experimental soft-gelatin formulation of saquinavir 1200 mg ) with an % increase in @DRUG$ AUC and a 4-fold in plasma A.C.	DDI-false
Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with @DRUG$, barbiturates should be employed with caution.	DDI-effect
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
Another antifungal @DRUG$ inhibits the , @DRUG$ its active desmethylastermizole QT intervals	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
begin @DRUG$ who increase any taking , @DRUG$ , or cyclosporine drugs	DDI-effect
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-advise
individuals with paroxetine or @DRUG$ of @DRUG$ is approximately to 8-fold , max is about 3- greater than	DDI-mechanism
Other drugs which may the of nondepolarizing as NUROMAX include certain antibiotics ( , tetracyclines @DRUG$ polymyxins lincomycin @DRUG$ ) , magnesium anesthetics , , and .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
of with @DRUG$ , acetaminophen @DRUG$ with high toxic concentrations decreases the the target	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
These drugs include @DRUG$ and corticosteroids , phe-nothiazines , products oral @DRUG$ nicotinic sympathomimet-ics , calcium blocking drugs , and isoniazid	DDI-false
increases of @DRUG$ may levels and .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Since @DRUG$ for CYP3A4 is potential the of John s Wort patients result reduced @DRUG$ levels	DDI-false
Demonstrated to be 3A Inhibitors Clinical the Basis of Clinical @DRUG$ ( caution is recommended coadministration with Coadministration of @DRUG$ the maximum alprazolam 46 , decreased by % increased half-life decreased measured performance .	DDI-false
It is avoid administration of @DRUG$ containing @DRUG$ hours following .	DDI-false
Since concomitant administration @DRUG$ with @DRUG$ the prothrombin by 100 % 3 to 4 days , dose of anticoagulant be reduced by one-third to one-half , and prothrombin should be	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Keppra   and other @DRUG$ carbamazepine gabapentin , @DRUG$ phenytoin primidone and were assessed by evaluating concentrations studies	DDI-false
results regression patient pharmacokinetic data co-administration other ( @DRUG$ , nevirapine dexamethasone , or carbamazepine @DRUG$ may result clinically caspofungin .	DDI-mechanism
In pharmacology indomethacin @DRUG$ was administered to patients	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Alpha-blockers: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	DDI-effect
Since @DRUG$ is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.	DDI-false
of @DRUG$ and androgens in @DRUG$.	DDI-false
@DRUG$ the : @DRUG$ ) ( long-term use ) or	DDI-int
In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.	DDI-mechanism
A possible interaction between @DRUG$ and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-false
following are examples substances that reduce the effect : corticosteroids niacin danazol diuretics , @DRUG$ ( , epinephrine terbutaline ) , phenothiazine derivatives , hormones , @DRUG$ e.g. , oral contraceptives	DDI-false
@DRUG$/Acetaminophen Pharmacokinetic pharmacodynamic have been and concomitantly 26 and 2 hours Argatroban 1   g/kg/min . 4 hours ) or @DRUG$ orally , hours prior and 6 12 hours subsequent to , of Argatroban . over 18 hours ) .	DDI-false
Digoxin increased by about % @DRUG$ and @DRUG$ concomitantly .	DDI-mechanism
possibility effects with @DRUG$ can minimized either discontinuing diuretic the intake prior initiation with or	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$.	DDI-false
: @DRUG$ generally not be given bumetanide they reduce renal add a risk @DRUG$ toxicity .	DDI-false
Example inhibitors include antifungals , ciprofloxacin , diclofenac , , , , @DRUG$ , protease , and @DRUG$.	DDI-false
Not Be Coadministered With Antiarrhythmics @DRUG$ @DRUG$ : astemizole , Antimigraine ergot rifampin Benzodiazepines midazolam , motility :	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Aspirin : Concomitant administration of @DRUG$ with @DRUG$ may in an risk of GI complications to	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Antifungals In in vivo data @DRUG$ @DRUG$ and ketoconazole the metabolism cisapride which result in increase in prolongation QT interval .	DDI-false
Patients receiving analgesics , general , phenothiazines @DRUG$ or depressants ( including @DRUG$ concomitantly DILAUDID depression	DDI-false
Cytochrome P-450 inducers , carbamazepine @DRUG$ , @DRUG$ metabolism , an plasma clonazepam levels	DDI-mechanism
Antidiabetic drugs: (oral agents and @DRUG$) - dosage adjustment of the @DRUG$ may be required.	DDI-false
The following examples of substances that blood-glucose-lowering effect : @DRUG$ , @DRUG$ , , sympathomimetic , , salbutamol terbutaline isoniazid , phenothiazine , hormones estrogens e.g. in contraceptives ) .	DDI-false
patient dose of @DRUG$ is patients concomitantly and @DRUG$.	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and @DRUG$).	DDI-false
Potential drug interactions @DRUG$ other @DRUG$ ( gabapentin lamotrigine , , , ) were also evaluating serum and these during placebo-controlled clinical studies .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
from studies alprazolam suggest possible with @DRUG$ the following @DRUG$ .	DDI-int
@DRUG$ ) , ether , @DRUG$ gallamine decamethonium potentiate the blocking effect be used extreme caution with M	DDI-false
Cohort received @DRUG$ plus @DRUG$ days and cohort 2 amprenavir for 4 .	DDI-false
Valproate: The addition of @DRUG$ to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
Therefore, a slower onset can be anticipated if @DRUG$ is administered concomitantly with, or immediately following, a @DRUG$.	DDI-effect
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
The use of @DRUG$ in patients receiving @DRUG$ may be rarely associated with ventricular fibrillation.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
Interactions occur and aspirin other @DRUG$ such garlic ( sativum @DRUG$ ( biloba ) .	DDI-false
The vitro @DRUG$ and @DRUG$ complex	DDI-int
: may interact with Monoamine inhibitors @DRUG$ affect flupenthixol pharmacodynamics Arecoline - Ethanol Ethanol cause additive CNS depression - antidepressants increases the effect @DRUG$	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antidiabetics: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-effect
Drugs That Should Not Be Coadministered @DRUG$ @DRUG$ quinidine : , terfenadine : derivatives : rifampin Benzodiazepines midazolam motility agents	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-false
there are no data evaluate the nitric donor , nitroprusside @DRUG$ , may an @DRUG$ on developing .	DDI-effect
the neuromuscular blocking include antibiotics ( g. aminoglycosides @DRUG$ lincomycin clindamycin colistin and sodium @DRUG$ lithium local anesthetics , , quinidine .	DDI-false
Cardiovascular Agents : @DRUG$ IV have been used concomitantly @DRUG$ , methyldopa , nitrates agents , , of interactions .	DDI-false
@DRUG$ : diabetic patients receiving diflunisal @DRUG$ , no significant were seen or	DDI-false
It is desirable to monitor @DRUG$ plasma levels whenever a @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6.	DDI-false
The ECG that may result from the administration @DRUG$ as loop diuretics ) can be by beta-agonists , when recommended dose @DRUG$ is exceeded	DDI-false
@DRUG$ cystic fluid were increased 2-fold in hydatid ( 10 mg/kg/day ) ( ) @DRUG$ 20 mg/kg/day n=12 .	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and warfarin administered with @DRUG$ as measured by prothrombin time.	DDI-false
Pretreatment of healthy volunteers multiple @DRUG$ single of , increased @DRUG$ 3.8-fold cmax AUC(0 - 8)	DDI-false
The pharmacokinetics of a @DRUG$ administered STADOL NS affected by the coadministration of @DRUG$ ( 300 )	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
Other enhance nondepolarizing as certain antibiotics e. aminoglycosides tetracyclines bacitracin , polymyxins , lincomycin , and colistimethate ) magnesium salts @DRUG$ , @DRUG$ , , and quinidine .	DDI-false
This increase is the inhibition @DRUG$ P450 @DRUG$ ( see CLINICAL : )	DDI-mechanism
: @DRUG$ apparent administered @DRUG$.	DDI-false
No information is available about the interaction of @DRUG$ and @DRUG$ following multiple doses of either drug.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
May thyroid ( e.g. , ) , iodine-containing antacids , ( @DRUG$ ) , pump , @DRUG$ , omeprazole )	DDI-false
interactions   and other ( , gabapentin @DRUG$ , phenytoin , primidone valproate were assessed the serum concentrations @DRUG$ clinical studies .	DDI-false
patients reaction be produced the ingestion	DDI-false
Although @DRUG$-induced hyperbilirubinemia confusion , dyspnea administration of these agents with PROLEUKIN reduce the antitumor effectiveness should be avoided . 12 Beta-blockers and @DRUG$ with PROLEUKIN .	DDI-false
These include the other diuretics , , phenothiazines thyroid , estrogens , oral contraceptives , , nicotinic acid @DRUG$ , calcium channel drugs and @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Dopamine Antagonists : Since dopamine , possible antagonists @DRUG$ , @DRUG$ thioxanthenes ) , the APOKYN	DDI-false
the , @DRUG$ @DRUG$ thyroid products , estrogens , , calcium drugs , isoniazid	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, @DRUG$, tranquilizers, etc).	DDI-false
@DRUG$ : @DRUG$ and receptors , thus the central effects and can used treat poisoning	DDI-false
In both species, @DRUG$, but not (+)-NANM, antagonized the rate-decreasing effects of @DRUG$ on FI and FR responding.	DDI-effect
Co-administration of @DRUG$ aminoglycosides other agents interfering with neuromuscular , @DRUG$ ) should only performed caution as the effect of toxin	DDI-advise
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.	DDI-false
Corticosteroids and @DRUG$ (ACTH): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
Other concomitant therapies In clinical trials , safety profile subjects concomitantly @DRUG$ , hypnotics @DRUG$ ( ) , non-opioid was to that subjects taking placebo with these	DDI-false
In , @DRUG$ that are cytochrome P450 inducers decrease	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antidepressants ( tricyclic ) or @DRUG$ , or @DRUG$ with produce chronotropic effects	DDI-false
acetaminophen/theophylline , , phenobarbital/acetaminophen , phenobarbital/valproic , quinidine/@DRUG$ theophylline/acetaminophen and valproic	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
As some other @DRUG$ , of ciprofloxacin @DRUG$ to elevated serum concentrations theophylline and prolongation of its half-life .	DDI-mechanism
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drug Contraceptives @DRUG$   daily ) not influence the pharmacokinetics an oral @DRUG$ containing 0.03 mg ethinyl 0.15 or the and progesterone , indicating impairment of contraceptive is .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
@DRUG$ bind drugs should take @DRUG$ at least 4 - hours after binding .	DDI-false
Nephrotoxic agents : Concomitant of and agents [ intravenous ( e.g. @DRUG$ , gentamicin amikacin ) , amphotericin B foscarnet intravenous , and @DRUG$ .	DDI-false
peripheral antiretroviral nucleoside analogues chloramphenicol , cisplatin @DRUG$ , @DRUG$ , gold hydralazine iodoquinol isoniazid nitrofurantoin phenytoin , ribavirin	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and @DRUG$.	DDI-false
@DRUG$ treatment and @DRUG$ be avoided because Accutane been associated with a number of cerebri benign intracranial hypertension ) of use of tetracyclines	DDI-false
@DRUG$: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).	DDI-false
In clinical trials used , @DRUG$ , vasodilators , and supplemental In pharmacokinetic substudy with heart @DRUG$ or digoxin was initiated , apparent oral values = 23 ( = 30 by % and % , respectively , on the second therapy had returned to baseline 87	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or phenobarbital.	DDI-false
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Anabolic ( nandrolone [ , ] @DRUG$ [ e.g. Anavar ] @DRUG$ [ , , stanozolol [ e.g. , ]	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with @DRUG$ or @DRUG$.	DDI-false
following are examples substances that may reduce the effect corticosteroids niacin , sympathomimetic agents ( @DRUG$ , terbutaline ) , @DRUG$ , thyroid , progestogens ( e.g. oral contraceptives )	DDI-false
following of that may reduce effect @DRUG$ niacin , danazol , diuretics , agents ( , , , phenothiazine somatropin , @DRUG$ ( , oral .	DDI-false
, lidocaine phenobarbital , quinidine , @DRUG$ , and @DRUG$ serum at	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
Multivalent Products : administration of quinolone ciprofloxacin , with products such magnesium or @DRUG$ sucralfate powder , containing , @DRUG$ may substantially of resulting than	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
These thiazides and @DRUG$ , , thyroid estrogens oral contraceptives , @DRUG$ acid , sympathomimet-ics , blocking .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Although specific studies have not been performed coadministration drugs that mainly metabolized calcium blockers , @DRUG$ , disopyramide , , cyclosporine , ergot pimozide carbamazepine @DRUG$ alfentanyl alprazolam and ) plasma concentrations when coadministered saquinavir	DDI-false
@DRUG$ Amphetamines may enhance of @DRUG$	DDI-false
a in which mg clonazepam orally disintegrating tablet with without propantheline ( an anticholinergic with multiple effects the GI tract , AUC clonazepam 10 % and the of @DRUG$ % lower the orally was given @DRUG$ compared to alone	DDI-mechanism
: aerosol of @DRUG$ @DRUG$ a model surfactant	DDI-false
@DRUG$ toxicity may be aggravated by the initial release of norepinephrine caused by @DRUG$ Injection.	DDI-effect
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-mechanism
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
@DRUG$ apparently on certain systems has been reduce the hepatic metabolism of warfarin-type , propranolol , , chlordiazepoxide diazepam certain @DRUG$ , and metronidazole , thereby and increasing levels of drugs .	DDI-mechanism
Lithium : @DRUG$ toxicity been reported patients lithium drugs elimination of sodium	DDI-false
Oral Contraceptives Coadministration @DRUG$ increased @DRUG$ and estradiol approximately	DDI-mechanism
Tagamet apparently an on certain systems , been reduce the hepatic metabolism @DRUG$ , phenytoin , propranolol , nifedipine , , @DRUG$ tricyclic antidepressants lidocaine , theophylline and thereby elimination and blood these	DDI-false
Since the therapeutic range of @DRUG$ is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Profound may @DRUG$ @DRUG$ are used .	DDI-effect
No Interactions Date @DRUG$ does have clinically important with captopril , beta-blockers , felodipine , @DRUG$ warfarin mononitrate , or itraconazole	DDI-false
studies that @DRUG$ have significant with phenytoin @DRUG$ , quinidine , clarithromycin .	DDI-false
The time of anticoagulant secobarbital @DRUG$ , and systematically in 16 patients receiving @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
It increase excretion barbiturates @DRUG$ and @DRUG$ may toxicity of .	DDI-false
Antiarrhythmic , class I such as , @DRUG$ ): with @DRUG$ have .	DDI-false
@DRUG$ Population pharmacokinetic analyses indicate that tiagabine clearance is % in @DRUG$ AEDs	DDI-false
drugs include thiazides other corticosteroids , , products , , @DRUG$ , nicotinic , , @DRUG$ , isoniazid .	DDI-false
Since @DRUG$ and potassium-sparing diuretics, including @DRUG$, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-effect
The administration anesthetic containing @DRUG$ or norepinephrine to patients oxidase inhibitors @DRUG$ may produce hypertension .	DDI-effect
Antiarrhythmics : antiarrhythmic drugs such quinidine , @DRUG$ , , used concurrently	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$ suggest @DRUG$ may effect	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some @DRUG$.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
ACE Inhibitors and Receptor Antagonists Congestive Heart Failure EPHESUS , 3020 ( 91 % receiving to mg received ACE inhibitors or @DRUG$ ( ACEI/@DRUG$ )	DDI-false
The of pills reduced by hepatic drugs as the anticonvulsants phenytoin , barbiturates , and @DRUG$	DDI-false
Probenecid: As with other @DRUG$, the renal excretion of @DRUG$ is inhibited by probenecid.	DDI-false
Serial and urine for @DRUG$ , @DRUG$ and , by .	DDI-false
To Levosimendan does not important pharmacokinetic @DRUG$ beta-blockers felodipine , @DRUG$ warfarin , isosorbide , carvedilol , ethanol or itraconazole .	DDI-false
Imidazoles , @DRUG$ , clotrimazole , , . vitro studies amphotericin B @DRUG$ that may induce resistance to amphotericin B.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Antibiotics : Chloramphenicol , @DRUG$ , tetracyclines interfere the	DDI-effect
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
In Study 1, patients with colorectal cancer were given irinotecan/@DRUG$/leucovorin (bolus-IFL) with or without @DRUG$.	DDI-false
Cation-Containing : a , including multivalent cation-containing products @DRUG$ or aluminum antacids , @DRUG$ pediatric or products calcium or may the ciprofloxacin , resulting serum considerably lower	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Drugs with a Therapeutic @DRUG$ : @DRUG$ did affect pharmacokinetic or pharmacodynamic profile digoxin ( for 8 days )	DDI-false
Important Interactions To Levosimendan does not have clinically interactions with beta-blockers , digoxin @DRUG$ , mononitrate , carvedilol , or	DDI-false
receiving , general @DRUG$ tranquilizers tricyclic CNS ( including ) with @DRUG$ exhibit CNS .	DDI-effect
adverse effects resulting cholinergic when @DRUG$ is administered concomitantly other antimuscarinics , monoamine oxidase ( ) @DRUG$ or antihistamines .	DDI-effect
@DRUG$   should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.	DDI-advise
Another oral @DRUG$ , the metabolism of @DRUG$ , in elevated of desmethylastermizole which QT intervals .	DDI-false
The concomitant use other inhibitors as and @DRUG$ transdermal @DRUG$ may result an in fentanyl concentrations , which increase adverse drug effects and depression .	DDI-mechanism
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ nevirapine have been compared to triple therapy with PI @DRUG$ 48 weeks as initial therapy , being nevirapine regimens observed .	DDI-false
Pyrantel (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
of closely related be increased by of methylphenidate or hepatic inhibitors , cimetidine @DRUG$ ) and by concomitant of hepatic enzyme inducers @DRUG$ phenytoin ) , an may anticipated with CMI as well	DDI-false
@DRUG$ serum levels monitored appropriate dose and	DDI-false
Cardiovasculars: @DRUG$: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
: @DRUG$ has used concomitantly with @DRUG$ without	DDI-false
addition , @DRUG$ and MHD of family ( CYP3A4 ) for metabolism of @DRUG$ and oral , resulting a of	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
5HT3 : on of apomorphine was administered with ondansetron , the of @DRUG$ with of the @DRUG$ ( including for , dolasetron palonosetron and alosetron is contraindicated .	DDI-advise
EM individuals @DRUG$ the of @DRUG$ is approximately 6- to 8-fold and , is to 4-fold greater alone	DDI-mechanism
This only clinically interaction of Mefloquine coadministration other drugs known alter ( eg , @DRUG$ calcium channel blockers @DRUG$ H1-blocking agents antidepressants and might of the .	DDI-false
using bromocriptine combination not been systematically , but @DRUG$ potentiate the side effects	DDI-effect
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions.	DDI-false
Because there are no data on the compatibility of @DRUG$ and crystalline zinc insulin preparations, @DRUG$ should not be mixed with these preparations.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Other inhibitors e.g. , @DRUG$ , @DRUG$ , ritonavir be .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
is that increased and high affinity binding @DRUG$ on serotonin2-receptors antipsychotic of @DRUG$ after their	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
Mineral Oil-Concomitant intake mineral and @DRUG$ may the	DDI-false
The aspirin decreases biologic half-life of @DRUG$ because of increase clearance that a greater amount @DRUG$ in urine	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, @DRUG$ and phenobarbital.	DDI-false
@DRUG$ with , , decongestant drugs , and medicines , lithium , norepinephrine like Aleve or and high medications	DDI-int
Other drug interactions @DRUG$ and no effect on @DRUG$.	DDI-false
that have neuropathy include , chloramphenicol , cisplatin , @DRUG$ @DRUG$ gold , hydralazine , iodoquinol , , ribavirin , and	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
@DRUG$ tubular blocking agent , administered dose of 500 times day change @DRUG$ twice daily	DDI-false
Tolbutamide : In diabetic receiving and @DRUG$ no significant seen on @DRUG$ plasma levels or fasting glucose	DDI-false
Antidepressants (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
: @DRUG$ plasma of	DDI-mechanism
Since @DRUG$ is an @DRUG$, it may have a strong affinity for anions other than the bile acids.	DDI-false
@DRUG$, tricyclic: Amphetamines may enhance the activity of tricyclic or @DRUG$;	DDI-false
The absorption of @DRUG$ , @DRUG$ , significantly colestipol	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Intravenous ) been effectively administered in of drugs such quinidine , beta-adrenergic , @DRUG$ and @DRUG$ , any change the reaction	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Although specific not been , with drugs are metabolized by calcium channel , dapsone disopyramide , quinine , amiodarone , quinidine , @DRUG$ , cyclosporine , ergot derivatives , pimozide , , alfentanyl alprazolam , and triazolam ) have elevated plasma concentrations coadministered with @DRUG$	DDI-mechanism
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Potential drug interactions between @DRUG$   ( gabapentin @DRUG$ primidone valproate ) evaluating the serum concentrations levetiracetam AEDs placebo-controlled clinical	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and @DRUG$ did not influence @DRUG$ clearance.	DDI-false
The effects of ruthenium red (@DRUG$) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Antidepressants, @DRUG$ Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	DDI-false
Other concomitant therapy specific not performed finasteride 1 or more were clinical acetaminophen , acid , , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors @DRUG$ benzodiazepines , beta blockers , blockers cardiac nitrates H2 antagonists HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors referred ) and @DRUG$ .	DDI-false
This antagonistic effect of @DRUG$ on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
has tolazoline @DRUG$ , dobutamine @DRUG$ high-frequency .	DDI-false
Therefore , interactions could occur following concomitant administration of e.g. @DRUG$ , @DRUG$ , sedatives tranquilizers )	DDI-false
between @DRUG$ and rifabutin @DRUG$ healthy males .	DDI-false
Central Nervous System use   ( system ) central system including but hypnotics , @DRUG$ @DRUG$ ) general phenothiazines , relaxants , alcohol may , hypotension , and profound sedation potentially result coma or	DDI-false
Other depressant drugs barbiturates tranquilizers , @DRUG$ anesthetics ) or effects with @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concomitant oral administration of @DRUG$ (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral @DRUG$.	DDI-mechanism
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Concurrent of @DRUG$ and of MAO class cause hypotension . Cimetidine , an drug metabolism and in a .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
resulting blockade may occur LEVSIN administered concomitantly other , , @DRUG$ oxidase MAO , antidepressants or some @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Erythromycin @DRUG$ ( PLENDIL ) with resulted in approximately fold increase in the Cmax , 2- in the half- life @DRUG$.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
@DRUG$: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Carbamazepine : Isoniazid known slow metabolism its serum levels should be determined concurrent with isoniazid and of @DRUG$ toxicity should be closely appropriate adjustment the @DRUG$	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	DDI-false
When CANCIDAS with inducers of as efavirenz , @DRUG$ , , @DRUG$ of daily mg CANCIDAS be	DDI-false
May interact thyroid medication ( ) , @DRUG$ ( e.g. famotidine , ranitidine ) , and proton pump ( e.g. @DRUG$	DDI-false
Rifabutin : Coadministration of rifabutin @DRUG$ resulted a @DRUG$ plasma a % increase in plasma A.C.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-effect
DCG-IV and @DRUG$ @DRUG$ locomotion and behavioral	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Benzthiazide with , decongestant , cold , medicines drugs lithium norepinephrine , @DRUG$ Ibuprofen , blood .	DDI-false
@DRUG$, tricyclic: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
@DRUG$ may decrease the amount of digoxin (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Lethargy somnolence have reported following of @DRUG$	DDI-effect
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
clinical studies concomitant oral ( warfarin , @DRUG$ ( @DRUG$ , piroxicam , and digoxin did not significantly of fondaparinux sodium	DDI-false
Anticonvulsants (@DRUG$): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
1 received @DRUG$ for , cohort received amprenavir @DRUG$	DDI-false
with thyroid medication ( @DRUG$ iodine-containing products antacids H2-antagonists ( e.g. @DRUG$ , ranitidine ) , ( , lansoprazole ) .	DDI-false
Repeated doses of @DRUG$ given prior to a single dose of propranolol in human trials have been reported to decrease @DRUG$ absorption.	DDI-false
@DRUG$ : @DRUG$ interaction when phenytoin .	DDI-false
Concurrent administration of low-dose @DRUG$ and @DRUG$ may produce an additive or potentiating effect on urine flow.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Multivalent Concurrent administration of a quinolone , including ciprofloxacin , with products magnesium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets pediatric powder or containing , iron or decrease absorption of @DRUG$ , and levels considerably than desired	DDI-false
Nervous : The concomitant system with other nervous system depressants , including but not limited , sedatives tranquilizers ( , @DRUG$ , general @DRUG$ , phenothiazines , skeletal muscle relaxants , respiratory , and profound in coma or death .	DDI-false
hypokalemia that the administration @DRUG$ such loop or @DRUG$ ) worsened by beta-agonists recommended dose is .	DDI-false
interact e.g. , iodine-containing , H2-antagonists ( , @DRUG$ , ranitidine ) @DRUG$ ( e.g. , )	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
addition , under the influence of sympatholytic medicinal products as @DRUG$ @DRUG$ , , of hypoglycemia may be reduced or absent .	DDI-false
The concomitant use of @DRUG$s, vasoconstricting agents (such as ergonovine) and some @DRUG$ may result in severe hypertension.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).	DDI-effect
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
@DRUG$ (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
implications @DRUG$ interactions five	DDI-int
: Lorazepam , like , of the central nervous system when administered with phenothiazines , inhibitors , other antidepressants @DRUG$ is used concomitantly injectable @DRUG$ an incidence of sedation hallucinations irrational behavior has	DDI-effect
@DRUG$ significantly decreased ) of amprenavir 82 % , but @DRUG$ no on rifampin pharmacokinetics .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Antibiotics: In vitro and/or in vivo data show that @DRUG$, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Central The concomitant use DURAGESIC @DRUG$ system with @DRUG$ , including but not limited to opioids , sedatives , , tranquilizers e.g. ) , general anesthetics , phenothiazines skeletal muscle relaxants , and , may respiratory , hypotension sedation or result in coma	DDI-effect
To determine whether probenecid has a direct effect on the distribution of @DRUG$, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
examples of substances may the effect : , danazol , diuretics epinephrine , salbutamol , isoniazid @DRUG$ , somatropin thyroid hormones @DRUG$ e.g. , oral contraceptives	DDI-false
concomitant Although studies , doses 1 or concomitantly used in studies @DRUG$ , acid , a-blockers analgesics enzyme ACE anticonvulsants , , blockers calcium-channel blockers cardiac , diuretics , H2 HMG-CoA inhibitors ( @DRUG$ ) and quinolone anti-infectives without evidence significant .	DDI-false
@DRUG$ @DRUG$ ) or	DDI-false
, or @DRUG$ zinc , or sucralfate should with , 2 administration of @DRUG$ , because they absorption lower serum levels .	DDI-advise
@DRUG$: Diclofenac decreases lithium renal clearance and increases @DRUG$ plasma levels.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-effect
Therefore, a starting daily dose of 25 mg of @DRUG$ should be considered for the treatment of osteoarthritis when @DRUG$ is co-administered with potent inducers of hepatic metabolism.	DDI-false
The successive application of @DRUG$ (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone.	DDI-false
Oral @DRUG$ gastrointestinal absorption penicillin oral vitamin B-12 , @DRUG$ .	DDI-mechanism
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	DDI-false
@DRUG$ , has interactions with @DRUG$ and nimodipine and losartan has significant plasma levels	DDI-false
Aspirin normal , decrease in @DRUG$ levels was observed when multiple @DRUG$ were administered	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with @DRUG$.	DDI-false
@DRUG$ should be administered concurrently @DRUG$ because for and/or cardiac arrhythmias	DDI-advise
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Potential between Keppra   ( carbamazepine lamotrigine phenobarbital phenytoin , @DRUG$ @DRUG$ ) were also concentrations of levetiracetam and during .	DDI-false
Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
Antidepressants @DRUG$ antidepressants or @DRUG$	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Drugs that been peripheral neuropathy include antiretroviral nucleoside chloramphenicol cisplatin disulfiram , @DRUG$ gold , @DRUG$ ribavirin , and vincristine .	DDI-false
@DRUG$ prior @DRUG$ may the emetic in the treatment of poisoning	DDI-false
The @DRUG$ @DRUG$ anesthesia digitalis	DDI-false
CANCIDAS reduced blood AUC0 - of tacrolimus by approximately , blood ( Cmax by % , 12-hour blood concentration ) by in subjects @DRUG$ 2 doses of apart was administered on the day of daily as compared results from period in @DRUG$ was .	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Valproate: @DRUG$ causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	DDI-mechanism
Phenytoin : @DRUG$ may delay intestinal absorption of @DRUG$	DDI-mechanism
@DRUG$ @DRUG$ )	DDI-false
Beta-blockers @DRUG$ salts , and @DRUG$ or the of insulin .	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
@DRUG$ , @DRUG$	DDI-false
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and magnesium.	DDI-mechanism
Concurrent administration of e.g. @DRUG$ , ) , myelotoxic ( , cytotoxic chemotherapy ) cardiotoxic @DRUG$ ) hepatotoxic ( , effects PROLEUKIN increase in systems	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-false
Other studies were @DRUG$ more concomitantly used in clinical studies with acid , analgesics , angiotensin-converting enzyme ACE benzodiazepines blockers , calcium-channel blockers cardiac , diuretics @DRUG$ , prostaglandin ( also to as NSAIDs , anti-infectives adverse interactions .	DDI-false
Drugs with peripheral neuropathy nucleoside , , cisplatin @DRUG$ disulfiram , glutethimide , , hydralazine , iodoquinol , metronidazole , @DRUG$ , .	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
of with @DRUG$ has conducted .	DDI-false
A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
@DRUG$ and @DRUG$ not .	DDI-false
Although results significant between @DRUG$ and @DRUG$ to patients anticoagulants extremely cautiously , and monitored	DDI-false
availability @DRUG$ (NNRTI)-based regimens for therapy concerns protease inhibitor disturbances to in treatment practices HIV .	DDI-false
Beta-blockers, @DRUG$, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
It may be necessary to the dosage of oral anticoagulants beginning or @DRUG$. since @DRUG$ may prothrombin time	DDI-false
It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping @DRUG$. since disulfiram may prolong prothrombin time.	DDI-advise
Lithium generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ : have produced an of plasma @DRUG$ and reduction renal lithium	DDI-false
Drugs Not Be Coadministered With VIRACEPT Antiarrhythmics quinidine : , terfenadine ergot @DRUG$ @DRUG$ motility cisapride	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	DDI-false
Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in @DRUG$ plasma levels suggesting that, at these doses, @DRUG$ is a weak inhibitor of 2D6.	DDI-false
In clinical trials FLOLAN was with , diuretics @DRUG$ , oral @DRUG$ , and oxygen . In a in patients with congestive heart receiving or in with FLOLAN initiated apparent clearance values furosemide ( 23 ) digoxin ( n 30 ) were % and 15 % respectively , second had to by day 87 .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-false
@DRUG$ , @DRUG$ , , Phenytoin , , carbamazepine , , Rifampin , Saquinavir .	DDI-false
@DRUG$ Amiodarone be in   blocking agents CYP3A4 inhibitor or calcium channel ( , @DRUG$ , substrate , a CYP3A4 inhibitor ) possible potentiation of bradycardia , sinus , and AV ;	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Plasma @DRUG$ concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
@DRUG$ (@DRUG$) and BROVANA may interfere with the effect of each other when administered concurrently.	DDI-false
@DRUG$ : In the administration of @DRUG$ antihypertensive , potassium-sparing and thiazide diuretics .	DDI-false
@DRUG$ ( @DRUG$ interfere effect other when .	DDI-false
tetracycline @DRUG$ @DRUG$ significantly when simultaneously with ;	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Caution be in or serial of @DRUG$ and polymyxins because they ototoxicity potentiate @DRUG$ effects	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Digoxin : @DRUG$ concentrations are increased by about 15 % @DRUG$ and carvedilol are administered concomitantly	DDI-false
Sedatives/Hypnotics: @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
@DRUG$ miconazole , , , in vitro animal the amphotericin B imidazoles suggest @DRUG$ resistance	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Following the administration of @DRUG$ of @DRUG$ should	DDI-advise
When Itraconazole was coadministered with @DRUG$, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Patients other narcotic analgesics , anesthetics , @DRUG$ , , other ( @DRUG$ concomitantly exhibit an depression .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine phenobarbital/acetaminophen , @DRUG$/valproic acid @DRUG$/lidocaine , theophylline/acetaminophen , valproic acid/phenobarbital	DDI-false
The to inhibit the other @DRUG$ inhibition of : nefazodone , fluvoxamine cimetidine @DRUG$.	DDI-mechanism
@DRUG$ : @DRUG$ increased plasma concentration AUC of cisapride is effect on cisapride when it with .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and ranitidine.	DDI-false
These include the thiazides other diuretics , corticosteroids , phe-nothiazines , thyroid products @DRUG$ oral contraceptives , phenytoin , acid sympathomimet-ics channel drugs , and @DRUG$.	DDI-false
exposure AUC ) @DRUG$ 62 coadministered @DRUG$ 38 % when coadministered ketoconazole	DDI-mechanism
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Drug/Laboratory Test cause low measurement of @DRUG$ with Tab   for @DRUG$.	DDI-false
@DRUG$: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
drugs the @DRUG$ and other @DRUG$ , corticosteroids thyroid products estrogens phenytoin , nicotinic , , calcium channel blocking , and isoniazid .	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Co-medications that induce dexamethasone , @DRUG$ , @DRUG$ or	DDI-false
Two 16 subjects dosed simultaneously @DRUG$ 10 and @DRUG$ mg a pressure 85 mm Hg .	DDI-effect
Cholestyramine and @DRUG$ @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The examples blood-glucose-lowering effect and hypoglycemia : oral antidiabetic , , , fibrates MAO ) , propoxyphene , @DRUG$ , @DRUG$ ) , sulfonamide .	DDI-false
, the effects of glutamate agonists @DRUG$ and @DRUG$ behavioral changes induced were found .	DDI-false
d-amphetamine @DRUG$ and @DRUG$ cause and of d-amphetamine in the brain ;	DDI-false
@DRUG$ to valproate chronically no , but @DRUG$ significantly tiagabine from to 94.8 % an increase of approximately % in the free tiagabine .	DDI-false
Ergot Dihydroergotamine , , , @DRUG$ CONTRAINDICATED serious life-threatening such as @DRUG$ toxicity characterized vasospasm extremities other .	DDI-false
Concomitant administration @DRUG$ equivalent to 145 ) @DRUG$ ( 20 mg ) daily for 10 days resulted 17 % ( 67 % decrease increase ) in atorvastatin 22 males .	DDI-mechanism
Aspirin/Acetaminophen Pharmacokinetic or drug-drug interactions have not demonstrated @DRUG$ concomitantly mg orally 26 prior initiation @DRUG$   g/kg/min . hours or 1000 mg orally 12 6 6 to over 18 ) .	DDI-false
to be only with Mefloquine , although theoretically , of known cardiac @DRUG$ or @DRUG$ , channel blockers agents , antidepressants ) to a prolongation .	DDI-false
Patients receiving both @DRUG$ and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	DDI-false
If treatment CYP3A4 activity ( as ketoconazole @DRUG$ , indinavir @DRUG$ erythromycin , ) , reduction the dose considered	DDI-false
H2 @DRUG$ leads plasma and of cisapride , is no cisapride absorption it coadministered	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
include corticosteroids @DRUG$ , thyroid estrogens @DRUG$ , phenytoin , acid , sympathomimetics , calcium and	DDI-false
Macrolide antibiotics the @DRUG$ that metabolized by i.e. , cerivastatin , @DRUG$ ) .	DDI-false
@DRUG$ adrenal suppression	DDI-false
Other : @DRUG$ and have been beta adrenergic-blocking , methyldopa nitrates @DRUG$ hydralazine clinically .	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
phenobarbital/acetaminophen acid , , , and valproic acid/phenobarbital .	DDI-false
report of consciousness caused overdose a @DRUG$ to alert clinicians the of @DRUG$ screen for tricyclic antidepressants .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
: Absorption of @DRUG$ moderately reduced approximately 25 ) with magnesium/aluminum-containing @DRUG$.	DDI-false
addition results from patient data suggest that co-administration other of ( efavirenz nevirapine phenytoin , dexamethasone , or ) @DRUG$ may clinically @DRUG$ concentrations .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
May interact with following , @DRUG$ use with @DRUG$ may prevent the from working ;	DDI-effect
Central Nervous The use of DURAGESIC   ( fentanyl transdermal , but not limited to other sedatives @DRUG$ ( , benzodiazepines ) , anesthetics , phenothiazines skeletal muscle , @DRUG$ cause depression and , result in or death	DDI-false
The of @DRUG$ be certain @DRUG$ drugs that are highly protein bound salicylates , sulfonamides , , probenecid coumarins , inhibitors and beta blocking agents .	DDI-effect
Another oral @DRUG$ ketoconazole inhibits the of , resulting in of astemizole @DRUG$ which may .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Concurrent @DRUG$ of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$ of microsomal drug , altretamines	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
@DRUG$ of low-dose aspirin VIOXX may an increased of GI other complications , to use @DRUG$ .	DDI-false
Drug Interactions : Flupenthixol may with , Monoamine inhibitors ): MAOI theoretically flupenthixol pharmacodynamics Arecoline - - @DRUG$ @DRUG$ and cause depression Tricyclic Flupenthixol increases the	DDI-false
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
of Interactions with strong inhibitors of such quinidine fluoxetine @DRUG$ ) have not been , but be to blood of the R(+ enantiomer @DRUG$ .	DDI-effect
The following are substances that may increase blood-glucose-lowering effect and : oral @DRUG$ , ACE inhibitors , @DRUG$ , , , oxidase MAO , , salicylates somatostatin e.g. , ) antibiotics .	DDI-false
Omeprazole : The and of absorption @DRUG$ given alone or when @DRUG$ given 2 after the that maximally suppresses gastric acid secretion	DDI-false
Drugs That Be VIRACEPT Antiarrhythmics @DRUG$ , quinidine : , terfenadine agents Benzodiazepines @DRUG$ triazolam GI motility agents :	DDI-false
Other reported interactions with @DRUG$: Fentanyl (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
alternative non-CYP3A4 substrate agent be considered taking @DRUG$ , @DRUG$ , phenobarbital .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
studies been , coadministration are mainly by ( , calcium channel , @DRUG$ quinine , , , @DRUG$ cyclosporine ergot pimozide carbamazepine , , alfentanyl alprazolam when coadministered ;	DDI-false
@DRUG$: The anorectic and stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	DDI-false
@DRUG$/Acetaminophen Pharmacokinetic or demonstrated and hours of @DRUG$ g/kg/min 4 ) ( 1000 mg 12 , and 0 to 6 and of Argatroban g/kg/min over 18 ) .	DDI-false
Antidepressants ( , @DRUG$ or other @DRUG$ or digitalis glycosides concurrent use with produce additive inotropic .	DDI-false
@DRUG$ : nonsteroial anti-inflammatory concomitantly cyclosporine been an in @DRUG$-induced toxicity , possibly decreased synthesis prostacyclin	DDI-false
@DRUG$ (@DRUG$)-A of eplerenone an has not been .	DDI-false
drugs the @DRUG$ and diuretics , corticosteroids , phe-nothiazines @DRUG$ , phenytoin acid , sympathomimet-ics calcium drugs and	DDI-false
This be clinically relevant this kind , theoretically coadministration drugs known to conduction ( , anti-arrhythmic or @DRUG$ @DRUG$ antihistamines or agents , antidepressants and phenothiazines ) might also contribute .	DDI-false
@DRUG$: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-false
These increased of @DRUG$ and ethinyl estradiol should be into consideration when selecting an oral @DRUG$.	DDI-false
Coadministration of valdecoxib (10 mg BID for 7 days) with @DRUG$ (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of @DRUG$.	DDI-false
Although there study data evaluate the @DRUG$ , nitroprusside @DRUG$ , an effect on of	DDI-false
@DRUG$ : a study healthy evidence a direct pharmacokinetic @DRUG$-digoxin interaction	DDI-false
Following the administration of @DRUG$, the dose of other @DRUG$ should be reduced.	DDI-advise
Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, @DRUG$, and phenytoin during concomitant therapy with amiodarone.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
@DRUG$ ( e.g. , , or @DRUG$ ) potassium supplements , to potassium .	DDI-false
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	DDI-advise
@DRUG$ should be used with caution in patients taking @DRUG$, and renal function should be carefully monitored.	DDI-advise
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
@DRUG$ not administered concurrently with , such butyrophenones @DRUG$ .	DDI-advise
@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and teniposide for injection concentrate) should not be treated with @DRUG$.	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
In clinical , the in subjects with Acamprosate concomitantly with @DRUG$ , hypnotics ( @DRUG$ ) , non-opioid analgesics to taking placebo with concomitant medications	DDI-false
Interactions with Agonist/Antagonist Opioid Agonist/antagonist analgesics ( eg , @DRUG$ nalbuphine , @DRUG$ NOT a patient who received or therapy a agonist opioid analgesic such .	DDI-false
A two-way interaction between the hydantoin antiepileptic, @DRUG$, and the @DRUG$s has been suggested.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
Data studies of @DRUG$ suggest a possible interaction following @DRUG$ nicardipine , and	DDI-int
containing side of , cefotetan cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ can cause vitamin deficiency .	DDI-false
Before , pharmacist of all prescription products may : , @DRUG$ ) cyclosporine , non-steroidal e.g. ibuprofen @DRUG$ .	DDI-false
@DRUG$ (@DRUG$) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.	DDI-false
@DRUG$: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	DDI-false
@DRUG$: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
The pressor effects of such as dopamine or @DRUG$ by	DDI-effect
@DRUG$ Since is a dopamine it is possible @DRUG$ , as neuroleptics , butyrophenones or metoclopramide may effectiveness of	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
pharmacokinetic revealed , NSAIDs @DRUG$ did not influence @DRUG$ clearance .	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, @DRUG$ or delavirdine).	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of @DRUG$.	DDI-effect
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ ( mg ) did not alcohol during the 4-hour in healthy when administered with @DRUG$ ( 0.5 g/kg body weight	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
inhibitors include azole ciprofloxacin clarithromycin diclofenac , , @DRUG$ , , isoniazid , nefazodone @DRUG$ , inhibitors , , and	DDI-false
Other drugs which may enhance action nondepolarizing agents such as include certain antibiotics e. g. aminoglycosides , , , polymyxins , @DRUG$ colistin and colistimethate ) , lithium , local , procainamide	DDI-false
If treatment CYP3A4 ( ketoconazole , indinavir , @DRUG$ @DRUG$ etc ) indicated reduction of the dose should considered	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and @DRUG$] is contraindicated.	DDI-false
@DRUG$ @DRUG$ , chlortetracycline , , have influence in vitro of in human	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
Therefore when @DRUG$ are administered concomitantly with @DRUG$ their dosage should be reduced.	DDI-advise
In @DRUG$ influenced pharmacodynamics of warfarin acid , @DRUG$ , and digoxin , nor of digoxin at steady .	DDI-false
Antihypertensives Amiodarone be used with in -receptor blocking agents ( e.g. propranolol , CYP3A4 inhibitor ) channel , , a @DRUG$ substrate , @DRUG$ , a inhibitor ) of the of sinus arrest block ;	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	DDI-false
@DRUG$ Trileptal with oral contraceptive been shown to concentrations the components @DRUG$ ( EE and ( ) .	DDI-false
were no reports myopathy in placebo-controlled trial 10 @DRUG$ with @DRUG$ ( 4 mg/kg 24 hours ) 14 .	DDI-false
administration of NS 1 mg @DRUG$ QID alter dose @DRUG$.	DDI-false
The of @DRUG$ to receiving oxidase , @DRUG$ or prolonged hypotension or hypertension	DDI-effect
addition results data of other of clearance ( efavirenz , nevirapine , @DRUG$ dexamethasone , or @DRUG$ with CANCIDAS reductions .	DDI-false
These drugs include the thiazides and other , estrogens oral contraceptives , @DRUG$ , @DRUG$ sympathomimetics calcium blocking and	DDI-false
Experience with of @DRUG$ limited therefore , given to suspending use of @DRUG$ in Fentanyl .	DDI-false
Other drug interactions Cimetidine, erythromycin and @DRUG$ had no effect on the pharmacokinetics of @DRUG$.	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ trough concentrations of @DRUG$ were about 56 when 8 mg dexamethasone was with each dose of ) in eight .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
possibility with @DRUG$ can the diuretic increasing the salt of treatment with @DRUG$ or enalaprilat	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
The effect and enalapril is @DRUG$ ( @DRUG$ ) .	DDI-false
Plasma valproate concentration should be when @DRUG$ @DRUG$ are , adjustments of be made .	DDI-advise
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
That Not Be Coadministered With @DRUG$ Antiarrhythmics : Antimigraine ergot derivatives agents : rifampin Benzodiazepines @DRUG$ , triazolam motility	DDI-advise
Response to @DRUG$ may enhanced by @DRUG$.	DDI-effect
tested in , phenytoin , @DRUG$ aminopyrine and @DRUG$.	DDI-false
however no interactions when @DRUG$ administered after narcotics inhalational , @DRUG$ muscle relaxant in conjunction anesthesia .	DDI-false
@DRUG$ and Tricyclic : FORADIL should be administered with extreme in treated with monoamine oxidase or @DRUG$ because the formoterol on cardiovascular system be potentiated by these .	DDI-false
Based , are not between @DRUG$ dapsone , trimethoprim/sulfamethoxazole @DRUG$ , or	DDI-false
of @DRUG$ on other Drugs @DRUG$ ) : Phenytoin : Tiagabine no effect on steady-state plasma concentrations of in patients epilepsy	DDI-false
Although studies were performed , finasteride of 1 mg more concomitantly in with acid , a-blockers @DRUG$ angiotensin-converting ACE @DRUG$ , benzodiazepines , , calcium-channel blockers cardiac nitrates , diuretics H2 antagonists reductase inhibitors , prostaglandin inhibitors ( referred to and quinolone without significant adverse	DDI-false
CONCLUSIONS : Macrolide antibiotics the metabolism of reductase inhibitors that are metabolized CYP3A4 , @DRUG$ , @DRUG$ .	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	DDI-false
@DRUG$: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-false
Acetaminophen : A report of @DRUG$ was reported in patient receiving @DRUG$.	DDI-effect
@DRUG$ : @DRUG$ in urine volume sodium seen during the bumetanide-induced increase in renin .	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
, @DRUG$ Fluconazole , Fluoxetine , , @DRUG$ , .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
Injection injectable , produces depression when administered ethyl alcohol , barbiturates @DRUG$ , other When @DRUG$ is with injectable increased of sedation , , irrational behavior has been observed	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-mechanism
include the thiazides other diuretics corticosteroids , phe-nothiazines @DRUG$ , oral , , nicotinic , sympathomimet-ics , @DRUG$ , isoniazid .	DDI-false
Based on , significant drug not and @DRUG$ trimethoprim/sulfamethoxazole , erythromycin , @DRUG$ or fluconazole	DDI-false
To evaluate the impact on the of HIV-related , , lymphoma ( ) authors a group with HIV-NHL were treated @DRUG$ doxorubicin prednisone CHOP ) plus with a 80 who were treated CHOP or CHOP-like , cyclophosphamide doxorubicin , @DRUG$ , with vincristine ) therapy	DDI-false
proteins may serum , ( i.e. CBG ) sex hormone globulin SHBG ) leading increased @DRUG$ @DRUG$ respectively	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
@DRUG$ and/or in , and inhibit metabolism cisapride result in @DRUG$ levels and prolongation QT interval on ECG .	DDI-false
- Antidiabetics ( you take of @DRUG$ sulfapyridine chance side effects affecting the blood the effects @DRUG$	DDI-false
@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	DDI-false
May interact thyroid , iodine-containing , H2-antagonists ( famotidine @DRUG$ , ( e.g. , lansoprazole , @DRUG$ .	DDI-false
Nervous Depressants concomitant DURAGESIC   ( @DRUG$ other central nervous not limited , @DRUG$ tranquilizers ( , benzodiazepines ) , general anesthetics phenothiazines , relaxants , and may cause respiratory depression sedation , potentially result in coma .	DDI-effect
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
impact the Cmax and AUC of @DRUG$ , significantly @DRUG$ tmax % exposure to phosphorylated by 110	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
of nervous when administered with ethyl , , @DRUG$ MAO , and @DRUG$.When scopolamine is concomitantly with injectable of sedation , hallucinations and has observed .	DDI-false
@DRUG$ : @DRUG$ may myopathy , which is as muscle or weakness associated .	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-effect
@DRUG$ : has apparent pharmacokinetic interaction when administered	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, @DRUG$, @DRUG$.	DDI-false
A clinical male ( ) demonstrated that @DRUG$ immediately produced in @DRUG$ , but the peak the total bioavailability not affected	DDI-false
The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
Drugs Should With Antiarrhythmics : @DRUG$ Antihistamines , Antimigraine : ergot Antimycobacterial agents rifampin Benzodiazepines , triazolam motility @DRUG$	DDI-false
Although no interaction between @DRUG$ and @DRUG$ has been observed, it is not recommended for use with MAO inhibitors.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with @DRUG$, antihypertensive agents, or other vasodilators.	DDI-effect
@DRUG$-containing therapies should not be used with @DRUG$ as they may diminish its pharmacologic action.	DDI-advise
Repeated doses @DRUG$ to in human decrease @DRUG$	DDI-false
@DRUG$ vitro data @DRUG$ inhibits the cisapride , can result in an increase levels and prolongation of the interval on the ECG .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
interactions concomitant of psychotropic drugs @DRUG$ , @DRUG$ , ) .	DDI-false
However , severe reactions , such hypotension requiring treatment requiring @DRUG$ , , of @DRUG$ therapy	DDI-false
Ingestion of @DRUG$ may increase serum concentrations of digoxin and methotrexate and increase @DRUG$ s nephrotoxicity.	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
A though , has @DRUG$ , sodium griseofulvin , @DRUG$ and with ampicillin 72	DDI-false
@DRUG$ : have produced an elevation plasma @DRUG$ levels a reduction clearance .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	DDI-mechanism
Rifampin: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
with blood , decongestant , cold and sinus medicines ) drugs , @DRUG$ , , @DRUG$ Ibuprofen , and high pressure	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Nifedipine: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
drug-drug study @DRUG$ in volunteers has shown decrease in @DRUG$ trough concentrations	DDI-mechanism
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$ of @DRUG$ the of renal , particularly volume-depleted patients .	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
of @DRUG$ are reduced concurrently with	DDI-mechanism
: In concomitant @DRUG$ @DRUG$ 50 % increase in of acetaminophen .	DDI-mechanism
are of substances that may reduce the effect corticosteroids , niacin danazol @DRUG$ , epinephrine , terbutaline @DRUG$ , thyroid , , contraceptives )	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of @DRUG$.	DDI-false
Anticholinesterases (neostgmine, physostigmine), @DRUG$, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
Coadministration of valdecoxib and @DRUG$ 1/35  increased the exposure of norethindrone and @DRUG$ by 20% and 34%, respectively.	DDI-false
The following specific been reported : Co-administration another formulation felodipine with @DRUG$ approximately in the , more 6- fold increase in Cmax , the half- life @DRUG$.	DDI-false
addition , results regression analyses patient that co-administration of other inducers drug clearance efavirenz , nevirapine , @DRUG$ @DRUG$ with result reductions in	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
Coadministration of @DRUG$ 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
occur administered concomitantly CNS depressants including @DRUG$	DDI-false
a study in patients with RA were for with Kineret and @DRUG$ therapy a % rate of observed was that observed with @DRUG$ ( 0 ) .	DDI-false
Interactions : Flupenthixol may with MAOI ): MAOI could affect @DRUG$ Ethanol : and Ethanol additive depression - Tricyclic : @DRUG$ the effect Tricyclic antidepressants	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ is the of and increase its levels should prior to concurrent isoniazid should be closely , dosage adjustment the @DRUG$ made .	DDI-false
@DRUG$ or colestipol resins the @DRUG$ and its absorption 43 percent , .	DDI-mechanism
in vitro benzodiazepines than @DRUG$ suggest possible the : @DRUG$ , nicardipine and nifedipine .	DDI-int
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Coadministration with @DRUG$ ( 40 BID 7 days a increase @DRUG$ levels suggesting these doses , valdecoxib is a weak 2D6	DDI-mechanism
Digoxin , Nimodipine and Losartan @DRUG$ has no interactions digoxin and nimodipine and @DRUG$ effect levels of bosentan	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : Since both @DRUG$ and tetracyclines can cause increased intracranial , use contraindicated .	DDI-false
In receiving @DRUG$ and steroid , any reduction steroid dosage order to the possible complications of @DRUG$ .	DDI-false
and @DRUG$ in @DRUG$ may reduce	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
In clinical trials FLOLAN was used diuretics @DRUG$ oral vasodilators , a with congestive heart failure receiving @DRUG$ in with oral clearance values furosemide = and digoxin ( n decreased by and 15 % respectively , the second values	DDI-false
Although the interaction @DRUG$ other potent CYP3A4 ( ritonavir , erythromycin has been to @DRUG$ be concomitantly .	DDI-false
@DRUG$ blunts the increases in sodium excretion @DRUG$ treatment and inhibits bumetanide-induced increase plasma .	DDI-mechanism
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
monitored @DRUG$ with @DRUG$.	DDI-advise
Other may enhance the action agents such NUROMAX include certain @DRUG$ ( g. , tetracyclines , , clindamycin , , and sodium colistimethate @DRUG$ local anesthetics , quinidine .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-mechanism
Other Cardiovascular Enalapril and enalapril have used with @DRUG$ , , nitrates calcium-blocking , @DRUG$ and digoxin without evidence of clinically	DDI-false
Important Interactions @DRUG$ have clinically important captopril , beta-blockers , felodipine , digoxin @DRUG$ , carvedilol ethanol or itraconazole .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or primidone concentrations when compared to placebo.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
studies have shown @DRUG$ can displace anticoagulants , @DRUG$ ,	DDI-mechanism
Antiacid @DRUG$ @DRUG$ , Phenytoin Phenobarbitol , Rifabutin , , , Saquinavir .	DDI-false
Drugs : , @DRUG$ , , @DRUG$ antidepressants QT-interval and an ventricular arrhythmia	DDI-false
may by anticonvulsants antihistamines , barbiturates inhibitors , @DRUG$ @DRUG$ , or other drugs that	DDI-false
Methotrexate @DRUG$ @DRUG$ increase the the liver the	DDI-false
Other Enalapril and IV have been used concomitantly agents , methyldopa @DRUG$ , @DRUG$ , and digoxin evidence of significant .	DDI-false
@DRUG$ may add to or potentiate the therapeutic effect of other @DRUG$.	DDI-effect
ketoconazole miconazole @DRUG$ . in and animal of @DRUG$ and imidazoles that fungal resistance B.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
drug may interact with @DRUG$ ( may the depressant these or @DRUG$ , medications ( anticholinergic effects be when medications used concurrently monoamine oxidase concurrent may prolong antihistamines ) .	DDI-false
, other containing @DRUG$ or @DRUG$ antacids or sucralfate should be with within 2 of administration of , because absorption resulting lower serum urine levels	DDI-false
The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
@DRUG$, warfarin, heparin, @DRUG$	DDI-false
@DRUG$ and , including , , gallamine , decamethonium and @DRUG$ , potentiate the neuromuscular blocking effect used with caution in Coly-Mycin M Parenteral .	DDI-false
Co-administration @DRUG$ and cerivastatin did alter the pharmacokinetics of @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
of patients RA or more ORENCIA : @DRUG$ @DRUG$ , TNF agents , azathioprine chloroquine gold , , sulfasalazine	DDI-false
When used concurrently with such drugs, the dose of @DRUG$ should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of @DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Concomitant cyclophosphamide , @DRUG$ , vincristine and @DRUG$ therapy virus-related non-Hodgkin .	DDI-false
Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-effect
Lorazepam injection like benzodiazepines nervous system with , , @DRUG$ inhibitors , and @DRUG$ is concomitantly with injectable lorazepam , an of sedation , hallucinations and behavior has been observed	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (@DRUG$, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
A possible interaction between glyburide and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
@DRUG$ , or other containing @DRUG$ , or sucralfate administered concomitantly with within the they may levels of norfloxacin	DDI-false
Drug/Laboratory Interaction Because @DRUG$ may affect , @DRUG$ plasma samples interfere one-stage on the APTT ( and	DDI-false
@DRUG$ use may	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-mechanism
: be used with in patients   -@DRUG$ blocking agents ( , propranolol CYP3A4 inhibitor ) or antagonists e.g. , , @DRUG$ and diltiazem a CYP3A4 inhibitor ) of , arrest and block ;	DDI-false
Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG-DRUG$.	DDI-false
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with anticholinergic or @DRUG$.	DDI-advise
of @DRUG$ and @DRUG$ reduce K.	DDI-mechanism
Interactions Mixed Opioid Analgesics : analgesics pentazocine @DRUG$ who is receiving a a analgesic @DRUG$.	DDI-advise
include antifungals @DRUG$ , , diclofenac erythromycin , imatinib propofol , @DRUG$ quinidine , and	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and MHD.	DDI-mechanism
are examples of may reduce the effect : niacin , danazol diuretics sympathomimetic agents ( e.g. @DRUG$ , , @DRUG$ isoniazid , derivatives , somatropin , hormones estrogens , ( , .	DDI-false
@DRUG$: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
there no study to evaluate the compounds , including @DRUG$ may an additive with @DRUG$ risk developing methemoglobinemia .	DDI-effect
@DRUG$ and @DRUG$: a drug interaction.	DDI-int
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and @DRUG$.	DDI-false
Central System Depressants use of DURAGESIC ( fentanyl transdermal system ) other central nervous system , including not opioids @DRUG$ hypnotics , ( e.g. benzodiazepines , anesthetics , , skeletal and @DRUG$ , may respiratory , and profound , result death	DDI-false
Sedatives/@DRUG$ : @DRUG$ to for serious and/or life-threatening as prolonged or increased sedation depression .	DDI-false
@DRUG$ is primarily by the kidneys , coadministration of with drugs reduce renal or compete tubular secretion may serum either @DRUG$ or the coadministered	DDI-false
If @DRUG$ is with that Pgp , increased concentrations @DRUG$ and should	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
RA received more medications with : @DRUG$ NSAIDs , corticosteroids blocking azathioprine chloroquine , hydroxychloroquine , @DRUG$ and anakinra	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
however deleterious were seen when @DRUG$ after , inhalational @DRUG$ , relaxants and muscle antagonists administered or anesthesia .	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions.	DDI-advise
such as @DRUG$ and @DRUG$ ;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
and AEDs ( @DRUG$ gabapentin , @DRUG$ , phenobarbital phenytoin primidone valproate ) were also evaluating levetiracetam and these AEDs during .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
a study in the 2 mg @DRUG$ orally tablet was without an @DRUG$ multiple effects on the GI ) volunteers AUC was 10 % and of clonazepam was lower disintegrating tablet was with compared it was	DDI-false
@DRUG$ . had no on bioavailability ( AUC maximum concentration ) of @DRUG$ with Vardenafil in volunteers	DDI-false
The co-administration of with IV as , nitroprusside @DRUG$ , ACE has not been ( not with @DRUG$	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.	DDI-int
local epinephrine or patients receiving @DRUG$ tricyclic antidepressants or @DRUG$ may severe hypotension hypertension .	DDI-false
in vitro of @DRUG$ other a drug for the following @DRUG$ cyclosporine , , , and	DDI-int
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Caution should also be taken in concurrent or serial use of other @DRUG$ and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ neuromuscular blocking effects.	DDI-false
Therefore, when hydroflumethiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
, oxcarbazepine and @DRUG$ a subgroup cytochrome 3A ( and the of @DRUG$ and resulting concentration of	DDI-false
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and @DRUG$.	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, propranolol, @DRUG$, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
In addition , influenced of @DRUG$ @DRUG$ nor the at .	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
Antiacid , , , , , Ketoconazole , @DRUG$ , Phenobarbitol @DRUG$ Rifampin ,	DDI-false
caution is recommended when with CYP3A4 that a @DRUG$ @DRUG$	DDI-false
Digoxin, @DRUG$, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
and @DRUG$ : Coadministration of VIRACEPT with OVCON-35 in a 47 % ethinyl and in @DRUG$ plasma concentrations	DDI-false
Concomitant use of agents in the @DRUG$ (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
Other concomitant specific studies were not , doses of 1 mg were used in clinical studies acid a-blockers , , angiotensin-converting enzyme ACE ) @DRUG$ benzodiazepines @DRUG$ blockers cardiac nitrates diuretics , H2 antagonists , HMG-CoA inhibitors , synthetase inhibitors also NSAIDs ) of clinically significant adverse .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
of @DRUG$ and @DRUG$ or other agents interfering e.g. , curare-like compounds ) should only performed caution as the effect of	DDI-advise
These results would seem to dictate against the clinical use of @DRUG$ with @DRUG$, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.	DDI-advise
suggest that acute @DRUG$ not affect behaviors closely with @DRUG$ intoxication	DDI-false
Antihypertensive medications, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Potential drug Keppra   AEDs , lamotrigine @DRUG$ , and @DRUG$ ) were also assessed the AEDs placebo-controlled studies	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
The majority of RA clinical studies one the @DRUG$ , , agents , azathioprine chloroquine , @DRUG$ , ,	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of @DRUG$ or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
In the of (-)-NANM , @DRUG$ @DRUG$ ,	DDI-false
Doxorubicin: @DRUG$ caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-effect
Other concomitant therapy Although specific not finasteride doses or were concomitantly used clinical acetaminophen acetylsalicylic acid a-blockers , angiotensin-converting , @DRUG$ , beta , blockers nitrates , diuretics H2 antagonists , HMG-CoA synthetase ( also referred ) , and @DRUG$ without of significant interactions	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Patients receiving @DRUG$, sulfonamides, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
from in benzodiazepines alprazolam suggest a drug interaction the following : ergotamine , @DRUG$ amiodarone nicardipine	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
Both @DRUG$ and its major metabolite, @DRUG$, are inhibitors of the cytochrome P450 3A4 enzyme system.	DDI-false
Protein , @DRUG$ interferes minimally or at all with the acid ( 20 % in binding ) , @DRUG$ % decrease in binding ) or	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Presumably, @DRUG$ acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the @DRUG$ and increased prothrombin-proconvertin concentrations.	DDI-mechanism
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or @DRUG$, and high blood pressure medications.	DDI-false
@DRUG$ : Anticoagulant be particularly few days initiating or VIOXX therapy in receiving @DRUG$ or agents these are at an risk bleeding complications	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
, through an effect on microsomal has reduce the hepatic metabolism , , @DRUG$ , , @DRUG$ certain tricyclic and metronidazole delaying elimination blood levels of drugs .	DDI-false
An interaction @DRUG$ @DRUG$ pharmacokinetics or activity .	DDI-false
Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
The action benzodiazepines may be potentiated by @DRUG$ antihistamines alcohol barbiturates , monoamine oxidase inhibitors @DRUG$ , medications or other drugs produce CNS .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
- @DRUG$ (e.g., AquaMEPHYTON, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Although no clinical studies been , likely metabolism @DRUG$ be by the such as , phenobarbital , @DRUG$ CYP3A4 antimycotics e.g. ,	DDI-mechanism
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
of VISTIDE and agents with nephrotoxic e.g. , intravenous @DRUG$ ( e.g. tobramycin @DRUG$ ) B , , intravenous , , is	DDI-false
@DRUG$ nondepolarizing ( , responsiveness to @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
The hypoglycemic of sulfonylurea may be potentiated anti-inflammatory drugs that protein @DRUG$ , sulfonamides , chloramphenicol probenecid , @DRUG$ inhibitors , blocking agents	DDI-false
interact with alcohol , blood decongestant cold and medicines ) drugs , , norepinephrine @DRUG$ like @DRUG$ high pressure	DDI-false
Iodine or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
While all the @DRUG$ (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
These and , @DRUG$ , estrogens nicotinic acid , @DRUG$ , calcium channel blocking , and	DDI-false
In clinical performed @DRUG$ of oral anticoagulants ( ) inhibitors @DRUG$ ) , NSAIDs ) , did not affect pharmacokinetics/pharmacodynamics of fondaparinux	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
there is little information administration of @DRUG$ @DRUG$ drugs often administered any interactions resulting effects or diminished efficacy .	DDI-false
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously.	DDI-mechanism
following examples of that increase blood-glucose-lowering to oral @DRUG$ ACE fibrates , oxidase ( MAO , , somatostatin analog e.g. , @DRUG$ , sulfonamide .	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Urinary agents agents ( , @DRUG$ . of species the @DRUG$ , excretion .	DDI-mechanism
H2 Receptor : Cimetidine leads increased plasma @DRUG$ there effect coadministered	DDI-false
include azole , ciprofloxacin , clarithromycin , , @DRUG$ , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine inhibitors , and verapamil	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
The following are examples of substances reduce the : corticosteroids , niacin , @DRUG$ , , sympathomimetic e.g. , epinephrine , phenothiazine derivatives somatropin , thyroid hormones , estrogens @DRUG$ ( e.g. in contraceptives .	DDI-false
Particular be observed with @DRUG$ since there are effect of @DRUG$ the of digoxin digitoxin .	DDI-effect
Two groups SH/DA ) submitted to hydroalcoholic @DRUG$ , methanol alcohols and @DRUG$ in the proportions those most common fermented alcoholic beverages ;	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
To impact of chemotherapy the clinical course with , non-Hodgkin lymphoma , the authors compared a of with were the cyclophosphamide , doxorubicin , vincristine , @DRUG$ ) regimen with of 80 who were CHOP ( i.e. , cyclophosphamide doxorubicin teniposide @DRUG$ vincristine ) antiretroviral therapy	DDI-false
At a median follow-up of 33 months, the combination of ARIMIDEX and @DRUG$ did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
@DRUG$ e.g. ) Use of sulfapyridine the of effects and/or @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Serious anticholinergic symptoms dry mouth , urinary , blurred been associated with the levels of @DRUG$ @DRUG$ added to the drug .	DDI-effect
@DRUG$ the of the metabolite administration of @DRUG$ erythromycin had significant effect administration .	DDI-false
Before using this , your all and may , especially : aminoglycosides ( e.g. , gentamicin @DRUG$ , B cyclosporine anti-inflammatory ( ibuprofen , @DRUG$.	DDI-false
Rifampin significantly decreased the AUC(ss) of @DRUG$ by 82%, but @DRUG$ had no effect on rifampin pharmacokinetics.	DDI-false
@DRUG$ : CONTRAINDICATED since the product @DRUG$ an regimen reduces the concentrations saquinavir .	DDI-false
Ethinyl Estradiol : @DRUG$ decrease estradiol and 18 decrease @DRUG$ concentrations .	DDI-false
report the adolescent caused @DRUG$ overdose a positive @DRUG$ to alert clinicians to the cross-reactivity carbamazepine for	DDI-effect
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific studies were , sodium was used angiotensin- converting enzyme betablockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( @DRUG$ without clinically interactions .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
Before using this medication , or all may use , especially ( e.g. gentamicin , amikacin ) , amphotericin , @DRUG$ , anti-inflammatory e.g. ibuprofen ) @DRUG$ , vancomycin	DDI-false
drugs include @DRUG$ other , @DRUG$ , , thyroid products , estrogens oral , channel drugs , and isoniazid	DDI-false
In rats simultaneous ingestion @DRUG$ and @DRUG$ for 78 has reported to cause and it has that in the stomach to form	DDI-effect
Digoxin: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Imidazoles ( @DRUG$ , miconazole , @DRUG$ , fluconazole , . ): animal studies with B and suggest that induce fungal resistance B.	DDI-false
@DRUG$ : Coadministration of a @DRUG$ daily for 7 days did produce interaction on performance	DDI-false
Use with @DRUG$: The principal pathway for detoxification of @DRUG$ is inhibited by allopurinol.	DDI-false
which may agents such as g. aminoglycosides , , , lincomycin , clindamycin , colistin , and colistimethate ) , @DRUG$ , @DRUG$ , procainamide , and .	DDI-false
@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
containing chains of N-methylthiotetrazole @DRUG$ @DRUG$ , , cefamandole ) ) vitamin and hypoprothrombinemia .	DDI-false
Pharmacokinetic or pharmacodynamic interactions have not been demonstrated aspirin ( 162.5 mg given and prior initiation Argatroban 1   g/kg/min . 4 hours ) or acetaminophen ( mg orally given hours and 6 and 12 hours initiation of @DRUG$ 1.5   g/kg/min . hours	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
that plasma concentrations Drugs that imatinib concentrations : is administering @DRUG$ with of ( ketoconazole , @DRUG$ clarithromycin ) .	DDI-advise
Other reported interactions with amiodarone Fentanyl ( @DRUG$ ) in combination @DRUG$ hypotension bradycardia , and	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ interfere with action @DRUG$	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
These effects were @DRUG$ 20 taken 24 before the	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Coadministration @DRUG$ not the	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
drug interactions between Keppra   and carbamazepine , gabapentin , lamotrigine phenobarbital , @DRUG$ , @DRUG$ ) were also assessed by evaluating serum of during clinical studies	DDI-false
drugs include @DRUG$ corticosteroids , phenothiazines , estrogens @DRUG$ , nicotinic , calcium channel blocking , and .	DDI-false
Resins : Since bile acid sequestrants may bind drugs , @DRUG$ least 1 hours a @DRUG$ to avoid .	DDI-mechanism
@DRUG$- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ produced an of plasma lithium a reduction in renal @DRUG$ clearance .	DDI-false
Although studies coadministration with CYP3A4 ( disopyramide quinine @DRUG$ , , , , ergot derivatives , pimozide , triazolam elevated concentrations when with @DRUG$ ;	DDI-mechanism
Drugs Should Coadministered VIRACEPT Antiarrhythmics amiodarone , @DRUG$ : ergot : rifampin Benzodiazepines @DRUG$ motility agents :	DDI-false
Vitamin K @DRUG$ Synkayvite @DRUG$ with these may side blood	DDI-false
Oral @DRUG$: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	DDI-effect
a of , protease ( ritonavir , @DRUG$ , and @DRUG$ ) CYP3A4 have not been clinical .	DDI-false
therapy were performed , finasteride doses mg or were studies with acetylsalicylic , a-blockers , angiotensin-converting ) , benzodiazepines , , calcium-channel blockers cardiac @DRUG$ @DRUG$ reductase , prostaglandin synthetase inhibitors ( also to as ) , and quinolone anti-infectives without significant interactions .	DDI-false
( , @DRUG$ triamterene , amiloride ) , potassium supplements , salt may significant in serum .	DDI-false
@DRUG$ Methylxanthines and Diuretics treatment with @DRUG$ or potentiate possible hypokalemic beta2-agonists	DDI-false
therapy specific were not performed , of mg or used in clinical with acetaminophen , acetylsalicylic , analgesics angiotensin-converting ACE , , @DRUG$ , @DRUG$ calcium-channel , cardiac , diuretics antagonists inhibitors prostaglandin inhibitors referred to as ) anti-infectives of .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
We report case of an adolescent with by carbamazepine @DRUG$ to to cross-reactivity of with toxicology screen @DRUG$.	DDI-false
concentrations of digoxin @DRUG$ , @DRUG$ piroxicam , andtolbutamide ketorolac tromethamine binding	DDI-false
data indicate @DRUG$ does not the AEDs these do not influence pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ @DRUG$ corticosteroids occur when used concurrently	DDI-false
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism, inhibitors of this enzyme system, notably oral @DRUG$, should be used cautiously in patients receiving clonazepam.	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, @DRUG$, etc).	DDI-false
Concomitant use of agents in the @DRUG$ (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.	DDI-false
comparison @DRUG$ tolerance dogs anesthetized with , @DRUG$ or pentobarbital , the dosage of needed tachycardia , as of ouabain , .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
In a clinical pharmacology coadministration of an @DRUG$ ( aluminum @DRUG$ , simethicone reduced levels urinary excretion compared fosinopril administered alone , suggesting that antacids may absorption of .	DDI-false
Interactions with Mixed eg , pentazocine , @DRUG$ , butorphanol , dezocine buprenorphine ) NOT be administered who received course therapy with opioid analgesic	DDI-advise
are examples known to inhibit metabolism other related through inhibition of : @DRUG$ , , cimetidine , diltiazem @DRUG$ macrolide antibiotics .	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Cation-Containing Products : quinolone including ciprofloxacin multivalent cation-containing such magnesium @DRUG$ , , VIDEX pediatric powder , products containing calcium @DRUG$ , zinc substantially decrease the absorption of resulting in serum levels	DDI-false
majority in clinical studies or concomitant medications with ORENCIA MTX @DRUG$ , corticosteroids agents , , chloroquine , hydroxychloroquine , @DRUG$ , sulfasalazine anakinra	DDI-false
Probenecid: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
include antifungals , , doxycycline , @DRUG$ , imatinib , isoniazid , nicardipine , @DRUG$ quinidine and	DDI-false
Theophylline: The pharmacokinetics of @DRUG$ (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
with or depressants ( may potentiate the CNS depressant either @DRUG$ , @DRUG$ or with anticholinergic activity effects may be these medications used concurrently with and monoamine MAO ) inhibitors ( use antihistamines may prolong and CNS depressant of antihistamines )	DDI-false
Anticholinesterases (neostgmine, @DRUG$), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	DDI-false
A association , though less marked been suggested , phenytoin sodium @DRUG$ , with and @DRUG$	DDI-false
@DRUG$ , apparently effect enzyme has reported the hepatic metabolism of @DRUG$ , phenytoin propranolol , certain tricyclic antidepressants lidocaine , and , delaying elimination these	DDI-mechanism
@DRUG$ @DRUG$ the sedative effect	DDI-false
@DRUG$ : @DRUG$ potentiate the effect of meperidine	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
@DRUG$ : like other @DRUG$ , affect renal the toxicity drugs .	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
@DRUG$ In decrease in diflunisal was when doses diflunisal and @DRUG$ concomitantly .	DDI-false
Although specific studies have , with that are by eg , calcium blockers , dapsone , disopyramide , quinidine warfarin tacrolimus @DRUG$ pimozide , , fentanyl , @DRUG$ , triazolam ) have elevated when coadministered ;	DDI-false
( nandrolone , , oxandrolone e.g. , @DRUG$ ] , oxymetholone [ Anadrol ] , @DRUG$ , ) or	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and CYP3A4.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
the ( @DRUG$ ) , @DRUG$ , paroxetine , and fluvoxamine , P450 2D6 , they may vary in of .	DDI-false
Effect @DRUG$ Pediatric Patients There about of apparent body clearance of levetiracetam co-administered enzyme-inducing	DDI-false
@DRUG$ The @DRUG$ ( aminophylline 5.8 mg/kg over 20 minutes unchanged following single oral ( ) in healthy	DDI-false
Because play role in hemostasis NSAIDs affect platelet well , NSAIDs @DRUG$ , and @DRUG$ close monitoring patients be certain that in their anticoagulant dosage is required .	DDI-advise
Losartan @DRUG$ has interactions digoxin and no effect plasma levels @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
@DRUG$: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.	DDI-false
@DRUG$: The concomitant use of Bepridil with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
@DRUG$: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
The pharmacokinetics of irbesartan were not affected by coadministration of @DRUG$ or @DRUG$	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
studies have not drugs are mainly CYP3A4 , calcium channel , @DRUG$ , disopyramide quinine , , , cyclosporine , derivatives @DRUG$ , , , ) may elevated plasma when coadministered ;	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	DDI-false
which neuromuscular blocking such as NUROMAX include certain @DRUG$ g. aminoglycosides , tetracyclines , bacitracin polymyxins lincomycin , clindamycin colistin @DRUG$ magnesium lithium local , and	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Coingestion of with @DRUG$ valproic @DRUG$ at high toxic concentrations decreases binding	DDI-false
@DRUG$ toxicity was usually reversible upon discontinuation of @DRUG$ and the ACE inhibitor.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
it would expected dosing @DRUG$ at given evening meal in a decrease in the effect @DRUG$.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Digoxin @DRUG$ Losartan : has no interactions @DRUG$ significant of bosentan .	DDI-false
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
ACE-inhibitors:Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of @DRUG$ increased by up to 40%, when @DRUG$ was given at doses above 1200 mg/day.	DDI-mechanism
: administration of warfarin @DRUG$ healthy not in changes in factor VII compared co-administration @DRUG$ and placebo	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
It is be with the paraclinical @DRUG$ to discriminate due to an intake requires supplementation and related a dysregulation of the mechanisms @DRUG$ requires less specific regulation causal .	DDI-false
The state plasma of @DRUG$ reported to be an average and 20 % , concomitant @DRUG$ in to 4 mg/day .	DDI-mechanism
acetaminophen/@DRUG$ , , acid , , and	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, @DRUG$).	DDI-false
@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The action of may potentiated by drugs including nonsteroidal other drugs are , , chloramphenicol @DRUG$ , @DRUG$ , monoamine oxidase inhibitors beta blocking	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
Close of are required @DRUG$ with @DRUG$ or sympathomimetic drugs	DDI-advise
availability potent reverse inhibitor @DRUG$ disturbances significant shifts in practices in .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of @DRUG$ by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-false
In addition , Fondaparinux influenced the pharmacodynamics @DRUG$ , acetylsalicylic acid , @DRUG$ , nor of digoxin at .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
It is recommended that serum @DRUG$ levels be monitored frequently if PRINIVIL is administered concomitantly with @DRUG$.	DDI-false
astemizole, bepridil, @DRUG$, and @DRUG$.	DDI-false
Epinephrine should not be administered concomitantly with other @DRUG$ (such as @DRUG$) because of possible additive effects and increased toxicity.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
International Normalized INR ) elevations events have reported in patients @DRUG$ while @DRUG$ therapy .	DDI-effect
Patients begin or increase diclofenac dose or @DRUG$ taking , @DRUG$ , or cyclosporine develop toxicity characteristics for drugs .	DDI-effect
However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$ may hemodynamic effects of @DRUG$	DDI-effect
@DRUG$ and @DRUG$ are not.	DDI-false
conversely, @DRUG$ may interfere with antihypertensive drugs (i.e., @DRUG$, a-methyldopa).	DDI-int
therapy @DRUG$ , penicillin @DRUG$ ;	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
@DRUG$ or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	DDI-effect
Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
Because there a basis that may additive ergotamine-containing or @DRUG$ like dihydroergotamine or ) @DRUG$ within of each other be .	DDI-advise
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
, @DRUG$ , @DRUG$ anticholinergic effect of clidinium .	DDI-false
Magnesium- products containing ( iron ) , multivitamin preparations zinc other metal , or @DRUG$ ( @DRUG$ or the pediatric for oral solution not be within 3 hours before or 2 .	DDI-false
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	DDI-false
Serial plasma of @DRUG$ rifabutin , their @DRUG$ measured by liquid .	DDI-false
@DRUG$ therapy of @DRUG$ increased and is reduced	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Saquinavir: The combination of @DRUG$, @DRUG$, and ZDV has been studied (as triple combination) in adults.	DDI-false
Antihypertensives : should be in   -receptor ( e.g. , ) @DRUG$ antagonists ( e.g. , , @DRUG$ , and a CYP3A4 inhibitor because possible of bradycardia , sinus , and	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$ have a significant on of @DRUG$ ( a CYP 2C9 and substrate ) .	DDI-false
: @DRUG$ @DRUG$ therapy , of amiodarone regularly increase serum digoxin concentration that reach toxic levels with toxicity .	DDI-false
Imidazoles ( e. g. , , @DRUG$ , fluconazole , etc ): animal studies with the of amphotericin and imidazoles suggest may induce resistance to @DRUG$.	DDI-false
Acetaminophen @DRUG$ , phenobarbital , quinidine , @DRUG$ , valproic acid added pooled serum at .	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ for 10 days, and cohort 2 received @DRUG$ plus rifampin for 4 days.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	DDI-false
specific studies have not performed with drugs are mainly metabolized by CYP3A4 eg , calcium disopyramide , @DRUG$ quinidine warfarin , tacrolimus , ergot , , @DRUG$ fentanyl , , alprazolam , triazolam ) may elevated when with saquinavir ;	DDI-false
The @DRUG$ ) on @DRUG$ ( responses in rat recording in fura-2	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$-Concomitant and @DRUG$ the absorption vitamin	DDI-false
The concentrations of @DRUG$ , the active metabolite @DRUG$ , % in patients receiving bolus-IFL combination with when bolus-IFL alone .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, @DRUG$ or itraconazole.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Carbamazepine : the serum levels Carbamazepine levels should be administration @DRUG$ , signs and symptoms of @DRUG$ toxicity should be monitored adjustment of anticonvulsant	DDI-false
of @DRUG$ patients receiving cyclopropane @DRUG$ such halothane which sensitize may cardiac ..	DDI-effect
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-false
Example include @DRUG$ , clarithromycin diclofenac , doxycycline erythromycin , imatinib , nicardipine propofol , inhibitors , quinidine and	DDI-false
of chemotherapy plus HAART clinical course , lymphoma HIV-NHL , authors a patients HIV-NHL who were treated the cyclophosphamide doxorubicin , vincristine ) regimen group 80 chemotherapy a CHOP-like ( i.e. , @DRUG$ doxorubicin teniposide and @DRUG$ bleomycin ) without receiving	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
include azole , , clarithromycin diclofenac , erythromycin imatinib , isoniazid , , protease inhibitors , @DRUG$ and	DDI-false
The effects @DRUG$ inositol (@DRUG$)-induced rat bone megakaryocytes with patch-clamp combination with fura-2 microfluorometry .	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
The vasopressors , agents ( as @DRUG$ ) some @DRUG$ result in severe	DDI-effect
the thiazides and other phenothiazines , thyroid products @DRUG$ , oral contraceptives phenytoin acid sympathomimetics , @DRUG$ isoniazid	DDI-false
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
to be the @DRUG$ , theoretically coadministration of other drugs known to alter cardiac eg or beta-adrenergic blocking agents , blockers , @DRUG$ H1-blocking agents antidepressants and ) might contribute prolongation of the QTc	DDI-effect
Protease Inhibitors : @DRUG$ ( mg t.i.d ) co-administered with Vardenafil resulted in AUC , 7-fold @DRUG$ a in vardenafil half-life	DDI-false
: Flupenthixol with some , like Monoamine MAOI affect cause - @DRUG$ increases effect of @DRUG$	DDI-false
Potassium-sparing diuretics e.g. , spironolactone @DRUG$ or amiloride ) , @DRUG$ or substitutes to significant serum	DDI-false
: Coadministration of @DRUG$ @DRUG$ in % in nelfinavir plasma 207 increase rifabutin plasma	DDI-mechanism
strong inhibitors CYP3A4 ( , itraconazole , clarithromycin , nefazodone @DRUG$ @DRUG$ , nelfinavir would be similarly	DDI-false
These increased @DRUG$ and ethinyl be into oral @DRUG$ for .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$ should be monitored loss control with @DRUG$ .	DDI-advise
@DRUG$ an anionic-binding , has lowering the and @DRUG$ bioavailability	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Cardiovascular Agents : and have used with adrenergic-blocking @DRUG$ , , hydralazine @DRUG$ without evidence clinically significant .	DDI-false
Co-medications , @DRUG$ , @DRUG$ , phenobarbital or	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Additive from with @DRUG$ , @DRUG$ haloperidol , , tricyclic antidepressants or some .	DDI-false
clinical , used with @DRUG$ , @DRUG$ , and supplemental . In a substudy in patients congestive heart failure receiving in therapy initiated , apparent oral for ( n digoxin n 30 were decreased % and % , the second day and had to baseline day	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, methotrexate and 5-fluorouracil.	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Poor metabolizers have higher than expected lasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example antifungals , diclofenac , @DRUG$ , @DRUG$ , nicardipine , propofol inhibitors and verapamil .	DDI-false
with to moderate hypertension , administration of 25 of @DRUG$ @DRUG$ , 10 40 for associated with an average increase in mean arterial pressure about 3 mm compared inhibitor	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
and (ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of @DRUG$ were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.	DDI-false
BACKGROUND : effects of combined @DRUG$ and verapamil @DRUG$ ) , a channel incidence of peritoneal metastasis adenocarcinomas induced ( AOM index of cancers were investigated male rats	DDI-false
pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ administered aspirin ( given 26 2 to of g/kg/min 4 ) acetaminophen ( orally 12 6 and 0 prior to and 12 hours subsequent , initiation 1.5   18	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
hypoglycemic sulfonylurea may drugs @DRUG$ and other drugs are highly protein bound , salicylates , , probenecid monoamine oxidase inhibitors and	DDI-false
@DRUG$ : no interaction with @DRUG$ or hydrochlorothiazide .	DDI-false
Corticosteroids Methylxanthines Diuretics Concomitant xanthine derivatives , steroids @DRUG$ potentiate a hypokalemic effect of @DRUG$	DDI-effect
Phenothiazines @DRUG$ may reduce or reverse the pressor	DDI-effect
of the of reactions in have a basis it important query patients their guardians benzodiazepine and @DRUG$ use as of the history prior to in which @DRUG$ is planned	DDI-false
of a single @DRUG$ 20 mg and @DRUG$ 20 mg for interaction .	DDI-false
In patients who have received muscle relaxants, @DRUG$ may temporarily mask the residual effects of @DRUG$.	DDI-effect
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
no vivo drug-drug estazolam and inducers CYP3A , that are ( such carbamazepine , @DRUG$ @DRUG$ would to decrease estazolam concentrations	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
antifungals , @DRUG$ , doxycycline , erythromycin imatinib , isoniazid , @DRUG$ , protease verapamil .	DDI-false
The are of may increase the blood-glucose-lowering to hypoglycemia : oral antidiabetic , @DRUG$ @DRUG$ , , oxidase inhibitors , , analog , ) antibiotics	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
System Depressants The concomitant use DURAGESIC ( system ) with other central nervous depressants , other @DRUG$ ( @DRUG$ ) , general phenothiazines relaxants and alcohol , may depression , and profound , or death	DDI-false
@DRUG$ ( @DRUG$ ) or other digitalis use may inotropic and/or chronotropic	DDI-false
Digoxin @DRUG$   not the pharmacokinetics ( ECG of @DRUG$ given as 0.25 dose every .	DDI-false
Saquinavir: The combination of @DRUG$, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
If treatment of CYP3A4 such @DRUG$ , , @DRUG$ , indinavir , saquinavir , . ) is budesonide dose considered	DDI-false
Therefore, the concomitant administration of @DRUG$ and glyburide is contraindicated, and alternative @DRUG$ should be considered.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-effect
In significant of of oxidized with cytochrome substrates/inhibitors @DRUG$ tolbutamide and @DRUG$.	DDI-false
@DRUG$ : treatment @DRUG$ be has been associated with a number cases hypertension , some use of	DDI-false
conversion of @DRUG$ @DRUG$ is catalyzed by aldehyde .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Enzyme Inducers , Inhibitors and : Drugs which cytochrome 3A4 ( enzyme activity e.g. barbiturates , @DRUG$ , carbamazepine , rifampin ) metabolism and that the dosage of the @DRUG$ be .	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
- @DRUG$: @DRUG$ should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
@DRUG$ (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.	DDI-mechanism
studies performed with concomitant oral @DRUG$ warfarin ) , acid , ( @DRUG$ , and did not sodium .	DDI-false
a change than 10 2- Pediatrics increase high @DRUG$ doses , levels phenytoin by up 40 % @DRUG$ above	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Cation-Containing Products Concurrent administration quinolone ciprofloxacin products as magnesium antacids VIDEX chewable/buffered tablets containing @DRUG$ , iron zinc decrease the @DRUG$ resulting and levels considerably lower desired	DDI-false
The progestin-only is by enzyme-inducing such the @DRUG$ , , and @DRUG$ , rifampin .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
@DRUG$ a of @DRUG$ .	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Concomitant cyclophosphamide, @DRUG$, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
@DRUG$ Norethindrone of with @DRUG$ a 47 % ethinyl estradiol and % plasma concentrations	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
The following are that increase blood-glucose-lowering effect to oral antidiabetic , @DRUG$ , , fibrates , monoamine oxidase ( ) inhibitors , @DRUG$ , analog ( e.g. , sulfonamide .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
: reports profound hypotension and loss consciousness administered with @DRUG$ the apomorphine drugs of class for example , , dolasetron , @DRUG$ ) is contraindicated .	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
After multiple dosing, @DRUG$ (AVONEX  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
While all the @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when @DRUG$ was used in conjunction with @DRUG$.	DDI-effect
Serial plasma samples @DRUG$ , rifampin @DRUG$ by liquid chromatography .	DDI-false
The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or @DRUG$ concentrations when compared to placebo.	DDI-false
It has been reported that results of studies in animals indicate that @DRUG$-induced ventricular arrhythmias during anesthesia can be reversed by @DRUG$.	DDI-effect
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Short-term that of warfarin and @DRUG$ and tablets in protein binding clearance free	DDI-false
The are examples known inhibit of other related benzodiazepines , through CYP3A nefazodone @DRUG$ cimetidine diltiazem isoniazide @DRUG$.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
, the co-administration @DRUG$ the @DRUG$ switching to the .	DDI-advise
@DRUG$: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and @DRUG$ therapy.	DDI-effect
Patients who treated with @DRUG$ to three of receive doses @DRUG$ ( 1/10	DDI-false
Interactions may occur between @DRUG$ supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
@DRUG$ Valdecoxib ) did not the metabolism oral norethindrone/ethinyl estradiol ( mg mcg @DRUG$ ) .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
ACE ( Heart Infarction)- In , 3020 ( 91 ) patients @DRUG$ 25 to also inhibitors or @DRUG$ ( )	DDI-false
either Tagamet 300 q.i.d mg h.s . with b.i.d . ( @DRUG$ , Key demonstrated less steady-state @DRUG$ serum levels the mg h.s regimen , particularly subjects and older	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Note: dissolution of aerosol particles of budesonide in @DRUG$, a model @DRUG$.	DDI-false
Iodine or @DRUG$ excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	DDI-false
Concomitant of @DRUG$ ( equivalent 145 mg TRICOR pravastatin ( mg ) daily days has been increase the mean for @DRUG$ ( 69 decrease to 321 % increase ) 28 % range 54 decrease 128 % , for 3 -hydroxy-iso-pravastatin by from 32 decrease increase ) and 39 range from decrease to 261 ) 23 adults	DDI-false
Other enhance action certain antibiotics ( e. g. aminoglycosides , , bacitracin , , , , @DRUG$ ) , magnesium salts lithium , local anesthetics ,	DDI-false
of @DRUG$ absorption of vitamin K.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Therefore, when using doses of @DRUG$ greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of @DRUG$ may be required.	DDI-advise
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
or iodine may effect of @DRUG$ and an @DRUG$ increase the .	DDI-false
Other drugs which may enhance blocking action nondepolarizing such certain antibiotics ( e. g. , @DRUG$ tetracyclines bacitracin , polymyxins lincomycin clindamycin , colistin , salts lithium , ,	DDI-false
Human data oral inhibits of @DRUG$ , a in AUC @DRUG$.	DDI-false
@DRUG$ may decrease amount @DRUG$ ( Lanoxin Lanoxicaps ) your body .	DDI-mechanism
@DRUG$, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
May interact with the following: cholestyramine, @DRUG$ (use with thiazide diuretics may prevent the @DRUG$ from working properly;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drugs which may enhance neuromuscular action of agents NUROMAX certain antibiotics ( g. @DRUG$ tetracyclines polymyxins , colistin , and sodium colistimethate ) , salts , lithium , @DRUG$	DDI-false
- Methotrexate (e.g., Mexate) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-effect
Antidepressants (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
cause in pH ranitidine or @DRUG$ concentrations of @DRUG$ and therefore potentially	DDI-mechanism
@DRUG$ @DRUG$ flecainide , , quinidine CONTRAINDICATED due potential life-threatening .	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-mechanism
into @DRUG$ coumarin ( @DRUG$	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Aspirin: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	DDI-effect
Antiepileptic drugs : @DRUG$ other @DRUG$ were assessed in .	DDI-false
In neither influenced @DRUG$ , @DRUG$ nor pharmacokinetics of steady	DDI-false
Antacids In clinical pharmacology study coadministration an antacid ( aluminum hydroxide @DRUG$ with fosinopril reduced serum urinary excretion of administered alone @DRUG$ impair of fosinopril	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
@DRUG$: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of @DRUG$ at steady state.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
, in the study , administration 12 @DRUG$ 1 before evening and mg @DRUG$ approximately 4 hours after the evening resulted in a decrease cerivastatin AUC of less than % decrease about % when dosing cerivastatin sodium .	DDI-mechanism
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
specific studies been performed coadministration are by CYP3A4 ( , channel , dapsone disopyramide , , quinidine , @DRUG$ tacrolimus , derivatives , fentanyl , @DRUG$ , triazolam may plasma concentrations saquinavir	DDI-false
reported interactions @DRUG$ in @DRUG$ cause , bradycardia and decreased	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
: of @DRUG$ 3 @DRUG$ daily for days produced pharmacokinetic or interaction	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
In of digitalis in anesthetized ketamine , Innovar Vet , pentobarbital , the dosage of to cause tachycardia was significantly higher , as the LD50 @DRUG$ , with @DRUG$ than with	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Drugs Should Be With VIRACEPT : @DRUG$ quinidine Antihistamines astemizole Antimigraine : ergot derivatives @DRUG$ : Benzodiazepines motility agents	DDI-false
@DRUG$ and @DRUG$ reduce or reverse of epinephrine	DDI-false
@DRUG$-Cephalosporins containing chains N-methylthiotetrazole cefmenoxime @DRUG$ , cefamandole latamoxef ) or ( cefazolin ) can cause vitamin and hypoprothrombinemia	DDI-false
effects @DRUG$ @DRUG$ insulin preparations produced by not	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
of the benzodiazepines may be by @DRUG$ , barbiturates , phenothiazines @DRUG$ or other drugs produce .	DDI-false
Magnesium/Aluminum-containing Antacid Absorption of @DRUG$ moderately reduced ( % ) when coadministered @DRUG$/aluminum-containing	DDI-false
reactions been in patients receiving combination regimens high dose antineoplastic agents specifically cis-platinum @DRUG$ @DRUG$.	DDI-false
of @DRUG$ 30 @DRUG$ , a 45 clearance of diazepam .	DDI-mechanism
@DRUG$: Coadministration of single doses of @DRUG$ 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
@DRUG$ should be used with patients blocking , inhibitor calcium channel antagonists ( e.g. a substrate , and @DRUG$ , a ) because the bradycardia sinus arrest ;	DDI-false
Because that these effects may , use of or ergot-type like dihydroergotamine or @DRUG$ AXERT within 24 hours of other should be avoided .	DDI-false
In monkeys was potent @DRUG$ in decreasing , whereas in pigeons @DRUG$ about equipotent (+)-NANM .	DDI-false
The administration of local or norepinephrine to receiving @DRUG$ @DRUG$ severe hypertension	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	DDI-effect
@DRUG$ above 2000 ng/mL @DRUG$ has to 80 % exposure a 38 decrease total body compared to etoposide	DDI-mechanism
@DRUG$ ( 1000 twice ) did not the pharmacokinetics	DDI-false
@DRUG$ : should used in patients receiving -receptor blocking ) or antagonists ( verapamil @DRUG$ substrate and diltiazem CYP3A4 inhibitor possible of , sinus , AV block	DDI-false
: Pharmacokinetic or pharmacodynamic interactions not been demonstrated concomitantly administered @DRUG$ orally given 26 prior to initiation of Argatroban 1 g/kg/min ) or acetaminophen 12 6 prior , and and 12 subsequent , initiation @DRUG$ g/kg/min 18 hours .	DDI-false
@DRUG$: @DRUG$ appear to have no significant effect on the bioavailability of ciprofloxacin.	DDI-false
acetaminophen/theophylline , , phenobarbital/@DRUG$ theophylline/acetaminophen and valproic	DDI-false
Antagonists : on reports hypotension and of when apomorphine @DRUG$ , the concomitant use of apomorphine of the antagonist ( including for example , ondansetron , granisetron , , @DRUG$ alosetron ) is contraindicated .	DDI-false
That Should Not Be With : amiodarone quinidine @DRUG$ astemizole , terfenadine derivatives agents : rifampin @DRUG$ , triazolam motility agents	DDI-false
Drugs Drugs such , , phenothiazines @DRUG$ , @DRUG$ an of ventricular arrhythmia	DDI-false
Both @DRUG$ @DRUG$ to triple with PI indinavir over initial , with responses being observed with nevirapine and observed .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Digoxin , Methotrexate , like other , renal prostaglandins , may cause in elimination of leading elevated serum levels of cyclosporine @DRUG$ @DRUG$ , and toxicity .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Interactions Opioid Analgesics ( , pentazocine nalbuphine , @DRUG$ dezocine ) should NOT a patient who or is receiving a of with a analgesic @DRUG$.	DDI-advise
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Concurrent administration of drugs nephrotoxic ( e.g. @DRUG$ myelotoxic e.g. e.g. doxorubicin or e.g. , asparaginase with @DRUG$ increase in these organ systems	DDI-effect
These results would seem to dictate against the clinical use of methotrexate with @DRUG$, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	DDI-false
When used in external subcutaneous infusion pumps for @DRUG$, @DRUG$ should not be mixed with any other insulins or diluent.	DDI-false
Adenocard ) has effectively administered in the presence of other drugs @DRUG$ , channel blocking , and @DRUG$ in adverse reaction profile	DDI-false
Effect on @DRUG$ : Literature that @DRUG$ that decreases acidity , not	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Administration of epinephrine to patients receiving cyclopropane or @DRUG$ such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, antihypertensive agents, or other @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and @DRUG$ (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
@DRUG$ been reported was in patients taking @DRUG$ , alprazolam ) .	DDI-false
Single doses cholestyramine @DRUG$ bind @DRUG$ and its up and 43 percent ,	DDI-false
However , neither @DRUG$ appears to @DRUG$	DDI-false
Garlic capsules not be used @DRUG$ ( @DRUG$ the sole protease inhibitor due to the of decreased saquinavir plasma .	DDI-false
( , @DRUG$ etc . in studies with the B and @DRUG$ that imidazoles induce fungal resistance B.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Tagamet , apparently on systems reported reduce the hepatic metabolism of @DRUG$ , chlordiazepoxide , diazepam , certain antidepressants , , theophylline @DRUG$ , thereby and blood these .	DDI-false
@DRUG$ There interaction @DRUG$ and zalcitabine which been confirmed clinically	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or amoxicillin.	DDI-false
John s wort) may increase the formation of @DRUG$, a metabolite of @DRUG$ associated with hemolysis.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
The effect of @DRUG$ on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.	DDI-false
@DRUG$: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
Single doses of either @DRUG$ or @DRUG$ resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
- : in volume sodium seen @DRUG$ treatment inhibits the in plasma activity	DDI-false
In evaluating the potential for interactions among co-administered antiepilepsy drugs (@DRUG$), whether or not an @DRUG$ induces or does not induce metabolic enzymes is an important consideration.	DDI-false
INOmax has been administered tolazoline , dopamine , dobutamine @DRUG$ @DRUG$ high-frequency ventilation	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.	DDI-effect
Cyclosporine: Increased activity of both @DRUG$ and @DRUG$ may occur when the two are used concurrently.	DDI-effect
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
Nonsteroidal Drugs The diflunisal @DRUG$ renal and significantly increased the plasma levels	DDI-false
The inhibition of CYP-2C19 by @DRUG$ and @DRUG$, however, is clinically relevant.	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
used with digoxin , diuretics vasodilators , oxygen In pharmacokinetic in with heart failure receiving or whom therapy with @DRUG$ apparent clearance values @DRUG$ ( n = and ( were % and on therapy and to 87	DDI-false
Central System : The use of @DRUG$   ( system ) other system limited other opioids sedatives , @DRUG$ ( , benzodiazepines general anesthetics , phenothiazines , skeletal muscle and may respiratory hypotension and result .	DDI-effect
and antagonize activity @DRUG$ and @DRUG$ .	DDI-false
@DRUG$ : is dopamine it is that dopamine antagonists the butyrophenones @DRUG$ , may the APOKYN	DDI-false
use @DRUG$s vasoconstricting agents ergonovine and some @DRUG$ may in .	DDI-effect
Lorazepam like injectable , the administered @DRUG$ , @DRUG$ MAO , and other . When scopolamine used concomitantly with , an increased incidence of , hallucinations , and has .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Corticosteroids @DRUG$ and Diuretics : treatment with , @DRUG$ , or may a hypokalemic beta2-agonists .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Theophylline: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
@DRUG$ as potent @DRUG$ of glucocorticoid-induced gene expression	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
EXTREME to @DRUG$ or @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, @DRUG$, and tetracyclines (72)	DDI-false
@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
In monkeys, (-)-NANM was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with @DRUG$.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
of @DRUG$ potentiated antihistamines , , monoamine oxidase inhibitors , narcotics , phenothiazines , @DRUG$ produce depression .	DDI-effect
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
Furosemide : studies , well as have @DRUG$ can the of and @DRUG$ in patients	DDI-effect
vitro that ertapenem does not transport of @DRUG$ that @DRUG$ is a for .	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
ACE Inhibitors and Congestive Post-Myocardial , ) patients receiving 25 50 @DRUG$ or angiotensin II receptor )	DDI-false
of @DRUG$ ( ) : @DRUG$ : had no effect the steady-state plasma concentrations of in patients epilepsy .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
lidocaine/quinidine phenobarbital/acetaminophen acid , quinidine/lidocaine , theophylline/acetaminophen and	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high @DRUG$ doses In vivo, the plasma levels of @DRUG$ increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.	DDI-false
Probenecid: As with other @DRUG$, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-mechanism
Studies in rats have shown that @DRUG$ administration attenuates certain types of @DRUG$ dependent hypertension, including ACTH hypertension.	DDI-false
Although specific interactions topical or systemic medications of IOPIDINE % , the possibility an additive effect @DRUG$ ( alcohol , , , @DRUG$ , anesthetics should be	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, carbamazepine, and @DRUG$.	DDI-false
No is available the use of @DRUG$ with @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
, @DRUG$ @DRUG$ other NSAIDs , may and the toxicity certain drugs	DDI-false
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy.	DDI-false
Specific confirmed these with @DRUG$ , @DRUG$	DDI-false
1 Effects Plasma Concentrations 0 - 24 hrs of @DRUG$ After 10 Coadministration @DRUG$ 10 mg in Normal Volunteers	DDI-false
@DRUG$ increase cardiac irritability may sensitize myocardium to the of intravenously catecholamines , as	DDI-effect
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
@DRUG$ @DRUG$ Congestive Heart Infarction)- In EPHESUS 3020 % ) patients receiving INSPRA 50 mg also received inhibitors angiotensin ) .	DDI-false
When is inducers of clearance such as @DRUG$ , @DRUG$ , of a of 70 CANCIDAS	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Additive cholinergic blockade occur LEVSIN administered other , haloperidol , @DRUG$ , @DRUG$ antihistamines .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
, and Losartan : Bosentan interactions digoxin @DRUG$ and losartan significant effect on plasma levels @DRUG$.	DDI-false
After multiple dosing, interferon beta-1a (@DRUG$  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
Example clarithromycin , , erythromycin , imatinib isoniazid , nefazodone propofol , @DRUG$ , @DRUG$.	DDI-false
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Therophylline recent shown that concomitan @DRUG$ and may elevated of theophylline , and in some slight decrease the of @DRUG$.	DDI-false
Antidepressants, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
: of @DRUG$ and @DRUG$ in decrease nelfinavir plasma A.C.	DDI-mechanism
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received @DRUG$ plus @DRUG$ for 4 days.	DDI-false
treatment with inhibitors ( such as , , ritonavir , indinavir , saquinavir @DRUG$ . is indicated reduction of the @DRUG$ should be	DDI-advise
when @DRUG$ oral @DRUG$ should during for days after concomitant administration .	DDI-advise
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
: single of @DRUG$ and @DRUG$ did have relevant pharmacodynamics of either drug .	DDI-false
Although performed that by ( , calcium blockers disopyramide , @DRUG$ @DRUG$ warfarin tacrolimus , cyclosporine , carbamazepine alfentanyl , , triazolam ) elevated plasma coadministered saquinavir	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or @DRUG$ (ACEI/ARB).	DDI-false
not recommended.@DRUG$ @DRUG$ , , .	DDI-false
@DRUG$ vivo that @DRUG$ , , and troleandomycin markedly the metabolism of cisapride , which can in an increase in plasma cisapride levels and of QT interval on the ECG .	DDI-false
@DRUG$ @DRUG$ and	DDI-false
of N-methylthiotetrazole @DRUG$ , cefoperazone @DRUG$ , ( ) cause vitamin deficiency hypoprothrombinemia .	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Tinnitus and decreased hearing have been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	DDI-effect
@DRUG$: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
also plasma other @DRUG$ that CYP3A4 such	DDI-false
Antiacid Didanosine Fluoxetine , Indanavir Ketoconazole Phenytoin , carbamazepine @DRUG$ , @DRUG$ , Ritanovir , Saquinavir	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
- @DRUG$: Indomethacin blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg @DRUG$ (e.g., 40 mg BID) have not been studied.	DDI-false
Cyclosporine : Administration nonsteroial drugs @DRUG$ been with in , possibly to decreased synthesis of renal .	DDI-false
with @DRUG$ Fentanyl is limited , consideration given to suspending inhibitors in receiving	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
Effects Plasma Concentrations ( 0 - 24 @DRUG$ @DRUG$ Days Coadministration ( Loratadine mg ) in	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
analyses MTX @DRUG$ , blocking did influence @DRUG$ clearance	DDI-false
Paroxetine: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Alcohol, @DRUG$, or @DRUG$: potentiation of orthostatic hypotension may occur.	DDI-false
Phenytoin experience there have of increases decreases @DRUG$ @DRUG$ co-administration , leading to alterations in	DDI-mechanism
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, @DRUG$) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when @DRUG$ is administered concomitantly.	DDI-effect
@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	DDI-false
- When or @DRUG$ is concurrently with anion-exchange ( ) , interval of hours should maintained between the medicines , since the @DRUG$ or Bezalip retard	DDI-false
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior.	DDI-false
of @DRUG$ @DRUG$ has not been formally .	DDI-false
ACE Inhibitors and Angiotensin Receptor Antagonists Post-Myocardial In , 3020 ( 91 ) receiving @DRUG$ to also received angiotensin antagonists ( @DRUG$/ARB ) .	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, methotrexate and 5-fluorouracil.	DDI-mechanism
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).	DDI-false
Ketoconazole @DRUG$ to the after , and @DRUG$ had no clinically significant administration	DDI-false
The are of substances that may reduce the blood-glucose-lowering niacin , @DRUG$ sympathomimetic epinephrine , derivatives , thyroid hormones , estrogens @DRUG$ e.g. in oral contraceptives )	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease @DRUG$ metabolism and increase @DRUG$ plasma concentrations.	DDI-false
agents @DRUG$ guanethidine , reserpine , HCl , ascorbic acid fruit juices @DRUG$.	DDI-mechanism
In separate studies of receiving of warfarin , @DRUG$ administration for 7 days no on the pharmacodynamics of @DRUG$ prothrombin time ) or pharmacokinetics of digoxin	DDI-false
drugs the @DRUG$ other phenothiazines , estrogens , , phenytoin nicotinic , @DRUG$ channel blocking , isoniazid .	DDI-false
: patients , steady-state @DRUG$ AUC and 24 % after with co-administration of @DRUG$ , inhibitor cytochrome P450	DDI-mechanism
Ephedrine: @DRUG$ may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-mechanism
Single doses of either @DRUG$ or colestipol @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, @DRUG$, and alcohol.	DDI-false
@DRUG$ gastrointestinal absorption of penicillin V @DRUG$ methotrexate .	DDI-mechanism
CANCIDAS reduced the AUC0 - 20 blood concentration Cmax ) and ( C12hr ) by % in subjects @DRUG$ 2 doses of 0.1 mg/kg 12 hours administered the day of @DRUG$ 70 results period which tacrolimus administered alone .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, @DRUG$, ethanol or itraconazole.	DDI-false
Before using this , doctor or pharmacist of and products , especially e.g. , gentamicin amikacin , amphotericin @DRUG$ @DRUG$ drugs ( ibuprofen , tacrolimus , vancomycin	DDI-false
drugs which may blocking nondepolarizing agents include antibiotics , , @DRUG$ , , colistin , @DRUG$ ) magnesium , , local anesthetics procainamide	DDI-false
following administration @DRUG$ with @DRUG$ diuretics such as furosemide .	DDI-effect
Short-term pharmacokinetic studies demonstrated that administration of @DRUG$ ( @DRUG$ capsules in protein binding there was change in the of warfarin .	DDI-mechanism
@DRUG$ or the increases in produced doses of either @DRUG$ pigeons but did antagonize in FI FR responding high PCP of	DDI-effect
@DRUG$ effect on @DRUG$ patients	DDI-false
That Be Coadministered : amiodarone , quinidine astemizole , @DRUG$ Antimigraine ergot agents : @DRUG$ agents :	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
3A Inhibitors of Possible Clinical Significance on the of Clinical Studies Involving @DRUG$ is recommended ): of fluoxetine with increased the maximum of @DRUG$ by , decreased by % , % , and measured psychomotor performance	DDI-false
@DRUG$ : atorvastatin pharmacokinetics antipyrine , interactions other @DRUG$ metabolized the cytochrome are .	DDI-false
Although there no formal interaction other than @DRUG$ , based on these in and vitro studies , is that co-administration a @DRUG$ drugs will result clinically drug inhibition cytochrome P450-mediated the	DDI-false
plasma of related @DRUG$ been reported be increased by the of or enzyme inhibitors ( , @DRUG$ ) and concomitant administration hepatic e.g. , barbiturates ) , and such anticipated well	DDI-mechanism
that neuropathy include analogues , , dapsone , ethionamide glutethimide gold , hydralazine , , , @DRUG$ , and	DDI-false
@DRUG$ A hypoglycemia has been in type diabetic patient on tolazamide 1 ) after the of @DRUG$ mg/day	DDI-false
Aerosol particles of @DRUG$ were generated from an @DRUG$ solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.	DDI-false
Macrolide antibiotics inhibit metabolism of HMG-CoA inhibitors that are by CYP3A4 i.e. atorvastatin , @DRUG$ @DRUG$ , .	DDI-false
altered ) barbiturates of hepatic microsomal of @DRUG$ @DRUG$ ( of corticosteroids )	DDI-false
@DRUG$ concomitant 5 mg of Vardenafil the and @DRUG$ were reduced	DDI-false
acetaminophen/theophylline lidocaine/quinidine phenobarbital/acetaminophen phenobarbital/valproic acid , and @DRUG$/phenobarbital	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ is added to the drug regimen.	DDI-effect
Skeletal , nondepolarizing ( e.g. , @DRUG$ ): increased responsiveness to the	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
, apparently microsomal systems been to reduce the hepatic @DRUG$ , propranolol , chlordiazepoxide , diazepam certain @DRUG$ , , and metronidazole , delaying and blood levels these	DDI-false
@DRUG$ Concomitant administration of @DRUG$ with VIOXX result increased of GI ulceration other complications ,	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
The adenosine @DRUG$ as and	DDI-false
Aspirin : Concomitant administration @DRUG$ aspirin is recommended because @DRUG$ is displaced sites the administration aspirin , resulting ,	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
The addition of @DRUG$ to patients taking valproate chronically had pharmacokinetics valproate @DRUG$ vitro from which in an increase of approximately % in tiagabine concentration	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ or fluoxetine , the is approximately 6- 8-fold and is about 3- to 4-fold greater @DRUG$ alone	DDI-false
Medications @DRUG$ : The adverse commonly patients concomitant @DRUG$ n ) compared patients not concomitant n = ): 10 % vs 4 % myocardial % vs 1 % serious vs 3 and joint % .	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, @DRUG$) and NovoSeven.	DDI-false
the @DRUG$ and other , @DRUG$ estrogens , phenytoin , blocking drugs ,	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
Potential interactions TAXOL a of CYP3A4 , and protease @DRUG$ saquinavir , , and @DRUG$ are and/or inhibitors , have not been trials .	DDI-false
therapy Although specific interaction were not finasteride 1 more were concomitantly used clinical , acid , a-blockers , analgesics , enzyme ) , benzodiazepines , blockers , cardiac nitrates , diuretics , @DRUG$ , , @DRUG$ to ) quinolone evidence clinically significant adverse	DDI-false
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or @DRUG$.	DDI-false
The @DRUG$ adverse profile Study ( without ( with @DRUG$ ) this alteration in clearance of TYSABRI   maintain ) .	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	DDI-effect
drugs diuretics , corticosteroids , products , contraceptives , @DRUG$ sympathomimet-ics , calcium blocking drugs ,	DDI-false
@DRUG$ may interfere with the absorption of @DRUG$.	DDI-mechanism
the benzodiazepines be potentiated by anticonvulsants , @DRUG$ , alcohol @DRUG$ , , phenothiazines medications or other drugs CNS depression .	DDI-false
@DRUG$ ( @DRUG$ or	DDI-false
@DRUG$: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-false
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with @DRUG$/@DRUG$.	DDI-false
Although studies have not been drugs that by CYP3A4 @DRUG$ dapsone , quinine , amiodarone , @DRUG$ , tacrolimus , carbamazepine , , alprazolam and ) may elevated concentrations with ;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Administration of epinephrine to patients receiving @DRUG$ or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
@DRUG$ should be in patients receiving @DRUG$ ..	DDI-advise
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
specific not , coadministration drugs metabolized eg , @DRUG$ quinine warfarin tacrolimus , cyclosporine , , carbamazepine , @DRUG$ triazolam may have elevated plasma concentrations when saquinavir ;	DDI-false
Central System Depressants : The concomitant of DURAGESIC   ( fentanyl ) other central nervous depressants but limited to other @DRUG$ , sedatives , tranquilizers ( e.g. , phenothiazines , @DRUG$ alcohol , cause depression , , and in coma or death	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Therefore , when @DRUG$ is given a warfarin , the @DRUG$ to excessive prolongation of	DDI-false
@DRUG$ may interfere with anti-glaucoma action of @DRUG$ or ;	DDI-effect
or halogenated increase and sensitize the myocardium the intravenously administered @DRUG$ , such	DDI-false
@DRUG$ and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
Example antifungals , , diclofenac doxycycline imatinib , @DRUG$ , , , , @DRUG$ ,	DDI-false
@DRUG$ coumarin derivatives , platelet aggregation inhibitors such nonsteroidal ( NSAIDs and may the risk of bleeding with @DRUG$.	DDI-effect
using , or pharmacist prescription nonprescription products may @DRUG$ , ) @DRUG$ non-steroidal e.g. ibuprofen ) , tacrolimus , vancomycin	DDI-false
These drugs include thiazides other diuretics , , products , @DRUG$ contraceptives @DRUG$ , sympathomimet-ics calcium blocking drugs and .	DDI-false
DIGOXIN: Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
of @DRUG$ or @DRUG$ produced transient increases in FI in sustained responding in	DDI-false
@DRUG$: Diclofenac and other NSAIDs can inhibit the activity of @DRUG$.	DDI-false
Alcohol : @DRUG$ : mL alcohol in a 70 kg person @DRUG$ plasma were dosed simultaneously	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
are examples substances may the blood-glucose-lowering susceptibility hypoglycemia antidiabetic , ACE inhibitors , disopyramide , fluoxetine oxidase ( , , salicylates , @DRUG$ , octreotide ) , @DRUG$.	DDI-false
separate studies maintenance @DRUG$ , @DRUG$ , or , had effect pharmacodynamics ( ) pharmacokinetics of digoxin	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Based on total @DRUG$ concentrations, @DRUG$ increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.	DDI-mechanism
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
All @DRUG$ should be used cautiously in patients taking @DRUG$.	DDI-advise
@DRUG$-Orlistat may decrease the absorption of @DRUG$.	DDI-false
Although specific studies have not performed , coadministration are metabolized by CYP3A4 , calcium dapsone , , @DRUG$ , @DRUG$ , cyclosporine , carbamazepine , alfentanyl alprazolam , concentrations coadministered with ;	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
drugs e.g. barbiturates , @DRUG$ , @DRUG$ and ) effects INAPSINE	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Drugs with a Narrow Therapeutic Digoxin : @DRUG$ ( 10 mg ) did affect or profile @DRUG$ ( mg 8 days )	DDI-false
neither dexamethasone nor @DRUG$ proliferation of in RPMI1640 @DRUG$ modify the effect of EGF .	DDI-false
Discontinuing @DRUG$ could pose health if a potentially toxic that bound the resin has been a maintenance the patient was taking	DDI-false
@DRUG$ 150 twice daily not interact with @DRUG$ AUC decreased 20 ) .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
inhibitors include antifungals ciprofloxacin , , , imatinib , isoniazid , , @DRUG$ , propofol protease @DRUG$	DDI-false
BACKGROUND The of bombesin @DRUG$ verapamil ) , a calcium on the incidence adenocarcinomas induced by @DRUG$ ( ) and the of cancers investigated Wistar rats	DDI-false
@DRUG$ Hallucinations have been when was drugs ( fluoxetine , @DRUG$ )	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
some patients the combined use @DRUG$ and @DRUG$ has gastrointestinal .	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
- When @DRUG$ retard used concurrently with resins e.g. cholestryramine ) an at hours should maintained between the two medicines , since absorption Bezalip @DRUG$ is	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	DDI-effect
Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., @DRUG$ and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-effect
local or norepinephrine to receiving oxidase inhibitors @DRUG$ or @DRUG$ may produce severe hypotension hypertension .	DDI-false
@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
@DRUG$ : generally should be given @DRUG$.	DDI-advise
Nephrotoxic : Concomitant of with nephrotoxic intravenous , gentamicin , and amphotericin B , @DRUG$ , @DRUG$ and non-steroidal contraindicated	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-advise
Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
Rifampin: Coadministration of @DRUG$ and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-mechanism
: administration of @DRUG$ , with multivalent cation-containing products such aluminum @DRUG$ VIDEX tablets or pediatric , calcium iron or may decrease absorption resulting in serum and urine considerably	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ @DRUG$ * potential for serious life-threatening arrhythmias .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Cephalosporins-Cephalosporins chains of N-methylthiotetrazole ( cefmenoxime @DRUG$ , @DRUG$ latamoxef methylthiadiazole cefazolin can	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
@DRUG$ at dose on the enhancement of intestinal @DRUG$ or location , type labeling index or intestinal , significantly decreased cancer metastasis	DDI-false
The concomitant use @DRUG$ is not recommended since @DRUG$ may antibacterial effect of Norfloxacin in urinary	DDI-false
Urinary acidifying agents These agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Lithium : @DRUG$ toxicity been @DRUG$ with drugs which of sodium including ACE .	DDI-false
of valdecoxib and Ortho-Novum 1/35   the exposure of @DRUG$ @DRUG$ by 20 34 % .	DDI-false
These drugs include the thiazides other @DRUG$ , @DRUG$ estrogens , oral , phenytoin , sympathomimet-ics , calcium channel blocking and isoniazid	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Additive adverse may occur when is other antimuscarinics , amantadine @DRUG$ , @DRUG$ , monoamine ( MAO ) tricyclic some antihistamines .	DDI-false
As with other @DRUG$ , it noted HALDOL may be potentiating @DRUG$ such as anesthetics , , and alcohol .	DDI-effect
Previous studies have demonstrated a significant reduction in the bioavailability of and @DRUG$ administered an @DRUG$ as morphine .	DDI-mechanism
Benzthiazide may interact with @DRUG$ , blood thinners , allergy cold and sinus ) @DRUG$ , Aleve Ibuprofen , high pressure .	DDI-false
addition , Fondaparinux neither pharmacodynamics of @DRUG$ , @DRUG$ , piroxicam , pharmacokinetics steady	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, @DRUG$, and ranitidine.	DDI-false
Investigations into the effect of @DRUG$ on the protein binding of @DRUG$ (warfarin) revealed no interaction.	DDI-false
@DRUG$: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.	DDI-false
Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
( patients , the @DRUG$ , antihypertensive effects of loop , potassium sparing @DRUG$.	DDI-effect
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-mechanism
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
In @DRUG$ , @DRUG$ had on	DDI-false
The administration @DRUG$ containing epinephrine or @DRUG$ patients inhibitors tricyclic antidepressants produce severe	DDI-false
Drug-Drug Interactions Between Keppra And Other Drugs ( @DRUG$ @DRUG$   ( 3000 mg daily had on pharmacokinetic disposition in refractory .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In with , the concomitant oral @DRUG$ ( warfarin , acid @DRUG$ ( , digoxin did affect of fondaparinux	DDI-false
following of substances that may reduce the @DRUG$ , , diuretics , agents e.g. , , @DRUG$ ) , derivatives thyroid , estrogens e.g. in contraceptives )	DDI-false
: @DRUG$ may the activity @DRUG$ or sympathomimetic agents	DDI-effect
Antibiotics : In in show that @DRUG$ , erythromycin , @DRUG$ markedly inhibit of cisapride , which an prolongation of interval .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	DDI-false
@DRUG$ @DRUG$ have cause a significant decrease clearance .	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
- @DRUG$ (e.g., @DRUG$) or	DDI-false
interaction study evaluated the of Gel % in combination with double strength ( 160 mg/800	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
a controlled that once daily dose , the 528 @DRUG$ -treated subjects @DRUG$ study entry .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of cloxacillin, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
has observed HMG-CoA inhibitors administered alone ( recommended or @DRUG$ including	DDI-false
, @DRUG$ may show of digoxin concentrations after of therapy with @DRUG$ , may significant in to digoxin .	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
@DRUG$ @DRUG$ , naproxen piroxicam acetaminophen andtolbutamide ketorolac tromethamine binding .	DDI-false
Although specific drug interactions with topical glaucoma medications were studies @DRUG$ Ophthalmic , possibility an additive or potentiating CNS alcohol barbiturates , opiates , @DRUG$ ) be .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
In FLOLAN was used with digoxin @DRUG$ anticoagulants vasodilators , supplemental a substudy patients with failure furosemide or whom FLOLAN was initiated apparent values @DRUG$ ( n and digoxin ( = decreased 13 , respectively , the therapy had returned to baseline values .	DDI-false
analyses that @DRUG$ , @DRUG$ blocking not abatacept .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The following are of substances reduce blood-glucose-lowering effect : , @DRUG$ , @DRUG$ diuretics agents e.g. , epinephrine , salbutamol terbutaline , isoniazid , phenothiazine derivatives somatropin hormones progestogens ( , oral	DDI-false
Hypersensitivity reactions have been patients receiving combination containing dose PROLEUKIN @DRUG$ specifically , cis-platinum @DRUG$ interferon-alfa .	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: @DRUG$	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
Drugs Not Coadministered With Antiarrhythmics : astemizole , terfenadine Antimigraine @DRUG$ @DRUG$ midazolam agents	DDI-false
@DRUG$ And ( AEDs ) @DRUG$ 3000 mg daily ) on the pharmacokinetic phenytoin in patients with refractory epilepsy .	DDI-false
No drug-drug interactions been in studies hydrochlorothiazide , digoxin , @DRUG$ @DRUG$	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
@DRUG$ (such as @DRUG$, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
May interact with the following: cholestyramine, @DRUG$ (use with @DRUG$ may prevent the diuretic from working properly;	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Drugs That Should Not Be Coadministered @DRUG$ : quinidine @DRUG$ : astemizole , terfenadine : agents : rifampin Benzodiazepines , GI motility :	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and alcohol.	DDI-effect
Cardiovascular Enalapril @DRUG$ have used concomitantly @DRUG$ nitrates , digoxin without of clinically .	DDI-false
Clidinium may decrease the effect of phenothiazines, @DRUG$, and @DRUG$.	DDI-false
@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
@DRUG$ norfloxacin may enhance oral @DRUG$ its derivatives similar agents	DDI-effect
Potential pharmacokinetic were clinical pharmacokinetic studies phenytoin , @DRUG$ digoxin , @DRUG$ ) and pharmacokinetic screening in clinical patients .	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, @DRUG$).	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, @DRUG$, and CYP3A4.	DDI-false
@DRUG$ erythromycins , sulfonamides tetracyclines interfere the of	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
Central Nervous Depressants concomitant use of transdermal with including but limited opioids , , , tranquilizers @DRUG$ anesthetics , @DRUG$ , skeletal relaxants and alcohol cause respiratory depression , hypotension , result in or death .	DDI-false
Nephrotoxic agents : Concomitant administration of and nephrotoxic potential intravenous ( , tobramycin , @DRUG$ , @DRUG$ , amphotericin , foscarnet pentamidine , vancomycin non-steroidal .	DDI-false
OTHER : specific interaction were not performed in studies , cerivastatin was used concomitantly with enzyme ( ACE ) inhibitors , @DRUG$ , diuretics @DRUG$ ( ) without of significant adverse	DDI-false
Since @DRUG$ is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$ hypotensive of @DRUG$.	DDI-effect
@DRUG$ Because may blood glucose dosage adjustments @DRUG$	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	DDI-false
all @DRUG$ SSRIs , e.g. sertraline , and @DRUG$ , inhibit P450 2D6 , they inhibition	DDI-false
small groups of patients 7 study the azathioprine , chloroquine , @DRUG$ @DRUG$ , did significantly affect peak levels values of	DDI-false
These would to @DRUG$ with or @DRUG$ therapy when levels are below normal .	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	DDI-false
@DRUG$ (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-false
In steroidal can reduce diuretic , natriuretic antihypertensive effects @DRUG-DRUG$.	DDI-false
However, because some quinolones have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with warfarin or its derivatives.	DDI-false
@DRUG$ : Elevated @DRUG$ reported in postmarketing experience SUPRAX is administered concomitantly	DDI-false
May anticoagulants ( barbiturates @DRUG$ and other microsomal ( effect ) @DRUG$ ( corticosteroids )	DDI-false
Additive blockade occur concomitantly other antimuscarinics , , @DRUG$ , monoamine ( MAO @DRUG$ or some antihistamines .	DDI-false
on known metabolic , interactions not expected @DRUG$ and dapsone trimethoprim/sulfamethoxazole , erythromycin @DRUG$ .	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
similar less marked , with phenylbutazone , , @DRUG$ griseofulvin with @DRUG$ tetracyclines .	DDI-false
@DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
that have been with neuropathy include @DRUG$ @DRUG$ , cisplatin dapsone , , glutethimide , hydralazine , , , metronidazole , , phenytoin , ,	DDI-false
@DRUG$ with the excretion is @DRUG$.	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Although specific studies not drugs are by CYP3A4 eg , channel blockers , , quinine , warfarin tacrolimus , pimozide @DRUG$ @DRUG$ , alprazolam , triazolam may have plasma concentrations with	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.	DDI-false
Lithium given with diuretics because they renal and @DRUG$ toxicity .	DDI-false
Thus @DRUG$ should administered concurrently with	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
This appears be relevant this Mefloquine , although of drugs to alter cardiac eg beta-adrenergic agents calcium blockers @DRUG$ @DRUG$ a of the QTc	DDI-false
Phase I trial doses of ( 110 mg/m2 ) @DRUG$ or given as infusions , myelosuppression more profound when TAXOL than sequence , TAXOL @DRUG$ .	DDI-false
acetaminophen/@DRUG$ lidocaine/quinidine , phenobarbital/@DRUG$ quinidine/lidocaine theophylline/acetaminophen , and valproic	DDI-false
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when @DRUG$ was administered on the same day as @DRUG$ than when these drugs were given on separate days (1.3%, 1/80 patients).	DDI-effect
Although specific studies not , coadministration metabolized by ( , blockers , , , quinine amiodarone @DRUG$ tacrolimus , @DRUG$ ergot derivatives , , carbamazepine , alprazolam triazolam concentrations with	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Close the are hydrochloride is used other @DRUG$ or	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Interactions : may some drugs , @DRUG$ MAOI MAOI could theoretically affect pharmacodynamics - Arecoline - Eproxindine @DRUG$ and cause CNS - antidepressants increases the effect of Tricyclic	DDI-false
Coadministration compounds are potent CYP3A4 , @DRUG$ , phenytoin , @DRUG$ result in plasma of	DDI-false
CONCLUSIONS : Macrolide inhibit @DRUG$ metabolized ( i.e. atorvastatin , @DRUG$	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Magnesium- , products containing multivitamin preparations containing or other metal cations , @DRUG$ ( ) tablets or the pediatric solution be within 3 hours before or 2 hours @DRUG$.	DDI-advise
Multivitamins , or other products containing @DRUG$ or not be concomitantly with or hours of , the administration of norfloxacin , absorption in lower serum and urine levels of @DRUG$.	DDI-false
@DRUG$ and @DRUG$ (Hypertension)- In studies of with the addition of to 100 mg ACE angiotensin II receptor antagonists potassium slightly - 0.13 mEq/L ) .	DDI-false
Aspirin, @DRUG$, @DRUG$, NSAIDs	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
@DRUG$: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
@DRUG$ monitored when @DRUG$ introduced or .	DDI-advise
The with vasodilators such as @DRUG$ , nitroprusside , inhibitors been these drugs were not co-administered with @DRUG$ in clinical .	DDI-false
Ambulatory @DRUG$ @DRUG$ is cleared body	DDI-false
Tetracycline, a @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-false
effects plasma concentrations @DRUG$ @DRUG$ were observed	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ should with receiving -receptor blocking ( e.g. , inhibitor channel ( e.g. , , and @DRUG$ , a ) of the potentiation of sinus arrest and	DDI-false
@DRUG$, such as dopamine and @DRUG$;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
However, because some quinolones have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives.	DDI-false
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-false
- e.g. , ) of @DRUG$ sulfapyridine may chance of side effects affecting liver of @DRUG$	DDI-false
Nonsteroidal Anti-Inflammatory study of @DRUG$ an @DRUG$ not been conducted .	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-mechanism
In patients receiving Nalfon and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
vivo drug-drug studies conducted and of CYP3A , compounds are potent such as carbamazepine , @DRUG$ , and @DRUG$ would be expected estazolam .	DDI-false
action of @DRUG$ may @DRUG$ antihistamines , monoamine inhibitors narcotics medications , other depression .	DDI-effect
In similar tamsulosin in healthy volunteers , 1 24 @DRUG$ @DRUG$ 0.4 mg separated 6 hours experienced a standing systolic blood pressure below	DDI-effect
Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	DDI-mechanism
Drugs That Alter Renal Excretion @DRUG$: @DRUG$ is known to affect renal function and, consequently, alter the renal excretion of other drugs.	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
@DRUG$ and @DRUG$ can administered concomitantly without decrease AUC , or	DDI-false
@DRUG$ @DRUG$ not be patients receiving coumarin	DDI-false
A similar association @DRUG$ phenytoin carbamazepine griseofulvin , @DRUG$ , and tetracyclines	DDI-false
Because prostaglandins play an @DRUG$ platelet function well concurrent therapy , including @DRUG$ and warfarin requires monitoring to be that change their anticoagulant is required .	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-effect
: vitro and/or data indicate fluconazole itraconazole , and oral @DRUG$ markedly inhibit metabolism of @DRUG$ , an plasma cisapride prolongation interval on .	DDI-mechanism
are examples substances that reduce blood-glucose-lowering , danazol diuretics , , , terbutaline ) , derivatives somatropin @DRUG$ , ( e.g. , oral @DRUG$	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
patients moderate , administration 25 mg daily of @DRUG$ with the @DRUG$ to mg weeks , associated with average increase of about 3 mm compared to inhibitor	DDI-false
The of anesthetic solutions epinephrine or @DRUG$ patients receiving monoamine inhibitors tricyclic @DRUG$ produce severe hypotension .	DDI-effect
Magnesium/Aluminum-containing @DRUG$ Absorption is 25 % antacid products	DDI-false
associated with include analogues , , @DRUG$ , , @DRUG$ gold hydralazine , , isoniazid , metronidazole , nitrofurantoin , , vincristine .	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, phenytoin and phenobarbital) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
@DRUG$ and @DRUG$ time , with or without clinical , has when cefixime is administered .	DDI-false
In vitro data suggest that @DRUG$, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-mechanism
@DRUG$ is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.	DDI-mechanism
Other @DRUG$ (e.g., @DRUG$) may also have this effect.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
This interact with @DRUG$ or other may potentiate depressant of or ) , or medications anticholinergic ( effects may potentiated when these are antihistamines ) oxidase ( MAO ( @DRUG$ prolong and intensify the and effects of antihistamines .	DDI-false
Exposure dose is about 1 % of mg oral , even when with	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
receptor @DRUG$ ) and @DRUG$ may of other when concurrently	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ is metabolized @DRUG$ by cytochrome P450 ( CYP450 group specifically P450 ( CYP3A4 )	DDI-false
@DRUG$: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-false
Glyburide: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
The of paper was to study the interaction between @DRUG$ and both @DRUG$ synthetic , on antinonciceptive effect of these peptides in injection	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, @DRUG$, and alosetron) is contraindicated .	DDI-false
In shown that occurs @DRUG$ are	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The concomitant use of @DRUG$s, vasoconstricting agents (such as @DRUG$) and some oxytocic drugs may result in severe hypertension.	DDI-false
@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	DDI-false
Coadministration of @DRUG$ the of @DRUG$ and by and 34 , .	DDI-false
@DRUG$: The anorectic and stimulatory effects of amphetamines may be inhibited by @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ @DRUG$ ): may may predispose the patient cardiac .	DDI-false
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
As with other @DRUG$ it should noted of CNS depressants such , opiates and	DDI-effect
@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
The possibility effects minimized either discontinuing @DRUG$ of @DRUG$.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
@DRUG$-Cephalosporins containing side N-methylthiotetrazole @DRUG$ cefoperazone cefamandole , or ( cefazolin can cause vitamin K .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
OBJECTIVE : Our was steady-state of @DRUG$ and INN , @DRUG$ coadministered kidney the year .	DDI-false
The of benzodiazepines may be by , @DRUG$ , barbiturates , monoamine inhibitors , @DRUG$ , medications , produce	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and @DRUG$) is contraindicated .	DDI-false
In clinical @DRUG$ was used digoxin diuretics , anticoagulants , oral and . In pharmacokinetic with congestive furosemide @DRUG$ in whom with was initiated apparent clearance furosemide ( n = and ( n ) by 13 and , , on the second day therapy and returned values day .	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, @DRUG$ treatment did not affect ribavirin distribution or clearance.	DDI-false
In monkeys, the effects of (-)-NANM, but not (+)-NANM or @DRUG$, were antagonized by @DRUG$;	DDI-false
of patients RA studies one more of the following concomitant with ORENCIA MTX , @DRUG$ corticosteroids TNF , azathioprine , hydroxychloroquine , sulfasalazine @DRUG$.	DDI-false
acetaminophen/@DRUG$ , acid , quinidine/lidocaine , theophylline/acetaminophen and valproic	DDI-false
Antiacid , , Fluconazole , , @DRUG$ , Rifampin Ritanovir , @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Nevertheless , as postmarketing have @DRUG$ @DRUG$ and thiazides some .	DDI-effect
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Moreover , additional interaction with @DRUG$ and @DRUG$ have demonstrated fluvastatin plasma levels , and patient resulted no difference the extent relative to data	DDI-false
intake mineral oil and vitamin the absorption of	DDI-false
are examples of increase blood-glucose-lowering susceptibility to oral products inhibitors , , fibrates @DRUG$ @DRUG$ somatostatin analog ( e.g. , octreotide ) , antibiotics	DDI-false
In addition to this interaction report chemical between @DRUG$ benzodiazepine @DRUG$ under acidic to found vivo , in a product .	DDI-mechanism
@DRUG$ : a study conducted healthy subjects , mean steady-state @DRUG$ levels increased 17 in receiving with CELEBREX BID alone	DDI-false
This increase is due to the inhibition of @DRUG$ metabolism via P450 2C9 by @DRUG$ (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Like 40 @DRUG$ 40 mg/kg ) the self-administration of @DRUG$ the oral and rats	DDI-false
drug and other @DRUG$ @DRUG$ phenobarbital primidone also assessed by evaluating the serum concentrations of and clinical .	DDI-false
Coadministration of Itraconazole and @DRUG$, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-false
Antidepressants ( tricyclic or @DRUG$ , or glycosides : concurrent with @DRUG$ may produce	DDI-false
concomitant therapy specific were not , @DRUG$ of 1 or more were concomitantly used in clinical with @DRUG$ , , analgesics , angiotensin-converting ACE ) anticonvulsants , , blockers , blockers nitrates diuretics reductase inhibitors , prostaglandin synthetase inhibitors also referred to NSAIDs , and quinolone of significant adverse .	DDI-false
Cholestyramine @DRUG$ of @DRUG$ is in of exchange resins .	DDI-false
@DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	DDI-false
not be concurrently with D2-antagonists , such as @DRUG$ butyrophenones or @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
intensity , and time course interference , secobarbital @DRUG$ , @DRUG$ and methaqualone were in patients therapy	DDI-false
Beta-blockers clonidine @DRUG$ may potentiate or weaken blood-glucose-lowering of @DRUG$.	DDI-effect
In clinical trials, @DRUG$ was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Anticoagulant inhibition was observed during the administration of phenobarbital, @DRUG$ and @DRUG$;	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, @DRUG$, and verapamil.	DDI-false
pharmacology @DRUG$ @DRUG$ patients receiving VASOTEC	DDI-false
Other concomitant Although specific interaction were not performed doses of mg clinical with , acid , analgesics @DRUG$ , anticonvulsants benzodiazepines calcium-channel , cardiac , diuretics , , inhibitors , prostaglandin also to @DRUG$ and quinolone anti-infectives evidence of clinically adverse interactions	DDI-false
comparison of in anesthetized with Innovar Vet , the of @DRUG$ needed to ventricular significantly , LD50 than with	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
@DRUG$ : Hallucinations @DRUG$ was in patients taking psychoactive ( alprazolam ) .	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Depressants : use of DURAGESIC ( transdermal system ) with @DRUG$ including but not @DRUG$ , ( , benzodiazepines anesthetics phenothiazines , and alcohol cause respiratory depression and profound or potentially in or	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
of digitalis tolerance with @DRUG$ , Vet , pentobarbital , the ouabain to was significantly , as LD50 of @DRUG$ , with or Innovar pentobarbital	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
cyclosporin A resulting concentrations ng/mL administered oral @DRUG$ has led to an 80 % in @DRUG$ with % decrease total body of compared etoposide .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of @DRUG$.	DDI-false
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ for animal cells.	DDI-false
@DRUG$ : of with @DRUG$ 600 mg daily , a potent inducer of produced approximate 50 % concentrations .	DDI-false
@DRUG$ tricyclic : the @DRUG$ or ;	DDI-false
@DRUG$ In subjects 500 doses @DRUG$ AUC by and 24 , and metformin decreased by 14 .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Since the therapeutic range of theophylline is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when @DRUG$, macrolide antibiotics, or azoles were administered concomitantly.	DDI-false
@DRUG$-Cephalosporins containing chains of N-methylthiotetrazole ( cefoperazone , cefotetan , cefamandole , @DRUG$ ( ) can vitamin deficiency .	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
, with irinotecan/@DRUG$/@DRUG$ bolus-IFL ) with or without .	DDI-false
Animal that @DRUG$ may be ineffective has recently received a	DDI-effect
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
It not known @DRUG$ or @DRUG$ or components excreted in .	DDI-false
comparison of digitalis in dogs anesthetized ketamine Innovar Vet , @DRUG$ , ouabain needed cause was higher the @DRUG$ with than pentobarbital	DDI-false
Central System Depressants The concomitant use of   ( fentanyl transdermal system system limited to opioids , @DRUG$ , hypnotics , @DRUG$ e.g. benzodiazepines ) , phenothiazines , muscle , and may cause depression hypotension and profound or result coma or .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
[Quantitative approach to treatment with incisive @DRUG$ by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports.	DDI-false
may displace drugs such as @DRUG$ @DRUG$ from their binding sites	DDI-false
Other therapy interaction were not , of or were concomitantly clinical , @DRUG$ , a-blockers , angiotensin-converting enzyme ( ACE inhibitors , , benzodiazepines , @DRUG$ , cardiac nitrates , H2 antagonists reductase prostaglandin inhibitors also referred to ) , and quinolone without clinically significant adverse .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of @DRUG$ relative to that observed with erythromycin alone.	DDI-mechanism
@DRUG$ and @DRUG$ increased blood glucose at different times after the glucose overload.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
May anticoagulants hypo-prothrombinemic , @DRUG$ and other inducers of hepatic microsomal system @DRUG$ ) corticosteroids ( effect of	DDI-false
@DRUG$ : An risk of in patients receiving concomitant therapy	DDI-false
Concomitant use of @DRUG$ supplements and @DRUG$ may increase calcium absorption	DDI-mechanism
@DRUG$ did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.	DDI-false
plasma levels of several closely related @DRUG$ have reported be increased by the of enzyme ( , cimetidine , and the concomitant enzyme inducers ( e.g. , , phenytoin ) and such may with @DRUG$ as	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or metoclopramide.	DDI-advise
Administration of receiving @DRUG$ @DRUG$ halothane the myocardium , may cardiac arrhythmia	DDI-false
Here show a of @DRUG$ or @DRUG$ be sensitize resistant faecalis level vancomycin-sensitive strains .	DDI-false
@DRUG$, lidocaine, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Antiarrhythmics : @DRUG$ , @DRUG$ , , due to for .	DDI-false
concomitantly @DRUG$ @DRUG$ serum 33 % days	DDI-false
These drugs the thiazides and , @DRUG$ products @DRUG$ phenytoin nicotinic sympathomimetics channel blocking and .	DDI-false
Non-steroidal Anti-inflammatory Drugs In administration a agent the diuretic and antihypertensive of	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antagonists Since apomorphine a it is possible @DRUG$ butyrophenones @DRUG$ ) or diminish the APOKYN	DDI-false
majority patients clinical studies received more concomitant medications MTX , NSAIDs , TNF blocking agents , @DRUG$ , , @DRUG$ and	DDI-false
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., @DRUG$ and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
A similar though marked , barbiturates , phenylbutazone , phenytoin , griseofulvin possibly with @DRUG$ @DRUG$ 72 .	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Other Agents: @DRUG$ has been used concomitantly with @DRUG$ and/or digoxin without evidence of clinically significant adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The concurrent use of intravenously or orally administered @DRUG$ (e.g., @DRUG$, theophylline) by patients receiving BROVANA has not been completely evaluated.	DDI-false
Drugs that with peripheral neuropathy antiretroviral , chloramphenicol cisplatin , dapsone , @DRUG$ @DRUG$ gold hydralazine isoniazid , metronidazole , phenytoin , vincristine .	DDI-false
, phenobarbital/valproic acid quinidine/lidocaine , valproic acid/phenobarbital .	DDI-false
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Poor metabolizers have higher than expected plasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	DDI-false
Warfarin @DRUG$ to enhance of the oral @DRUG$ or its	DDI-false
, @DRUG$ enhance the activity of @DRUG$ or sympathomimetic ;	DDI-effect
Therapeutic concentrations of , naproxen @DRUG$ did not alter @DRUG$ protein .	DDI-false
avoid the occurrence all patients treated should premedicated @DRUG$ ( as dexamethasone , and H2 ( @DRUG$ or ranitidine	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
: @DRUG$ and @DRUG$ diuretics .	DDI-false
When @DRUG$ is co-administered clearance , as , , phenytoin , or carbamazepine , use of a daily 70 mg @DRUG$ be	DDI-false
@DRUG$ , @DRUG$ and alcohol either weaken effect of .	DDI-false
WARFARIN : Co- @DRUG$ to healthy volunteers in in prothrombin time clotting VII co-administration @DRUG$ placebo	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ may or potentiate of	DDI-effect
Ephedrine : may enhance metabolic clearance of @DRUG$ , in decreased levels requiring increase in @DRUG$ dosage	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
poor of @DRUG$ : Interactions with of ( as , fluoxetine , paroxetine and @DRUG$ ) been studied but expected to increase levels of the R(+ enantiomer carvedilol .	DDI-false
Date Levosimendan have clinically pharmacokinetic captopril beta-blockers , @DRUG$ , @DRUG$ or itraconazole .	DDI-false
, fever , tremulousness confusion extrapyramidal , , elevated , , and FBS irreversible damage has in a few patients @DRUG$ @DRUG$.	DDI-effect
Patients taking @DRUG$ diclofenac any other @DRUG$ while taking digoxin methotrexate cyclosporine may toxicity these	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Adverse reactions related to @DRUG$s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of @DRUG$ in this population.	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
include thiazides other @DRUG$ corticosteroids , phenothiazines , , , , @DRUG$ calcium blocking drugs , and .	DDI-false
Injection : Lorazepam , other injectable produces of nervous system when administered , @DRUG$ , , @DRUG$ , and . When scopolamine used with lorazepam , an increased of sedation hallucinations and has	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
and urine samples of @DRUG$ , @DRUG$ , rifampin and metabolites , were measured high-performance chromatography	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Multivalent Cation-Containing administration of ciprofloxacin , cation-containing products such @DRUG$ or antacids , tablets pediatric powder , products containing , @DRUG$ , zinc may substantially of , serum and urine	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
In patients chronic C treated @DRUG$ in with COPEGUS @DRUG$ did not affect ribavirin or clearance .	DDI-false
Other drugs enhance neuromuscular blocking of nondepolarizing such NUROMAX @DRUG$ ( e. g. , , , , lincomycin , clindamycin ) , lithium , , @DRUG$.	DDI-false
These drugs include the thiazides other diuretics , corticosteroids phe-nothiazines , products , estrogens , oral , phenytoin , @DRUG$ calcium channel drugs	DDI-false
In the present study, the atypical antipsychotic @DRUG$ was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Corticosteroids and Corticotropin (@DRUG$): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
Lithium : @DRUG$ mg BID 7 days produced significant in lithium clearance % ) and renal clearance ( 34 serum compared to @DRUG$ .	DDI-false
Nervous System Depressants : The concomitant use of   ( @DRUG$ transdermal ) with other central nervous depressants including opioids , e.g. ) , general @DRUG$ , skeletal , alcohol hypotension and sedation or potentially result coma	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, @DRUG$ (e.g., in oral contraceptives).	DDI-false
@DRUG$-A drug interaction study of @DRUG$ with lithium has not been conducted.	DDI-false
Single doses of either cholestyramine or @DRUG$ @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-effect
@DRUG$ may the of @DRUG$ administered .	DDI-effect
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
selective serotonin reuptake ( @DRUG$ , e.g. citalopram , escitalopram fluoxetine sertraline and @DRUG$ P450 , they may vary extent of inhibition	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In these subjects, @DRUG$ did not alter the anticoagulant effect of @DRUG$ as determined by prothrombin time.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
Micro-dosed : progesterone preparations minipills not an @DRUG$ may an during @DRUG$	DDI-false
containing chains ( cefoperazone cefotetan , ) ( @DRUG$ cause vitamin K and hypoprothrombinemia .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Concurrent of MAO inhibitor class hypotension.@DRUG$ , an inhibitor of drug metabolism , increased @DRUG$s rat model	DDI-mechanism
Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
The risk during with of class is concurrent of @DRUG$ acid , niacin acid ) @DRUG$ , antifungals .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
, in study pharmacokinetics butorphanol were significantly decrease in AUC and 38 in ) when a 1-mg of @DRUG$ administered after 20-mg of @DRUG$	DDI-mechanism
Anabolic nandrolone [ , Anabolin oxandrolone e.g. , @DRUG$ , @DRUG$ , stanozolol ] or	DDI-false
, nitroglycerin @DRUG$ as for of or drugs should if possible , be discontinued starting @DRUG$.	DDI-advise
There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-false
Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
Although studies have not been performed drugs that metabolized by ( , channel dapsone , , , , @DRUG$ cyclosporine ergot derivatives , , fentanyl , alfentanyl , alprazolam and @DRUG$ ) have elevated concentrations with saquinavir ;	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-mechanism
Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$, including @DRUG$.	DDI-false
The possibility hypotensive effects @DRUG$ @DRUG$ can be by either the the intake prior to initiation treatment with enalapril enalaprilat	DDI-false
Standard includes @DRUG$ as @DRUG$ and gentamicin	DDI-false
Before using this medication pharmacist of all prescription and nonprescription you , especially of e.g. ) B @DRUG$ , anti-inflammatory drugs ( , @DRUG$ vancomycin .	DDI-false
Drug Interactions : @DRUG$ interact with drugs , like Monoamine oxidase ( ): MAOI could - Eproxindine - Flupenthixol and additive CNS depression @DRUG$ : effect of antidepressants	DDI-false
@DRUG$ : been reported TORADOL was used ( fluoxetine , @DRUG$ )	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Concurrent of drugs possessing nephrotoxic , aminoglycosides @DRUG$ ) myelotoxic ( cytotoxic chemotherapy cardiotoxic e.g. , doxorubicin hepatotoxic e.g. @DRUG$ ) effects with PROLEUKIN toxicity in systems .	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
inhibitors azole antifungals ciprofloxacin diclofenac doxycycline imatinib , isoniazid @DRUG$ @DRUG$ propofol quinidine and	DDI-false
bradycardia been oral amiodarone in combination with @DRUG$ @DRUG$ ) given local .	DDI-false
@DRUG$: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-mechanism
concentrations AUC 0 - hrs of @DRUG$ decreased of to @DRUG$ alone .	DDI-false
Ingestion may increase serum concentrations of digoxin @DRUG$ and increase @DRUG$ nephrotoxicity .	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
The action of sulfonylurea may certain including @DRUG$ other drugs that are highly sulfonamides , , probenecid @DRUG$ , monoamine oxidase and beta blocking agents .	DDI-false
ibogaine ( ) 18-MC 40 mg/kg ) decreases self-administration of @DRUG$ and and the oral self-administration and @DRUG$ in	DDI-false
@DRUG$ ( 1000 mg twice daily ) did not the	DDI-false
@DRUG$ to have neuromuscular that the of other @DRUG$.	DDI-effect
this effect noted even @DRUG$ was given 4 hours to @DRUG$ , regimen result diminished .	DDI-effect
, @DRUG$ and Diuretics treatment xanthine , steroids or @DRUG$ potentiate a possible of	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
, was with digoxin @DRUG$ , oral @DRUG$ and supplemental . In a pharmacokinetic receiving furosemide digoxin in whom therapy FLOLAN , apparent clearance values for furosemide 23 n ) were by 15 % respectively , on the second day of therapy values by 87 .	DDI-false
Drug/Laboratory Test Interaction Because @DRUG$ may affect the APTT assay, @DRUG$ present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).	DDI-false
Moreover , additional interaction studies with and @DRUG$ have not demonstrated effect levels a @DRUG$ difference in extent of relative control .	DDI-false
Non-steroidal In patients , the of a non-steroidal anti-inflammatory can , effects	DDI-false
which enhance the neuromuscular blocking nondepolarizing agents such as @DRUG$ include ( e. aminoglycosides , @DRUG$ , bacitracin polymyxins , lincomycin , colistin , , magnesium salts lithium , quinidine	DDI-effect
@DRUG$ diminished binding of @DRUG$ a 9.9 percentage increase in , 21.2 % ) at 1732 micromol/L.	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.	DDI-mechanism
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-mechanism
include @DRUG$ theophylline , @DRUG$ , diazepam antipyrine .	DDI-false
caution is necessary when using ROMAZICON since such as and cardiac dysrhythmias ) other drugs taken ( @DRUG$ ) may reversal benzodiazepine by	DDI-false
Warfarin: The effects of @DRUG$ and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-effect
primarily the kidneys coadministration @DRUG$ that reduce compete for secretion may increase of @DRUG$ or the coadministered	DDI-false
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of @DRUG$.	DDI-effect
@DRUG$ and @DRUG$ should not be coadministered.	DDI-advise
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
clearance of @DRUG$ be with of	DDI-mechanism
of GABITRIL with Drugs : Cimetidine : @DRUG$ mg/day patients taking chronically @DRUG$ pharmacokinetics	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
Other therapy Although interaction were not finasteride 1 concomitantly used in clinical studies acetaminophen , acetylsalicylic acid a-blockers analgesics angiotensin-converting ( ACE ) @DRUG$ benzodiazepines , @DRUG$ , cardiac nitrates , H2 HMG-CoA inhibitors , inhibitors ( also referred to ) quinolone of clinically significant adverse interactions	DDI-false
@DRUG$ decrease tubular @DRUG$ resulting in and/or .	DDI-mechanism
Naproxen : concomitant of @DRUG$ and in normal volunteers effect of , decreased the urinary @DRUG$ glucuronide .	DDI-false
@DRUG$ subjects , a for 7 days systemic exposure AUC @DRUG$ was and half-life increased to control	DDI-false
@DRUG$/quinidine phenobarbital/acetaminophen phenobarbital/valproic acid , , valproic	DDI-false
A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The are of to inhibit of , through inhibition CYP3A @DRUG$ , cimetidine diltiazem , @DRUG$.	DDI-false
Coadministration of valdecoxib 40 ( day ) and mg 2 7 ) with @DRUG$ 5 QD not affect the ( ) ( glucose and of @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Example inhibitors include azole , , @DRUG$ , doxycycline , , @DRUG$ , , quinidine and verapamil	DDI-false
In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
@DRUG$   has in combination	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
In neither case were the pharmacokinetics of @DRUG$ affected by coadministration with @DRUG$.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
- The action of @DRUG$ and insulin may be enhanced by @DRUG$ or Bezalip retard.	DDI-effect
@DRUG$ - Taking piperazine and @DRUG$ together may effects of piperazine .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
drug may interact with or other depressants ( potentiate the CNS depressant effects of medications antihistamines , @DRUG$ or other with activity when are concurrently with @DRUG$ ) monoamine ) inhibitors use antihistamines prolong CNS effects of antihistamines .	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Interactions @DRUG$ : @DRUG$ ( , , butorphanol dezocine be to patient received or is therapy with opioid analgesic as .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
However in , of @DRUG$ significantly 29 decrease in AUC 38 % in 1-mg NS was administered 1 a dose of @DRUG$ nasal spray .	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
@DRUG$ increase plasmaconcentration of metabolized drugs triazolo-benzodiazepines @DRUG$ , HMG-CoA inhibitors , etc	DDI-mechanism
@DRUG$ , ampicillin @DRUG$ , cephalothin , and sulfamethoxazole have no in on the protein diclofenac in .	DDI-false
or products containing or zinc antacids not , within hours of , the of @DRUG$ , they may resulting in and urine levels of @DRUG$.	DDI-false
In FLOLAN used with @DRUG$ , anticoagulants , oral , and supplemental oxygen . In a pharmacokinetic in with congestive heart receiving furosemide digoxin with was initiated clearance furosemide n = 23 ) and @DRUG$ n = and 15 % respectively , the second day therapy had to	DDI-false
Drugs : Drugs , procainamide , @DRUG$ , @DRUG$ , tricyclic antidepressants may be with and an increased risk	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
Drug may with some drugs , oxidase inhibitors ): MAOI could theoretically affect - @DRUG$ - Eproxindine - Ethanol : @DRUG$ Ethanol CNS Flupenthixol increases the effect antidepressants	DDI-false
Anticoagulants: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-false
MAO as a @DRUG$ @DRUG$ metabolism .	DDI-mechanism
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ : Because of relationship of to , should be advised taking @DRUG$ containing avoid	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
Cation-Containing a quinolone including @DRUG$ with cation-containing such as magnesium aluminum antacids , , VIDEX tablets or pediatric , products , @DRUG$ the absorption resulting in serum urine desired .	DDI-mechanism
possibility of effects with enalapril @DRUG$ can be minimized by the @DRUG$ prior to with enalapril or enalaprilat	DDI-effect
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, @DRUG$, and alcohol.	DDI-false
clinical @DRUG$ was used with @DRUG$ anticoagulants oral and supplemental oxygen . a substudy with failure receiving or digoxin with FLOLAN was apparent oral clearance for furosemide ( n = ) digoxin ( ) decreased by 13 % 15 the therapy to values 87	DDI-false
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
@DRUG$ should be taken as directed and @DRUG$ should be taken with a main meal of the day, preferably the evening meal..	DDI-false
Therefore, when Hydrochlorothiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
Rifabutin : Coadministration of rifabutin @DRUG$ in a % decrease plasma a @DRUG$	DDI-false
receiving narcotic general anesthetics , , tranquilizers @DRUG$ @DRUG$ including ) additive depression	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ should be drugs e.g. , digitalis @DRUG$ the myocardium the of sympathomimetic .	DDI-advise
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
In about 30% of patients, the dose of @DRUG$ had to be reduced in order to maintain @DRUG$ concentrations within the therapeutic range, while in the remainder no adjustment was needed.	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and digoxin).	DDI-mechanism
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
@DRUG$ decrease the phenothiazines levodopa ,	DDI-effect
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Other : pharmacokinetic interactions observed between the following : glyburide , @DRUG$ Maalox , and	DDI-false
depression antihistamines are other @DRUG$ including barbiturates @DRUG$ , and alcohol .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
administration of fenofibrate ( equivalent to mg @DRUG$ ) pravastatin ( 40 mg ) once days has shown to increase the Cmax @DRUG$ by range % to 321 % ) 28 128 3 -hydroxy-iso-pravastatin 55 % range from 32 to ) range from 24 % decrease 261 increase 23	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other @DRUG$ in patients receiving @DRUG$ for heart failure are not available;	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
@DRUG$ t.i.d co-administered with Vardenafil 10 a in @DRUG$ AUC a increase Cmax and increase half-life .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
substances that may blood-glucose-lowering : @DRUG$ niacin , , diuretics sympathomimetic e.g. epinephrine , terbutaline @DRUG$ , derivatives , thyroid , , ( e.g. contraceptives	DDI-false
Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn.	DDI-advise
@DRUG$ Because @DRUG$ can nephrotoxicity with creatinine clearance rises creatinine and because excretion elimination route drugs including TRICOR a interaction deterioration	DDI-false
Drugs that been associated with neuropathy antiretroviral nucleoside , dapsone disulfiram , , glutethimide , hydralazine , @DRUG$ , @DRUG$ ribavirin ,	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$-@DRUG$ can antagonize warfarin	DDI-false
@DRUG$ of A patients should be advised vitamin @DRUG$ additive toxic effects	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
The use of NUROMAX before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	DDI-false
Because has been shown produce effect that obtained with @DRUG$ and @DRUG$ of of Nalfon , the use of Nalfon and salicylates is recommended	DDI-false
@DRUG$ including coumarin derivatives , derivatives and such as @DRUG$ ( may increase the risk bleeding when administered with ardeparin	DDI-false
Amiodarone may suppress certain enzymes @DRUG$ @DRUG$ , and .	DDI-false
@DRUG$ : @DRUG$ 20 mg not potentiate the increase bleeding time by ( two mg )	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Antihypertensives : patients receiving -@DRUG$ , @DRUG$ inhibitor ) or ( e.g. verapamil a , diltiazem a of of bradycardia , and AV block ;	DDI-false
Nalfon been to effect beyond that with alone aspirin increases rate of concomitant use @DRUG$ and @DRUG$ is not recommended	DDI-advise
Potential between TAXOL substrate of CYP3A4 , @DRUG$ @DRUG$ , and nelfinavir ) , which are substrates and/or inhibitors of , have not evaluated clinical	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
This be blockade @DRUG$ of elimination of @DRUG$ liver	DDI-mechanism
Injection injectable benzodiazepines depression the nervous with , @DRUG$ barbiturates , and other antidepressants When is used concomitantly with @DRUG$ , an increased incidence sedation irrational behavior observed	DDI-false
@DRUG$ ( mg did potentiate hypotensive @DRUG$ during period in healthy volunteers when with alcohol ( 0.5 g/kg weight )	DDI-false
Drug Flupenthixol interact with drugs , oxidase inhibitors @DRUG$ ): could flupenthixol - Arecoline - Eproxindine Ethanol : Flupenthixol and Ethanol cause CNS antidepressants : @DRUG$ of	DDI-false
evaluate the impact of the course of with HIV-related , non-Hodgkin lymphoma ( ) authors compared retrospectively a group of patients HIV-NHL who were with the cyclophosphamide , vincristine and ( ) chemotherapy plus group 80 patients who chemotherapy a cyclophosphamide , @DRUG$ teniposide , and @DRUG$ with plus bleomycin ) without antiretroviral	DDI-false
In , data suggest that of other inducers of clearance @DRUG$ nevirapine , or result meaningful @DRUG$ concentrations	DDI-false
In a pharmacokinetic study @DRUG$ , bioavailability parameters of binding , anticoagulant ( measured time ) @DRUG$ .	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
interaction studies have shown that @DRUG$ not have any interactions with phenytoin warfarin quinidine , @DRUG$ or amoxicillin	DDI-false
Antihypertensives @DRUG$ the effect various @DRUG$ necessitating reduction the dosage these	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	DDI-false
@DRUG$ like @DRUG$ , produces depression of the central ethyl alcohol phenothiazines barbiturates and antidepressants . When is concomitantly with lorazepam increased incidence sedation , irrational behavior been observed .	DDI-false
drugs may the neuromuscular action agents NUROMAX include certain @DRUG$ g. aminoglycosides , @DRUG$ , lincomycin , , colistin sodium colistimethate , procainamide , .	DDI-false
@DRUG$ (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-false
: Probenecid interferes with renal tubular secretion of @DRUG$ and produces increase level @DRUG$ in serum .	DDI-false
Cardiovascular @DRUG$ @DRUG$ been used concomitantly adrenergic-blocking agents , methyldopa nitrates , calcium-blocking hydralazine , prazosin and digoxin without evidence of clinically interactions	DDI-false
: treatment @DRUG$ Accutane use been associated a of of benign intracranial hypertension of @DRUG$	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
Other drugs e.g. @DRUG$ , , @DRUG$ and anesthetics have INAPSINE	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
apparently effect certain systems to the of warfarin-type , @DRUG$ , nifedipine , , @DRUG$ certain antidepressants and , thereby elimination and blood levels these .	DDI-false
@DRUG$: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
@DRUG$, warfarin, @DRUG$, NSAIDs	DDI-false
@DRUG$ the clearance of add a risk of @DRUG$ toxicity .	DDI-effect
Insulin or Oral @DRUG$: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
In the presence of these @DRUG$ , larger doses adenosine may be required @DRUG$ may not be .	DDI-advise
muscle eg other drugs succinylcholine @DRUG$ , @DRUG$ sodium blocking effect and used caution being Coly-Mycin M Parenteral .	DDI-false
Sinus bradycardia @DRUG$ combination @DRUG$ substrate for local anesthesia .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
- steroids nandrolone e.g. , @DRUG$ ] oxandrolone e.g. @DRUG$ [ e.g. , Anadrol ] , stanozolol [ e.g.	DDI-false
These increases considered when an oral @DRUG$ a @DRUG$.	DDI-advise
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ may bind , take TRICOR at least 1 hour 4 - 6 hours a @DRUG$ to impeding .	DDI-false
@DRUG$ and @DRUG$ inhibit and or proliferation prostatic epithelium .	DDI-false
Example inhibitors include @DRUG$ , @DRUG$ clarithromycin diclofenac , erythromycin , , nicardipine propofol protease inhibitors and verapamil	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
HMG-CoA : @DRUG$ ( @DRUG$ ) in combination associated with .	DDI-false
the @DRUG$ to antagonize effects @DRUG$ than times higher than to the effects of morphine	DDI-effect
CNS depressant drugs barbiturates @DRUG$ opioids and @DRUG$ have potentiating .	DDI-false
It may increase excretion of @DRUG$, lithium, and ASA and may also increase the toxicity of @DRUG$.	DDI-false
associated include analogues , chloramphenicol , @DRUG$ , dapsone , @DRUG$ , , , iodoquinol , nitrofurantoin phenytoin , , and .	DDI-false
Ingestion of serum of @DRUG$ and increase @DRUG$ s	DDI-false
FLEXERIL may the @DRUG$ , @DRUG$ , and other depressants .	DDI-false
inhibitors azole antifungals , ciprofloxacin , @DRUG$ @DRUG$ doxycycline , erythromycin isoniazid nicardipine , , protease inhibitors	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal.	DDI-false
through an on certain enzyme has hepatic metabolism anticoagulants , @DRUG$ , chlordiazepoxide , diazepam , @DRUG$ lidocaine theophylline delaying elimination and blood levels these	DDI-false
Although specific drug interactions with drugs systemic were identified in clinical IOPIDINE possibility additive or with ( , @DRUG$ , @DRUG$ , sedatives , ) should .	DDI-false
@DRUG$ @DRUG$ dopamine in nucleus ;	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ increase the of antihypertensive drugs , @DRUG$ reserpine	DDI-effect
However, the pharmacodynamics of coadministration of @DRUG$ and @DRUG$ have not been evaluated.	DDI-false
The following the : corticosteroids , danazol @DRUG$ ( epinephrine , salbutamol , ) somatropin @DRUG$ progestogens ( , .	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
@DRUG$ (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
@DRUG$ , @DRUG$ ethosuximide	DDI-false
Because theoretical that be additive use ergot-type @DRUG$ hours of other should be	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
evaluating for @DRUG$ ) , whether an @DRUG$ or enzymes is an consideration .	DDI-false
@DRUG$ ( ): ( , , fluvoxamine @DRUG$ ) been to cause , , and when coadministered agonists .	DDI-false
Magnesium- @DRUG$ products sulfate ( preparations containing zinc other , or Videx @DRUG$ ) chewable/buffered tablets or powder for oral should not taken within before 2 hours	DDI-false
drugs possessing nephrotoxic ( e.g. aminoglycosides , indomethacin myelotoxic , @DRUG$ chemotherapy ( e.g. @DRUG$ hepatotoxic e.g. , effects toxicity in systems .	DDI-false
Dopamine Antagonists : apomorphine a agonist , it possible that , as phenothiazines , @DRUG$ or @DRUG$ may diminish effectiveness of .	DDI-false
Again @DRUG$ neutralized in after @DRUG$ diabetic and	DDI-false
: other @DRUG$ , excretion of loracarbef is inhibited @DRUG$ resulted an % in AUC for loracarbef .	DDI-mechanism
Results demonstrate that @DRUG$ and its pharmacologically active 10-monohydroxy metabolite (@DRUG$) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$ @DRUG$ an plasma lithium levels and reduction renal lithium clearance	DDI-false
@DRUG$: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
CNS-Active Ethanol : potentiated the effects of ethanol g/kg @DRUG$ administration and digit test DSST , , and component of the divided attention for 2.5 hours after @DRUG$ administration .	DDI-false
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving @DRUG$ therapy and concomitant @DRUG$.	DDI-effect
An interaction study with @DRUG$ showed no clinically significant effect of anastrozole on @DRUG$ pharmacokinetics or anticoagulant activity.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
The concomitant use of nitrofurantoin is not recommended since @DRUG$ may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-effect
Potential interactions Keppra   and other @DRUG$ ( gabapentin , , phenobarbital , primidone @DRUG$ also by the serum of AEDs during placebo-controlled clinical studies	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
It @DRUG$ plasma levels whenever a @DRUG$ is to be with another drug known inhibitor of P450	DDI-false
is therefore administering @DRUG$ to receiving	DDI-advise
metabolizers @DRUG$ with inhibitors of CYP2D6 ( @DRUG$ , , paroxetine propafenone studied , blood levels the R(+ ) enantiomer carvedilol .	DDI-false
However , @DRUG$ have reported to enhance anticoagulant @DRUG$ or its derivatives in patients , time or suitable coagulation test should closely a is administered derivatives	DDI-effect
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Patients receiving high doses of @DRUG$ concomitantly with furosemide, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	DDI-false
@DRUG$ 10 20 mg to healthy either simultaneously 6 after mg dose of @DRUG$ significant hypotension developed in a substantial of subjects .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
man , @DRUG$ , diazepam , @DRUG$ antipyrine	DDI-false
Prior administration of @DRUG$ has no clinically important effect on the neuromuscular blocking action of @DRUG$.	DDI-false
: of VIRACEPT with @DRUG$ resulted 47 decrease @DRUG$ and an % decrease plasma .	DDI-false
Phase using doses 200 mg/m2 ) and cisplatin ( 50 75 sequential , more @DRUG$ cisplatin than with the sequence ie , TAXOL before @DRUG$	DDI-false
@DRUG$ including derivatives indandione derivatives , and @DRUG$ such nonsteroidal drugs NSAIDs , and increase the of when .	DDI-false
Plasma @DRUG$ concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and @DRUG$.	DDI-effect
@DRUG$ may antagonize the neuron blockade produced by @DRUG$ resulting in decreased antihypertensive effect and requiring increased dosage of the latter.	DDI-effect
Multivalent Cation-Containing Products a , ciprofloxacin multivalent cation-containing as magnesium or @DRUG$ antacids , @DRUG$ , chewable/buffered or pediatric containing calcium , iron , substantially decrease of ciprofloxacin resulting in serum and	DDI-false
@DRUG$ : Based profound hypotension consciousness when administered , the apomorphine of the 5HT3 class ( for , granisetron , @DRUG$ , and ) is .	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
, mg of @DRUG$ q12h for increased max 23 % and @DRUG$ by .	DDI-mechanism
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of tiagabine given as a single dose.	DDI-false
trough concentrations of @DRUG$ 56 % mg @DRUG$ was each of ( 15 in eight patients .	DDI-false
In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	DDI-false
: In study of antacid ( , @DRUG$ , simethicone ) with reduced and fosinoprilat as with @DRUG$ administered alone , that may of fosinopril .	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
with compounds are potent inducers of CYP3A4 ( , , phenytoin @DRUG$ @DRUG$ may result decreased plasma of .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
@DRUG$, bepridil, @DRUG$, and terodiline.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Antidepressants (@DRUG$), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Drugs have reported when TORADOL was used in taking psychoactive ( @DRUG$ @DRUG$ ) .	DDI-false
In pigeons, naloxone did not systematically alter the effects of @DRUG$, @DRUG$ or PCP.	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
: In clinical coadministration of an antacid ( aluminum hydroxide magnesium and reduced urinary excretion of fosinoprilat compared @DRUG$ administered suggesting @DRUG$ may absorption of fosinopril .	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ unchanged following coadministration @DRUG$ )	DDI-false
Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of loratadine relative to that observed with @DRUG$ alone.	DDI-false
lidocaine/quinidine phenobarbital/acetaminophen , phenobarbital/valproic acid quinidine/@DRUG$ , valproic acid/phenobarbital .	DDI-false
Warfarin: The effect of valdecoxib on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
specific studies finasteride mg more concomitantly in clinical acetylsalicylic , a-blockers , ( ACE , anticonvulsants beta blockers , @DRUG$ , cardiac H2 , HMG-CoA , prostaglandin synthetase inhibitors ( referred as ) , @DRUG$ without of adverse	DDI-false
These results would seem to dictate against the clinical use of @DRUG$ with ELSPAR, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	DDI-false
Other neuromuscular of nondepolarizing such include e. g. aminoglycosides , bacitracin , @DRUG$ clindamycin colistin , and ) , salts , @DRUG$ anesthetics , procainamide and quinidine	DDI-false
@DRUG$ should not be used with @DRUG$.	DDI-advise
However, neither @DRUG$ nor @DRUG$ appears to affect Dantrium metabolism.	DDI-false
- The action of sulphonylureas and @DRUG$ may be enhanced by Bezalip or @DRUG$.	DDI-effect
@DRUG$: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Warfarin: Concomitant administration of @DRUG$ (6 mg/kg once every 24 hours for 5 days) and @DRUG$ (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	DDI-effect
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-false
Therapeutic concentrations @DRUG$ , ibuprofen naproxen , @DRUG$ , acetaminophen , phenytoin ketorolac tromethamine protein binding .	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$ and @DRUG$ exaggerate prolongation the interval observed with bepridil	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
@DRUG$ ( nandrolone e.g. , Anabolin ] [ , @DRUG$ e.g. ] , stanozolol [ e.g. , ] or	DDI-false
The majority of RA one of concomitant with ORENCIA , NSAIDs blocking agents , @DRUG$ , , @DRUG$ , .	DDI-false
co-administration @DRUG$ IV such as , , or IV ACE inhibitors has been ( not co-administered with @DRUG$ clinical	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
When other potent parental antihypertensive drugs, such as @DRUG$, are used in combination with @DRUG$, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, @DRUG$, and nifedipine.	DDI-false
Drug Interactions : may some drugs like Monoamine MAOI MAOI affect flupenthixol - Arecoline - : @DRUG$ @DRUG$ depression - Tricyclic antidepressants Flupenthixol effect of Tricyclic	DDI-effect
include antifungals clarithromycin , , @DRUG$ , isoniazid , , @DRUG$ protease inhibitors , verapamil	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
Warfarin: The effect of @DRUG$ on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
If ( ketoconazole intraconazole @DRUG$ , indinavir @DRUG$ , , ) is indicated , reduction the budesonide dose be considered	DDI-false
We adolescent with altered consciousness caused @DRUG$ overdose with positive antidepressant clinicians cross-reactivity of a screen for @DRUG$.	DDI-false
If NovoLog is @DRUG$ , @DRUG$ into syringe	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
To @DRUG$ , and distribution cloxacillin studied in patients five kidney function and one with partially renal function absence @DRUG$.	DDI-false
Ritonavir ( 600 mg b.i.d . co-administered @DRUG$ in 49-fold in vardenafil in @DRUG$ Cmax	DDI-false
acetaminophen theophylline @DRUG$ and @DRUG$ with at high of the .	DDI-false
@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
@DRUG$ a @DRUG$ , may antagonize effect penicillin and use these drugs should avoided .	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
@DRUG$: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Drugs That Inhibit Oxidase @DRUG$ : Cimetidine inhibits both aldehyde ( in ) and ( in vitro vivo ) , and secondary , respectively responsible @DRUG$ metabolism .	DDI-false
The intensity uniformity time course @DRUG$ , glutethimide hydrate @DRUG$ investigated .	DDI-false
@DRUG$ could pose a hazard to health potentially toxic that is bound to the @DRUG$ has been titrated to while hydrochloride .	DDI-false
@DRUG$: Coadministration of a single dose of Sonata 20 mg and @DRUG$ 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
Although @DRUG$ have shown to reduce , hyperbilirubinemia , of these agents with @DRUG$ of and should be avoided . Beta-blockers and antihypertensives may potentiate hypotension seen PROLEUKIN .	DDI-false
Central Nervous : The concomitant of fentanyl system central nervous system depressants but to other @DRUG$ , sedatives e.g. , ) , general @DRUG$ , skeletal alcohol , may respiratory depression , , and , potentially in or .	DDI-false
@DRUG$: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	DDI-false
Nephrotoxic agents : Concomitant administration @DRUG$ and agents nephrotoxic , intravenous e.g. tobramycin gentamicin @DRUG$ ) , amphotericin B intravenous , and non-steroidal contraindicated	DDI-advise
@DRUG$ doxorubicin , @DRUG$ , and therapy patients with human virus-related , lymphoma	DDI-false
@DRUG$ is for @DRUG$ that protects against renal .	DDI-effect
Amiodarone taken concomitantly @DRUG$ for increases plasma concentrations procainamide @DRUG$ by % and 33 respectively	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
The administration of other @DRUG$ with @DRUG$ has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.	DDI-effect
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Drugs that associated with peripheral analogues , , dapsone , , ethionamide , @DRUG$ , iodoquinol metronidazole , @DRUG$ and .	DDI-false
Concomitant @DRUG$, doxorubicin, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Standard monitoring of be continued @DRUG$ administered	DDI-false
@DRUG$: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ direct effect of cloxacillin , the and distribution of @DRUG$ studied in six patients , kidney function and one impaired renal , in presence or absence probenecid	DDI-false
Patients CYP3A4 have cholesterol monitored after @DRUG$ initiated to the @DRUG$ needs	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
oral @DRUG$ @DRUG$ hepatic metabolism certain , thereby their	DDI-false
effect on certain microsomal enzyme systems , reported to the hepatic metabolism of warfarin-type anticoagulants , phenytoin , nifedipine , chlordiazepoxide @DRUG$ , certain tricyclic antidepressants , @DRUG$ , and delaying and increasing blood levels these drugs .	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
@DRUG$ : of severe hypoglycemia in diabetic patient on @DRUG$ 1 gm/day ) 11 days ( 75 mg/day .	DDI-false
careful adjustment the required when @DRUG$ used with other or	DDI-advise
Example antifungals , ciprofloxacin clarithromycin @DRUG$ @DRUG$ , isoniazid , , , , and	DDI-false
Antacids : , of an aluminum , magnesium and ) @DRUG$ serum levels and urinary excretion fosinoprilat as compared alone , that antacids impair of	DDI-false
specific been performed coadministration that CYP3A4 calcium blockers , disopyramide , , warfarin , , @DRUG$ fentanyl alfentanyl @DRUG$ , and triazolam ) have coadministered with saquinavir ;	DDI-false
Additive CNS may antihistamines with depressants including @DRUG$ , @DRUG$ alcohol .	DDI-false
@DRUG$ , , @DRUG$	DDI-false
patients in RA clinical studies received of the medications : MTX NSAIDs , , @DRUG$ , chloroquine gold @DRUG$ leflunomide sulfasalazine , and anakinra .	DDI-false
tested in man include , @DRUG$ , , and @DRUG$ no meaningful found .	DDI-false
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
with @DRUG$ the time onset block @DRUG$ lengthened and duration shortened patients carbamazepine .	DDI-false
System Depressants The concomitant of with central depressants , including limited other @DRUG$ , e.g. , benzodiazepines ) general @DRUG$ , and alcohol cause depression , , profound sedation , coma death .	DDI-false
- Indomethacin: @DRUG$ blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-effect
The benefits and risks of using @DRUG$ with @DRUG$ and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed	DDI-advise
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
The following of the blood-glucose-lowering : , , danazol , diuretics , e.g. , salbutamol , @DRUG$ phenothiazine derivatives , thyroid @DRUG$ , ( , )	DDI-false
Because of the increased adverse reactions have been taking @DRUG$ on basis is important physicians patients or their carefully alcohol and of to any which of @DRUG$ is planned .	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
appears clinically this kind with , , other drugs to cardiac conduction ( blocking agents , calcium channel blockers @DRUG$ , @DRUG$ phenothiazines ) might also contribute a prolongation of the QTc interval .	DDI-false
@DRUG$ Gastrointestinal acidifying ( guanethidine @DRUG$ , ascorbic juices ) absorption of amphetamines .	DDI-false
No significant found studies @DRUG$ , digoxin , and @DRUG$.	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
5HT3 : on loss of @DRUG$ with ondansetron , concomitant use apomorphine with drugs the 5HT3 antagonist ( , for example , , , dolasetron , @DRUG$ and )	DDI-false
is not recommended.@DRUG$ had no effect on of , @DRUG$ or	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
Clidinium may decrease the effect of @DRUG$, levodopa, and @DRUG$.	DDI-false
These that both @DRUG$ and possibly other glucocorticoids and retinoids may the dose-dependent modification of the @DRUG$ EGF	DDI-effect
interaction evaluated the of the @DRUG$ , , combination strength ( ( @DRUG$/SMX	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
include thiazides , corticosteroids phe-nothiazines , @DRUG$ contraceptives phenytoin @DRUG$ sympathomimet-ics channel drugs and isoniazid	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
Therefore , interactions occur following of psychotropic drugs e.g. , @DRUG$ antiemetics , @DRUG$ , )	DDI-false
Because changes in glucose concentrations with @DRUG$ coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for @DRUG$ (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
- Methotrexate (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
@DRUG$ and reduced when either administered	DDI-false
small occasional doses of @DRUG$ , may be when @DRUG$ are used a schedule	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
@DRUG$ with , of @DRUG$ with theophylline lead elevated concentrations theophylline and prolongation its .	DDI-false
Oral @DRUG$ Coadministration of @DRUG$ and AUC and estradiol by approximately 30 and 20 .	DDI-false
through effect on microsomal systems has been to the of phenytoin , chlordiazepoxide , diazepam @DRUG$ @DRUG$ metronidazole thereby elimination and levels drugs	DDI-false
This be the clinically relevant interaction of kind with although of other known cardiac ( , anti-arrhythmic beta-adrenergic blocking calcium channel blockers @DRUG$ or H1-blocking @DRUG$ phenothiazines ) also contribute of the interval .	DDI-false
For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with @DRUG$ or Bezalip retard and then titrated according to the blood clotting parameters	DDI-advise
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
@DRUG$ eg @DRUG$ and ether , succinylcholine , sodium , the effect used with extreme caution being treated with Coly-Mycin M	DDI-false
Valdecoxib caused increase in exposures R-warfarin and @DRUG$ , respectively ) ( prothrombin time , measured INR of	DDI-false
for adult-onset diabetics, dosage adjustment of @DRUG$ may be necessary during and after @DRUG$ therapy;	DDI-advise
@DRUG$: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and atorvastatin were coadministered.	DDI-false
Because not to any that obtained with @DRUG$ increases the of excretion of @DRUG$ the concomitant use of is not .	DDI-mechanism
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
The absorption of tetracycline, furosemide, penicillin G, @DRUG$, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
Beta-blockers, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
Nonsteroidal Anti-Inflammatory Drugs : The administration @DRUG$ normal receiving decreased the and increased the plasma of	DDI-false
No data clinical trials currently exist comparing approved @DRUG$ @DRUG$ .	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, diltiazem, and @DRUG$.	DDI-false
The following are examples of substances may reduce the blood-glucose-lowering effect corticosteroids niacin , agents , @DRUG$ , ) @DRUG$ phenothiazine , thyroid hormones estrogens progestogens ( oral contraceptives ) .	DDI-false
Concurrent therapy with @DRUG$ and @DRUG$ is not recommended.	DDI-advise
@DRUG$ @DRUG$ , , quinidine , theophylline , and valproic pooled serum at therapeutic concentrations .	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	DDI-advise
on known profiles clinically significant between VIRACEPT and trimethoprim/sulfamethoxazole clarithromycin , @DRUG$ , or	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
and/or aluminum-containing , products containing , @DRUG$ zinc other cations , or Videx ( didanosine ) tablets or pediatric powder for within hours or hours .	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-mechanism
Although specific have been , with that metabolized by CYP3A4 ( eg @DRUG$ , dapsone disopyramide quinine , @DRUG$ , quinidine , warfarin , cyclosporine , ergot derivatives , carbamazepine , alfentanyl alprazolam and ) plasma concentrations saquinavir ;	DDI-false
Dihydroergotamine , , @DRUG$ CONTRAINDICATED due to and life-threatening reactions as @DRUG$ characterized peripheral vasospasm of the extremities and tissues	DDI-false
Drugs That Induce CYP3A4 (@DRUG$) Racemic @DRUG$ exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.	DDI-false
: @DRUG$ the activity @DRUG$.	DDI-effect
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
adjustment is not recommended . had no on carbamazepine @DRUG$ @DRUG$ .	DDI-false
Antiarrhythmics @DRUG$ drugs as , , and , have	DDI-false
Central Nervous System Depressants The concomitant @DRUG$ transdermal system ) with central but , @DRUG$ , , , skeletal relaxants and alcohol may depression and profound result in or	DDI-effect
CANCIDAS with clearance such @DRUG$ dexamethasone , use of @DRUG$ should be considered	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
an certain microsomal , has been reported to the warfarin-type phenytoin , , chlordiazepoxide , @DRUG$ certain @DRUG$ , lidocaine , theophylline and thereby delaying elimination blood of these drugs	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
studies have reduction @DRUG$ and @DRUG$ when an intravenous as .	DDI-false
Even so @DRUG$ in doses @DRUG$ were almost 5-fold than those in CYP poor adjustment not	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Injection : Lorazepam , injectable , depression system when phenothiazines , @DRUG$ @DRUG$ . When is with , of sedation and irrational has been	DDI-false
patients have @DRUG$ temporarily mask the residual effects of @DRUG$.	DDI-effect
Diltiazem, @DRUG$, @DRUG$	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-false
@DRUG$ , of an aluminum , magnesium hydroxide , simethicone ) fosinopril serum levels and as with @DRUG$ administered , suggesting that antacids .	DDI-false
@DRUG$ @DRUG$ , NSAIDs	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
Interactions with Mixed Opioid analgesics @DRUG$ @DRUG$ dezocine buprenorphine ) should NOT administered a patient who has or is a pure Levo-Dromoran	DDI-false
No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with propranolol or @DRUG$.	DDI-false
@DRUG$ amount ( @DRUG$ ) absorbed your body .	DDI-mechanism
Therefore , interactions could occur following concomitant of , narcotics @DRUG$ antiemetics @DRUG$ )	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
of potentiated by drugs @DRUG$ and that are , @DRUG$ , monoamine inhibitors beta adrenergic blocking	DDI-false
interaction studies have shown esomeprazole does any clinically with phenytoin , @DRUG$ , @DRUG$ or amoxicillin	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Patients receiving @DRUG$s , general anesthetics phenothiazines , tranquilizers , sedative-hypnotics , other depressants @DRUG$ ) DILAUDID additive CNS depression .	DDI-false
clinical studies performed with Fondaparinux concomitant anticoagulants ( , @DRUG$ ( acid @DRUG$ digoxin not fondaparinux sodium .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
apparently effect on systems , has been reported to the metabolism , , nifedipine @DRUG$ , certain tricyclic antidepressants , @DRUG$ theophylline metronidazole delaying elimination increasing of .	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-false
: Since @DRUG$ may bind other drugs concurrently , take at - 6 a @DRUG$ to avoid its .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$-@DRUG$ large doses may vitamin reductase in deficiency .	DDI-false
@DRUG$ can with @DRUG$ of chlorpromazine	DDI-mechanism
Potential drug Keppra AEDs ( @DRUG$ phenobarbital , phenytoin , primidone and ) were also serum concentrations of levetiracetam and these @DRUG$ during .	DDI-false
Oral Coadministration of @DRUG$ AUC values for @DRUG$ and by approximately 30 % and % .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
drugs enhance the action nondepolarizing such @DRUG$ certain antibiotics g. , , , bacitracin @DRUG$ colistin and sodium colistimethate ) , , lithium , local anesthetics , quinidine .	DDI-effect
The following of that may blood-glucose-lowering and hypoglycemia oral antidiabetic , @DRUG$ , fibrates , monoamine oxidase ( MAO inhibitors , @DRUG$ , salicylates , ( e.g. , octreotide ,	DDI-false
pigeons , not systematically alter @DRUG$ , @DRUG$ or PCP .	DDI-false
Betaseron administration to cancer a dose range to 2.2 led to dose-dependent of @DRUG$ The alternate-day of 0.25 mg @DRUG$ drug metabolism patients unknown	DDI-false
a comparison digitalis tolerance dogs anesthetized @DRUG$ , pentobarbital , dosage of needed cause ventricular was significantly as the LD50 @DRUG$ with Innovar than pentobarbital	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
following examples of that may effect and susceptibility to : oral antidiabetic products , ACE , @DRUG$ , fluoxetine MAO ) inhibitors , propoxyphene , @DRUG$ analog octreotide ,	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
action sulfonylurea may potentiated certain drugs anti-inflammatory agents and other drugs that are , sulfonamides , @DRUG$ , @DRUG$ , beta adrenergic blocking .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
agents : administration VISTIDE and potential aminoglycosides ( e.g. , @DRUG$ @DRUG$ amikacin ) amphotericin , foscarnet , intravenous pentamidine , and non-steroidal agents is .	DDI-false
Therophylline A study has concomitan administration isoniazid and @DRUG$ cause plasma of @DRUG$ some instances a decrease in the elimination of .	DDI-false
studies been performed are metabolized by CYP3A4 ( , @DRUG$ dapsone , quinine amiodarone , , tacrolimus , ergot derivatives carbamazepine , @DRUG$ alfentanyl , ) may plasma concentrations when with	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Even so @DRUG$ plasma concentrations in the presence of high doses of @DRUG$ were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.	DDI-mechanism
Consequently, estazolam should be avoided in patients receiving @DRUG$ and @DRUG$, which are very potent inhibitors of CYP3A.	DDI-false
EM individuals treated with or , of @DRUG$ is approximately 6- 8-fold Css , is greater @DRUG$	DDI-false
effect TORADOL @DRUG$ has not , cases of increased lithium plasma @DRUG$ have reported	DDI-false
To evaluate the chemotherapy clinical of patients HIV-related , systemic non-Hodgkin lymphoma HIV-NHL ) , group who treated with cyclophosphamide @DRUG$ , vincristine and CHOP plus HAART group of 80 were with CHOP or a regimen ( , , prednisone vincristine ) without @DRUG$ .	DDI-false
A possible interaction between glyburide and @DRUG$, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-false
in clinical study who were established with @DRUG$ @DRUG$ was were to in counts in groups CI alone	DDI-effect
Therapeutic concentrations of digoxin, warfarin, @DRUG$, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The majority patients in clinical one of the following concomitant medications with MTX , NSAIDs , @DRUG$ , hydroxychloroquine , leflunomide @DRUG$.	DDI-false
May altered hypo-prothrombinemic ) , barbiturates , rifampin and enzyme oxidation ( effect @DRUG$ ) , ( of @DRUG$ )	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
@DRUG$ Eszopiclone administered daily for 5 days not the , were changes pharmacodynamic profile time ) a single mg oral of	DDI-false
@DRUG$: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
@DRUG$ : has been @DRUG$ clinical of postoperative pain of adverse	DDI-false
co-administration vasodilators as @DRUG$ , @DRUG$ , milrinone or IV ACE inhibitors ( these drugs co-administered in clinical ) .	DDI-false
@DRUG$, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Potential interactions between @DRUG$ CYP3A4 ( , saquinavir , @DRUG$ ) , are and/or of CYP3A4 , not been evaluated clinical trials	DDI-false
This interact with @DRUG$ or CNS depressants ( effects of either medications ) anticholinergics other medications with ( effects when concurrently @DRUG$ ) , and oxidase MAO inhibitors use with antihistamines and anticholinergic and CNS depressant effects antihistamines	DDI-false
is therefore necessary to be with of magnesium magnesium deficiency due to which only requires supplementation @DRUG$ related of control @DRUG$ status requires or specific of causal dysregulation	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, @DRUG$, alprazolam).	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
In the same study it was shown that didanosine and @DRUG$ had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	DDI-false
Other drugs which may the neuromuscular action of nondepolarizing agents NUROMAX include certain @DRUG$ ( e. @DRUG$ , tetracyclines , , , lincomycin clindamycin , colistin and , salts , lithium , anesthetics .	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
glucocorticoids have to reduce PROLEUKIN-induced side insufficiency confusion and dyspnea with the antitumor PROLEUKIN and thus be other @DRUG$ may with	DDI-effect
@DRUG$ added dosage adjustment of @DRUG$ may be .	DDI-advise
@DRUG$ had effect anticoagulant healthy stable @DRUG$ .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Cardiovasculars : receiving @DRUG$ , of oral results an @DRUG$ concentration reach toxic with .	DDI-false
Other which may enhance the blocking such as include antibiotics ( , , @DRUG$ polymyxins , clindamycin colistin and ) , local	DDI-false
The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	DDI-false
examples include : @DRUG$ @DRUG$ known to varying degrees .	DDI-false
Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of cisapride.	DDI-mechanism
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-effect
@DRUG$: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.	DDI-false
To impact of plus HAART clinical with , non-Hodgkin lymphoma ( ) , authors retrospectively of patients HIV-NHL who were cyclophosphamide , @DRUG$ , @DRUG$ CHOP regimen plus a group of CHOP regimen ( cyclophosphamide , teniposide with vincristine bleomycin without antiretroviral therapy .	DDI-false
and of : @DRUG$ plasma concentrations of @DRUG$ 70 %	DDI-mechanism
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-mechanism
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	DDI-false
Digitalis glycosides: @DRUG$-induced hypokalemia may potentiate @DRUG$ toxicity.	DDI-effect
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
that have been associated include nucleoside , chloramphenicol @DRUG$ , , glutethimide , hydralazine , , , @DRUG$ phenytoin , and	DDI-false
There not a p > AUC ( 48.59 + /- 8.52 + /- , Cmax 7.73 /- vs. 6.6 + /- 2.0 , and 1.1 + 1.6 + for @DRUG$ levofloxacin/@DRUG$	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, @DRUG$).	DDI-false
Promethazine a single dose zaleplon and @DRUG$ ( 10 and 25 mg respectively ) resulted 15 % decrease @DRUG$ , but no change in the the .	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of tiagabine given as a single dose.	DDI-false
Tacrolimus  @DRUG$ may increase the blood concentration of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
reductions in @DRUG$ is , @DRUG$ , or vasodilators .	DDI-effect
An additive hypotensive effect has been reported with the combination of systemic @DRUG$ and @DRUG$ therapy.	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
: @DRUG$ 20 , co-administered @DRUG$ or 60 mg , not bioavailability ( ( Cmax metabolized	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
The following examples of that may blood-glucose-lowering effect and susceptibility hypoglycemia @DRUG$ , inhibitors disopyramide fluoxetine , @DRUG$ , propoxyphene , salicylates analog e.g. , , antibiotics .	DDI-false
Other specific studies were performed finasteride doses of 1 mg used in clinical studies analgesics angiotensin-converting ) inhibitors anticonvulsants , @DRUG$ , @DRUG$ , , , H2 antagonists , HMG-CoA reductase , inhibitors ( to NSAIDs ) evidence significant adverse	DDI-false
The extent to which @DRUG$-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	DDI-int
The use of administered methylxanthines ( , @DRUG$ theophylline ) patients receiving @DRUG$	DDI-false
@DRUG$ phenobarbital theophylline @DRUG$ were serum concentrations .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, @DRUG$, digoxin, Maalox, and ranitidine.	DDI-false
Products : a quinolone , ciprofloxacin , with cation-containing products as magnesium aluminum VIDEX or , @DRUG$ zinc decrease the absorption @DRUG$ , and urine levels than	DDI-false
to reactions all patients treated with be ( @DRUG$ ) and antagonists @DRUG$ ) .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ Dihydroergotamine @DRUG$ , ergotamine , CONTRAINDICATED due potential and life-threatening as acute ergot toxicity extremities and tissues .	DDI-false
These drugs include the thiazides diuretics corticosteroids , , products , estrogens oral phenytoin , nicotinic , @DRUG$ calcium blocking , @DRUG$.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
CANCIDAS co-administered inducers of such as @DRUG$ nevirapine , , , or carbamazepine of a dose of @DRUG$	DDI-false
In to the occurrence of severe hypersensitivity patients with TAXOL be premedicated with @DRUG$ ( dexamethasone diphen-hydramine @DRUG$ ( such cimetidine .	DDI-false
concomitantly @DRUG$ @DRUG$ in heart failure were not significantly altered	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and related drugs may decrease arterial responsiveness to @DRUG$.	DDI-effect
Aspirin administration @DRUG$ valdecoxib may result in an risk GI ulceration compared to @DRUG$ alone	DDI-false
@DRUG$ interact with drugs to the conventional	DDI-false
potent non-nucleoside regimens for and concerns regarding @DRUG$ (@DRUG$)-related disturbances led to significant practices infection	DDI-false
Furosemide studies as post , shown that @DRUG$ can reduce the natriuretic @DRUG$ in	DDI-effect
@DRUG$ : @DRUG$ adrenergic of norepinephrine	DDI-false
@DRUG$: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-false
@DRUG$ or products iron or , @DRUG$ or should not be with , within of the administration of because they may with absorption resulting serum and levels norfloxacin	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine.	DDI-false
Central : The concomitant use DURAGESIC fentanyl transdermal system other central other opioids @DRUG$ @DRUG$ , ( , ) phenothiazines , muscle , and alcohol may depression hypotension , and profound , in death	DDI-false
combined 12-week placebo controlled trials included @DRUG$ doses of 15 daily , twice daily , and 50 mcg once @DRUG$ -treated subjects theophylline study	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
Notably , systemic exposure ( - 12 of @DRUG$ ( DHA than of	DDI-false
interactions and other @DRUG$ , lamotrigine , @DRUG$ , , primidone valproate ) were also evaluating serum concentrations levetiracetam and during placebo-controlled	DDI-false
This appears the clinically of this kind Mefloquine , although , coadministration drugs known cardiac eg , anti-arrhythmic beta-adrenergic blocking calcium channel @DRUG$ or H1-blocking tricyclic @DRUG$ ) might also contribute prolongation of the interval .	DDI-false
drugs which neuromuscular nondepolarizing as include aminoglycosides , , @DRUG$ , @DRUG$ clindamycin colistimethate ) , local , , quinidine	DDI-false
Other therapy Although studies were not finasteride of or more concomitantly in studies acid , a-blockers @DRUG$ @DRUG$ , , , blockers calcium-channel blockers , cardiac nitrates , , , reductase inhibitors , synthetase inhibitors ( also to , anti-infectives without clinically interactions .	DDI-false
There was no evidence of any pharmacokinetic interactions between @DRUG$ and @DRUG$.	DDI-false
@DRUG$ : volunteers no significant interaction occurred @DRUG$ and administered concomitantly 6 days .	DDI-false
of substances reduce the effect : , danazol diuretics , ( e.g. , salbutamol @DRUG$ , , phenothiazine derivatives , somatropin @DRUG$ progestogens ( in oral contraceptives	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
The hypoglycemic may by including anti-inflammatory agents other drugs that are bound @DRUG$ , chloramphenicol , coumarins @DRUG$ agents	DDI-false
Methylxanthines and Diuretics Concomitant @DRUG$ , or @DRUG$ may potentiate a effect beta2-agonists .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
Like ibogaine mg/kg 40 mg/kg ) decreases the self-administration of @DRUG$ and the of @DRUG$ nicotine rats ;	DDI-false
Hormonal @DRUG$ of @DRUG$ an contraceptive has been shown to influence the concentrations the two components ethinylestradiol ( LNG )	DDI-false
side of N-methylthiotetrazole @DRUG$ , cefotetan cefamandole , @DRUG$ ) cefazolin ) vitamin K hypoprothrombinemia .	DDI-false
May with medication ( e.g. ) @DRUG$-containing antacids , , famotidine , @DRUG$ ) pump e.g. , , omeprazole )	DDI-false
In vitro studies have shown @DRUG$ can displace @DRUG$s, such as warfarin, from their protein-binding sites.	DDI-mechanism
Influence of @DRUG$ On @DRUG$ Concentration (Mean change, 90% Confidence Interval)	DDI-false
@DRUG$ is inhibited by @DRUG$.	DDI-mechanism
Olanzapine: Coadministration of @DRUG$ 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	DDI-effect
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-effect
, including @DRUG$ , the effects oral @DRUG$ , including its similar .	DDI-effect
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Coadministration of @DRUG$ with Itraconazole has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-false
, lidocaine/quinidine @DRUG$/acetaminophen phenobarbital/@DRUG$ , quinidine/lidocaine theophylline/acetaminophen , valproic .	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
may or CNS depressants ( may the depressant effects either these or antihistamines , or medications with anticholinergic activity ( anticholinergic potentiated these medications are used with @DRUG$ , and monoamine oxidase ( MAO ) inhibitors @DRUG$ and intensify and depressant effects of antihistamines )	DDI-false
In study clonazepam @DRUG$ ( an anticholinergic effects on the GI tract to healthy , clonazepam 10 % and the Cmax @DRUG$ was 20 % the orally with propantheline to when given alone	DDI-false
Serotonin Reuptake Inhibitors ( ): SSRIs e.g. @DRUG$ @DRUG$ , sertraline ) have reported cause hyperreflexia , when coadministered with 5-HT1 .	DDI-false
other @DRUG$ or @DRUG$ used concomitantly the FLOLAN to the of bleeding	DDI-false
@DRUG$: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.	DDI-false
@DRUG$ such @DRUG$ .	DDI-effect
all the @DRUG$ ( ) , citalopram , @DRUG$ , paroxetine , , may inhibition .	DDI-false
of that may the blood-glucose-lowering effect and to : @DRUG$ @DRUG$ , , monoamine oxidase MAO ) , , , ( e.g. ) sulfonamide .	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, @DRUG$, pimozide.	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
@DRUG$ ) , atropine or other agents , with @DRUG$ may produce .	DDI-false
The effects of concomitant @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
Coadministration of @DRUG$ and drugs that induce CYP3A may decrease @DRUG$ plasma concentrations and reduce its therapeutic effect.	DDI-false
( e. g. , , , clotrimazole , @DRUG$ etc ): in B and imidazoles may @DRUG$.	DDI-false
: reports of hypotension and loss consciousness when apomorphine the @DRUG$ with drugs of the class including , ondansetron granisetron @DRUG$ , palonosetron , alosetron contraindicated .	DDI-advise
Patients taking @DRUG$ or who increase their diclofenac dose any other NSAID @DRUG$ , , or cyclosporine develop toxicity characteristics for .	DDI-effect
Central Nervous Depressants The concomitant use DURAGESIC with other central nervous system but not to , , @DRUG$ , tranquilizers e.g. @DRUG$ , general , phenothiazines , muscle alcohol respiratory , hypotension and profound sedation potentially or death .	DDI-false
In patients , administration of a @DRUG$ reduce the natriuretic antihypertensive effects ,	DDI-effect
Although results not interaction between and warfarin or heparin the @DRUG$ to patients taking @DRUG$ be done extremely cautiously , and should closely monitored	DDI-advise
to avoid the of , all patients treated with @DRUG$ should premedicated with such as ) and H2 ( as @DRUG$ or ranitidine ) .	DDI-false
Therefore, prothrombin time should be carefully monitored in patients receiving @DRUG$ and @DRUG$-like drugs simultaneously.	DDI-advise
That Coadministered VIRACEPT : @DRUG$ , @DRUG$ : , terfenadine Antimigraine : ergot Antimycobacterial agents : midazolam , GI :	DDI-false
Other drugs may enhance the blocking of nondepolarizing agents such include antibiotics ( g. , , tetracyclines , bacitracin , , lincomycin , clindamycin , colistin , and @DRUG$ salts @DRUG$ , and .	DDI-false
certain @DRUG$ such @DRUG$ ) ;	DDI-false
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users.	DDI-false
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping @DRUG$. since @DRUG$ may prolong prothrombin time.	DDI-false
Plasma valproate concentration should be monitored when @DRUG$ and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-advise
peripheral neuropathy , , disulfiram , , glutethimide , , @DRUG$ @DRUG$ , nitrofurantoin , , and vincristine .	DDI-false
In Study 1, patients with colorectal cancer were given irinotecan/5-FU/@DRUG$ (bolus-IFL) with or without @DRUG$.	DDI-false
@DRUG$ @DRUG$ can exert additive properties on renal and circulation	DDI-false
, time course of interference by @DRUG$ @DRUG$ , chloral hydrate and systematically in 16 coumarin therapy .	DDI-false
It has not been if pharmacokinetic interaction between @DRUG$ @DRUG$.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Drugs That Induce CYP3A4 @DRUG$: CYP3A4 is ordinarily a minor metabolizing enzyme of @DRUG$.	DDI-false
These include and other @DRUG$ , , , estrogens , , nicotinic acid , @DRUG$ , and	DDI-false
The absorption of tetracycline @DRUG$ , @DRUG$ , and gemfibrozil was simultaneously colestipol	DDI-false
Antacids In clinical study coadministration of ( aluminum hydroxide , , ) with @DRUG$ levels @DRUG$ as with alone antacids may absorption fosinopril	DDI-false
In clinical Fondaparinux the concomitant of anticoagulants ( @DRUG$ ( acid NSAIDs piroxicam digoxin significantly the pharmacokinetics/pharmacodynamics @DRUG$.	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
@DRUG$, a @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	DDI-false
with @DRUG$ Agonist/antagonist analgesics ( eg , , , dezocine should administered who or is receiving a course of therapy a @DRUG$	DDI-false
In well-controlled patients undergoing concurrent therapy with @DRUG$, a decrease in the steady-state serum concentrations of @DRUG$ may occur when cime-tidine therapy is discontinued.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and @DRUG$.	DDI-false
Other 5-HT1B/1D Agonists Concomitant use of other @DRUG$ within 24 hours of treatment with @DRUG$ is contraindicated.	DDI-advise
@DRUG$ Lithium generally not be such as @DRUG$ ) because reduce its renal add high of	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an @DRUG$ containing @DRUG$ and magnesium.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
BACKGROUND : The @DRUG$ verapamil hydrochloride ( verapamil ) a @DRUG$ , incidence metastasis adenocarcinomas ) and the index of were investigated in male .	DDI-false
Agents Causing Release : effect of and @DRUG$ IV is augmented @DRUG$ that cause release , diuretics )	DDI-effect
Conversely, the administration of STADOL NS (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	DDI-false
@DRUG$ ingestion of may decrease @DRUG$ to apomorphine in the poisoning	DDI-false
Moreover , additional studies @DRUG$ and propranolol have not fluvastatin plasma and administration to population receiving resulted in no difference in of @DRUG$ relative data	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Because of the increased risk of reactions in who been @DRUG$ regular basis , it is particularly physicians their carefully @DRUG$ , and as prior any procedure which use of planned	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
- @DRUG$ (e.g., AquaMEPHYTON, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Other drugs enhance the action nondepolarizing agents such NUROMAX include certain ( e. g. , @DRUG$ , , polymyxins , clindamycin , , and magnesium salts , @DRUG$ , anesthetics , procainamide ,	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of astemizole with @DRUG$ is contraindicated.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
The concomitant intake of not affect the of either @DRUG$	DDI-false
: @DRUG$ ( @DRUG$ reserpine , HCl , juices , etc . ) lower of	DDI-false
Lack an effect of on the disposition of @DRUG$ @DRUG$ in HIV-infected	DDI-false
The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	DDI-false
Tagamet , apparently through microsomal enzyme , has been reported to hepatic warfarin-type phenytoin propranolol , @DRUG$ chlordiazepoxide , certain tricyclic , @DRUG$ , , elimination and increasing blood levels of these drugs	DDI-false
@DRUG$ : As @DRUG$ is by an approximate 80 in the for	DDI-false
Standard monitoring of @DRUG$-related toxicity should be continued if @DRUG$ and methotrexate are administered concomitantly.	DDI-false
caution should be used @DRUG$ @DRUG$ since these are increased risk .	DDI-advise
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Amiodarone with caution patients receiving   -@DRUG$ blocking e.g. , propranolol , @DRUG$ inhibitor antagonists ( , verapamil , a CYP3A4 diltiazem CYP3A4 inhibitor because the possible potentiation bradycardia , sinus arrest and ;	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
of @DRUG$ has effect on of	DDI-false
@DRUG$ @DRUG$ : of is impaired in the presence of anionic exchange resins	DDI-false
drug studies with @DRUG$ @DRUG$ prodrug .	DDI-false
May with thyroid medication e.g. , levothyroxine ) , , H2-antagonists e.g. , @DRUG$ @DRUG$ , lansoprazole ) .	DDI-false
Administration repeat doses of had no on pharmacokinetics of theophylline , @DRUG$ an @DRUG$/levonorgestrol oral contraceptive healthy	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-effect
has @DRUG$ dopamine , , @DRUG$ , , and .	DDI-false
@DRUG$ an elevation of plasma @DRUG$ levels and a in lithium	DDI-mechanism
@DRUG$ has @DRUG$ clinically significant adverse .	DDI-false
containing @DRUG$ , administered concomitantly @DRUG$ reduce both rate and of absorption .	DDI-mechanism
The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	DDI-false
Therefore, @DRUG$ should be discontinued at least two weeks prior to the cautious initiation of therapy with @DRUG$.	DDI-advise
Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent @DRUG$ and @DRUG$ is uncertain.	DDI-false
: of @DRUG$ concomitantly cyclosporine has associated with in @DRUG$-induced toxicity , possibly due to synthesis	DDI-false
the other currently available HMGCoA @DRUG$ simvastatin , @DRUG$ , leading unique biopharmaceutical properties to other of this class	DDI-false
Selective Reuptake Inhibitors ): ( e.g. , , fluvoxamine , @DRUG$ @DRUG$ have rarely to , and when coadministered agonists .	DDI-false
@DRUG$ e.g. , @DRUG$ or	DDI-false
In a coadministration of antacid ( aluminum hydroxide @DRUG$ , and simethicone ) with fosinopril and urinary excretion of suggesting absorption of	DDI-false
The action may potentiated by certain drugs agents and other drugs that are highly protein bound salicylates , , @DRUG$ , , @DRUG$ , and adrenergic .	DDI-false
The coadministration of @DRUG$ decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ has to be antagonistic , @DRUG$ , on studies and time kill with gram-negative .	DDI-effect
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
, @DRUG$ avoided in receiving @DRUG$ itraconazole are potent inhibitors CYP3A	DDI-advise
Numerous possible anticonvulsant , such as @DRUG$ @DRUG$ which microsomal	DDI-false
following examples that the and susceptibility @DRUG$ @DRUG$ , salicylates somatostatin analog e.g. , octreotide , antibiotics	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
study in which the mg @DRUG$ administered with without @DRUG$ anticholinergic with on the GI ) volunteers the clonazepam was 10 % and Cmax of clonazepam when the orally was given with compared it	DDI-mechanism
action @DRUG$ potentiated by certain drugs including agents and are salicylates sulfonamides , chloramphenicol , probenecid , , monoamine inhibitors and	DDI-effect
Drug Interactions Contraceptives Keppra 500 did not influence of an @DRUG$ 0.03 mg ethinyl estradiol and @DRUG$ of the luteinizing progesterone , indicating impairment of .	DDI-false
@DRUG$ diminished binding of @DRUG$ by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.	DDI-mechanism
Interaction @DRUG$ other than @DRUG$ has not	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
d-amphetamine with or @DRUG$ possibly other @DRUG$ striking and sustained increases	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Because there are no data on the compatibility of NovoLog and crystalline @DRUG$ preparations, @DRUG$ should not be mixed with these preparations.	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Be With VIRACEPT amiodarone quinidine Antihistamines : terfenadine Antimigraine ergot Antimycobacterial : @DRUG$ Benzodiazepines midazolam @DRUG$ motility agents :	DDI-false
retinyl of prostatic in RPMI1640 transferrin they modify mitogenic of @DRUG$ and @DRUG$.	DDI-false
The oral @DRUG$ @DRUG$ were sheep .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
with , it be @DRUG$ may capable @DRUG$ as anesthetics , opiates and alcohol .	DDI-effect
Other concomitant therapy were , @DRUG$ doses 1 mg were concomitantly used studies acetaminophen acid , a-blockers analgesics enzyme inhibitors anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac diuretics H2 , HMG-CoA reductase inhibitors inhibitors ( also referred NSAIDs , and quinolone anti-infectives evidence clinically adverse .	DDI-false
Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Five of @DRUG$ treatment not significantly steady-state pharmacokinetic @DRUG$ with ;	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
When the @DRUG$ was administered 30 minutes after the @DRUG$ nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
of MYOBLOC aminoglycosides or other with neuromuscular transmission ( , @DRUG$ performed as @DRUG$ potentiated .	DDI-false
@DRUG$-@DRUG$ may the vitamin K the body the microflora	DDI-false
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$ @DRUG$ toxicity has reported in patients drugs elimination ,	DDI-false
Preliminary animal and human studies have shown that small quantities of systemically administered @DRUG$ enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual @DRUG$ concentrations following intrathecal administration.	DDI-false
Again, @DRUG$ neutralized the increase in glycemia after @DRUG$ overload both in diabetic and non-diabetic rats.	DDI-false
Drugs that peripheral neuropathy include antiretroviral nucleoside analogues chloramphenicol , @DRUG$ , ethionamide gold , @DRUG$ nitrofurantoin , and vincristine	DDI-false
Warfarin and @DRUG$ prothrombin time or without clinical @DRUG$ is administered concomitantly .	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Lethargy and somnolence have been reported following doses of @DRUG$ and @DRUG$.	DDI-effect
Cyclosporine Increased both @DRUG$ and @DRUG$ occur the two .	DDI-effect
Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, alfentanil, and @DRUG$.	DDI-false
INOmax has been administered with tolazoline, @DRUG$, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
The absorption @DRUG$ , G @DRUG$ gemfibrozil was significantly given with colestipol hydrochloride ;	DDI-false
This interact with @DRUG$ or other depressants may effects these or , @DRUG$ other medications anticholinergic effects potentiated medications antihistamines ) , monoamine MAO ) ( use may prolong and intensify depressant effects .	DDI-false
In separate of patients maintenance of @DRUG$ hydrochlorothiazide , digoxin , @DRUG$ administration 7 no on the pharmacodynamics of prothrombin digoxin .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
@DRUG$ , , , @DRUG$ , , imatinib , nefazodone , propofol , .	DDI-false
No Interactions Date does not clinically important pharmacokinetic with captopril , felodipine , @DRUG$ , , @DRUG$ or itraconazole	DDI-false
The administration local containing epinephrine @DRUG$ patients receiving @DRUG$ or severe hypertension .	DDI-effect
These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	DDI-advise
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$ and ibogaine for opioid and possibly 18-MC has lower affinities than @DRUG$ for NMDA and sigma-2 .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Which Dose Reduction Coadminstered With @DRUG$ @DRUG$ : rifabutin	DDI-advise
inducers carbamazepine @DRUG$ and shown plasma of @DRUG$ ( 29 )	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
interactions had no effect the pharmacodynamics @DRUG$ glucose and concentrations @DRUG$ ( prothrombin parameters .	DDI-false
Enzyme and Substrates : which induce 3A4 ( CYP 3A4 , barbiturates @DRUG$ carbamazepine @DRUG$ the require the dosage of corticosteroid be .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
neither @DRUG$ retinyl acetate proliferation of transferrin alone , modify the mitogenic of @DRUG$.	DDI-effect
Therefore , when @DRUG$ non-steroidal , the patient be closely to determine the effect of @DRUG$ is obtained .	DDI-false
inducers of enzymes ( i.e. , phenytoin @DRUG$ ) have to decrease the of @DRUG$ 40 %	DDI-false
@DRUG$ mg/kg ( 30 , 0.25 mg/kg , @DRUG$ 20 mg/kg ) 30 ) or was .	DDI-false
Co-administration of @DRUG$ antiplatelet agents @DRUG$ , anticoagulants increase of .	DDI-effect
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, cimetidine and @DRUG$.	DDI-false
@DRUG$ should taken as directed and @DRUG$ be with main , preferably evening	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
drugs/substances are the @DRUG$ by stimulating the synthesis @DRUG$	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.	DDI-false
agents agents with potential [ e.g. , intravenous @DRUG$ e.g. , @DRUG$ gentamicin and amikacin ) , foscarnet intravenous vancomycin , and non-steroidal anti-inflammatory agents contraindicated .	DDI-false
@DRUG$ enhance @DRUG$.	DDI-false
following substances may reduce blood-glucose-lowering effect : corticosteroids , , , diuretics sympathomimetic ( , @DRUG$ ) , isoniazid @DRUG$ , thyroid , ( , in oral .	DDI-false
are examples of substances that reduce the : @DRUG$ diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , , isoniazid , @DRUG$ , somatropin , thyroid hormones , ( oral contraceptives	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR in patients lowered the @DRUG$ concentrations undetectable .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-false
not , with that are mainly metabolized by CYP3A4 eg , channel @DRUG$ quinine quinidine , warfarin , , ergot @DRUG$ alfentanyl , alprazolam and triazolam have plasma concentrations coadministered ;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and @DRUG$.	DDI-false
Other : Drugs , @DRUG$ , procainamide phenothiazines antihistamines , @DRUG$ may associated with QT-interval increased	DDI-false
Should Not With @DRUG$ Antiarrhythmics : amiodarone , quinidine @DRUG$ : astemizole , terfenadine : ergot derivatives agents Benzodiazepines midazolam GI motility agents :	DDI-advise
similar association , though has been suggested with barbiturates , phenytoin sodium @DRUG$ possibly with @DRUG$ , ampicillin and tetracyclines 72 )	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, @DRUG$, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
of with class increased with concurrent administration cyclosporine , fibric acid derivatives , niacin ( acid , @DRUG$ ,	DDI-false
@DRUG$ may sensitivity the	DDI-effect
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water).	DDI-false
To injection of thiosulfate permit @DRUG$ to , dose of thiosulfate given intravenously hours concurrently with of	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
In digitalis tolerance with ketamine Vet or @DRUG$ of needed cause ventricular , as of with @DRUG$ with	DDI-false
However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
@DRUG$ ( Steady ( of @DRUG$ mg BID 12 was by co-administered doses 300 12 ) a CYP 3A4 inducer	DDI-false
Benzylpenicillin , oxacillin , chlortetracycline @DRUG$ @DRUG$ , sulfamethoxazole have protein binding of human serum	DDI-false
oral ketoconazole , inhibits the metabolism of @DRUG$ resulting in @DRUG$ and active metabolite desmethylastermizole which may prolong .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Interactions interact some drugs , like oxidase ( @DRUG$ ): @DRUG$ affect flupenthixol - - : and additive - Tricyclic antidepressants : Flupenthixol the Tricyclic antidepressants	DDI-false
glucose concentrations be carefully monitored @DRUG$ @DRUG$ .	DDI-advise
@DRUG$ TORADOL IV/IM response @DRUG$ normovolemic healthy % mean and output	DDI-false
include , ciprofloxacin clarithromycin @DRUG$ erythromycin imatinib , nefazodone @DRUG$ , protease , quinidine , verapamil	DDI-false
Additive effects from blockade may when LEVSIN is administered concomitantly other @DRUG$ amantadine , @DRUG$ or .	DDI-false
: @DRUG$ ( soft-gelatin 1200 mg ) with @DRUG$ resulted in increase in nelfinavir plasma saquinavir	DDI-mechanism
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
rifampin the @DRUG$ of our patient appeared maximal 5 the initiation of @DRUG$ and extended length of after	DDI-false
However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Antihypertensives should be with caution receiving blocking ( propranolol , CYP3A4 @DRUG$ e.g. verapamil , a substrate @DRUG$ , ) of possible of , sinus arrest AV block	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/@DRUG$).	DDI-false
@DRUG$ been to a patient on chronic @DRUG$ following the initiation therapy	DDI-false
Because prostaglandins important hemostasis , @DRUG$ as concurrent @DRUG$ close monitoring patients to change in dosage is	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Aspirin , @DRUG$ , heparin @DRUG$	DDI-false
the and diuretics , phenothiazines thyroid products estrogens @DRUG$ @DRUG$ , calcium channel drugs , isoniazid	DDI-false
A interaction the effect of use @DRUG$ , in with double strength mg ) @DRUG$/sulfamethoxazole ( TMP/SMX ) .	DDI-false
@DRUG$ : Concomitant administration @DRUG$ blood-pressure-	DDI-false
Drugs ( Rifampicin ) Racemic @DRUG$ exposure decreased 80 @DRUG$ a CYP3A4 .	DDI-mechanism
@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-false
Drugs have peripheral include @DRUG$ dapsone disulfiram ethionamide , gold , metronidazole nitrofurantoin , phenytoin ribavirin , @DRUG$.	DDI-false
@DRUG$ ): Steady plasma exposure ( ) of valdecoxib ( 40 mg 12 was decreased by 27 % with ( mg QD for @DRUG$ ( a CYP 3A4 inducer ) .	DDI-false
a comparison of digitalis tolerance in anesthetized @DRUG$ , Vet , or dosage of @DRUG$ to cause ventricular tachycardia significantly higher , was of ouabain than .	DDI-effect
Based on @DRUG$ , of astemizole with @DRUG$ is	DDI-false
@DRUG$ @DRUG$ concomitantly , any dosage be in order avoid the possible	DDI-advise
Example @DRUG$ , ciprofloxacin , diclofenac , , nefazodone , nicardipine propofol , @DRUG$ , quinidine and verapamil	DDI-false
CANCIDAS is with drug , as efavirenz , @DRUG$ phenytoin , or carbamazepine , use of of mg @DRUG$ be	DDI-false
Non-steroidal Drugs : some , of non-steroidal can reduce diuretic , natriuretic and loop	DDI-false
Patients taking low-dose @DRUG$ plus @DRUG$ were not studied.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with @DRUG$ or dicumarol.	DDI-false
are examples that increase the blood-glucose-lowering effect and to antidiabetic , inhibitors @DRUG$ , fibrates , fluoxetine oxidase ( MAO inhibitors , propoxyphene , @DRUG$ somatostatin ( e.g. ) , antibiotics .	DDI-false
including , aggregation inhibitors such as @DRUG$ NSAIDs ) , @DRUG$ may the risk of administered with ardeparin	DDI-false
Other therapy performed doses 1 mg or more were concomitantly in studies acetaminophen , acetylsalicylic , analgesics enzyme ( ) , @DRUG$ , blockers calcium-channel blockers nitrates , , H2 , HMG-CoA reductase , @DRUG$ ( referred as ) , quinolone without significant	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-mechanism
Cardiovasculars @DRUG$ : digoxin , administration of oral results in an in @DRUG$ may reach levels toxicity .	DDI-false
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
agents Gastrointestinal agents @DRUG$ , etc increase absorption	DDI-mechanism
Drugs been with peripheral neuropathy antiretroviral nucleoside analogues , chloramphenicol , , ethionamide glutethimide gold hydralazine , @DRUG$ , isoniazid metronidazole @DRUG$ , ribavirin , vincristine .	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Methotrexate: Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
interaction studies were not , doses mg in clinical with @DRUG$ analgesics , enzyme ACE , , benzodiazepines beta blockers blockers , cardiac nitrates diuretics antagonists , HMG-CoA reductase inhibitors , @DRUG$ also to NSAIDs significant interactions .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
@DRUG$ (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
In an antacid ( @DRUG$ , hydroxide ) fosinopril reduced urinary excretion of @DRUG$ as compared fosinopril administered alone suggesting antacids may impair	DDI-false
@DRUG$ : @DRUG$ BID did show significant plasma exposure or renal clearance .	DDI-false
Benzthiazide may with , blood , decongestant drugs allergy cold , and sinus medicines , , lithium , norepinephrine , @DRUG$ like @DRUG$ or and high pressure	DDI-false
To evaluate impact chemotherapy the clinical of patients with HIV-related , , ( ) , the compared retrospectively a group 24 patients with the cyclophosphamide , doxorubicin , vincristine , @DRUG$ ( regimen HAART with group of 80 patients who were with CHOP CHOP-like ( cyclophosphamide doxorubicin @DRUG$ , and prednisone bleomycin therapy	DDI-false
Physicians needing to treatpatients co-infected with tuberculosis @DRUG$ containing regimen @DRUG$ .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
CONCOMITANT THERAPY : Although were performed , in , @DRUG$ with @DRUG$ , blockers , , and NSAIDs ) without of clinically significant adverse	DDI-false
has reported patients receiving @DRUG$ and is that the of @DRUG$ may have the of .	DDI-effect
for , dosage of @DRUG$ may and after @DRUG$ therapy ;	DDI-advise
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/@DRUG$-containing antacids.	DDI-false
Therefore, the concomitant administration of TRACLEER and @DRUG$ is contraindicated, and alternative @DRUG$ should be considered.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of @DRUG$.	DDI-false
@DRUG$ ( , phosphate ) of the @DRUG$ , thereby increasing excretion .	DDI-mechanism
@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
have performed , coadministration that by ( eg , , disopyramide , quinine @DRUG$ quinidine , warfarin @DRUG$ , cyclosporine derivatives , , fentanyl , alprazolam may have elevated plasma concentrations coadministered with saquinavir	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
inhibitors , , diclofenac , doxycycline , @DRUG$ , imatinib , @DRUG$ , nefazodone , propofol , quinidine .	DDI-false
Furosemide : @DRUG$ IV/IM to @DRUG$ normovolemic healthy by approximately % mean output decreased %	DDI-effect
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
intravenously orally @DRUG$ , @DRUG$ by has been completely	DDI-false
Norepinephrine @DRUG$ enhance the effect of	DDI-effect
The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	DDI-false
Drugs Demonstrated to CYP Possible Significance on the of Involving is recommended during coadministration with @DRUG$ ): Coadministration of fluoxetine with maximum plasma concentration @DRUG$ by , clearance 21 by 17 % , measured psychomotor	DDI-false
These drugs include the and other corticosteroids , @DRUG$ , estrogens , , , sympathomimetics , @DRUG$ and isoniazid	DDI-false
Other not performed finasteride doses of 1 or were concomitantly in clinical studies with acetaminophen , , , ( ACE ) , anticonvulsants , , beta , , cardiac @DRUG$ , H2 antagonists inhibitors inhibitors ( also to as NSAIDs ) , and @DRUG$ without adverse	DDI-false
Amiodarone may , including @DRUG$ , @DRUG$ , and CYP3A4	DDI-false
@DRUG$ and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for @DRUG$), that may affect strategies during conversion from one drug to the other.	DDI-false
studies have coadministration with drugs that by CYP3A4 ( eg , calcium blockers , @DRUG$ , amiodarone quinidine warfarin , derivatives , @DRUG$ , carbamazepine , fentanyl alprazolam and triazolam ) may have elevated plasma concentrations when with	DDI-false
FLEXERIL may enhance the effects of @DRUG$, @DRUG$, and other CNS depressants.	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Concomitant administration of @DRUG$ ( equivalent to 145 @DRUG$ ) with 20 ) once daily for in approximately % decrease ( 67 % decrease to 44 increase in values 22 healthy	DDI-false
Example antifungals ciprofloxacin , clarithromycin , doxycycline , @DRUG$ nefazodone propofol protease inhibitors , @DRUG$ and verapamil	DDI-false
Broad-Spectrum Antibiotics-@DRUG$ may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
of @DRUG$ -associated profile between 1 ( co-administered and Study 2 AVONEX ) indicates that alteration clearance not reduction of @DRUG$ dose to maintain	DDI-false
hypoglycemic may be potentiated certain including and other drugs highly protein , @DRUG$ , , chloramphenicol , @DRUG$ , monoamine oxidase inhibitors , and adrenergic blocking	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ concomitantly quinidine @DRUG$ by after days .	DDI-false
Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
A , though has with , phenylbutazone phenytoin , carbamazepine @DRUG$ @DRUG$ , possibly with and .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	DDI-mechanism
Example inhibitors include clarithromycin @DRUG$ doxycycline , , isoniazid nefazodone , @DRUG$ propofol protease .	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
Antimycobacterial @DRUG$ CONTRAINDICATED since coadministration of product @DRUG$ in an antiretroviral regimen reduces the plasma saquinavir .	DDI-false
: Based on of profound and loss of consciousness apomorphine administered @DRUG$ , the of @DRUG$ drugs 5HT3 class including for example , ondansetron , granisetron , and alosetron	DDI-false
In are have one pharmacologic similar , including anti-arrhythmic agents as @DRUG$ and @DRUG$	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-effect
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of @DRUG$.	DDI-mechanism
demonstrated that @DRUG$ @DRUG$ the systemic its major metabolites .	DDI-false
@DRUG$: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
@DRUG$: Aminoglutethimide may diminish adrenal suppression by @DRUG$.	DDI-false
: Amiodarone , flecainide , @DRUG$ @DRUG$ CONTRAINDICATED .	DDI-false
Intravenous ( @DRUG$ ) been the as quinidine , @DRUG$ blocking , enzyme inhibitors without any in the adverse profile	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
, occur following @DRUG$ ( e.g. , , analgesics , @DRUG$ sedatives )	DDI-false
agents administration @DRUG$ agents nephrotoxic potential [ e.g. , intravenous aminoglycosides e.g. , , amikacin ) , @DRUG$ , foscarnet intravenous , vancomycin , agents contraindicated	DDI-advise
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of @DRUG$ should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.	DDI-advise
In patients taking diclofenac and @DRUG$ concomitantly, @DRUG$ toxicity may develop.	DDI-false
other agents it capable depressants as @DRUG$ and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ : ( @DRUG$ ) 3A4 2C19 substrate .	DDI-false
hypoglycemic action of be potentiated anti-inflammatory and other drugs that are protein , @DRUG$ , coumarins , @DRUG$ adrenergic blocking agents	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
acetaminophen/@DRUG$, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Anticoagulants including derivatives , such as nonsteroidal anti-inflammatory drugs ( @DRUG$ ) , and @DRUG$ increase the of when administered concomitantly with .	DDI-false
Drug with some drugs , ( MAOI theoretically affect flupenthixol - - and @DRUG$ cause additive effect @DRUG$	DDI-false
pharmacokinetic interactions were assessed in clinical pharmacokinetic studies , , , , @DRUG$ , @DRUG$ and screening in studies	DDI-false
High-dose cyclosporin in above 2000 ng/mL with oral etoposide has 80 in @DRUG$ % decrease total @DRUG$ to etoposide .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, @DRUG$, and anakinra.	DDI-false
, may @DRUG$ , @DRUG$	DDI-false
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of dopamine HCl should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
concomitant Although specific interaction , mg or concomitantly used clinical studies acetaminophen @DRUG$ , a-blockers analgesics , angiotensin-converting ( ) inhibitors , @DRUG$ , blockers , blockers , nitrates , , H2 , reductase inhibitors , prostaglandin inhibitors to as NSAIDs ) , without evidence	DDI-false
, and @DRUG$ are , the should be observed determine @DRUG$ obtained .	DDI-false
Inhibitors @DRUG$ ( Failure Post-Myocardial Infarction)- EPHESUS 91 INSPRA 25 mg received @DRUG$ ACEI/ARB ) .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
which inhibit 3A4 ( , ketoconazole , antibiotics such as @DRUG$ potential increased concentrations	DDI-mechanism
of @DRUG$ mg BID days @DRUG$ ( 5 QD 10 mg BID affect the exposure .	DDI-false
second study administration of g @DRUG$ hour 0.3 after same resulted a cerivastatin AUC less 8 , a of % when to dosing @DRUG$ .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In addition regression analyses inducers of clearance ( , @DRUG$ , dexamethasone or @DRUG$ ) CANCIDAS result clinically meaningful reductions in caspofungin	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
@DRUG$ , @DRUG$ vincristine prednisone plus highly active antiretroviral in with , non-Hodgkin lymphoma .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
no have been conducted is likely that metabolism of @DRUG$ be affected by the CYP3A4 inducers such phenytoin @DRUG$ , inhibitors ( antimycotics e.g. ,	DDI-mechanism
- Anabolic steroids ( nandrolone , @DRUG$ e.g. Anavar oxymetholone Anadrol , stanozolol , @DRUG$ )	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Concomitant of @DRUG$ ( TRICOR ) @DRUG$ ( 40 ) 10 has shown to Cmax and AUC by % ( range from 69 to increase ) and 28 % range from 54 increase ) , , for 3 -hydroxy-iso-pravastatin by % ( range from to 314 ) and 39 ( from 24 decrease 261 , respectively in 23 adults	DDI-mechanism
If treatment of ( such @DRUG$ indinavir , erythromycin , etc . is , reduction of @DRUG$ should be considered	DDI-advise
@DRUG$ : Clinical well as marketing , have can reduce natriuretic of furosemide and @DRUG$ some .	DDI-false
Reuptake SSRIs ( fluoxetine , fluvoxamine , paroxetine , @DRUG$ ) have been reported cause , hyperreflexia coadministered with @DRUG$.	DDI-effect
CONCOMITANT specific interaction studies were performed , , sodium was concomitantly with @DRUG$ betablockers , @DRUG$ diuretics , and nonsteroidal anti-inflammatory drugs NSAIDs ) without adverse interactions .	DDI-false
This appears be the clinically relevant of kind with @DRUG$ drugs to cardiac conduction , @DRUG$ , antihistamines or H1-blocking antidepressants and ) might also contribute to prolongation of the interval	DDI-effect
Patients receiving other analgesics , anesthetics , phenothiazines @DRUG$ or @DRUG$ ) concomitantly with DILAUDID exhibit an additive depression	DDI-false
These the diuretics , @DRUG$ , , products , oral contraceptives , nicotinic acid , , @DRUG$	DDI-false
Coadministration of Itraconazole and @DRUG$, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-false
@DRUG$ therapy excretion amphetamines is increased , and is reduced , by @DRUG$ used in .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Particular is @DRUG$ in mixed drug overdosage the effects such as cardiac of especially @DRUG$ emerge with the the benzodiazepine effect flumazenil .	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ @DRUG$ can the .	DDI-false
Magnesium- @DRUG$-containing , products sulfate iron ) multivitamin containing metal cations @DRUG$ didanosine ) tablets or the pediatric powder for oral not taken 3 hours before or 2 .	DDI-false
@DRUG$ : Hallucinations been was used in psychoactive ( @DRUG$ , thiothixene , .	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
have these effects sevoflurane , isoflurane , propofol @DRUG$	DDI-false
doses @DRUG$ may the	DDI-effect
Central Nervous System Depressants : The DURAGESIC   ( fentanyl with nervous system depressants but other @DRUG$ , e.g. , benzodiazepines anesthetics @DRUG$ , muscle , and may cause respiratory depression and profound sedation potentially in or	DDI-false
@DRUG$ and @DRUG$	DDI-false
These drugs thiazides diuretics corticosteroids phenothiazines thyroid , , @DRUG$ phenytoin , acid sympathomimetics , blocking drugs @DRUG$.	DDI-false
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Diphenhydramine additive CNS ( , @DRUG$ @DRUG$ , etc )	DDI-false
inhibitors clarithromycin diclofenac doxycycline , , , , @DRUG$ , nicardipine , , quinidine	DDI-false
These would seem against the use of @DRUG$ @DRUG$ , or during the when levels are	DDI-advise
Drug may interact drugs , oxidase MAOI ): MAOI theoretically affect @DRUG$ Ethanol Flupenthixol cause additive CNS depression antidepressants : Flupenthixol the effect of @DRUG$	DDI-false
It recommended that @DRUG$ levels be @DRUG$ is with .	DDI-false
@DRUG$ agents and @DRUG$ - dosage adjustment of the antidiabetic drug be required .	DDI-false
Although specific not , with that are mainly metabolized by calcium channel blockers @DRUG$ , quinine , amiodarone , , , , derivatives , carbamazepine , , alfentanyl @DRUG$ may have elevated concentrations ;	DDI-false
In , @DRUG$ used with digoxin , diuretics @DRUG$ , oral vasodilators , and supplemental . a with receiving furosemide in therapy FLOLAN was clearance furosemide and digoxin ( n 30 ) were by % and 15 , respectively of therapy returned baseline by day	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-effect
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$ , effect on microsomal enzyme has been reported reduce the warfarin-type anticoagulants phenytoin , , nifedipine , chlordiazepoxide diazepam , certain antidepressants @DRUG$ and metronidazole thereby and increasing blood levels these drugs	DDI-mechanism
Bacteriostatic Antibiotics : Chloramphenicol @DRUG$ , @DRUG$ , or may interfere with the bactericidal	DDI-false
@DRUG$ Concomitant administration levels	DDI-false
@DRUG$ decreased @DRUG$.	DDI-effect
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
In , drugs this isoenzyme @DRUG$ ( antidepressants , @DRUG$ , and others ) , may this isoenzyme , may normal metab-olizers metabolizers with with metabolized system to drug interactions	DDI-false
Drugs Not Be With @DRUG$ , @DRUG$ Antihistamines : astemizole , Antimigraine agents : cisapride	DDI-advise
Drugs been neuropathy nucleoside analogues chloramphenicol cisplatin dapsone , disulfiram , @DRUG$ glutethimide gold , iodoquinol , @DRUG$ metronidazole nitrofurantoin , phenytoin ribavirin , and vincristine	DDI-false
Coingestion @DRUG$ , with @DRUG$ , and acid toxic of target drug .	DDI-false
Imidazoles ( ketoconazole , miconazole @DRUG$ , . ): vitro and animal studies and @DRUG$ may induce B.	DDI-false
pharmacokinetic @DRUG$ and @DRUG$ , propofol alfentanil , midazolam .	DDI-false
@DRUG$ Amphetamines inhibit the hypotensive effect @DRUG$.	DDI-false
The effects of ruthenium red (@DRUG$) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
The of patients in RA following concomitant medications with ORENCIA @DRUG$ NSAIDs , corticosteroids , , gold @DRUG$ , leflunomide sulfasalazine , .	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
concomitant administration @DRUG$ @DRUG$ may result in increased rate ulceration or complications use of CELEBREX .	DDI-effect
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
drugs include thiazides other diuretics , @DRUG$ thyroid products estrogens , oral @DRUG$ , , calcium channel isoniazid .	DDI-false
@DRUG$-Vitamin K can @DRUG$	DDI-false
Close supervision and adjustment dosage required @DRUG$ is administered with anticholinergic or @DRUG$.	DDI-advise
could occur administration @DRUG$ e.g. , narcotics , analgesics , @DRUG$ )	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and @DRUG$.	DDI-false
In a digitalis tolerance in dogs anesthetized ketamine , @DRUG$ or @DRUG$ dosage needed to cause ventricular tachycardia was significantly LD50 of ouabain ketamine pentobarbital	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ : @DRUG$ CONTRAINDICATED since the coadministration saquinavir reduces saquinavir	DDI-false
@DRUG$ of @DRUG$ and not recommended diclofenac from its during the , , peak plasma , and	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	DDI-false
increase slightly the of antihypertensive , @DRUG$ @DRUG$ , reserpine .	DDI-false
Cyclosporine , @DRUG$ like through effects renal prostaglandins may cause changes the these levels @DRUG$ , and increased toxicity .	DDI-mechanism
@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
@DRUG$-based regimens may have advantages @DRUG$-based , lower volume drug interactions , and system penetration .	DDI-false
For patients receiving both therapies, standard monitoring of @DRUG$ blood concentrations and appropriate @DRUG$ dosage adjustments are recommended.	DDI-false
@DRUG$: Co-administration with @DRUG$ should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
That Not Be With VIRACEPT : @DRUG$ : astemizole , Antimigraine : midazolam @DRUG$ GI motility agents	DDI-false
Drugs that have been associated peripheral neuropathy include antiretroviral nucleoside analogues chloramphenicol , cisplatin disulfiram , , glutethimide , @DRUG$ , iodoquinol isoniazid , @DRUG$ ribavirin , and vincristine .	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when @DRUG$ and doxorubicin are used in combination.	DDI-false
Products Concurrent administration of a quinolone , ciprofloxacin , multivalent products such as magnesium @DRUG$ VIDEX tablets pediatric , products containing , zinc may substantially @DRUG$ serum than	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Investigations into the effect of on the binding @DRUG$ ( @DRUG$ no interaction .	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;	DDI-false
Agents Increasing Serum Potassium: @DRUG$ attenuates potassium loss caused by @DRUG$.	DDI-effect
@DRUG$ apomorphine is a @DRUG$ , it is possible dopamine , as phenothiazines , ) or metoclopramide effectiveness	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
In the case that you are taking @DRUG$ while taking aminosalicylic acid, higher doses of @DRUG$ may be needed.	DDI-false
therapy interaction performed , doses studies acetaminophen acid analgesics ACE inhibitors anticonvulsants , beta blockers calcium-channel blockers cardiac , @DRUG$ , @DRUG$ , inhibitors prostaglandin inhibitors also referred to NSAIDs ) and anti-infectives without clinically significant interactions	DDI-false
Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	DDI-false
drug interact alcohol CNS may potentiate the of either medications or , or other with anticholinergic activity may be potentiated concurrently antihistamines ) monoamine oxidase inhibitors ( @DRUG$ may prolong the CNS depressant @DRUG$ )	DDI-false
Because of its lack of platelet effects, @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
plasmaconcentration other CYP3A4 drugs ( e.g. , @DRUG$ HMG-CoA , etc . )	DDI-false
Therefore @DRUG$ and @DRUG$ concomitantly , the patient should closely the desired effect . )	DDI-advise
has additive effects with @DRUG$ and @DRUG$ ( , sedatives , tranquilizers )	DDI-false
Other given @DRUG$ 50 by 84 of	DDI-false
Antiacid , Didanosine , Fluconazole , @DRUG$ Phenobarbitol carbamazepine @DRUG$ Rifampin Ritanovir , Saquinavir .	DDI-false
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with @DRUG$ or its derivatives.	DDI-advise
Drug Interactions : Flupenthixol with , like Monoamine inhibitors MAOI ): MAOI theoretically affect flupenthixol @DRUG$ - @DRUG$ depression Tricyclic antidepressants Flupenthixol increases the effect Tricyclic antidepressants	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$ Macrolide reported to a in @DRUG$ .	DDI-false
Hypoglycemics : @DRUG$ blood-sugar-reducing of insulin and	DDI-effect
No Important To not have interactions with @DRUG$ , warfarin @DRUG$ carvedilol , ethanol or	DDI-false
Theophylline As with @DRUG$ , ciprofloxacin with theophylline may elevated serum of @DRUG$ and prolongation of its elimination .	DDI-false
May the following : @DRUG$ ( diuretics the @DRUG$ working properly ;	DDI-false
Drug interaction shown esomeprazole have any clinically interactions warfarin @DRUG$ or	DDI-false
Warfarin : of @DRUG$ ( 6 once 24 for ) and @DRUG$ 25 mg single dose ) had effect the pharmacokinetics either drug and the was	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and allopurinol were administered concomitantly for 6 days.	DDI-false
- @DRUG$ used with anion-exchange resins ( @DRUG$ an interval least should be the , absorption retard	DDI-advise
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ saquinavir ( using experimental capsule of @DRUG$ 1200 mg in an nelfinavir plasma AUC 4-fold in A.C.	DDI-false
specific have not been , drugs that mainly metabolized ( , channel , dapsone , quinine amiodarone , quinidine @DRUG$ , cyclosporine ergot derivatives , pimozide @DRUG$ , , alprazolam , triazolam ) have plasma coadministered with ;	DDI-false
: is a dopamine agonist , it is possible @DRUG$ , the @DRUG$ thioxanthenes ) or , may diminish the	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- Vitamin K (e.g., AquaMEPHYTON, @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
@DRUG$ may decrease the amount of digoxin (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
Derivatives @DRUG$ @DRUG$ , CONTRAINDICATED to potential and reactions such ergot characterized by vasospasm and ischemia of the extremities and .	DDI-false
Administration of @DRUG$ may potentiate @DRUG$-induced neuromuscular block.	DDI-effect
dissolution of aerosol of @DRUG$ , a @DRUG$.	DDI-false
@DRUG$: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of @DRUG$.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, @DRUG$, and increased toxicity.	DDI-false
Potassium-sparing diuretics e.g. , @DRUG$ , potassium supplements or @DRUG$-containing salt may significant serum potassium	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, @DRUG$ and @DRUG$) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that been associated @DRUG$ , dapsone , @DRUG$ , , glutethimide gold , , isoniazid , nitrofurantoin phenytoin , ribavirin and vincristine	DDI-false
adverse from concomitantly with other , amantadine , @DRUG$ , , ( ) tricyclic or @DRUG$.	DDI-false
Both @DRUG$ and nevirapine been compared triple therapy with PI indinavir over as initial therapy being observed with @DRUG$ superiority observed with efavirenz	DDI-false
Example inhibitors include antifungals , @DRUG$ , clarithromycin diclofenac , doxycycline , imatinib , isoniazid , nefazodone , propofol , protease inhibitors , @DRUG$ , and .	DDI-false
and @DRUG$ @DRUG$ , midazolam demonstrated	DDI-false
, , oxacillin , , @DRUG$ @DRUG$ and influence in the protein binding of .	DDI-false
Effect @DRUG$ on the : Clonazepam appear alter the of phenytoin , @DRUG$	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
These increased exposures of norethindrone and @DRUG$ should be taken into consideration when selecting an oral contraceptive for women taking @DRUG$.	DDI-false
: @DRUG$ reduced @DRUG$ response to furosemide normovolemic healthy approximately mean sodium and output decreased % )	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
It is suggested that in patients receiving dopamine HCl, alternatives to @DRUG$ should be used if @DRUG$ therapy is needed.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
( 1968 , higher serum @DRUG$ @DRUG$ after of probenecid are not slower renal also to an altered in the body .	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
@DRUG$ did alter the plasma levels @DRUG$ when .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
These other diuretics , , estrogens phenytoin , @DRUG$ , @DRUG$ , channel isoniazid	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
If with CYP3A4 activity ( such as ketoconazole , @DRUG$ , indinavir , erythromycin etc ) indicated , reduction the @DRUG$ .	DDI-advise
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ may decrease the effect of phenothiazines, levodopa, and @DRUG$.	DDI-effect
@DRUG$ @DRUG$ renal tubular of produces increase in level	DDI-false
Drugs alter imatinib plasma that may increase plasma : Caution @DRUG$ with inhibitors of the CYP3A4 family , @DRUG$ , , clarithromycin	DDI-advise
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with dexamethasone co-administration, leading to alterations in seizure control.	DDI-false
The solutions containing @DRUG$ @DRUG$ receiving monoamine oxidase tricyclic antidepressants may , prolonged .	DDI-false
@DRUG$: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
@DRUG$, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Digoxin: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-mechanism
Pharmacokinetic Interaction between @DRUG$ and @DRUG$ or rifampin in healthy males.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, @DRUG$, and alcohol.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
following examples of substances that reduce corticosteroids niacin , danazol @DRUG$ @DRUG$ , , phenothiazine , , thyroid hormones , ( e.g. in contraceptives .	DDI-false
: of @DRUG$ @DRUG$ resulted in 83 % increase nelfinavir plasma a % indinavir plasma	DDI-mechanism
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Particular recommended @DRUG$ with substrates have a therapeutic ( , @DRUG$ .	DDI-advise
evaluate the chemotherapy on the clinical of patients with , systemic , lymphoma ) retrospectively a group of with who treated with the cyclophosphamide doxorubicin @DRUG$ chemotherapy plus with 80 patients who with chemotherapy CHOP-like i.e. , cyclophosphamide , doxorubicin teniposide , prednisone @DRUG$ ) without antiretroviral .	DDI-false
Due inter-patient variability and limited sampling , the the concurrent @DRUG$ and @DRUG$ is	DDI-false
@DRUG$ as @DRUG$ , nifedipine , inhibit in vitro platelet intravascularly	DDI-false
@DRUG$ enhance of @DRUG$ associated	DDI-effect
Other may neuromuscular of nondepolarizing agents such as NUROMAX include certain e. @DRUG$ , tetracyclines , , @DRUG$ lincomycin , clindamycin , and sodium ) , , local anesthetics , and quinidine	DDI-false
to plasma is not significantly altered by diazepam , @DRUG$ , or @DRUG$.	DDI-false
Digoxin, @DRUG$ and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
When is co-administered inducers of drug clearance , such efavirenz , nevirapine , , @DRUG$ of a mg of @DRUG$ should	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Drug/Laboratory Interactions @DRUG$ , @DRUG$ known to a positive Coombs test .	DDI-false
- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-false
Rhabdomyolysis been in patients @DRUG$ administered alone ( at recommended ) immunosuppressive drugs	DDI-effect
Terfenadine : @DRUG$ @DRUG$ resulted the appearance unchanged in	DDI-false
ampicillin oxacillin @DRUG$ , @DRUG$ cephalothin , erythromycin , sulfamethoxazole have influence in vitro on the in .	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
) many for other @DRUG$ , phenothiazines , and the antiarrhythmics @DRUG$ ) .	DDI-false
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Amiodarone taken with procainamide for less seven days plasma concentrations @DRUG$ and @DRUG$ by and 33 % .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Nephrotoxic : of and nephrotoxic [ e.g. , , , @DRUG$ , and amikacin ) amphotericin , , @DRUG$ , vancomycin , agents ] is	DDI-false
: No significant differences observed pharmacokinetics @DRUG$ or @DRUG$ with addition of given as a single dose .	DDI-false
Probenecid May decrease renal @DRUG$ in and/or @DRUG$ .	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-false
Although specific studies not performed , coadministration drugs mainly eg , blockers , , , warfarin tacrolimus , cyclosporine derivatives , pimozide @DRUG$ , , alprazolam and ) plasma concentrations when @DRUG$ ;	DDI-mechanism
@DRUG$ was occasionally intensify of @DRUG$ taken concomitantly patients suffering hypertension	DDI-effect
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, simvastatin).	DDI-false
These thiazides and @DRUG$ phenothiazines , thyroid products estrogens oral @DRUG$ , phenytoin , nicotinic sympathomimetics , blocking , isoniazid .	DDI-false
That Not Coadministered With VIRACEPT Antiarrhythmics @DRUG$ : astemizole : Antimycobacterial : @DRUG$ midazolam , GI motility : cisapride	DDI-false
- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	DDI-advise
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
@DRUG$ Coadministration of @DRUG$ 32 % and 207 increase in rifabutin	DDI-false
concomitant In clinical trials , the in treated Acamprosate concomitantly @DRUG$ @DRUG$ including similar to subjects taking placebo with these concomitant	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Example ciprofloxacin , , doxycycline @DRUG$ , nefazodone propofol , inhibitors , , @DRUG$.	DDI-false
possessing ( , @DRUG$ ( cytotoxic chemotherapy , ( e.g. ) or hepatotoxic methotrexate @DRUG$ with PROLEUKIN may toxicity systems	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
indicate that ketoconazole potently of @DRUG$ resulting in	DDI-false
In % patients , the dose @DRUG$ had to be reduced in to maintain @DRUG$ concentrations the , in the remainder needed	DDI-false
Amiodarone, @DRUG$, @DRUG$	DDI-false
@DRUG$ significantly decreased the of @DRUG$ by , but effect on pharmacokinetics .	DDI-mechanism
Magnesium- antacids products ferrous sulfate ( iron ) @DRUG$ other or Videx ( @DRUG$ or the for oral should taken hours 2 hours after .	DDI-false
@DRUG$ may antihypertensive effect of inhibitors including @DRUG$.	DDI-effect
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (@DRUG$ substrate) given for local @DRUG$.	DDI-false
Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
, , @DRUG$ @DRUG$ Rifabutin , Rifampin ,	DDI-false
The @DRUG$ @DRUG$ does affect pharmacokinetics either alcohol acamprosate	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
@DRUG$: @DRUG$ BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.	DDI-false
The pressor effects of @DRUG$ such as @DRUG$ or norepinephrine are enhanced by Bretylium Tosylate.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Interactions may occur between @DRUG$ supplements and other non-steroidal anti-inflammatory and herbs as ( Allium and @DRUG$ Ginkgo biloba .	DDI-int
Hormonal Contraceptives Including Oral , , and : An of bosentan and @DRUG$ decreases @DRUG$ and ethinyl % 31 ,	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Coadministration of @DRUG$ and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.	DDI-mechanism
@DRUG$ Potentiation of @DRUG$ and ) almost seen patients receiving amiodarone can result in .	DDI-false
( ) , ( mg/kg , @DRUG$ ( 0.25 mg/kg fluoxetine ( @DRUG$ 30 mg/kg ) was .	DDI-false
The hypoglycemic action sulfonylureas be potentiated by @DRUG$ and that bound , , sulfonamides , @DRUG$ , monoamine oxidase , adrenergic blocking .	DDI-false
@DRUG$ ( e.g. tranquilizers @DRUG$ and ) have or potentiating effects	DDI-false
The pressor effects of @DRUG$ such as dopamine or norepinephrine are enhanced by @DRUG$.	DDI-effect
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-effect
A association , less marked , been suggested with , , @DRUG$ , @DRUG$ , , and 72 )	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-mechanism
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	DDI-false
Benzylpenicillin ampicillin @DRUG$ cephalothin , @DRUG$ , and have no influence binding of diclofenac in	DDI-false
A oral @DRUG$ oral @DRUG$ leading hypoglycemia has been	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs may enhance the of nondepolarizing antibiotics ( e. , tetracyclines bacitracin , polymyxins @DRUG$ , and @DRUG$ magnesium salts , lithium local , procainamide and quinidine	DDI-false
@DRUG$ or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
The of sulfonylurea certain drugs including nonsteroidal and drugs are highly , , @DRUG$ @DRUG$ , , beta adrenergic agents .	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Antagonists @DRUG$ is dopamine it is possible antagonists , neuroleptics ( , , thioxanthenes or metoclopramide may diminish of	DDI-false
Injection injection , like injectable benzodiazepines of central system when alcohol @DRUG$ , @DRUG$ MAO . concomitantly with injectable lorazepam increased incidence of sedation , and irrational behavior been observed	DDI-false
effectiveness progestin-only is by hepatic phenytoin @DRUG$ , and @DRUG$ drug	DDI-false
While the inhibitors @DRUG$ ) , paroxetine , @DRUG$ P450 2D6 , they may the of	DDI-false
: Enalapril and enalapril been concomitantly @DRUG$ , agents , and @DRUG$ without evidence of clinically significant interactions	DDI-false
The may by @DRUG$ , alcohol , @DRUG$ , monoamine inhibitors phenothiazines psychotropic , drugs that CNS	DDI-false
Dopamine Antagonists : apomorphine a dopamine is possible that dopamine antagonists such the ( @DRUG$ @DRUG$ , ) or of .	DDI-false
Garlic capsules be used while @DRUG$ FORTOVASE ) @DRUG$ plasma	DDI-false
ACE Inhibitors Angiotensin Heart Infarction)- In ( INSPRA 25 50 mg received or II antagonists ( @DRUG$/@DRUG$ )	DDI-false
While all the @DRUG$ (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
association , though less , been barbiturates , @DRUG$ phenytoin @DRUG$ griseofulvin , topiramate with 72 .	DDI-false
To of chemotherapy plus HAART course of patients HIV-related , non-Hodgkin HIV-NHL , retrospectively of with HIV-NHL who treated with the cyclophosphamide , , , and prednisone CHOP HAART patients who treated CHOP chemotherapy or ( i.e. , , and @DRUG$ @DRUG$ without .	DDI-false
@DRUG$ @DRUG$ ( 1000 mg twice daily pharmacokinetics of and	DDI-false
@DRUG$ therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-false
: Amiodarone should receiving , a inhibitor @DRUG$ antagonists ( , CYP3A4 , a the bradycardia , arrest , AV block ;	DDI-false
progestin-only is hepatic such as the anticonvulsants phenytoin , @DRUG$ and barbiturates , and the @DRUG$ rifampin	DDI-false
@DRUG$ : Ephedrine enhance the clearance , levels lessened physiologic requiring @DRUG$ dosage .	DDI-false
@DRUG$ In studies in peripheral cells U937 cells revealed @DRUG$ significantly inhibited zalcitabine phosphorylation in a dependent manner	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	DDI-false
on known metabolic clinically drug are not between VIRACEPT @DRUG$ clarithromycin or fluconazole .	DDI-false
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with @DRUG$ were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.	DDI-false
Before this , tell or pharmacist prescription nonprescription may use , especially of : , , , amphotericin B cyclosporine @DRUG$ drugs ( ) , @DRUG$ ,	DDI-false
Drugs have neuropathy include antiretroviral nucleoside analogues chloramphenicol , @DRUG$ , @DRUG$ , , gold , hydralazine , , metronidazole nitrofurantoin , ,	DDI-false
HIV : Indinavir mg t.i.d ) co-administered 10 mg resulted in in @DRUG$ AUC , increase vardenafil Cmax a 2-fold @DRUG$ half-life	DDI-false
Alpha-blockers When @DRUG$ or 20 to volunteers simultaneously or hours after 10 mg of @DRUG$ , significant hypotension developed in a substantial .	DDI-effect
Garlic Capsules Garlic capsules should not be used while taking saquinavir sole @DRUG$ to risk @DRUG$ plasma concentrations .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
should be frequently if @DRUG$ administered concomitantly with @DRUG$.	DDI-advise
Pharmacokinetic studies have demonstrated that omeprazole and @DRUG$ significantly increased the systemic exposure of @DRUG$ and/or its major metabolites.	DDI-mechanism
however it unlikely that lamivudine concentration is significance , as @DRUG$ is a deoxycytidine kinase than	DDI-false
The patients in RA one or the concomitant ORENCIA , @DRUG$ corticosteroids TNF blocking agents , @DRUG$ , , leflunomide sulfasalazine anakinra .	DDI-false
Multivitamins or other products containing @DRUG$ zinc @DRUG$ or sucralfate not be with , or 2 , the may interfere with absorption in lower and levels of .	DDI-false
In addition, @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In Phase I escalating doses TAXOL 110 - ) and cisplatin 50 or was more @DRUG$ was @DRUG$ with the ( ie before cisplatin )	DDI-effect
Patients azathioprine and @DRUG$ have a dose reduction of @DRUG$ to usual dose	DDI-false
DISCUSSION : @DRUG$ potent inhibitor CYP3A4 enzyme for @DRUG$ metabolism	DDI-mechanism
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
Should Not @DRUG$ : quinidine Antihistamines : , Antimigraine : ergot derivatives : rifampin @DRUG$ midazolam , triazolam agents	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Alcohol @DRUG$ or @DRUG$ : orthostatic hypotension occur .	DDI-false
@DRUG$ the inhibitors metabolized ( i.e. @DRUG$ cerivastatin .	DDI-mechanism
Potential between a of CYP3A4 and @DRUG$ ( saquinavir indinavir , and @DRUG$ , are inhibitors CYP3A4 , been evaluated in trials .	DDI-false
Colestipol-Concomitant intake colestipol @DRUG$ may the absorption of	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
It is that increased between @DRUG$ high affinity binding sites dopamine2- underlies @DRUG$ after their prolonged	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	DDI-false
Potential between   ( carbamazepine @DRUG$ phenobarbital phenytoin , primidone and @DRUG$ ) also by evaluating the serum of levetiracetam and these AEDs during clinical studies .	DDI-false
levels of several @DRUG$ to be by concomitant of or inhibitors ( , @DRUG$ , fluoxetine and the administration hepatic enzyme e.g. barbiturates ) such effect may be anticipated with CMI as well	DDI-mechanism
@DRUG$ mg/kg once every hours for days ) and @DRUG$ ( single dose ) had significant drug , the INR was not altered	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
such @DRUG$ sulfinpyrazone inhibit renal @DRUG$.	DDI-mechanism
of Other : @DRUG$ @DRUG$ ( mg/day to patients tiagabine effect on pharmacokinetics	DDI-false
the literature suggest that levels of @DRUG$ ( and its active doxorubicinol ) @DRUG$ and doxorubicin used combination .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
@DRUG$: It has not been established if there is a pharmacokinetic interaction between @DRUG$ and combined oral contraceptives.	DDI-false
Promethazine: Coadministration of a single dose of @DRUG$ and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-mechanism
@DRUG$ reduce absorption @DRUG$.	DDI-false
@DRUG$ ( tricyclic , @DRUG$ or other or digitalis glycosides arbutamine may additive inotropic chronotropic effects	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$ and @DRUG$.	DDI-false
@DRUG$ a antibiotic , may antagonize the effect @DRUG$ and concurrent use of drugs be avoided .	DDI-effect
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Interactions Keppra   And Other @DRUG$ ( ) @DRUG$ mg had no disposition phenytoin with	DDI-false
antifungals , ciprofloxacin , @DRUG$ , erythromycin , imatinib , nefazodone , nicardipine , @DRUG$ , quinidine , and verapamil .	DDI-false
Although have not coadministration with drugs ( eg calcium channel blockers , , disopyramide , quinine , amiodarone warfarin , tacrolimus , cyclosporine , ergot pimozide carbamazepine fentanyl @DRUG$ , @DRUG$ have elevated plasma concentrations when coadministered saquinavir ;	DDI-false
There was apparent pharmacokinetic @DRUG$ @DRUG$ following administration 10 , respectively ) drug	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
It is recommended that serum lithium levels be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, @DRUG$, or metoclopramide.	DDI-false
Other drug interactions @DRUG$, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Patients receiving other narcotic , general phenothiazines , , tricyclic antidepressants other @DRUG$ ) with @DRUG$ may an CNS depression .	DDI-effect
Tricyclic antidepressants to the effect of not known use these @DRUG$ humans with the IOP lowering effect .	DDI-false
@DRUG$ agents reserpine glutamic HCl @DRUG$ fruit juices , etc ) lower of .	DDI-false
The risk of treatment drugs of this class increased with concurrent of cyclosporine fibric acid derivatives , @DRUG$ nicotinic	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of @DRUG$ on the availability of digoxin and digitoxin.	DDI-effect
I trial @DRUG$ ( - mg/m2 ) and 50 or 75 mg/m2 as sequential , when given @DRUG$ with before cisplatin	DDI-false
Other concomitant Although specific studies not performed doses of mg more with acetaminophen , acid a-blockers enzyme ( ) inhibitors , @DRUG$ , , beta blockers , nitrates , H2 antagonists , reductase , @DRUG$ ( also as NSAIDs ) anti-infectives evidence significant	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Curariform muscle relaxants and other drugs , ether @DRUG$ , , @DRUG$ potentiate neuromuscular used with extreme in being treated with Coly-Mycin M Parenteral .	DDI-false
Pretreatment megakaryocytes with @DRUG$ ( 50 ) @DRUG$-induced .	DDI-effect
phenobarbital/valproic acid quinidine/lidocaine , and valproic	DDI-false
@DRUG$ ('@DRUG$') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Drugs That Inhibit CYP3A4 (@DRUG$) CYP3A4 is a major metabolic pathway for elimination of @DRUG$.	DDI-false
Central Depressants The use of   ( @DRUG$ transdermal ) other central system but not opioids , sedatives hypnotics tranquilizers ( , , general , phenothiazines skeletal muscle , @DRUG$ , may depression , hypotension profound sedation result in or death	DDI-effect
that been include analogues , cisplatin dapsone disulfiram , ethionamide , glutethimide , hydralazine , iodoquinol , , @DRUG$ , ribavirin	DDI-false
Antiarrhythmics @DRUG$ , , @DRUG$ , to for	DDI-false
Therophylline : A study has that of isoniazid and theophylline plasma levels of @DRUG$ , and in some decrease in of @DRUG$.	DDI-false
Haloperidol: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-effect
@DRUG$ : Coadministration of @DRUG$ in an nelfinavir A.C.	DDI-false
may @DRUG$ , @DRUG$ , and ASA and may increase the toxicity salicylates	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
therefore, the use of @DRUG$ does not necessitate an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
The following are that may the blood-glucose-lowering : niacin , danazol , @DRUG$ sympathomimetic , epinephrine , @DRUG$ ) , somatropin , hormones , e.g. .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ has been administered with tolazoline, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
No pharmacokinetic interactions between @DRUG$ and isoflurane, @DRUG$, alfentanil, and midazolam have been demonstrated.	DDI-false
@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
@DRUG$ Concomitant administration of @DRUG$ ( 6 ) warfarin ( 25 oral ) had effect the of either and the not altered .	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-int
@DRUG$: Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-false
Alkalinizing agents: Gastrointestinal alkalinizing agents (@DRUG$, etc.) increase absorption of @DRUG$.	DDI-mechanism
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
: Clinical studies , as post-marketing , that @DRUG$ the natriuretic effect of @DRUG$ in patients .	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
reactions have been high dose agents , specifically , @DRUG$ @DRUG$ and interferon-alfa .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
While in studies conducted estazolam inducers of , that are potent CYP3A such as @DRUG$ , barbiturates would be expected @DRUG$	DDI-false
@DRUG$/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Data suggest that coadministration of oral @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG.	DDI-effect
No information is available about the use of @DRUG$ concurrently with @DRUG$.	DDI-false
@DRUG$ Receptor studies of with hypertension the addition @DRUG$ 50 to 100 to ACE and II receptor antagonists increased mean slightly ( 0.09 - mEq/L ) .	DDI-false
Considerable caution if @DRUG$ administered concurrently Phenurone ( @DRUG$ paranoid symptoms have during combination	DDI-advise
@DRUG$ elimination of @DRUG$ serum and t1/2 .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
In pharmacology of @DRUG$ magnesium , with serum and compared fosinopril , that impair	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
@DRUG$: The potential for pharmacokinetic drug-drug interactions between @DRUG$ and other agents has not been formally studied.	DDI-false
glycosides may potentiate @DRUG$ toxicity .	DDI-effect
In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.	DDI-false
Although specific studies been coadministration with drugs mainly CYP3A4 ( eg , channel blockers dapsone @DRUG$ amiodarone , quinidine , warfarin , tacrolimus , , ergot derivatives pimozide , carbamazepine , , @DRUG$ , , may plasma coadministered with saquinavir ;	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, @DRUG$, anesthetics) should be considered.	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
: Patients on Diuretic Therapy : @DRUG$ and whom diuretic therapy , occasionally an reduction of after initiation of @DRUG$ or enalaprilat	DDI-effect
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
The intensity and time course of anticoagulant interference phenobarbital , glutethimide , @DRUG$ @DRUG$ systematically investigated patients receiving .	DDI-false
Indinavir of @DRUG$ with resulted an in @DRUG$ AUC increase in indinavir plasma A.C.	DDI-false
The following are examples substances may reduce blood-glucose-lowering , danazol , diuretics , terbutaline , isoniazid , @DRUG$ thyroid , estrogens , @DRUG$ ( contraceptives )	DDI-false
@DRUG$ such as verapamil diltiazem @DRUG$ , inhibit activation in vitro , and intravascularly	DDI-false
Antacids : clinical @DRUG$ , @DRUG$ and ) with levels and as compared with suggesting may impair absorption fosinopril .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
@DRUG$ is to concentrations @DRUG$ have CYP3A4 lovastatin .	DDI-mechanism
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
Patients treated with @DRUG$ may be resistant to the effects of @DRUG$.	DDI-effect
however, it adversely affected response duration suggesting that @DRUG$ should not be administered with HEXALEN and/or @DRUG$.1	DDI-advise
is structurally distinct currently @DRUG$ @DRUG$ , pravastatin , to biopharmaceutical the this class .	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
: Since apomorphine a dopamine possible dopamine the phenothiazines butyrophenones , @DRUG$ , may the effectiveness @DRUG$.	DDI-effect
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
Concomitant @DRUG$ doxorubicin , and chemotherapy plus @DRUG$ in patients with immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
drug interactions @DRUG$ and dextropropoxyphene effect the pharmacokinetics	DDI-false
Additive adverse effects resulting blockade occur when is concomitantly with other , amantadine , haloperidol , phenothiazines monoamine oxidase ) , @DRUG$ or @DRUG$.	DDI-false
Be Coadministered With @DRUG$ : amiodarone , quinidine : @DRUG$ , terfenadine derivatives Antimycobacterial agents rifampin Benzodiazepines midazolam , triazolam motility :	DDI-advise
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
may with like @DRUG$ ): MAOI theoretically affect flupenthixol - Arecoline - - Ethanol and depression Tricyclic antidepressants Flupenthixol increases @DRUG$	DDI-false
results of these is concluded @DRUG$ be with zidovudine	DDI-false
@DRUG$: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.	DDI-false
Antiacid clarithromycin @DRUG$ , Ketoconazole Phenytoin , Phenobarbitol @DRUG$ , Rifabutin Ritanovir ,	DDI-false
@DRUG$ In diabetic patients receiving @DRUG$ tolbutamide no significant effects were seen on plasma levels or fasting blood .	DDI-false
@DRUG$ has reported patients receiving lithium elimination sodium including	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
No significant drug-drug interactions been found in interaction with @DRUG$ @DRUG$ cimetidine and .	DDI-false
no between @DRUG$ Levo-Dromoran has been observed , recommended with	DDI-false
These drugs the and @DRUG$ corticosteroids , phenothiazines , thyroid , estrogens , @DRUG$ nicotinic acid sympathomimetics , calcium channel blocking drugs and .	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and @DRUG$) decrease gefitinib metabolism and increase gefitinib plasma concentrations.	DDI-false
Potential drug interactions and other AEDs @DRUG$ , @DRUG$ , phenytoin , and valproate were by serum concentrations levetiracetam these AEDs during placebo-controlled clinical studies	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
@DRUG$: Concomitant use of anticholinesterase agents and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
BACKGROUND : effects of combined administration bombesin hydrochloride ( ) , @DRUG$ , on incidence of intestinal adenocarcinomas induced by @DRUG$ ( AOM ) intestinal cancers in rats	DDI-false
pharmacokinetic studies have of warfarin Lodine ( and tablets results in protein of @DRUG$ , there was in the free @DRUG$.	DDI-false
the pressor activity @DRUG$ compared to , large of @DRUG$ should used with pressor agents careful patient	DDI-false
@DRUG$ should not be used concomitantly with @DRUG$ because of the possibility of ototoxicity.	DDI-advise
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Drugs be 3A of Clinical Significance Basis Clinical Studies Involving @DRUG$ caution during @DRUG$ ): Coadministration of increased maximum of alprazolam by 46 % , clearance by % , increased by 17 % and performance .	DDI-false
Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Drugs That Should Not Be Coadministered VIRACEPT : , Antihistamines astemizole , terfenadine : Antimycobacterial agents : @DRUG$ @DRUG$ triazolam motility agents cisapride	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	DDI-false
ampicillin @DRUG$ , doxycycline , cephalothin , and @DRUG$ no in on the binding of human serum	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
@DRUG$ : should be used with caution receiving -receptor agents , ) or calcium channel , , diltiazem , @DRUG$ because possible potentiation bradycardia AV	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Dexamethasone: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, aminopyrine and @DRUG$.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (@DRUG$ substrate) given for local anesthesia.	DDI-false
Although inhibition of CYP 3A4/5 by @DRUG$ and @DRUG$ did occur at high concentrations, it is not likely to be of clinical significance.	DDI-false
@DRUG$s and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
INOmax has been administered with tolazoline, dopamine, @DRUG$, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
@DRUG$: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.	DDI-false
and @DRUG$ similarly inhibit @DRUG$-induced prostatic .	DDI-effect
Although studies have not been , coadministration drugs are mainly by CYP3A4 eg , calcium blockers , @DRUG$ , quinidine warfarin , tacrolimus ergot , , @DRUG$ fentanyl , alprazolam and ) may elevated plasma concentrations when coadministered saquinavir	DDI-false
In patients receiving @DRUG$ and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, secobarbital and @DRUG$;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	DDI-false
No Important Interactions To Date not have important pharmacokinetic with captopril , beta-blockers , @DRUG$ , , carvedilol , @DRUG$ or .	DDI-false
The immediate release , not coat-core of @DRUG$ plasma @DRUG$ by 20 %	DDI-mechanism
aim to interaction neurotensin and enkephalins its @DRUG$ , or @DRUG$ on the effect of these intracisternal .	DDI-false
which enhance the nondepolarizing agents such antibiotics ( g. @DRUG$ , polymyxins , clindamycin , , ) , @DRUG$ salts , and	DDI-false
: @DRUG$ have produced an elevation of reduction renal @DRUG$	DDI-false
Other therapies profile treated @DRUG$ concomitantly with ( including @DRUG$ , or non-opioid analgesics was that placebo	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Although have , coadministration with mainly by ( , , @DRUG$ , quinine , quinidine , , ergot , , , alprazolam , and triazolam ) have plasma when with @DRUG$ ;	DDI-mechanism
@DRUG$ should not be taken within 2 hours of @DRUG$.	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Example include azole antifungals , clarithromycin , diclofenac , doxycycline , , , nefazodone nicardipine , @DRUG$ , @DRUG$ verapamil	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Although specific studies have , coadministration drugs mainly by CYP3A4 eg , calcium disopyramide quinine quinidine , @DRUG$ , @DRUG$ , , , carbamazepine , alfentanyl alprazolam triazolam ) may elevated concentrations when coadministered saquinavir ;	DDI-false
METHOD : This randomized of were randomly to receive @DRUG$ at doses 0.5 , 1 or 2 daily with @DRUG$ and prednisone	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
@DRUG$ @DRUG$ and pyrantel the effects piperazine .	DDI-false
of doses of warfarin , @DRUG$ or digoxin irbesartan administration for 7 had warfarin ) or of @DRUG$.	DDI-false
The majority patients RA clinical or more following medications @DRUG$ , blocking agents chloroquine , , hydroxychloroquine leflunomide @DRUG$	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and @DRUG$ for injection concentrate) should not be treated with @DRUG$.	DDI-advise
Other concomitant Although specific were performed , @DRUG$ 1 mg or more used studies with acetaminophen a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines beta blockers , calcium-channel , , H2 , reductase , prostaglandin to as NSAIDs ) and anti-infectives	DDI-false
@DRUG$- @DRUG$-containing antacids , products containing ferrous ( , multivitamin metal cations , ( ) tablets the powder for solution be taken within 3 2 FACTIVE .	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
@DRUG$ excess decrease the Carbimazole and iodine deficiency increase the effect @DRUG$.	DDI-false
Should With VIRACEPT Antiarrhythmics amiodarone , @DRUG$ : , Antimigraine ergot derivatives Antimycobacterial : Benzodiazepines midazolam triazolam : @DRUG$	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (@DRUG$, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ or excess may effect Carbimazole and @DRUG$ deficiency the of Carbimazole	DDI-false
Pyrantel (e.g., @DRUG$) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
some the of a anti-inflammatory , of loop , @DRUG-DRUG$.	DDI-false
When the @DRUG$ was administered 30 minutes after the sumatriptan nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Drugs have associated with neuropathy include , chloramphenicol , dapsone ethionamide gold , , iodoquinol , @DRUG$ metronidazole nitrofurantoin phenytoin @DRUG$ ,	DDI-false
The of @DRUG$ ranitidine is when with @DRUG$.	DDI-mechanism
@DRUG$: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
@DRUG$ : In steady-state cerivastatin Cmax 50 and 24 after 10 days with of @DRUG$ , a of P450	DDI-false
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and Descarboethoxyloratadine After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-mechanism
@DRUG$: @DRUG$ have been reported to cause a significant decrease in corticosteroid clearance.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	DDI-false
Iodine or @DRUG$ of , iodine increase the	DDI-false
Cation-Containing of quinolone , including @DRUG$ , cation-containing products as magnesium sucralfate chewable/buffered or pediatric or , or substantially the of @DRUG$ , in and urine levels considerably	DDI-mechanism
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
The pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of cimetidine (300 mg QID).	DDI-false
These data indicate that @DRUG$ does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of levetiracetam.	DDI-false
used external subcutaneous infusion @DRUG$ NovoLog should mixed with any other @DRUG$ diluent .	DDI-false
These drugs include and other @DRUG$ , estrogens oral nicotinic channel drugs , and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The concomitant use other CYP3A4 inhibitors diltiazem and @DRUG$ may also in an increase @DRUG$ which drug effects and may cause serious depression	DDI-false
@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Cohort 1 then received plus rifabutin 10 2 received @DRUG$ plus @DRUG$	DDI-false
Because @DRUG$ been to any beyond obtained with alone and because the rate @DRUG$ Nalfon and is not	DDI-false
interaction was not in a clinical trial there have more concomitant therapies ( , @DRUG$ acid ) @DRUG$.	DDI-false
side , cefoperazone , @DRUG$ , ) or ( @DRUG$ ) can vitamin deficiency and hypoprothrombinemia	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
other antiplatelet agents or @DRUG$ used @DRUG$ the bleeding	DDI-effect
The effect of @DRUG$  on @DRUG$ was not studied.	DDI-false
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with @DRUG$ plus @DRUG$.	DDI-effect
reactions have been in patients receiving regimens containing @DRUG$ @DRUG$ , cis-platinum .	DDI-effect
@DRUG$/valproic acid , quinidine/lidocaine , valproic acid/phenobarbital .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, @DRUG$, pimozide.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
inhibitors of CYP3A4 , @DRUG$ , troleandomycin , ritonavir @DRUG$ to behave similarly .	DDI-false
interact @DRUG$ ( altered , and other inducers hepatic microsomal enzyme ( effect of @DRUG$ corticosteroids ( increased of	DDI-false
Inhibitors ( SSRIs ( @DRUG$ , paroxetine ) been rarely reported cause , hyperreflexia and incoordination with @DRUG$.	DDI-effect
Therefore, when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Coadministration of @DRUG$ @DRUG$ of terfenadine , resulting of life- threatening cardiac and .	DDI-mechanism
Other Agents: @DRUG$ has been used concomitantly with nitrates and/or @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Caution should be exercised when administering @DRUG$ with drugs that are known to inhibit phosphatase activities (e.g., @DRUG$).	DDI-advise
No pharmacodynamic have in studies @DRUG$ , warfarin , @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ zinc or other metal cations , Videx @DRUG$ ) the powder for taken 3 before or 2 hours	DDI-false
blockers , such as @DRUG$ , @DRUG$ in and decrease .	DDI-false
Bacteriostatic : @DRUG$ , erythromycins sulfonamides or @DRUG$ may interfere bactericidal	DDI-false
Psychoactive : Hallucinations been reported @DRUG$ in patients ( fluoxetine , thiothixene @DRUG$	DDI-effect
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, @DRUG$, and cimetidine.	DDI-false
@DRUG$ such , @DRUG$ , inhibit activation in vitro , decrease platelet adhesion	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
are of that reduce blood-glucose-lowering effect danazol @DRUG$ sympathomimetic e.g. , salbutamol , , phenothiazine , somatropin , @DRUG$ , e.g. contraceptives .	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	DDI-false
substrate @DRUG$ considered in inducers as @DRUG$ phenytoin and	DDI-false
Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	DDI-effect
It is recommended not to exceed a single 5 mg dose of @DRUG$ in a 24-hour period when used in combination with @DRUG$.	DDI-advise
@DRUG$/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
To the impact plus HAART on course of patients , non-Hodgkin lymphoma ) the retrospectively with HIV-NHL were @DRUG$ doxorubicin vincristine , prednisone ) chemotherapy regimen a who were or CHOP-like regimen ( , @DRUG$ teniposide bleomycin receiving .	DDI-false
Other : In ( 7 - 10/interaction study of azathioprine @DRUG$ , D-penicillamine , prednisolone doxycycline , digitoxin affect the levels	DDI-false
from in studies of @DRUG$ suggest interaction the , amiodarone nicardipine , and	DDI-int
- , diabetes medicine you take by mouth ) of oral @DRUG$ may increase the of blood and/or side effects or oral @DRUG$	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
drugs enhance neuromuscular blocking of agents as NUROMAX e. g. , tetracyclines @DRUG$ , polymyxins , lincomycin @DRUG$ , and colistimethate ) magnesium salts local procainamide quinidine	DDI-false
@DRUG$ Lodine with its protein binding is , the @DRUG$ altered .	DDI-false
@DRUG$ : Chlorpromazine and , thus stimulant of @DRUG$ and can used amphetamine poisoning	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Keppra other carbamazepine , gabapentin , lamotrigine , phenobarbital @DRUG$ primidone ) were also by concentrations of and these @DRUG$ placebo-controlled studies .	DDI-false
Single doses of either @DRUG$ or colestipol resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-mechanism
and/or aluminum-containing antacids @DRUG$ preparations containing zinc or @DRUG$ didanosine ) tablets or oral taken hours or 2 hours FACTIVE .	DDI-false
Results in multiple sclerosis taking   and @DRUG$ (   mcg IM weekly were with to for dose adjustment @DRUG$ acetate .	DDI-false
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (@DRUG$).	DDI-false
A association , though less barbiturates , , , @DRUG$ topiramate , @DRUG$ 72 .	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Data from studies benzodiazepines than alprazolam suggest possible for : ergotamine , cyclosporine , @DRUG$ , , @DRUG$.	DDI-false
therefore necessary to be acquainted clinical paraclinical @DRUG$ deficit to @DRUG$ deficiency due insufficient magnesium intake which only requires oral physiological and related dysregulation the control magnesium status less specific regulation of dysregulation .	DDI-false
Antihypertensive Medications and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, @DRUG$), though this has not been studied	DDI-mechanism
Additive resulting cholinergic blockade may LEVSIN concomitantly other @DRUG$ @DRUG$ or antihistamines	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for Digoxin.	DDI-false
In the @DRUG$ study, @DRUG$ had no effect on the prothrombin time or other pharmacodynamic parameters.	DDI-false
@DRUG$ the predominant is only weak inducer UDP-glucuronyl , have that are mainly eliminated by conjugation transferase e.g. , acid @DRUG$ ) .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
It of barbiturates and @DRUG$ and may also increase the toxicity @DRUG$.	DDI-false
@DRUG$ : sulfoxide concentrations bile fluid ( about cyst with @DRUG$ ( 10 mg/kg/day compared with albendazole ( )	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Before this tell doctor or pharmacist all products you use especially : @DRUG$ ( gentamicin , amikacin , B , cyclosporine @DRUG$ drugs ( e.g. ibuprofen ) ,	DDI-false
The effects of @DRUG$ ) inositol 1,4,5-trisphosphate (@DRUG$)-induced responses rat bone megakaryocytes with the patch-clamp recording microfluorometry	DDI-false
The examples substances may reduce the effect corticosteroids niacin danazol , , sympathomimetic e.g. , @DRUG$ salbutamol , , , derivatives , , @DRUG$ estrogens , progestogens e.g. , in contraceptives	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
@DRUG$ rifampin CONTRAINDICATED the of this saquinavir in regimen reduces concentrations @DRUG$.	DDI-false
Based on of profound hypotension and of was administered @DRUG$ , of apomorphine with 5HT3 antagonist class , for example , @DRUG$ granisetron , palonosetron , alosetron is contraindicated	DDI-false
of @DRUG$ @DRUG$ led plasma of three drugs .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and ranitidine.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
Patients treated with @DRUG$ and @DRUG$ concomitantly may need to be monitored for increases in INR and prothrombin time.	DDI-effect
Interaction with @DRUG$, lidocaine and @DRUG$ has also been reported to produce adverse clinical effects.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
@DRUG$-containing ferrous sulfate ( , preparations other ( @DRUG$ ) pediatric oral solution not be within 3 before or 2 hours after FACTIVE .	DDI-false
Coingestion of @DRUG$ with @DRUG$, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
@DRUG$ (Phenytoin): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
@DRUG$: Simvastatin (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
clinical trials , FLOLAN was digoxin , diuretics , , supplemental pharmacokinetic substudy patients with heart receiving @DRUG$ or in whom therapy with initiated apparent clearance for furosemide n = and digoxin = ) decreased 15 % , the second therapy had returned baseline by	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
OTHER Although specific interaction were performed , clinical studies @DRUG$ was with converting ( ACE , @DRUG$ calcium-channel and nonsteroidal anti-inflammatory ( NSAIDs ) adverse	DDI-false
Although specific have performed , coadministration mainly metabolized calcium blockers dapsone , , amiodarone quinidine warfarin , tacrolimus cyclosporine @DRUG$ , @DRUG$ , , triazolam ) elevated when coadministered with	DDI-false
@DRUG$-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Prednisone/@DRUG$: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
These drugs include the thiazides , corticosteroids , , estrogens oral , phenytoin , sympathomimetics , @DRUG$ and @DRUG$.	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Although the interaction inhibitors itraconazole @DRUG$ , ) not exposures to @DRUG$ may almotriptan medications .	DDI-false
: on hypotension loss of consciousness when was administered with , the use with of the 5HT3 , for example ondansetron , granisetron @DRUG$ , @DRUG$ ) is .	DDI-false
Plasma exposure (AUC) to @DRUG$ was increased 62% when coadministered with @DRUG$ and 38% when coadministered with ketoconazole.	DDI-mechanism
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
5HT3 Antagonists : Based on of and of when @DRUG$ was , use of drugs of the antagonist including example , @DRUG$ , granisetron , palonosetron alosetron ) is	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
higher than recommended @DRUG$ once concentrations 23 by AUC0 receiving @DRUG$ to 15 for rheumatoid arthritis .	DDI-mechanism
interaction the effect use of % in with ( mg/800 mg trimethoprim/@DRUG$ TMP/@DRUG$	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
is structurally from available @DRUG$ lovastatin , @DRUG$ , and pravastatin , to unique biopharmaceutical properties relative to of this .	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
@DRUG$ the effect @DRUG$ , levodopa and	DDI-effect
acetaminophen/theophylline , , , @DRUG$/lidocaine , valproic	DDI-false
The majority of patients clinical studies or more following with ORENCIA MTX , @DRUG$ , agents chloroquine gold @DRUG$ , sulfasalazine , anakinra	DDI-false
@DRUG$ : 3 mg and @DRUG$ produced decrease in DSST scores .	DDI-false
In a Phase trial using of TAXOL 200 mg/m2 ) and given sequential , myelosuppression more profound when TAXOL was given @DRUG$ the alternate sequence , @DRUG$	DDI-false
In another study, TORADOLIV/IM was given with two doses of 5000 U of @DRUG$ to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for @DRUG$ alone and 5.1 minutes (3.5 to 8.5 min) for placebo.	DDI-false
drugs include the and , products , @DRUG$ nicotinic acid @DRUG$ , drugs and .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
In addition neither , , @DRUG$ and digoxin of @DRUG$ at steady	DDI-false
When @DRUG$ was coadministered with phenytoin @DRUG$ , H2antagonists of itraconazole	DDI-mechanism
A drug-drug study evaluated the of ACZONE 5 , in 160 mg/800 ) ) .	DDI-false
Data from vitro studies of benzodiazepines other than @DRUG$ suggest a interaction for the following , cyclosporine , amiodarone , @DRUG$ and .	DDI-int
In the same study it was shown that @DRUG$ and @DRUG$ had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-mechanism
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Physiological oral @DRUG$ best @DRUG$ and the first of its treatment	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
, in in , of @DRUG$ were altered ( 29 and 38 % Cmax a 1-mg dose of @DRUG$ was administered minute after a nasal .	DDI-false
Agents @DRUG$ has nitrates @DRUG$ without evidence clinically significant interactions .	DDI-false
action @DRUG$ by @DRUG$ retard .	DDI-effect
Lithium : has in patients @DRUG$ cause elimination of , including @DRUG$.	DDI-effect
@DRUG$ ( once daily been coadministered with erythromycin , @DRUG$ controlled clinical pharmacology studies volunteers	DDI-false
poor metabolizers Interactions of @DRUG$ with inhibitors of as @DRUG$ fluoxetine , ) have not been , these be blood of the	DDI-false
Example azole antifungals , , doxycycline , , @DRUG$ isoniazid nefazodone nicardipine propofol , , @DRUG$.	DDI-false
healthy has a 50 increase mean @DRUG$ and % increase under curve after week course @DRUG$ 1,000 mg/day and nimodipine at 90 .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
@DRUG$: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Other Cardiovascular Agents @DRUG$ IV been concomitantly with beta , , @DRUG$ calcium-blocking , hydralazine , clinically significant adverse .	DDI-false
The extent to which interactions may clinical problems the degree of inhibition and pharmacokinetics of @DRUG$	DDI-false
nor @DRUG$ affected proliferation of prostatic transferrin they modify the of	DDI-effect
have associated with neuropathy include analogues , @DRUG$ cisplatin dapsone ethionamide , glutethimide @DRUG$ , iodoquinol , isoniazid , , phenytoin	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 @DRUG$: @DRUG$ inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.	DDI-false
The Natrecor vasodilators such @DRUG$ , milrinone , or IV @DRUG$ has not these not co-administered with in trials ) .	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and cimetidine.	DDI-advise
In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
a comparison of in dogs with ketamine , , the dosage ouabain needed cause ventricular tachycardia was significantly higher , , @DRUG$ or Innovar than with	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
in Patients There was about % apparent total body of @DRUG$ it was with @DRUG$.	DDI-mechanism
Cyclosporine , Lodine other NSAIDs effects prostaglandins cause in elimination to elevated serum levels @DRUG$ , @DRUG$ , toxicity	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Concurrent administration of a TNF antagonist with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	DDI-false
@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	DDI-effect
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
was a significant ( p 0.05 /- 8.52 vs. + Cmax 7.73 vs. + 2.0 ) , and 1.1 0.6 1.6 + 1.1 ) for @DRUG$ @DRUG$/oxycodone .	DDI-false
Central System Depressants : The use of ( system with other central depressants , including but not limited other opioids tranquilizers , ) , @DRUG$ phenothiazines @DRUG$ and , cause depression hypotension and profound , result coma death .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
it that the levobupivacaine be the CYP3A4 inducers ( such as @DRUG$ , ) ( azole antimycotics e.g. @DRUG$ ;	DDI-false
@DRUG$ BID day and QD days 2 7 @DRUG$ ( mg the exposure pharmacodynamics ( glucose and ) .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
intensity uniformity and time course of @DRUG$ interference by , @DRUG$ glutethimide , hydrate were systematically investigated coumarin	DDI-false
Coadministration of single, oral doses of @DRUG$ with @DRUG$ (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-mechanism
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$: In a single-dose interaction study in NIDDM subjects, decreases in @DRUG$ AUC and Cmax were observed, but were highly variable.	DDI-false
No Important Levosimendan important pharmacokinetic with captopril , beta-blockers @DRUG$ @DRUG$ , carvedilol , itraconazole .	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
Methotrexate: @DRUG$ BID did not show a significant effect on the plasma exposure or renal clearance of @DRUG$.	DDI-false
Sedatives/@DRUG$: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
The absorption tetracycline furosemide , G , @DRUG$ when given simultaneously @DRUG$	DDI-mechanism
No pharmacokinetic dexmedetomidine isoflurane @DRUG$ @DRUG$ been demonstrated	DDI-false
necessary to be the clinical and of magnesium and to discriminate between deficiency to an @DRUG$ intake only physiological supplementation and magnesium depletion related a of @DRUG$ specific of causal .	DDI-false
@DRUG$ ( PLENDIL @DRUG$ 2.5- the , and 2- prolongation in the life of .	DDI-false
Cytochrome P-450 inducers such , @DRUG$ phenobarbital induce , causing approximately decrease @DRUG$	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
In a study coadministration of an antacid hydroxide and ) fosinopril levels and excretion @DRUG$ as @DRUG$ , suggesting antacids may impair of fosinopril .	DDI-false
No data available coadministration INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules .	DDI-false
@DRUG$ had levels	DDI-false
Digoxin and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
The availability potent non-nucleoside reverse (NNRTI)-based regimens for @DRUG$ and @DRUG$ (PI)-related metabolic disturbances have led to treatment in HIV infection .	DDI-false
@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-false
Drugs have been associated with peripheral neuropathy include antiretroviral , , cisplatin dapsone , disulfiram , ethionamide , gold , @DRUG$ , isoniazid metronidazole nitrofurantoin @DRUG$ ,	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
that have with peripheral include nucleoside cisplatin , disulfiram , , glutethimide , gold , hydralazine , iodoquinol , isoniazid , nitrofurantoin , @DRUG$ @DRUG$ .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In the same study it was shown that @DRUG$ and stavudine had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	DDI-false
increased concentrations ( 0 - 24 hrs ) of @DRUG$ following coadministration of loratadine each drugs ( 24 in ) there were no the safety @DRUG$ parameters clinical laboratory tests , signs , adverse events	DDI-false
): @DRUG$ , , @DRUG$ ) have rarely weakness , hyperreflexia and incoordination when coadministered .	DDI-false
poor of : Interactions of @DRUG$ with strong inhibitors CYP2D6 ( quinidine , , @DRUG$ , ) have , but these drugs would expected increase blood R(+ enantiomer of .	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Important Levosimendan does not have clinically interactions @DRUG$ , beta-blockers , , digoxin , @DRUG$ , isosorbide carvedilol ethanol or	DDI-false
Beta-blockers @DRUG$ , @DRUG$ salts , and may either potentiate the .	DDI-false
@DRUG$ does inhibit ( CYP1A2 , CYP2A6 , CYP2E1 ) in vitro , @DRUG$ to interact with other drugs in vivo inhibition of metabolism mediated these	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Certain endocrine and liver function tests may be affected by @DRUG$-containing oral @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: A report of severe @DRUG$ toxicity was reported in a patient receiving Isoniazid.	DDI-false
: stimulatory effects of @DRUG$ inhibited	DDI-effect
may the of @DRUG$ @DRUG$ and increase frequency in .	DDI-false
drugs @DRUG$ and diuretics , @DRUG$ , products , estrogens contraceptives , , acid , and .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The effects of @DRUG$ are antagonized by methylxanthines such as @DRUG$ and theophylline.	DDI-effect
5 ) @DRUG$ ( 30 mg/kg ) , @DRUG$ ( ) , fluoxetine 20 mg/kg ) ( mg/kg .	DDI-false
There is thus an enhancement effect of @DRUG$ upon the reaction of placental vessels to @DRUG$ in vitro.	DDI-effect
Acetaminophen, @DRUG$, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-advise
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Saquinavir : combination of @DRUG$ , , and @DRUG$ has in .	DDI-false
Ritonavir : @DRUG$ a 152 in in @DRUG$ plasma	DDI-false
and @DRUG$ be administered safely without caution during oral @DRUG$ therapy	DDI-false
Antibiotics: @DRUG$ have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-mechanism
not been observed between @DRUG$ @DRUG$.	DDI-false
with compounds that are inducers of CYP3A4 eg @DRUG$ @DRUG$ carbamazepine ) may decreased of .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Interaction with @DRUG$, @DRUG$ and theophylline has also been reported to produce adverse clinical effects.	DDI-false
of digoxin @DRUG$ , piroxicam , @DRUG$ did alter ketorolac protein .	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
@DRUG$ : @DRUG$ delay absorption phenytoin ;	DDI-false
In clinical studies @DRUG$ the oral ) , platelet inhibitors ) , @DRUG$ ) , not affect .	DDI-false
@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	DDI-false
@DRUG$: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
Potassium Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	DDI-false
Adenocard @DRUG$ presence drugs , as blocking agents calcium channel @DRUG$ , without change in reaction profile	DDI-false
Additive effects from blockade may when LEVSIN administered concomitantly other , , @DRUG$ phenothiazines @DRUG$ , antidepressants some antihistamines .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
has administered the of other cardioactive as , @DRUG$ , @DRUG$ and angiotensin inhibitors , change reaction	DDI-false
metabolizers @DRUG$ Interactions of @DRUG$ with inhibitors ( as quinidine , , ) have but these drugs be expected blood of	DDI-false
@DRUG$ may the hypotensive effects of @DRUG$.	DDI-false
Although @DRUG$ been to reduce @DRUG$-induced side including fever , renal insufficiency and , agents may reduce antitumor effectiveness PROLEUKIN should 12 Beta-blockers and other antihypertensives may hypotension .	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ and @DRUG$ should not be administered to patients receiving coumarin drugs.	DDI-false
There was no evidence any pharmacokinetic interactions @DRUG$ and	DDI-false
and @DRUG$ Absorption of @DRUG$ in the	DDI-false
@DRUG$ of relationship @DRUG$ to vitamin patients against vitamin supplements A avoid toxic effects	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ Hypoglycemics : @DRUG$ the blood-sugar-reducing insulin hypoglycemics .	DDI-false
that have been associated peripheral include antiretroviral analogues , , , @DRUG$ , gold iodoquinol , metronidazole , , @DRUG$ and	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Based metabolic significant are VIRACEPT dapsone , @DRUG$ , , @DRUG$ .	DDI-false
Although clinical studies been , it is that the metabolism may be by known inducers such @DRUG$ @DRUG$ rifampin ) ( e.g. , ;	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
Selective Reuptake @DRUG$ ): SSRIs fluvoxamine @DRUG$ have been rarely weakness , hyperreflexia , incoordination when coadministered 5-HT1 .	DDI-false
Because @DRUG$ may blood glucose concentrations dosage adjustments @DRUG$ may required	DDI-effect
@DRUG$ : of indinavir with @DRUG$ an nelfinavir AUC and a 51 % increase A.C.	DDI-false
Rifabutin of @DRUG$ VIRACEPT a @DRUG$ plasma AUC a 207 % increase rifabutin	DDI-false
doses @DRUG$ or @DRUG$ and its from the up to 85 and 43 percent respectively	DDI-false
Tagamet , an on certain microsomal enzyme systems , has been reported metabolism anticoagulants , @DRUG$ , @DRUG$ , , , diazepam certain tricyclic antidepressants , theophylline , delaying and increasing blood levels of drugs	DDI-false
To determine of @DRUG$ permit doses @DRUG$ be , 9.9-g/m2 dose of thiosulfate was given three concurrently with escalating doses	DDI-false
@DRUG$ plus @DRUG$ was poorly , and 5 subjects therapy .	DDI-effect
@DRUG$ In healthy individuals , plasma concentrations @DRUG$ increased 40 % of and , of P450 3A4	DDI-false
@DRUG$ report severe @DRUG$ toxicity was Isoniazid .	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
of methotrexate-related toxicity continued @DRUG$ @DRUG$ concomitantly	DDI-advise
Interactions @DRUG$ , Monoamine inhibitors ( MAOI ): MAOI could theoretically flupenthixol Arecoline - Ethanol : Flupenthixol and @DRUG$ additive CNS antidepressants : the effect Tricyclic	DDI-false
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Amiodarone certain CYP450 CYP1A2 @DRUG$ @DRUG$ ,	DDI-false
@DRUG$ normal volunteers concomitant diflunisal significantly increased plasma @DRUG$.	DDI-false
@DRUG$ transport of @DRUG$ may by concomitant of ciprofloxacin potentially leading to increased of methotrexate .	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
interactions : @DRUG$ had no the @DRUG$ glucose and insulin ) prothrombin time or other pharmacodynamic )	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Interactions To Date Levosimendan does pharmacokinetic interactions captopril , beta-blockers , @DRUG$ , warfarin mononitrate , carvedilol ethanol @DRUG$.	DDI-false
muscle relaxants ( eg , and other drugs , ether succinylcholine @DRUG$ decamethonium neuromuscular blocking effect and should extreme caution in patients with @DRUG$ Parenteral .	DDI-effect
Quetiapine fumarate ('@DRUG$') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
, other , , pre@DRUG$ and anesthetic @DRUG$ nondepolarizing used	DDI-false
Drugs that been associated with peripheral neuropathy nucleoside analogues @DRUG$ cisplatin , dapsone , disulfiram , ethionamide , @DRUG$ gold hydralazine , metronidazole ribavirin , and .	DDI-false
@DRUG$ may enhance the effects of @DRUG$, barbiturates, and other CNS depressants.	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or @DRUG$).	DDI-false
Although have to PROLEUKIN-induced side effects including , confusion , and , concomitant agents @DRUG$ may reduce the effectiveness PROLEUKIN thus should be . @DRUG$ other may potentiate hypotension seen .	DDI-false
A causal not the that @DRUG$ alter a diabetic patient s response @DRUG$ agents .	DDI-effect
increased and @DRUG$ should be selecting @DRUG$ women .	DDI-false
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Antiarrhythmics : @DRUG$ , @DRUG$ CONTRAINDICATED due potential for serious and/or reactions .	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Concurrent of drugs possessing e.g. aminoglycosides ) , myelotoxic e.g. , chemotherapy ) ( , @DRUG$ ) , @DRUG$ effects with PROLEUKIN increase in	DDI-false
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
existing trials suggest significant between @DRUG$ and other commonly in MS , use @DRUG$ to days	DDI-false
Benzthiazide may interact with @DRUG$, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Other therapy specific not performed , of mg or used in studies , acetylsalicylic , a-blockers analgesics , ( ) inhibitors , @DRUG$ , benzodiazepines , calcium-channel blockers , , diuretics H2 , @DRUG$ synthetase referred NSAIDs ) and quinolone of clinically significant .	DDI-false
These drugs include the thiazides and other , phenothiazines , thyroid products , @DRUG$ oral contraceptives , acid @DRUG$ , blocking , and isoniazid .	DDI-false
: @DRUG$ interferes with tubular @DRUG$ and increase the level ciprofloxacin serum .	DDI-mechanism
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
acetaminophen/theophylline , , , acid quinidine/lidocaine , theophylline/@DRUG$ and valproic	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Phenytoin : pharmacokinetic indicate that @DRUG$ 60 % patients or @DRUG$.	DDI-false
Antibiotics : vivo data show that @DRUG$ , troleandomycin markedly result in an increase plasma @DRUG$ levels of QT on	DDI-false
CNS ( e.g. barbiturates , @DRUG$ opioids and anesthetics ) have additive or	DDI-effect
specific have not been performed coadministration that mainly by CYP3A4 eg calcium , disopyramide , amiodarone quinidine , warfarin , tacrolimus , cyclosporine ergot , pimozide @DRUG$ fentanyl alfentanyl , alprazolam , and @DRUG$ have when coadministered with ;	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Since concomitant of @DRUG$ increases by 4 the @DRUG$ be , monitored .	DDI-false
Drug Interactions with some , like oxidase inhibitors ( MAOI ): MAOI could theoretically - @DRUG$ : Ethanol cause additive - @DRUG$ increases effect of	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, @DRUG$), though this has not been studied	DDI-false
In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	DDI-false
@DRUG$ (neostgmine, @DRUG$), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
addition from that of other inducers ( @DRUG$ , , dexamethasone , with @DRUG$ may in meaningful in caspofungin concentrations	DDI-mechanism
Co-medications that induce CYP3A4 ( e.g. , dexamethasone @DRUG$ carbamazepine , @DRUG$ or	DDI-false
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
, @DRUG$ , @DRUG$ , , have no in on the binding of human serum	DDI-false
Drug Interactions may some drugs , Monoamine inhibitors ( MAOI ): MAOI could affect flupenthixol - - Ethanol and @DRUG$ additive @DRUG$ increases of	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
The gastrointestinal absorption of cimetidine and @DRUG$ is accelerated when they are coadministered with @DRUG$.	DDI-mechanism
Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of @DRUG$ with itraconazole is contraindicated.	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, simvastatin).	DDI-mechanism
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
At a follow-up 33 months , @DRUG$ did demonstrate any @DRUG$ in all well the hormone receptor-positive subpopulation .	DDI-false
@DRUG$ with than increases plasma concentrations procainamide @DRUG$ by and 33 , respectively .	DDI-false
are of may the blood-glucose-lowering effect corticosteroids , niacin , danazol , , sympathomimetic agents ( e.g. , salbutamol terbutaline ) , @DRUG$ , hormones , @DRUG$ e.g. , in contraceptives ) .	DDI-false
@DRUG$: It is recommended that @DRUG$ be administered on an empty stomach;	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, @DRUG$, Maalox, and ranitidine.	DDI-false
In the of @DRUG$ , (+)-NANM @DRUG$ , by ;	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
Drug Interactions Flupenthixol may interact with some , like oxidase inhibitors ): MAOI theoretically affect - @DRUG$ - Eproxindine - Flupenthixol and Ethanol cause additive CNS depression Flupenthixol increases the effect of @DRUG$	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
As with other b-lactams excretion of @DRUG$ is inhibited @DRUG$.	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$  has not been formally evaluated in combination with @DRUG$.	DDI-false
inhibitors include @DRUG$ , clarithromycin , , @DRUG$ , erythromycin imatinib isoniazid nefazodone nicardipine propofol , protease , and	DDI-false
concomitant therapy Although specific interaction were not performed , doses were used clinical with , , , , @DRUG$ , anticonvulsants , benzodiazepines beta blockers , @DRUG$ , cardiac nitrates , diuretics H2 antagonists , inhibitors ( also referred as NSAIDs ) , and quinolone evidence significant adverse	DDI-false
Because prostaglandins play role in hemostasis and as well , concurrent therapy @DRUG$ diclofenac @DRUG$ requires close to be that no change in their anticoagulant required .	DDI-advise
of @DRUG$ @DRUG$ use may be similar personality in user as and sensation .	DDI-false
( 40 mg not the combination @DRUG$ norethindrone/ethinyl estradiol ( 1 /35 @DRUG$	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
controlled studies in volunteers , @DRUG$ either effect one study associated with , % ( two in steady-state serum @DRUG$	DDI-mechanism
Hypersensitivity have receiving regimens containing dose PROLEUKIN and @DRUG$ , specifically dacarbazine @DRUG$ and .	DDI-false
That Should With @DRUG$ Antiarrhythmics : @DRUG$ quinidine agents : rifampin , :	DDI-advise
@DRUG$ : and/or clarithromycin @DRUG$ and inhibit cisapride , which can in an increase levels of the QT the	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
It is recommended that if @DRUG$ is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.	DDI-advise
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or @DRUG$.	DDI-false
interactions have also been concomitant administration propranolol @DRUG$ @DRUG$.	DDI-false
: VISTIDE agents with aminoglycosides ( e.g. , , gentamicin @DRUG$ ) , amphotericin , , intravenous @DRUG$ vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated	DDI-false
Note: dissolution of aerosol particles of @DRUG$ in Survanta, a model @DRUG$.	DDI-false
These increased exposures of norethindrone and @DRUG$ should be taken into consideration when selecting an oral @DRUG$ for women taking valdecoxib.	DDI-false
@DRUG$ Because nephrotoxicity with decreases creatinine clearance and in , because the primary elimination route fibrate drugs @DRUG$ there is risk that an deterioration	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
, @DRUG$ sulfonamides , or @DRUG$ interfere the effect .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ is also expected concentrations of other statins have metabolism by , as and @DRUG$.	DDI-mechanism
@DRUG$ @DRUG$ significant on time when to patients receiving chronic treatment	DDI-false
May interact thyroid medication e.g. levothyroxine iodine-containing products , @DRUG$ ( famotidine @DRUG$ ) , and pump , omeprazole )	DDI-false
Concomitant administration @DRUG$ the undesirable effects	DDI-effect
not been to any obtained with @DRUG$ alone and increases of excretion Nalfon , the of Nalfon @DRUG$ is not recommended	DDI-false
In studies show significant inhibition the irbesartan the known CYP 2C9 @DRUG$ , @DRUG$ and nifedipine .	DDI-false
Digoxin: @DRUG$ concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	DDI-false
evaluate the of chemotherapy on the of patients with HIV-related , non-Hodgkin HIV-NHL ) , the authors compared group of HIV-NHL the @DRUG$ , , and prednisone ( chemotherapy regimen plus group were with or a ( @DRUG$ , , teniposide , and with vincristine without receiving	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	DDI-effect
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, @DRUG$).	DDI-false
Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
@DRUG$, tricyclic: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
Drugs That Should Not Be With VIRACEPT amiodarone , : ergot derivatives agents : @DRUG$ Benzodiazepines GI @DRUG$	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
that both and @DRUG$ , and possibly @DRUG$ the proliferation epithelium by dose-dependent modification the and	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
The following are examples may , agents ( , epinephrine , salbutamol terbutaline @DRUG$ , somatropin , thyroid hormones @DRUG$ , progestogens ( e.g. in contraceptives ) .	DDI-false
Nalfon been shown produce any effect with @DRUG$ alone the rate of of @DRUG$ the of Nalfon is not	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or @DRUG$ alone.	DDI-false
Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-false
action sulfonylureas may be potentiated certain including anti-inflammatory agents and other drugs , , , , @DRUG$ ,	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Hypotension    Patients @DRUG$ Therapy : on diuretics and those therapy was instituted as on dietary salt or experience precipitous of usually hour receiving initial dose of @DRUG$.	DDI-false
therefore, @DRUG$ or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.	DDI-false
action of the be potentiated by @DRUG$ , @DRUG$ inhibitors narcotics , psychotropic medications , or other CNS depression	DDI-false
DIGOXIN: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drug-Drug Keppra   Other ( @DRUG$ Phenytoin Keppra ( 3000 mg had no effect on disposition of @DRUG$ in with	DDI-false
Reciprocal with concomitant of drugs that increase inhibit the P450 ( , , carbamazepine @DRUG$ , @DRUG$ ) has not	DDI-false
Interactions with Agonist/antagonist ( eg @DRUG$ butorphanol @DRUG$ ) NOT administered a patient is receiving a of a such Levo-Dromoran	DDI-false
@DRUG$ also increased rate of dissolution, in a manner similar to @DRUG$.	DDI-false
, lidocaine/quinidine , phenobarbital/acetaminophen phenobarbital/@DRUG$ quinidine/lidocaine , theophylline/acetaminophen , and .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
A study the with double strength 160 mg/800 ( @DRUG$/SMX )	DDI-false
following examples of that may effect hypoglycemia oral antidiabetic , , fibrates , fluoxetine oxidase MAO @DRUG$ , analog e.g. , @DRUG$ ) , .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking cephalexin and @DRUG$.	DDI-false
Antimycobacterial : @DRUG$ CONTRAINDICATED coadministration this product saquinavir @DRUG$ regimen reduces the concentrations .	DDI-false
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and @DRUG$, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
@DRUG$ depression conduction observed with	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The concomitant administration of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
@DRUG$ of @DRUG$ valdecoxib risk to valdecoxib alone	DDI-false
@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with glyburide.	DDI-false
When other @DRUG$ or anticoagulants are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	DDI-effect
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
@DRUG$ @DRUG$ may the hypotensive effects	DDI-false
Saquinavir of saquinavir ( an experimental capsule formulation 1200 mg resulted an 18 increase in @DRUG$ AUC a 4-fold @DRUG$ A.C.	DDI-false
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Theophylline: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
acetaminophen/theophylline @DRUG$/@DRUG$ , phenobarbital/acetaminophen phenobarbital/valproic acid quinidine/lidocaine , theophylline/acetaminophen .	DDI-false
Drugs Be VIRACEPT : astemizole , Antimigraine ergot derivatives Antimycobacterial : rifampin @DRUG$ midazolam GI : @DRUG$	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, @DRUG$, and midazolam.	DDI-false
@DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The following examples of drugs known to the related @DRUG$ , presumably through inhibition of CYP3A , fluvoxamine cimetidine @DRUG$ isoniazide some macrolide antibiotics	DDI-mechanism
Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-false
@DRUG$ produced distinctive effects in each task: it substituted for the training dose in @DRUG$ discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.	DDI-false
The use as @DRUG$ drugs in severe hypertension	DDI-false
(@DRUG$ may increase the responsiveness to @DRUG$.)	DDI-effect
In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ hyperuricemic	DDI-effect
, @DRUG$ and Bosentan has no with , losartan has no significant effect of	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced , renal , hyperbilirubinemia confusion , and dyspnea agents with @DRUG$ the of thus should be and other potentiate the with @DRUG$.	DDI-false
( @DRUG$ @DRUG$.	DDI-effect
@DRUG$ MAOI as of furazolidone @DRUG$	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Warfarin @DRUG$ 3 daily affect the (R)- @DRUG$ , nor there changes in pharmacodynamic profile ( ) 25 oral of	DDI-false
Tagamet , apparently an effect certain systems has been the warfarin-type phenytoin , propranolol nifedipine , , diazepam tricyclic , @DRUG$ and @DRUG$ levels of these .	DDI-false
Flupenthixol with some drugs like Monoamine oxidase inhibitors ( MAOI ): MAOI theoretically pharmacodynamics - Arecoline - Ethanol : @DRUG$ and Ethanol CNS depression - @DRUG$ : increases effect Tricyclic antidepressants	DDI-false
It is suggested that in patients receiving @DRUG$, alternatives to @DRUG$ should be used if anticonvulsant therapy is needed.	DDI-advise
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/@DRUG$ phenobarbital/valproic theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
: studies as well as marketing shown that the natriuretic of @DRUG$ @DRUG$ some patients	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
If @DRUG$ mixed with , @DRUG$ drawn syringe first .	DDI-false
Concomitant administration of fenofibrate equivalent to 145 @DRUG$ with atorvastatin ( 20 once for 10 days resulted approximately 17 % decrease 67 decrease to 44 % increase in @DRUG$ in 22 males .	DDI-false
@DRUG$: The stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.	DDI-mechanism
HMG-CoA Reductase : @DRUG$ ( substrate ) combination with @DRUG$ has associated of myopathy/rhabdomyolysis .	DDI-false
Cardiovascular : and have with beta agents , methyldopa , nitrates , @DRUG$ @DRUG$ , without .	DDI-false
The hypoglycemic sulfonylurea may be potentiated drugs @DRUG$ and other drugs that protein bound , sulfonamides , @DRUG$ , inhibitors , beta adrenergic agents	DDI-false
@DRUG$ tricyclic antidepressants and @DRUG$ clidinium	DDI-false
Other specific studies not performed , doses 1 mg or were concomitantly @DRUG$ , , , analgesics , ( ACE inhibitors , anticonvulsants , benzodiazepines @DRUG$ , calcium-channel blockers , H2 HMG-CoA inhibitors prostaglandin ( also referred as NSAIDs ) evidence significant	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
To of chemotherapy plus HAART on clinical patients with , lymphoma ( ) , a group of 24 patients HIV-NHL who doxorubicin @DRUG$ , prednisone regimen plus with patients treated or a CHOP-like regimen , doxorubicin , , @DRUG$ vincristine bleomycin without	DDI-false
Both the toxicity of filipin and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
May with thyroid ( @DRUG$ iodine-containing , antacids , ( , @DRUG$ , pump ( , , ) .	DDI-false
The effect @DRUG$ on the requirement appeared to the initiation rifampin and extended length of time after @DRUG$	DDI-false
Based on metabolic , clinically interactions VIRACEPT dapsone , @DRUG$/@DRUG$ , itraconazole or	DDI-false
The Natrecor with as @DRUG$ , , milrinone @DRUG$ not evaluated ( these were not co-administered with in trials .	DDI-false
In clinical studies with @DRUG$ use ( @DRUG$ ) , platelet ( acetylsalicylic ) , NSAIDs piroxicam and digoxin pharmacokinetics/pharmacodynamics sodium .	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Drugs have been associated peripheral neuropathy , chloramphenicol , cisplatin dapsone , disulfiram , , , gold iodoquinol @DRUG$ @DRUG$ , nitrofurantoin phenytoin .	DDI-false
include @DRUG$ ciprofloxacin , , , doxycycline erythromycin , imatinib @DRUG$ , propofol protease , quinidine and	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ In some patients , the of anti-inflammatory can reduce natriuretic antihypertensive of potassium-sparing and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
@DRUG$ may interact with @DRUG$ or other CNS depressants, causing increased sedative effects.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
These thiazides and , @DRUG$ , , , , oral contraceptives , @DRUG$ sympathomimetics , isoniazid .	DDI-false
: @DRUG$ interact with oxidase ( - - : Ethanol additive depression : @DRUG$ increases the effect antidepressants	DDI-false
After multiple dosing, @DRUG$ (@DRUG$  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
The of butorphanol as @DRUG$ were not by @DRUG$ 300 ) .	DDI-false
@DRUG$ Injectable , Transdermal , : demonstrated that of the oral hormonal of @DRUG$ ethinyl estradiol % and 31 % , .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
@DRUG$: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.	DDI-false
These thiazides other diuretics , phenothiazines thyroid , oral @DRUG$ , phenytoin , @DRUG$ sympathomimetics , calcium blocking drugs , isoniazid .	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH TRICOR.	DDI-false
The effects mixing @DRUG$ of animal @DRUG$ by other manufacturers not been studied .	DDI-false
Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
Multivalent Products administration a @DRUG$ ciprofloxacin , with multivalent products @DRUG$ or aluminum antacids sucralfate VIDEX tablets or powder products calcium iron , or zinc may substantially absorption of ciprofloxacin , in and urine levels lower than desired	DDI-mechanism
Drugs have been with neuropathy antiretroviral analogues , chloramphenicol dapsone @DRUG$ , ethionamide glutethimide gold , hydralazine iodoquinol isoniazid , @DRUG$ , , ribavirin , and .	DDI-false
@DRUG$/@DRUG$: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
of paper was @DRUG$ and enkephalins or synthetic or @DRUG$ antinonciceptive effect of intracisternal	DDI-false
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.	DDI-false
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Other Cardiovascular : Enalapril enalapril been concomitantly with beta adrenergic-blocking methyldopa , nitrates , @DRUG$ hydralazine @DRUG$ and evidence of clinically interactions	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, @DRUG$, and vincristine.	DDI-false
The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of bromocriptine mesylate.	DDI-false
Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
@DRUG$ or @DRUG$: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.	DDI-false
OTHER : interaction performed in , cerivastatin was used concomitantly @DRUG$ , @DRUG$ , blockers , , and evidence of clinically significant	DDI-false
drug @DRUG$   and AEDs , gabapentin , phenobarbital , phenytoin , primidone and valproate ) were assessed by the serum of @DRUG$ and these AEDs placebo-controlled studies .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-effect
Particular @DRUG$ in of mixed overdosage as convulsions cardiac ) of other taken in overdose ( cyclic antidepressants ) may emerge the reversal the benzodiazepine	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The hypoglycemic may potentiated @DRUG$ and are bound , @DRUG$ , coumarins , oxidase , and beta adrenergic	DDI-false
addition , products as @DRUG$ , @DRUG$ of hypoglycemia be or .	DDI-false
concomitant administration of @DRUG$ CELEBREX may in increased of or compared to of @DRUG$ alone	DDI-false
Coadministration with valdecoxib 40 mg for 7 days in significant increase in @DRUG$ suggesting at these @DRUG$ a of 2D6	DDI-false
@DRUG$ may displace phenytoin @DRUG$ from binding sites .	DDI-mechanism
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Tagamet , apparently effect on certain microsomal has to metabolism of warfarin-type , phenytoin , , , diazepam , certain @DRUG$ @DRUG$ , , thereby elimination levels of these drugs	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	DDI-false
Selective Serotonin ( SSRIs ): @DRUG$ , @DRUG$ , fluvoxamine , , ) have been rarely , incoordination with	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Potential drug Keppra   and @DRUG$ ( carbamazepine , gabapentin lamotrigine , , , and were also assessed the serum of @DRUG$ during clinical	DDI-false
Interactions @DRUG$ ( , nalbuphine , @DRUG$ should to a patient received receiving a course of therapy pure agonist Levo-Dromoran .	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (tricyclic antidepressants, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
The following of substances that effect : corticosteroids , , e.g. epinephrine @DRUG$ , , isoniazid , @DRUG$ thyroid hormones , e.g. , oral ) .	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ of @DRUG$ 3 olanzapine produced DSST scores .	DDI-false
Standard therapy includes @DRUG$, such as penicillin and @DRUG$;	DDI-false
tested include @DRUG$ , digoxin , @DRUG$ , warfarin and no meaningful .	DDI-false
relaxants ) and , @DRUG$ @DRUG$ and citrate , potentiate the neuromuscular blocking effect and used Coly-Mycin Parenteral .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
drugs may enhance neuromuscular action of nondepolarizing certain ( g. , , @DRUG$ , , polymyxins @DRUG$ clindamycin , sodium ) salts , and .	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and @DRUG$.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, and nifedipine.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, @DRUG$).	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
These and other diuretics @DRUG$ , phenothiazines thyroid products estrogens , contraceptives phenytoin , @DRUG$ , calcium channel blocking , .	DDI-false
@DRUG$, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
Cholestyramine and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	DDI-false
specific studies have not drugs mainly metabolized CYP3A4 , channel , dapsone , quinine , , @DRUG$ , , @DRUG$ , ergot derivatives , carbamazepine , alfentanyl alprazolam and triazolam may have plasma concentrations coadministered with ;	DDI-false
Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-mechanism
DOSTINEX should not be administered concurrently D2-antagonists @DRUG$ , @DRUG$ , or	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
( ) has been with therapeutic doses of @DRUG$ , @DRUG$ clinical in volunteers .	DDI-false
@DRUG$ @DRUG$ ( body weight approximately mL of absolute in a and vardenafil not when dosed simultaneously	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
@DRUG$ had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable @DRUG$ therapy.	DDI-false
Therefore @DRUG$ may the absorption of gastric pH is important determinant bioavailability ( , ketoconazole iron salts @DRUG$ .	DDI-mechanism
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
the @DRUG$ glyburide is contraindicated , alternative @DRUG$ should be .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The concomitant use of vasopressors, vasoconstricting agents (such as @DRUG$) and some @DRUG$ may result in severe hypertension.	DDI-effect
In vitro data suggest that itraconazole, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
CONCLUSIONS/INTERPRETATION: @DRUG$ and @DRUG$ can exert additive vasodilator properties on renal and ocular circulation.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Hormonal , Transdermal , and @DRUG$ interaction demonstrated co-administration @DRUG$ hormonal average decreases of norethindrone and estradiol 14 % 31 respectively .	DDI-false
Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
@DRUG$ 40 mg days produced significant @DRUG$ clearance % and renal clearance 30 with a % higher exposure to lithium	DDI-mechanism
It is suggested that receiving @DRUG$ , alternatives should @DRUG$ is needed .	DDI-false
Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and @DRUG$.	DDI-false
@DRUG$ , other , , pre@DRUG$ agents used or skeletal-muscle , nondepolarizing , in	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ antagonize activity @DRUG$ and zidovudine HIV	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Although the occurrence has not been reported with @DRUG$, nephrotoxicity has been reported following concomitant administration of other cephalosporins and @DRUG$.	DDI-false
MAO Inhibitors @DRUG$   is not use in who MAOI days @DRUG$ has with analgesics	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
: effects combined of bombesin and hydrochloride ) , calcium channel blocker , on incidence peritoneal @DRUG$ ( @DRUG$ ) the index of cancers Wistar rats .	DDI-false
The effects of adenosine are antagonized by methylxanthines such as @DRUG$ and @DRUG$.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
(1968, 1970), the higher serum concentrations of penicillins and @DRUG$ reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-mechanism
Oral @DRUG$ : interactions between @DRUG$ and ) have not been .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
of tetracycline , , @DRUG$ , , and gemfibrozil was significantly simultaneously @DRUG$ ;	DDI-mechanism
Benzthiazide may interact with alcohol @DRUG$s , ( allergy cold sinus ) , @DRUG$ norepinephrine NSAIDs Aleve or Ibuprofen high	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In avoid the occurrence of severe , patients treated TAXOL premedicated @DRUG$ ( @DRUG$ ) ( such ranitidine .	DDI-false
Cephalosporins-Cephalosporins containing side N-methylthiotetrazole ( @DRUG$ , cefoperazone cefotetan , , latamoxef @DRUG$ cause hypoprothrombinemia	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
use @DRUG$ @DRUG$ some the side effects of has studied .	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing antacids.	DDI-advise
@DRUG$ phenothiazines thyroid , oral , phenytoin nicotinic acid @DRUG$ ,	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
@DRUG$ , , cephalothin and sulfamethoxazole have on the protein binding @DRUG$ serum .	DDI-false
: Lorazepam injection , other @DRUG$ depression central nervous alcohol barbiturates , MAO inhibitors and other @DRUG$ used , an increased incidence of irrational behavior has been observed .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
drugs neuromuscular action of nondepolarizing such @DRUG$ include certain antibiotics ( e. , aminoglycosides , , polymyxins @DRUG$ , ) magnesium , local anesthetics , procainamide , and .	DDI-effect
Cardiac effects of dopamine are antagonized by @DRUG$, such as @DRUG$ and metoprolol.	DDI-false
The of in RA clinical received more the concomitant medications with @DRUG$ , @DRUG$ , chloroquine , gold hydroxychloroquine leflunomide , , .	DDI-false
Patients narcotic , general @DRUG$ phenothiazines , sedative-hypnotics @DRUG$ other depressants ( including ) DILAUDID exhibit CNS depression	DDI-false
@DRUG$ and isoflurane , and @DRUG$	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ @DRUG$ enhance the and/or effects of stimulants	DDI-false
Experience co-administration of @DRUG$ and @DRUG$ patients limited should be given to of inhibitors patients receiving	DDI-false
begin or increase dose other while taking @DRUG$ or @DRUG$ may develop for these drugs .	DDI-false
- The action of @DRUG$ and @DRUG$ may be enhanced by Bezalip or Bezalip retard.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$   not influence the pharmacokinetics containing ethinyl estradiol and 0.15 mg @DRUG$ or of luteinizing and progesterone levels , that of is unlikely .	DDI-false
Because of adverse reactions in patients have taking on , particularly important that physicians or guardians about @DRUG$ , @DRUG$ as any in the ROMAZICON is planned	DDI-false
The absorption of , @DRUG$ hydrochlorothiazide @DRUG$ was when simultaneously with	DDI-false
Cohort received @DRUG$ plus rifabutin 10 and cohort received @DRUG$ 4 days .	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ g. ketoconazole , clotrimazole . ): vitro animal the combination of @DRUG$ and suggest imidazoles induce amphotericin B.	DDI-false
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
@DRUG$ may absorption @DRUG$.	DDI-mechanism
Drug/LaboratoryTest Interactions @DRUG$ may interfere with bioassay procedures for the determination of @DRUG$ levels.	DDI-false
Specific studies have confirmed these effects with @DRUG$, isoflurane, @DRUG$, alfentanil, and midazolam.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Saquinavir saquinavir ( experimental capsule @DRUG$ mg ) with an 18 % @DRUG$ AUC and increase in saquinavir	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
The action sulfonylurea be potentiated by nonsteroidal and drugs protein bound , salicylates , sulfonamides , @DRUG$ @DRUG$ , coumarins oxidase inhibitors , and beta agents	DDI-false
Agents Release : The effect of @DRUG$ and enalapril IV is by @DRUG$ cause	DDI-effect
however , response duration suggesting that @DRUG$ not with @DRUG$ and/or	DDI-advise
@DRUG$ enhances of @DRUG$.	DDI-false
concomitant Although interaction studies were , doses mg more concomitantly used clinical , acetylsalicylic acid , angiotensin-converting enzyme ACE ) inhibitors , , benzodiazepines blockers blockers cardiac , @DRUG$ H2 antagonists , prostaglandin inhibitors @DRUG$ , quinolone anti-infectives of clinically adverse .	DDI-false
Drugs peripheral nucleoside , chloramphenicol @DRUG$ , disulfiram , glutethimide , gold , , isoniazid , , phenytoin , @DRUG$ and vincristine .	DDI-false
class ( as @DRUG$ @DRUG$ , or quinidine ): use with arbutamine may have effect	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ : Patients on diuretics , those excessive blood pressure after initiation of with	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ :   for use in patients who received MAOI 14 because and potentiation by @DRUG$ has	DDI-false
Coadministration of @DRUG$ did not affect the pharmacokinetics of @DRUG$.	DDI-false
Example antifungals @DRUG$ , clarithromycin diclofenac doxycycline , , imatinib isoniazid @DRUG$ , nicardipine , , verapamil	DDI-false
@DRUG$ no apparent interaction administered @DRUG$.	DDI-false
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Aspirin @DRUG$ , @DRUG$	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, @DRUG$, quinidine, and verapamil.	DDI-false
Lack of an effect of @DRUG$ on the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ : Increased serum levels symptoms toxicity have concomitant lithium @DRUG$ .	DDI-false
@DRUG$ : Reports suggest NSAIDs may antihypertensive effect of	DDI-false
@DRUG$ moclobemide increased @DRUG$ at different times the .	DDI-false
, that , many @DRUG$ ( @DRUG$ serotonin reuptake and others may the activity isoenzyme thus make normal metab-olizers resemble metabolizers regard concomitant therapy other drugs by this enzyme leading drug interactions	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
@DRUG$ inhibits the , and @DRUG$ are of ERMBT	DDI-false
In monkeys, the effects of (-)-NANM, but not @DRUG$ or @DRUG$, were antagonized by naloxone;	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Antibiotics show @DRUG$ @DRUG$ and troleandomycin markedly the cisapride which plasma and prolongation the QT interval .	DDI-false
Although studies coadministration drugs that are metabolized by blockers , dapsone , , , @DRUG$ , warfarin , , @DRUG$ ergot derivatives carbamazepine , , and may elevated concentrations coadministered ;	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
However because some quinolones have enhance anticoagulant of @DRUG$ or its in , the or suitable should be @DRUG$ is administered with or derivatives	DDI-false
The RA received more the concomitant ORENCIA : , blocking , , , hydroxychloroquine @DRUG$ @DRUG$ and .	DDI-false
In binding serum indicate @DRUG$ differently than and not interact with or @DRUG$.	DDI-false
Patients receiving these drugs who are given @DRUG$, or any other @DRUG$, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.	DDI-false
Considerable caution should be exercised if @DRUG$ is administered concurrently with @DRUG$ (phenacemide) since paranoid symptoms have been reported during therapy with this combination.	DDI-advise
Reuptake ( @DRUG$ @DRUG$ e.g. fluvoxamine , paroxetine , have rarely reported to cause incoordination coadministered agonists	DDI-false
Benzylpenicillin ampicillin , @DRUG$ , chlortetracycline , doxycycline , @DRUG$ no influence protein of diclofenac in human serum	DDI-false
With Narrow Index @DRUG$ A dose of 3 mg affect pharmacokinetics @DRUG$ measured state following dosing of 0.5 for one day 0.25 next days	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
local anesthetic solutions epinephrine @DRUG$ to patients oxidase , @DRUG$ or phenothiazines produce prolonged hypertension	DDI-effect
, FLOLAN with @DRUG$ diuretics , anticoagulants , vasodilators supplemental . In pharmacokinetic patients heart failure furosemide or digoxin whom therapy with @DRUG$ initiated clearance for ( 23 ) and digoxin 30 by 13 % and 15 , , on day had returned to by 87 .	DDI-false
@DRUG$: Concomitant use of @DRUG$ may increase the risk of renal impairment, particularly in volume-depleted patients.	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Pregnancy : @DRUG$ ) teratogenic and/or embryocidal effects been in animal @DRUG$.	DDI-false
eg , other drugs , including ether , @DRUG$ , gallamine , decamethonium neuromuscular blocking and should be used caution being with @DRUG$ Parenteral	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
[ Quantitative to incisive @DRUG$ ; problems encountered treatment of psychotic with @DRUG$ are six case .	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
@DRUG$ : When doses of and , steady-state @DRUG$ concentrations increased approximately .	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
: In clinical , the safety in treated @DRUG$ with @DRUG$ , and sedatives including was to that of subjects concomitant .	DDI-false
ACE Inhibitors @DRUG$ In clinical studies of addition @DRUG$ and II receptor increased mean potassium slightly 0.09 0.13 )	DDI-false
Amantadine, tricyclic antidepressants, and @DRUG$ may increase anticholinergic effect of @DRUG$.	DDI-effect
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Estrogens, including oral @DRUG$: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
Since higher doses ketoconazole ( mg daily may in higher Cmax and a of @DRUG$ be in in with @DRUG$ 400 mg	DDI-advise
@DRUG$ injection , other injectable benzodiazepines , produces of system when administered with ethyl , barbiturates , other . When scopolamine with @DRUG$ , an incidence sedation , irrational has observed .	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
concomitant therapy specific studies were , finasteride 1 or more were concomitantly with acetaminophen acetylsalicylic acid , analgesics enzyme , , beta blockers calcium-channel , cardiac , @DRUG$ , , @DRUG$ ( also to NSAIDs ) without of clinically significant adverse	DDI-false
Potassium-sparing ( e.g. , @DRUG$ , , @DRUG$ or substitutes may lead significant serum .	DDI-false
@DRUG$ @DRUG$ an elevation of lithium levels in renal	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
3 mg daily for 5 affect @DRUG$ nor were any in the profile time following single of @DRUG$	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$ , @DRUG$ CONTRAINDICATED to potential for serious reactions such as prolonged or increased respiratory .	DDI-false
Aspirin, @DRUG$, heparin, @DRUG$	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
that @DRUG$ did influence @DRUG$ clearance	DDI-false
Therefore patients @DRUG$ should @DRUG$ deleted from therapeutic regimen	DDI-advise
effect @DRUG$   on @DRUG$	DDI-false
- @DRUG$: @DRUG$ may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.	DDI-false
When @DRUG$ inducers clearance , such as efavirenz @DRUG$ , , carbamazepine use of dose of 70 CANCIDAS should	DDI-advise
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
Although have not been with drugs @DRUG$ dapsone , quinine , , , cyclosporine ergot , , , alfentanyl , @DRUG$ have plasma when	DDI-false
glucocorticoids to PROLEUKIN-induced effects including fever , renal , hyperbilirubinemia , dyspnea concomitant administration agents reduce antitumor effectiveness PROLEUKIN and should avoided @DRUG$ @DRUG$ potentiate hypotension .	DDI-false
in have shown that @DRUG$ attenuates certain adrenocortical steroid , including @DRUG$ .	DDI-effect
Substances of ( eg , and @DRUG$ ) decrease metabolism increase @DRUG$ concentrations .	DDI-mechanism
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
be exercised @DRUG$ administered drugs that may decrease the or activity steroid as , @DRUG$ and .	DDI-advise
are of that reduce blood-glucose-lowering niacin , danazol , diuretics @DRUG$ ( e.g. @DRUG$ salbutamol terbutaline ) phenothiazine , somatropin thyroid hormones , estrogens progestogens ( )	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-effect
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, @DRUG$ GI motility agents: cisapride	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
To evaluate impact chemotherapy plus HAART the clinical course of patients systemic , non-Hodgkin ( retrospectively a with who were treated with @DRUG$ , doxorubicin , and @DRUG$ CHOP ) plus with 80 who were treated a CHOP-like ( i.e. , cyclophosphamide , and prednisone vincristine bleomycin antiretroviral	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
5HT3 Antagonists Based reports of and of when @DRUG$ administered @DRUG$ , the concomitant use of with drugs of the ( including , , , granisetron , palonosetron , and ) contraindicated .	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
(1968, 1970), the higher serum concentrations of @DRUG$ and cephaloridine reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-mechanism
, , Didanosine , , Indanavir , @DRUG$ , carbamazepine , @DRUG$ , .	DDI-false
Oral Contraceptives Coadministration of @DRUG$ oral and @DRUG$ by approximately % and %	DDI-mechanism
Although specific studies were not @DRUG$ doses of 1 mg were concomitantly in studies acetaminophen , acid , analgesics , angiotensin-converting enzyme ) benzodiazepines , beta calcium-channel blockers cardiac , diuretics H2 antagonists , reductase , synthetase inhibitors to ) , @DRUG$ without evidence significant .	DDI-false
in medium consisting medium RPMI1640 containing transferrin 1 , @DRUG$ ( 10 ) @DRUG$ ( 3.7 micrograms/ml or IU/ml	DDI-false
@DRUG$ : Patients @DRUG$ with volume may experience an of blood pressure after initiation of fosinopril	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
While @DRUG$ @DRUG$ ) , e.g. , escitalopram , fluoxetine , and paroxetine 2D6 , they in extent of inhibition .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Lithium usually reversible discontinuation of @DRUG$ and @DRUG$.	DDI-effect
To evaluate plus HAART clinical course of patients , systemic , ( ) compared of HIV-NHL treated with the cyclophosphamide doxorubicin and @DRUG$ ( regimen plus HAART 80 who were treated or a , @DRUG$ , teniposide , prednisone plus bleomycin without receiving antiretroviral	DDI-false
These drugs and other corticosteroids phenothiazines , @DRUG$ , contraceptives @DRUG$ , acid , sympathomimetics , calcium drugs , and .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, @DRUG$, and vincristine.	DDI-false
In clinical FLOLAN was with diuretics , oral vasodilators and In a pharmacokinetic in with furosemide @DRUG$ , clearance values furosemide = and @DRUG$ n 30 were 13 15 % , on the of therapy and had values	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
include @DRUG$ , @DRUG$ , phenothiazines , , oral , phenytoin nicotinic acid sympathomimetics channel blocking drugs ,	DDI-false
Although specific studies were performed @DRUG$ doses concomitantly in clinical acetaminophen , acetylsalicylic acid , , , angiotensin-converting ) inhibitors , , benzodiazepines , blockers , , , , antagonists HMG-CoA @DRUG$ also referred to NSAIDs , and anti-infectives without evidence of clinically significant .	DDI-false
Other reported interactions with @DRUG$: Fentanyl (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
Drugs Should Not With VIRACEPT : @DRUG$ Antihistamines : astemizole Antimigraine ergot Antimycobacterial rifampin , @DRUG$ motility	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other Cardiovascular Agents and enalapril IV have been beta , @DRUG$ , nitrates , @DRUG$ and digoxin of clinically significant interactions	DDI-false
magnitude of changes diazepam coadministered with @DRUG$ not sufficient to warrant adjustments , patients enhanced sedative increased exposure @DRUG$ this	DDI-effect
Anti-arrhythmics and @DRUG$ could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
@DRUG$ supplements L-lysine may @DRUG$ absorption	DDI-false
Compounds man , @DRUG$ , phenytoin @DRUG$ , .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
may increase slightly the of @DRUG$ , , methyldopa	DDI-false
@DRUG$: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
study in which the 2 mg @DRUG$ orally disintegrating was with and without ( anticholinergic agent with on ) to volunteers , AUC of clonazepam was 10 lower the Cmax was 20 tablet was given @DRUG$ given alone	DDI-false
: subjects given single doses of cephalexin @DRUG$ @DRUG$ cmax and increased by an average % 24 , and metformin mean clearance by .	DDI-false
Ethanol : @DRUG$ potentiated CNS-impairing effects @DRUG$ 0.75 testing and reaction time ethanol administration and on digit symbol DSST ) copying the component ethanol administration	DDI-effect
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Drugs : In of ( 7 - , the of azathioprine @DRUG$ , chloroquine , , , , @DRUG$ not affect peak levels of diclofenac	DDI-false
The intensity , and time course anticoagulant interference @DRUG$ glutethimide , chloral hydrate @DRUG$ systematically patients coumarin .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Multivalent Products quinolone including , with cation-containing products @DRUG$ or antacids , sucralfate , or products containing @DRUG$ , decrease ciprofloxacin , in serum .	DDI-false
a of digitalis tolerance dogs anesthetized with Vet , pentobarbital , the of ouabain to significantly , was the LD50 of @DRUG$ with ketamine Innovar	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
The administration local solutions containing @DRUG$ or norepinephrine patients receiving inhibitors , @DRUG$ may prolonged hypotension hypertension	DDI-effect
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
a study the clonazepam disintegrating was administered without @DRUG$ with GI healthy volunteers of lower and was the orally disintegrating with @DRUG$ compared to when alone	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Anticoagulants : studies have shown @DRUG$ to interact the warfarin caution exercised nonetheless , since been seen with @DRUG$.	DDI-advise
clinical studies performed Fondaparinux use @DRUG$ @DRUG$ ) , acetylsalicylic ) , ( piroxicam ) , did the pharmacokinetics/pharmacodynamics of sodium	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
Lithium carbonate: The anorectic and stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
Oxidase FORADIL should administered in being with @DRUG$ or antidepressants because of @DRUG$ on the cardiovascular system be potentiated by these agents	DDI-false
( @DRUG$ ): @DRUG$ concentrations not affected of .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
: small patients ( 7 - 10/interaction the administration azathioprine , gold chloroquine , @DRUG$ @DRUG$ did significantly the levels and values of .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
An alternative @DRUG$ may be CYP3A4 as @DRUG$ , and	DDI-false
@DRUG$ : It not been there a interaction between acitretin	DDI-false
This study demonstrates that concurrent administration of @DRUG$ permits at least a twofold increase in dose and total exposure to @DRUG$.	DDI-mechanism
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Drugs That Should : @DRUG$ , , : @DRUG$ agents : Benzodiazepines triazolam motility agents : cisapride	DDI-false
The are of substances reduce the : , danazol diuretics sympathomimetic ( , , @DRUG$ , isoniazid , @DRUG$ , thyroid , , e.g. , in oral contraceptives	DDI-false
Drug : @DRUG$ interact with some drugs Monoamine ( MAOI ): theoretically pharmacodynamics - Eproxindine @DRUG$ Flupenthixol and Ethanol depression Tricyclic the	DDI-false
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
between @DRUG$ , , @DRUG$ and have been .	DDI-false
Paroxetine: Coadministration of a single dose of @DRUG$ 20 mg and @DRUG$ 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with PRINIVIL.	DDI-false
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
action of sulfonylurea potentiated certain drugs including other drugs that , salicylates , , @DRUG$ monoamine inhibitors ,	DDI-false
receiving other , @DRUG$ tranquilizers sedative-hypnotics , other CNS ( including alcohol concomitantly with DILAUDID may exhibit an depression .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Drugs that with peripheral include antiretroviral nucleoside analogues disulfiram , , @DRUG$ , , , iodoquinol @DRUG$ , nitrofurantoin , phenytoin , ribavirin and .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
have associated with neuropathy include antiretroviral nucleoside analogues cisplatin , @DRUG$ , ethionamide , @DRUG$ hydralazine isoniazid phenytoin , ,	DDI-false
studies reduction in oral administered concomitantly an @DRUG$ such @DRUG$.	DDI-false
@DRUG$: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	DDI-false
pharmacokinetic have demonstrated concomitant administration of and ( @DRUG$ tablets reduced protein @DRUG$ , there was no in the free	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Data studies @DRUG$ suggest drug interaction the following , amiodarone , and	DDI-int
Imidazoles ( e. g. , @DRUG$ , miconazole . ): studies of B that resistance to	DDI-false
Ergot Derivatives: @DRUG$, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
INOmax has been administered with @DRUG$, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), @DRUG$.	DDI-false
- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	DDI-advise
@DRUG$ , including oral : @DRUG$ hepatic metabolism thereby their effect	DDI-false
Serial urine of amprenavir @DRUG$ , and @DRUG$ and their 25-O-desacetyl metabolites , were chromatography .	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
Patients on @DRUG$ should receive of @DRUG$	DDI-advise
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
and @DRUG$ are used observed to determine if of @DRUG$ .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Aspirin: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	DDI-false
The effects of @DRUG$ (RR) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Both and @DRUG$ decrease extracellular levels of in @DRUG$ of serotonin accumbens .	DDI-false
While and ibogaine have affinities for opioid nicotinic receptors @DRUG$ affinities @DRUG$ for NMDA sigma-2 receptors sodium and	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
effects resulting from blockade may occur is with other @DRUG$ @DRUG$ , phenothiazines monoamine oxidase MAO inhibitors antidepressants or antihistamines .	DDI-false
These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
A two-way interaction between the @DRUG$, phenytoin, and the @DRUG$s has been suggested.	DDI-int
Use with @DRUG$: The principal pathway for detoxification of azathioprine is inhibited by @DRUG$.	DDI-false
@DRUG$, but not @DRUG$, decreases heart rate at high doses.	DDI-false
been : extended formulation of @DRUG$ with itraconazole increase in the AUC 6- in the , and 2-fold prolongation the half- life of	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-mechanism
@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-false
However , crossover in healthy subjects receiving either @DRUG$ 300 . 800 mg h.s . concomitantly a 300 mg . of @DRUG$ Theo-Dur , , Inc. ) less alteration theophylline serum levels the mg regimen particularly in subjects 54 and .	DDI-mechanism
Nervous : The concomitant fentanyl system ) with other nervous including but limited @DRUG$ , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) @DRUG$ skeletal muscle and alcohol , respiratory depression , hypotension and sedation or result in	DDI-false
The extent to SSRI-@DRUG$interactions pose clinical of pharmacokinetics the @DRUG$ involved	DDI-false
Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-false
@DRUG$ Concomitant administration of @DRUG$ at 200 QD resulted in plasma concentration	DDI-false
A direct causal relationship has been , physicians consider the @DRUG$ alter patient @DRUG$.	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Carbamazepine @DRUG$ reported @DRUG$ is administered concomitantly	DDI-mechanism
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
As with some other @DRUG$, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	DDI-false
Lithium generally @DRUG$ reduce lithiums clearance risk @DRUG$ toxicity .	DDI-false
@DRUG$ ( 40 mg/kg ) 18-MC 40 mg/kg ) self-administration and cocaine the oral self-administration of and @DRUG$ rats	DDI-false
@DRUG$: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
Particular caution should with @DRUG$ there are for effect of hydrochloride on of @DRUG$ digitoxin	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
concomitant therapy Although specific interaction studies performed of mg more concomitantly clinical studies with acetaminophen acid , a-blockers analgesics angiotensin-converting , benzodiazepines blockers , @DRUG$ @DRUG$ , , H2 antagonists HMG-CoA reductase , inhibitors ( also as NSAIDs and quinolone without adverse interactions .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Anti-inflammatory Drugs : patients the administration of @DRUG$ the diuretic , , antihypertensive effects loop @DRUG$.	DDI-effect
@DRUG$ and colestipol resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
on known , significant interactions are expected between dapsone trimethoprim/@DRUG$ @DRUG$ , , itraconazole or fluconazole .	DDI-false
The of @DRUG$ IV vasodilators such as nitroglycerin @DRUG$ milrinone has evaluated were not co-administered clinical )	DDI-false
@DRUG$, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
@DRUG$ : of zalcitabine reduced ( % when antacid products	DDI-false
Hepatic Enzyme , and Substrates Drugs cytochrome P450 ) enzyme @DRUG$ @DRUG$ , carbamazepine , may the metabolism of corticosteroids require the dosage of the corticosteroid .	DDI-false
DURAGESIC ( transdermal ) with central nervous system including but to other opioids , , e.g. benzodiazepines , @DRUG$ @DRUG$ skeletal muscle and may respiratory depression hypotension and sedation or death .	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Benzylpenicillin , @DRUG$ , oxacillin , chlortetracycline , doxycycline cephalothin , @DRUG$ have influence vitro the protein of diclofenac in serum .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
@DRUG$ : @DRUG$	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
5HT3 Antagonists : Based on profound of consciousness @DRUG$ with ondansetron , use of drugs class ( including , ondansetron @DRUG$ , and .	DDI-false
) Taking @DRUG$ and @DRUG$ together may decrease piperazine .	DDI-effect
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Example inhibitors include azole antifungals , @DRUG$ @DRUG$ , , , erythromycin , imatinib , , , inhibitors , quinidine and .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
@DRUG$ @DRUG$ Amphetamines of antidepressants	DDI-false
receiving analgesics , general anesthetics @DRUG$ sedative-hypnotics , tricyclic or other CNS depressants ( ) concomitantly @DRUG$ exhibit an CNS .	DDI-effect
These include @DRUG$ and , @DRUG$ , phenothiazines , thyroid , estrogens , contraceptives phenytoin acid , sympathomimetics and	DDI-false
- @DRUG$ (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Antagonists : on reports profound hypotension consciousness was with , the use with drugs of @DRUG$ ( including example ondansetron @DRUG$ and alosetron	DDI-false
Patients other narcotic @DRUG$ , @DRUG$ CNS depressants ( alcohol ) concomitantly may an CNS depression .	DDI-false
following are substances may blood-glucose-lowering effect and hypoglycemia antidiabetic products ACE inhibitors , disopyramide , @DRUG$ @DRUG$ , MAO inhibitors propoxyphene , salicylates , somatostatin analog e.g. octreotide antibiotics .	DDI-false
This interact with other depressants of medications , @DRUG$ or medications with anticholinergic activity ( effects be when medications used concurrently with antihistamines and ( MAO ( concurrent with antihistamines may and intensify anticholinergic and CNS depressant @DRUG$ )	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), erythromycin, @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
In patients taking diclofenac and @DRUG$ concomitantly , @DRUG$ toxicity develop .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
The a between @DRUG$ @DRUG$ concentrates not or clinical	DDI-false
@DRUG$ Coadministration doses of Sonata and @DRUG$ mg additive effects on impaired performance 2 to 4 hours after administration .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
The following examples of substances that may the effect to : oral antidiabetic products ACE inhibitors , , fibrates , fluoxetine , ( ) inhibitors , @DRUG$ , somatostatin analog ( e.g. , @DRUG$ ) , antibiotics	DDI-false
vitro studies human serum proteins indicate that @DRUG$ binds than @DRUG$ and does not or dicumarol	DDI-false
Other drugs which may enhance blocking agents antibiotics e. g. , aminoglycosides , bacitracin polymyxins , lincomycin clindamycin colistin , colistimethate , , @DRUG$ , @DRUG$ , and quinidine .	DDI-false
Cardiovascular : and @DRUG$ have used beta agents , agents , @DRUG$ prazosin and without evidence of clinically significant adverse	DDI-false
Reports in the suggest levels ( its active @DRUG$ ) be increased when @DRUG$ combination .	DDI-false
@DRUG$ : 800 t.i.d ) co-administered Vardenafil resulted in a in vardenafil a in @DRUG$ increase in half-life	DDI-false
, diclofenac interferes all with the protein binding of salicylic 20 % decrease binding ) @DRUG$ ( 10 % decrease in )	DDI-false
@DRUG$ of ritonavir resulted % increase plasma AUC and very change @DRUG$	DDI-false
: b-lactam , excretion of @DRUG$ @DRUG$ and resulted increase for .	DDI-mechanism
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
@DRUG$ be caution to receiving Antabuse @DRUG$ , Wyeth-Ayerst Laboratories )	DDI-advise
SINCE THE ADMINISTRATION OF THESE DRUGS LEAD @DRUG$ TO ADMINISTERING DISULFIRAM TO THERAPY @DRUG$ LEVEL SHOULD BE .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
aluminum-containing antacids products ferrous sulfate @DRUG$ preparations or , or @DRUG$ the pediatric powder for oral should be within hours before or FACTIVE .	DDI-false
With the morning dose of @DRUG$ on day 6, each volunteer received a single intravenous infusion of @DRUG$ (4 mg/kg).	DDI-false
In a pharmacokinetic interaction study with @DRUG$, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of @DRUG$ were not significantly changed.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
To Date Levosimendan not have clinically important with @DRUG$ , , felodipine digoxin warfarin @DRUG$ , carvedilol itraconazole .	DDI-false
- @DRUG$: Bumetanide may potentiate the effect of various @DRUG$, necessitating a reduction in the dosage of these drugs.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
In vitro @DRUG$ not binding of salicylic ) , tolbutamide , ,	DDI-mechanism
@DRUG$ has not been effect obtained with @DRUG$ and excretion of concomitant use not recommended .	DDI-false
systemic ( AUC0 12 @DRUG$ ( ) was than doubled of .	DDI-false
@DRUG$ : Eszopiclone daily did not the or , nor there any changes in the pharmacodynamic ( prothrombin 25 oral dose of @DRUG$	DDI-false
@DRUG$: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
- The sulphonylureas and insulin be @DRUG$ or	DDI-false
@DRUG$ When @DRUG$ aspirin its binding , of free etodolac	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
Concomitant administration ( mg ) @DRUG$ 20 mg ) for % ( % to ) @DRUG$ in 22 healthy .	DDI-false
Potentiation warfarin-type @DRUG$ and substrate ) @DRUG$ response always seen result in serious or fatal bleeding	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Drugs With A Therapeutic Index @DRUG$ single of @DRUG$ mg did not pharmacokinetics digoxin state following daily for day daily for next days	DDI-false
@DRUG$ with Other Drugs : @DRUG$ cimetidine ( 800 mg/day patients taking had effect on tiagabine	DDI-false
@DRUG$ Concomitant use of @DRUG$ and corticosteroids may weakness in .	DDI-false
Other therapy interaction studies performed finasteride or were concomitantly clinical @DRUG$ acetylsalicylic acid a-blockers , enzyme ACE inhibitors , @DRUG$ calcium-channel , , H2 , inhibitors inhibitors ( referred to as and quinolone of significant interactions	DDI-false
@DRUG$ on : does to of @DRUG$ carbamazepine or .	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-false
of patients taking TYSABRI @DRUG$ mcg IM once weekly ) or glatiramer acetate inconclusive with to the need for or	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Reciprocal occur concomitant use of @DRUG$ and inhibit the cytochrome system ( e.g. , @DRUG$ , ketoconazole though this	DDI-mechanism
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ , including @DRUG$ enhance of , its or	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ ( ) , atropine other @DRUG$ or digitalis glycosides : concurrent arbutamine and/or chronotropic effects	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ Coadministration @DRUG$ resulted in 27 almotriptan clearance and an increase of approximately 6	DDI-false
The extent to @DRUG$-@DRUG$interactions pose clinical problems on the degree of inhibition pharmacokinetics the involved	DDI-int
- maleate or @DRUG$ potential must not administered together Bezalip or @DRUG$.	DDI-advise
reduced the - @DRUG$ 20 % , peak blood Cmax by % , and 12-hour ( C12hr 26 % in healthy ( doses mg/kg 12 on 10th of CANCIDAS 70 mg daily results from control period in which @DRUG$ was administered alone .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Nephrotoxic of VISTIDE agents nephrotoxic [ , @DRUG$ ( , tobramycin , , amikacin ) B , @DRUG$ pentamidine vancomycin and anti-inflammatory agents is contraindicated	DDI-false
ibogaine ( 40 , @DRUG$ mg/kg intravenous ethanol and @DRUG$ rats ;	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, @DRUG$, topiramate, or lamotrigine.	DDI-false
Antihypertensive Medications and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Additive CNS depression may occur when @DRUG$ with @DRUG$ including and .	DDI-effect
under the influence sympatholytic products as @DRUG$ @DRUG$ , guanethidine , the hypoglycemia be absent	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other Drugs on the of Literature reports @DRUG$ , decreases stomach alter @DRUG$ pharmacokinetics	DDI-false
Vitamin A : of @DRUG$ vitamin A patients should be advised taking @DRUG$ containing avoid additive effects	DDI-false
concomitant Although @DRUG$ of more were used studies with , @DRUG$ , , angiotensin-converting enzyme ( ) anticonvulsants blockers blockers nitrates , diuretics , H2 , reductase inhibitors , prostaglandin synthetase ( also referred to NSAIDs ) quinolone evidence of clinically adverse interactions	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : @DRUG$ , renal tubular blocking agent , mg four , did the twice	DDI-false
Multivalent Products of a @DRUG$ including , with cation-containing products antacids , @DRUG$ tablets pediatric , products , iron , zinc substantially of , resulting in serum and urine levels considerably than .	DDI-mechanism
@DRUG$: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Theophylline with quinolones , concurrent of @DRUG$ with @DRUG$ may to elevated theophylline prolongation of its half-life .	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and @DRUG$ that resulted in apnea.	DDI-false
in , , @DRUG$	DDI-false
studies with , concomitant oral warfarin , platelet @DRUG$ ) @DRUG$ ( piroxicam and affect the pharmacokinetics/pharmacodynamics of fondaparinux .	DDI-false
@DRUG$ and Corticotropin (@DRUG$): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
In performed Fondaparinux the use oral @DRUG$ ( ) inhibitors ( ) , ) , and digoxin significantly affect the pharmacokinetics/pharmacodynamics	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
drugs may enhance neuromuscular blocking action of such include certain e. g. , aminoglycosides , tetracyclines , polymyxins , lincomycin , , , @DRUG$ , salts @DRUG$ , local and	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-false
Imipramine ( 5 mg/kg @DRUG$ ( 30 , clonazepam 0.25 mg/kg , @DRUG$ ( ) sertraline ( ) or was administered	DDI-false
Additionally , paroxetine did not alter the pharmacokinetics @DRUG$ , reflecting of a role of CYP2D6 @DRUG$ .	DDI-false
containing side N-methylthiotetrazole @DRUG$ , cefoperazone cefotetan , @DRUG$ or methylthiadiazole ( cefazolin cause vitamin deficiency .	DDI-false
: pharmacokinetic interactions were and the glyburide , @DRUG$ , , and @DRUG$.	DDI-false
steroids @DRUG$ ] @DRUG$ ] , oxymetholone Anadrol e.g. , ]	DDI-false
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving cyclopropane or @DRUG$.	DDI-advise
studies have that does not have any clinically significant interactions with phenytoin , @DRUG$ , quinidine clarithromycin or	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$ effect warfarin was in a healthy doses of - 5 mg @DRUG$.	DDI-false
concomitant therapy interaction studies were @DRUG$ of 1 mg with acetaminophen , , @DRUG$ , angiotensin-converting ( ACE ) inhibitors , , beta calcium-channel blockers , nitrates diuretics , H2 antagonists inhibitors , prostaglandin synthetase ( as NSAIDs ) quinolone without evidence of interactions	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	DDI-false
- Lithium: @DRUG$ should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
Drugs That Be VIRACEPT @DRUG$ Antihistamines astemizole , Antimigraine @DRUG$ , GI motility agents :	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Further, in clinical studies with @DRUG$ (@DRUG$, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.	DDI-false
@DRUG$ have reported blunt the systemic	DDI-effect
Concurrent administration possessing nephrotoxic ( e.g. , @DRUG$ ) , myelotoxic ( , chemotherapy ) ( e.g. , doxorubicin ) hepatotoxic e.g. , methotrexate @DRUG$ ) effects with PROLEUKIN may increase toxicity in these organ	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or phenobarbital.	DDI-false
5HT3 Antagonists : reports of hypotension when was administered with the use of apomorphine with of the @DRUG$ , for example , ondansetron , dolasetron palonosetron , and @DRUG$ ) contraindicated	DDI-false
Benzylpenicillin , , oxacillin , @DRUG$ @DRUG$ erythromycin and have in vitro on binding in human .	DDI-false
Patients receiving other narcotic general @DRUG$ phenothiazines , @DRUG$ tricyclic CNS depressants ( alcohol with exhibit an additive CNS	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-mechanism
following of drugs the of related benzodiazepines , inhibition of CYP3A nefazodone , @DRUG$ , @DRUG$ isoniazide , macrolide	DDI-false
to which pose clinical will degree inhibition and pharmacokinetics @DRUG$ involved	DDI-false
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, @DRUG$.	DDI-false
The following of to other related @DRUG$ through : nefazodone @DRUG$ , diltiazem , isoniazide , macrolide .	DDI-mechanism
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
All @DRUG$ 1,200 mg a day for washout , by rifabutin ( 300 mg once a day QD ) 1 @DRUG$ ( 600 ) ( 2 for days .	DDI-false
not significantly @DRUG$ @DRUG$ , or .	DDI-false
Drugs Should Not Be With : @DRUG$ , terfenadine Antimigraine derivatives Antimycobacterial agents Benzodiazepines , triazolam GI motility agents @DRUG$	DDI-false
poor @DRUG$ : Interactions of with strong ( such , paroxetine , and not been studied but these drugs would be increase blood levels @DRUG$ .	DDI-false
In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
@DRUG$/acetaminophen , and valproic .	DDI-false
A study in healthy volunteers n=24 mixing with @DRUG$ before injection produced some attenuation in the concentration of @DRUG$ but and not	DDI-false
@DRUG$: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-effect
of hypotensive effects the @DRUG$ intake one week of with @DRUG$ , USP or therapy with doses 6.25 or 12.5 .	DDI-false
Ethinyl and @DRUG$ : Coadministration @DRUG$ resulted a 47 ethinyl estradiol and 18 decrease norethindrone plasma	DDI-false
the impact chemotherapy plus HAART clinical of patients HIV-related , systemic , lymphoma , the of with who were @DRUG$ @DRUG$ vincristine and ( chemotherapy regimen a of 80 patients were treated with CHOP CHOP-like regimen doxorubicin , , with plus without antiretroviral	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
of clinical studies or of concomitant with @DRUG$ : @DRUG$ NSAIDs corticosteroids TNF blocking agents azathioprine , , , hydroxychloroquine , sulfasalazine .	DDI-false
Although there no to the possibility , @DRUG$ and , may have an effect @DRUG$ on of developing .	DDI-effect
Results of studies in multiple sclerosis @DRUG$   and interferon beta-1a (   30 mcg weekly were regard need for dose the beta-interferon or @DRUG$.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
In a in mg disintegrating tablet with and without @DRUG$ ( an anticholinergic agent effects the volunteers AUC of @DRUG$ was 10 % lower and of clonazepam lower when the orally tablet was with propantheline to it given	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
The following of substances blood-glucose-lowering effect : corticosteroids @DRUG$ , danazol e.g. epinephrine , salbutamol , isoniazid , derivatives somatropin hormones , @DRUG$ e.g. oral .	DDI-false
@DRUG$ possibly other tricyclics striking concentration of @DRUG$ in brain ;	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ @DRUG$ are inhibited by amphetamines.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
changes from , or without @DRUG$ replacement alter the pharmacokinetics certain , such and	DDI-false
The absorption @DRUG$ hydrochlorothiazide and @DRUG$ significantly when simultaneously with colestipol hydrochloride ;	DDI-false
Two percent of @DRUG$ and @DRUG$ neutropenia ( 1 x .	DDI-effect
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Anabolic steroids ( nandrolone [ , @DRUG$ e.g. , , oxymetholone [ @DRUG$ , e.g. , ]	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, @DRUG$, sulfasalazine, and anakinra.	DDI-false
The of local containing or @DRUG$ oxidase @DRUG$ may , prolonged .	DDI-effect
Example include antifungals , ciprofloxacin , , doxycycline , , nefazodone @DRUG$ @DRUG$ , , quinidine , and verapamil .	DDI-false
@DRUG$: Macrolide antibiotics have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-false
that have been associated peripheral include antiretroviral @DRUG$ , cisplatin , , , , @DRUG$ , , ribavirin vincristine .	DDI-false
with @DRUG$ use of angiotensin enzyme control hypertension in @DRUG$ has induce severe leukopenia	DDI-false
Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking @DRUG$ and metformin.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
evaluate plus course systemic lymphoma ( HIV-NHL ) , the authors retrospectively of patients with who were the cyclophosphamide , , @DRUG$ regimen group 80 who treated or a CHOP-like i.e. , teniposide , prednisone @DRUG$ antiretroviral .	DDI-false
CONCOMITANT THESE TWO PRIOR TO DISULFIRAM TO @DRUG$ , BASELINE @DRUG$ LEVEL SHOULD BE OBTAINED .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Potassium Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by @DRUG$.	DDI-effect
( [ e.g. , oxandrolone [ ] , e.g. ] , @DRUG$ e.g. , @DRUG$ ] )	DDI-false
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The co-administration of Natrecor with IV vasodilators such as @DRUG$, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Nervous System : of DURAGESIC   transdermal system ) with nervous depressants , but not to opioids sedatives hypnotics @DRUG$ e.g. general , @DRUG$ skeletal muscle relaxants , and , respiratory , hypotension and , coma .	DDI-false
Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Saquinavir Coadministration @DRUG$ ( soft-gelatin capsule formulation of 1200 mg with an 18 % in @DRUG$ plasma and a A.C.	DDI-false
Beta-blocking Agents : use @DRUG$ @DRUG$ with angina	DDI-false
A similar marked , suggested @DRUG$ phenylbutazone , carbamazepine @DRUG$ topiramate , and and tetracyclines .	DDI-false
Because changes concentrations @DRUG$ coadministration within the individual above or dose adjustment for ( mg QD 10 mg BID ) with @DRUG$ coadministration 40 mg QD ) is indicated .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Use with Allopurinol: The principal pathway for detoxification of @DRUG$ is inhibited by @DRUG$.	DDI-mechanism
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Both @DRUG$ and morphine-induced and @DRUG$-induced dopamine the nucleus accumbens	DDI-effect
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
the concomitant of oral @DRUG$ ) platelet @DRUG$ piroxicam and digoxin significantly the of sodium	DDI-false
, , , @DRUG$/valproic , , theophylline/acetaminophen and acid/phenobarbital .	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
@DRUG$ : @DRUG$ enhances warfarin .	DDI-effect
Although no specific drug with glaucoma or systemic medications were identified clinical studies of IOPIDINE 0.5 Ophthalmic , the additive effect with depressants @DRUG$ , @DRUG$ opiates , anesthetics ) considered .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
Administration of @DRUG$ to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 @DRUG$: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for @DRUG$ metabolism.	DDI-false
It is recommended that if CASODEX is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	DDI-false
The following that reduce blood-glucose-lowering effect corticosteroids @DRUG$ , danazol diuretics sympathomimetic e.g. , epinephrine , ) , @DRUG$ derivatives , hormones estrogens in oral ) .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Because prostaglandins an in @DRUG$ platelet as concurrent therapy all NSAIDs , including diclofenac , and to no change in @DRUG$ dosage required	DDI-false
, Nimodipine and @DRUG$ : has no pharmacokinetic interactions with @DRUG$ and nimodipine and no effect on plasma of .	DDI-false
When CANCIDAS clearance , such @DRUG$ , @DRUG$ , , carbamazepine 70 mg CANCIDAS be considered	DDI-false
Clidinium may decrease the effect of @DRUG$ and	DDI-false
, @DRUG$ of @DRUG$ ( by approximately 50 ) by the same .	DDI-mechanism
The concomitant use CYP3A4 inhibitors such as @DRUG$ and erythromycin transdermal fentanyl result @DRUG$ plasma which increase or prolong adverse drug and respiratory	DDI-false
effect @DRUG$ @DRUG$ not due action but is to its of	DDI-mechanism
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
- of @DRUG$ may be enhanced by @DRUG$	DDI-effect
@DRUG$: Caution should be used if @DRUG$ is administered concomitantly with methotrexate.	DDI-false
of in RA clinical or more the following concomitant medications ORENCIA : , NSAIDs , agents @DRUG$ @DRUG$ gold , hydroxychloroquine leflunomide , and anakinra .	DDI-false
results suggest that @DRUG$ and @DRUG$ , and possibly glucocorticoids regulate proliferation of prostate epithelium a of and EGF	DDI-false
Chemotherapy Agents a , concomitant administration @DRUG$ capecitabine did not meaningfully the metabolites of @DRUG$ )	DDI-false
It may be necessary to adjust the dosage @DRUG$ upon beginning or disulfiram . @DRUG$ prolong prothrombin .	DDI-false
Non-selective tranylcypromine phenelzine , @DRUG$ : Concomitant use @DRUG$ and non-selective hypertension	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Multivalent Cation-Containing : Concurrent administration , ciprofloxacin , with multivalent aluminum antacids , tablets or products calcium , @DRUG$ , or @DRUG$ the absorption of ciprofloxacin levels lower than desired	DDI-false
As with agents it noted HALDOL may be capable of potentiating @DRUG$ as , @DRUG$ .	DDI-false
Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-effect
Warfarin : of effect of @DRUG$ 8 mg/day in healthy of @DRUG$ BID 7 days .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
of non-nucleoside transcriptase and concerns regarding inhibitor (@DRUG$)-related led significant in HIV	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
@DRUG$: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.	DDI-false
Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead.	DDI-false
@DRUG$ : administration of @DRUG$ levels , by protein-binding	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
and decreased been reported in concomitantly receiving @DRUG$ and	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
@DRUG$ : Plasma concentrations of @DRUG$ 25 when colestipol atorvastatin were	DDI-false
Digoxin @DRUG$ , like @DRUG$ , through effects on renal may changes the elimination these drugs elevated of digoxin methotrexate toxicity	DDI-false
The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$ may potentiated by drugs agents and drugs are protein , sulfonamides , @DRUG$ coumarins inhibitors and adrenergic	DDI-effect
Cephalosporins-Cephalosporins side chains of N-methylthiotetrazole ( cefoperazone @DRUG$ @DRUG$ latamoxef ) can vitamin K and hypoprothrombinemia .	DDI-false
In comparison of in with Vet , pentobarbital the cause significantly the LD50 of @DRUG$ , ketamine @DRUG$ than pentobarbital	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving @DRUG$.	DDI-advise
Patients @DRUG$ and @DRUG$ closely to determine the diuretic and/or of achieved	DDI-advise
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Lithium NSAIDs elevation of @DRUG$ @DRUG$ clearance .	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
@DRUG$ Supplements Potassium-Sparing : can loss caused by	DDI-false
These drugs include other diuretics , @DRUG$ , phe-nothiazines , thyroid estrogens oral @DRUG$ , , sympathomimet-ics drugs and isoniazid .	DDI-false
Beta-blockers, @DRUG$, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
following examples of reduce : corticosteroids , sympathomimetic agents ( e.g. , @DRUG$ salbutamol , ) isoniazid , derivatives , , hormones , estrogens progestogens e.g. , in oral @DRUG$ )	DDI-false
Other may enhance neuromuscular such @DRUG$ antibiotics g. , aminoglycosides tetracyclines , polymyxins , lincomycin , sodium magnesium salts @DRUG$ , , , .	DDI-effect
Steady-state concentrations @DRUG$ about % higher dexamethasone was dose of @DRUG$ ( 15 in .	DDI-false
Like ( 40 , @DRUG$ mg/kg decreases cocaine self-administration of @DRUG$ nicotine in rats	DDI-false
The pharmacokinetics of @DRUG$ (Cmax and AUC) were not affected during multiple-dose @DRUG$, suggesting no clinically significant pharmacokinetic interaction.	DDI-false
Although no drug topical glaucoma drugs identified clinical studies 0.5 % , the possibility additive effect CNS depressants @DRUG$ barbiturates opiates @DRUG$ , should	DDI-false
Reciprocal concomitant of @DRUG$ increase inhibit cytochrome P450 cimetidine @DRUG$ ) , this	DDI-mechanism
These drugs the and other diuretics , , , @DRUG$ , oral contraceptives , , @DRUG$ , , calcium , and .	DDI-false
@DRUG$: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
@DRUG$ : @DRUG$ CYP substrate 2C19 inhibitor	DDI-false
Compounds these categories in decreased efficacy of bromocriptine , @DRUG$ @DRUG$ pimozide .	DDI-false
with medication e.g. , ) , @DRUG$-containing , @DRUG$ famotidine and e.g. , lansoprazole .	DDI-false
@DRUG$ could of the QT interval with @DRUG$.	DDI-effect
A between and a @DRUG$ reported resulting a hypoglycemic of @DRUG$.	DDI-false
therefore , use of @DRUG$ an @DRUG$ to maintain therapeutic .	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Stavudine @DRUG$ can in vitro stavudine and @DRUG$ HIV	DDI-false
@DRUG$ ( ) , 40 decreases @DRUG$ and oral and in rats	DDI-false
conversely, @DRUG$ may interfere with antihypertensive drugs (i.e., guanethidine, @DRUG$).	DDI-int
This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites.	DDI-mechanism
Plasma exposure of diazepam 10 mg was increased by % following administration @DRUG$ mg BID 12 days , while @DRUG$ 40 BID ) not increased of diazepam ( mg BID ) 12 days .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
@DRUG$- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
with @DRUG$ : analgesics ( eg pentazocine , @DRUG$ , ) should be to a has received is receiving a course therapy analgesic such Levo-Dromoran	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-advise
Chlorpromazine Chlorpromazine and thus inhibiting the @DRUG$ and be used @DRUG$	DDI-false
@DRUG$ concentrations be closely therapy with receiving @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
: Lorazepam injection like @DRUG$ nervous system when with @DRUG$ , MAO inhibitors antidepressants . When scopolamine concomitantly with lorazepam an increased incidence of , hallucinations , and irrational been	DDI-effect
Vardenafil (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	DDI-false
Cimetidine: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	DDI-mechanism
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
As @DRUG$ , it should that capable of as , @DRUG$ alcohol .	DDI-effect
@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and PEGASYS.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Antagonists : Since @DRUG$ is a agonist , it is @DRUG$ , such the ( , , diminish the of APOKYN .	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Aspirin/@DRUG$ : or have not been demonstrated Argatroban and 162.5 orally 26 and hours to Argatroban 1 over 4 ) or @DRUG$ ( mg given 12 , 0 prior , and and to ,   g/kg/min . over 18 .	DDI-false
Drugs That Should VIRACEPT @DRUG$ amiodarone quinidine : , terfenadine : derivatives Antimycobacterial agents : @DRUG$ Benzodiazepines midazolam triazolam GI agents cisapride	DDI-false
@DRUG$ : Administration of nonsteroial with @DRUG$ has with an cyclosporine-induced possibly synthesis renal	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Plasma exposure (AUC) to @DRUG$ was increased 62% when coadministered with fluconazole and 38% when coadministered with @DRUG$.	DDI-mechanism
Beta-Blocking Agents  A pharmacokinetic study of @DRUG$ in conjunction with @DRUG$ demonstrated no significant effects on the pharmacokinetics of felodipine.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
For of @DRUG$ @DRUG$ in combination Drug under PHARMACOLOGY	DDI-false
for from in infants a decision made discontinue discontinue @DRUG$ @DRUG$ treatment .	DDI-false
Dopamine Antagonists Since apomorphine a agonist , it possible that @DRUG$ , such neuroleptics ( butyrophenones , ) or @DRUG$ , diminish effectiveness	DDI-effect
a clinical , ( aluminum magnesium hydroxide @DRUG$ ) fosinopril reduced serum levels and urinary fosinoprilat as compared with @DRUG$ alone that impair absorption .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
similar association , though has been barbiturates sodium , carbamazepine with griseofulvin @DRUG$ , and @DRUG$ (	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ as @DRUG$ , , or concurrent may effect .	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
May interact following @DRUG$ ( use @DRUG$ the diuretic from working properly ;	DDI-effect
@DRUG$ to slow of increase should determined concurrent administration @DRUG$ signs and of toxicity monitored and dosage anticonvulsant should .	DDI-false
@DRUG$ are antagonized @DRUG$ , as and .	DDI-effect
Ergot Derivatives , @DRUG$ @DRUG$ due to potential for serious reactions acute characterized by and ischemia of the extremities and .	DDI-false
the impact HAART on the of patients HIV-related systemic , lymphoma ) , the authors compared retrospectively a group with HIV-NHL were treated cyclophosphamide , doxorubicin vincristine and @DRUG$ ( CHOP with a group 80 who treated chemotherapy a CHOP-like ( , doxorubicin , teniposide , and with @DRUG$ bleomycin ) receiving	DDI-false
A association , marked , has suggested with phenyl-butazone , , carbamazepine and @DRUG$ and @DRUG$ )	DDI-false
been with include antiretroviral , , , dapsone , @DRUG$ , hydralazine , @DRUG$ , isoniazid , , phenytoin , and .	DDI-false
these decreased @DRUG$ @DRUG$ haloperidol , , .	DDI-effect
Plasma to @DRUG$ 62 when with fluconazole when coadministered with @DRUG$.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
@DRUG$ : @DRUG$ appear to no significant on the of	DDI-false
Cytochrome P-450 , @DRUG$ , @DRUG$ 30 in plasma clonazepam .	DDI-mechanism
: Coadministration a single dose @DRUG$ promethazine ( 10 and 25 ) resulted in a % in plasma concentrations of @DRUG$ in the area plasma concentration-time	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
Other Drugs : small groups patients - ) , the administration of chloroquine , prednisolone @DRUG$ or digitoxin did affect the peak and values	DDI-false
Reports in the suggest that levels of and active metabolite @DRUG$ may increased when @DRUG$ are in .	DDI-false
Potential between and other AEDs @DRUG$ , gabapentin , , phenobarbital @DRUG$ , also assessed concentrations of and these AEDs during placebo-controlled clinical .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
may with , @DRUG$ ( cold , ) , drugs , @DRUG$ , and high blood medications .	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
following are examples that may increase blood-glucose-lowering effect susceptibility hypoglycemia oral @DRUG$ , inhibitors , @DRUG$ , fluoxetine monoamine ) , propoxyphene , ( , octreotide sulfonamide antibiotics	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
high doses concomitantly @DRUG$ in rheumatic may experience @DRUG$ at lower of excretory sites	DDI-false
Important Interactions To not have clinically captopril @DRUG$ , felodipine , warfarin , , ethanol @DRUG$.	DDI-false
Antidepressants ( @DRUG$ ) or anticholinergic agents @DRUG$ : use with produce additive inotropic	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
agents Concomitant VISTIDE and agents with potential , ( e.g. tobramycin @DRUG$ and amikacin B , intravenous pentamidine @DRUG$ and non-steroidal agents ]	DDI-false
Should Be With VIRACEPT : , quinidine Antihistamines astemizole : ergot derivatives @DRUG$ @DRUG$ midazolam GI :	DDI-false
The concentrations of SN38, the active metabolite of @DRUG$, were on average 33% higher in patients receiving bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone.	DDI-false
: In vitro vivo indicate fluconazole , @DRUG$ , @DRUG$ markedly inhibit metabolism , result an in cisapride of the the .	DDI-false
These drugs the and other diuretics corticosteroids @DRUG$ , thyroid , oral contraceptives , nicotinic channel blocking @DRUG$.	DDI-false
In addition, @DRUG$ alone can inhibit adrenal @DRUG$ synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.	DDI-effect
The of @DRUG$ and L-CCG-1 upon @DRUG$ behavioral	DDI-false
Insulin or Oral @DRUG$ Agents enhance blood-sugar-reducing insulin and oral	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
@DRUG$ should administered concurrently with D2-antagonists , as @DRUG$ , thioxanthines , or metoclopramide .	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
conversely, diethylpropion may interfere with @DRUG$ (i.e., @DRUG$, a-methyldopa).	DDI-false
on known metabolic , clinically significant are not expected between , , , erythromycin , @DRUG$ fluconazole	DDI-false
clinical digoxin , , anticoagulants , oral , and a substudy patients heart receiving or digoxin in therapy with FLOLAN initiated , apparent oral values @DRUG$ ( n = 23 and @DRUG$ ( n 30 ) by 13 % and 15 % respectively , on the second of had by .	DDI-false
of the increased reactions patients have been taking a basis , it is physicians query patients their carefully @DRUG$ alcohol and @DRUG$ use as the history to any procedure the use of ROMAZICON .	DDI-false
Ritonavir VIRACEPT resulted in a 152 increase @DRUG$ very change in @DRUG$ plasma	DDI-false
Other drugs which enhance neuromuscular nondepolarizing agents such as certain ( @DRUG$ tetracyclines , , clindamycin colistin , and sodium ) , @DRUG$ salts local anesthetics , procainamide , and .	DDI-false
A , though , has been suggested with phenylbutazone , , carbamazepine , @DRUG$ topiramate possibly and @DRUG$ .	DDI-false
derivatives derivatives @DRUG$ such anti-inflammatory drugs and aspirin risk bleeding administered concomitantly with @DRUG$.	DDI-effect
Patients receiving hydantoins, @DRUG$, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
Although studies have been performed , coadministration that by ( , calcium channel blockers @DRUG$ disopyramide , , , , pimozide , carbamazepine , fentanyl @DRUG$ alprazolam , and ) may concentrations when with	DDI-false
When STADOL 30 minutes the @DRUG$ , the of @DRUG$ increased Cmax decreased 18 % .	DDI-false
@DRUG$ is a it possible that such @DRUG$ , , thioxanthenes diminish the effectiveness of	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Studies in rats have shown that @DRUG$ administration attenuates certain types of adrenocortical steroid dependent hypertension, including @DRUG$ hypertension.	DDI-effect
Effect of @DRUG$ on Pharmacokinetics Other alter the pharmacokinetics , ,	DDI-false
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
May interact thyroid ( levothyroxine , products , @DRUG$ ( e.g. , famotidine , @DRUG$ , proton pump ) .	DDI-false
Serial plasma and urine samples for measurement of @DRUG$, @DRUG$, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
, , @DRUG$ , @DRUG$ Ketoconazole Phenytoin Phenobarbitol carbamazepine Rifabutin , Ritanovir Saquinavir .	DDI-false
MAO inhibitors @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-mechanism
Nevertheless, caution is indicated in the co-administration of @DRUG$ with any of the @DRUG$ and also in switching from one class to the other.	DDI-advise
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
use intravenously or @DRUG$ , @DRUG$ , theophylline ) by patients receiving not been evaluated	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and @DRUG$.	DDI-false
@DRUG$: @DRUG$ IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or hydrochlorothiazide.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
Therapeutic @DRUG$ @DRUG$ naproxen , acetaminophen andtolbutamide alter ketorolac protein binding .	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, @DRUG$ and phenobarbital.	DDI-false
@DRUG$ Concomitant of and @DRUG$ may severe weakness patients	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (CYP3A4 substrate) given for local @DRUG$.	DDI-false
plasma tricyclic have been reported to be the administration @DRUG$ hepatic enzyme inhibitors e.g. , @DRUG$ ) the concomitant administration of inducers ( e.g. barbiturates , phenytoin , and effect be anticipated well	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : should be with extreme treated or @DRUG$ of formoterol on cardiovascular may be by these .	DDI-false
clinical significance of this hence @DRUG$ is recommended to simultaneously magnesium/@DRUG$-containing antacids .	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Central Nervous System Depressants The use @DRUG$ ( fentanyl transdermal ) central nervous system depressants , including limited other opioids , , tranquilizers ) anesthetics , @DRUG$ , skeletal relaxants may depression hypotension and sedation , or potentially result in coma death .	DDI-effect
Plasma valproate concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Uricosuric drugs, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
: to its @DRUG$ levels determined administration isoniazid and symptoms of @DRUG$ toxicity should be monitored closely dosage adjustment anticonvulsant should be	DDI-false
@DRUG$ The effect @DRUG$ on the anti-coagulant of group of healthy subjects receiving doses 2 - 5 .	DDI-false
( ketoconazole @DRUG$ , , @DRUG$ , and animal studies with of amphotericin B resistance amphotericin B.	DDI-false
Hypotension - Patients on Diuretic Therapy: Patients on @DRUG$, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
These thiazides diuretics , corticosteroids , phenothiazines products @DRUG$ @DRUG$ nicotinic acid , , blocking drugs , .	DDI-false
Naproxen : The concomitant of diflunisal @DRUG$ in had no plasma , urinary of @DRUG$ its glucuronide metabolite	DDI-false
@DRUG$ Other @DRUG$ , such quinidine disopyramide and phenytoin , used	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
similar study with @DRUG$ in , 1 24 subjects @DRUG$ mg tamsulosin mg separated 6 hours systolic blood below 85 Hg	DDI-false
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
interact e.g. , ( famotidine , , proton ( e.g. @DRUG$ , )	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ (but not aspirin): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
that have with @DRUG$ chloramphenicol cisplatin , @DRUG$ , , gold iodoquinol , , , nitrofurantoin ribavirin and .	DDI-false
Clinical studies with @DRUG$ have identified potentially significant interactions with fluconazole and @DRUG$.	DDI-int
Hormonal @DRUG$ Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-false
The of may increase the and susceptibility to antidiabetic products , ACE inhibitors , @DRUG$ monoamine ( MAO , propoxyphene , , somatostatin analog ( octreotide ) ,	DDI-false
@DRUG$ may interact blood thinners , decongestant diabetic drugs , @DRUG$ NSAIDs like and .	DDI-int
Imidazoles e. g. , , @DRUG$ , clotrimazole fluconazole , etc . and the B imidazoles that @DRUG$ may fungal resistance B.	DDI-false
Antiacid Didanosine Fluconazole , Indanavir , Ketoconazole , , @DRUG$ Ritanovir	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Concurrent administration drugs e.g. , aminoglycosides , @DRUG$ ) ( e.g. , ) hepatotoxic , ) @DRUG$ increase in systems .	DDI-effect
action @DRUG$ may potentiated including nonsteroidal and other that are bound , salicylates , chloramphenicol , probenecid @DRUG$ , oxidase , and adrenergic agents .	DDI-effect
: with b-lactam antibiotics , excretion loracarbef is by @DRUG$ resulted in approximate % increase in the AUC for @DRUG$.	DDI-false
Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
clinical is not , hence @DRUG$ ingested simultaneously	DDI-advise
Cytochrome P-450 inducers, such as @DRUG$, @DRUG$ and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
In digitalis in dogs anesthetized with Vet , or @DRUG$ , the dosage ouabain to tachycardia significantly higher , as was ouabain , with or Innovar than with	DDI-false
Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that @DRUG$, an agent that decreases stomach acidity, does not greatly alter @DRUG$ pharmacokinetics.	DDI-false
May interact thyroid e.g. , levothyroxine , products , antacids ( e.g. @DRUG$ , @DRUG$ , and proton lansoprazole omeprazole .	DDI-false
Tolbutamide patients @DRUG$ and @DRUG$ , effects were on plasma levels glucose	DDI-false
Rifampin: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
receiving high-dose @DRUG$ @DRUG$ anorexia , , coma a possible drug	DDI-advise
Potential drug interactions between @DRUG$  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
These drugs include thiazides and corticosteroids @DRUG$ products oral , acid @DRUG$ , calcium .	DDI-false
Warfarin : @DRUG$ the	DDI-false
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and @DRUG$ were coadministered.	DDI-mechanism
Plasma exposure 10 by % @DRUG$ ( BID ) while plasma exposure of valdecoxib 40 BID ) was not substantially following @DRUG$ 10 BID ) days	DDI-false
@DRUG$ - Taking piperazine and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-false
The celecoxib on the effect of @DRUG$ was in group daily doses of of	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
No Important Interactions To does not clinically interactions with @DRUG$ @DRUG$ , , warfarin isosorbide mononitrate ethanol or .	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).	DDI-false
Antiacid , clarithromycin , @DRUG$ Fluconazole Fluoxetine , @DRUG$ Phenytoin Phenobarbitol Rifabutin Rifampin , Ritanovir Saquinavir .	DDI-false
: Albendazole sulfoxide and fluid were increased ( 2-fold patients treated @DRUG$ 10 mg/kg/day n=7 ) with @DRUG$ 20 ( )	DDI-false
The effects of @DRUG$ (@DRUG$) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
The intensity phenobarbital , @DRUG$ , , methaqualone were systematically 16 patients receiving @DRUG$ .	DDI-false
@DRUG$ : interferes tubular of @DRUG$ produces in the of in serum	DDI-false
following are of substances : corticosteroids , @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , , terbutaline phenothiazine derivatives , thyroid , @DRUG$ ( , in oral contraceptives	DDI-false
Binding to plasma protein is not significantly altered by diazepam, @DRUG$, or @DRUG$.	DDI-false
Coadministration of Itraconazole and cyclosporine, @DRUG$ or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-false
of @DRUG$ were affected by of @DRUG$	DDI-false
patients with to , administration 25 mg daily the @DRUG$ 10 mg for weeks , was associated an average increase mean arterial pressure about Hg @DRUG$	DDI-false
: antiarrhythmic drugs , as @DRUG$ , procainamide , @DRUG$ , and have used amiodarone	DDI-false
, clinically significant drug are not expected between VIRACEPT , trimethoprim/@DRUG$ itraconazole @DRUG$.	DDI-false
Potential were pharmacokinetic studies @DRUG$ , valproate contraceptive digoxin @DRUG$ , ) and screening the in	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-false
@DRUG$ of   fentanyl transdermal system depressants not to opioids , sedatives benzodiazepines ) , general @DRUG$ muscle relaxants , and alcohol , depression , hypotension , and sedation , potentially coma or	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, @DRUG$, or phenobarbital.	DDI-false
@DRUG$ potassium-sparing , @DRUG$ , each be with increased serum potential effects on potassium kinetics and function should be considered when agents are concurrently	DDI-effect
The concomitant use @DRUG$ other @DRUG$ is recommended due the increased gastrointestinal toxicity , with or no increase efficacy	DDI-effect
In trials , @DRUG$ with digoxin , anticoagulants , oral @DRUG$ and oxygen . In a substudy in congestive receiving or in with FLOLAN was apparent oral values for n = 23 ) and ( n = 30 ) decreased 13 % , second day therapy returned to baseline values by	DDI-false
Studies in that types of @DRUG$ hypertension , including @DRUG$	DDI-false
Drugs that associated peripheral antiretroviral , , dapsone , @DRUG$ , glutethimide gold hydralazine , iodoquinol , , metronidazole , @DRUG$ , phenytoin ribavirin and vincristine .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
@DRUG$, nifedipine, @DRUG$	DDI-false
Coadministration of ( mg BID ( day 1 ) 40 mg ) ) glyburide 10 mg @DRUG$ 21 % increase glyburide AUC0 - 12 16 % in @DRUG$ Cmax to % glucose AUC0 24 .	DDI-false
may enzymes @DRUG$ and	DDI-false
Drugs that with @DRUG$ , ethionamide , , @DRUG$ hydralazine isoniazid nitrofurantoin , phenytoin , ribavirin , and .	DDI-false
effects of DCG-IV and L-CCG-1 @DRUG$ locomotion and behavioral changes .	DDI-false
evaluate the of chemotherapy HAART the course patients with HIV-related , systemic non-Hodgkin lymphoma ( HIV-NHL ) , a group patients with were treated , doxorubicin vincristine and prednisone ( chemotherapy plus with a group of treated with or a CHOP-like regimen ( @DRUG$ @DRUG$ and prednisone with plus bleomycin receiving	DDI-false
( valdecoxib was increased % when coadministered with @DRUG$ % coadministered @DRUG$.	DDI-false
interactions @DRUG$ and @DRUG$ digoxin	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either @DRUG$ (300 mg once a day [QD]) (cohort 1) or @DRUG$ (600 mg QD) (cohort 2) for 14 days.	DDI-false
@DRUG$ , such as @DRUG$ , inhibit renal of nitrofurantoin	DDI-false
A study eight volunteers has shown % increase in nimodipine concentrations and 90 % in area the one week @DRUG$ at @DRUG$ mg/day	DDI-mechanism
Coadministration of 30 and @DRUG$ , CYP2C19 % in clearance @DRUG$.	DDI-false
drugs ( e.g. aminoglycosides myelotoxic ( , cytotoxic chemotherapy ) cardiotoxic ( , @DRUG$ ) or methotrexate @DRUG$ ) effects PROLEUKIN toxicity systems	DDI-false
@DRUG$ : @DRUG$ due potential serious and/or life-threatening arrhythmias .	DDI-false
Co-administration of dose @DRUG$ no effect on pharmacokinetics of	DDI-false
Therefore , @DRUG$ and @DRUG$ not be	DDI-advise
When used in external subcutaneous infusion pumps for insulin, @DRUG$ should not be mixed with any other @DRUG$ or diluent.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
, interaction studies with and @DRUG$ have not plasma , and administration a patient population chronically receiving resulted in no bioavailability @DRUG$ data	DDI-false
with Mixed : Agonist/antagonist analgesics ( eg , @DRUG$ nalbuphine @DRUG$ dezocine and be administered a is therapy a pure agonist as	DDI-false
@DRUG$ significantly decreased the AUC(ss) of amprenavir by 82%, but @DRUG$ had no effect on rifampin pharmacokinetics.	DDI-false
The absorption of tetracycline, furosemide, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
OBJECTIVE : was to the everolimus and @DRUG$ ( INN @DRUG$ ) when coadministered novo recipients the first year transplantation .	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	DDI-false
Lamivudine : vitro studies in blood mononuclear , U937 Molt-4 revealed that @DRUG$ significantly @DRUG$ a dependent manner .	DDI-effect
Antidepressants , Amphetamines may enhance @DRUG$ @DRUG$	DDI-false
These that both and acetate , and other @DRUG$ retinoids , may regulate of by a the @DRUG$ EGF .	DDI-effect
with Allopurinol : The principal pathway detoxification of @DRUG$ is inhibited by @DRUG$.	DDI-mechanism
administration low-dose @DRUG$ @DRUG$ may additive potentiating effect on flow	DDI-effect
The effects of @DRUG$ and of Innovar anesthesia on @DRUG$ tolerance in dogs.	DDI-false
@DRUG$ metoprolol @DRUG$ serum and pharmacologic may increased .	DDI-false
a @DRUG$ ketamine , Innovar Vet or the of ouabain needed ventricular was significantly as was the LD50 , @DRUG$ than pentobarbital	DDI-false
interact drugs , inhibitors ( MAOI could affect pharmacodynamics : Flupenthixol and additive depression - @DRUG$ : @DRUG$ effect of Tricyclic	DDI-false
In patients who have received @DRUG$ , @DRUG$	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
If of activity as , intraconazole , ritonavir , @DRUG$ , @DRUG$ etc is reduction of the budesonide considered .	DDI-false
This drug with alcohol other @DRUG$ ( potentiate the CNS depressant of either , @DRUG$ other medications ( effects potentiated when medications are concurrently with antihistamines ) , and oxidase ) inhibitors concurrent with may anticholinergic depressant of	DDI-false
inhibitors @DRUG$ primarily by the pathway @DRUG$.	DDI-false
These drugs @DRUG$ , @DRUG$ , phenothiazines products estrogens , contraceptives phenytoin nicotinic acid sympathomimetics , and	DDI-false
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
drugs include the and other diuretics corticosteroids , , , , , @DRUG$ , @DRUG$ , blocking , and .	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Treatment @DRUG$ for in healthy was associated with an inhibition P450 1A2 and 25 @DRUG$ AUC .	DDI-mechanism
Coadministration ( 40 ( ) and 40 QD days 2 7 ) with @DRUG$ BID ) resulted in 21 increase in - and a @DRUG$ leading to a % decrease glucose 24 .	DDI-false
known , clinically significant are @DRUG$ @DRUG$ , trimethoprim/sulfamethoxazole itraconazole or fluconazole	DDI-false
Oral neomycin inhibits the absorption of penicillin , @DRUG$ , @DRUG$	DDI-false
Results sclerosis taking and concomitant ( @DRUG$   mcg IM ) or @DRUG$ regard the need for dose the beta-interferon glatiramer acetate .	DDI-false
@DRUG$ (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.	DDI-mechanism
, when @DRUG$ is given to a @DRUG$ of be prevent excessive the prothrombin time .	DDI-advise
Other concomitant therapy Although specific studies were performed , doses of or more were concomitantly clinical studies with , , a-blockers @DRUG$ , angiotensin-converting enzyme ( ) , anticonvulsants benzodiazepines beta calcium-channel , nitrates , diuretics H2 antagonists , @DRUG$ synthetase ( also referred , anti-infectives without evidence of clinically significant adverse	DDI-false
In addition expected serum @DRUG$ have been observed when therapy is in already taking @DRUG$.	DDI-mechanism
: Increased serum levels @DRUG$ have patients concomitant @DRUG$ and .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Terfenadine : Administration of @DRUG$ with of @DRUG$ ;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
At a median follow-up of 33 months, the combination of @DRUG$ and @DRUG$ did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
Other concomitant therapy Although specific studies performed , finasteride doses of more were used clinical studies , , a-blockers , angiotensin-converting ( , @DRUG$ , beta , calcium-channel , cardiac @DRUG$ , , H2 antagonists reductase referred to as NSAIDs , and quinolone anti-infectives without clinically significant adverse interactions	DDI-false
In monkeys, @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with (+)-NANM.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
In addition, there have been cases reported in which concomitant use of @DRUG$ and @DRUG$ was followed by cardiac enlargement and congestive heart failure.	DDI-effect
drugs which enhance neuromuscular action NUROMAX certain ( e. g. , aminoglycosides , tetracyclines bacitracin , polymyxins , , colistin , and @DRUG$ , salts , ,	DDI-false
, no on @DRUG$ prothrombin were observed in a study involving concomitant administration of @DRUG$ fluvastatin	DDI-false
@DRUG$: Simvastatin (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
been greater than previously plasma antidepressants , @DRUG$ , when @DRUG$ been administered agents .	DDI-mechanism
@DRUG$: @DRUG$ enhances the effect of warfarin.	DDI-effect
In these subjects , @DRUG$ did not alter effect of @DRUG$ as determined time	DDI-false
Promethazine: Coadministration of a single dose of @DRUG$ and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Numerous drug interactions are possible with some @DRUG$, such as phenobarbitone and @DRUG$, which affect hepatic microsomal enzyme systems.	DDI-false
@DRUG$ and Upon concomitant administration of of with mg @DRUG$ , the Cmax and AUC of 20 .	DDI-false
Magnesium/@DRUG$-containing Products zalcitabine moderately reduced ( approximately 25 % ) when with @DRUG$/aluminum-containing antacid	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
examples of substances that may reduce effect corticosteroids @DRUG$ , , sympathomimetic agents ( , , terbutaline isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , progestogens e.g. oral contraceptives )	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;	DDI-false
addition to the interactions chronic weeks oral @DRUG$ impairs of , @DRUG$ , and	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and @DRUG$ administered with Lodine as measured by prothrombin time.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	DDI-mechanism
@DRUG$ on anticoagulant @DRUG$ ( 1 mg/day was in subjects by of BEXTRA 40 7 days .	DDI-false
When a @DRUG$ is therapy of a patient @DRUG$ additional effect is usually observed	DDI-effect
The absorption of tetracycline, @DRUG$, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
- @DRUG$: Interaction studies in humans have shown @DRUG$ to have no effect on warfarin metabolism or on plasma prothrombin activity.	DDI-false
concentrations @DRUG$ ( ( - activity	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
of one or the concomitant with ORENCIA : , NSAIDs , TNF azathioprine chloroquine , @DRUG$ , sulfasalazine @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
action the be , antihistamines , barbiturates , oxidase inhibitors , @DRUG$ @DRUG$ drugs that CNS	DDI-false
The of was the @DRUG$ its analogue D-Ala2-metenkephalinamide , @DRUG$ , the antinonciceptive mice injection .	DDI-false
This drug may with or CNS ( may the depressant of or antihistamines , medications activity anticholinergic these medications with @DRUG$ ) and use may prolong and depressant of @DRUG$ ) .	DDI-false
not @DRUG$ with	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-mechanism
concomitant Although not finasteride 1 or were used in @DRUG$ acetylsalicylic a-blockers analgesics enzyme ( ACE ) , benzodiazepines beta blockers blockers cardiac @DRUG$ , , H2 inhibitors prostaglandin synthetase inhibitors ( also , and of clinically .	DDI-false
Antiacid @DRUG$ Didanosine , Fluconazole , Fluoxetine , Phenobarbitol @DRUG$ , Rifabutin , Saquinavir .	DDI-false
The effects of mixing @DRUG$ with insulins of animal source or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
Clidinium may decrease the effect of @DRUG$, @DRUG$, and ketoconazole.	DDI-false
Oral @DRUG$ : 40 BID the metabolism combination @DRUG$ ( mg /35 mcg combination , .	DDI-false
Although specific studies coadministration drugs that are mainly by CYP3A4 ( calcium blockers dapsone disopyramide , , quinidine warfarin tacrolimus @DRUG$ derivatives , fentanyl , , , and @DRUG$ plasma concentrations when coadministered saquinavir ;	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
thiazides and other diuretics , , , , phenytoin , nicotinic acid @DRUG$ and	DDI-false
In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Experience with co-administration HMG-CoA reductase @DRUG$ patients is limited , , should be temporarily suspending use @DRUG$ .	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
In a comparison of digitalis tolerance dogs anesthetized ketamine , Vet , @DRUG$ , the dosage ouabain to cause was higher , the of ouabain , with @DRUG$ or Innovar than with .	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
@DRUG$ SHOULD BE IN THOSE REVEIVING @DRUG$ ITS .	DDI-advise
Antagonists : Since is a possible that dopamine antagonists , as the neuroleptics ( @DRUG$ ) or metoclopramide may effectiveness of @DRUG$.	DDI-effect
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other enhance neuromuscular blocking action of nondepolarizing agents such include certain , @DRUG$ @DRUG$ bacitracin polymyxins colistin colistimethate ) , , lithium , procainamide and	DDI-false
Central System : concomitant DURAGESIC   ( fentanyl transdermal ) @DRUG$ not limited to other , , , tranquilizers e.g. @DRUG$ ) , general , skeletal muscle relaxants alcohol , may cause respiratory depression hypotension and , or in or .	DDI-false
@DRUG$: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-false
Dopamine Antagonists : is a dopamine agonist it is that @DRUG$ , such as neuroleptics ( phenothiazines , @DRUG$ ) or , may the effectiveness of APOKYN .	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
@DRUG$ : @DRUG$ concentrations and LDL-C reduction not by coadministration cimetidine	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
interact with depressants ( may CNS depressant of these or ) anticholinergics or other medications anticholinergic ( effects be when medications used concurrently with and @DRUG$ with @DRUG$ and intensify the CNS depressant antihistamines .	DDI-false
from in benzodiazepines than alprazolam possible drug for following ergotamine , cyclosporine @DRUG$ @DRUG$.	DDI-false
@DRUG$ ( g. @DRUG$ , . ): in vitro and animal with combination of imidazoles may induce amphotericin	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
In @DRUG$ @DRUG$ tested in an of two-lever and mixed signalled-unsignalled differential-reinforcement-of-low-rates DRL procedures	DDI-false
@DRUG$: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of theophylline at steady state.	DDI-false
@DRUG$ (such as @DRUG$);	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
administration of and @DRUG$ may in levels of	DDI-false
@DRUG$ : of clearance to an increase plasma @DRUG$ concentration has some drugs	DDI-false
In a comparison of with Innovar Vet , or pentobarbital , the dosage of @DRUG$ to significantly higher was the of @DRUG$ or Innovar than with pentobarbital .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
possibility effects with @DRUG$ by the increasing the salt intake approximately one of treatment with @DRUG$ captopril tablets , USP or initiating therapy ( or 12.5 mg .	DDI-false
Other and IV have been concomitantly with beta , @DRUG$ calcium-blocking agents , @DRUG$ prazosin and without evidence clinically interactions .	DDI-false
no effects warfarin levels or prothrombin times observed a study involving concomitant of @DRUG$ and	DDI-false
In Study 1, patients with colorectal cancer were given @DRUG$/@DRUG$/leucovorin (bolus-IFL) with or without AVASTIN.	DDI-false
@DRUG$ of warfarin @DRUG$ volunteers did in in prothrombin time or clotting factor compared to of placebo	DDI-false
Methotrexate Renal tubular @DRUG$ may inhibited by concomitant of @DRUG$ , leading increased plasma levels methotrexate .	DDI-mechanism
Antagonists : Based reports hypotension and consciousness @DRUG$ was with , the concomitant use drugs of 5HT3 antagonist class including , , ondansetron granisetron , @DRUG$ , and is contraindicated	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, and @DRUG$.	DDI-false
using medication , tell your doctor pharmacist of and products use of e.g. , ) B , @DRUG$ ( , @DRUG$ , vancomycin	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ (but not @DRUG$): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
, systemic exposure ( AUC0 - hydroxylamine ( @DRUG$ was doubled in the	DDI-false
The coadministration of aspirin decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	DDI-false
5HT3 Antagonists : Based on reports hypotension and of was administered with ondansetron of @DRUG$ with of 5HT3 antagonist for example , ondansetron , granisetron , palonosetron , and @DRUG$ .	DDI-advise
@DRUG$ of that are metabolized by i.e. , @DRUG$ simvastatin ) .	DDI-mechanism
Interactions with @DRUG$: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Additive adverse effects from cholinergic may LEVSIN with @DRUG$ , amantadine , monoamine oxidase ( MAO ) inhibitors @DRUG$ or some antihistamines .	DDI-false
@DRUG$: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
Interactions   @DRUG$ )   ( ) had no effect the pharmacokinetic @DRUG$ in refractory .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Interactions Oral @DRUG$ Keppra   twice ) did not influence the pharmacokinetics oral containing @DRUG$ or of the luteinizing and progesterone levels , indicating efficacy is .	DDI-false
almotriptan other potent ( itraconazole , @DRUG$ and erythromycin studied exposures may be @DRUG$ with medications .	DDI-advise
In healthy , the pharmacokinetics of a dose @DRUG$ @DRUG$ affected the of subcutaneous dose of	DDI-false
Acetaminophen, lidocaine, @DRUG$, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Imidazoles e. g. , miconazole , @DRUG$ @DRUG$ etc . ): and studies with the combination amphotericin B and imidazoles suggest that imidazoles fungal amphotericin B.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
@DRUG$ administration of aspirin may result an risk compared @DRUG$ alone .	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
@DRUG$ a substrate for and CYP2C8 , that inhibit these isoenzymes may the and concentration of	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	DDI-effect
Adrenergic blockers: @DRUG$ are inhibited by @DRUG$.	DDI-effect
A similar association, though less marked, has been suggested with @DRUG$, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Multivitamins, or other products containing iron or zinc, @DRUG$ or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
have been associated with peripheral neuropathy @DRUG$ chloramphenicol cisplatin , disulfiram , , hydralazine , , , nitrofurantoin , phenytoin , @DRUG$ .	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, @DRUG$, metoclopramide, pimozide.	DDI-false
@DRUG$ The concomitant use @DRUG$ and beta-blocking agents well tolerated with stable angina	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
following of that may reduce the blood-glucose-lowering effect : corticosteroids @DRUG$ diuretics , sympathomimetic ( e.g. , epinephrine , salbutamol , terbutaline , isoniazid , phenothiazine derivatives @DRUG$ , hormones estrogens progestogens ( , .	DDI-false
Administration @DRUG$ during therapy @DRUG$   stimulating   some patients .	DDI-effect
Vitamin A: Because of the relationship of @DRUG$ to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-effect
is a for an with other drugs that are metabolized by CYP , @DRUG$ , @DRUG$ )	DDI-false
is understand to @DRUG$   @DRUG$ ) with supplied AerolizerTM be in other COPD they are taking	DDI-false
Example inhibitors antifungals , ciprofloxacin diclofenac , , erythromycin , @DRUG$ nefazodone , inhibitors and	DDI-false
@DRUG$ should not administered with D2-antagonists , @DRUG$ , .	DDI-advise
@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
Response to @DRUG$ may be enhanced by @DRUG$.	DDI-effect
Drug Interaction During Pregnancy: @DRUG$ and @DRUG$ were studied following subcutaneous injections in pregnant mice.	DDI-false
Although between and ( , @DRUG$ , and erythromycin ) has studied , increased to may be @DRUG$ used concomitantly these .	DDI-advise
CONCLUSIONS inhibit HMG-CoA reductase are metabolized CYP3A4 ( i.e. @DRUG$ , , @DRUG$ )	DDI-false
: should used with patients e.g. , @DRUG$ , a or calcium channel ( e.g. , verapamil a @DRUG$ substrate a ) possible potentiation of , sinus , block	DDI-false
Diuretic reduce the renal of @DRUG$ add a high @DRUG$	DDI-false
@DRUG$ ) and many that are for ( antidepressants @DRUG$ 1C antiarrhythmics propafenone .	DDI-false
, phenobarbital/acetaminophen phenobarbital/valproic acid quinidine/lidocaine , valproic	DDI-false
Antidiabetic drugs : agents @DRUG$ - the @DRUG$ may required .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	DDI-false
general have one or pharmacologic activities @DRUG$ , including anti-arrhythmic such @DRUG$ procainamide , cardiac tricyclic anti-depressants	DDI-false
: Enalapril and enalapril IV been used concomitantly @DRUG$ @DRUG$ , prazosin and without clinically interactions	DDI-false
METHODS : the of the experiment , 10 injections of AOM 7.4 body @DRUG$ 40 ) every other , week , of @DRUG$ ( or body weight ) every other the end the week	DDI-false
Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, aminopyrine and @DRUG$.	DDI-false
Clinical interaction @DRUG$ the coadministration of @DRUG$ these drugs does result in clinically- significant drug interactions .	DDI-false
@DRUG$: Diclofenac decreases @DRUG$ renal clearance and increases lithium plasma levels.	DDI-false
@DRUG$ combination with drugs has not been @DRUG$ may potentiate side of	DDI-false
In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., @DRUG$]) or	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Vitamin A Because of relationship of @DRUG$ vitamin A be against @DRUG$ avoid	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for @DRUG$ (5 mg QD and 10 mg BID) with @DRUG$ coadministration (up to 40 mg QD) is not indicated.	DDI-advise
@DRUG$ heparin , @DRUG$	DDI-false
In with mild to hypertension , mg @DRUG$ benazepril , 10 to 40 weeks , was associated with average in pressure 3 Hg compared to @DRUG$ alone	DDI-false
Acetaminophen @DRUG$ , phenobarbital quinidine , and @DRUG$ to pooled at concentrations	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
In vitro CYP3A4 isoform mediate metabolism of @DRUG$ @DRUG$ levobupivacaine	DDI-false
@DRUG$ @DRUG$ primarily and to a lesser extent by	DDI-false
( ) , moclobemide ( 30 mg/kg , @DRUG$ ( mg/kg ) @DRUG$ ( mg/kg ) ( mg/kg ) or	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$/Hypnotics : @DRUG$ CONTRAINDICATED potential serious and/or reactions prolonged or sedation or depression	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Inhibitors and @DRUG$ : FORADIL should be caution in patients being treated @DRUG$ tricyclic formoterol the cardiovascular may be potentiated by these agents	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
drug interactions topical were clinical of IOPIDINE 0.5 additive with @DRUG$ alcohol , barbiturates sedatives , @DRUG$ should be considered	DDI-false
@DRUG$ In vitro and/or vivo fluconazole , @DRUG$ , and oral ketoconazole the metabolism cisapride , can in an plasma levels and of interval on ECG .	DDI-false
Slow-channel blockers , as @DRUG$ and @DRUG$ , platelet in vitro , decrease platelet adhesion	DDI-false
increased levels of @DRUG$ and @DRUG$ activity;	DDI-false
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
@DRUG$ tricyclic the interval @DRUG$.	DDI-effect
observed after concomitant @DRUG$ diltiazem	DDI-false
the @DRUG$ and other corticosteroids , , thyroid products , estrogens , contraceptives , , @DRUG$ calcium channel	DDI-false
Although the occurrence has been with @DRUG$ , has been reported following concomitant of cephalosporins and @DRUG$.	DDI-false
addition , Fondaparinux influenced the warfarin , @DRUG$ , piroxicam , and digoxin nor the @DRUG$ steady state	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
include the and other diuretics @DRUG$ , oral , nicotinic @DRUG$ and isoniazid	DDI-false
Although studies have not been , drugs that are mainly metabolized by eg , calcium , dapsone , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus , cyclosporine @DRUG$ , , fentanyl alfentanyl , alprazolam triazolam elevated concentrations coadministered with	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	DDI-mechanism
The effects of ruthenium red (RR) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
shown side , renal , , confusion concomitant these with PROLEUKIN the of PROLEUKIN thus avoided and other hypotension	DDI-false
In an emergency situation when opioid analgesia must be administered to a patient receiving @DRUG$, the amount of @DRUG$ required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.	DDI-effect
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
The extent to which @DRUG$-TCA interactions may clinical problems will depend on the of the pharmacokinetics the @DRUG$ involved .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated certain including anti-inflammatory agents and drugs that are bound , salicylates , @DRUG$ , , @DRUG$ and adrenergic .	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
been following administration @DRUG$ with antibiotics @DRUG$ such furosemide .	DDI-effect
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	DDI-false
effects mixing @DRUG$ of animal source @DRUG$ preparations produced by other have not been studied .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
@DRUG$ may be potentiated drugs nonsteroidal anti-inflammatory agents and other are protein , , , @DRUG$ , , , oxidase inhibitors beta blocking agents .	DDI-effect
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
plasma related antidepressants been reported be by the administration of methylphenidate enzyme ( , , @DRUG$ ) decreased by the hepatic inducers phenytoin ) may be anticipated with @DRUG$ as well .	DDI-mechanism
@DRUG$ : concomitant use DURAGESIC transdermal ) with nervous depressants not , sedatives @DRUG$ , ) , , , skeletal relaxants , alcohol and profound sedation result in or	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and @DRUG$ 72.	DDI-false
Concurrent administration of possessing nephrotoxic e.g. aminoglycosides , indomethacin ) ( , cytotoxic chemotherapy ) , cardiotoxic , ) or e.g. , @DRUG$ , asparaginase ) with @DRUG$ may in systems .	DDI-effect
- Anabolic e.g. , , @DRUG$ e.g. , Anavar oxymetholone , @DRUG$ [ e.g. Winstrol ] or	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
@DRUG$ Renal tubular of may be by administration of @DRUG$ , to increased plasma levels .	DDI-false
Drugs which inhibit CYP 3A4 ( e.g. , , @DRUG$ as have the to result increased	DDI-mechanism
Antibiotics In and/or in vivo show , @DRUG$ and troleandomycin markedly which can an in @DRUG$ levels QT interval on the .	DDI-false
Lithium @DRUG$ decreases @DRUG$ clearance and increases lithium	DDI-mechanism
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with @DRUG$.	DDI-false
The steady state plasma concentrations of imipramine and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, simvastatin).	DDI-mechanism
@DRUG$ @DRUG$ ): Cerivastatin concentrations not affected by co-administration of antacid .	DDI-false
Plasma @DRUG$ levels @DRUG$ clearance at were affected by cerivastatin .	DDI-false
The ECG and/or that may result from administration of sparing @DRUG-DRUG$ worsened , when the dose is .	DDI-false
hydrochloride has additive with alcohol and other CNS @DRUG$ , @DRUG$ , etc	DDI-false
@DRUG$/Hypnotics : @DRUG$ , CONTRAINDICATED to for such or sedation depression .	DDI-false
Acetaminophen: A report of severe @DRUG$ toxicity was reported in a patient receiving @DRUG$.	DDI-effect
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, dextromethorphan, and @DRUG$.	DDI-false
The effects of oral @DRUG$ on @DRUG$ induced hypertension were examined in conscious sheep.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than @DRUG$ and does not interact with salicylate or dicumarol.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Stavudine and @DRUG$ @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
Lithium: @DRUG$ decreases @DRUG$ renal clearance and increases lithium plasma levels.	DDI-mechanism
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
The addition of limited number of patients three studies no in @DRUG$ or @DRUG$ when to placebo .	DDI-false
Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, @DRUG$ and antipyrine.	DDI-false
In receiving @DRUG$ , the addition of @DRUG$ prothrombin time	DDI-effect
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
increased exposures norethindrone and @DRUG$ consideration selecting oral contraceptive for	DDI-false
It has been reported that @DRUG$ enhances the anticoagulant effect of @DRUG$-like drugs.	DDI-effect
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
, or other products containing @DRUG$ zinc antacids or sucralfate be concomitantly 2 of administration norfloxacin because they with urine levels of @DRUG$.	DDI-false
@DRUG$ significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of @DRUG$ by 13.3-fold.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-false
treatment with Accutane tetracyclines avoided @DRUG$ use associated with of of cerebri ) some of which use @DRUG$	DDI-effect
no studies have been conducted , administration and @DRUG$ the metabolism @DRUG$ ;	DDI-false
As @DRUG$, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., @DRUG$, lamotrigine).	DDI-false
The effects of ketamine and of @DRUG$ anesthesia on @DRUG$ tolerance in dogs.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
risk of in patients who have taking benzodiazepines regular basis that physicians query or guardians carefully about benzodiazepine @DRUG$ and @DRUG$ as part the prior to in use of ROMAZICON is	DDI-false
Preliminary indicate that concomitant use @DRUG$ and @DRUG$ a cardiac output and usually wedge either is .	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In patients receiving @DRUG$ and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
No Date Levosimendan not have interactions captopril beta-blockers , , digoxin , , , @DRUG$ @DRUG$.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
These @DRUG$ , corticosteroids , products , @DRUG$ , oral contraceptives phenytoin nicotinic acid , sympathomimet-ics , channel blocking drugs and isoniazid .	DDI-false
Aspirin, warfarin, @DRUG$, @DRUG$	DDI-false
ACE Inhibitors @DRUG$ studies of hypertension the addition 50 to 100 @DRUG$ receptor mean ( about - mEq/L .	DDI-false
suggested that patients receiving @DRUG$ alternatives @DRUG$ be therapy	DDI-advise
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Presumably , @DRUG$ acts a stimulator coumarin has to cause of the @DRUG$ prothrombin-proconvertin concentrations	DDI-mechanism
@DRUG$ Digoxin increased by % @DRUG$	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
@DRUG$-@DRUG$ in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.	DDI-false
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
Other concomitant therapy not finasteride doses 1 were concomitantly with , , a-blockers analgesics enzyme ) inhibitors , anticonvulsants benzodiazepines , beta , @DRUG$ , cardiac nitrates diuretics , , reductase , @DRUG$ ( NSAIDs ) , and quinolone anti-infectives without evidence of significant interactions	DDI-false
@DRUG$ : In receiving CYP3A4 , @DRUG$ , mg twice daily days 200 systemic exposure approximately 72	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
- or MAO-inhibitors not be administered together with @DRUG$ @DRUG$.	DDI-false
: Amiodarone used caution in receiving -receptor blocking agents ( , a @DRUG$ inhibitor ) or @DRUG$ antagonists e.g. , , CYP3A4 , a inhibitor the possible sinus arrest , and block ;	DDI-false
Potential Keppra and other AEDs , @DRUG$ phenobarbital , , @DRUG$ were assessed the serum concentrations of levetiracetam and these placebo-controlled clinical .	DDI-false
Based on chemical resemblance itraconazole and @DRUG$ of @DRUG$ with itraconazole	DDI-false
@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
: Coadministration of saquinavir soft-gelatin formulation of @DRUG$ 1200 mg with VIRACEPT resulted an plasma and 4-fold increase @DRUG$	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, @DRUG$, pimozide.	DDI-effect
Consequently, drugs with a low therapeutic margin, such as @DRUG$, phenytoin, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
, @DRUG$ , @DRUG$ clotrimazole , fluconazole etc ): vitro combination of amphotericin B and imidazoles that may fungal resistance to amphotericin	DDI-false
clinical pharmacology @DRUG$ sulindac was administered to	DDI-false
intensity time of by phenobarbital @DRUG$ , , @DRUG$ investigated in 16 patients receiving therapy	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
Based on chemical of @DRUG$ @DRUG$ coadministration itraconazole	DDI-false
: known the metabolism carbamazepine and its serum levels be to administration with @DRUG$ , signs carbamazepine toxicity , and appropriate of the @DRUG$ should be .	DDI-false
The AUC and Cmax of both the (R) and (S) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Other Drug Interactions Oral @DRUG$ @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
may @DRUG$ that may plasma is recommended Gleevec ( ketoconazole @DRUG$ , , clarithromycin	DDI-false
In particular, convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs.	DDI-effect
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Based the chemical @DRUG$ ketoconazole coadministration @DRUG$ is	DDI-false
this reason , dose @DRUG$ be reduced 30 50 % of treatment or @DRUG$ according to	DDI-advise
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Severe hypoglycemia in patients concomitantly @DRUG$ and oral @DRUG$.	DDI-effect
In to avoid of , patients treated @DRUG$ ( dexamethasone , @DRUG$ cimetidine or ) .	DDI-false
5HT3 Antagonists : Based on reports and consciousness when administered ondansetron concomitant with drugs the class , ondansetron , @DRUG$ @DRUG$ .	DDI-false
: 3 mg days not the pharmacokinetics , there ( time ) following single dose warfarin	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$ is metabolized by CYP2C9 and who require anticoagulation receive weight	DDI-false
CANCIDAS co-administered with of such @DRUG$ , @DRUG$ , carbamazepine daily should	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Although no studies have been conducted, concomitant administration of Itraconazole and @DRUG$ may alter the metabolism of @DRUG$;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of succinylcholine.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antagonists @DRUG$ possible that dopamine , such phenothiazines butyrophenones @DRUG$ metoclopramide diminish of APOKYN .	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when paclitaxel and @DRUG$ are used in combination.	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
In subjects given single 500 @DRUG$ and plasma metformin cmax and AUC increased an average of 34 24 % , and @DRUG$ clearance by 14 .	DDI-false
concomitant specific interaction , finasteride doses were studies with , , , @DRUG$ , angiotensin-converting enzyme ACE ) anticonvulsants , beta blockers , @DRUG$ cardiac , inhibitors also , and evidence of clinically adverse interactions .	DDI-false
Should Not , astemizole ergot derivatives Antimycobacterial agents rifampin midazolam @DRUG$ GI agents @DRUG$	DDI-false
: @DRUG$ @DRUG$ is not its binding administration of , resulting in concentrations peak , and .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant theophylline at study entry.	DDI-false
Thioridazine: Coadministration of single doses of @DRUG$ 20 mg and @DRUG$ 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-effect
@DRUG$ Hydroxide @DRUG$ were not affected by co-administration of antacid	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Selective Reuptake Inhibitors @DRUG$ ): ( , fluoxetine , @DRUG$ paroxetine have been to weakness and coadministered 5-HT1 agonists	DDI-false
Although specific studies not been performed with drugs that metabolized by CYP3A4 ( , @DRUG$ , dapsone , @DRUG$ quinine , , quinidine , warfarin tacrolimus cyclosporine ergot derivatives carbamazepine alfentanyl , triazolam plasma concentrations when coadministered with	DDI-false
To evaluate impact of chemotherapy plus HAART course HIV-related non-Hodgkin lymphoma ( HIV-NHL ) the a group of patients with HIV-NHL who with the cyclophosphamide @DRUG$ , and ( ) chemotherapy with group of 80 who were treated with chemotherapy a CHOP-like , , and prednisone with @DRUG$ ) without receiving therapy .	DDI-false
the coadministration of @DRUG$ and @DRUG$ been evaluated	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating @DRUG$ and @DRUG$, respectively.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Additional drugs are not for with @DRUG$ and @DRUG$ are below .	DDI-false
Cholestyramine and @DRUG$ resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
@DRUG$ not have clinically interactions with captopril , felodipine , , warfarin , , @DRUG$ ethanol .	DDI-false
The absorption of tetracycline, @DRUG$, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Benzthiazide interact with blood @DRUG$ ( , sinus medicines , drugs lithium @DRUG$ , and blood .	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-effect
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
In these patients whose hypertension was controlled with @DRUG$, @DRUG$ 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.	DDI-effect
with @DRUG$ : Agonist/antagonist analgesics , pentazocine , butorphanol dezocine and buprenorphine ) a patient who received or a of with pure such as	DDI-false
Azithromycin had no impact AUC @DRUG$ , although it decreased the zidovudine tmax and the intracellular exposure to phosphorylated @DRUG$ by	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
Drugs Be Coadministered With Antiarrhythmics : @DRUG$ Antimigraine ergot : @DRUG$ Benzodiazepines midazolam triazolam GI motility : cisapride	DDI-false
following examples of may niacin , , @DRUG$ ( epinephrine @DRUG$ , terbutaline isoniazid , , hormones , , progestogens , in contraceptives ) .	DDI-false
: treatment with @DRUG$ and avoided because @DRUG$ associated with number of cases of pseudotumor ( benign intracranial hypertension ) , some of concomitant use of	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
@DRUG$ : Rofecoxib 75 mg once daily for not alter concentration or renal of @DRUG$ after dose	DDI-false
@DRUG$ has also been shown to inhibit P450 1A2, an isoform also involved in @DRUG$metabolism.	DDI-mechanism
Pediatric The safety effectiveness @DRUG$ , alone or in @DRUG$ patients the age of years have been established	DDI-false
@DRUG$ and Zidovudine @DRUG$ the vitro activity of stavudine and zidovudine HIV	DDI-false
drugs the and other @DRUG$ @DRUG$ thyroid products contraceptives , sympathomimetics , calcium channel	DDI-false
, no were seen when @DRUG$ was @DRUG$ , muscle relaxants muscle relaxant in sedation anesthesia	DDI-false
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	DDI-effect
Hepatic Inducers Inhibitors : which induce cytochrome 3A4 ( enzyme ( , @DRUG$ , phenytoin carbamazepine @DRUG$ ) enhance the metabolism corticosteroids require dosage of the be	DDI-false
following are substances that increase blood-glucose-lowering susceptibility hypoglycemia oral antidiabetic products , disopyramide , fibrates , , propoxyphene @DRUG$ , @DRUG$ ( e.g. , octreotide ) sulfonamide .	DDI-false
Patients begin who diclofenac dose or @DRUG$ while , methotrexate or @DRUG$ develop toxicity characteristics for drugs	DDI-effect
@DRUG$ together with @DRUG$ - ) inhibited both Ca(2 ) and responses )	DDI-effect
addition @DRUG$ influenced pharmacodynamics of piroxicam , digoxin nor the @DRUG$ steady .	DDI-false
Administration of @DRUG$ concomitantly oral amiodarone result in serum	DDI-false
@DRUG$, including norfloxacin, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Protease ( 800 mg . with Vardenafil 10 mg in @DRUG$ AUC , a increase @DRUG$ Cmax and a 2-fold .	DDI-false
WARFARIN: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
@DRUG$ e.g. @DRUG$ ) of sulfapyridine with medicines may increase effects of	DDI-false
: The of to patients @DRUG$ chronically had effect on tiagabine , valproate decreased @DRUG$ binding in from to , which in increase % in concentration .	DDI-false
Beta-blockers clonidine , @DRUG$ salts @DRUG$ may either potentiate or effect insulin	DDI-false
Indomethacin @DRUG$ blunts increases in urine and sodium seen bumetanide the @DRUG$-induced increase renin	DDI-effect
and @DRUG$, such as @DRUG$.	DDI-false
is to reduce concentrations other @DRUG$ that have significant metabolism by CYP3A4 , @DRUG$ and atorvastatin .	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Compounds include , @DRUG$ , @DRUG$ antipyrine .	DDI-false
Antacids : a study an aluminum hydroxide , @DRUG$ , @DRUG$ with fosinopril reduced urinary excretion of as with fosinopril administered , suggesting that antacids impair of	DDI-false
Magnesium- antacids , products sulfate @DRUG$ multivitamin preparations containing @DRUG$ or metal , tablets or the pediatric powder for should not be taken within hours before FACTIVE	DDI-false
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Potential pharmacokinetic were pharmacokinetic phenytoin @DRUG$ , @DRUG$ ) pharmacokinetic in the in epilepsy patients	DDI-false
@DRUG$ significantly increased the area under at state ( @DRUG$ by the AUC(ss of by	DDI-mechanism
While vivo drug-drug interaction between @DRUG$ and inducers of potent CYP3A ( such carbamazepine phenytoin , rifampin , and barbiturates ) would @DRUG$	DDI-mechanism
Anticoagulants While not diclofenac interact @DRUG$ caution be exercised , nonetheless since interactions have been seen with @DRUG$.	DDI-false
Pregnancy: Category X: Use With @DRUG$ (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to @DRUG$.	DDI-false
@DRUG$ , @DRUG$ sulfonamides effect of .	DDI-false
Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-mechanism
Antidepressants : @DRUG$ be extreme caution in with oxidase inhibitors or @DRUG$ action on the may by agents .	DDI-advise
interactions were assessed clinical pharmacokinetic studies @DRUG$ , , digoxin , warfarin , @DRUG$ ) through screening the studies epilepsy patients	DDI-false
@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Saquinavir : Coadministration of saquinavir using an capsule of saquinavir mg @DRUG$ resulted an % increase in @DRUG$ plasma in saquinavir	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with warfarin or its derivatives.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ (@DRUG$, propranolol) serum concentrations and pharmacologic effects may be increased.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
, , phenobarbital/valproic , theophylline/acetaminophen , valproic acid/phenobarbital .	DDI-false
The continued need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established, and discontinuation ordinarily should be attempted.	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
These data indicate that levetiracetam not influence the of other @DRUG$ these @DRUG$ do influence pharmacokinetics of	DDI-false
of @DRUG$ and the therapeutic value @DRUG$ rationalized at the molecular by observations i ) polyene effects on ;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Interaction with @DRUG$ lidocaine @DRUG$ been clinical .	DDI-false
The enalapril and @DRUG$ is by antihypertensive that release e.g. , @DRUG$ ) .	DDI-effect
In a controlled trial included a 50 once daily @DRUG$ 30 528 @DRUG$ subjects concomitant theophylline study entry .	DDI-false
Two of treated @DRUG$ @DRUG$ neutropenia (    1 x .	DDI-effect
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug @DRUG$.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	DDI-false
however no deleterious were seen when ROMAZICON administered narcotics @DRUG$ , @DRUG$ muscle antagonists in with	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
BACKGROUND : The combined of and verapamil ) a @DRUG$ , the incidence peritoneal intestinal adenocarcinomas by ( @DRUG$ ) of investigated male Wistar rats .	DDI-false
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
Before this medication , tell your or pharmacist of all prescription and products of aminoglycosides ( , gentamicin , amikacin ) @DRUG$ , non-steroidal anti-inflammatory ( , ibuprofen )	DDI-false
These increased exposures of @DRUG$ and ethinyl estradiol should be taken into consideration when selecting an oral @DRUG$ for women taking valdecoxib.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug-Drug Interactions Between @DRUG$   And Antiepileptic Drugs AEDs @DRUG$ ( 3000 daily of with	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT @DRUG$: @DRUG$	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$ AquaMEPHYTON , Synkayvite ) Use of @DRUG$ increase chance side effects affecting	DDI-false
to package insert @DRUG$ before use of such preparations with @DRUG$.	DDI-advise
Cytochrome P-450 as , @DRUG$ and induce @DRUG$ , causing 30 clonazepam	DDI-mechanism
@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.	DDI-false
Although studies not , with drugs that are by , , @DRUG$ , , , warfarin tacrolimus , @DRUG$ , ergot derivatives , pimozide , fentanyl , , alprazolam , and triazolam have elevated concentrations when coadministered saquinavir ;	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Treatment with @DRUG$ can directly interfere with blood glucose levels or may interact with @DRUG$.	DDI-int
@DRUG$: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including @DRUG$.	DDI-effect
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	DDI-false
@DRUG$, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
intensity and time of interference by @DRUG$ , glutethimide chloral hydrate and investigated in 16 receiving @DRUG$ therapy .	DDI-false
@DRUG$ is the first @DRUG$ be for clinical studied humans 1986 .	DDI-false
@DRUG$ ( , Use of @DRUG$ with medicines increase chance of effects medicines	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Concomitant administration of aspirin with @DRUG$ result in increased risk of GI ulceration and @DRUG$ .	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Agents since coadministration this with @DRUG$ antiretroviral reduces plasma	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
( 1970 ) the higher concentrations and @DRUG$ reached after administration @DRUG$ are due only to renal but an distribution in body	DDI-mechanism
Use with @DRUG$: The use of @DRUG$ to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.	DDI-false
indandione , and @DRUG$ ( @DRUG$ ) and may the bleeding when with .	DDI-false
The following are examples of drugs known metabolism of @DRUG$ inhibition of CYP3A @DRUG$ cimetidine , diltiazem , and some macrolide .	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ : studies humans have no effect on @DRUG$ blood	DDI-false
Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated.	DDI-effect
administration of @DRUG$ prothrombin time 3 to the of @DRUG$ be reduced by to , and times should be monitored closely	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
Since chronic dosing is required for therapeutic efficacy of @DRUG$, future studies should focus on investigation of chronic dosing effects of these drugs in combination with @DRUG$.	DDI-false
@DRUG$ does not alter @DRUG$ protein binding.	DDI-false
Other which may the blocking of nondepolarizing such NUROMAX include ( e. g. , aminoglycosides @DRUG$ , lincomycin , clindamycin @DRUG$ and colistimethate ) , magnesium , anesthetics , procainamide quinidine	DDI-false
To @DRUG$ intoxication , appropriate adjustment of the @DRUG$ should made	DDI-false
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-advise
The pharmacokinetics of @DRUG$ were not significantly affected by @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Potassium-sparing diuretics ( e.g. spironolactone , @DRUG$ , @DRUG$ ) , substitutes may lead to increases in serum potassium .	DDI-false
: Pharmacokinetic not been between @DRUG$ @DRUG$ ( mg 2 initiation of 1   g/kg/min . 4 hours ) ( 1000 mg orally given , , and 6 and 12 subsequent initiation   . 18 hours	DDI-false
, FLOLAN was used with @DRUG$ diuretics anticoagulants oral vasodilators , and supplemental oxygen . In a in with congestive failure receiving in FLOLAN was initiated apparent clearance values for @DRUG$ = ) and 30 were % and % , , on second therapy and returned to baseline by	DDI-false
@DRUG$ should not be used in patients receiving @DRUG$..	DDI-advise
Nevertheless, the effects of @DRUG$ on travelers receiving comedication, particularly diabetics or patients using @DRUG$, should be checked before departure.	DDI-advise
@DRUG$ pharmacology study , coadministration an ( hydroxide magnesium , simethicone ) with serum levels urinary excretion of as with fosinopril alone , suggesting that @DRUG$ may of .	DDI-false
Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
specific studies have not been with that metabolized by CYP3A4 , calcium channel blockers , dapsone @DRUG$ , quinine , amiodarone quinidine tacrolimus derivatives , , , , , and triazolam may have when @DRUG$ ;	DDI-mechanism
Like ibogaine ( ) @DRUG$ ( 40 ) the intravenous of @DRUG$ cocaine and self-administration ethanol nicotine in rats	DDI-false
Interactions may occur between @DRUG$ supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
When @DRUG$ @DRUG$ , anticoagulation frequently .	DDI-advise
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Antibiotics In vitro show clarithromycin erythromycin @DRUG$ the of @DRUG$ , an in plasma cisapride prolongation the .	DDI-mechanism
Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other @DRUG$ or @DRUG$.	DDI-false
Dosage adjustment of @DRUG$ coadministered with CYP2D6 , , paroxetine , @DRUG$ , and .	DDI-advise
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ (NSAIDs)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
@DRUG$ Gastrointestinal agents ( guanethidine , @DRUG$ ascorbic acid , etc . of .	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
Close the is recommended @DRUG$ to patients receiving such @DRUG$ , additive effects and the production and/or bradycardia which may , syncope postural hypotension .	DDI-advise
conversely , with @DRUG$ guanethidine @DRUG$ .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
A , been , phenyl-butazone , phenytoin sodium carbamazepine and possibly @DRUG$ @DRUG$ and tetracyclines 72	DDI-false
May @DRUG$ hypo-prothrombinemic effect , @DRUG$ , and inducers of system decreased of , ( effect of corticosteroids ) .	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
@DRUG$, @DRUG$, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Plasma valproate concentration be when isoniazid @DRUG$ co and appropriate dosage adjustments @DRUG$ .	DDI-false
Drugs : of @DRUG$ @DRUG$ and the plasma levels of indomethacin	DDI-mechanism
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
include antifungals clarithromycin , , @DRUG$ , @DRUG$ nefazodone , nicardipine , propofol inhibitors , , and verapamil	DDI-false
While the serotonin reuptake ( e.g. @DRUG$ , , and @DRUG$ 2D6 they may in the of inhibition	DDI-false
Other which neuromuscular blocking action nondepolarizing NUROMAX antibiotics ( , bacitracin polymyxins , @DRUG$ , @DRUG$ and colistimethate magnesium , lithium , anesthetics , procainamide , and quinidine	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
Products Concurrent administration a quinolone , @DRUG$ , cation-containing as antacids @DRUG$ VIDEX powder , or products containing calcium , zinc substantially decrease of , serum and considerably than .	DDI-mechanism
administration of drugs possessing nephrotoxic e.g. @DRUG$ indomethacin ) myelotoxic e.g. , @DRUG$ cardiotoxic ( e.g. , doxorubicin ) or ( e.g. , methotrexate , effects with increase in systems .	DDI-false
pharmacokinetic interactions have been found in interaction , @DRUG$ , warfarin @DRUG$ phenobarbital	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
impact of on with systemic ( HIV-NHL ) authors compared retrospectively a group 24 patients HIV-NHL treated with cyclophosphamide , , and ( CHOP ) plus 80 patients who were treated or CHOP-like regimen i.e. , doxorubicin @DRUG$ , @DRUG$ with vincristine plus ) receiving antiretroviral	DDI-false
which may enhance the neuromuscular of nondepolarizing agents NUROMAX include certain ( e. g. @DRUG$ , , @DRUG$ , , sodium ) magnesium salts , local procainamide ,	DDI-false
The concomitant use of @DRUG$ is not recommended since @DRUG$ may antagonize the antibacterial effect of Norfloxacin in the urinary tract.	DDI-false
increase their @DRUG$ dose other taking digoxin @DRUG$ , or cyclosporine toxicity characteristics	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
The effects of @DRUG$ and of @DRUG$ anesthesia on digitalis tolerance in dogs.	DDI-false
@DRUG$ ( @DRUG$ or ): concurrent use with a proarrhythmic effect .	DDI-false
Interaction of @DRUG$ of cimetidine 800 ) patients taking @DRUG$ had no .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
are examples of substances that blood-glucose-lowering : corticosteroids @DRUG$ , , epinephrine , , , isoniazid , derivatives , estrogens progestogens in oral @DRUG$ ) .	DDI-false
of may anticonvulsants @DRUG$ , monoamine , narcotics @DRUG$ , , or other that produce .	DDI-false
It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
for the @DRUG$ after @DRUG$ established , and discontinuation ordinarily should attempted	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
: may interact drugs , like Monoamine ): @DRUG$ affect - Ethanol cause CNS - : Flupenthixol increases effect @DRUG$	DDI-false
Administration of rifampin concomitantly oral @DRUG$ has been shown result in decreases in serum amiodarone @DRUG$.	DDI-false
indicate a TORADOL and @DRUG$ or heparin the administration of @DRUG$ patients taking be extremely cautiously , should monitored .	DDI-false
examples of substances that reduce the blood-glucose-lowering niacin , agents ( , epinephrine , @DRUG$ , , somatropin , thyroid , @DRUG$ progestogens ( e.g. in .	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	DDI-advise
Digoxin  When given concomitantly with @DRUG$ the pharmacokinetics of @DRUG$ in patients with heart failure were not significantly altered.	DDI-false
As with agents , it be noted that @DRUG$ may of potentiating CNS anesthetics , @DRUG$ alcohol	DDI-effect
Acidifying agents: @DRUG$ (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
- @DRUG$ blunts increases in sodium excretion seen during @DRUG$ treatment and the increase in plasma activity	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ : The addition patients @DRUG$ chronically had effect valproate tiagabine binding vitro from 96.3 to 94.8 % resulted of 40 the concentration .	DDI-false
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, @DRUG$, alprazolam).	DDI-false
@DRUG$ : rate of absorption @DRUG$ bioequivalent when Proquin XR given when Proquin XR was 2 hours at dose that	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
The following examples of substances that the and susceptibility antidiabetic , inhibitors , monoamine oxidase MAO @DRUG$ , @DRUG$ , somatostatin analog ( , octreotide sulfonamide .	DDI-false
conversely, diethylpropion may interfere with @DRUG$ (i.e., guanethidine, @DRUG$).	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
Drugs with a Narrow Therapeutic Index Digoxin: @DRUG$ (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ (0.375 mg q24h for 8 days).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/@DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ potentiated by	DDI-effect
hypoglycemic @DRUG$ may be potentiated certain nonsteroidal anti-inflammatory other that protein , , chloramphenicol , @DRUG$ , monoamine oxidase inhibitors , and adrenergic agents .	DDI-effect
: Concomitant diclofenac @DRUG$ is not because diclofenac displaced from sites concomitant administration of @DRUG$ in lower plasma concentrations levels and AUC values .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ : mg when with slow-release 30 mg or 60 mg once did not relative bioavailability ( ) or concentration @DRUG$ , drug that is via	DDI-false
Since therapeutic of @DRUG$ is narrow @DRUG$ , and appropriate adjustments of made	DDI-false
The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-false
When other potent , @DRUG$ are used in combination @DRUG$ patients be observed several hours any fall	DDI-false
Data in vitro studies alprazolam suggest drug for following : , @DRUG$ , @DRUG$ and nifedipine .	DDI-false
At a median follow-up of 33 months, the combination of @DRUG$ and tamoxifen did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
Carbamazepine : @DRUG$ known metabolism carbamazepine increase serum levels @DRUG$ should be prior to administration with , signs and symptoms of carbamazepine toxicity should closely appropriate dosage adjustment be	DDI-false
@DRUG$ , @DRUG$ and may increase effect	DDI-false
@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	DDI-false
@DRUG$ , through on microsomal enzyme been reported the metabolism of warfarin-type , , propranolol nifedipine chlordiazepoxide , , , , theophylline @DRUG$ thereby delaying elimination and increasing of these drugs .	DDI-mechanism
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Agents : Patients agents b-blocking properties drug catecholamines ( e.g. , @DRUG$ and @DRUG$ should be closely signs of and/or severe	DDI-false
Antidepressants, @DRUG$: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
@DRUG$ , including Estrogens may @DRUG$ increasing effect .	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
The hypoglycemic action may be including @DRUG$ other drugs that highly , salicylates sulfonamides @DRUG$ and beta .	DDI-false
interfere absorption where pH an determinant of ( , ketoconazole , @DRUG$ and @DRUG$ )	DDI-false
FLEXERIL may enhance the effects of @DRUG$ , and @DRUG$.	DDI-false
, @DRUG$ to be cessation heparin therapy , allow time heparins on the to initiation @DRUG$	DDI-false
also with e.g. , @DRUG$ , ) the to actions @DRUG$.	DDI-false
aluminum-containing containing @DRUG$ iron preparations zinc or metal cations Videx ( ) chewable/buffered or the pediatric powder for oral not be taken within 2 hours .	DDI-false
These exposures of @DRUG$ and @DRUG$ should into women taking valdecoxib .	DDI-false
rats shown @DRUG$ administration certain @DRUG$ hypertension , ACTH hypertension	DDI-false
While serotonin reuptake inhibitors SSRIs ) @DRUG$ , @DRUG$ , and inhibit P450 2D6 they may vary inhibition	DDI-false
In vitro in vivo indicate @DRUG$ , , and ketoconazole the of @DRUG$ can result increase in plasma cisapride and the interval on the ECG .	DDI-mechanism
All subjects @DRUG$ ( 1,200 mg twice a day ) 4 , by 7-day by @DRUG$ ( 300 once ] ( 1 or rifampin 600 mg QD ( 2 for days	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
METHODS beginning of the experiment given subcutaneous of @DRUG$ ( mg/kg and subcutaneous injections bombesin body weight and 16 of @DRUG$ ( or mg/kg every other the week 45	DDI-false
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	DDI-effect
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	DDI-false
A two-way interaction between the @DRUG$, @DRUG$, and the coumarin anticoagulants has been suggested.	DDI-int
An interaction study with @DRUG$ showed no clinically significant effect of @DRUG$ on warfarin pharmacokinetics or anticoagulant activity.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Effect of @DRUG$ on the apparent volume of distribution and elimination of @DRUG$.	DDI-false
ACE and Receptor clinical studies patients hypertension addition of INSPRA to @DRUG$ @DRUG$ potassium about 0.09 - 0.13 ) .	DDI-false
, patients under @DRUG$ monitored concomitant @DRUG$ .	DDI-advise
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Presumably, @DRUG$ acts as a stimulator of @DRUG$ metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.	DDI-mechanism
Antiacid @DRUG$ , Didanosine , Indanavir , , , @DRUG$ , Ritanovir Saquinavir .	DDI-false
@DRUG$ While @DRUG$ interact with the , should be exercised nonetheless since interactions have been NSAIDs	DDI-false
Cholestyramine and @DRUG$ Absorption hydrochlorothiazide impaired in the of @DRUG$.	DDI-false
Studies in rats have shown that neomycin administration attenuates certain types of @DRUG$ dependent hypertension, including @DRUG$ hypertension.	DDI-false
the between almotriptan and other potent e.g. , itraconazole @DRUG$ @DRUG$ ) not been studied , increased to may be expected when almotriptan is with medications	DDI-false
@DRUG$ healthy single 500 of and @DRUG$ by an % and 24 % respectively and metformin renal clearance decreased by 14	DDI-false
of local @DRUG$ norepinephrine receiving oxidase inhibitors @DRUG$ may produce hypertension	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
: As @DRUG$ @DRUG$ is probenecid	DDI-false
Microdosed minipill @DRUG$ preparations are not recommended for use with @DRUG$.	DDI-advise
no specific drug with glaucoma systemic identified in IOPIDINE , the an additive or effect CNS depressants @DRUG$ , @DRUG$ ) be considered	DDI-false
tricyclic , and @DRUG$ may @DRUG$.	DDI-effect
@DRUG$: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-int
The action of @DRUG$ be by drugs including @DRUG$ other drugs highly , sulfonamides , chloramphenicol , , monoamine oxidase inhibitors , and agents .	DDI-effect
@DRUG$: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
between   and @DRUG$ , lamotrigine , valproate ) were the serum of levetiracetam @DRUG$ studies	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
of is reduced concomitant an @DRUG$ containing @DRUG$ and	DDI-false
@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ : produced an elevation plasma levels and a reduction in @DRUG$ clearance	DDI-false
There been 2-fold previously of other @DRUG$ , including @DRUG$ , when been combination with these agents .	DDI-false
resulting cessation , with or without @DRUG$ replacement , may of certain medications , such @DRUG$ theophylline	DDI-false
@DRUG$: Elevated @DRUG$ levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.	DDI-false
This drug with @DRUG$ or other depressants ( depressant effects these or , other effects these medications are used concurrently with ) @DRUG$ use intensify the anticholinergic and CNS	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-mechanism
Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below.	DDI-false
Amiodarone may certain , including CYP1A2 @DRUG$ , @DRUG$.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
@DRUG$: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
studies not relationship , should aware an coagulation have been in oral @DRUG$	DDI-effect
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Cytochrome , @DRUG$ , carbamazepine and @DRUG$ , metabolism , causing approximately clonazepam	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
* table not * @DRUG$ may be to decreased @DRUG$ in patients these agents concomitantly	DDI-false
Aspirin/@DRUG$ Pharmacokinetic pharmacodynamic drug-drug interactions have not been between @DRUG$ and concomitantly administered 162.5 2 hours prior to initiation of g/kg/min 4 ) or orally , and 6 and 12 subsequent 1.5 g/kg/min . 18 .	DDI-false
the of @DRUG$ ( 1 @DRUG$ ) did not alter the a of cimetidine .	DDI-false
effects from blockade occur when administered concomitantly with other @DRUG$ , amantadine , @DRUG$ MAO inhibitors tricyclic or some antihistamines	DDI-false
the results it concluded @DRUG$ may safely coadministered both @DRUG$	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other therapy Although studies were not , finasteride concomitantly clinical with acetaminophen acid a-blockers , analgesics , angiotensin-converting ( , , benzodiazepines , beta blockers , @DRUG$ , nitrates , H2 antagonists @DRUG$ , inhibitors also referred as , and anti-infectives clinically significant adverse	DDI-false
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Serious symptoms ( , severe blurred ) have been associated with in levels @DRUG$ when @DRUG$ is	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
The @DRUG$ @DRUG$ clearance has not been studied	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.	DDI-advise
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	DDI-false
Although of CYP 3A4/5 @DRUG$ @DRUG$ did occur high concentrations it not to be of clinical .	DDI-false
doses either or @DRUG$ @DRUG$ the the and ,	DDI-false
the combined @DRUG$ @DRUG$ generally be avoided	DDI-advise
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ : Gastrointestinal acidifying @DRUG$ , reserpine , glutamic acid , ascorbic acid fruit juices etc . ) absorption of	DDI-false
to the clinically this kind with Mefloquine although theoretically coadministration to alter cardiac conduction ( anti-arrhythmic beta-adrenergic , @DRUG$ , @DRUG$ tricyclic might also contribute of .	DDI-false
@DRUG$ , ciprofloxacin clarithromycin , , @DRUG$ , imatinib , , , , protease , .	DDI-false
Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-false
@DRUG$ related drugs decrease arterial to	DDI-effect
@DRUG$ of @DRUG$ and in a 24 % increase concentrations of	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-mechanism
@DRUG$ is a substrate for both @DRUG$ and CYP3A4.	DDI-false
specific been performed by eg , @DRUG$ dapsone , , quinine , @DRUG$ , , , , alprazolam , ) when with	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
) that 2D6 ( antidepressants , , and Type @DRUG$ and @DRUG$ .	DDI-false
In separate studies patients receiving maintenance doses warfarin , hydrochlorothiazide , or @DRUG$ , @DRUG$ days no on pharmacodynamics of warfarin ) or of digoxin .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Co-administration of and aminoglycosides or other agents interfering neuromuscular e.g. @DRUG$ should be performed with as the effect of the @DRUG$ may potentiated .	DDI-false
@DRUG$ may potentiate the adverse effects of other @DRUG$ administered concomitantly.	DDI-effect
With Narrow Index @DRUG$ 3 mg not of @DRUG$ measured following mg daily next 6	DDI-false
studies not performed , coadministration with drugs that are by CYP3A4 calcium channel , disopyramide , , @DRUG$ ergot , , fentanyl , , have plasma coadministered with @DRUG$ ;	DDI-mechanism
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
The are examples of substances may reduce blood-glucose-lowering effect corticosteroids , @DRUG$ , , diuretics sympathomimetic agents , @DRUG$ terbutaline ) , derivatives somatropin thyroid hormones estrogens progestogens ( e.g. , oral contraceptives .	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	DDI-mechanism
Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
@DRUG$ effect on microsomal enzyme systems , been the of @DRUG$ , propranolol nifedipine chlordiazepoxide , tricyclic antidepressants , , theophylline and metronidazole , thereby and levels of these drugs	DDI-mechanism
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Co-administration of and @DRUG$ or other agents interfering neuromuscular e.g. curare-like compounds ) only be as the effect of the @DRUG$ be potentiated .	DDI-false
ACE and @DRUG$ ( Heart Failure Post-Myocardial Infarction)- EPHESUS ( 91 % patients receiving ACE or angiotensin	DDI-false
This drug interact @DRUG$ @DRUG$ ( may potentiate depressant effects of either these or ) with anticholinergic activity these used concurrently , and monoamine ( MAO inhibitors concurrent use with may intensify anticholinergic and of antihistamines )	DDI-false
These drugs include the and other diuretics , , , @DRUG$ , @DRUG$ , , , calcium , isoniazid	DDI-false
However, it has been established that @DRUG$ interferes with the contraceptive effect of microdosed @DRUG$ minipill preparations.	DDI-effect
Terfenadine: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
use of @DRUG$ @DRUG$ absorption	DDI-mechanism
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-advise
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
@DRUG$:Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
patients @DRUG$ @DRUG$ , toxicity may develop	DDI-effect
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Important To Date Levosimendan does not have clinically important interactions with captopril , beta-blockers , , @DRUG$ , @DRUG$ , ethanol itraconazole	DDI-false
@DRUG$ ( e.g. , , or amiloride ) , potassium or @DRUG$-containing lead to significant in serum potassium	DDI-false
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
The action of @DRUG$ be by certain nonsteroidal and other drugs that highly bound salicylates , sulfonamides chloramphenicol @DRUG$ , , adrenergic agents	DDI-effect
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Antidepressants, tricyclic: Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	DDI-false
: In a , ( @DRUG$ , @DRUG$ fosinopril reduced and of fosinoprilat fosinopril alone suggesting antacids impair absorption fosinopril	DDI-false
Methotrexate Renal methotrexate inhibited by administration @DRUG$ leading to increased @DRUG$.	DDI-false
specific studies not been coadministration drugs that are by CYP3A4 ( eg @DRUG$ , , amiodarone , quinidine warfarin , tacrolimus , ergot , pimozide @DRUG$ , alprazolam may elevated concentrations ;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering and ACE inhibitors , @DRUG$ , fluoxetine , @DRUG$ propoxyphene , salicylates somatostatin ( octreotide ) , sulfonamide .	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
Aspirin: Concomitant administration of @DRUG$ and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ : NSAIDs produced an of lithium a reduction @DRUG$ clearance	DDI-false
@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	DDI-false
Antagonism @DRUG$ and @DRUG$ has been .	DDI-effect
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
therefore, @DRUG$ or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	DDI-advise
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
and @DRUG$ In clinical patients the addition INSPRA 50 to inhibitors and @DRUG$ increased serum potassium slightly about mEq/L )	DDI-false
Nephrotoxicity has administration of cephalosporins @DRUG$ or diuretics	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
Strong inducers of cytochrome ( i.e. @DRUG$ @DRUG$ phenobarbital ) have decrease the plasma levels of ( 29 %	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or @DRUG$.	DDI-false
- @DRUG$ @DRUG$ Anabolin ] , oxandrolone [ e.g. , Anavar oxymetholone [ , ] , e.g. , Winstrol ] ) or	DDI-false
metabolizers debrisoquin : Interactions @DRUG$ CYP2D6 as fluoxetine , paroxetine ) have not been would be blood of @DRUG$ .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
Drug Interactions some , oxidase MAOI ): theoretically affect pharmacodynamics - @DRUG$ and additive CNS - : increases @DRUG$	DDI-false
studies have and @DRUG$ significantly the systemic @DRUG$ its major	DDI-mechanism
The effect of TORADOL on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during @DRUG$ therapy have been reported.	DDI-mechanism
Drugs Coadministered @DRUG$ Antiarrhythmics : amiodarone , : , terfenadine @DRUG$ Antimycobacterial agents Benzodiazepines motility agents	DDI-advise
@DRUG$ and @DRUG$ : a drug interaction	DDI-int
The pharmacokinetics of @DRUG$ were not affected by multiple-dose administration of @DRUG$.	DDI-false
The sulfonylureas may potentiated by nonsteroidal anti-inflammatory agents other are highly bound salicylates , sulfonamides , probenecid @DRUG$ @DRUG$ adrenergic agents .	DDI-false
These include @DRUG$ corticosteroids , phenothiazines thyroid products estrogens , oral , phenytoin , @DRUG$ sympathomimetics channel .	DDI-false
Uricosuric as probenecid @DRUG$ , of	DDI-mechanism
The successive application of @DRUG$ (5 or 10 mg/kg egg weight (e.w.) and @DRUG$ (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.	DDI-effect
evaluate the of plus on of HIV-related , non-Hodgkin lymphoma ( ) , the authors patients with HIV-NHL treated the cyclophosphamide , @DRUG$ vincristine ( ) chemotherapy regimen plus group 80 patients were treated CHOP or a i.e. , cyclophosphamide @DRUG$ and prednisone with vincristine ) receiving antiretroviral .	DDI-false
Contraceptives , Injectable , and Implantable Contraceptives An study demonstrated co-administration oral contraceptive @DRUG$ norethindrone and @DRUG$ levels 14 %	DDI-false
@DRUG$: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.	DDI-false
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either alpha- or @DRUG$.	DDI-false
majority of patients RA clinical studies received one or of the concomitant ORENCIA : @DRUG$ , , TNF blocking agents , azathioprine , @DRUG$ hydroxychloroquine leflunomide , and	DDI-false
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
drugs other @DRUG$ phenothiazines , , oral phenytoin , nicotinic , @DRUG$ and	DDI-false
Magnesium- and/or @DRUG$-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
When @DRUG$ is added to or withdrawn from treatment, dosage adjustment of @DRUG$ may be required.	DDI-advise
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
the @DRUG$ SSRIs ) , @DRUG$ , sertraline , paroxetine , P450 , they the inhibition	DDI-false
@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
Erythromycin Co-administration of felodipine (PLENDIL) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
@DRUG$ : should be used with agents ( e.g. , propranolol , a @DRUG$ inhibitor or calcium channel antagonists e.g. diltiazem , a CYP3A4 ) because potentiation sinus arrest and AV ;	DDI-false
Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ by approximately 40%.	DDI-mechanism
The action of @DRUG$ may enhanced by or	DDI-effect
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
Corticosteroids and @DRUG$ ACTH ): may potentiate induced hypokalemia which the patient to cardiac .	DDI-effect
Drug studies that @DRUG$ not any clinically interactions with @DRUG$ , quinidine , or	DDI-false
@DRUG$ (NSAIDs)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	DDI-false
Theophylline: The pharmacokinetics of @DRUG$ (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Although no been conducted likely that the of be by CYP3A4 such as phenytoin phenobarbital @DRUG$ ) , ( @DRUG$ ;	DDI-false
In studies of of @DRUG$ , @DRUG$ had no on warfarin ( time or of digoxin	DDI-false
Drugs That Not Coadministered With Antiarrhythmics : amiodarone Antihistamines : , terfenadine Antimigraine : @DRUG$ Benzodiazepines @DRUG$ , cisapride	DDI-false
Patients receiving anesthetics , phenothiazines , @DRUG$ , tricyclic other ( alcohol ) DILAUDID additive depression	DDI-false
The pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of @DRUG$ (300 mg QID).	DDI-false
@DRUG$ was % of apparent clearance @DRUG$ when was enzyme-inducing AEDs	DDI-false
These drugs include the @DRUG$ and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-false
Coadministration of this oral @DRUG$ influence	DDI-false
The majority of RA studies one more the concomitant medications ORENCIA @DRUG$ , corticosteroids , blocking , , hydroxychloroquine leflunomide @DRUG$ and anakinra	DDI-false
Central System : The concomitant use @DRUG$ transdermal system other central depressants , not limited to other opioids , tranquilizers ( , , general , phenothiazines , skeletal muscle and @DRUG$ , may depression hypotension , profound , or potentially result coma or	DDI-effect
Slow-channel calcium blockers , as @DRUG$ , diltiazem @DRUG$ activation in , and decrease intravascularly .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
exposure of ( mg ) was increased % of mg BID ) for days , plasma of @DRUG$ ( 40 mg ) was increased @DRUG$ ( 10 ) for 12 .	DDI-false
Antibiotics : @DRUG$ erythromycins @DRUG$ or may with the	DDI-false
of disturbance ( have @DRUG$ is @DRUG$.	DDI-effect
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Valproate : The of tiagabine valproate chronically effect @DRUG$ pharmacokinetics , @DRUG$ decreased tiagabine binding 96.3 to 94.8 resulted in an of % the free tiagabine	DDI-false
Protein Binding In @DRUG$ minimally or not all with the binding of acid % @DRUG$ , ( binding , or warfarin .	DDI-mechanism
concomitant Although specific interaction finasteride of in clinical studies @DRUG$ a-blockers analgesics angiotensin-converting enzyme ACE ) @DRUG$ , calcium-channel , cardiac , H2 antagonists HMG-CoA synthetase inhibitors ( referred , without evidence significant interactions .	DDI-false
Combination @DRUG$ with other @DRUG$ therapy for patients ventricular incompletely responsive to single agent or	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including @DRUG$, when fluoxetine hydrochloride has been administered in combination with these agents.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
, colorectal given irinotecan/5-FU/@DRUG$ with without	DDI-false
@DRUG$ Lithium reported in patients lithium concomitantly drugs which cause elimination	DDI-false
metabolizers have higher plasma @DRUG$ ( @DRUG$ when given usual doses	DDI-false
Interaction effect @DRUG$ and or @DRUG$.	DDI-effect
@DRUG$ , , Injectable , , Contraceptives : interaction study co-administration and the oral @DRUG$ Ortho-Novum decreases of norethindrone and ethinyl estradiol of 14 % and 31 , respectively	DDI-false
Multivitamins , or containing iron or , @DRUG$ sucralfate should administered concomitantly , or within hours of , the of @DRUG$ interfere absorption resulting in and urine levels of norfloxacin	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ had no effect on plasma levels of @DRUG$.	DDI-false
Substances are potent of CYP3A4 activity , @DRUG$ itraconazole ) decrease @DRUG$ metabolism gefitinib	DDI-mechanism
At steady state, @DRUG$ 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) @DRUG$, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-false
Pharmacokinetic Interaction between @DRUG$ and rifabutin or @DRUG$ in healthy males.	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to @DRUG$ or oral hypoglycemic agents.	DDI-effect
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
the of HAART on clinical course of patients with systemic , HIV-NHL ) authors compared retrospectively group 24 patients with who the cyclophosphamide vincristine prednisone ( CHOP regimen plus a of 80 who were treated with CHOP chemotherapy or a CHOP-like ( @DRUG$ , doxorubicin @DRUG$ with plus bleomycin without receiving antiretroviral .	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral @DRUG$, methotrexate and 5-fluorouracil.	DDI-false
Acidifying agents Gastrointestinal acidifying agents @DRUG$ @DRUG$ juices , etc . of amphetamines	DDI-false
other potent @DRUG$ @DRUG$ , are used in combination , patients be observed for several hours any pressure .	DDI-effect
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Dexamethasone and @DRUG$ inhibit and stimulate of epithelium	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of @DRUG$ to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-advise
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
clinical studies performed with Fondaparinux use oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ piroxicam ) significantly affect of sodium .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of @DRUG$).	DDI-false
may interact with any of the following - @DRUG$ , @DRUG$ (	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	DDI-mechanism
Depressants : The concomitant use of DURAGESIC   ( fentanyl system @DRUG$ , limited other , , ( , ) general @DRUG$ , skeletal muscle , and alcohol , , hypotension and , coma or death	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other may enhance the neuromuscular blocking of such as NUROMAX include certain antibiotics ( @DRUG$ , bacitracin , , , @DRUG$ and sodium colistimethate magnesium salts lithium , anesthetics , procainamide quinidine	DDI-false
The be drugs including @DRUG$ and other that are highly bound salicylates @DRUG$ chloramphenicol probenecid , coumarins , monoamine inhibitors and adrenergic agents .	DDI-false
This interaction be in patients @DRUG$ with @DRUG$.	DDI-advise
@DRUG$ with caution in patients   -receptor ( , @DRUG$ a inhibitor ) calcium antagonists e.g. , , a , and , CYP3A4 ) because of bradycardia , arrest , block	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Drugs Should Coadministered With VIRACEPT Antiarrhythmics : , Antihistamines : , Antimigraine : ergot derivatives Antimycobacterial : @DRUG$ Benzodiazepines @DRUG$ , triazolam GI motility	DDI-false
The use of NUROMAX @DRUG$ to of @DRUG$ has not been	DDI-false
@DRUG$ ( ): e.g. , @DRUG$ , , sertraline have rarely reported to cause weakness , hyperreflexia , and incoordination coadministered with agonists	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Other therapies clinical trials , safety profile with with anxiolytics , hypnotics and sedatives ( including @DRUG$ ) or @DRUG$ was taking placebo these medications .	DDI-false
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	DDI-effect
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-advise
Lithium serum @DRUG$ and @DRUG$ reported in receiving and inhibitor therapy	DDI-false
Therefore , occur following concomitant of psychotropic e.g. @DRUG$ , , sedatives @DRUG$	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$ 40 mg for produced decreases @DRUG$ clearance % ) clearance % 34 % higher serum alone .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Antidepressants FORADIL be administered with extreme in being treated with monoamine @DRUG$ because action @DRUG$ may these .	DDI-false
is recommended to avoid @DRUG$ hydroxide @DRUG$ for least hours following ethambutol	DDI-false
Anticholinesterases ( neostgmine , physostigmine ) @DRUG$ , @DRUG$ toxicity and cause .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
may decrease effect of @DRUG$ , @DRUG$ ketoconazole	DDI-false
data are for coadministration and .	DDI-false
Elevated serum levels of @DRUG$ with concomitant of @DRUG$	DDI-false
efavirenz @DRUG$ have compared triple the @DRUG$ 48 initial with responses being nevirapine regimens and observed with .	DDI-false
receiving general anesthetics , @DRUG$ tranquilizers , antidepressants other @DRUG$ including concomitantly with DILAUDID may exhibit .	DDI-false
plasma levels of several closely related antidepressants been to be by the concomitant methylphenidate or hepatic ( cimetidine fluoxetine and by the administration inducers ( e.g. @DRUG$ ) and effect be anticipated @DRUG$ as well .	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-mechanism
OTHER CONCOMITANT Although specific studies in , concomitantly with @DRUG$ , , calcium-channel blockers , diuretics anti-inflammatory drugs @DRUG$ ) evidence of adverse .	DDI-false
It may to adjust the of oral @DRUG$ beginning stopping disulfiram prolong prothrombin	DDI-advise
- [ @DRUG$ ] , oxandrolone , oxymetholone [ e.g. , @DRUG$ , e.g. ,	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.	DDI-false
@DRUG$ : excretion is increased , and , used @DRUG$ therapy	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$: @DRUG$ (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).	DDI-false
Other drugs which enhance neuromuscular action nondepolarizing NUROMAX ( e. g. , aminoglycosides tetracyclines , bacitracin , @DRUG$ , , sodium colistimethate magnesium , anesthetics , procainamide and @DRUG$.	DDI-false
The action benzodiazepines may be @DRUG$ , antihistamines , @DRUG$ , , oxidase narcotics , phenothiazines , psychotropic medications , other drugs that CNS depression	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ (TMP/SMX).	DDI-false
digoxin , @DRUG$ , naproxen , acetaminophen , phenytoin andtolbutamide not alter @DRUG$ protein binding	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, @DRUG$, or lamotrigine.	DDI-false
of the benzodiazepines be potentiated anticonvulsants , @DRUG$ , alcohol , barbiturates oxidase , , @DRUG$ drugs that produce .	DDI-false
Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, aminopyrine and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Therefore , a potential an drugs are 1A2 ( @DRUG$ @DRUG$ )	DDI-false
While the serotonin reuptake inhibitors SSRIs ) , e.g. , @DRUG$ fluoxetine , @DRUG$ , they in the inhibition .	DDI-false
Influence @DRUG$ @DRUG$ Concentration Mean change , 90 )	DDI-false
The are examples substances effect : @DRUG$ niacin , danazol , sympathomimetic e.g. epinephrine , @DRUG$ , terbutaline ) , isoniazid , hormones estrogens , progestogens , in contraceptives )	DDI-false
Drug Interactions Flupenthixol with , like Monoamine oxidase ( MAOI could theoretically pharmacodynamics - @DRUG$ - Ethanol : Flupenthixol CNS @DRUG$ the effect of Tricyclic	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and alcohol.	DDI-effect
Co-administration ( ) @DRUG$ fold in and , and about fold in half- of @DRUG$.	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
of tetracycline furosemide penicillin @DRUG$ and was decreased given @DRUG$	DDI-mechanism
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
the doses of @DRUG$ required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of @DRUG$.	DDI-effect
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or @DRUG$.	DDI-false
Natrecor with @DRUG$ as nitroglycerin , nitroprusside , milrinone , ACE not been drugs were with @DRUG$ in ) .	DDI-false
Therefore use of @DRUG$ with @DRUG$ may render these less effective	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
pharmacokinetic @DRUG$ , corticosteroids and TNF blocking did not influence @DRUG$ .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
that @DRUG$ enhances the anticoagulant of @DRUG$-like drugs	DDI-effect
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
Other strong CYP3A4 ( e.g. , nefazodone , , @DRUG$ , @DRUG$ ) would be expected to behave	DDI-false
@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
have been peripheral neuropathy antiretroviral nucleoside analogues , dapsone , ethionamide , glutethimide hydralazine @DRUG$ , isoniazid , nitrofurantoin @DRUG$ ribavirin .	DDI-false
the clinical of patients , systemic , non-Hodgkin HIV-NHL , the compared group 24 patients with were treated @DRUG$ doxorubicin vincristine prednisone ( CHOP regimen HAART with a of 80 patients CHOP chemotherapy CHOP-like ( cyclophosphamide doxorubicin teniposide , and prednisone with vincristine plus @DRUG$ ) receiving antiretroviral therapy .	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
effects @DRUG$ a substantial period discontinuation of the drug , and borne mind when another following @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Due to high inter-patient variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent @DRUG$ and AVASTIN is uncertain.	DDI-false
@DRUG$: @DRUG$-induced hypokalemia may potentiate digitalis toxicity.	DDI-false
studies of @DRUG$ alone or combination @DRUG$ numbers of 65 to determine whether differently younger subjects	DDI-false
@DRUG$: Coadministration of a single dose of @DRUG$ 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
Since entecavir is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and @DRUG$).	DDI-mechanism
The pressure effect @DRUG$ tended to greater in than no other @DRUG$	DDI-false
Cardiovascular Agents : and have with @DRUG$ , @DRUG$ , without of clinically significant .	DDI-false
@DRUG$ : single doses of @DRUG$ 50 mg produced decreased alertness psychomotor performance to 4 after .	DDI-false
co-administration @DRUG$ is limited , should to suspending use of inhibitors patients	DDI-false
been associated peripheral neuropathy include antiretroviral analogues , cisplatin , dapsone , @DRUG$ hydralazine iodoquinol , isoniazid , phenytoin , and	DDI-false
@DRUG$ , or PCP , antagonized @DRUG$	DDI-effect
The , uniformity course of @DRUG$ , glutethimide , hydrate methaqualone systematically patients receiving @DRUG$ therapy	DDI-false
@DRUG$, tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
a I using doses @DRUG$ ( ) and @DRUG$ ( 75 sequential infusions , myelosuppression more given after cisplatin than alternate sequence TAXOL before	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
clinical , FLOLAN used with @DRUG$ , oral and supplemental oxygen In congestive heart failure receiving furosemide digoxin in FLOLAN , apparent oral clearance values n = 23 and @DRUG$ ( n 30 by % 15 % , on day baseline by day .	DDI-false
@DRUG$ produced distinctive each : it for the in @DRUG$ discrimination it increased of short interresponse as well increasing overall response rates DRL	DDI-false
May interact ) , @DRUG$ @DRUG$ other of microsomal enzyme oxidation system diethylstilbestrol ) increased effect corticosteroids .	DDI-false
The of @DRUG$ containing @DRUG$ to oxidase , tricyclic antidepressants may , prolonged hypotension or hypertension	DDI-false
@DRUG$ with theophylline @DRUG$ acetaminophen , valproic acid with phenobarbital at to decreases binding the drug .	DDI-false
Analysis of the concentration of @DRUG$ following ultracentrifugation indicated that there is rapid equilibration of budesonide between the @DRUG$ and aqueous phase.	DDI-false
No Important Interactions To Date clinically important pharmacokinetic captopril , beta-blockers , @DRUG$ @DRUG$ , isosorbide , carvedilol , itraconazole	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
@DRUG$ at state AUC(ss ) of and the AUC(ss ) @DRUG$ .	DDI-mechanism
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.	DDI-false
include @DRUG$ , clarithromycin , doxycycline , , , @DRUG$ protease inhibitors , and verapamil	DDI-false
Therapeutic concentrations , ibuprofen , naproxen piroxicam , @DRUG$ did alter @DRUG$ binding .	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$-Concomitant of @DRUG$ may the absorption of	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-mechanism
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
drugs which neuromuscular blocking of such certain e. , @DRUG$ lincomycin , colistin , and sodium colistimethate , local @DRUG$ procainamide quinidine	DDI-false
Although the between and @DRUG$ @DRUG$ , exposures may be almotriptan used with medications	DDI-false
drugs include other diuretics , corticosteroids phenothiazines thyroid , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics @DRUG$ and isoniazid .	DDI-false
Interactions Between And Other Antiepileptic Drugs AEDs @DRUG$ Keppra   3000 mg ) on the pharmacokinetic disposition @DRUG$ in with refractory	DDI-false
@DRUG$ may counteract effect of @DRUG$ , phenytoin and increase the susceptible pediatric patients	DDI-effect
drugs thiazides other diuretics , corticosteroids thyroid products @DRUG$ , oral nicotinic , sympathomimetics @DRUG$ , .	DDI-false
may the @DRUG$ , barbiturates @DRUG$.	DDI-false
, @DRUG$ may the of drugs an important determinant of eg ketoconazole , @DRUG$ and	DDI-mechanism
exercised @DRUG$ @DRUG$ are .	DDI-advise
@DRUG$: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Multivalent Cation-Containing Products Concurrent of , ciprofloxacin multivalent cation-containing such magnesium aluminum antacids sucralfate , @DRUG$ pediatric , products calcium , , @DRUG$ may substantially decrease absorption of , resulting in urine lower desired	DDI-false
@DRUG$ ( SSRIs ): ( fluoxetine , , @DRUG$ , ) been weakness , , incoordination when .	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
@DRUG$ anesthesia @DRUG$ tolerance in dogs	DDI-false
@DRUG$ bumetanide natriuresis is not but is probably its inhibitory on secretion of	DDI-false
possible with some @DRUG$ such as @DRUG$ , which microsomal enzyme .	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/SMX).	DDI-false
@DRUG$ VIRACEPT a 47 decrease in @DRUG$ decrease in norethindrone plasma	DDI-false
absorption impacted by of @DRUG$ and	DDI-false
ECG may from administration of non-potassium sparing diuretics ( loop @DRUG$ ) can acutely worsened by @DRUG$ especially when of the beta-agonist .	DDI-effect
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
Coadministration with are potent inducers of CYP3A4 , @DRUG$ , dexamethasone result in of @DRUG$.	DDI-mechanism
Concomitant administration of other related compounds eg @DRUG$ @DRUG$ and may and increase of convulsions .	DDI-false
Digoxin Nimodipine Losartan @DRUG$ has interactions @DRUG$ and losartan has no significant effect plasma bosentan .	DDI-false
Although these do not indicate interaction and @DRUG$ the of to taking @DRUG$ should be , patients monitored	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Patients @DRUG$ concomitantly @DRUG$ reported both weight gain loss compared either alone .	DDI-effect
Valproate patients @DRUG$ chronically effect on @DRUG$ pharmacokinetics valproate significantly binding from to % , in an 40 % the free tiagabine .	DDI-false
* This table is not all inclusive ** @DRUG$ may not be effective due to decreased @DRUG$ plasma concentrations in patients taking these agents concomitantly	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
the first study of 0.2 sodium g @DRUG$ resulted more than AUC % compared to dosing @DRUG$ alone .	DDI-false
Delayed Reactions to Contrast A revealed that ( range - of patients various @DRUG$ regimens were @DRUG$ experienced , atypical reactions .	DDI-effect
In , @DRUG$ can inhibit adrenal @DRUG$ may insufficiency during corticosteroid withdrawal .	DDI-effect
, we have shown @DRUG$ is tool with which examine the @DRUG$-mediated of megakaryocytes	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
@DRUG$ : synergistic @DRUG$ has been , use of flucytosine by possibly increasing cellular uptake and/or impairing its renal excretion .	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen , quinidine/lidocaine , theophylline/acetaminophen	DDI-false
Drug/LaboratoryTest Interactions @DRUG$ interfere with for the determination @DRUG$ .	DDI-false
an @DRUG$ on the @DRUG$ dideoxyinosine HIV-infected patients .	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
not coadministration with drugs that mainly by ( , channel blockers , dapsone quinine , @DRUG$ tacrolimus cyclosporine , ergot @DRUG$ fentanyl alfentanyl and ) may plasma concentrations when coadministered	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
studies @DRUG$ concomitant use oral anticoagulants ( , acid , @DRUG$ ( piroxicam , and did	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Anticoagulants : Potentiation of @DRUG$-type CYP2C9 @DRUG$ substrate ) anticoagulant receiving result serious or bleeding .	DDI-false
of GABITRIL : 800 ) taking @DRUG$ chronically no on @DRUG$ pharmacokinetics	DDI-false
In trials , FLOLAN diuretics anticoagulants @DRUG$ , and supplemental @DRUG$.In a in heart in was initiated apparent for ( ) n 30 by % and 15 respectively , the second day of and by day .	DDI-false
@DRUG$ , as @DRUG$ ;	DDI-false
Drugs : In of patients 7 10/interaction study concomitant administration , @DRUG$ , , @DRUG$ or affect the peak and values diclofenac	DDI-false
Oral agents Pharmacokinetic @DRUG$ and @DRUG$ ( 7.5 mg single oral ) not been	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ @DRUG$ may reduce the vitamin K.	DDI-mechanism
Injection like other , produces depression system when with ethyl , @DRUG$ , , MAO inhibitors scopolamine used with injectable , an of sedation , hallucinations and irrational behavior observed	DDI-false
Digoxin, Nimodipine and @DRUG$: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$ : @DRUG$ mg , when co-administered nifedipine mg once daily , did not affect ( or maximum concentration Cmax ) drug is metabolized	DDI-false
These include the thiazides other diuretics , corticosteroids phenothiazines @DRUG$ , estrogens oral contraceptives , sympathomimetics , @DRUG$	DDI-false
It to be with the paraclinical deficit between @DRUG$ due an insufficient @DRUG$ which requires physiological magnesium to a dysregulation of the control mechanisms magnesium which more of dysregulation .	DDI-false
drug between @DRUG$   other AEDs ( @DRUG$ , , phenobarbital phenytoin valproate evaluating serum concentrations of and these AEDs during placebo-controlled clinical	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Central concomitant @DRUG$ ( ) with other central , including but not limited opioids , @DRUG$ , hypnotics tranquilizers e.g. , benzodiazepines ) , phenothiazines , skeletal relaxants and alcohol , respiratory , hypotension , profound sedation or in coma or death	DDI-effect
@DRUG$ interference @DRUG$ , secobarbital , and systematically in 16 patients receiving coumarin	DDI-false
Chlorpromazine @DRUG$ blocks dopamine norepinephrine receptors inhibiting the central stimulant effects @DRUG$ and can treat amphetamine poisoning .	DDI-effect
@DRUG$ : The concomitant administration diflunisal naproxen in normal volunteers the of , but significantly decreased the @DRUG$ and its glucuronide	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-false
Interactions @DRUG$ and aspirin other non-steroidal and such as Allium sativum ) and ginkgo ( @DRUG$	DDI-int
Other therapies : the profile treated @DRUG$ ( including ) , or @DRUG$ was to placebo with	DDI-false
have been treated with MAO inhibitors within two three weeks prior the of @DRUG$ receive doses of @DRUG$ no greater than ( 1/10 ) .	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-effect
following examples of that reduce the effect , @DRUG$ diuretics , agents e.g. , epinephrine salbutamol , terbutaline ) isoniazid , @DRUG$ , thyroid progestogens , in oral .	DDI-false
Sulfapyridine may interact with any of the following: - @DRUG$ (e.g., @DRUG$) (with long-term, high-dose use) or	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Cephalosporins-@DRUG$ chains ( @DRUG$ , , ) ( cefazolin ) vitamin deficiency hypoprothrombinemia .	DDI-false
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and @DRUG$.	DDI-false
Multivalent Cation-Containing Products : a quinolone , @DRUG$ , multivalent cation-containing products such as aluminum antacids , , VIDEX chewable/buffered pediatric , or products @DRUG$ , or may decrease the resulting in and urine levels considerably lower than	DDI-mechanism
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, carbamazepine, and phenobarbital.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-advise
@DRUG$ : The of increased gastric pH on the bioavailability @DRUG$ in 18 healthy adult volunteers .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with @DRUG$ or dicumarol.	DDI-false
@DRUG$ ( 400 b.i.d . ) had no bioavailability ) and concentration ( ) of vardenafil when co-administered with @DRUG$ in volunteers	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : The of DURAGESIC   ( @DRUG$ transdermal system other central limited sedatives , tranquilizers , benzodiazepines general anesthetics phenothiazines muscle , and depression and , result coma or .	DDI-false
For example, when @DRUG$ are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other therapy Although specific interaction studies , of 1 more were concomitantly , , , enzyme ( ) inhibitors blockers , @DRUG$ , diuretics H2 reductase inhibitors @DRUG$ also ) , without clinically significant adverse .	DDI-false
interaction studies @DRUG$ does not clinically with phenytoin @DRUG$ , clarithromycin or .	DDI-false
- Anabolic steroids ( @DRUG$ e.g. @DRUG$ ] , e.g. , Anavar oxymetholone [ , Anadrol ] , ] ) or	DDI-false
In small patients 7 - study , concomitant administration @DRUG$ , , chloroquine , , @DRUG$ , digitoxin did not affect peak .	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
Nephrotoxic : Concomitant administration and potential , intravenous e.g. , and @DRUG$ , intravenous pentamidine , vancomycin , @DRUG$ ] contraindicated	DDI-false
In monkeys, the effects of @DRUG$, but not @DRUG$ or PCP, were antagonized by naloxone;	DDI-false
@DRUG$ : inhibiting the central stimulant effects @DRUG$.	DDI-false
basis the selective of @DRUG$ yeast and @DRUG$ for animal cells	DDI-false
Potential interactions between TAXOL a substrate CYP3A4 , and protease inhibitors @DRUG$ @DRUG$ , and nelfinavir ) are substrates and/or of , have evaluated clinical	DDI-false
Inducers , Inhibitors : Drugs which induce P450 activity e.g. , barbiturates , phenytoin , @DRUG$ , ) may of that dosage of @DRUG$ increased .	DDI-false
Upon concomitant administration of of @DRUG$ with the and AUC @DRUG$ were by approximately % .	DDI-false
specific performed , doses 1 mg or more concomitantly in @DRUG$ , acetylsalicylic @DRUG$ , calcium-channel , nitrates , antagonists , , ( referred as ) without evidence of clinically significant interactions .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, @DRUG$, and some macrolide antibiotics.	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Therefore , if @DRUG$ is administered with @DRUG$ should be alert to the levels .	DDI-mechanism
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
containing of N-methylthiotetrazole ( @DRUG$ latamoxef methylthiadiazole ( cefazolin cause K .	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-effect
using this medication all and nonprescription may , especially : ( gentamicin amikacin @DRUG$ , @DRUG$ ( e.g. , , tacrolimus vancomycin	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ Potentiation of warfarin-type CYP2C9 CYP3A4 substrate anticoagulant seen in receiving @DRUG$ and or fatal bleeding .	DDI-false
Iodine or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of @DRUG$.	DDI-effect
has additive effects with alcohol and ( @DRUG$ , , @DRUG$ , ) .	DDI-false
Warfarin-@DRUG$ can antagonize the effect of @DRUG$	DDI-effect
Aspirin: Concomitant administration of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
Furosemide: @DRUG$ IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
Co-administration @DRUG$ and @DRUG$ other with neuromuscular ( e.g. , curare-like ) the the	DDI-advise
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-false
studies designed to drug been done it was noted that or @DRUG$ of up to to patients ( receiving	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Hepatic Enzyme , and : which cytochrome ( ) ( e.g. , @DRUG$ , rifampin enhance of @DRUG$ and that the the corticosteroid be	DDI-mechanism
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	DDI-false
interactions vitro studies using indicate @DRUG$ and @DRUG$ are not ( CYP CYP2D6 , CYP2E1 , CYP1A2 .	DDI-false
Lithium: @DRUG$ 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-mechanism
5HT3 Antagonists : reports profound hypotension of consciousness apomorphine administered ondansetron the with of the including , for , @DRUG$ , @DRUG$ , palonosetron , alosetron .	DDI-false
Example inhibitors @DRUG$ , nefazodone , @DRUG$ inhibitors , quinidine and	DDI-false
studies of benzodiazepines than alprazolam possible drug interaction for @DRUG$ cyclosporine , @DRUG$ nicardipine , and nifedipine .	DDI-false
Administration of doxapram to patients who are receiving @DRUG$ or @DRUG$ may result in an additive pressor effect .	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
, absolute number alcohol-related deaths is greater of deaths in @DRUG$ or @DRUG$ .	DDI-false
: antibiotics inhibit metabolism of @DRUG$ are ( i.e. @DRUG$ cerivastatin lovastatin simvastatin )	DDI-false
Other which neuromuscular blocking of certain antibiotics ( e. g. aminoglycosides bacitracin , @DRUG$ , and magnesium salts , @DRUG$ anesthetics , , quinidine .	DDI-false
similar less , has suggested with phenylbutazone , @DRUG$ , carbamazepine griseofulvin and possibly @DRUG$ tetracyclines 72 .	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Other which enhance blocking action of agents such as aminoglycosides , , , polymyxins clindamycin , @DRUG$ and ) , magnesium salts local anesthetics @DRUG$	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
@DRUG$ @DRUG$ causes increase ( about in the free fraction of .	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, @DRUG$, or metoclopramide.	DDI-false
As with @DRUG$ the onset neuromuscular is and the patients @DRUG$	DDI-effect
significant difference in the pharmacodynamic @DRUG$ administered alone and warfarin administered @DRUG$ as measured by prothrombin time	DDI-false
Interactions @DRUG$ pentazocine nalbuphine , butorphanol @DRUG$ and ) NOT to patient who has therapy with a pure agonist analgesic such Levo-Dromoran	DDI-false
Drugs that peripheral include antiretroviral , @DRUG$ cisplatin , dapsone disulfiram , gold hydralazine iodoquinol , , metronidazole @DRUG$ and vincristine	DDI-false
therapy were performed , of 1 mg more were concomitantly used clinical with @DRUG$ acetylsalicylic acid a-blockers , angiotensin-converting ACE ) inhibitors , anticonvulsants , beta blockers , , cardiac nitrates , , @DRUG$ , HMG-CoA reductase inhibitors , synthetase to as and quinolone anti-infectives without evidence of adverse	DDI-false
Lymphocytopenia has been reported in patients receiving @DRUG$, and it is possible that the administration of @DRUG$ as antiemetic prophylaxis may have enhanced the likelihood of this effect.	DDI-effect
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, @DRUG$ or itraconazole.	DDI-false
Multivalent Cation-Containing Concurrent administration quinolone , with cation-containing such as aluminum @DRUG$ VIDEX chewable/buffered pediatric powder , @DRUG$ , zinc may of ciprofloxacin serum and urine than	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
In both species , but not @DRUG$ , antagonized @DRUG$ on FI FR responding	DDI-false
Co-administration of MYOBLOC @DRUG$ or other agents with neuromuscular transmission ( @DRUG$ be effect of	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	DDI-false
Demonstrated be CYP 3A Inhibitors of Significance on the Basis Studies caution recommended during coadministration with @DRUG$ ): Coadministration of with @DRUG$ increased the maximum concentration of alprazolam , decreased , half-life 17 % and measured psychomotor performance	DDI-false
@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
Compounds tested in man include warfarin, theophylline, @DRUG$, @DRUG$, aminopyrine and antipyrine.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
@DRUG$ should not be administered concomitantly with other @DRUG$ (such as isoproterenol) because of possible additive effects and increased toxicity.	DDI-advise
Magnesium- and/or aluminum-containing @DRUG$ ( @DRUG$ , preparations containing or , Videx ( didanosine chewable/buffered the pediatric powder should taken within hours before or after FACTIVE .	DDI-false
single @DRUG$ and @DRUG$ , prothrombin INR ) increased by approximately to 11 % .	DDI-effect
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Drug that does have clinically @DRUG$ , @DRUG$ .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Nervous System Depressants concomitant use @DRUG$ ( transdermal system with other central nervous system depressants including not other opioids , sedatives hypnotics tranquilizers e.g. , @DRUG$ ) general , , muscle , alcohol may cause depression hypotension , sedation , or or	DDI-effect
@DRUG$: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
A similar association , has suggested @DRUG$ phenylbutazone @DRUG$ , carbamazepine griseofulvin topiramate , and possibly with and tetracyclines 72 .	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-effect
@DRUG$ : some function are nonsteroidal drugs the @DRUG$ may result a further deterioration renal function	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
In , effects of @DRUG$ , but not @DRUG$ or PCP antagonized naloxone	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving theophylline.	DDI-false
@DRUG$ serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving @DRUG$.	DDI-false
Example inhibitors include antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , , isoniazid nefazodone , @DRUG$ , @DRUG$ quinidine verapamil .	DDI-false
Fulminant rhabdomyolysis as early as weeks after of @DRUG$ and @DRUG$ seen several months .	DDI-effect
of @DRUG$ may @DRUG$-induced block	DDI-effect
Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
This may with alcohol other @DRUG$ ( the either medications or antihistamines anticholinergics medications with activity effects potentiated these medications are used concurrently antihistamines ) and monoamine concurrent use @DRUG$ may prolong and CNS effects of antihistamines ) .	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
@DRUG$: The stimulatory effects of amphetamines may be inhibited by @DRUG$.	DDI-false
While selective reuptake inhibitors ( e.g. citalopram , escitalopram , @DRUG$ , @DRUG$ , and , inhibit they may	DDI-false
: study a multicenter randomized study 101 patients randomly assigned tablets of 0.5 , 1 , daily @DRUG$ and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
the blocking action of as include @DRUG$ ( e. g. , tetracyclines polymyxins and sodium colistimethate , @DRUG$ , local anesthetics and quinidine	DDI-false
@DRUG$ In and/or in data indicate fluconazole itraconazole , oral inhibit metabolism of @DRUG$ an increase in plasma cisapride levels and prolongation of the QT on .	DDI-false
These thiazides @DRUG$ , corticosteroids phenothiazines , @DRUG$ , , oral contraceptives , sympathomimetics , blocking , isoniazid .	DDI-false
of benzodiazepines may potentiated , antihistamines @DRUG$ , oxidase , @DRUG$ or other	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Similarly dialyzed were phenobarbital, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
following substances may reduce the blood-glucose-lowering effect @DRUG$ danazol , ( epinephrine , salbutamol , terbutaline ) , , phenothiazine derivatives , thyroid @DRUG$ , e.g. , )	DDI-false
that been associated with peripheral nucleoside analogues , chloramphenicol , , , @DRUG$ , glutethimide , gold , iodoquinol , isoniazid metronidazole , nitrofurantoin , , @DRUG$.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.	DDI-false
The patients in studies received or of with : @DRUG$ agents , @DRUG$ chloroquine , gold leflunomide sulfasalazine and anakinra	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
@DRUG$ : an study rheumatoid taking @DRUG$ not the of	DDI-false
Intravenous @DRUG$: Treatment with @DRUG$ should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
Intravenous @DRUG$ (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/aluminum-containing @DRUG$.	DDI-advise
that reduce the : @DRUG$ niacin , sympathomimetic agents ( @DRUG$ , terbutaline , , phenothiazine , thyroid hormones , ( e.g. , in contraceptives	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to @DRUG$ and 3-hydroxy levobupivacaine, respectively.	DDI-false
of was interaction between neurotensin both @DRUG$ synthetic @DRUG$ , or antinonciceptive of these peptides mice intracisternal	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of @DRUG$, dextromethorphan, and methotrexate.	DDI-false
@DRUG$ the of	DDI-false
Drugs been associated antiretroviral analogues , , , , @DRUG$ , , iodoquinol isoniazid metronidazole , ribavirin	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
receiving both @DRUG$ be closely to if diuretic and/or of @DRUG$ achieved .	DDI-false
@DRUG$ , @DRUG$ and has no significant interactions nimodipine , and effect levels bosentan	DDI-false
When Bezalip or retard used @DRUG$ ( e.g. cholestryramine an of least hours be maintained the , since Bezalip @DRUG$ impaired	DDI-false
@DRUG$: (oral agents and insulin) - dosage adjustment of the @DRUG$ may be required.	DDI-false
@DRUG$ and use be rarely with ventricular combined @DRUG$.	DDI-effect
Although specific interaction not , finasteride or concomitantly used clinical studies acetaminophen acetylsalicylic , a-blockers , angiotensin-converting inhibitors , , beta , blockers cardiac @DRUG$ , diuretics , , @DRUG$ prostaglandin synthetase inhibitors as ) and anti-infectives evidence significant	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and @DRUG$.	DDI-false
Although the between and potent inhibitors e.g. itraconazole , @DRUG$ not been , increased to @DRUG$ may when almotriptan medications .	DDI-false
@DRUG$ ( ( mg/kg ( 0.25 , fluoxetine ( mg/kg @DRUG$ 30 mg/kg ) or administered	DDI-false
Interactions Opioid : analgesics ( eg , nalbuphine , @DRUG$ , @DRUG$ should be administered to a who has received a of a opioid as .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
A drug-drug the of use @DRUG$ % , in double ( mg/800 mg trimethoprim/sulfamethoxazole TMP/@DRUG$ .	DDI-false
Accordingly, when @DRUG$ is administered with oral @DRUG$, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
studies CYP3A4 CYP1A2 isoform the metabolism of @DRUG$ to desbutyl and @DRUG$ respectively .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, @DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
selective serotonin reuptake ( ) , citalopram , @DRUG$ , , and @DRUG$ , P450 2D6 , may in the of inhibition	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	DDI-advise
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
poor : carvedilol strong of such , @DRUG$ , @DRUG$ studied , be expected levels of the ) of carvedilol	DDI-false
FACTIVE had no significant effect on the anticoagulant effect of @DRUG$ in healthy subjects on stable @DRUG$ therapy.	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Concurrent administration of ( aminoglycosides ) ( @DRUG$ chemotherapy cardiotoxic e.g. , doxorubicin ( , @DRUG$ with PROLEUKIN systems .	DDI-false
The @DRUG$ , penicillin G , was significantly simultaneously @DRUG$	DDI-mechanism
Benzthiazide interact with alcohol thinners , drugs ( cold , , @DRUG$ , norepinephrine @DRUG$ Aleve or medications	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to @DRUG$ or oral @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Other drug interactions Cimetidine, @DRUG$ and @DRUG$ had no effect on the pharmacokinetics of MHD.	DDI-false
Urinary acidifying agents These agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ : ergonovine @DRUG$ methylergonovine to potential serious and life-threatening reactions such as toxicity by and ischemia the extremities and .	DDI-false
Compounds result a decreased efficacy of @DRUG$ : , @DRUG$.	DDI-effect
drug interact with CNS depressants may the CNS depressant either these medications or ) @DRUG$ or may be when these with @DRUG$ ( antihistamines and the and CNS effects )	DDI-false
Based on known , clinically significant drug not between clarithromycin erythromycin , or @DRUG$.	DDI-false
To Levosimendan not have important captopril @DRUG$ @DRUG$ digoxin warfarin , , ethanol or	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
: @DRUG$ hypotensive effect of	DDI-effect
Drugs Should Not Coadministered With VIRACEPT @DRUG$ , quinidine : astemizole , terfenadine Antimigraine ergot derivatives @DRUG$ , GI motility agents :	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Potassium-sparing ( @DRUG$ triamterene , or amiloride , @DRUG$ supplements , or substitutes may significant increases in serum .	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
of the potentiated by anticonvulsants , alcohol , @DRUG$ @DRUG$ , , drugs that depression .	DDI-false
When @DRUG$ was 30 @DRUG$ nasal , butorphanol increased 11 % Cmax 18 .	DDI-mechanism
Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after @DRUG$ is initiated to see whether the @DRUG$ dose needs adjustment.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$s and Vasodilators events more commonly receiving concomitant medications @DRUG$ 94 compared not concomitant drugs 456 10 % 4 % , infarction % % serious 5 vs 3 falls % vs % and and % vs	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (@DRUG$/SMX).	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Antiacid , , Didanosine , Fluconazole Fluoxetine , Ketoconazole , Phenytoin , Phenobarbitol @DRUG$ , @DRUG$ , Rifampin , Ritanovir ,	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or @DRUG$.	DDI-false
no drug-drug interaction between inducers of compounds that as carbamazepine , phenytoin rifampin @DRUG$ @DRUG$ concentrations .	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other Drug Interactions No interactions were following @DRUG$ warfarin @DRUG$ Maalox , and .	DDI-false
Therefore , interactions could of psychotropic ( analgesics , antiemetics @DRUG$ @DRUG$ )	DDI-false
The of 540 of @DRUG$ ( 340 the maximum recommended daily dose adults on mg/m2 basis 2.7 of @DRUG$ ( approximately 7 times the maximum recommended daily inhalation in adults mg/m2 basis to increased the incidence resorptions	DDI-effect
Dose is no effect plasma concentrations carbamazepine @DRUG$ topiramate @DRUG$.	DDI-false
@DRUG$ @DRUG$ may the effect of Angiotensin Enzyme ( ACE inhibitors .	DDI-false
: The effects of combined bombesin hydrochloride @DRUG$ ) , a calcium blocker metastasis of induced by azoxymethane ( @DRUG$ ) the labeling index of were investigated male Wistar rats .	DDI-false
It is not known whether other @DRUG$, such as implants and injectables, are adequate methods of contraception during @DRUG$ therapy.	DDI-false
primary of @DRUG$ conduction , higher block may be produced @DRUG$.	DDI-effect
@DRUG$ : Because @DRUG$ does affect the pharmacokinetics antipyrine , other metabolized isozymes are	DDI-false
@DRUG$: Coadministration of @DRUG$ 3 mg and olanzapine 10 mg produced a decrease in DSST scores.	DDI-false
Antifungals : In vitro in vivo @DRUG$ itraconazole and @DRUG$ inhibit the metabolism of cisapride can in levels prolongation of the interval on the .	DDI-false
@DRUG$: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
If a @DRUG$ is also used, it may increase the risk of @DRUG$ toxicity.	DDI-effect
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ (200 m m M i.e., 350 mg/L) was 17-28%.	DDI-mechanism
@DRUG$ : of @DRUG$ with VIRACEPT resulted the plasma ;	DDI-false
Drugs that been associated peripheral , @DRUG$ , disulfiram glutethimide gold hydralazine @DRUG$ , nitrofurantoin , ribavirin ,	DDI-false
The @DRUG$ before succinylcholine some of side of @DRUG$	DDI-false
no in interaction conducted between estazolam , compounds that potent CYP3A ( @DRUG$ rifampin , and @DRUG$ ) would expected concentrations .	DDI-false
inhibitors include azole , clarithromycin , @DRUG$ , doxycycline , , , isoniazid nefazodone nicardipine , protease inhibitors , @DRUG$ .	DDI-false
phenobarbital/acetaminophen phenobarbital/valproic acid , @DRUG$/lidocaine and	DDI-false
Omeprazole rate extent of absorption @DRUG$ bioequivalent was or when @DRUG$ was hours after the dose that suppresses secretion	DDI-false
appears to only interaction this kind with @DRUG$ , , coadministration of other known to , beta-adrenergic blocking agents , calcium channel , antihistamines agents antidepressants and @DRUG$ might also prolongation of the QTc .	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
It may increase excretion of barbiturates, @DRUG$, and @DRUG$ and may also increase the toxicity of salicylates.	DDI-false
@DRUG$ Chloramphenicol , @DRUG$ may interfere the effect of penicillins .	DDI-false
The examples reduce blood-glucose-lowering : niacin , danazol , , @DRUG$ ( epinephrine , derivatives , , @DRUG$ , estrogens progestogens ( e.g. , in oral .	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and @DRUG$ did not influence abatacept clearance.	DDI-false
@DRUG$ : of VIOXX with mg , inducer metabolism , produced an approximate 50 % decrease @DRUG$ .	DDI-false
Multivalent Products Concurrent a quinolone , including ciprofloxacin with magnesium or , @DRUG$ chewable/buffered or , or products containing @DRUG$ or decrease the absorption of ciprofloxacin resulting and than .	DDI-false
In @DRUG$ not @DRUG$ , antagonized rate-decreasing of morphine FI and .	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	DDI-effect
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	DDI-mechanism
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced @DRUG$ levels.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$ @DRUG$ as as metabolite of , .	DDI-false
Other therapy specific interaction studies not @DRUG$ of or more were studies with , , a-blockers , analgesics , angiotensin-converting ACE ) inhibitors blockers , calcium-channel cardiac nitrates , @DRUG$ HMG-CoA inhibitors , inhibitors ( also to as ) , evidence clinically	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
evaluate the impact chemotherapy HAART clinical , ( ) , the authors patients HIV-NHL treated with cyclophosphamide doxorubicin , vincristine , @DRUG$ ( CHOP chemotherapy regimen plus of who were CHOP a ( i.e. , and with @DRUG$ receiving antiretroviral therapy .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
studies have not coadministration with drugs are CYP3A4 ( eg , calcium , disopyramide , quinine @DRUG$ , , warfarin , , , @DRUG$ , pimozide , carbamazepine , fentanyl alfentanyl , alprazolam , ) may elevated concentrations ;	DDI-false
To chemotherapy the patients HIV-related , systemic lymphoma ( , the authors group of 24 patients with HIV-NHL who were treated the @DRUG$ , vincristine , prednisone CHOP HAART a group patients who were with or regimen , , doxorubicin , with @DRUG$ ) therapy	DDI-false
@DRUG$ : side even been reported following the concomitant of certain drugs with	DDI-false
Psychoactive Drugs : been @DRUG$ was in patients taking psychoactive @DRUG$ , , alprazolam )	DDI-effect
@DRUG$-@DRUG$ may decrease the absorption of vitamin K.	DDI-false
plasma concentrations ( AUC ) @DRUG$ and/or @DRUG$ observed following of with volunteers ( there were no clinically in the safety profile as clinical laboratory tests , vital signs , events	DDI-false
However , may show elevations digoxin after initiation of @DRUG$ significant patients @DRUG$ toxicity .	DDI-false
: Potentiation @DRUG$ CYP3A4 anticoagulant almost in patients receiving amiodarone and can result in serious or .	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
To a direct effect the distribution , distribution @DRUG$ was studied in patients lacking kidney function one a impaired function in the presence or	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
are ( for the some @DRUG$ deficit i.e. acute pharmacological ( of @DRUG$ status -- aetiopathogenic--(for complications alcoholism )	DDI-false
drug may interact other CNS depressant of these medications @DRUG$ ) anticholinergics or anticholinergic ( may medications concurrently @DRUG$ , monoamine MAO ) inhibitors concurrent may and CNS effects of antihistamines .	DDI-false
Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
The @DRUG$ penicillin G , hydrochlorothiazide , and gemfibrozil was decreased simultaneously with @DRUG$	DDI-mechanism
absorption tetracycline @DRUG$ , penicillin G , , @DRUG$ was decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$: Serious side effects and even death have been reported following the concomitant use of certain drugs with @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
levels several closely related @DRUG$ have reported be increased by the administration enzyme e.g. cimetidine , fluoxetine decreased by the concomitant administration ( e.g. @DRUG$ , and such an effect may be anticipated CMI as well .	DDI-mechanism
following are inhibit metabolism other , through inhibition of , fluvoxamine @DRUG$ , isoniazide , @DRUG$.	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-mechanism
Antacids a clinical pharmacology study coadministration @DRUG$ aluminum magnesium and simethicone excretion compared with fosinopril alone , impair of @DRUG$.	DDI-false
@DRUG$ e. ketoconazole , , clotrimazole , fluconazole . in vitro and studies combination of and @DRUG$ suggest that imidazoles induce fungal resistance to amphotericin	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an @DRUG$ containing aluminum and @DRUG$.	DDI-false
evaluate the of chemotherapy plus clinical of patients , , non-Hodgkin lymphoma HIV-NHL ) patients with who were the , @DRUG$ , vincristine and @DRUG$ ( CHOP ) HAART with were with CHOP or a regimen cyclophosphamide doxorubicin , , and prednisone vincristine ) receiving antiretroviral therapy	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$: @DRUG$ concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.	DDI-false
The @DRUG$ on of @DRUG$	DDI-false
@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	DDI-false
Drugs have been associated peripheral include antiretroviral nucleoside , chloramphenicol , cisplatin disulfiram , , glutethimide gold , @DRUG$ nitrofurantoin , ribavirin	DDI-false
In , are or to hydrochloride anti-arrhythmic as @DRUG$ , @DRUG$ and tricyclic .	DDI-false
Promethazine of a dose @DRUG$ @DRUG$ 10 mg , respectively resulted % in maximal plasma zaleplon but no in the under curve	DDI-mechanism
To impact HAART on of HIV-related , ( HIV-NHL ) , compared a group of 24 patients with who treated the cyclophosphamide , vincristine and @DRUG$ ( CHOP ) a group 80 patients who CHOP chemotherapy CHOP-like regimen ( i.e. cyclophosphamide , @DRUG$ , teniposide prednisone with vincristine plus bleomycin without receiving therapy	DDI-false
interfere with the action of @DRUG$ @DRUG$ ;	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
These drugs include and other @DRUG$ , , , thyroid products , estrogens oral contraceptives nicotinic , @DRUG$ and isoniazid .	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ not shown produce any additional beyond obtained aspirin alone and Nalfon , the @DRUG$ not recommended .	DDI-false
@DRUG$, @DRUG$, ethosuximide	DDI-false
of @DRUG$ and @DRUG$ may be by	DDI-false
FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users.	DDI-false
The of treatment drugs is increased with concurrent administration of cyclosporine @DRUG$ niacin ( nicotinic ) , erythromycin @DRUG$.	DDI-false
Insulin @DRUG$ may the blood-sugar-reducing effect of @DRUG$ .	DDI-effect
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
in result efficacy of @DRUG$ metoclopramide ,	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
specific have not been coadministration drugs mainly by CYP3A4 ( eg , @DRUG$ , dapsone , , , quinidine , tacrolimus , , @DRUG$ , , , alfentanyl , and triazolam have concentrations with saquinavir	DDI-false
Nervous Depressants : The concomitant use   @DRUG$ with other central but not to other @DRUG$ , sedatives , hypnotics tranquilizers , , skeletal muscle relaxants , and respiratory depression , and sedation , or potentially coma or death	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Hallucinations have been reported when TORADOL was used patients taking drugs fluoxetine @DRUG$ @DRUG$ .	DDI-false
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
Example inhibitors azole clarithromycin , doxycycline , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine propofol , @DRUG$ quinidine , and .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
effects ruthenium RR ) on @DRUG$ were in with the patch-clamp technique in combination microfluorometry .	DDI-false
The @DRUG$ or @DRUG$ an additive	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
acetaminophen/theophylline , phenobarbital/valproic acid , , and valproic acid/@DRUG$.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Benzthiazide may with @DRUG$ , thinners , ( allergy , , drugs , norepinephrine NSAIDs like @DRUG$ , high .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
a study which clonazepam orally disintegrating administered with without @DRUG$ multiple effects on the GI tract AUC @DRUG$ lower and the of was lower when disintegrating given propantheline compared was	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ @DRUG$: rifabutin	DDI-advise
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
When @DRUG$ Bezalip used concurrently with @DRUG$ ) an interval least between two Bezalip Bezalip retard is impaired	DDI-advise
in the literature that plasma of @DRUG$ ( its active metabolite @DRUG$ may be increased paclitaxel are in .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Lithium @DRUG$ have of plasma @DRUG$ and reduction renal .	DDI-mechanism
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Cephalosporins-@DRUG$ side of N-methylthiotetrazole cefmenoxime cefoperazone , @DRUG$ , cefamandole latamoxef ( cefazolin can cause K and	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ of other CYP3A4 drugs ( e.g. , triazolo-@DRUG$ , calcium channel blockers , HMG-CoA , . .	DDI-mechanism
Because prostaglandins an role in , and as well , therapy @DRUG$ , and requires of patients to in @DRUG$ .	DDI-false
Other reported interactions with @DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
the @DRUG$ and other , phenothiazines , thyroid , contraceptives , phenytoin , nicotinic acid , @DRUG$ and	DDI-false
poor metabolizers of @DRUG$: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
specific studies have performed coadministration with drugs that are metabolized by CYP3A4 ( , calcium channel , @DRUG$ @DRUG$ , , quinidine tacrolimus cyclosporine , , , and ) elevated plasma concentrations with ;	DDI-false
@DRUG$ As with b-lactam , of is inhibited probenecid and in approximate 80 % increase the for	DDI-false
Lithium : should generally with diuretics such as @DRUG$ clearance and risk @DRUG$	DDI-false
The absorption of tetracycline, @DRUG$, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
@DRUG$ (such as flecainide, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
@DRUG$ to the @DRUG$ requirements human subjects ingesting these agents simultaneously .	DDI-mechanism
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
May medication e.g. levothyroxine ) products , H2-antagonists ( e.g. , ranitidine ) and @DRUG$ e.g. , @DRUG$ .	DDI-false
As with @DRUG$ , renal excretion cephalexin	DDI-false
When other potent parental @DRUG$, such as diazoxide, are used in combination with @DRUG$, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-effect
Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and @DRUG$ were administered concomitantly for 6 days.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
These drugs include the thiazides and other @DRUG$, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
, Digoxin @DRUG$ like NSAIDs through effects renal may cause in elimination of of @DRUG$ , digoxin , methotrexate toxicity	DDI-mechanism
Binding In , minimally with the salicylic acid % decrease in @DRUG$ , @DRUG$ ( 10 % ) ,	DDI-false
the doses of @DRUG$ required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of morphine.	DDI-effect
@DRUG$ extent absorption ciprofloxacin was when XR was given when @DRUG$ was given 2 after omeprazole the acid secretion	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Cardiac effects of @DRUG$ are antagonized by @DRUG$, such as propranolol and metoprolol.	DDI-effect
@DRUG$ to @DRUG$.	DDI-effect
Beta-blockers (@DRUG$, @DRUG$) serum concentrations and pharmacologic effects may be increased.	DDI-false
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an antacid containing aluminum and @DRUG$.	DDI-mechanism
@DRUG$ retinyl acetate affected the of epithelium @DRUG$ , mitogenic of	DDI-false
Two groups ( SH/DA SH/FA ) were submitted daily treatment containing ethanol , @DRUG$ and @DRUG$ same proportions those found in most distilled and fermented alcoholic ;	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/@DRUG$).	DDI-false
Coadministration of @DRUG$ and 1/35   exposure @DRUG$ by % 34 % .	DDI-false
Fluoxetine and @DRUG$ increased blood @DRUG$ at different times after the glucose overload.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ Since apomorphine is a dopamine agonist is such as phenothiazines @DRUG$ , thioxanthenes ) or , may the effectiveness of .	DDI-false
These results suggest that the hepatoxicity of @DRUG$ in alcoholic beverages is enhanced by interaction with its congeners and @DRUG$;	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	DDI-false
In the presence of these methylxanthines, larger doses of @DRUG$ may be required or @DRUG$ may not be effective.	DDI-false
Chloramphenicol shown antagonistic @DRUG$ @DRUG$ , vitro studies and time kill curves with enteric gram-negative	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-mechanism
@DRUG$ can antagonize in vitro antiviral activity and @DRUG$ against	DDI-false
In clinical , FLOLAN used with digoxin , diuretics , oral and supplemental oxygen . In pharmacokinetic patients with congestive heart failure or @DRUG$ in whom therapy with FLOLAN was initiated oral ( 23 and @DRUG$ 30 were 13 and % respectively , day of had to baseline by day	DDI-false
Coadministration of valdecoxib @DRUG$   increased the @DRUG$ % ,	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ : therapy may response to toxoids and @DRUG$ due to antibody .	DDI-false
@DRUG$ In controlled studies in healthy volunteers , hydrochloride no effect ) or associated with modest increases , about % ( two in steady-state @DRUG$ concentrations	DDI-false
examples of that may reduce the blood-glucose-lowering corticosteroids danazol , diuretics ( , salbutamol , , @DRUG$ phenothiazine derivatives , , e.g. , @DRUG$ )	DDI-false
Vardenafil ( mg ) not the hypotensive @DRUG$ the in volunteers @DRUG$ g/kg weight ) .	DDI-false
CONCOMITANT THERAPY : interaction , clinical sodium concomitantly with angiotensin- converting enzyme inhibitors betablockers @DRUG$ , diuretics , and @DRUG$ without of clinically significant adverse interactions .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
if @DRUG$ in patients already @DRUG$ , prothrombin adjustment of the anticoagulant dose may necessary	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
Nervous use DURAGESIC   ( system ) depressants but not limited other , sedatives @DRUG$ @DRUG$ benzodiazepines ) , anesthetics phenothiazines , skeletal muscle relaxants , respiratory depression hypotension , profound sedation , or in coma	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
@DRUG$ generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	DDI-false
@DRUG$ increases by 50 % ) , @DRUG$ and valproates	DDI-false
Coadministration @DRUG$ and drugs primarily metabolized by CYP3A @DRUG$ may plasma concentrations of drug that increase or prolong both its and adverse effects .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Cardiovascular Agents and IV been with beta agents @DRUG$ @DRUG$ calcium-blocking hydralazine and without of clinically significant interactions .	DDI-false
Rifampin significantly decreased the AUC(ss) of @DRUG$ by 82%, but amprenavir had no effect on @DRUG$ pharmacokinetics.	DDI-false
@DRUG$, clonazepam, @DRUG$	DDI-false
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, @DRUG$, and zileuton).	DDI-false
Anticoagulants: While studies have not shown @DRUG$ to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
@DRUG$ Concomitant treatment Accutane should be avoided because @DRUG$ use with cases intracranial hypertension , some which of tetracyclines	DDI-false
@DRUG$ : ( 0.5 approximately 40 mL alcohol in a 70 ) and @DRUG$ levels dosed	DDI-false
However, neither @DRUG$ nor diazepam appears to affect @DRUG$ metabolism.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Consequently, the combination of @DRUG$ with @DRUG$ is also contraindicated.	DDI-advise
In a which the clonazepam disintegrating tablet administered ( an @DRUG$ on the ) to the AUC of was lower and Cmax of 20 % when orally disintegrating @DRUG$ it was alone	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with @DRUG$.	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for tricyclic antidepressants.	DDI-false
Additive depression @DRUG$ are administered with including barbiturates , tranquilizers ,	DDI-effect
Although specific studies have been performed with that are mainly by eg , @DRUG$ dapsone , , , amiodarone , , , cyclosporine ergot pimozide , @DRUG$ , alprazolam , triazolam concentrations when ;	DDI-false
The hypoglycemic of sulfonylureas potentiated certain drugs anti-inflammatory agents and other drugs that highly protein bound , sulfonamides @DRUG$ @DRUG$ , coumarins monoamine agents	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac , , , imatinib isoniazid @DRUG$ , nicardipine , , , , and verapamil .	DDI-false
In you are @DRUG$ aminosalicylic , higher of @DRUG$ may be needed .	DDI-false
The @DRUG$ containing or to patients monoamine , tricyclic or @DRUG$ may produce severe prolonged hypotension or hypertension .	DDI-effect
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other @DRUG$ and @DRUG$.	DDI-effect
@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
If @DRUG$ is mixed with @DRUG$, NovoLog should be drawn into the syringe first.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
Verapamil : of @DRUG$ @DRUG$ resulted 24 % increase .	DDI-mechanism
@DRUG$: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
that associated include analogues chloramphenicol , dapsone @DRUG$ , ethionamide , glutethimide , hydralazine , isoniazid , metronidazole , nitrofurantoin @DRUG$ , .	DDI-false
Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
: @DRUG$ administered with @DRUG$ , its binding is reduced free not altered .	DDI-mechanism
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Consequently, @DRUG$ should be avoided in patients receiving ketoconazole and @DRUG$, which are very potent inhibitors of CYP3A.	DDI-advise
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
- @DRUG$: Lithium should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Valdecoxib 40 BID did not induce metabolism of @DRUG$ 1 /35 , )	DDI-false
on total @DRUG$ concentrations , @DRUG$ increased by renal by and % , respectively .	DDI-mechanism
@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	DDI-false
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral @DRUG$ for women taking @DRUG$.	DDI-advise
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
@DRUG$: @DRUG$ is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.	DDI-false
concomitantly with @DRUG$ shown in @DRUG$ desethylamiodarone .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The action be potentiated by drugs including agents and drugs are protein , @DRUG$ @DRUG$ probenecid coumarins oxidase , .	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for tricyclic antidepressants.	DDI-false
Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$ ( 5 30 , @DRUG$ 0.25 mg/kg 20 mg/kg ( 30 mg/kg ) or vehicle administered .	DDI-false
in blood pressure occur when @DRUG$ is administered with @DRUG$ antihypertensive agents , or .	DDI-effect
lidocaine/quinidine @DRUG$/@DRUG$ phenobarbital/valproic quinidine/lidocaine , valproic	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when @DRUG$ and doxorubicin are used in combination.	DDI-false
, @DRUG$ , @DRUG$	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Hypotension @DRUG$ Therapy : Patients @DRUG$ and especially in whom diuretic therapy was instituted , as well dietary salt or dialysis , may occasionally a reduction pressure within first hour receiving initial dose of .	DDI-false
A association , marked been suggested with @DRUG$ phenylbutazone sodium carbamazepine , and with @DRUG$ .	DDI-false
@DRUG$ @DRUG$ increased blood times .	DDI-false
Coadministration of and @DRUG$ @DRUG$ or digoxin to increased of latter drugs	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, @DRUG$, etc).	DDI-false
have case reports steady-state @DRUG$ , @DRUG$ during concomitant therapy with amiodarone .	DDI-false
Reactions with of severe EL eg , for injection concentrate @DRUG$ for injection should not be @DRUG$.	DDI-advise
At higher than recommended doses, @DRUG$ 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving @DRUG$ 7.5 to 15 mg/week for rheumatoid arthritis.	DDI-mechanism
drugs which may enhance nondepolarizing agents @DRUG$ certain antibiotics e. g. , aminoglycosides tetracyclines , @DRUG$ , polymyxins , lincomycin , colistin and colistimethate , magnesium , , anesthetics and .	DDI-effect
following examples of substances may increase blood-glucose-lowering hypoglycemia : @DRUG$ , ACE inhibitors disopyramide , fibrates , fluoxetine , monoamine oxidase MAO , propoxyphene salicylates , @DRUG$ ( sulfonamide .	DDI-false
@DRUG$ In some patients compromised who with @DRUG$ the co-administration in a .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
While serotonin reuptake SSRIs ) , e.g. , @DRUG$ , @DRUG$ , and P450 , they may the .	DDI-false
@DRUG$ @DRUG$	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$ known slow the metabolism of and increase its levels Carbamazepine levels should determined prior with and symptoms @DRUG$ toxicity should be and of anticonvulsant .	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
tricyclic ) , anticholinergic agents or @DRUG$ concurrent with @DRUG$ produce additive and/or	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
: @DRUG$ , glutamic HCl , @DRUG$ , juices , etc . ) lower absorption amphetamines	DDI-false
@DRUG$: Adrenergic blockers are inhibited by @DRUG$.	DDI-false
Use with Angiotensln Inhibitors : of @DRUG$ control hypertension patients on @DRUG$ been induce .	DDI-effect
In @DRUG$-dependent , @DRUG$ may withdrawal .	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
@DRUG$ ) quinine @DRUG$ enhance toxicity depression	DDI-false
@DRUG$ , @DRUG$ high .	DDI-false
@DRUG$ coumarin derivatives indandione derivatives platelet inhibitors such nonsteroidal @DRUG$ , may risk of concomitantly with ardeparin	DDI-false
In Study 1, patients with colorectal cancer were given @DRUG$/5-FU/leucovorin (bolus-IFL) with or without @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-advise
Phenothiazines and @DRUG$ may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
@DRUG$ propafenone , @DRUG$ CONTRAINDICATED for serious reactions .	DDI-false
@DRUG$ levels at steady-state were co-administration 0.2 @DRUG$.	DDI-false
When other @DRUG$ or @DRUG$ are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.	DDI-false
It increase of barbiturates @DRUG$ and ASA and also the	DDI-false
@DRUG$ concentrations were not coadministration of @DRUG$.	DDI-false
@DRUG$ in may counteract antiepileptic effect of @DRUG$ and primidone , increase the frequency seizures	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Dopamine Since is a @DRUG$ that dopamine , @DRUG$ ( , or may of APOKYN	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (increases bioavailability by 50%), @DRUG$, and valproates.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$) would be expected to decrease @DRUG$ concentrations.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Dopamine Antagonists is dopamine is that dopamine antagonists as the @DRUG$ , , thioxanthenes or @DRUG$ , may diminish the effectiveness of	DDI-false
drugs which may enhance neuromuscular certain @DRUG$ , tetracyclines , @DRUG$ , colistin and , , , local anesthetics and .	DDI-false
It is recommended that if @DRUG$ is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	DDI-advise
Drugs that with peripheral analogues chloramphenicol , , , disulfiram , ethionamide , , gold , iodoquinol , metronidazole @DRUG$ , @DRUG$ , and vincristine .	DDI-false
Antihypertensives : @DRUG$ caution patients receiving -@DRUG$ ( , propranolol a CYP3A4 ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 CYP3A4 because of potentiation of bradycardia , arrest and AV block	DDI-false
concomitant therapy Although specific studies were not , of 1 mg more with acid , , analgesics enzyme ACE ) inhibitors , @DRUG$ beta blockers calcium-channel blockers cardiac diuretics , @DRUG$ , HMG-CoA reductase inhibitors inhibitors also referred to ) quinolone anti-infectives evidence of adverse	DDI-false
@DRUG$ , salts , and @DRUG$ may either potentiate or blood-glucose-lowering effect insulin	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The effects of @DRUG$ anesthesia on @DRUG$ tolerance in	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
drug interact with CNS ( may potentiate CNS depressant effects either these or ) , anticholinergics or other medications with ( effects may these are concurrently antihistamines ) , and @DRUG$ concurrent use antihistamines may the depressant of @DRUG$ ) .	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
The clearance of @DRUG$ may be increased with concurrent use of @DRUG$.	DDI-mechanism
Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-mechanism
This @DRUG$ does inhibition hepatic responsible the metabolism @DRUG$.	DDI-false
With simultaneous dosing of @DRUG$ 10 mg and @DRUG$ 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	DDI-effect
the action of agents such as NUROMAX antibiotics e. g. , aminoglycosides , polymyxins , lincomycin , @DRUG$ and sodium colistimethate magnesium lithium local @DRUG$ , , quinidine .	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
@DRUG$ (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of piperazine.	DDI-false
Hepatic Inducers , Inhibitors which induce 3A4 CYP e.g. @DRUG$ , @DRUG$ ) metabolism require that the corticosteroid .	DDI-false
In a of digitalis in , @DRUG$ , or pentobarbital the dosage @DRUG$ cause ventricular was significantly as LD50 of , ketamine or Innovar than pentobarbital .	DDI-effect
@DRUG$ @DRUG$ absorption of phenytoin ;	DDI-false
@DRUG$: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Benzthiazide may interact with @DRUG$ thinners , ( allergy , cold , medicines drugs lithium , , like @DRUG$ or high pressure medications	DDI-false
@DRUG$ Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.	DDI-false
Drugs may alter @DRUG$ concentrations that may @DRUG$ plasma concentrations is when with CYP3A4 family ( ketoconazole erythromycin , .	DDI-false
addition @DRUG$ to patients taking @DRUG$ chronically had effect on tiagabine pharmacokinetics but decreased tiagabine binding in 94.8 , an increase of % in tiagabine concentration	DDI-false
action of sulfonylurea may be potentiated by drugs nonsteroidal drugs are highly protein bound salicylates , @DRUG$ , probenecid , , inhibitors , and	DDI-false
@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
Losartan @DRUG$ has no significant with digoxin and @DRUG$ significant on plasma of bosentan	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Micro-dosed Preparations : @DRUG$ preparations ( minipills that do an @DRUG$ may inadequate method of contraception Accutane .	DDI-false
@DRUG$ : of profound hypotension and when apomorphine was with ondansetron , the concomitant use of drugs antagonist class including , for example , @DRUG$ granisetron palonosetron , and ) is	DDI-false
Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
@DRUG$ Clinical , post-marketing , NSAIDs effect @DRUG$ in some	DDI-false
H2 Receptor : coadministration leads to an increased concentration there is effect @DRUG$ it @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ may interact with any of the following: - Acetaminophen (e.g., @DRUG$) (with long-term, high-dose use) or	DDI-int
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
@DRUG$ should be withdrawn at least 48 hours before conducting an @DRUG$-mediated stress test.	DDI-advise
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	DDI-effect
Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
of studies in @DRUG$ and @DRUG$ mcg IM once ) or acetate were inconclusive need for dose of the or .	DDI-false
To evaluate the impact of HAART the clinical patients with HIV-related non-Hodgkin lymphoma HIV-NHL compared retrospectively group of 24 patients HIV-NHL , doxorubicin , and prednisone ) HAART with group patients who were treated with CHOP chemotherapy or a regimen , doxorubicin @DRUG$ , vincristine plus bleomycin receiving @DRUG$ .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
@DRUG$/Aluminum-containing Antacid Absorption of zalcitabine is reduced approximately % coadministered magnesium/aluminum-containing	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Patients receiving , @DRUG$ phenothiazines tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS @DRUG$ ) concomitantly with exhibit additive depression	DDI-false
Dexamethasone: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg dexamethasone was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Seizure , @DRUG$ , concomitant @DRUG$.	DDI-false
Before medication , tell doctor pharmacist of nonprescription use , of ( , gentamicin , @DRUG$ ) amphotericin , cyclosporine , non-steroidal ( @DRUG$ ) , , .	DDI-false
and/or aluminum-containing @DRUG$ , products containing ferrous ( iron ) , preparations @DRUG$ other Videx tablets pediatric powder not within 3 hours or hours after .	DDI-false
Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
In a pharmacology study , an antacid ( magnesium ) fosinopril reduced and urinary compared @DRUG$ administered alone antacids impair absorption @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Methenamine Urinary excretion of @DRUG$ is and is by used @DRUG$ therapy .	DDI-mechanism
@DRUG$ : recommended that @DRUG$ administered on stomach	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
@DRUG$: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Example include , , @DRUG$ doxycycline @DRUG$ , nefazodone , propofol protease inhibitors , and verapamil .	DDI-false
Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ therapy is initiated.	DDI-effect
Benzthiazide may interact alcohol , decongestant drugs ( allergy , and sinus medicines ) diabetic lithium , NSAIDs @DRUG$ and pressure medications .	DDI-false
@DRUG$ Coadministration saquinavir using an experimental soft-gelatin capsule formulation with @DRUG$ an % plasma AUC 4-fold increase saquinavir plasma A.C.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$ (neostgmine, physostigmine), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
Clonidine: Concomitant administration of @DRUG$ with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-effect
@DRUG$ and @DRUG$ Coadministration of VIRACEPT with OVCON-35 resulted % in estradiol 18 decrease concentrations .	DDI-false
@DRUG$ Adrenergic inhibited by @DRUG$.	DDI-false
In a of digitalis tolerance dogs with ketamine , @DRUG$ , dosage ouabain cause significantly as the LD50 of ouabain , ketamine @DRUG$ pentobarbital .	DDI-false
Drugs that been with include antiretroviral analogues , chloramphenicol , @DRUG$ , , disulfiram , ethionamide , glutethimide , , , @DRUG$ , isoniazid , metronidazole phenytoin , .	DDI-false
: When atorvastatin and @DRUG$ plasma @DRUG$ concentrations approximately 20	DDI-false
All subjects @DRUG$ alone following treatment 100 of @DRUG$ as a seven days .	DDI-false
majority of one or more following with @DRUG$ , @DRUG$ , blocking agents , chloroquine , hydroxychloroquine , , ,	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
clarithromycin , @DRUG$ @DRUG$ Indanavir Phenytoin Phenobarbitol , carbamazepine , Rifampin .	DDI-false
Phase using escalating doses - @DRUG$ ( or given sequential infusions , myelosuppression more profound was @DRUG$ with sequence ( ie TAXOL cisplatin	DDI-false
Suppression by verapamil of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
The examples of substances that the blood-glucose-lowering : corticosteroids , , agents ( e.g. , epinephrine , terbutaline , @DRUG$ , @DRUG$ , somatropin ( e.g. in oral )	DDI-false
which enhance the neuromuscular action agents as NUROMAX include certain antibiotics ( g. aminoglycosides bacitracin , @DRUG$ clindamycin , sodium ) @DRUG$ salts , lithium local anesthetics , quinidine	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
in sclerosis patients TYSABRI   (   30 weekly or @DRUG$ were the dose adjustment the beta-interferon @DRUG$.	DDI-false
Cyclosporine of @DRUG$ concomitantly @DRUG$ been associated with increase cyclosporine-induced due decreased synthesis of renal	DDI-mechanism
Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
@DRUG$ toxicity of @DRUG$ during inhibitor considered .	DDI-false
- Anabolic ( [ e.g. ] e.g. , Anavar ] @DRUG$ [ @DRUG$ ] , [ Winstrol )	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-advise
The of sulfonylurea be potentiated by drugs including nonsteroidal anti-inflammatory and other that protein bound , salicylates , probenecid , @DRUG$ , and	DDI-false
Compounds tested man warfarin theophylline , @DRUG$ , @DRUG$ , aminopyrine and antipyrine	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$ and glutethimide should not be administered to patients receiving @DRUG$.	DDI-advise
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Inhibitors : @DRUG$   is not for use in patients who within severe potentiation has been reported @DRUG$	DDI-false
Example inhibitors include @DRUG$, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
effects @DRUG$ are @DRUG$ such as caffeine and .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, @DRUG$, and verapamil.	DDI-false
@DRUG$ ( , atropine or other , or glycosides : concurrent with @DRUG$ produce inotropic chronotropic	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
action the @DRUG$ may be potentiated by , barbiturates , inhibitors , @DRUG$ , , psychotropic medications other drugs produce CNS	DDI-effect
therefore @DRUG$ or @DRUG$ ( as used of ) other drugs vasodilator activity should possible be captopril .	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Careful @DRUG$ concurrently with	DDI-advise
@DRUG$: Concomitant administration of clonidine with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-false
uniformity and time course @DRUG$ interference phenobarbital , @DRUG$ and methaqualone were systematically investigated patients .	DDI-false
In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$:Reports suggest NSAIDs the	DDI-false
@DRUG$: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
nc a mean than 10 % 2- Pediatrics 3- increase high @DRUG$ , the plasma @DRUG$ increased up , when Trileptal was given at .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Metformin : In healthy single mg doses cephalexin and @DRUG$ AUC increased an 34 % and respectively @DRUG$ mean clearance decreased 14	DDI-false
Anticonvulsants (@DRUG$): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-false
occur between EPA supplements @DRUG$ and anti-inflammatory drugs herbs as garlic ( sativum and @DRUG$ (	DDI-false
Antihypertensives : Amiodarone should be used caution receiving -receptor ( propranolol , a inhibitor or @DRUG$ ( , verapamil CYP3A4 , @DRUG$ inhibitor the potentiation , sinus arrest and AV block ;	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, @DRUG$, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-false
A recent has shown concomitan isoniazid @DRUG$ may elevated plasma levels , and some decrease the elimination	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
: apomorphine is dopamine , it possible that @DRUG$ , as @DRUG$ ( , ) or may effectiveness APOKYN	DDI-false
inhibitors azole antifungals ciprofloxacin @DRUG$ diclofenac , isoniazid , , protease inhibitors @DRUG$ , and verapamil .	DDI-false
Studies evaluate between @DRUG$ and than @DRUG$ have been performed	DDI-false
Antiarrhythmics : antiarrhythmic drugs , such as quinidine , @DRUG$ @DRUG$ and have amiodarone .	DDI-false
Hormonal Co-administration of Trileptal with oral contraceptive has components , @DRUG$ ( ) @DRUG$ ( LNG .	DDI-false
Other drugs which enhance blocking action as include ( , aminoglycosides , @DRUG$ @DRUG$ polymyxins , clindamycin , colistimethate , local , procainamide and quinidine .	DDI-false
Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
These include thiazides , corticosteroids , phe-nothiazines , @DRUG$ oral @DRUG$ nicotinic calcium drugs , and isoniazid	DDI-false
In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-false
@DRUG$ do not contain an @DRUG$ ) may inadequate during	DDI-false
@DRUG$: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.	DDI-false
Imidazoles (e. g., @DRUG$, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
determine whether injection of @DRUG$ doses cisplatin to a dose of given intravenously with escalating @DRUG$.	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
In a @DRUG$ dogs anesthetized with @DRUG$ , Innovar or dosage of ouabain cause ventricular tachycardia significantly , of ketamine Innovar with pentobarbital .	DDI-false
There are 3 types of indications: specific (for the treatment of some forms of @DRUG$ deficit i.e. acute), pharmacological (i.e. without alterations of @DRUG$ status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
local @DRUG$ @DRUG$ monoamine inhibitors or may severe , prolonged hypertension	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Dopamine Antagonists a @DRUG$ dopamine such , @DRUG$ thioxanthenes ) metoclopramide diminish APOKYN	DDI-false
Injection : injection other injectable @DRUG$ , the system with ethyl , @DRUG$ , MAO inhibitors , and concomitantly with injectable , of irrational behavior has observed .	DDI-effect
@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-digoxin interaction could be found.	DDI-false
Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Serial plasma and urine samples for measurement of amprenavir, @DRUG$, and @DRUG$ and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
of in @DRUG$ plasma when coadministered @DRUG$ were sufficient , patients enhanced side caused exposure of diazepam under this .	DDI-false
following are of may reduce : diuretics @DRUG$ ( e.g. , ) @DRUG$ , hormones estrogens progestogens ( in	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Effect of Other Drugs on the Pharmacokinetics of @DRUG$: Literature reports suggest that @DRUG$, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.	DDI-false
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
specific drug interactions with topical drugs medications were identified studies of 0.5 Ophthalmic possibility of an or with depressants ( alcohol , @DRUG$ opiates , @DRUG$ ) should considered .	DDI-false
Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-effect
hypoglycemic sulfonylurea may be certain drugs agents drugs that highly bound , , sulfonamides chloramphenicol @DRUG$ , @DRUG$ monoamine oxidase , agents	DDI-false
The following are examples of substances that may reduce blood-glucose-lowering effect : , niacin , @DRUG$ epinephrine , salbutamol , terbutaline , , @DRUG$ , thyroid , in oral	DDI-false
Indinavir: Coadministration of @DRUG$ with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-mechanism
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
, @DRUG$/quinidine , phenobarbital/acetaminophen , acid @DRUG$/lidocaine theophylline/acetaminophen valproic acid/phenobarbital	DDI-false
have associated with include antiretroviral nucleoside analogues , chloramphenicol , dapsone @DRUG$ , gold hydralazine , @DRUG$ , , , ribavirin vincristine .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Patients a study were on @DRUG$ to which ENBREL was added to develop in comparison to treated with either CI @DRUG$ alone .	DDI-false
did not affect the @DRUG$ to the metabolite after intravenous administration @DRUG$ , and had no clinically effect after	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$: @DRUG$ is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Furosemide : as well post-marketing , shown that NSAIDs effect of @DRUG$ and @DRUG$ some	DDI-false
Since the concomitant administration of @DRUG$ with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Thus, concomitant therapy with @DRUG$ and @DRUG$ should not require dosage adjustment of either drug.	DDI-false
Concomitant administration @DRUG$ with @DRUG$	DDI-advise
of phenytoin 40 mg @DRUG$ in epileptic lowered @DRUG$ to undetectable levels	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
medication doctor or and products you use : @DRUG$ e.g. gentamicin , @DRUG$ ) , amphotericin B , cyclosporine ( e.g. ) tacrolimus	DDI-false
Magnesium/@DRUG$-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and @DRUG$ (LNG).	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Magnesium- @DRUG$-containing antacids containing @DRUG$ multivitamin zinc other metal cations , powder oral not be taken within 3 before or 2 hours FACTIVE	DDI-false
@DRUG$ @DRUG$ blocks , inhibiting effects of	DDI-false
Therefore @DRUG$ at hour 4 - hours after a @DRUG$ to avoid impeding absorption	DDI-advise
When @DRUG$ or Bezalip resins ( e.g. ) interval least 2 hours should maintained the medicines , since the @DRUG$ or impaired	DDI-false
@DRUG$ did increase levels of	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
@DRUG$ hydrocarbon anesthetics increase the myocardium to administered catecholamines , such @DRUG$.	DDI-effect
determine injection thiosulfate larger @DRUG$ administered , 9.9-g/m2 dose @DRUG$ given three concurrently with of cisplatin	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (@DRUG$) was more than doubled in the presence of TMP/SMX.	DDI-false
drugs include diuretics , thyroid products estrogens @DRUG$ phenytoin , nicotinic , @DRUG$ ,	DDI-false
Patients @DRUG$ along intravenous @DRUG$ should monitored possible , ventricular failure and .	DDI-advise
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (@DRUG$, thiothixene, alprazolam).	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
drugs neuromuscular blocking of nondepolarizing such as @DRUG$ include certain g. tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ ) , lithium , anesthetics , procainamide and .	DDI-effect
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-effect
Acetaminophen, lidocaine, phenobarbital, quinidine, @DRUG$, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
amiodarone is a @DRUG$ there is the potential that the of John s Wort patients receiving amiodarone could in @DRUG$	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-mechanism
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Additional reductions pressure may occur FLOLAN administered @DRUG$ agents @DRUG$.	DDI-false
Other concomitant specific interaction studies were performed , doses 1 mg more were concomitantly clinical studies with acetaminophen , acetylsalicylic acid a-blockers analgesics , angiotensin-converting ACE , anticonvulsants , @DRUG$ , calcium-channel blockers , cardiac nitrates diuretics H2 , @DRUG$ , synthetase inhibitors ( also to ) and quinolone evidence of significant interactions .	DDI-false
Cardiovascular Agents : IV been with @DRUG$ nitrates calcium-blocking agents , hydralazine @DRUG$ and evidence clinically significant adverse	DDI-false
Coadministration @DRUG$ and cyclosporine , or @DRUG$ has led to increased plasma concentrations the	DDI-mechanism
Conversely, the @DRUG$ have been reported to increase the serum levels and prolong the serum half-life of @DRUG$ by inhibiting its metabolism.	DDI-mechanism
Although specific studies not , coadministration with that are mainly metabolized by eg calcium dapsone , @DRUG$ , amiodarone , warfarin , tacrolimus @DRUG$ ergot derivatives , , , have elevated plasma	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
studies not clinically significant with phenytoin , warfarin @DRUG$ , clarithromycin	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
The majority patients in studies more following concomitant medications : MTX , , @DRUG$ , azathioprine , chloroquine , gold hydroxychloroquine , @DRUG$ sulfasalazine and anakinra	DDI-false
or pharmacodynamic drug-drug been concomitantly administered mg orally given 26 and 2 hours prior orally , 6 to , and 6 12 subsequent , initiation @DRUG$ 1.5 . hours )	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	DDI-effect
The absorption of @DRUG$, @DRUG$, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	DDI-false
Although there have been no formal interaction studies other than with @DRUG$, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of @DRUG$ with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.	DDI-false
Methotrexate ( e.g. , @DRUG$ of @DRUG$ with increase the chance of effects affecting and/or the side effects methotrexate	DDI-false
Other reported interactions @DRUG$ : Fentanyl CYP3A4 in @DRUG$ may cause hypotension , bradycardia decreased .	DDI-false
A association though less suggested with @DRUG$ phenyl-butazone , @DRUG$ and possibly with , ampicillin tetracyclines 72 )	DDI-false
@DRUG$ sulfonamides , or @DRUG$ should be observed for activity of these , signs of toxicity from these drugs	DDI-false
have these sevoflurane , isoflurane @DRUG$ ,	DDI-false
Other Drugs : In small patients 7 , the concomitant administration azathioprine , , chloroquine , , @DRUG$ , , or @DRUG$ significantly peak and AUC of diclofenac .	DDI-false
Coadministration of @DRUG$ decreased the of @DRUG$ by , decreased clearance by 38 , and half-life .	DDI-mechanism
These include the and , @DRUG$ , products , estrogens @DRUG$ , sympathomimetics calcium drugs , and isoniazid	DDI-false
: In subjects @DRUG$ a CYP3A4 inhibitor , at daily 7 , AUC ) to @DRUG$ was to approximately 3.6-fold of half-life 1.7-fold of control	DDI-mechanism
When @DRUG$ was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$: The combination of HIVID, @DRUG$, and ZDV has been studied (as triple combination) in adults.	DDI-false
pharmacokinetic interactions been in studies with , digoxin @DRUG$ , @DRUG$.	DDI-false
The following are substances reduce the blood-glucose-lowering effect corticosteroids , danazol diuretics sympathomimetic agents ( e.g. epinephrine , @DRUG$ terbutaline , , derivatives , , hormones estrogens @DRUG$ e.g. , in oral contraceptives .	DDI-false
Blood for the of @DRUG$ and @DRUG$ performed on 1 1 , and 4 , months 2 3 , 9 , and	DDI-false
Nephrotoxic agents Concomitant administration and agents with nephrotoxic potential [ intravenous aminoglycosides e.g. @DRUG$ , and amikacin , B foscarnet , intravenous , , and @DRUG$ ]	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
agents : Concomitant administration of @DRUG$ and with nephrotoxic potential , @DRUG$ ( e.g. , , and ) , amphotericin , and non-steroidal agents contraindicated	DDI-advise
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Concomitant administration of VISTIDE and agents e.g. , aminoglycosides ( tobramycin , and @DRUG$ ) amphotericin B @DRUG$ , intravenous pentamidine , and non-steroidal ] contraindicated .	DDI-false
Nephrotoxic agents administration of with e.g. intravenous aminoglycosides ( , tobramycin , ) , amphotericin , @DRUG$ @DRUG$ contraindicated	DDI-false
administration drugs nephrotoxic @DRUG$ , @DRUG$ , myelotoxic e.g. , cytotoxic ) cardiotoxic ( e.g. , ) hepatotoxic ( , ) PROLEUKIN may in organ systems	DDI-false
Close supervision careful of the are when @DRUG$ with @DRUG$	DDI-advise
acetaminophen/@DRUG$ lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic quinidine/lidocaine theophylline/acetaminophen and .	DDI-false
Patients other narcotic , @DRUG$ @DRUG$ , antidepressants or other depressants including concomitantly DILAUDID may additive depression .	DDI-false
may with or other CNS depressants ( may depressant these @DRUG$ ) anticholinergics or other medications with activity ( may potentiated ) , oxidase ( ) ( concurrent @DRUG$ may prolong and depressant .	DDI-false
Antihypertensive medications, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
Intravenous @DRUG$ adenosine ) has effectively the of other cardioactive , such @DRUG$ agents , blocking , and enzyme without in	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	DDI-false
of acetaminophen with @DRUG$ with acid @DRUG$ toxic decreases	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
in literature suggest that levels of @DRUG$ ( and active metabolite doxorubicinol may increased when and @DRUG$ are used	DDI-false
Another oral azole , astemizole in of @DRUG$ its active @DRUG$ intervals	DDI-false
@DRUG$ - Taking @DRUG$ and a phenothiazine together may increase the risk of convulsions (seizures).	DDI-false
Acidifying agents @DRUG$ ( , @DRUG$ glutamic acid , juices , lower of amphetamines	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
@DRUG$ : @DRUG$ mg for 11 days the of 0.5	DDI-false
Anticoagulants have not shown @DRUG$ @DRUG$ , should be nonetheless , since interactions have been other NSAIDs	DDI-false
Acetaminophen, @DRUG$, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ or anticoagulants are used concomitantly , there potential for @DRUG$	DDI-effect
Lorazepam like other , produces depression the central when with @DRUG$ phenothiazines , barbiturates MAO , antidepressants . When @DRUG$ lorazepam an increased incidence hallucinations , and irrational been observed	DDI-false
Effect of Other Drugs on the Pharmacokinetics of @DRUG$: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter @DRUG$ pharmacokinetics.	DDI-false
studies been performed with drugs that mainly metabolized by CYP3A4 , blockers dapsone , quinine , @DRUG$ warfarin , pimozide , carbamazepine fentanyl , and @DRUG$ have elevated concentrations when with saquinavir	DDI-false
Interaction with phenytoin, @DRUG$ and @DRUG$ has also been reported to produce adverse clinical effects.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
demonstrated @DRUG$ and @DRUG$ .	DDI-effect
Antacids: Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	DDI-mechanism
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving @DRUG$ or @DRUG$.	DDI-false
Amiodarone should be with caution patients receiving   agents e.g. @DRUG$ , a @DRUG$ or calcium , a , CYP3A4 ) of the possible sinus , AV	DDI-false
efavirenz and @DRUG$ have triple @DRUG$ indinavir weeks as similar responses observed with regimens and efavirenz	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The @DRUG$ with and @DRUG$ been tolerated in stable angina .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Lithium: @DRUG$ 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Therefore , @DRUG$ agents concomitantly the patient be determine the effect of @DRUG$ is obtained .	DDI-false
The co-administration of Natrecor with vasodilators as @DRUG$ , @DRUG$ or IV ACE ( these drugs were with clinical .	DDI-false
@DRUG$ 10 mg and @DRUG$ ( mg an 85 % increase in the Cmax zaleplon .	DDI-mechanism
@DRUG$ : Cimetidine leads to an plasma concentration and AUC of @DRUG$ there absorption when it coadministered .	DDI-false
Compounds in these result in a decreased efficacy of mesylate : @DRUG$ , @DRUG$ ,	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
that may @DRUG$ concentrations Drugs may increase plasma Caution is when the ( @DRUG$ , itraconazole ,	DDI-false
@DRUG$: Tiagabine causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	DDI-false
Example inhibitors include antifungals ciprofloxacin , diclofenac @DRUG$ , @DRUG$ , isoniazid nefazodone nicardipine , , protease ,	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/@DRUG$).	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
@DRUG$ @DRUG$ that gets into your body	DDI-false
The are examples of that may increase the effect to : antidiabetic , ACE , , @DRUG$ monoamine oxidase MAO inhibitors , , @DRUG$ ( e.g. ) , sulfonamide antibiotics	DDI-false
Nephrotoxic agents administration of agents potential e.g. intravenous aminoglycosides tobramycin , gentamicin , , @DRUG$ intravenous @DRUG$ and anti-inflammatory ] .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drugs that imatinib concentrations Drugs that imatinib plasma concentrations Caution is recommended administering with family ( e.g. , ketoconazole @DRUG$ @DRUG$ ,	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
concomitant therapy specific were @DRUG$ mg used clinical studies acetaminophen acetylsalicylic acid , a-blockers , , angiotensin-converting ( ) , anticonvulsants , benzodiazepines , @DRUG$ calcium-channel blockers cardiac diuretics antagonists , prostaglandin synthetase , quinolone without significant	DDI-false
Concomitant @DRUG$ ( TRICOR ) with ( ) 10 in approximately decrease % @DRUG$ values in 22	DDI-false
, ventricular severe rhabdomyolysis be @DRUG$ @DRUG$ concurrently	DDI-effect
receiving @DRUG$ and concomitantly should have @DRUG$ , to 1/3 1/4 dose .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ been reported decrease tubular of @DRUG$ and to .	DDI-mechanism
Example clarithromycin , , @DRUG$ , imatinib , , @DRUG$ , propofol ,	DDI-false
Ethanol @DRUG$ potentiated CNS-impairing g/kg testing time hour @DRUG$ administration the digit test ( , symbol , the variability component test for hours ethanol .	DDI-false
@DRUG$ : @DRUG$ may enhance the effect of insulin hypoglycemics .	DDI-false
have been associated with antiretroviral nucleoside , , @DRUG$ , dapsone , @DRUG$ , ethionamide , glutethimide gold , hydralazine , isoniazid , metronidazole , , vincristine .	DDI-false
Quinolones including norfloxacin may oral @DRUG$ , @DRUG$ or derivatives similar .	DDI-false
@DRUG$ : The HIVID @DRUG$ , and been studied ( as combination in adults	DDI-false
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-false
@DRUG$ : In in healthy subjects lithium approximately 17 % BID with 200 BID as to subjects @DRUG$ alone	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$/quinidine , phenobarbital/@DRUG$ phenobarbital/valproic quinidine/lidocaine , and valproic	DDI-false
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Other drugs may blocking of nondepolarizing include e. g. , tetracyclines , bacitracin polymyxins @DRUG$ , @DRUG$ sodium salts , anesthetics , .	DDI-false
effects resulting cholinergic blockade when @DRUG$ concomitantly with , amantadine , haloperidol @DRUG$ , MAO ) inhibitors tricyclic or antihistamines .	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
of with Drugs : Cimetidine : Co-administration of @DRUG$ ( ) taking @DRUG$ had	DDI-false
Administration @DRUG$ to who sympathomimetic or @DRUG$ may an additive effect	DDI-effect
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
Coadministration @DRUG$ increased exposure @DRUG$ ) .	DDI-mechanism
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
@DRUG$ eg tubocurarine ) drugs , , @DRUG$ , and , effect and should patients being Coly-Mycin	DDI-false
The pharmacokinetics of @DRUG$ are unaltered in the presence of @DRUG$ and vice versa.	DDI-false
, , acid , @DRUG$/lidocaine , and valproic acid/phenobarbital	DDI-false
Antacid Products : of zalcitabine is reduced approximately 25 ) when coadministered with	DDI-false
Drugs : small groups of ( 7 - study , concomitant gold , @DRUG$ , @DRUG$ , prednisolone , or digitoxin did affect the and AUC of .	DDI-false
@DRUG$ desipramine @DRUG$ and possibly cause striking sustained in the concentration of in brain	DDI-mechanism
Sedatives/@DRUG$: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
patients chronic with @DRUG$ in combination @DRUG$ treatment did not affect ribavirin distribution or clearance .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and @DRUG$ (72)	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
@DRUG$ Preparations : Micro-dosed ( minipills that do contain ) may inadequate during @DRUG$	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
In @DRUG$ was used with digoxin , , anticoagulants , oral vasodilators and oxygen substudy in patients congestive heart failure furosemide or in therapy @DRUG$ initiated , apparent values = ) and n = 30 decreased 13 respectively , the of therapy had baseline day 87	DDI-false
Although specific studies were not performed , 1 mg or more were concomitantly used in with @DRUG$ a-blockers angiotensin-converting ACE , , , beta calcium-channel cardiac , , @DRUG$ , synthetase as and without evidence adverse interactions .	DDI-false
Adverse Reactions @DRUG$ A review of the % ( range - 28 % ) 501 treated with various @DRUG$ containing who were radiographic iodinated contrast media atypical adverse reactions	DDI-false
Substances potent inhibitors CYP3A4 activity ( , @DRUG$ @DRUG$ ) decrease and increase gefitinib plasma concentrations .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
: In small groups of patients ( 7 - ) the concomitant administration @DRUG$ @DRUG$ chloroquine D-penicillamine prednisolone doxycycline digitoxin did not affect the peak values of diclofenac	DDI-false
Drugs that associated peripheral include nucleoside analogues , @DRUG$ , , ethionamide , gold , , isoniazid metronidazole , @DRUG$ , phenytoin ribavirin , .	DDI-false
@DRUG$ , products containing iron or , @DRUG$ should be concomitantly within hours of , the of , absorption in lower of norfloxacin	DDI-false
Animal studies indicate that @DRUG$ may be ineffective if the patient has recently received a @DRUG$.	DDI-effect
@DRUG$ : of ritonavir resulted in a 152 in @DRUG$ plasma AUC and little plasma A.C.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Although studies have not coadministration drugs that are metabolized by @DRUG$ , quinine amiodarone quinidine , @DRUG$ fentanyl , triazolam may have plasma with saquinavir ;	DDI-false
be HMG-CoA inhibitor drugs that may levels or of steroid hormones , @DRUG$ @DRUG$ , .	DDI-false
Drug/Laboratory @DRUG$ may cause a false serum @DRUG$ with Digi- Tab RIA Digoxin .	DDI-false
Curariform relaxants eg , drugs , , , @DRUG$ @DRUG$ , neuromuscular used extreme patients being treated with M Parenteral	DDI-false
@DRUG$ were not affected coadministration of or @DRUG$	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
There have case reports increased levels of , @DRUG$ phenytoin concomitant therapy with @DRUG$.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, and @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
increased risk of patients have been taking @DRUG$ on a regular basis , it is particularly that physicians query patients about benzodiazepine , @DRUG$ part of prior to any the use .	DDI-false
: drug-drug interactions have been demonstrated Argatroban and concomitantly aspirin ( 162.5 hours prior of @DRUG$ 1   over hours or @DRUG$ orally given , and 0 hours , and 12 subsequent initiation of 1.5 18 hours	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, @DRUG$, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
Other nephrotoxic medications: agents such as @DRUG$, @DRUG$, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
The oral significantly by concomitant of @DRUG$ aluminum @DRUG$.	DDI-false
action of the benzodiazepines may be potentiated , antihistamines , , @DRUG$ @DRUG$ , phenothiazines medications , other produce CNS depression	DDI-false
Diphenhydramine hydrochloride effects other @DRUG$ ( @DRUG$ sedatives , tranquilizers etc ) .	DDI-false
recommended to a single 5 mg of @DRUG$ in 24-hour used in	DDI-advise
@DRUG$ 1000 twice did the @DRUG$.	DDI-false
Co-medications induce CYP3A4 ( e.g. , dexamethasone @DRUG$ , rifampin , @DRUG$ or St.	DDI-false
- @DRUG$ e.g. , Anabolin [ e.g. , Anavar ] , @DRUG$ stanozolol [ , Winstrol )	DDI-false
@DRUG$ been shown to inhibit P450 1A2 isoform also in @DRUG$metabolism	DDI-mechanism
Digoxin , Nimodipine and Losartan Bosentan no significant pharmacokinetic interactions and , and @DRUG$ has no effect on of	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
): SSRIs ( e.g. , fluoxetine , , @DRUG$ , sertraline reported , , when @DRUG$.	DDI-effect
Concomitant administration 10 ) @DRUG$ 800 ) produced % in mean Cmax @DRUG$.	DDI-false
Erythromycin Co-administration of felodipine (@DRUG$) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
Hypersensitivity have been in containing sequential high PROLEUKIN and antineoplastic specifically , @DRUG$ , @DRUG$	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Multivalent Products : quinolone including , cation-containing products magnesium @DRUG$ , VIDEX tablets or , or products @DRUG$ , or may substantially the absorption of ciprofloxacin , resulting urine levels desired .	DDI-false
Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
@DRUG$ : Concomitant administration diclofenac aspirin not because @DRUG$ displaced its sites the concomitant of in concentrations , peak levels , AUC .	DDI-false
Other @DRUG$ (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Notably systemic - 12 @DRUG$ ( @DRUG$ than doubled the TMP/SMX	DDI-false
, through microsomal systems , reported to reduce the hepatic metabolism of @DRUG$ , diazepam certain tricyclic @DRUG$ and , thereby delaying elimination and increasing drugs	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
A study in eight healthy volunteers has shown a 50% increase in mean peak @DRUG$ plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and @DRUG$ at 90 mg/day.	DDI-false
@DRUG$ and , and possibly glucocorticoids and @DRUG$ may regulate proliferation of prostate epithelium by a modification of the activity EGF	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Edema has patients @DRUG$ and	DDI-effect
A of @DRUG$ in conjunction with demonstrated no effects on the of @DRUG$.	DDI-false
of this is not known , hence @DRUG$ is recommended ingested simultaneously with magnesium/aluminum-containing @DRUG$.	DDI-advise
Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
Amantadine, @DRUG$, and @DRUG$ may increase anticholinergic effect of clidinium.	DDI-false
In a Phase trial using TAXOL ) ( or given sequential myelosuppression was profound when @DRUG$ given than with the alternate sequence ( ie , @DRUG$ before cisplatin	DDI-false
@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with @DRUG$.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Dosage of @DRUG$ may when inhibitors , e.g. , @DRUG$ fluoxetine , and quinidine	DDI-advise
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
healthy , the pharmacokinetics of a 1-mg of as @DRUG$ were affected coadministration of 6-mg dose of	DDI-false
In , @DRUG$ did systematically alter the (-)-NANM @DRUG$ or .	DDI-false
Ethinyl Estradiol @DRUG$ : VIRACEPT @DRUG$ % decrease ethinyl estradiol and an % decrease in norethindrone plasma concentrations .	DDI-false
Coadministration @DRUG$ using an soft-gelatin formulation of 1200 mg ) with increase plasma AUC increase in @DRUG$ plasma A.C.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Although specific have not been performed with that are mainly metabolized ( , calcium channel blockers , disopyramide , quinine quinidine warfarin , tacrolimus , cyclosporine , @DRUG$ pimozide , carbamazepine , fentanyl alfentanyl , and may have elevated with @DRUG$ ;	DDI-mechanism
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drug Interactions : may ( could affect flupenthixol pharmacodynamics Arecoline Eproxindine - Ethanol @DRUG$ cause additive depression - Tricyclic antidepressants the effect of @DRUG$	DDI-false
Analysis @DRUG$ following indicated there of budesonide @DRUG$ and aqueous phase	DDI-false
Ephedrine: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
this reduction not known not recommended be ingested with @DRUG$.	DDI-false
Experience HMG-CoA inhibitors and patients is , temporarily of @DRUG$ in patients @DRUG$.	DDI-advise
poor of @DRUG$ : Interactions strong inhibitors of such quinidine @DRUG$ , paroxetine , and not , but would to increase levels of enantiomer carvedilol	DDI-false
@DRUG$ @DRUG$ may interfere with the effect each when administered concurrently	DDI-effect
@DRUG$ Lithium toxicity been reported in patients @DRUG$ with drugs cause ACE .	DDI-false
Valdecoxib ( 40 mg ) did induce the of oral contraceptive @DRUG$/@DRUG$ ( 1 combination , 1/35 )	DDI-false
Digoxin @DRUG$ @DRUG$ : Bosentan no significant pharmacokinetic interactions with and no significant effect on plasma levels .	DDI-false
@DRUG$ of @DRUG$ patients valproate had effect tiagabine , but tiagabine binding 96.3 % , resulted increase of approximately 40 % free tiagabine concentration .	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
These results suggest that acute dosing with @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication.	DDI-false
side of N-methylthiotetrazole ( , @DRUG$ , cefotetan , cefamandole @DRUG$ ) methylthiadiazole ( cefazolin ) can cause K deficiency and hypoprothrombinemia .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The effects of adenosine are antagonized by @DRUG$ such as @DRUG$ and theophylline.	DDI-false
No important pharmacokinetic occurred used concomitantly with @DRUG$ @DRUG$.	DDI-false
separate studies of doses warfarin @DRUG$ , administration for days effect @DRUG$ ( prothrombin ) or of digoxin .	DDI-false
which may the blocking action agents such as NUROMAX certain @DRUG$ ( , @DRUG$ polymyxins lincomycin , colistin , and , magnesium , , anesthetics .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when @DRUG$ is used concomitantly with these medications.	DDI-false
Antiacid clarithromycin , , @DRUG$ , Indanavir Ketoconazole @DRUG$ Phenobarbitol , carbamazepine Rifabutin , Rifampin ,	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Since the therapeutic range of is narrow @DRUG$ levels adjustments @DRUG$ should made .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-false
Like @DRUG$ ) @DRUG$ mg/kg the and cocaine and the oral of ethanol and ;	DDI-false
@DRUG$ 40 BID 1 ) 40 QD ( days 2 - ) ) @DRUG$ ) resulted in 21 in Cmax to 16 decrease in AUC0 - 24	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
Therefore , @DRUG$ and @DRUG$ are used the patient should be closely desired diuretic is obtained .	DDI-advise
, lidocaine/quinidine , phenobarbital/acetaminophen , , valproic acid/phenobarbital	DDI-false
As @DRUG$, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, @DRUG$).	DDI-false
@DRUG$ : Coadministration resulted decrease in @DRUG$ plasma AUC a 207 increase in rifabutin	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other concomitant therapy Although interaction not , of 1 more with acid , a-blockers analgesics , inhibitors , anticonvulsants , @DRUG$ beta , calcium-channel , cardiac nitrates , , prostaglandin synthetase also referred to @DRUG$ and without	DDI-false
Cardiovascular @DRUG$ and enalapril used with methyldopa nitrates , @DRUG$ prazosin and digoxin evidence clinically significant	DDI-false
@DRUG$ : In normal , a decrease @DRUG$ levels was observed when multiple of diflunisal aspirin administered	DDI-false
Cytochrome inducers as phenytoin carbamazepine phenobarbital @DRUG$ causing 30 in plasma @DRUG$ levels .	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
@DRUG$ increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and t1/2.	DDI-false
possibility of effects with enalapril enalaprilat be the @DRUG$ or the prior to initiation of treatment with or @DRUG$.	DDI-false
a dose 25 @DRUG$ should be considered treatment osteoarthritis when @DRUG$ is inducers hepatic metabolism .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
have not with drugs are mainly metabolized by calcium channel dapsone disopyramide , @DRUG$ , amiodarone quinidine , , ergot derivatives , pimozide , , , @DRUG$ and triazolam may elevated plasma concentrations when with saquinavir ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ , Didanosine , , Indanavir , , Phenytoin , , , Rifampin , Ritanovir , @DRUG$.	DDI-false
Non-selective including sulfate , @DRUG$ and HC1 @DRUG$ may hypertension	DDI-false
metabolized @DRUG$ have levels @DRUG$ initiated whether the dose adjustment .	DDI-advise
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), EGF (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Serum @DRUG$ levels should be monitored frequently if @DRUG$ is administered concomitantly with lithium.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
and @DRUG$ have compared to triple therapy PI as with being @DRUG$ observed with .	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with salicylate or @DRUG$.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
The hypotensive effects with @DRUG$ or can by discontinuing the diuretic increasing the prior initiation of with @DRUG$ or enalaprilat	DDI-false
transfer to @DRUG$ dose of previously administered agents by to % several after the addition of @DRUG$.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, @DRUG$ and 5-fluorouracil.	DDI-false
@DRUG$ been reported to enhance the anticoagulant effects its , time test be closely if a is concomitantly with @DRUG$ or derivatives	DDI-false
For it is felt , subjects have had unsatisfactory alone , the possible @DRUG$ and a @DRUG$ the risks rhabdomyolysis ,	DDI-effect
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
Antidepressants (tricyclic), @DRUG$ or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
If treatment inhibitors activity ( such ketoconazole , indinavir , @DRUG$ , , . ) is indicated , reduction @DRUG$ should considered .	DDI-advise
following are examples of may reduce the blood-glucose-lowering effect : danazol , diuretics sympathomimetic agents ( e.g. epinephrine , terbutaline ) @DRUG$ @DRUG$ estrogens , progestogens , oral contraceptives )	DDI-false
Oral Contraceptives: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
The @DRUG$ is not nitrofurantoin antagonize antibacterial effect of @DRUG$ in urinary	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Imidazoles ( g. , @DRUG$ @DRUG$ , etc . ): vitro with the of B and suggest that induce fungal amphotericin	DDI-false
with compounds that are potent CYP3A4 eg phenobarbital phenytoin , @DRUG$ ) result in decreased plasma levels @DRUG$.	DDI-mechanism
Use with Angiotensln Converting Enzyme Inhibitors: The use of @DRUG$ to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	DDI-effect
Central System Depressants : The use of ( system other central system depressants , limited other @DRUG$ , sedatives , @DRUG$ ( benzodiazepines ) , , phenothiazines , skeletal muscle relaxants and alcohol cause , hypotension sedation , or in or death .	DDI-false
The @DRUG$ to patients receiving @DRUG$ phenothiazines , prolonged hypotension or hypertension	DDI-effect
@DRUG$ : Amphetamines the adrenergic of	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Other Although were not performed @DRUG$ doses mg more used studies with acid , analgesics ) , , beta , cardiac nitrates , @DRUG$ , , HMG-CoA reductase inhibitors , prostaglandin synthetase ( also to ) quinolone anti-infectives of clinically adverse interactions	DDI-false
Digoxin : @DRUG$ 75 daily does alter the profile renal of @DRUG$ after single 0.5 mg dose	DDI-false
In of hypersensitivity reactions with @DRUG$ premedicated with corticosteroids ( dexamethasone antagonists or @DRUG$	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Oral neomycin inhibits absorption @DRUG$ , @DRUG$ and 5-fluorouracil	DDI-false
@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	DDI-effect
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Drug may interact drugs like Monoamine inhibitors ): MAOI could affect @DRUG$ pharmacodynamics - - @DRUG$ : Flupenthixol and Ethanol cause additive CNS - antidepressants : Flupenthixol the Tricyclic antidepressants	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
interactions HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
@DRUG$/@DRUG$ due serious and/or life-threatening such prolonged or increased respiratory .	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ containing ferrous sulfate ( , preparations or other metal cations or @DRUG$ ( ) or the pediatric powder for solution 3 before	DDI-false
@DRUG$ concentrations were 3- 4-fold in the absence @DRUG$.	DDI-mechanism
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
No To Date does not have pharmacokinetic interactions with , @DRUG$ , warfarin @DRUG$ , or itraconazole	DDI-false
of @DRUG$ , phenytoin and phenobarbital have to of @DRUG$ ( 29	DDI-false
Both efavirenz and nevirapine have the @DRUG$ indinavir 48 weeks therapy with being @DRUG$ regimens and superiority observed efavirenz .	DDI-false
interactions occur concomitant administration ( , narcotics , analgesics @DRUG$ , @DRUG$ , .	DDI-false
Another oral azole antifungal, @DRUG$, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-mechanism
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
- @DRUG$ (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Fenfluramine may slightly @DRUG$ , e.g. guanethidine , @DRUG$	DDI-false
@DRUG$: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-false
The action , antihistamines , alcohol , @DRUG$ @DRUG$ , phenothiazines psychotropic , other drugs that	DDI-false
is a significant increase in exposure @DRUG$ when Gleevec is with @DRUG$ ( inhibitor )	DDI-false
Injection : Lorazepam injection like injectable , depression the central nervous when with @DRUG$ , , barbiturates MAO inhibitors and other antidepressants scopolamine is with @DRUG$ an increased incidence sedation and been observed	DDI-false
However, interactions may be expected, and @DRUG$ should NOT be used in combination with other @DRUG$.	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Folic acid may antiepileptic of @DRUG$ , @DRUG$ and , and the seizures susceptible pediatric patients .	DDI-false
healthy subjects the CYP3A4 @DRUG$ at mg 3 twice daily 17 systemic exposure ) @DRUG$ was 72 .	DDI-mechanism
@DRUG$ be administered concomitantly with other sympathomimetic drugs as @DRUG$ possible additive effects increased	DDI-advise
Some known to metabolism @DRUG$ synthesis of ( enzyme ) .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the @DRUG$ has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.	DDI-false
Multivalent Products : Concurrent of @DRUG$ including with cation-containing or sucralfate , VIDEX tablets or pediatric powder or products calcium @DRUG$ or zinc absorption resulting in serum and desired .	DDI-mechanism
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-effect
The that may reduce : niacin danazol diuretics , e.g. @DRUG$ , salbutamol , ) , phenothiazine thyroid , @DRUG$ contraceptives	DDI-false
, @DRUG$ enhance the of @DRUG$ sympathomimetic agents ;	DDI-false
of single oral @DRUG$ with erythromycin 10 mg and , respectively , a CYP3A4 inhibitor produced a @DRUG$s and % increase the area under curve .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Central Nervous System The ( system ) depressants including but limited opioids , @DRUG$ , , e.g. benzodiazepines ) , @DRUG$ , phenothiazines , skeletal muscle relaxants and alcohol respiratory , , and profound sedation or coma death	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In study it shown @DRUG$ no significant effect @DRUG$ peripheral blood .	DDI-false
Antidepressants (@DRUG$), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, @DRUG$ and @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for @DRUG$.	DDI-false
Example inhibitors @DRUG$ , @DRUG$ , doxycycline , erythromycin , isoniazid propofol inhibitors , quinidine ,	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Based on these data, @DRUG$ should not be used in patients on @DRUG$ therapy.	DDI-advise
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
As other , it noted may be capable depressants @DRUG$ , and @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ @DRUG$ ) increase of the ionized the amphetamine , urinary excretion	DDI-false
Be VIRACEPT Antiarrhythmics amiodarone Antihistamines @DRUG$ , Antimigraine : ergot agents rifampin @DRUG$ midazolam , : cisapride	DDI-false
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
@DRUG$ had on the intracellular of @DRUG$ peripheral blood cells	DDI-false
Haloperidol or eliminated the increases FI responding intermediate doses of @DRUG$ @DRUG$ in , but not antagonize the decreases FI or responding produced by high doses or either NANM .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
enhance neuromuscular action nondepolarizing agents as NUROMAX include antibiotics ( g. , , tetracyclines , , , clindamycin , colistin @DRUG$ local anesthetics @DRUG$ and .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Digoxin and @DRUG$ : @DRUG$ no significant with digoxin , and significant on plasma bosentan .	DDI-false
@DRUG$ : Quinolones have been reported to of the oral @DRUG$	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$: There is no significant pharmacokinetic interaction between ZDV and @DRUG$ which has been confirmed clinically.	DDI-false
@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy.	DDI-effect
@DRUG$: @DRUG$ causes increase (by about 80%) in the free fraction of etodolac.	DDI-false
@DRUG$ : Coadministration rifampin @DRUG$ 82 decrease nelfinavir	DDI-false
cimetidine and that are for ( , @DRUG$ @DRUG$ propafenone )	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
A similar association though less marked been with phenytoin @DRUG$ @DRUG$ , with ampicillin tetracyclines 72	DDI-false
This may interact with @DRUG$ or CNS ( CNS of either ) , or with anticholinergic effects may be potentiated when these medications with ) , and MAO ) concurrent use with and anticholinergic and CNS of @DRUG$	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
agents : Concomitant administration and agents potential [ , intravenous aminoglycosides tobramycin , gentamicin , and ) , @DRUG$ , foscarnet , intravenous pentamidine @DRUG$ , non-steroidal ] is	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
a comparison of digitalis tolerance in dogs @DRUG$ Vet , pentobarbital the dosage needed tachycardia the LD50 ouabain , with ketamine Innovar than @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Oral of @DRUG$ oral vitamin , @DRUG$ 5-fluorouracil .	DDI-false
In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	DDI-false
clinical was used diuretics , , oral , in patients with failure @DRUG$ whom FLOLAN , clearance values for furosemide n = 23 ) digoxin ( n 30 by and % , , the day of and had returned to values .	DDI-false
Little or the drug when @DRUG$ was with lamivudine @DRUG$.	DDI-false
@DRUG$ not only block the therapeutic effects of @DRUG$, but may produce severe bronchospasm in COPD patients.	DDI-effect
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Therophylline has concomitan @DRUG$ and cause elevated plasma @DRUG$ , and in a slight decrease in elimination .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ , including CYP1A2 CYP2C9 @DRUG$ , CYP3A4 .	DDI-false
The hypoglycemic sulfonylurea may drugs including nonsteroidal anti-inflammatory and drugs that highly bound , @DRUG$ sulfonamides chloramphenicol probenecid , coumarins , monoamine inhibitors @DRUG$.	DDI-false
@DRUG$: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by probenecid.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
astemizole , @DRUG$ , @DRUG$	DDI-false
Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Other drugs which may neuromuscular action of agents such include certain e. g. , tetracyclines , , , clindamycin colistin and sodium ) , lithium , , @DRUG$ and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
vitro diclofenac interferes or at with protein of salicylic acid 20 % , , @DRUG$ 10 % ) ,	DDI-false
This appears to be the only relevant interaction of this kind Mefloquine although other drugs ( , @DRUG$ beta-adrenergic agents calcium blockers , H1-blocking agents , antidepressants and @DRUG$ might to prolongation of .	DDI-false
Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of astemizole with @DRUG$ is contraindicated.	DDI-false
Based the chemical of @DRUG$ , coadministration @DRUG$ is .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
may with drugs ( cold , sinus ) , diabetic drugs , lithium , @DRUG$ NSAIDs or , high blood	DDI-false
CONCLUSIONS @DRUG$ inhibit of HMG-CoA inhibitors that are metabolized CYP3A4 i.e. , , @DRUG$ simvastatin	DDI-mechanism
@DRUG$ may acidic such as @DRUG$ or tolbutamide from their .	DDI-mechanism
Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.	DDI-advise
serum @DRUG$ and ) have @DRUG$.	DDI-mechanism
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
interaction @DRUG$ showed significant of @DRUG$ pharmacokinetics or anticoagulant	DDI-false
@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
There are , from marketing experiences , of in effects of @DRUG$ oral hypoglycemic in @DRUG$ changes doses agents	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
This appears to only relevant interaction of this with Mefloquine , , coadministration cardiac conduction ( , anti-arrhythmic @DRUG$ channel antihistamines or @DRUG$ tricyclic antidepressants and phenothiazines ) might contribute to prolongation of .	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], @DRUG$ [e.g., Winstrol]) or	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
order the occurrence hypersensitivity , all should premedicated with dexamethasone ) and @DRUG$ ( @DRUG$ )	DDI-false
@DRUG$: amphotericin B-induced hypokalemia may potentiate @DRUG$ toxicity.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	DDI-false
Benzylpenicillin @DRUG$ , oxacillin , , , , erythromycin , and sulfamethoxazole influence on protein of @DRUG$ serum	DDI-false
@DRUG$ Taking piperazine and a @DRUG$ may the risk of convulsions ( .	DDI-false
Patients receiving both @DRUG$ and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.	DDI-advise
Although glucocorticoids been side , renal insufficiency , hyperbilirubinemia , confusion these agents with antitumor effectiveness of @DRUG$ be avoided Beta-blockers may hypotension seen with @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
: on Diuretic Therapy : Patients especially in diuretic therapy recently , occasionally experience an of pressure initiation of @DRUG$ @DRUG$.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
System Depressants The concomitant use of @DRUG$ fentanyl system with other central including but limited other opioids , sedatives benzodiazepines general @DRUG$ phenothiazines , skeletal relaxants respiratory and profound , or result coma or death .	DDI-effect
The incidence of clinical trials of the weekly dosage schedule greater ( 8.5 4/47 patients @DRUG$ was same day as @DRUG$ than drugs separate days , patients .	DDI-effect
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ and its metabolite have long to 16 days @DRUG$ that conversion drug to	DDI-false
When @DRUG$ is taken concurrently with oral @DRUG$, attenuation of immunization cannot be excluded.	DDI-effect
@DRUG$ : In , ketoconazole metabolism of , which can increase in plasma @DRUG$ levels prolongation of QT interval on .	DDI-false
Aspirin: Concomitant administration of @DRUG$ with @DRUG$ may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
co-administration of with such , nitroprusside milrinone IV @DRUG$ not been co-administered @DRUG$ in clinical	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In view long half-life @DRUG$ potential for drug interactions not only medication administered after	DDI-false
Patients hydantoins @DRUG$ , or @DRUG$ be activity these and , toxicity drugs .	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, tolbutamide and @DRUG$.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
@DRUG$ : cases conduction disturbance ( rarely hemodynamic ) have been observed co-administered with @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Additionally, higher than expected @DRUG$ levels have been observed when they are begun in patients already taking @DRUG$.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
specific studies been drugs are metabolized CYP3A4 ( eg calcium , , @DRUG$ quinine , amiodarone @DRUG$ , warfarin , cyclosporine , ergot , pimozide , alfentanyl , alprazolam , triazolam ) may have elevated plasma concentrations with ;	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Pyrantel (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of @DRUG$.	DDI-false
Although retinyl affected proliferation prostatic epithelium RPMI1640 @DRUG$ alone modify the mitogenic effect of @DRUG$.	DDI-false
however, it adversely affected response duration suggesting that pyridoxine should not be administered with @DRUG$ and/or @DRUG$.1	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-advise
Broad-Spectrum may the the @DRUG$ to the body the intestinal microflora .	DDI-false
Should Coadministered VIRACEPT @DRUG$ : amiodarone Antihistamines : , : derivatives Antimycobacterial agents rifampin @DRUG$ , triazolam GI motility	DDI-false
@DRUG$ excess @DRUG$ an increase the	DDI-false
Concomitant use of the @DRUG$ which Anafranil drugs that can inhibit 2D6 may require doses prescribed for either the @DRUG$ drug .	DDI-false
@DRUG$ CAUTION SHOULD BE COUMARIN @DRUG$.	DDI-false
decreased levels of anti-factor Xa and @DRUG$, decreased @DRUG$ activity;	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, @DRUG$ and 5-fluorouracil.	DDI-false
@DRUG$ In post-marketing been of both increases and @DRUG$ co-administration leading to alterations in control	DDI-false
Compounds that have been tested in man include @DRUG$, digoxin, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
The majority of studies more the following medications MTX , @DRUG$ blocking , chloroquine , , hydroxychloroquine @DRUG$ , and anakinra .	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and ranitidine.	DDI-false
patients in clinical studies or of medications with ORENCIA : , corticosteroids TNF blocking , , chloroquine , gold @DRUG$ @DRUG$ sulfasalazine , and	DDI-false
: and @DRUG$ resulted a 24 in plasma	DDI-false
A two-way interaction between @DRUG$ , phenytoin and the @DRUG$s has been suggested	DDI-int
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
following examples of that blood-glucose-lowering : corticosteroids , , diuretics , sympathomimetic agents ( e.g. @DRUG$ , terbutaline , @DRUG$ , derivatives , thyroid hormones , ( , in oral contraceptives ) .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
However some quinolones been to enhance anticoagulant of warfarin or patients or should be closely if a @DRUG$ administered concomitantly with @DRUG$ or its derivatives .	DDI-advise
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Drugs Should Be @DRUG$ : amiodarone , quinidine Antihistamines : , : ergot derivatives Antimycobacterial : @DRUG$ , GI motility agents :	DDI-false
Before this medication tell your doctor or of all and products you use , especially ( e.g. , gentamicin , ) , @DRUG$ , drugs e.g. , @DRUG$ ) ,	DDI-false
@DRUG$: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	DDI-false
Haemodynamic effects of @DRUG$ and insulin were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine.	DDI-false
Administration of of @DRUG$ had effect on the repeat of theophylline digoxin or an oral contraceptive in subjects	DDI-false
@DRUG$ @DRUG$ produces psychotomimetic effects schizophrenia symptoms .	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, @DRUG$, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
lidocaine/quinidine , @DRUG$/acetaminophen phenobarbital/valproic , quinidine/lidocaine , , and acid/phenobarbital	DDI-false
Plasma concentrations of @DRUG$ are reduced when given concurrently with @DRUG$.	DDI-mechanism
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Potentiation occurs @DRUG-DRUG$.	DDI-false
@DRUG$ concomitant DURAGESIC ( transdermal with other @DRUG$ including but limited to other sedatives , hypnotics tranquilizers ( e.g. benzodiazepines , anesthetics , skeletal muscle alcohol may cause depression , sedation or result in death .	DDI-false
reports increased @DRUG$ , @DRUG$ during with	DDI-false
clinical trials was used with , , anticoagulants oral @DRUG$ oxygen . pharmacokinetic heart failure @DRUG$ in whom with was oral clearance for n = = by % % respectively on the day of therapy by day .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
Hydrochlorothiazide In volunteers of @DRUG$ resulted in increased plasma levels of	DDI-false
Uricosuric drugs, such as probenecid and @DRUG$, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
This study that potent P450 enzyme-inducer @DRUG$ did indeed marked effect the metabolism @DRUG$ , resulting in clearance concomitantly patients with , schizoaffective disorder , disorder .	DDI-mechanism
, @DRUG$ , Didanosine , Fluoxetine , @DRUG$ , , carbamazepine , Rifabutin , Rifampin Ritanovir	DDI-false
Antidepressants ) @DRUG$ or other anticholinergic @DRUG$ concurrent use arbutamine may produce additive inotropic effects	DDI-false
@DRUG$ : The of @DRUG$   ( ) other central system depressants but to opioids , , phenothiazines , alcohol may cause profound , death	DDI-false
Cyclosporine : Because @DRUG$ produce with decreases and , renal the elimination route drugs @DRUG$ , is a interaction will lead	DDI-effect
@DRUG$ be by anticonvulsants , antihistamines , barbiturates inhibitors , @DRUG$ psychotropic medications , that	DDI-effect
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ and II Receptor Antagonists In clinical of with INSPRA 50 mg to ACE inhibitors @DRUG$ mean ( 0.09	DDI-false
( coadministered doses of erythromycin , @DRUG$ and @DRUG$ pharmacology studies adult volunteers	DDI-false
In patients taking @DRUG$ and lithium @DRUG$ toxicity may .	DDI-false
In the presence of these @DRUG$, larger doses of @DRUG$ may be required or adenosine may not be effective.	DDI-advise
Although specific have been , with that CYP3A4 eg calcium blockers , @DRUG$ , amiodarone , quinidine warfarin , tacrolimus derivatives , @DRUG$ carbamazepine fentanyl , alfentanyl , and triazolam have elevated concentrations when with ;	DDI-false
INOmax has @DRUG$ , dobutamine @DRUG$ ventilation .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Should Not Coadministered With : amiodarone quinidine Antihistamines @DRUG$ terfenadine Antimigraine ergot : @DRUG$ GI : cisapride	DDI-false
1968 higher serum concentrations @DRUG$ and after administration of @DRUG$ are not only slower renal elimination also to altered distribution in body	DDI-mechanism
Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.	DDI-effect
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, @DRUG$, Ritanovir, Saquinavir.	DDI-false
This with or depressants ( potentiate the depressant effects of , or other anticholinergic activity ( be when are used @DRUG$ and @DRUG$ ( antihistamines may and anticholinergic depressant effects ) .	DDI-false
Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Cephalosporins-Cephalosporins containing side N-methylthiotetrazole cefmenoxime @DRUG$ , @DRUG$ latamoxef ) ) cause vitamin deficiency and	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	DDI-false
These drugs the thiazides other diuretics , @DRUG$ phe-nothiazines , thyroid , , @DRUG$ , nicotinic acid , sympathomimet-ics drugs , isoniazid .	DDI-false
The following examples that blood-glucose-lowering : niacin , danazol , diuretics ( , salbutamol , ) isoniazid , derivatives thyroid hormones @DRUG$ progestogens e.g. , in oral @DRUG$ .	DDI-false
@DRUG$ and other compounds eg @DRUG$ , quinidine and ) may electrocardiographic and increase the of convulsions .	DDI-effect
Not Be With VIRACEPT : , : astemizole terfenadine : Antimycobacterial @DRUG$ , @DRUG$ GI	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$/@DRUG$	DDI-false
Particular be observed preparations there are conflicting results the of on availability @DRUG$ and @DRUG$.	DDI-false
, or other containing @DRUG$ zinc antacids @DRUG$ with within hours , the administration of norfloxacin interfere resulting lower serum and urine norfloxacin .	DDI-false
Digoxin, @DRUG$, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
drugs which may enhance the blocking action ( e. g. , aminoglycosides , , @DRUG$ , clindamycin , colistin , sodium colistimethate ) , lithium , local @DRUG$ procainamide , and	DDI-false
@DRUG$, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
between Keppra and other AEDs @DRUG$ phenobarbital , primidone ) also assessed by concentrations levetiracetam @DRUG$ during .	DDI-false
Saquinavir The combination @DRUG$ @DRUG$ and ZDV studied as triple combination in adults	DDI-false
therefore, @DRUG$ should be administered (with food) one hour after or more than two hours before @DRUG$.	DDI-advise
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon anesthetics.	DDI-advise
following are examples substances that reduce blood-glucose-lowering effect @DRUG$ , @DRUG$ diuretics , , , isoniazid derivatives , somatropin thyroid , ( oral contraceptives	DDI-false
rifampin the of this product with saquinavir an @DRUG$ regimen the of @DRUG$.	DDI-false
evaluate chemotherapy plus HAART on the clinical patients , , ( HIV-NHL , the authors compared retrospectively group with who treated the cyclophosphamide , doxorubicin , and ( CHOP ) chemotherapy regimen HAART a patients who were treated with CHOP CHOP-like regimen i.e. , , , , and prednisone with @DRUG$ @DRUG$ antiretroviral	DDI-false
Therefore , concurrent of @DRUG$ may render these @DRUG$ effective	DDI-false
@DRUG$ @DRUG$ antagonism	DDI-false
Hormonal Contraceptives , Including , Implantable Contraceptives : interaction study demonstrated co-administration of @DRUG$ average decreases @DRUG$ of 14 and 31 , respectively	DDI-false
co-administration Natrecor @DRUG$ such as , nitroprusside , @DRUG$ not been these co-administered in clinical trials .	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
At follow-up the of @DRUG$ and @DRUG$ did not demonstrate any benefit when compared with tamoxifen in patients well receptor-positive subpopulation .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
May with ( e.g. , levothyroxine iodine-containing , @DRUG$ , @DRUG$ famotidine ) and proton pump inhibitors ( , lansoprazole omeprazole	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
Ingestion of diclofenac may increase serum concentrations of @DRUG$ and methotrexate and increase @DRUG$ s nephrotoxicity.	DDI-false
No interactions been found interaction studies digoxin , @DRUG$ and	DDI-false
@DRUG$ : @DRUG$ been reported to produce clinically significant fluctuations in various antidepressants .	DDI-false
@DRUG$ : It has established a pharmacokinetic between @DRUG$ and combined .	DDI-false
: Flupenthixol interact some drugs , oxidase inhibitors ( MAOI @DRUG$ could flupenthixol pharmacodynamics Ethanol Tricyclic antidepressants @DRUG$ increases the effect of Tricyclic	DDI-false
@DRUG$ with @DRUG$ or possibly striking and sustained in the concentration of in the	DDI-mechanism
Hypotension    Patients @DRUG$ Patients on especially those in whom @DRUG$ recently instituted those on dietary salt or , occasionally a precipitous of within the hour after dose of .	DDI-false
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ , quinidine , @DRUG$ , were to at therapeutic	DDI-false
plasma @DRUG$ have with concomitant @DRUG$	DDI-mechanism
In clinical performed , concomitant oral anticoagulants ) , ( ) , ( piroxicam ) @DRUG$ did significantly affect the pharmacokinetics/pharmacodynamics @DRUG$.	DDI-false
@DRUG$ and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	DDI-false
Central Depressants The concomitant DURAGESIC ( fentanyl ) @DRUG$ but to , , tranquilizers , general skeletal muscle relaxants @DRUG$ may cause profound or result or death .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, @DRUG$.	DDI-false
mg/kg ) , 18-MC ( ) decreases the intravenous of morphine @DRUG$ and the oral self-administration of @DRUG$ and in rats	DDI-false
Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
addition , of medicinal products such beta-blockers , clonidine , @DRUG$ , @DRUG$ , of hypoglycemia or .	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
While in vivo drug-drug interaction were between inducers of CYP3A are CYP3A ( as @DRUG$ and barbiturates ) be expected @DRUG$	DDI-false
there no significant prothrombin the trials @DRUG$ and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.	DDI-false
Drugs Require a When With @DRUG$ : @DRUG$	DDI-advise
@DRUG$ eliminated by of @DRUG$ drugs reduce function or compete active secretion increase serum concentrations either or the coadministered .	DDI-false
pharmacokinetic were assessed in studies ( @DRUG$ , @DRUG$ , , digoxin , warfarin ) and through pharmacokinetic screening the epilepsy	DDI-false
Corticosteroids Methylxanthines @DRUG$ : Concomitant xanthine derivatives , steroids , diuretics may potentiate a possible effect of @DRUG$	DDI-false
drugs may the neuromuscular blocking of agents such NUROMAX include certain e. aminoglycosides , tetracyclines lincomycin clindamycin @DRUG$ , sodium colistimethate ) @DRUG$ salts , .	DDI-false
Patients who begin @DRUG$ who increase @DRUG$ dose any other digoxin methotrexate , or cyclosporine may toxicity	DDI-false
that may alter @DRUG$ that may concentrations : is administering @DRUG$ with CYP3A4 family e.g. itraconazole erythromycin clarithromycin	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or @DRUG$.	DDI-false
, phenobarbital/valproic acid , theophylline/acetaminophen and @DRUG$/phenobarbital .	DDI-false
@DRUG$ @DRUG$ concentrations are by about 15 concomitantly .	DDI-false
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of @DRUG$ on the availability of @DRUG$ and digitoxin.	DDI-mechanism
concomitant Although interaction studies doses mg or more used clinical with acetaminophen acetylsalicylic a-blockers , analgesics angiotensin-converting ( ACE inhibitors , , benzodiazepines beta blockers , blockers , diuretics , H2 antagonists , @DRUG$ inhibitors as @DRUG$ ) , and quinolone significant adverse interactions .	DDI-false
@DRUG$ : Concomitant with @DRUG$ may result in of ulceration compared to valdecoxib alone .	DDI-false
Central System use of   ( fentanyl transdermal ) other central system , including but to , sedatives , hypnotics , ( e.g. benzodiazepines , anesthetics , @DRUG$ muscle relaxants and @DRUG$ may cause respiratory hypotension and , in death .	DDI-false
administration of other @DRUG$ @DRUG$ has shown antihypertensive in some and result in severe hyperkalemia in patients renal	DDI-effect
or drug-drug not between and concomitantly @DRUG$ orally given and of Argatroban g/kg/min . 4 hours acetaminophen ( 1000 orally given 12 , prior , of 1.5 over 18	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
@DRUG$   ( 1500 twice ) not alter the of @DRUG$ in volunteers .	DDI-false
@DRUG$ : antiarrhythmic drugs such quinidine procainamide , and @DRUG$ , concurrently amiodarone	DDI-false
Presumably, phenytoin acts as a stimulator of @DRUG$ metabolism and has been reported to cause decreased serum levels of the @DRUG$ and increased prothrombin-proconvertin concentrations.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
and/or @DRUG$-containing @DRUG$ , ferrous sulfate ( iron ) containing zinc metal cations ( didanosine ) chewable/buffered tablets pediatric for be taken within hours hours after	DDI-false
Theophylline The pharmacokinetics @DRUG$ ( mg/kg 20 ) unchanged following a of @DRUG$ 400 mg 6 healthy subjects .	DDI-false
5HT3 profound hypotension and of when administered ondansetron @DRUG$ with of the 5HT3 class example , , , @DRUG$ , ) contraindicated .	DDI-advise
Similarly dialyzed were @DRUG$, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$ injection other injectable benzodiazepines , of central when with ethyl alcohol , , MAO inhibitors and antidepressants When @DRUG$ is used concomitantly injectable incidence of , hallucinations , and behavior	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
: of young male evidence of pharmacokinetic @DRUG$-@DRUG$ interaction could found .	DDI-false
@DRUG$ Nimodipine and Losartan : Bosentan pharmacokinetic with , @DRUG$ on plasma .	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	DDI-false
@DRUG$ A 10 of tiagabine did not the @DRUG$ at .	DDI-false
Beta-Blocking Agents   pharmacokinetic of @DRUG$ in with @DRUG$ demonstrated no the of .	DDI-false
Rhabdomyolysis been observed in @DRUG$ recommended dosages concomitantly @DRUG$ including cyclosporine	DDI-effect
and @DRUG$ have opioid and possibly receptors , has lower @DRUG$ , channels , transporter .	DDI-false
Other concomitant therapy Although specific interaction were not performed , more were concomitantly used in clinical with , acetylsalicylic a-blockers , enzyme ACE , anticonvulsants , benzodiazepines , blockers , @DRUG$ , , @DRUG$ , HMG-CoA prostaglandin synthetase inhibitors also referred NSAIDs and quinolone anti-infectives without of adverse interactions	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Other agents @DRUG$ , @DRUG$ , pentamidine may enhance the for renal toxicity and with .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Urinary ( @DRUG$ , thiazides increase of the the @DRUG$ thereby decreasing urinary	DDI-mechanism
Hepatic , Inhibitors Substrates : Drugs which cytochrome P450 ( CYP ) activity , , phenytoin carbamazepine , may enhance the metabolism of @DRUG$ and that the @DRUG$	DDI-false
Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
this , doctor all prescription and products you , aminoglycosides gentamicin , amikacin amphotericin B @DRUG$ drugs e.g. , ) , tacrolimus , @DRUG$.	DDI-false
@DRUG$ nandrolone [ e.g. , e.g. Anavar oxymetholone , , stanozolol [ e.g. @DRUG$ ] )	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-mechanism
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
@DRUG$ : @DRUG$ erythromycins or may interfere with .	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Digoxin Nimodipine significant pharmacokinetic interactions with @DRUG$ and @DRUG$ and losartan has no significant effect on levels .	DDI-false
@DRUG$ @DRUG$ protein binding	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (@DRUG$/SMX).	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
is of drug such as @DRUG$ or @DRUG$ , of a daily of 70 mg of CANCIDAS should	DDI-false
Drugs increase @DRUG$ Caution administering with of ( e.g. ketoconazole , @DRUG$ , erythromycin , clarithromycin )	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Digoxin, @DRUG$, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
@DRUG$ administered tolazoline dopamine , steroids @DRUG$ and ventilation .	DDI-false
@DRUG$ , , flecainide @DRUG$ to potential life-threatening	DDI-false
The effectiveness pills is reduced by as the @DRUG$ phenytoin antituberculosis @DRUG$.	DDI-false
The are examples known inhibit of benzodiazepines through inhibition CYP3A : @DRUG$ , diltiazem @DRUG$ , and	DDI-false
Tagamet apparently through an effect on certain systems , been reduce hepatic metabolism , @DRUG$ , propranolol chlordiazepoxide , certain tricyclic , theophylline @DRUG$ elimination and levels	DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	DDI-advise
inhibitors include azole antifungals , @DRUG$ clarithromycin , diclofenac , , @DRUG$ isoniazid , , , protease verapamil	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
@DRUG$ has been to be @DRUG$ , based vitro and kill enteric bacilli	DDI-effect
Nephrotoxic agents administration of VISTIDE and agents with nephrotoxic [ @DRUG$ ( tobramycin , gentamicin ) , foscarnet intravenous @DRUG$ , and non-steroidal agents ] is contraindicated .	DDI-false
Because prostaglandins an role hemostasis , function , with all NSAIDs including @DRUG$ and requires patients be change their @DRUG$ is required	DDI-false
Concomitant @DRUG$ , , vincristine @DRUG$ plus therapy patients immunodeficiency , non-Hodgkin lymphoma	DDI-false
Therefore , if @DRUG$ is administered , be the in @DRUG$ levels .	DDI-false
In vitro indicate that fluconazole @DRUG$ , oral the metabolism of cisapride , which an @DRUG$ prolongation of the on the ECG .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In studies that @DRUG$ not inhibit digoxin or vinblastine that @DRUG$ not a for transport	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-false
( , , triamterene @DRUG$ or salt substitutes may to significant increases serum potassium	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Patients receiving narcotic general anesthetics tranquilizers sedative-hypnotics , @DRUG$ other CNS ) @DRUG$ may CNS depression	DDI-effect
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
These increased exposures of @DRUG$ and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking @DRUG$.	DDI-false
The effects of adenosine as @DRUG$ @DRUG$.	DDI-false
@DRUG$ e.g. , - piperazine and together may the effects	DDI-false
@DRUG$ : delay intestinal @DRUG$	DDI-false
Nephrotoxic : of VISTIDE agents with potential [ e.g. intravenous ( e.g. , , gentamicin , @DRUG$ , @DRUG$ , , and agents is contraindicated .	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
pharmacokinetics of naltrexone and metabolite @DRUG$ unaffected following with @DRUG$.	DDI-false
receiving high doses @DRUG$ with , as rheumatic disease may @DRUG$ toxicity at lower because of competitive renal excretory	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
of agents in the @DRUG$ @DRUG$ inhibit cytochrome P450 lower than usually for tricyclic antidepressant agent other drug	DDI-false
Therefore following administration of psychotropic drugs ( , analgesics , @DRUG$ , @DRUG$ ) .	DDI-false
therapy includes antibiotics such @DRUG$ @DRUG$	DDI-false
@DRUG$ @DRUG$ CONTRAINDICATED for serious .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
, other containing @DRUG$ administered with , or within 2 the of @DRUG$ , because they may interfere absorption in serum and urine levels of norfloxacin .	DDI-advise
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Drug Interactions : interact with some Monoamine oxidase MAOI @DRUG$ @DRUG$ pharmacodynamics - Eproxindine - Ethanol : Flupenthixol CNS antidepressants : increases the antidepressants	DDI-effect
Influence of @DRUG$ on @DRUG$ Concentration (Mean change, 90% Confidence Interval)	DDI-false
Cyclosporine can nephrotoxicity decreases in creatinine rises because renal the route @DRUG$ including @DRUG$ , there is risk that an interaction will to deterioration	DDI-false
@DRUG$ SSRIs SSRIs e.g. , fluoxetine , , paroxetine sertraline have to weakness , incoordination coadministered with @DRUG$.	DDI-false
Antiarrhythmics Other @DRUG$ drugs as @DRUG$ procainamide , disopyramide phenytoin , amiodarone .	DDI-false
patients the administration of @DRUG$ diuretic , natriuretic , and antihypertensive @DRUG$.	DDI-effect
a patients with were treated for 24 weeks with concurrent @DRUG$   @DRUG$ a 7 % rate of observed , which than   alone ( % .	DDI-effect
Urinary alkalinizing agents (@DRUG$, some thiazides) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	DDI-mechanism
@DRUG$: Potential interactions between @DRUG$ and other AEDs were assessed in clinical studies.	DDI-false
clinical , FLOLAN used with digoxin diuretics , oral vasodilators , pharmacokinetic congestive furosemide digoxin in with FLOLAN initiated , values @DRUG$ ( = 23 ) digoxin n 30 ) were decreased by 15 % respectively second therapy to baseline by day .	DDI-false
@DRUG$ , ampicillin , , chlortetracycline @DRUG$ , sulfamethoxazole no influence on the of diclofenac in serum	DDI-false
The @DRUG$ dopamine @DRUG$ by Bretylium Tosylate	DDI-false
: Amiodarone @DRUG$ , @DRUG$ for life-threatening	DDI-false
@DRUG$ interferes renal tubular secretion of ciprofloxacin increase the level of @DRUG$ .	DDI-false
Drugs that have been associated with peripheral antiretroviral @DRUG$ , cisplatin dapsone , ethionamide glutethimide , hydralazine , , isoniazid @DRUG$ nitrofurantoin , ribavirin ,	DDI-false
@DRUG$ Absorption of @DRUG$ moderately 25 when magnesium/aluminum-containing products	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, @DRUG$ or some antihistamines.	DDI-false
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-false
@DRUG$ the - 12 of tacrolimus by % ( ) by 16 % 12-hour blood concentration ( C12hr by 26 % in subjects @DRUG$ ( doses administered on the 10th of CANCIDAS mg , as compared period which tacrolimus was alone .	DDI-false
addition there been cases use of @DRUG$ @DRUG$ followed enlargement and congestive heart	DDI-effect
High-dose @DRUG$ resulting in ng/mL administered with oral etoposide to % increase in with 38 % decrease in to @DRUG$ alone	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or lamotrigine.	DDI-false
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Fondaparinux the concomitant use anticoagulants @DRUG$ platelet ( acetylsalicylic acid NSAIDs ( piroxicam digoxin not significantly affect of	DDI-false
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-false
Drug have shown that does not any significant with @DRUG$ warfarin quinidine	DDI-false
of @DRUG$ were affected by multiple-dose administration @DRUG$.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when @DRUG$, @DRUG$, or azoles were administered concomitantly.	DDI-false
drugs include thiazides and other diuretics , @DRUG$ @DRUG$ thyroid products , , acid , sympathomimetics channel and	DDI-false
Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	DDI-mechanism
Interaction Other Drugs : @DRUG$ : cimetidine ( 800 mg/day ) to patients chronically had effect on @DRUG$ .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
In study in which mg clonazepam orally tablet and without @DRUG$ an @DRUG$ with effects the tract to volunteers AUC was % lower was % when orally was propantheline compared alone .	DDI-false
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, tacrine, and @DRUG$).	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
@DRUG$ , Including Oral Injectable Implantable @DRUG$ demonstrated of bosentan and oral hormonal Ortho-Novum average levels of 14 % 31 % , respectively .	DDI-false
@DRUG$ with than 40 mg QD @DRUG$ has been	DDI-false
@DRUG$ : principal pathway for detoxification of @DRUG$ is inhibited	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
results that hepatoxicity @DRUG$ in alcoholic beverages is enhanced with congeners and @DRUG$	DDI-effect
Cytochrome P-450 phenytoin @DRUG$ and @DRUG$ , induce metabolism , causing an 30 % decrease in plasma .	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ that protects against renal damage.	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	DDI-false
Coadministration and an AUC for @DRUG$ and @DRUG$ 30 20 % .	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for @DRUG$.	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
The during with this class increased concurrent administration cyclosporine , fibric acid derivatives , @DRUG$ ( nicotinic acid , @DRUG$ , antifungals .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, @DRUG$, ribavirin, and vincristine.	DDI-false
While all the reuptake ) @DRUG$ escitalopram @DRUG$ sertraline , P450 vary in	DDI-false
Amprenavir the at steady ( ) @DRUG$ 2.93-fold ) of @DRUG$ 13.3-fold .	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Agonist/Antagonist analgesics eg , @DRUG$ nalbuphine , , @DRUG$ and ) be administered to a patient who received or course of therapy with opioid such .	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite @DRUG$) may be increased when paclitaxel and doxorubicin are used in combination.	DDI-false
@DRUG$ : @DRUG$ is reported to weak inhibitor oxidase in liver , but inhibitory in liver are	DDI-false
Clinical studies with @DRUG$ have identified potentially significant interactions with @DRUG$ and lithium.	DDI-int
Compounds that have been tested in man include @DRUG$, digoxin, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	DDI-false
Clidinium decrease effect of phenothiazines @DRUG$ @DRUG$.	DDI-false
Primary secondary @DRUG$ deficiencies indication of @DRUG$ therapy .	DDI-false
similarity of the adverse profile without @DRUG$ and ( with @DRUG$ that this alteration does necessitate   maintain , General .	DDI-false
An interaction study with warfarin showed no clinically significant effect of @DRUG$ on @DRUG$ pharmacokinetics or anticoagulant activity.	DDI-false
@DRUG$: Amiodarone, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Tetracyclines: Concomitant treatment with @DRUG$ and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-advise
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	DDI-mechanism
: profound hypotension and loss of consciousness when apomorphine was with ondansetron , the of apomorphine of antagonist class ( including for example , dolasetron @DRUG$ , @DRUG$ )	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
following examples of that may the effect to : oral antidiabetic ACE , disopyramide , @DRUG$ @DRUG$ propoxyphene , salicylates , analog ( ) , antibiotics .	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Oral Valdecoxib ( mg ) did of the contraceptive ( 1 mg /35 mcg , @DRUG$ .	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
enhance of nondepolarizing agents as certain e. g. aminoglycosides , tetracyclines , , polymyxins , @DRUG$ , sodium ) salts , , local @DRUG$ procainamide , and quinidine .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
These drugs include , @DRUG$ , , estrogens oral @DRUG$ , sympathomimetics , channel blocking drugs , and isoniazid .	DDI-false
Additional reductions pressure diuretics , @DRUG$ , other @DRUG$.	DDI-false
Probenecid : As with other b-lactam antibiotics , renal of @DRUG$ is inhibited by probenecid resulted an increase the AUC @DRUG$.	DDI-false
If intravenous @DRUG$ treat carinii pneumonia treatment @DRUG$ interrupted	DDI-advise
Hormonal Co-administration of with @DRUG$ shown to influence the two components , ethinylestradiol EE ) and @DRUG$ ( )	DDI-false
plasma of closely related been to increased by administration of or ( e.g. , cimetidine , and by concomitant administration of hepatic enzyme e.g. , @DRUG$ , @DRUG$ ) , effect with CMI	DDI-false
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
The following examples of that may blood-glucose-lowering effect : corticosteroids , , danazol sympathomimetic agents , epinephrine , @DRUG$ ) @DRUG$ , , hormones progestogens contraceptives	DDI-false
Other Drugs : In groups ( 7 - study the concomitant administration , @DRUG$ D-penicillamine , prednisolone , affect the levels AUC of @DRUG$.	DDI-false
In clinical trials was used with , , anticoagulants , oral @DRUG$ , and . pharmacokinetic in with heart @DRUG$ whom with FLOLAN initiated , clearance values for furosemide ( 23 and digoxin ) by 13 % 15 % respectively , on second therapy returned to baseline 87	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
, @DRUG$ the pharmacodynamics of warfarin @DRUG$ , piroxicam nor pharmacokinetics digoxin state .	DDI-false
action of the @DRUG$ potentiated antihistamines , @DRUG$ , barbiturates , oxidase , psychotropic drugs	DDI-effect
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
of @DRUG$ Drugs : Cimetidine : ) to chronically had effect on @DRUG$ .	DDI-false
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with @DRUG$.	DDI-false
of @DRUG$ , known may associated with decrease in the half-life of	DDI-mechanism
Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
@DRUG$ toxicity may aggravated initial of caused by @DRUG$ Injection	DDI-effect
administration of other related ( eg , @DRUG$ @DRUG$ electrocardiographic abnormalities increase the of	DDI-false
is concluded that @DRUG$ methaqualone be safely without additional in prothrombin test during oral @DRUG$	DDI-false
@DRUG$: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Although these results indicate significant interaction between TORADOL and or @DRUG$ , TORADOL to taking @DRUG$ be done , and patients should closely	DDI-false
Drugs That Should Be Coadministered Antiarrhythmics : amiodarone astemizole terfenadine Antimigraine @DRUG$ agents rifampin Benzodiazepines @DRUG$ , triazolam agents :	DDI-false
studies have these with sevoflurane @DRUG$ , , and	DDI-false
of saquinavir using an experimental soft-gelatin capsule formulation saquinavir mg with @DRUG$ in % increase in plasma and increase @DRUG$ plasma	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, @DRUG$).	DDI-false
medication tell doctor or of all products you may , ( , @DRUG$ , ) B @DRUG$ , ( e.g. ) , .	DDI-false
BACKGROUND of combined administration @DRUG$ ( @DRUG$ ) a calcium channel blocker , the intestinal by ( AOM ) and the labeling index of intestinal cancers investigated Wistar	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
with Agonist/Antagonist : Agonist/antagonist eg @DRUG$ dezocine buprenorphine a patient who received or is a of with a @DRUG$ such as	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
@DRUG$: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
Drug : Flupenthixol interact with drugs like Monoamine MAOI ): @DRUG$ could flupenthixol @DRUG$ - - : Ethanol cause Tricyclic antidepressants : increases effect Tricyclic antidepressants	DDI-false
of potent @DRUG$ regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related have led significant shifts in treatment practices in .	DDI-false
following are that may reduce the blood-glucose-lowering effect @DRUG$ niacin , danazol , agents ( , ) , somatropin hormones , estrogens , @DRUG$ oral contraceptives ) .	DDI-false
Antiacid clarithromycin , @DRUG$ , Fluconazole , , Ketoconazole , , , , @DRUG$ ,	DDI-false
May : @DRUG$ use with the @DRUG$	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
The pharmacokinetics of @DRUG$ were not affected by coadministration of nifedipine or @DRUG$	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Coadministration with @DRUG$ (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, @DRUG$ is a weak inhibitor of 2D6.	DDI-false
Although specific studies not been coadministration with drugs that mainly by CYP3A4 eg blockers , , , quinidine , warfarin , @DRUG$ , cyclosporine , @DRUG$ pimozide carbamazepine , , alfentanyl alprazolam and may have elevated when coadministered saquinavir	DDI-false
simultaneous @DRUG$ 10 and @DRUG$ mg , experienced of less 85 Hg	DDI-effect
Drugs Should Coadministered : , quinidine Antihistamines astemizole , Antimigraine : @DRUG$ Antimycobacterial Benzodiazepines , triazolam GI motility : @DRUG$	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
@DRUG$ retinyl affected the RPMI1640 transferrin alone , they the mitogenic effect of @DRUG$ and	DDI-effect
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving @DRUG$.	DDI-false
@DRUG$ In a pharmacology study an ( , magnesium and ) reduced serum urinary excretion of @DRUG$ as alone , suggesting that may impair absorption fosinopril	DDI-false
@DRUG$ of conduction rarely with ) have observed @DRUG$ co-administered diltiazem .	DDI-false
Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and @DRUG$ did not influence abatacept clearance.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	DDI-false
Chemotherapy In a study , administration of @DRUG$ with @DRUG$ did meaningfully the pharmacokinetics of ( or the .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ administration to over a of 0.025 to 2.2 mg led dose-dependent @DRUG$ elimination.14 alternate-day of 0.25 mg of drug is	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
: Plasma @DRUG$ decreased when @DRUG$ .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Compounds tested in man include @DRUG$, theophylline, @DRUG$, diazepam, aminopyrine and antipyrine.	DDI-false
Patients already stabilized on @DRUG$ should be closely monitored for loss of symptom control with @DRUG$ coadministration.	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
action of benzodiazepines be potentiated by @DRUG$ barbiturates @DRUG$ narcotics , phenothiazines , psychotropic or other CNS .	DDI-false
Other drugs which the blocking action nondepolarizing agents as NUROMAX ( , aminoglycosides , , @DRUG$ , clindamycin , , and sodium colistimethate salts , @DRUG$ , procainamide , and .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
that have associated with neuropathy include , cisplatin , , ethionamide @DRUG$ , hydralazine , iodoquinol , metronidazole nitrofurantoin , phenytoin @DRUG$ , and vincristine .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
The patients in RA clinical received one of following with ORENCIA , NSAIDs corticosteroids , @DRUG$ , gold , @DRUG$ sulfasalazine , and anakinra	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Patients receiving azathioprine and @DRUG$ concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	DDI-false
bradycardia oral @DRUG$ in combination lidocaine @DRUG$ ) for local anesthesia	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
patients in RA studies received one or more following concomitant medications with ORENCIA : @DRUG$ , @DRUG$ , corticosteroids , TNF , azathioprine , gold , leflunomide sulfasalazine , and	DDI-false
appears to be clinically relevant interaction @DRUG$ although , coadministration of drugs to cardiac conduction eg @DRUG$ or beta-adrenergic , channel blockers , antihistamines or H1-blocking agents and phenothiazines ) contribute to a QTc interval	DDI-effect
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
Saquinavir: The combination of HIVID, @DRUG$, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
has with @DRUG$ @DRUG$ evidence clinically .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (@DRUG$) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.	DDI-false
specific studies have been drugs mainly metabolized by CYP3A4 calcium , @DRUG$ , , @DRUG$ quinidine warfarin , , , ergot , fentanyl , alprazolam , and may elevated plasma concentrations when with saquinavir ;	DDI-false
No To important pharmacokinetic , digoxin isosorbide , @DRUG$ , @DRUG$.	DDI-false
@DRUG$ and Tricyclic Antidepressants @DRUG$ extreme in being with oxidase the action of formoterol the system may be potentiated	DDI-false
of is the @DRUG$ may be necessary when @DRUG$ is concomitantly .	DDI-advise
of VISTIDE agents with [ e.g. , aminoglycosides ( e.g. , tobramycin @DRUG$ , and , @DRUG$ , vancomycin non-steroidal agents ] is contraindicated	DDI-false
Expected in of PT INR were after @DRUG$ administration but these not affected @DRUG$ administration	DDI-false
Plasma @DRUG$ should be monitored when @DRUG$ valproate co administered and valproate should made .	DDI-false
Oral neomycin inhibits the , @DRUG$ , methotrexate @DRUG$.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
elevation in antagonists such as @DRUG$ or plasma @DRUG$ and therefore potentially may	DDI-mechanism
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
Since @DRUG$ , @DRUG$ associated serum levels the potential effects on potassium kinetics and function be these agents administered .	DDI-false
Concomitant of mg @DRUG$ @DRUG$ 40 daily for 10 days has shown to increase the Cmax and for by 36 % ( 69 decrease to % range from 54 % to , respectively , and for ( range from decrease to 314 increase ) and % range from % decrease % ) respectively in healthy .	DDI-mechanism
include the thiazides and other @DRUG$ , corticosteroids phe-nothiazines , products , @DRUG$ , acid , blocking , and .	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
A of @DRUG$/@DRUG$ to 533/133 mg daily with combination	DDI-false
@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.	DDI-false
Aspirin Concomitant of diclofenac and @DRUG$ is @DRUG$ from its concomitant administration aspirin , resulting in lower plasma , .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and @DRUG$.	DDI-false
Antihypertensives : Amiodarone be used caution patients agents inhibitor ) or calcium channel e.g. verapamil a CYP3A4 , @DRUG$ a CYP3A4 of of bradycardia , , and block ;	DDI-false
, products containing ferrous ( iron containing @DRUG$ Videx ( @DRUG$ ) chewable/buffered or pediatric powder for oral solution should be taken within 3 hours before 2 hours FACTIVE	DDI-false
Administration repeat doses had on the repeat dose pharmacokinetics of @DRUG$ , @DRUG$ or an contraceptive subjects .	DDI-false
In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 @DRUG$ -treated subjects received concomitant theophylline at study entry.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
@DRUG$: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	DDI-false
and Norethindrone : Coadministration @DRUG$ @DRUG$ in 47 decrease and an decrease norethindrone plasma .	DDI-mechanism
However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	DDI-effect
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
may formation of @DRUG$ , a metabolite @DRUG$ associated with .	DDI-false
Inducers and Inhibitors of Hepatic Metabolism: @DRUG$ reduced plasma concentrations of @DRUG$ by about 70%.	DDI-mechanism
, through an effect certain microsomal systems , has reported to reduce hepatic metabolism of , phenytoin , @DRUG$ , @DRUG$ , , lidocaine theophylline metronidazole , delaying elimination and of these drugs .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (@DRUG$/ARB).	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
subjects received ( 1,200 a days by a washout either @DRUG$ once a QD ] ( cohort @DRUG$ 600 QD cohort for .	DDI-false
Other Although specific studies not , of were clinical @DRUG$ , a-blockers , analgesics , inhibitors , , , blockers , @DRUG$ , cardiac nitrates , diuretics , antagonists , inhibitors , inhibitors , and quinolone anti-infectives without significant adverse .	DDI-false
- Lithium: @DRUG$ should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
- dapsone hydroxylamine ( @DRUG$ ) was than in the presence	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
doses of either cholestyramine @DRUG$ resins the @DRUG$ and reduce absorption the gastrointestinal up 85 43 percent respectively	DDI-mechanism
Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or @DRUG$.	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, @DRUG$, corticosteroids, and TNF blocking agents did not influence abatacept clearance.	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
@DRUG$ and colestipol : Absorption of @DRUG$ is impaired in the presence anionic .	DDI-false
Drugs have been associated peripheral neuropathy include nucleoside , chloramphenicol , cisplatin , dapsone disulfiram glutethimide , @DRUG$ hydralazine iodoquinol , @DRUG$ metronidazole phenytoin .	DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
These drugs include the thiazides diuretics , , phe-nothiazines products , estrogens , @DRUG$ @DRUG$ , , channel and isoniazid .	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
that been peripheral neuropathy nucleoside , dapsone , disulfiram , @DRUG$ , , iodoquinol , isoniazid , , @DRUG$ , .	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, cimetidine and phenobarbital.	DDI-false
Dopamine-induced and is by	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
intensity uniformity and course of anticoagulant secobarbital , , chloral hydrate and @DRUG$ were systematically in @DRUG$	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Coadministration of @DRUG$ and cyclosporine, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
hydrochloride has additive effects with @DRUG$ and CNS depressants @DRUG$ , ,	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
It is concluded that @DRUG$ and @DRUG$ be administered safely caution prothrombin monitoring .	DDI-false
Antiarrhythmic agents, class I (such as flecainide, lidocaine, or @DRUG$): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
@DRUG$ reduced the of @DRUG$ by approximately % , concentration ( ) 16 % 12-hour ) by 26 % subjects tacrolimus 2 of 0.1 mg/kg 12 apart was administered the 10th day of CANCIDAS 70 daily , a in which was administered alone	DDI-mechanism
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
Drug @DRUG$ like @DRUG$ ( MAOI theoretically affect pharmacodynamics - : and Ethanol depression antidepressants increases the of Tricyclic	DDI-int
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., @DRUG$, @DRUG$).	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$ CYP450 , including CYP2C9 and	DDI-false
, or or @DRUG$ within of , administration , they interfere absorption lower serum urine levels of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Warfarin: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
However, patients on @DRUG$ may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.	DDI-false
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	DDI-effect
has administered @DRUG$ @DRUG$ dobutamine , steroids surfactant , high-frequency .	DDI-false
@DRUG$ In some with renal function are being @DRUG$ the co-administration of may a further deterioration .	DDI-false
following examples of the blood-glucose-lowering effect and susceptibility to hypoglycemia oral inhibitors fibrates , @DRUG$ , ( MAO ) inhibitors , , salicylates , somatostatin analog ( e.g. @DRUG$ , sulfonamide antibiotics	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The possibility hypotensive effects or enalaprilat can minimized the @DRUG$ or increasing prior treatment @DRUG$ or enalaprilat	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
a comparison with @DRUG$ , Innovar @DRUG$ dosage of ouabain needed tachycardia significantly , as the LD50 ketamine or than	DDI-false
However of aspirin with @DRUG$ in increased , use @DRUG$ alone	DDI-false
@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-false
Haloperidol reduced or eliminated the increases FI produced intermediate doses of @DRUG$ or PCP in did not antagonize in FI FR produced high doses PCP or either stereoisomer	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ @DRUG$ are inhibited amphetamines .	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
THERAPY studies were performed in , sodium was used converting enzyme ) inhibitors betablockers , @DRUG$ , @DRUG$ , and nonsteroidal drugs ( ) evidence clinically significant adverse	DDI-false
general , drugs that have or pharmacologic activities @DRUG$ including anti-arrhythmic such as procainamide @DRUG$.	DDI-false
Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Therefore, @DRUG$ should be taken at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption .	DDI-advise
: , @DRUG$ @DRUG$ , quinidine CONTRAINDICATED due potential for and/or reactions .	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-false
Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and theophylline.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
have not been performed , drugs that mainly CYP3A4 ( calcium blockers , @DRUG$ amiodarone , quinidine tacrolimus @DRUG$ ergot derivatives , , , alfentanyl and triazolam have elevated plasma coadministered ;	DDI-false
If inhibitors ( , @DRUG$ @DRUG$ erythromycin , etc . is reduction of budesonide be	DDI-false
Effect Clonazepam the of Drugs @DRUG$ does appear the pharmacokinetics of @DRUG$ carbamazepine , or	DDI-false
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and @DRUG$ may occur.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ @DRUG$ of is in the of resins	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Therefore, in patients taking @DRUG$ or oral @DRUG$, regular monitoring of blood glucose is recommended.	DDI-false
include azole ciprofloxacin clarithromycin , diclofenac , erythromycin , @DRUG$ , , nefazodone , , @DRUG$ protease inhibitors quinidine .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
effects of @DRUG$ L-CCG-1 (@DRUG$)-induced behavioral in .	DDI-false
of other @DRUG$ @DRUG$ Tiagabine had plasma concentrations phenytoin in with epilepsy .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
@DRUG$ (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Patients receiving @DRUG$ and allopurinol concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	DDI-false
Ethopropazine may interact with @DRUG$ or other @DRUG$, causing increased sedative effects.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, cimetidine and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	DDI-mechanism
majority of patients in RA clinical one or more of following medications MTX , , @DRUG$ , azathioprine @DRUG$ , gold , hydroxychloroquine sulfasalazine , and	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin.	DDI-false
poor debrisoquin : Interactions @DRUG$ strong of CYP2D6 ( as quinidine fluoxetine paroxetine and @DRUG$ not been studied would R(+ ) enantiomer carvedilol .	DDI-false
Other reported interactions with amiodarone: @DRUG$ (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Cation-Containing Products : of , including multivalent cation-containing products as magnesium or @DRUG$ chewable/buffered or pediatric powder , or products @DRUG$ , iron zinc may substantially decrease the absorption ciprofloxacin resulting serum and levels lower	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and ranitidine.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
reactions patients high dose @DRUG$ and antineoplastic , specifically @DRUG$ , and interferon-alfa	DDI-effect
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	DDI-false
using medication your doctor pharmacist of and nonprescription products you of : @DRUG$ gentamicin , amikacin amphotericin , drugs ( e.g. @DRUG$ ) , tacrolimus , .	DDI-false
drugs thiazides @DRUG$ corticosteroids , , thyroid , phenytoin , , @DRUG$ , channel blocking ,	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
As @DRUG$ , predominant plasma only inducer it unlikely to have an effect mainly transferase ( @DRUG$ ,	DDI-false
Additive adverse effects resulting from blockade is concomitantly with other @DRUG$ amantadine , , phenothiazines , monoamine ( MAO inhibitors , tricyclic antidepressants some @DRUG$.	DDI-false
@DRUG$/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
@DRUG$: As with other @DRUG$, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
It is recommended not to exceed a single 2.5 mg @DRUG$ dose in a 24-hour period when used in combination with @DRUG$.	DDI-advise
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-false
Short-term studies demonstrated that @DRUG$ @DRUG$   ( ) in of warfarin , no the clearance free .	DDI-mechanism
, ampicillin , oxacillin , @DRUG$ , @DRUG$ erythromycin have no in on the in human .	DDI-false
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the @DRUG$ effect by flumazenil.	DDI-false
@DRUG$ resins of hydrochlorothiazide is impaired presence @DRUG$.	DDI-false
, @DRUG$ not in glucuronidation of	DDI-false
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
@DRUG$-Broad-spectrum antibiotics sterilize the bowel and decrease the @DRUG$ by .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-mechanism
: and/or in vivo , @DRUG$ , and markedly of @DRUG$ , which result in plasma cisapride levels and QT interval .	DDI-mechanism
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and alcohol.	DDI-effect
@DRUG$ Potentiation of warfarin-type ( and @DRUG$ substrate ) anticoagulant response is almost patients receiving in bleeding .	DDI-false
@DRUG$ metabolism of are by ( , cerivastatin , @DRUG$	DDI-mechanism
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring @DRUG$, angioedema, or generalized urticaria require immediate discontinuation of @DRUG$ and aggressive symptomatic therapy.	DDI-false
In a of anesthetized , Innovar , of @DRUG$ needed to ventricular significantly , LD50 ouabain @DRUG$ or Innovar with	DDI-false
@DRUG$ Ortho-Novum exposure @DRUG$ ethinyl % and .	DDI-false
enhance neuromuscular blocking of nondepolarizing such NUROMAX antibiotics ( , bacitracin @DRUG$ , lincomycin clindamycin sodium colistimethate ) , magnesium salts , lithium , local @DRUG$ quinidine .	DDI-false
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of @DRUG$ should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), @DRUG$, vancomycin.	DDI-false
Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
The are of substances blood-glucose-lowering effect to @DRUG$ @DRUG$ , fibrates monoamine oxidase ( MAO inhibitors , analog e.g. ) sulfonamide antibiotics	DDI-false
The that may effect : , danazol , @DRUG$ ( e.g. , salbutamol , , isoniazid , phenothiazine , hormones , e.g. , in @DRUG$ )	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other drugs enhance the blocking action nondepolarizing such as @DRUG$ e. g. tetracyclines bacitracin polymyxins , , clindamycin , colistin and , magnesium , lithium local anesthetics @DRUG$ , and	DDI-effect
This only clinically relevant kind with @DRUG$ , , , or blocking , calcium antihistamines or @DRUG$ tricyclic and phenothiazines also to a of interval	DDI-effect
@DRUG$ ( Cmax and ) not affected @DRUG$ suggesting interaction	DDI-false
have been associated neuropathy , chloramphenicol cisplatin , dapsone disulfiram ethionamide glutethimide @DRUG$ , , nitrofurantoin , phenytoin , ribavirin @DRUG$.	DDI-false
Warfarin Eszopiclone daily for 5 did the of@DRUG$n nor in the ( prothrombin time ) a 25 mg oral dose of @DRUG$	DDI-false
@DRUG$ : Histamine H2-receptor appear to have no significant on the of @DRUG$.	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	DDI-effect
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG-DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
of drugs possessing nephrotoxic , aminoglycosides @DRUG$ ) , myelotoxic ( e.g. @DRUG$ ) , cardiotoxic ( e.g. , doxorubicin ) hepatotoxic ( methotrexate , asparaginase PROLEUKIN may toxicity in these organ systems .	DDI-false
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either @DRUG-DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
@DRUG$ can the vitro activity @DRUG$ HIV	DDI-effect
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ , clonazepam , @DRUG$	DDI-false
Multivitamins , or other products iron or zinc antacids or @DRUG$ not be administered , 2 administration @DRUG$ they may with resulting in and urine norfloxacin	DDI-advise
@DRUG$ may anticholinergic of @DRUG$.	DDI-effect
Plasma levels of @DRUG$ have been reported to increase in the presence of oral @DRUG$;	DDI-false
relaxants ( , @DRUG$ drugs , ether succinylcholine decamethonium and sodium citrate , potentiate neuromuscular blocking effect and should be used with extreme in being treated with @DRUG$ .	DDI-effect
include azole , ciprofloxacin , , @DRUG$ , , , nefazodone nicardipine propofol , protease , @DRUG$ , and verapamil .	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of @DRUG$ therapy.	DDI-false
Oral Contraceptives : of @DRUG$ and oral @DRUG$ values by approximately and .	DDI-mechanism
Flupenthixol may , Monoamine oxidase inhibitors ( @DRUG$ pharmacodynamics Arecoline - @DRUG$ : cause CNS antidepressants the of	DDI-false
The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	DDI-effect
: In data that @DRUG$ metabolism @DRUG$ , result in increase in plasma and QT interval on the ECG .	DDI-mechanism
Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
@DRUG$ plus @DRUG$ was poorly tolerated, and 5 of 11 subjects discontinued therapy.	DDI-effect
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing @DRUG$.	DDI-false
should be with in patients receiving   ( , @DRUG$ , CYP3A4 inhibitor or channel antagonists e.g. , , CYP3A4 , and @DRUG$ a CYP3A4 ) because of possible , sinus and AV	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
through on certain microsomal , reduce hepatic of warfarin-type propranolol nifedipine chlordiazepoxide , antidepressants , , @DRUG$ and @DRUG$ , thereby delaying blood levels of these .	DDI-false
@DRUG$ : normal administration diflunisal and in an % increase plasma levels @DRUG$.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
The majority of studies one of the following concomitant : MTX corticosteroids @DRUG$ @DRUG$ , , hydroxychloroquine	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, cimetidine and phenobarbital.	DDI-false
@DRUG$ (such as flecainide, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and @DRUG$.	DDI-false
rifampin and @DRUG$ resulted in an @DRUG$ plasma A.C.	DDI-false
Administration repeat @DRUG$ effect the oral @DRUG$ in subjects	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.	DDI-false
No significant pharmacokinetic interactions been in @DRUG$ , digoxin , @DRUG$ and phenobarbital	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$ ( SSRIs , @DRUG$ , fluvoxamine , P450 , vary in extent of	DDI-false
analyses NSAIDs @DRUG$ , @DRUG$ clearance	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Coadministration of almotriptan and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Study , patients with colorectal cancer were given ( bolus-IFL ) or	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
@DRUG$, lidocaine, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ should administered ( food one hour or more two @DRUG$.	DDI-advise
Co-administration @DRUG$ ) erythromycin resulted approximately increase in the , about 2- fold prolongation in @DRUG$.	DDI-false
repeat doses of had no effect on repeat dose of @DRUG$ an ethinylestradiol/levonorgestrol @DRUG$ healthy .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
concomitant with @DRUG$ and @DRUG$ require adjustment of drug .	DDI-false
@DRUG$ , well metabolite @DRUG$ , metabolism	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
Ergot Derivatives : @DRUG$ ergonovine methylergonovine potential for and @DRUG$ toxicity characterized by of tissues	DDI-false
using doctor or pharmacist of all prescription products may , especially of : ( e.g. @DRUG$ , amphotericin , drugs e.g. ) , tacrolimus @DRUG$.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Drugs have been peripheral @DRUG$ chloramphenicol cisplatin , , , , gold , iodoquinol , metronidazole @DRUG$ phenytoin ribavirin , vincristine .	DDI-false
caution should be with there are conflicting of @DRUG$ on the availability digoxin @DRUG$.	DDI-mechanism
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
In the administration a @DRUG$ can reduce diuretic natriuretic effects loop , @DRUG$.	DDI-effect
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with @DRUG$ or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-false
Drugs : - administration of azathioprine , @DRUG$ , @DRUG$ , , or digitoxin not significantly affect the peak levels and	DDI-false
agents Concomitant administration of @DRUG$ and with [ intravenous ( , , intravenous @DRUG$ , ] .	DDI-advise
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
The addition of 540 mg/kg/day of @DRUG$ (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of @DRUG$ (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.	DDI-effect
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-false
@DRUG$ : Vardenafil 10 20 mg not potentiate bleeding time caused @DRUG$ 81 mg tablets	DDI-false
There is thus @DRUG$ upon the reaction of placental vessels to @DRUG$ .	DDI-effect
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-effect
therefore, @DRUG$ should not be administered concurrently with @DRUG$ because of the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-advise
@DRUG$ and other corticosteroids , , thyroid products @DRUG$ , oral contraceptives , phenytoin , calcium blocking , and .	DDI-false
@DRUG$ and @DRUG$ exert renal vasodilator effects on healthy humans	DDI-false
concurrently , such phenothiazines , @DRUG$ thioxanthines or @DRUG$.	DDI-false
May interact thyroid medication ( @DRUG$ ) iodine-containing products , antacids H2-antagonists ( famotidine ranitidine ) @DRUG$ ( lansoprazole )	DDI-false
It would be expected that @DRUG$ use during therapy with @DRUG$ would worsen the incidence or severity of diarrhea, but this has not been studied.	DDI-effect
@DRUG$ impact the and it significantly decreased the tmax by 44 and increased the @DRUG$ by 110 .	DDI-mechanism
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
Ritonavir Coadministration of ritonavir @DRUG$ resulted 152 increase in @DRUG$ plasma AUC and very little change in A.C.	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ : Coadministration a single @DRUG$ 20 mg and 20 mg daily days not any interaction on psychomotor performance	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$ ( mg once daily therapeutic of @DRUG$ , and ketoconazole in controlled clinical pharmacology studies in adult .	DDI-false
Agents : antihypertensive effect @DRUG$ and enalapril IV augmented agents that cause e.g. @DRUG$ ) .	DDI-effect
Coadministration of terfenadine with @DRUG$ has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-false
amiodarone a substrate for CYP3A4 , potential that of St. Wort patients receiving @DRUG$ @DRUG$ levels	DDI-false
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
May thyroid medication ( e.g. levothyroxine ) @DRUG$-containing , , ) , and @DRUG$ ( e.g. , lansoprazole omeprazole ) .	DDI-false
nandrolone [ ] oxandrolone , @DRUG$ ] oxymetholone [ e.g. , , stanozolol [ @DRUG$	DDI-false
@DRUG$ : Eszopiclone 3 administered days did not affect pharmacokinetics (R)- or @DRUG$ , nor any in the pharmacodynamic ( time a 25 mg dose warfarin	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Therefore when hydroflumethiazide @DRUG$ are the should observed to determine if the desired effect the @DRUG$ is .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-advise
The concomitant administration @DRUG$ other @DRUG$ have previous of rhabdomyolysis .	DDI-effect
@DRUG$ and/or in vivo data itraconazole @DRUG$ markedly inhibit cisapride can result in an increase in plasma levels and of QT on the ECG .	DDI-false
@DRUG$ and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
- Vitamin K (e.g., @DRUG$, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
acetaminophen/theophylline , @DRUG$/@DRUG$ theophylline/acetaminophen , and acid/phenobarbital	DDI-false
Interactions Mixed Opioid Agonist/antagonist ( pentazocine nalbuphine , dezocine and buprenorphine NOT patient has or receiving a @DRUG$ such @DRUG$.	DDI-advise
The , and time course of @DRUG$ , secobarbital , glutethimide @DRUG$ and were patients coumarin therapy	DDI-false
Antihypertensives @DRUG$ should be with in e.g. , a @DRUG$ verapamil , CYP3A4 diltiazem inhibitor of potentiation of bradycardia arrest , and ;	DDI-false
, @DRUG$ Diuretics treatment with @DRUG$ , , diuretics may possible effect   beta2-agonists .	DDI-false
Ergot Derivatives : @DRUG$ , , @DRUG$ CONTRAINDICATED serious and life-threatening reactions acute peripheral vasospasm of the other tissues .	DDI-false
In interactions noted chronic ( weeks oral administration metabolism of @DRUG$ dextromethorphan , @DRUG$.	DDI-false
@DRUG$ Valdecoxib mg not a effect plasma or renal clearance @DRUG$.	DDI-false
interact ( altered effect ) , @DRUG$ rifampin inducers microsomal enzyme ( decreased of @DRUG$ , corticosteroids ( corticosteroids .	DDI-false
Additive CNS depression may occur when @DRUG$ are administered depressants barbiturates @DRUG$ ,	DDI-effect
@DRUG$ may also potentiate the replication of some organisms contained in @DRUG$.	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
These results suggest that retinyl acetate possibly other glucocorticoids @DRUG$ may regulate proliferation of epithelium of insulin and	DDI-effect
Co-administration of @DRUG$ @DRUG$ not alter pharmacokinetics of .	DDI-false
@DRUG$ aminoglycosides interfering transmission e.g. curare-like caution of the @DRUG$ be potentiated	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ serum concentration during concomitant protease inhibitor therapy should be considered.	DDI-false
The , uniformity and course of anticoagulant by phenobarbital @DRUG$ , @DRUG$ chloral hydrate and methaqualone were systematically in patients receiving therapy	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, @DRUG$ or amoxicillin.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other Drugs groups patients - 10/interaction study ) , concomitant of , gold chloroquine , @DRUG$ , doxycycline , or digitoxin not affect the levels values of @DRUG$.	DDI-false
Other which may enhance the neuromuscular action of agents such g. , , tetracyclines , polymyxins , , @DRUG$ colistin and sodium colistimethate , anesthetics , @DRUG$ and quinidine .	DDI-false
Pharmacokinetic @DRUG$ @DRUG$ rifampin males	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving @DRUG$ therapy.	DDI-false
@DRUG$ : normal volunteers , decrease in diflunisal @DRUG$ and .	DDI-false
@DRUG$ concentration be when @DRUG$ are administered , and dosage adjustments valproate should be .	DDI-false
Patients analgesics , general @DRUG$ @DRUG$ , , tricyclic or other depressants including alcohol ) DILAUDID depression	DDI-false
Drugs Coadministered VIRACEPT : @DRUG$ quinidine Antihistamines : astemizole : ergot Antimycobacterial Benzodiazepines midazolam @DRUG$ GI : cisapride	DDI-false
administered with @DRUG$ , @DRUG$ , , high-frequency ventilation .	DDI-false
of in RA clinical studies received one or more the following with : MTX corticosteroids , @DRUG$ , azathioprine , chloroquine , , hydroxychloroquine , leflunomide , @DRUG$ , and anakinra	DDI-false
was difference the effect @DRUG$ and @DRUG$ Lodine by	DDI-false
@DRUG$ used in taking @DRUG$.	DDI-advise
thyroid medication e.g. levothyroxine ) , iodine-containing antacids @DRUG$ e.g. , famotidine @DRUG$ e.g. , )	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Co-administration : use of Argatroban agents , @DRUG$ , and other @DRUG$ may increase the of .	DDI-false
The following are examples substances increase blood-glucose-lowering effect and hypoglycemia : , fluoxetine , monoamine oxidase inhibitors salicylates somatostatin @DRUG$ ) @DRUG$.	DDI-false
Garlic not be while saquinavir ( @DRUG$ sole protease to the of decreased @DRUG$ concentrations .	DDI-false
drugs thiazides corticosteroids , @DRUG$ oral contraceptives , , nicotinic acid , blocking and @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Ethopropazine @DRUG$ @DRUG$ increased sedative	DDI-false
The patients received one more of ORENCIA NSAIDs TNF agents , azathioprine , , @DRUG$ leflunomide , @DRUG$ and anakinra	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.	DDI-false
glycosides receiving @DRUG$ , administration @DRUG$ regularly results in an increase in serum concentration may reach toxic levels resultant clinical .	DDI-false
Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	DDI-effect
- Methotrexate @DRUG$ Use sulfapyridine increase the chance side affecting the liver and/or of @DRUG$	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Reports that @DRUG$ may diminish the of	DDI-effect
be in receiving   blocking agents e.g. a @DRUG$ or antagonists e.g. , @DRUG$ , substrate , diltiazem inhibitor because the possible potentiation of bradycardia , and AV block ;	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
: pharmacokinetic indicate @DRUG$ 60 patients taking @DRUG$ without other enzyme- inducing AEDs	DDI-mechanism
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
of in clinical studies received or of following with ORENCIA : MTX , @DRUG$ , chloroquine , , hydroxychloroquine , leflunomide ,	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ toxicity was usually reversible upon discontinuation of lithium and the @DRUG$.	DDI-false
It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing antacids for at least 4 hours following @DRUG$ administration.	DDI-false
Drugs alter plasma concentrations that increase plasma recommended when administering Gleevec with inhibitors of family ( e.g. ketoconazole , @DRUG$ , , @DRUG$ ) .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
hydrochloride could a hazard a potentially toxic drug that bound @DRUG$ has the was @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Hepatic Enzyme and Substrates Drugs induce cytochrome P450 3A4 ( CYP ( e.g. carbamazepine @DRUG$ may enhance the of @DRUG$ and require dosage corticosteroid be .	DDI-mechanism
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered @DRUG$ in patients to whom @DRUG$ are also being given should be avoided, except in life-threatening conditions.	DDI-advise
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., @DRUG$]) or	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, @DRUG$, and methotrexate.	DDI-false
The majority of in received the following medications with : MTX , NSAIDs , , @DRUG$ , , @DRUG$ , , hydroxychloroquine leflunomide .	DDI-false
@DRUG$ Clinical studies as post-marketing , have that @DRUG$ can reduce in	DDI-false
Capsules not used while taking saquinavir ( @DRUG$ ) as the sole @DRUG$ the risk plasma concentrations .	DDI-false
The hypoglycemic action @DRUG$ may potentiated by certain drugs including nonsteroidal anti-inflammatory agents are highly bound salicylates , chloramphenicol probenecid , , @DRUG$ , adrenergic blocking	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, @DRUG$, nicardipine, and nifedipine.	DDI-false
The , time of phenobarbital @DRUG$ , @DRUG$ and were systematically patients receiving coumarin .	DDI-false
adjustment warranted when @DRUG$ is concurrently CYP3A4 inhibitors CYP1A2 @DRUG$ toxicity	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
, and adjustment metformin in patients concomitantly taking @DRUG$	DDI-advise
@DRUG$ @DRUG$ metabolic resulting in decreased levels and thus requiring increase in corticosteroid dosage	DDI-false
A study in eight healthy volunteers has shown a 50% increase in mean peak @DRUG$ plasma concentrations and a 90% increase in mean area under the curve, after a one week course of @DRUG$ at 1,000 mg/day and nimodipine at 90 mg/day.	DDI-false
The action be by drugs including nonsteroidal agents and other drugs that are protein @DRUG$ , chloramphenicol @DRUG$ , coumarins , oxidase , agents .	DDI-false
However, concomitant administration of aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of @DRUG$ relative to that observed with @DRUG$ alone.	DDI-false
separate patients maintenance doses of @DRUG$ , , irbesartan administration 7 days had no effect pharmacodynamics ( prothrombin time pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
Antidepressants (@DRUG$), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
evaluate impact of HAART on clinical course of patients with HIV-related systemic , , compared retrospectively a group of with HIV-NHL were , , , and prednisone ) chemotherapy regimen with who treated CHOP chemotherapy regimen ( cyclophosphamide , doxorubicin and prednisone vincristine @DRUG$ ) @DRUG$ therapy	DDI-false
by @DRUG$ @DRUG$-enhanced peritoneal metastasis of azoxymethane rats	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and @DRUG$.	DDI-false
The safety and efficacy of concomitant use of @DRUG$ and @DRUG$ is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.	DDI-effect
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Interactions Opioid : @DRUG$ eg , butorphanol , should NOT administered to a patient has or is receiving a with a pure agonist opioid	DDI-advise
Other nephrotoxic medications: agents such as aminoglycosides, @DRUG$, and @DRUG$ may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	DDI-false
Concomitant use of @DRUG$ with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
adverse effects resulting from cholinergic occur @DRUG$ administered concomitantly with other @DRUG$ , phenothiazines monoamine MAO ) antidepressants some antihistamines	DDI-effect
Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Concomitant administration of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-false
@DRUG$ ( mg . ) with 5 in 49-fold increase AUC @DRUG$ Cmax	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-effect
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
Both @DRUG$ and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Pretreatment of megakaryocytes with extracellular @DRUG$ (50 microM) also inhibited @DRUG$-induced responses.	DDI-effect
Potential drug between @DRUG$   and other @DRUG$ , lamotrigine , and valproate ) assessed by the of levetiracetam AEDs during placebo-controlled studies .	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
H2 : @DRUG$ coadministration leads to peak AUC of @DRUG$ , there no effect absorption when it ranitidine	DDI-mechanism
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
drugs may the of such NUROMAX include certain antibiotics ( @DRUG$ , , bacitracin , , lincomycin , colistin , @DRUG$ , magnesium , and	DDI-false
Ephedrine: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
@DRUG$: while a synergistic relationship with @DRUG$ has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-false
Oral @DRUG$ gastrointestinal absorption @DRUG$ oral vitamin , .	DDI-mechanism
It may increase excretion of @DRUG$, @DRUG$, and ASA and may also increase the toxicity of salicylates.	DDI-false
- @DRUG$: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Use in Ambulatory Patients The effects of @DRUG$ may wear off before a @DRUG$ is completely cleared from the body.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	DDI-false
@DRUG$ ( 800 mg t.i.d . co-administered with @DRUG$ 10 resulted in a 16-fold increase in vardenafil AUC 7-fold vardenafil in half-life	DDI-mechanism
interact with medication e.g. levothyroxine products @DRUG$ , H2-antagonists ( e.g. , @DRUG$ , ranitidine ) , and ( e.g. , omeprazole	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
of CYP3A4 and @DRUG$ with fentanyl result increase @DRUG$ plasma which or effects and may serious .	DDI-false
interact , ) products , ( e.g. , @DRUG$ ) and inhibitors e.g. , omeprazole	DDI-false
Experience with co-administration of @DRUG$ and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving Fentanyl.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ : should be used if @DRUG$ administered concomitantly .	DDI-false
May anticoagulants ( , @DRUG$ of microsomal decreased effect of , @DRUG$ ( ) .	DDI-false
This indicates that @DRUG$ does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of @DRUG$.	DDI-false
that may have resulted a interaction between @DRUG$ and @DRUG$ molecular basis this has been	DDI-effect
A possible interaction between @DRUG$ and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-int
Although specific not been metabolized @DRUG$ dapsone disopyramide quinine , amiodarone quinidine @DRUG$ cyclosporine , ergot derivatives , pimozide , fentanyl alfentanyl , , triazolam may have plasma with saquinavir ;	DDI-false
For example, @DRUG$ (e.g., @DRUG$) may activate the renin-angiotensin-aldosterone system.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Results of TYSABRI and concomitant beta-1a ( @DRUG$ 30 IM weekly ) or acetate with to the need for dose of the @DRUG$ or acetate	DDI-false
Antiacid , , @DRUG$ Fluoxetine , , Phenobarbitol , carbamazepine , , , @DRUG$.	DDI-false
@DRUG$ : synergistic relationship amphotericin has been may the toxicity @DRUG$ by possibly increasing its cellular uptake impairing its renal excretion	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
effect @DRUG$ the anti-coagulant effect of warfarin was in group receiving daily doses of 2 5 of @DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
On administration of oral @DRUG$, the need for @DRUG$ therapy should be reviewed and the dose reduced by approximately 50% or discontinued.	DDI-advise
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	DDI-false
INOmax has been administered with @DRUG$, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
@DRUG$ Diclofenac and can activity of	DDI-false
Although no with topical glaucoma systemic medications were identified in studies of @DRUG$ % , additive or potentiating effect @DRUG$ alcohol barbiturates , opiates sedatives anesthetics should considered	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
A similar , , has been with , @DRUG$ , possibly , , and @DRUG$ ( 72	DDI-false
The following are examples that may the corticosteroids , niacin , danazol , agents e.g. epinephrine , ) phenothiazine derivatives , @DRUG$ @DRUG$ progestogens e.g. , contraceptives )	DDI-false
@DRUG$ Bound : data @DRUG$ is 96 % bound to human protein and therefore has to with compounds	DDI-false
In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Drugs That Not VIRACEPT : amiodarone quinidine Antihistamines @DRUG$ terfenadine : ergot derivatives Antimycobacterial agents : Benzodiazepines , triazolam motility agents @DRUG$	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and @DRUG$) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
@DRUG$ @DRUG$ in with gravis	DDI-effect
These drugs @DRUG$ , corticosteroids , @DRUG$ thyroid , oral , nicotinic , sympathomimetics , drugs , .	DDI-false
however, 150 mg of ranitidine q12h for 3 days increased the @DRUG$ C max by 23% and @DRUG$ AUC by 16%.	DDI-false
acetaminophen/@DRUG$ , phenobarbital/acetaminophen , theophylline/acetaminophen , valproic acid/@DRUG$.	DDI-false
The eight drug combinations were studied @DRUG$/@DRUG$.	DDI-false
Tagamet , effect enzyme systems the metabolism , phenytoin , , @DRUG$ chlordiazepoxide , @DRUG$ antidepressants lidocaine , metronidazole , thereby delaying elimination and increasing levels drugs	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
Phenobarbital toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of @DRUG$ therapy.	DDI-effect
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.	DDI-false
hypoglycemic @DRUG$ may be potentiated nonsteroidal agents @DRUG$ , sulfonamides chloramphenicol probenecid , oxidase inhibitors , beta adrenergic agents	DDI-effect
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus @DRUG$/@DRUG$ regimens.	DDI-false
@DRUG$ use agonists 24 hours of treatment @DRUG$ is	DDI-false
Concurrent administration of a quinolone , including ciprofloxacin with cation-containing @DRUG$ , , @DRUG$ tablets or or calcium , may absorption ciprofloxacin , and urine levels than desired .	DDI-false
Therapeutic concentrations of @DRUG$, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
administration possessing nephrotoxic aminoglycosides indomethacin ) , myelotoxic e.g. @DRUG$ , ( e.g. , ) , @DRUG$ , asparaginase may increase toxicity in organ systems .	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
@DRUG$ : The of ( with other central nervous system including opioids , hypnotics , tranquilizers @DRUG$ ) anesthetics , phenothiazines , relaxants and alcohol cause respiratory depression and or potentially result in coma or .	DDI-false
@DRUG$ Dihydroergotamine , CONTRAINDICATED potential for serious and reactions such as @DRUG$ toxicity by peripheral vasospasm and of extremities tissues	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
@DRUG$ @DRUG$ increased the of norethindrone ethinyl and % ,	DDI-mechanism
Fluconazole of @DRUG$ QD two-fold increase in @DRUG$ .	DDI-mechanism
@DRUG$ with or and @DRUG$ cause striking increases of d-amphetamine brain	DDI-mechanism
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
the interaction almotriptan inhibitors e.g. @DRUG$ , ritonavir has not been studied increased to @DRUG$ expected is used concomitantly these .	DDI-false
strong inhibitors of ( , @DRUG$ , , troleandomycin @DRUG$ , would be to similarly	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Because is a these may be additive use of ergotamine-containing ergot-type medications @DRUG$ or methysergide ) and @DRUG$ hours of each other avoided .	DDI-advise
Ingestion of @DRUG$ may increase serum concentrations of digoxin and @DRUG$ and increase cyclosporine s nephrotoxicity.	DDI-mechanism
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
There are however from experiences , of changes in insulin @DRUG$ the presence @DRUG$ that necessitated changes in such	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
Administration @DRUG$ patients @DRUG$ hydrocarbon such as , ..	DDI-effect
@DRUG$ : In data indicate nefazodone inhibits the metabolism of @DRUG$ result in increase plasma cisapride levels the ECG .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: The combination of @DRUG$, saquinavir, and ZDV has been studied (as triple combination) in adults.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30% and 20%.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and @DRUG$ concurrently, and evidence of decreased plasma concentrations of methadone.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-effect
it adversely response suggesting that should not be administered with @DRUG$ and/or @DRUG$.1	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Potential interactions and other lamotrigine , @DRUG$ valproate were evaluating the serum @DRUG$ these during placebo-controlled studies .	DDI-false
In clinical with Fondaparinux concomitant use of ( warfarin platelet @DRUG$ @DRUG$ not affect sodium	DDI-false
Although studies been , with drugs are mainly by CYP3A4 eg calcium blockers , @DRUG$ , , quinine , tacrolimus cyclosporine , ergot pimozide carbamazepine , fentanyl , , and @DRUG$ may have plasma when ;	DDI-false
however, 150 mg of @DRUG$ q12h for 3 days increased the ceftibuten C max by 23% and @DRUG$ AUC by 16%.	DDI-mechanism
The effect of @DRUG$ on the pharmacokinetics of @DRUG$ administered orally has not been investigated.	DDI-false
The following are may the blood-glucose-lowering : @DRUG$ , , , diuretics @DRUG$ e.g. , epinephrine , salbutamol , ) , , thyroid hormones , , progestogens contraceptives ) .	DDI-false
While all the selective reuptake inhibitors SSRIs ) , , , @DRUG$ , paroxetine and @DRUG$ , P450 2D6 , they may vary extent	DDI-false
Potential interactions @DRUG$ and other ( , gabapentin , lamotrigine , phenytoin primidone @DRUG$ also the and AEDs during placebo-controlled	DDI-false
Antacids : In clinical of an @DRUG$ hydroxide and ) with fosinopril levels and excretion of as compared fosinopril alone , that @DRUG$ may .	DDI-false
The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	DDI-false
The use of @DRUG$ @DRUG$ may effect .	DDI-false
Although has been reported with Cefizox nephrotoxicity has been concomitant administration other @DRUG$	DDI-effect
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
clinical well as postmarketing shown that @DRUG$ reduce natriuretic effect of @DRUG$ in patients	DDI-effect
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
Antiarrhythmic agents, class I (such as @DRUG$, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ may also the replication some contained	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
to be the clinically relevant with , , coadministration of other known to alter conduction ( or @DRUG$ , calcium channel blockers , agents and @DRUG$ also contribute a prolongation the .	DDI-false
It that @DRUG$ use with @DRUG$ the or severity of has been studied	DDI-effect
@DRUG$ used effect pupil size , resulting from BETAGAN and @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
: Although specific interaction studies not , in was concomitantly angiotensin- converting , betablockers , , @DRUG$ @DRUG$ NSAIDs without of clinically	DDI-false
with @DRUG$ , , nalbuphine , @DRUG$ dezocine buprenorphine NOT be administered patient who received or a therapy with agonist analgesic as Levo-Dromoran .	DDI-false
Use @DRUG$ : of @DRUG$ control hypertension patients azathioprine has been induce severe leukopenia	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
was not p > 0.05 ) 48.59 49.9 + /- 9.93 ) , Cmax + /- , and ( /- vs. + 1.1 @DRUG$/@DRUG$ regimens	DDI-false
, phenobarbital/acetaminophen phenobarbital/valproic , and @DRUG$/phenobarbital .	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
A similar though less marked , has with , @DRUG$ @DRUG$ with , , and tetracyclines (	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
@DRUG$ should taking @DRUG$ , and renal function be carefully monitored	DDI-advise
Antacid Products Absorption of zalcitabine reduced approximately 25 % coadministered	DDI-false
studies @DRUG$ does inhibit P-glycoprotein-mediated @DRUG$ vinblastine that is not a for transport .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
may enhance the neuromuscular blocking action of as @DRUG$ e. g. , aminoglycosides , , bacitracin polymyxins , , clindamycin , @DRUG$ , sodium ) , salts , local anesthetics , procainamide , and quinidine	DDI-false
on : Patients @DRUG$ especially in whom @DRUG$ therapy was recently on salt restriction or may experience precipitous of blood within the first initial .	DDI-false
all the serotonin SSRIs ) @DRUG$ sertraline @DRUG$ , inhibit 2D6 , they may vary in extent .	DDI-false
Lack effect of @DRUG$ on disposition @DRUG$ in HIV-infected patients .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Other interactions: @DRUG$ had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).	DDI-false
or the pharmacokinetics either was when VIRACEPT was with @DRUG$	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
repeat doses of no effect on repeat dose pharmacokinetics @DRUG$ , @DRUG$/levonorgestrol subjects	DDI-false
@DRUG$ effects amphetamines @DRUG$.	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-false
Pyrantel ( @DRUG$ ) Taking @DRUG$ pyrantel together may decrease the effects	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Drug/Laboratory Test Interactions The urine of patients who take @DRUG$ can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other @DRUG$ Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with @DRUG$ is contraindicated.	DDI-false
Olanzapine : @DRUG$ and @DRUG$ 10 mg a decrease in scores .	DDI-effect
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Valproate @DRUG$ a slight about % steady-state @DRUG$ .	DDI-mechanism
( mg b.i.d . ) had no @DRUG$ AUC ) ) @DRUG$ when co-administered mg in healthy volunteers .	DDI-false
Because been shown produce any effect aspirin and aspirin increases the rate of excretion @DRUG$ concomitant use of @DRUG$ and .	DDI-false
Cimetidine @DRUG$ concentrations and cystic fluid were increased ( in patients treated @DRUG$ ( 10 n=7 compared with ( mg/kg/day ) alone n=12	DDI-mechanism
Coadministration @DRUG$ mg days ) with glyburide mg or 10 BID not affect the ( exposure of @DRUG$.	DDI-false
The absorption of tetracycline, furosemide, @DRUG$, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
administration @DRUG$ with has been associated with an increased significant additional over @DRUG$ alone .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
@DRUG$ had on the plasma concentrations @DRUG$ its metabolite in patients with .	DDI-false
( @DRUG$ ): by co-administration @DRUG$.	DDI-false
Antiarrhythmics: @DRUG$, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ have significant interactions and @DRUG$.	DDI-int
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Specific interaction studies have demonstrated the following: @DRUG$: During the first day of concomitant administration, trough concentrations of @DRUG$ were increased by about 30-fold.	DDI-false
Some @DRUG$/substances are metabolism of stimulating the synthesis @DRUG$ ( ) .	DDI-false
clinical studies have been conducted , @DRUG$ may affected by the known CYP3A4 inducers such as phenobarbital ) e.g. @DRUG$	DDI-mechanism
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
SINCE THE THESE @DRUG$ , TO ADMINISTERING @DRUG$ A PATIENT ON THERAPY A PHENYTOIN LEVEL SHOULD BE OBTAINED .	DDI-false
Benzthiazide interact with alcohol thinners , @DRUG$ , and sinus medicines ) diabetic @DRUG$ , norepinephrine , NSAIDs Aleve or , and high blood medications	DDI-false
Probenecid: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-mechanism
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ not be with @DRUG$ because of ototoxicity .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$ In a subjects in @DRUG$ AUC Cmax were , but	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
monitoring theophylline plasma concentrations considered when @DRUG$ is or changed @DRUG$.	DDI-advise
not performed coadministration mainly CYP3A4 ( calcium blockers dapsone , @DRUG$ , , @DRUG$ , warfarin , tacrolimus , , ergot derivatives pimozide , , fentanyl alprazolam , plasma concentrations when with	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
Although performed drugs are mainly metabolized eg , quinine amiodarone , quinidine , warfarin , , ergot carbamazepine , @DRUG$ , , @DRUG$ ) elevated coadministered	DDI-false
- @DRUG$ e.g. @DRUG$ )	DDI-false
Magnesium- and/or antacids products ferrous iron multivitamin zinc metal , Videx ( @DRUG$ ) powder oral not be hours or 2 hours	DDI-advise
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), @DRUG$ (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
acetaminophen/theophylline , quinidine/lidocaine acid/phenobarbital	DDI-false
trial doses of ( 110 - 200 ) and @DRUG$ 50 75 mg/m2 as infusions myelosuppression profound when @DRUG$ after with alternate sequence ( ie , cisplatin	DDI-false
In rats, simultaneous ingestion of @DRUG$ and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-effect
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Single doses of either cholestyramine or colestipol @DRUG$ bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Lithium: Diclofenac decreases @DRUG$ renal clearance and increases @DRUG$ plasma levels.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
administration a quinolone , including multivalent such magnesium or aluminum @DRUG$ @DRUG$ , chewable/buffered tablets pediatric powder or , or zinc decrease the absorption of and levels lower than desired .	DDI-false
- @DRUG$ (e.g., Mesantoin) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-effect
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
@DRUG$ : The concomitant administration and @DRUG$ volunteers lowering of the plasma of the metabolite approximately .	DDI-false
Interactions Date @DRUG$ does not clinically with , digoxin warfarin @DRUG$ , carvedilol , ethanol itraconazole .	DDI-false
To evaluate the impact plus HAART on the clinical patients , systemic , lymphoma ( , authors of patients were with the @DRUG$ , doxorubicin ( a group 80 a i.e. , cyclophosphamide , doxorubicin , teniposide and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-advise
is by hepatic drugs as @DRUG$ , carbamazepine and , and the antituberculosis drug .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ : differences were observed in pharmacokinetics of R-warfarin or @DRUG$ with addition of a	DDI-false
Therapeutic of digoxin @DRUG$ @DRUG$ , , piroxicam did ketorolac tromethamine binding	DDI-false
No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and @DRUG$.	DDI-false
Although not , coadministration with that are mainly metabolized by ( eg calcium channel blockers , , quinine @DRUG$ , , tacrolimus , , , , , @DRUG$ , and triazolam may have concentrations with saquinavir ;	DDI-false
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
clinical studies have been , based on involvement of the cytochrome P-450 3A in metabolism , inhibitors of system , oral @DRUG$ , cautiously in receiving @DRUG$.	DDI-advise
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
subjects , the concurrent @DRUG$ at did not of @DRUG$ tablets	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
The majority of RA one or of the following @DRUG$ MTX , , blocking , , , @DRUG$ , , sulfasalazine and	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The @DRUG$ anticoagulant of @DRUG$ ( - 8 ) was in healthy coadministration 7 .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
been associated include antiretroviral nucleoside , chloramphenicol , cisplatin , dapsone , ethionamide , gold @DRUG$ , @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
The concurrent use of @DRUG$ with @DRUG$ has not been formally studied.	DDI-false
These drugs include @DRUG$ other diuretics , phenothiazines thyroid products estrogens , contraceptives phenytoin , @DRUG$ sympathomimetics calcium blocking	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ did not affect the pharmacokinetics of @DRUG$.	DDI-false
interact alcohol , blood thinners drugs cold and sinus diabetic NSAIDs like @DRUG$ or @DRUG$ , blood	DDI-false
@DRUG$, Methotrexate, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
The @DRUG$ and @DRUG$ warfarin complex	DDI-false
@DRUG$ @DRUG$ ): SSRIs ( e.g. , ) been rarely reported to hyperreflexia , incoordination when .	DDI-false
Acidifying agents : acidifying ( @DRUG$ @DRUG$ , acid , fruit , lower .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
When @DRUG$ is co-administered with @DRUG$, anticoagulation levels should be monitored frequently.	DDI-advise
Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, antihypertensive agents, or other @DRUG$.	DDI-false
Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing @DRUG$ to avoid additive toxic effects	DDI-false
drug interactions between Keppra other , , lamotrigine @DRUG$ , @DRUG$ , also assessed evaluating the serum of and these clinical studies	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Terfenadine: Administration of @DRUG$ with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
Probenecid: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by @DRUG$.	DDI-mechanism
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability.	DDI-mechanism
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
While @DRUG$ and @DRUG$ have similar for kappa possibly nicotinic receptors , 18-MC much than ibogaine and sigma-2 receptors and transporter	DDI-false
concomitant therapy specific not , 1 mg or more were concomitantly used in studies acid analgesics , enzyme ( ACE inhibitors @DRUG$ , beta calcium-channel blockers , , @DRUG$ antagonists , , prostaglandin inhibitors referred as ) , quinolone evidence clinically significant	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
Example , ciprofloxacin clarithromycin , , , erythromycin , @DRUG$ @DRUG$ , propofol , verapamil	DDI-false
@DRUG$: Amiodarone, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Although dexamethasone nor retinyl acetate prostatic RPMI1640 containing @DRUG$ alone modify the mitogenic effect of @DRUG$ and	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Be VIRACEPT @DRUG$ : quinidine Antihistamines : , terfenadine Antimigraine @DRUG$ Antimycobacterial agents , triazolam GI : cisapride	DDI-false
@DRUG$: Concomitant administration of antacids may reduce plasma levels of @DRUG$.	DDI-false
MHD , predominant plasma only weak inducer it unlikely to an effect on drugs that are mainly eliminated transferase ( e.g. @DRUG$ @DRUG$ .	DDI-false
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-int
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$/Hypnotics: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Benzthiazide may interact with alcohol , blood thinners , allergy cold sinus , , lithium , @DRUG$ @DRUG$ or Ibuprofen high	DDI-false
@DRUG$ ( nandrolone e.g. , ] @DRUG$ , , [ , Anadrol , [	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
The suggest @DRUG$ a spectrum of will have a substantially therapeutic than @DRUG$.	DDI-false
If with CYP3A4 activity ( , intraconazole @DRUG$ , , erythromycin etc is @DRUG$ dose considered .	DDI-advise
The examples drugs through inhibition of : @DRUG$ , @DRUG$ , , and .	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
Inhibitors Endogenous Prostaglandin It has @DRUG$ reduce @DRUG$ , in cases of low renin	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Compounds man include @DRUG$ , diazepam , @DRUG$ and antipyrine .	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or amoxicillin.	DDI-false
These include the other @DRUG$ , corticosteroids phe-nothiazines , thyroid , estrogens oral @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
@DRUG$, such as @DRUG$ and isoproterenol;	DDI-false
: pharmacodynamic interactions been and @DRUG$ ( given 26 and to initiation of @DRUG$ 4 1000 orally , 6 prior to , 12 hours subsequent , 1.5   g/kg/min over hours	DDI-false
The risk of with drugs of class is with concurrent administration of @DRUG$ derivatives niacin @DRUG$.	DDI-false
@DRUG$ , the irinotecan , 33 patients receiving bolus-IFL @DRUG$ when with bolus-IFL alone	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Vaccines @DRUG$ may response toxoids @DRUG$ inhibition antibody response	DDI-effect
@DRUG$ or protriptyline and possibly other tricyclics cause striking and increases in concentration of @DRUG$ in the	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
It was concluded that oral @DRUG$ and @DRUG$ can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	DDI-false
Ethosuximide : @DRUG$ delay intestinal absorption @DRUG$.	DDI-mechanism
These include the other diuretics , corticosteroids , , products , , contraceptives , @DRUG$ , acid sympathomimetics @DRUG$ , and isoniazid .	DDI-false
data for the @DRUG$/ritonavir or and garlic capsules .	DDI-false
Although studies not , with that CYP3A4 ( eg , calcium blockers , , , quinidine , , , derivatives pimozide , , @DRUG$ and may have plasma concentrations with @DRUG$	DDI-mechanism
drug interact with alcohol or depressants potentiate depressant effects either these antihistamines , @DRUG$ medications with anticholinergic anticholinergic effects be potentiated when these are concurrently with antihistamines oxidase ( MAO inhibitors concurrent with @DRUG$ may prolong intensify anticholinergic and CNS depressant of ) .	DDI-false
tubular @DRUG$ may by concomitant administration of , to increased levels of @DRUG$.	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-advise
However established @DRUG$ with the of @DRUG$ .	DDI-effect
Interactions Date Levosimendan does interactions with captopril , @DRUG$ , digoxin , isosorbide mononitrate carvedilol , @DRUG$	DDI-false
@DRUG$ may decrease hepatic of @DRUG$ increasing their effect .	DDI-false
Warfarin: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
acetaminophen/theophylline , , acid , quinidine/lidocaine valproic acid/@DRUG$.	DDI-false
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with @DRUG$.	DDI-effect
The following substances that may the blood-glucose-lowering effect corticosteroids niacin , danazol sympathomimetic agents ( , salbutamol terbutaline , phenothiazine , somatropin , thyroid , @DRUG$ ( e.g. oral @DRUG$ ) .	DDI-false
vitro studies than alprazolam suggest a drug interaction the following : , cyclosporine @DRUG$ @DRUG$ nifedipine .	DDI-false
@DRUG$ Other antiarrhythmic drugs such as @DRUG$ , , and phenytoin , have amiodarone .	DDI-false
e. g. @DRUG$ , , , in vitro and with the combination @DRUG$ and imidazoles suggest imidazoles induce resistance to amphotericin B.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and @DRUG$.	DDI-advise
on @DRUG$ prothrombin in a involving administration warfarin and @DRUG$.	DDI-false
Drugs may alter @DRUG$ plasma concentrations may increase imatinib concentrations Caution is recommended administering Gleevec with of CYP3A4 ( ketoconazole itraconazole , , @DRUG$	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with @DRUG$.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The pills reduced drugs as the @DRUG$ @DRUG$ , carbamazepine and barbiturates antituberculosis .	DDI-false
was , @DRUG$ , , reduced of @DRUG$ were reported .	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ and : Coadministration VIRACEPT with OVCON-35 in a decrease ethinyl estradiol 18 % decrease @DRUG$ concentrations	DDI-false
Benzylpenicillin , , @DRUG$ , , doxycycline cephalothin have binding of @DRUG$ human	DDI-false
: @DRUG$ are inhibited by	DDI-effect
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
levels several closely related antidepressants reported be increased by the concomitant administration @DRUG$ ( , cimetidine , ) concomitant administration of hepatic inducers ( , @DRUG$ and may with CMI well .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Substances are potent inhibitors of , ketoconazole @DRUG$ ) @DRUG$ metabolism and increase gefitinib	DDI-mechanism
Because there are no data on the compatibility of @DRUG$ and crystalline @DRUG$ preparations, NovoLog should not be mixed with these preparations.	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
@DRUG$ interact , increasing the of @DRUG$.	DDI-false
The are of substances that reduce blood-glucose-lowering effect : , , danazol diuretics sympathomimetic ( e.g. , @DRUG$ , , terbutaline ) isoniazid derivatives somatropin , hormones , estrogens @DRUG$ e.g. , in contraceptives ) .	DDI-false
CONCOMITANT Although studies not , @DRUG$ used angiotensin- enzyme ( ACE ) betablockers @DRUG$ diuretics ) without evidence clinically significant interactions .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
clinically this with , theoretically coadministration drugs known to alter cardiac ( , or blocking agents calcium channel blockers H1-blocking agents , @DRUG$ and @DRUG$ also contribute a prolongation of the QTc interval	DDI-false
that significant @DRUG$ such as or cimetidine ) @DRUG$ therefore reduce .	DDI-mechanism
clinical trials FLOLAN was digoxin , @DRUG$ , , vasodilators supplemental in patients congestive heart failure receiving furosemide in therapy with initiated oral clearance for n = 23 digoxin ( n = decreased by and % respectively , the second therapy and had returned to values day 87 .	DDI-false
interactions with topical drugs or were studies of % Solution the possibility additive potentiating with @DRUG$ ( alcohol barbiturates @DRUG$ , anesthetics ) considered .	DDI-false
These include the other , corticosteroids phe-nothiazines @DRUG$ estrogens oral @DRUG$ , , calcium channel blocking , isoniazid .	DDI-false
When inducers drug clearance , such efavirenz @DRUG$ or @DRUG$ , a daily dose 70 of should	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Omeprazole The and extent of absorption of @DRUG$ was bioequivalent when given or when XR hours after @DRUG$ at the dose suppresses gastric .	DDI-false
That Should Not Be With VIRACEPT Antiarrhythmics : @DRUG$ : @DRUG$ Antimigraine derivatives Antimycobacterial agents : rifampin Benzodiazepines cisapride	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Carbamazepine, @DRUG$, @DRUG$	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Co- of @DRUG$ and @DRUG$ to volunteers not changes time or VII when compared co-administration	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
receiving @DRUG$ , @DRUG$ , or should be activity and therefore , toxicity from these drugs .	DDI-false
@DRUG$ dopamine reuptake thus the central stimulant effects @DRUG$.	DDI-false
Although specific studies have not performed , coadministration are mainly metabolized CYP3A4 ( calcium channel blockers , @DRUG$ disopyramide , amiodarone @DRUG$ , carbamazepine fentanyl , , have elevated when coadministered saquinavir	DDI-false
In clinical trials FLOLAN was diuretics , @DRUG$ . In pharmacokinetic substudy in patients congestive heart failure furosemide or whom initiated , apparent ( n @DRUG$ ) were decreased by 13 % , the second of and to baseline by day	DDI-false
@DRUG$ : @DRUG$ ( mg . co-administered 10 mg in vardenafil AUC increase in 2-fold increase vardenafil .	DDI-false
@DRUG$ 800 . ) co-administered with mg a 16-fold increase in vardenafil , a 7-fold increase vardenafil Cmax a 2-fold @DRUG$ .	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Hormonal Oral , Transdermal Contraceptives : interaction demonstrated co-administration @DRUG$ and oral @DRUG$ produced average estradiol levels of 14 % 31 % , .	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, @DRUG$, methotrexate, and increased toxicity.	DDI-false
DIGOXIN @DRUG$ digoxin steady-state were not affected by 0.2	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	DDI-false
5HT3 reports of of consciousness apomorphine was administered with concomitant apomorphine with of the antagonist class ( including , example ondansetron , granisetron , @DRUG$ , @DRUG$ , and alosetron	DDI-false
Drug Interactions , Monoamine inhibitors ( ): MAOI affect - Eproxindine - Ethanol @DRUG$ cause additive antidepressants @DRUG$ effect Tricyclic	DDI-false
Patients these combination with @DRUG$ should monitored for toxicity and the @DRUG$ if	DDI-false
Interactions Flupenthixol interact drugs , like Monoamine ( MAOI ): pharmacodynamics - Ethanol : @DRUG$ and additive - Tricyclic : @DRUG$ the	DDI-false
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
( 600 mg . with @DRUG$ 5 in increase in @DRUG$ AUC and a 13-fold increase vardenafil Cmax	DDI-false
may enhance the neuromuscular blocking action agents such certain e. g. , , bacitracin @DRUG$ , colistin and colistimethate , @DRUG$ lithium , local anesthetics procainamide , quinidine .	DDI-false
Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
concomitant therapy not performed finasteride or concomitantly in with , acetylsalicylic a-blockers analgesics angiotensin-converting enzyme ( ) inhibitors , @DRUG$ , benzodiazepines , blockers calcium-channel cardiac @DRUG$ diuretics , H2 antagonists , inhibitors , prostaglandin synthetase inhibitors also referred to as NSAIDs , and evidence of significant adverse .	DDI-false
specific not been , drugs by ( @DRUG$ @DRUG$ quinine , , quinidine , , , cyclosporine , pimozide , , alprazolam and triazolam elevated concentrations saquinavir ;	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, @DRUG$ or amoxicillin.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with @DRUG$ and 38% when coadministered with @DRUG$.	DDI-false
This was expected because @DRUG$ is primarily metabolized and renal excretion of unchanged @DRUG$ accounts for less than 1% of the administered dose.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
@DRUG$, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
in study could potentially arise co-administration of @DRUG$ @DRUG$ tubular secretion organic transporter .	DDI-mechanism
@DRUG$: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Concurrent of drugs possessing aminoglycosides , indomethacin ( chemotherapy , hepatotoxic , @DRUG$ ) @DRUG$ may increase toxicity these systems	DDI-effect
performed with @DRUG$ , the of oral ( ) , platelet ( acetylsalicylic acid NSAIDs ( , and significantly affect @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
In clinical trials digoxin @DRUG$ , oral vasodilators , and supplemental a in congestive receiving or in initiated apparent oral values @DRUG$ and digoxin ( = 30 ) were by 15 % second and baseline values by day .	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
Investigations into the effect of @DRUG$ on the protein binding of anticoagulants of the coumarin type (@DRUG$) revealed no interaction.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
beginning experiment injections @DRUG$ 7.4 mg/kg and subcutaneous of @DRUG$ 40 weight ) every and from 16 , injections ( 10 every day the fo the experiment in 45	DDI-false
It is suggested that in patients receiving @DRUG$, alternatives to phenytoin should be used if @DRUG$ therapy is needed.	DDI-false
@DRUG$ : The concomitant of long- and @DRUG$ has been safely in patients	DDI-false
The following substances reduce effect : corticosteroids , danazol agents e.g. salbutamol , @DRUG$ ) isoniazid , phenothiazine derivatives somatropin , hormones @DRUG$ ( oral contraceptives .	DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Aspirin: Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ with mg/day @DRUG$ ( = 7 ) ( to 600 [ = ] ) for Days 8 21 of 21-day 100 , times/day	DDI-false
Digoxin , @DRUG$ , like other @DRUG$ , affect renal and increase the of certain drugs	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, @DRUG$ and @DRUG$.	DDI-false
Potential @DRUG$ a substrate protease ( @DRUG$ , and which substrates and/or CYP3A4 have not been evaluated in trials .	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-false
To evaluate the on of patients with , lymphoma ) authors compared group patients treated with the cyclophosphamide , , @DRUG$ prednisone ) regimen plus with a 80 who chemotherapy regimen ( i.e. doxorubicin , teniposide , prednisone with vincristine bleomycin ) without @DRUG$ .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Previous studies a significant reduction the oral bioavailability @DRUG$ when administered concomitantly opiate	DDI-mechanism
Rifampin : Co-administration @DRUG$ with mg daily a of produced approximate 50 decrease in @DRUG$ concentrations	DDI-false
@DRUG$ may decrease arterial responsiveness to @DRUG$.	DDI-effect
Other concomitant specific not @DRUG$ doses of mg concomitantly in with acid , a-blockers , , angiotensin-converting enzyme ( ACE ) , , , , cardiac , antagonists inhibitors prostaglandin synthetase ( to as @DRUG$ ) quinolone anti-infectives without clinically significant interactions .	DDI-false
similar association less marked , barbiturates , phenyl-butazone , @DRUG$ and with griseofulvin @DRUG$ )	DDI-false
Administration @DRUG$ has reported levels @DRUG$ concomitantly .	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
of patients RA clinical studies received one medications with @DRUG$ : , NSAIDs , blocking , , chloroquine , @DRUG$ , leflunomide , sulfasalazine , anakinra	DDI-false
Dopamine Antagonists: Since @DRUG$ is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
@DRUG$, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
- ( , Use of methotrexate with @DRUG$ side the and/or effects @DRUG$	DDI-false
impact of plus HAART on of HIV-related systemic , lymphoma the retrospectively group with who were the cyclophosphamide , doxorubicin , vincristine , prednisone ( chemotherapy regimen plus HAART with of 80 who were treated with chemotherapy a regimen , , , @DRUG$ with vincristine bleomycin receiving @DRUG$ .	DDI-false
from with @DRUG$ for the following : @DRUG$.	DDI-int
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-effect
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction performed , in clinical cerivastatin sodium used concomitantly enzyme ( ACE inhibitors , @DRUG$ , calcium-channel , , nonsteroidal ( @DRUG$ ) without clinically significant .	DDI-false
co-administration , levels @DRUG$ and @DRUG$ were essentially	DDI-false
Therapeutic , naproxen @DRUG$ phenytoin @DRUG$ .	DDI-false
caused statistically @DRUG$ and 12 15 % , respectively ) and in the pharmacodynamic prothrombin time , measured as INR	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ Cimetidine coadministration an peak plasma AUC cisapride no effect @DRUG$ absorption it coadministered ranitidine	DDI-false
Mineral Oil-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Benzylpenicillin, @DRUG$, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
No Date have clinically important with , , @DRUG$ @DRUG$ , warfarin isosorbide mononitrate carvedilol ethanol or itraconazole	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
clinical trials , with digoxin , , anticoagulants , oral , In pharmacokinetic substudy patients congestive failure receiving @DRUG$ digoxin in FLOLAN initiated apparent oral values @DRUG$ ( n ) and digoxin ( n = 30 were 13 % 15 % respectively the second day therapy returned by day	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, @DRUG$ and phenobarbital) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
Analysis of the concentration of @DRUG$ following ultracentrifugation indicated that there is rapid equilibration of @DRUG$ between the Survanta and aqueous phase.	DDI-false
Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
Although no studies have been conducted, concomitant administration of @DRUG$ and @DRUG$ may alter the metabolism of phenytoin;	DDI-mechanism
The following examples the blood-glucose-lowering : , , diuretics , agents ( @DRUG$ salbutamol , terbutaline ) , , @DRUG$ , , e.g. in ) .	DDI-false
In view of the long and variable half-life of @DRUG$, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
imatinib concentrations may imatinib Caution administering @DRUG$ with inhibitors family ( @DRUG$ , , )	DDI-advise
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	DDI-false
@DRUG$ In experience there have been both increases and decreases levels with @DRUG$ alterations in .	DDI-false
@DRUG$ and procainamide doses should be reduced by one-third when either is administered with @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
performed coadministration mainly CYP3A4 ( eg calcium blockers , , quinine , amiodarone , quinidine , @DRUG$ @DRUG$ , ergot derivatives , carbamazepine fentanyl , alfentanyl , alprazolam , and elevated when saquinavir ;	DDI-false
Non-steroidal ( @DRUG$ These drugs in high doses of @DRUG$ shown provoke in pre-clinical studies	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ Based on reports when administered of apomorphine antagonist class , for , @DRUG$ dolasetron alosetron )	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
: diabetic @DRUG$ no effects on @DRUG$ plasma levels fasting blood	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
hypoglycemic action @DRUG$ may potentiated certain anti-inflammatory agents other that protein , chloramphenicol , probenecid coumarins oxidase inhibitors @DRUG$.	DDI-effect
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of @DRUG$.	DDI-false
Injection , benzodiazepines nervous system administered with , phenothiazines barbiturates @DRUG$ and @DRUG$.When lorazepam of sedation and has .	DDI-false
include , , @DRUG$ , erythromycin , , , @DRUG$ , protease quinidine	DDI-false
@DRUG$ of	DDI-false
Dopamine Antagonists : Since @DRUG$ , it , such as @DRUG$ ( or may diminish effectiveness of APOKYN	DDI-false
@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
@DRUG$ : DURAGESIC   is recommended patients who have @DRUG$ days because severe inhibitors has been reported	DDI-false
THERAPY Although studies not , in , @DRUG$ used angiotensin- enzyme inhibitors , betablockers calcium-channel blockers , @DRUG$ without significant adverse interactions	DDI-false
The effects of nonbenzodiazepine agonists @DRUG$ and others are also blocked by @DRUG$.	DDI-effect
The effects of @DRUG$ are antagonized by methylxanthines such as caffeine and @DRUG$.	DDI-effect
Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
In vitro in data @DRUG$ , , metabolism of which result in increase in plasma @DRUG$ levels and QT on the ECG .	DDI-false
@DRUG$ augment activity of @DRUG$.	DDI-effect
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
In addition , analyses of that of of @DRUG$ , phenytoin , @DRUG$ ) CANCIDAS clinically meaningful in caspofungin .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
The are examples of reduce the effect niacin , danazol , ( salbutamol ) , isoniazid @DRUG$ somatropin , @DRUG$ , estrogens , progestogens e.g. , oral contraceptives	DDI-false
In vitro @DRUG$ does not transport digoxin or @DRUG$ ertapenem is substrate for P-glycoprotein-mediated transport .	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
clinical , FLOLAN was used with digoxin diuretics , oral @DRUG$ supplemental oxygen . In a pharmacokinetic substudy in patients receiving or digoxin whom @DRUG$ was apparent clearance values for 23 ) digoxin ( = 30 ) by % and , day of and returned to baseline by 87	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Therefore , potential for an interaction that are metabolized 1A2 ( e.g. , @DRUG$ , @DRUG$ , and zileuton ) .	DDI-false
Drugs that have been with nucleoside , cisplatin , disulfiram , ethionamide , glutethimide , gold hydralazine @DRUG$ , metronidazole nitrofurantoin , phenytoin , ribavirin ,	DDI-false
Interactions Agonist/Antagonist Opioid Agonist/antagonist analgesics ( @DRUG$ , @DRUG$ , dezocine and NOT be administered to a who received or receiving course of therapy analgesic Levo-Dromoran	DDI-false
Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
that been associated with nucleoside , dapsone @DRUG$ , , glutethimide , @DRUG$ , iodoquinol , metronidazole phenytoin ribavirin , and vincristine	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ Keppra twice ) not pharmacokinetics of and	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-mechanism
may with some , like Monoamine ( theoretically @DRUG$ - Arecoline Eproxindine - @DRUG$ cause additive depression Tricyclic antidepressants Flupenthixol the effect Tricyclic antidepressants	DDI-false
agents class such as , lidocaine , @DRUG$ ): use with @DRUG$ may	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
INOmax has been administered @DRUG$ , @DRUG$ surfactant , and ventilation .	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
The drug interaction studies with @DRUG$ were performed both with @DRUG$ and a rapidly hydrolyzed intravenous prodrug form.	DDI-false
Corticosteroids @DRUG$ Diuretics Concomitant treatment with xanthine , or a effect   @DRUG$	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-effect
@DRUG$ should monitored dose adjustments for patients @DRUG$ and PEGASYS .	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Warfarin: Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	DDI-false
- @DRUG$ @DRUG$ should generally be given with diuretics ( such as reduce clearance add	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Products : Concurrent of a quinolone , including ciprofloxacin products such as magnesium or @DRUG$ , , chewable/buffered tablets or products calcium or @DRUG$ may substantially decrease of serum levels considerably desired .	DDI-false
appears the only clinically relevant interaction this kind Mefloquine although of drugs known to conduction ( eg , @DRUG$ or beta-adrenergic blocking agents , calcium blockers , antihistamines or H1-blocking @DRUG$ phenothiazines ) also contribute a of the QTc interval .	DDI-false
Drugs with antiretroviral analogues , , dapsone disulfiram , ethionamide , @DRUG$ gold , , , isoniazid @DRUG$ ,	DDI-false
@DRUG$: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-mechanism
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or @DRUG$.	DDI-false
significant been in interaction with @DRUG$ , , @DRUG$ , and phenobarbital .	DDI-false
drugs include the corticosteroids , , thyroid , estrogens oral @DRUG$ , phenytoin acid sympathomimetics , blocking drugs and	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Therefore, when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
@DRUG$ generally should not be with diuretics because lithiums renal clearance and add a high risk @DRUG$	DDI-false
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and @DRUG$ and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
@DRUG$ (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	DDI-false
@DRUG$ or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
By contrast, @DRUG$ (1 mM) and @DRUG$ (1 mM) had no significant effect on the translocation when added alone.	DDI-false
data prospective clinical currently the 3 approved agents ( @DRUG$ , @DRUG$ delavirdine )	DDI-false
In monkeys, @DRUG$ was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.	DDI-false
Two percent of patients treated concurrently with @DRUG$  and @DRUG$ developed neutropenia (ANC   1 x 109/L).	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$ ( but aspirin ): These drugs combination with high @DRUG$ been shown studies .	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
drugs which may enhance of include aminoglycosides @DRUG$ bacitracin lincomycin clindamycin , , @DRUG$ ) , ,	DDI-false
Therefore, concurrent use of Trileptal with @DRUG$ may render these @DRUG$ less effective.	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Drugs such as @DRUG$ , procainamide , @DRUG$ , antihistamines antidepressants be associated with QT-interval prolongation an risk of ventricular arrhythmia .	DDI-false
Physiological changes resulting with without replacement , may certain concomitant as @DRUG$ @DRUG$.	DDI-false
drugs include the thiazides other , , @DRUG$ , thyroid products , , , nicotinic , sympathomimetics calcium channel blocking drugs @DRUG$.	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
The action @DRUG$ antihistamines , alcohol , @DRUG$ narcotics phenothiazines , medications , CNS depression .	DDI-effect
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
Drug-Drug Between @DRUG$   And Other @DRUG$ Phenytoin Keppra 3000 mg daily no on the pharmacokinetic disposition with refractory .	DDI-false
CNS-Active Drugs Sonata mg potentiated the @DRUG$ 0.75 g/kg balance reaction time 1 ethanol administration on symbol substitution ( DSST , symbol copying test the component of the divided attention for 2.5 @DRUG$ administration	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Antihypertensive medications, other, especially @DRUG$, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
@DRUG$, Methotrexate, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ @DRUG$ or are enhanced by Bretylium	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-mechanism
@DRUG$-A drug interaction study of eplerenone with @DRUG$ has not been conducted.	DDI-false
@DRUG$ no clinically significant effect prothrombin when administered to patients @DRUG$ treatment .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Therefore, concurrent use of @DRUG$ with @DRUG$ may render these contraceptives less effective.	DDI-effect
of agents in ( includes @DRUG$ drugs that can 2D6 doses usually prescribed @DRUG$ other	DDI-false
is a consequence of hepatic metabolism of @DRUG$ @DRUG$ , highly CYP3A4 inhibitor also inhibits .	DDI-mechanism
the selective inhibitors SSRIs ) , fluoxetine , sertraline , @DRUG$ , and @DRUG$ inhibit P450 2D6 they may vary in the extent of inhibition .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
concomitant finasteride doses of mg or more clinical studies acetaminophen , , a-blockers @DRUG$ angiotensin-converting ( ) inhibitors , , beta blockers , , @DRUG$ diuretics , H2 inhibitors also referred NSAIDs , without evidence of clinically	DDI-false
Antacids or @DRUG$: The effect of increased gastric pH on the bioavailability of @DRUG$ was evaluated in 18 healthy adult volunteers.	DDI-false
into the effect @DRUG$ protein binding of @DRUG$ revealed no .	DDI-false
Potential interactions were in pharmacokinetic studies @DRUG$ , contraceptive @DRUG$ warfarin ) through screening the placebo-controlled clinical in epilepsy	DDI-false
@DRUG$ and that are substrates P450 2D6 other , phenothiazines , and propafenone and @DRUG$	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Barbiturates and @DRUG$ not administered receiving	DDI-advise
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Orlistat-@DRUG$ may the absorption	DDI-mechanism
Drugs Should With : amiodarone , quinidine @DRUG$ : @DRUG$ derivatives midazolam triazolam motility agents :	DDI-false
including coumarin , platelet inhibitors @DRUG$ aspirin may increase the of administered with	DDI-effect
of @DRUG$ and @DRUG$ : drug discrimination and behavioral inhibition	DDI-false
@DRUG$ , and @DRUG$ has no pharmacokinetic with nimodipine , has no levels	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and @DRUG$ rarely associated with ventricular fibrillation combined with .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$ should be administered with caution to patients taking @DRUG$, because of the possibility of conduction disturbances.	DDI-advise
To the impact of HAART the clinical patients with HIV-related , systemic non-Hodgkin HIV-NHL , authors with HIV-NHL who were , vincristine and ( ) regimen plus with group of 80 treated with chemotherapy a ( @DRUG$ , , and with plus without receiving @DRUG$ therapy	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
of its lack of anti-platelet @DRUG$ is a @DRUG$ for cardiovascular prophylaxis	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-false
Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	DDI-effect
levels of been increased the concomitant administration of @DRUG$ or hepatic enzyme e.g. , administration inducers e.g. an be anticipated with @DRUG$ as well	DDI-mechanism
Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-false
: of @DRUG$ to taking valproate no @DRUG$ tiagabine binding in from 96.3 to % , which resulted an increase in tiagabine concentration	DDI-false
@DRUG$ has antagonize the skeletal relaxing tubocurarine may potentiate action of @DRUG$.	DDI-effect
Coadministration , oral doses of @DRUG$ @DRUG$ ( mg and 800 , respectively , a a 34 increase in zaleplons concentrations and a % in area under plasma concentration-time curve .	DDI-mechanism
The following examples of that reduce : , niacin @DRUG$ agents ( e.g. salbutamol , isoniazid phenothiazine , somatropin hormones estrogens , progestogens e.g. , @DRUG$ .	DDI-false
System : The use of DURAGESIC   fentanyl transdermal ) with central system depressants , but not limited other opioids , ( e.g. , @DRUG$ ) , , phenothiazines , @DRUG$ , and , cause respiratory depression , and profound potentially in or .	DDI-false
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterase agents.	DDI-int
@DRUG$ the of @DRUG$ absorbed your body .	DDI-false
the neuromuscular blocking of agents such certain @DRUG$ ( e. g. , tetracyclines , bacitracin , polymyxins @DRUG$ , colistin and sodium , salts , , , quinidine .	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and @DRUG$.	DDI-mechanism
: Dihydroergotamine , @DRUG$ , @DRUG$ CONTRAINDICATED due potential for and of the and tissues	DDI-false
therefore concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
@DRUG$ did not have a statistically significant effect on the pharmacokinetics of @DRUG$ (a CYP 2C9 and CYP 2C19 substrate).	DDI-false
Aspirin : @DRUG$ aspirin , protein binding clearance @DRUG$ is	DDI-false
: This study randomized double-blind study 101 randomly assigned to @DRUG$ at doses mg , 1 mg daily @DRUG$.	DDI-false
@DRUG$ , diclofenac , doxycycline erythromycin , imatinib , inhibitors , quinidine , and	DDI-false
Patients @DRUG$ observed closely the diuretic antihypertensive of @DRUG$ achieved	DDI-false
@DRUG$: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$ tubular transport of methotrexate be concomitant administration of ciprofloxacin to of @DRUG$.	DDI-false
@DRUG$ : In some patients the administration anti-inflammatory can reduce diuretic , natriuretic antihypertensive effects of loop @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
bepridil , @DRUG$ , and @DRUG$.	DDI-false
been reports prolongation without TdP patients taking @DRUG$ when @DRUG$ , , or were administered	DDI-false
That Should Be With VIRACEPT : quinidine @DRUG$ astemizole @DRUG$ Antimigraine derivatives agents rifampin Benzodiazepines , triazolam GI motility : cisapride	DDI-false
@DRUG$: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
Coadministration of valdecoxib mg ( day 1 40 ( days - ) with ( mg @DRUG$ ) in % @DRUG$ AUC0 - a 16 increase Cmax % decrease in glucose AUC0 24 .	DDI-false
d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
2 @DRUG$ disintegrating was with anticholinergic with tract to healthy AUC of @DRUG$ and the of the tablet was with propantheline was .	DDI-false
action sulfonylurea potentiated by drugs nonsteroidal agents and drugs that highly bound , @DRUG$ , @DRUG$ , coumarins , monoamine , and beta blocking agents	DDI-false
evaluate the impact plus HAART on clinical of patients with , lymphoma HIV-NHL , compared retrospectively a treated with cyclophosphamide , @DRUG$ @DRUG$ , and prednisone ( HAART 80 who with regimen ( , doxorubicin , teniposide and prednisone with plus bleomycin ) .	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$ or hydrochlorothiazide	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Digoxin: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Lithium serum concentrations should be monitored closely when initiating or changing therapy with @DRUG$ in patients receiving @DRUG$.	DDI-advise
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
CONCOMITANT Although interaction performed studies , cerivastatin was with @DRUG$ , betablockers diuretics , and @DRUG$ clinically interactions	DDI-false
May interact with the following: @DRUG$, colestipol (use with @DRUG$ may prevent the diuretic from working properly;	DDI-effect
The @DRUG$ are a family of @DRUG$ and hypnotic drugs.	DDI-false
@DRUG$ substitute for oral or inhaled @DRUG$.	DDI-false
Other drug interactions @DRUG$, erythromycin and @DRUG$ had no effect on the pharmacokinetics of MHD.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and @DRUG$.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
studies shown @DRUG$ displace , such as , .	DDI-mechanism
Central : concomitant use of transdermal system @DRUG$ other opioids sedatives , @DRUG$ , benzodiazepines anesthetics , phenothiazines and may , , profound sedation potentially or	DDI-false
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of @DRUG$ tolerance 30 min after @DRUG$ overload.	DDI-false
Similarly were @DRUG$ , @DRUG$ , and theophylline , at concentrations in serum ethanol different .	DDI-false
@DRUG$ concomitant administration of @DRUG$ and sulindac in normal in lowering of the of the sulfide metabolite by approximately one-third .	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	DDI-false
- Lithium: Lithium should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
CNS drugs ( e.g. , tranquilizers , @DRUG$ @DRUG$ have potentiating with .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	DDI-false
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and methadone concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Verapamil: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$ or Oral Hypoglycemics Agents b-blocking properties may the blood-sugar-reducing of @DRUG$ and hypoglycemics	DDI-false
- @DRUG$ , @DRUG$	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
concentrations of @DRUG$ , ibuprofen , piroxicam @DRUG$ alter tromethamine binding .	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than zalcitabine.	DDI-false
clinical male ( that mixing @DRUG$ immediately produced attenuation the NovoLog , the bioavailability of @DRUG$ were significantly .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-advise
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Antagonists Since apomorphine is possible that @DRUG$ as the neuroleptics ( phenothiazines , butyrophenones metoclopramide , the effectiveness of	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
are of substances blood-glucose-lowering effect susceptibility to hypoglycemia : antidiabetic , @DRUG$ , disopyramide , fibrates , @DRUG$ monoamine oxidase , , salicylates ) antibiotics	DDI-false
Aspirin: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
In that therapeutic @DRUG$ ( g/mL ) @DRUG$ was from approximately 99.2 % to 97.5 representing potential twofold increase unbound ketorolac levels .	DDI-mechanism
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that @DRUG$ may reduce the antihypertensive effect of @DRUG$, especially in cases of low renin hypertension.	DDI-effect
amprenavir and @DRUG$ or @DRUG$ in males .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Co-medications , @DRUG$ @DRUG$ or St.	DDI-false
Although specific with glaucoma drugs in clinical studies of IOPIDINE possibility of or potentiating effect with depressants @DRUG$ opiates sedatives @DRUG$ .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
in categories result in decreased of bromocriptine : @DRUG$ @DRUG$ , ,	DDI-false
been to produce any effect obtained with aspirin alone and @DRUG$ increases of Nalfon concomitant of and @DRUG$ is recommended .	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Warfarin: @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
In monkeys , the effects of (-)-NANM (+)-NANM or @DRUG$ , were by @DRUG$ ;	DDI-false
Antiacid @DRUG$ , Didanosine Fluoxetine , , carbamazepine , @DRUG$ , Rifampin , Ritanovir Saquinavir	DDI-false
Having Vasodilator on the of use other @DRUG$ @DRUG$ for not	DDI-false
to this pharmacological interaction , describes a chemical @DRUG$ ( a @DRUG$ ) and under conditions those in vivo	DDI-false
Therefore @DRUG$ , the should to the of @DRUG$ .	DDI-false
Drug : some drugs @DRUG$ MAOI could affect pharmacodynamics - @DRUG$ Ethanol : cause additive Tricyclic : Flupenthixol effect antidepressants	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Contraceptives , Oral , Transdermal and Implantable study the oral contraceptive @DRUG$ of @DRUG$ and estradiol levels 14 % , .	DDI-false
Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	DDI-mechanism
appears of this Mefloquine although theoretically , of other drugs known alter eg , @DRUG$ beta-adrenergic blocking agents , calcium channel blockers antihistamines or @DRUG$ , phenothiazines might contribute a of the QTc	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Therapeutic concentrations digoxin , warfarin , @DRUG$ @DRUG$ piroxicam did ketorolac binding	DDI-false
of @DRUG$ tolerance in dogs with ketamine , Innovar , @DRUG$ , the ventricular tachycardia was significantly , the LD50 , ketamine or Innovar .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
were clinical , @DRUG$ oral contraceptive , @DRUG$ , probenecid ) and through pharmacokinetic in the placebo-controlled clinical studies .	DDI-false
@DRUG$ or protriptyline other tricyclics striking sustained increases in concentration @DRUG$ in the ;	DDI-false
In a Phase I escalating doses of TAXOL 110 200 mg/m2 and @DRUG$ 50 or 75 mg/m2 ) sequential infusions , myelosuppression was TAXOL was after than the sequence @DRUG$ before ) .	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Other drug interactions Cimetidine, @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
These drugs include the and , @DRUG$ phenothiazines , estrogens oral contraceptives phenytoin , nicotinic , sympathomimetics , blocking drugs , @DRUG$.	DDI-false
The following examples substances reduce , niacin @DRUG$ , diuretics , sympathomimetic agents ( e.g. epinephrine @DRUG$ , isoniazid thyroid hormones ( oral contraceptives	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
administration of @DRUG$ doubled @DRUG$.	DDI-mechanism
Potential between @DRUG$ substrate CYP3A4 , @DRUG$ ritonavir saquinavir indinavir , ) which substrates and/or of , not been evaluated in trials	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
pharmacokinetic data indicate oral @DRUG$ markedly in a of	DDI-false
Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Another @DRUG$ inhibits the metabolism of astemizole , concentrations of astemizole and its @DRUG$ may QT intervals	DDI-false
: Amiodarone should be caution in receiving -@DRUG$ agents ( e.g. , a CYP3A4 or channel , verapamil , a @DRUG$ inhibitor ) because of potentiation bradycardia , sinus arrest , ;	DDI-false
Antiarrhythmic agents , such @DRUG$ , , @DRUG$ have effect	DDI-false
Urinary alkalinizing agents (@DRUG$, some @DRUG$) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.	DDI-false
In patients with chronic hepatitis PEGASYS in with @DRUG$ did affect @DRUG$ distribution clearance	DDI-false
@DRUG$, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Antihypertensives Amiodarone should used with caution in   -receptor blocking agents e.g. propranolol CYP3A4 ) or @DRUG$ e.g. @DRUG$ a substrate and CYP3A4 because the potentiation bradycardia arrest , and AV ;	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
that have associated peripheral neuropathy include antiretroviral analogues , @DRUG$ , , , glutethimide , hydralazine , , metronidazole , nitrofurantoin , phenytoin , @DRUG$ , .	DDI-false
vasopressors, such as @DRUG$ and @DRUG$;	DDI-false
No significant or ) interactions have been found interaction studies @DRUG$ , @DRUG$ warfarin , nifedipine .	DDI-false
Another @DRUG$ , ketoconazole , inhibits the resulting plasma of @DRUG$ active metabolite which	DDI-false
The following of may reduce the blood-glucose-lowering : , , @DRUG$ , @DRUG$ agents , salbutamol , terbutaline , phenothiazine , thyroid estrogens , e.g. in oral	DDI-false
Concomitant of @DRUG$ that cytochrome P450 2D6 may doses than for the @DRUG$ or the .	DDI-false
@DRUG$ has been @DRUG$ , dobutamine , , and	DDI-false
MAO inhibitors @DRUG$ as well as of , @DRUG$ metabolism	DDI-mechanism
that both dexamethasone and retinyl acetate , possibly other glucocorticoids @DRUG$ of prostate a dose-dependent of @DRUG$ and EGF .	DDI-effect
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
In Europe, @DRUG$  was observed to occasionally intensify the effect of @DRUG$ taken concomitantly by patients suffering from hypertension;	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Because has not shown to any effect aspirin alone and the of excretion @DRUG$ the Nalfon @DRUG$ is not .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
celecoxib have significant with @DRUG$ and @DRUG$.	DDI-false
clinical significance reduction is not known , recommended to be ingested with .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
associated peripheral neuropathy include antiretroviral nucleoside analogues @DRUG$ @DRUG$ , , disulfiram ethionamide , iodoquinol , isoniazid , metronidazole , nitrofurantoin , , and	DDI-false
@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
@DRUG$ (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Based on known profiles clinically are VIRACEPT dapsone , , erythromycin @DRUG$ .	DDI-false
Hypotension Patients Diuretic Therapy : especially those whom @DRUG$ therapy instituted well those dietary restriction dialysis experience reduction blood usually within hour the initial dose @DRUG$.	DDI-false
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-false
Drug Interactions Flupenthixol interact with some @DRUG$ ( MAOI ): could theoretically pharmacodynamics - Eproxindine - Ethanol Flupenthixol and @DRUG$ additive CNS - Tricyclic : the Tricyclic antidepressants	DDI-false
@DRUG$ with , phenobarbital acetaminophen , and @DRUG$ with phenobarbital at high the of the target .	DDI-false
The hypoglycemic action of sulfonylurea drugs @DRUG$ and drugs that are highly protein , @DRUG$ chloramphenicol , probenecid , , monoamine , and beta adrenergic agents	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
intake @DRUG$ K may reduce absorption vitamin K.	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, carbamazepine, and phenobarbital.	DDI-false
lidocaine/quinidine , @DRUG$/valproic quinidine/lidocaine theophylline/acetaminophen ,	DDI-false
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with @DRUG$ including @DRUG$.	DDI-false
@DRUG$ had no significant effect prothrombin time when receiving chronic @DRUG$ treatment .	DDI-false
Binding to plasma protein is not significantly altered by @DRUG$, @DRUG$, or phenylbutazone.	DDI-false
In several @DRUG$ s that cytochrome P450 decrease plasma of @DRUG$ .	DDI-mechanism
Drug-Drug Between Keppra Other Drugs ( ) @DRUG$   ) had no on the of @DRUG$ epilepsy	DDI-false
Use With @DRUG$ @DRUG$ is genotoxic and mutagenic.	DDI-false
inhibitors sulfate , @DRUG$ HC1 Concomitant of @DRUG$ and cause .	DDI-false
Rifampin: Co-administration of @DRUG$ with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-mechanism
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Interactions Mixed Opioid @DRUG$ ( eg @DRUG$ , butorphanol , dezocine and ) should a patient has or a with pure agonist opioid such	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
These results suggest that both @DRUG$ and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
HIV Protease Inhibitors 800 @DRUG$ in a 16-fold in vardenafil AUC , increase @DRUG$ and a	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of @DRUG$ given as a single dose.	DDI-false
That Coadministered Antiarrhythmics amiodarone Antihistamines : @DRUG$ , @DRUG$ rifampin Benzodiazepines GI motility cisapride	DDI-false
Important Levosimendan does not clinically important @DRUG$ beta-blockers , , @DRUG$ itraconazole .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
- @DRUG$ @DRUG$ bumetanide ) reduce renal add risk lithium toxicity .	DDI-advise
, phenobarbital/acetaminophen quinidine/lidocaine , and valproic acid/phenobarbital .	DDI-false
@DRUG$ interact with thinners , drugs cold and ) , drugs , , @DRUG$ , blood	DDI-int
Colestipol-Concomitant intake of @DRUG$ @DRUG$ absorption	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
inhibitors azole antifungals , , doxycycline , erythromycin , @DRUG$ , nicardipine , @DRUG$ , quinidine verapamil .	DDI-false
The absorption of tetracycline, furosemide, @DRUG$, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen , acid and acid/@DRUG$.	DDI-false
Other Oral @DRUG$ ( 500 daily did not influence the pharmacokinetics of oral @DRUG$ ethinyl estradiol mg the and progesterone indicating that impairment is .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Coadministration ( 40 mg BID day and 40 mg ( 2 - 7 ) with glyburide glyburide resulted in % @DRUG$ AUC0 12 and @DRUG$ Cmax 16 decrease in glucose AUC0 - 24	DDI-false
@DRUG$: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-false
Nephrotoxic agents Concomitant and agents with e.g. aminoglycosides ( e.g. , tobramycin , @DRUG$ ) B , intravenous pentamidine , @DRUG$ , and non-steroidal anti-inflammatory ] contraindicated .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/@DRUG$).	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-mechanism
@DRUG$, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
HMG-CoA Reductase Inhibitors @DRUG$ in @DRUG$ reports of myopathy/rhabdomyolysis	DDI-false
@DRUG$: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
conversely, @DRUG$ may interfere with @DRUG$ (i.e., guanethidine, a-methyldopa).	DDI-int
with Analgesics : Agonist/antagonist ( eg , @DRUG$ , @DRUG$ ) NOT be patient has received a course of with a agonist opioid analgesic such .	DDI-false
@DRUG$ and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
Estrogens, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
Two ; ) submitted to daily treatment with synthetic solutions @DRUG$ methanol , higher @DRUG$ acetaldehyde proportions as those found in common fermented alcoholic beverages ;	DDI-false
Central System Depressants : use DURAGESIC @DRUG$ transdermal system ) other central nervous , but other , @DRUG$ , hypnotics , tranquilizers ( e.g. benzodiazepines skeletal muscle relaxants , and alcohol , , sedation or in or	DDI-effect
Ingestion of diclofenac may increase serum concentrations of digoxin and @DRUG$ and increase @DRUG$ s nephrotoxicity.	DDI-false
5HT3 of hypotension and loss consciousness when apomorphine administered @DRUG$ the use with drugs 5HT3 antagonist class for ondansetron , , @DRUG$ , , contraindicated .	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
@DRUG$ therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.	DDI-false
@DRUG$, @DRUG$, and MAOIs may increase anticholinergic effect of clidinium.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
Standard monitoring of methotrexate-related toxicity should be continued if @DRUG$ and @DRUG$ are administered concomitantly.	DDI-advise
intake colestipol and vitamin absorption @DRUG$.	DDI-false
Diuretics: @DRUG$ and other NSAIDs can inhibit the activity of @DRUG$.	DDI-effect
@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
@DRUG$ had no significant effect on the anticoagulant effect of @DRUG$ in healthy subjects on stable warfarin therapy.	DDI-false
: should used with caution -receptor blocking agents propranolol @DRUG$ inhibitor or calcium e.g. verapamil , , @DRUG$ inhibitor because of of bradycardia arrest ,	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
The superiority of @DRUG$ over @DRUG$-based regimens has been observed in comparative data in a subset of patients with high viral loads.	DDI-false
following are examples substances the corticosteroids @DRUG$ , diuretics , sympathomimetic agents ( , isoniazid , , somatropin thyroid hormones progestogens ( e.g. , @DRUG$ )	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
These and other diuretics corticosteroids phenothiazines , @DRUG$ , oral , @DRUG$ nicotinic , , channel	DDI-false
Edema has been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	DDI-effect
Other therapy studies were not finasteride or were used clinical acetaminophen , acid a-blockers angiotensin-converting ( ACE ) inhibitors , benzodiazepines , blockers cardiac , diuretics , @DRUG$ HMG-CoA reductase inhibitors synthetase also referred to as ) , @DRUG$ without evidence of clinically interactions .	DDI-false
@DRUG$ : of 5 of @DRUG$ 600 mg BID AUC ritonavir %	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Dose adjustment is . effect concentrations @DRUG$ ,	DDI-false
Multivitamins, or other products containing @DRUG$ or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or amoxicillin.	DDI-false
plasma may @DRUG$ plasma concentrations : Caution is recommended when of the CYP3A4 family ( , ketoconazole , itraconazole @DRUG$ , clarithromycin ) .	DDI-false
with alcohol , blood thinners , drugs , cold , sinus medicines , diabetic @DRUG$ NSAIDs like @DRUG$ , and pressure	DDI-false
@DRUG$ ( ): SSRIs , @DRUG$ , paroxetine , sertraline have been reported to cause hyperreflexia , coadministered with agonists .	DDI-false
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
treatment CYP3A4 activity ( @DRUG$ ritonavir @DRUG$ , erythromycin etc . reduction of the budesonide should be .	DDI-false
@DRUG$ of @DRUG$ digoxin were digoxin by approximately 20	DDI-false
Conversely administration of @DRUG$ 1 mg not alter dose of	DDI-false
Other therapy specific interaction were not performed finasteride of 1 mg or more concomitantly in clinical with @DRUG$ acetylsalicylic acid , angiotensin-converting ACE ) inhibitors benzodiazepines beta , blockers cardiac , H2 antagonists @DRUG$ ( also referred as ) and quinolone anti-infectives without evidence of clinically adverse	DDI-false
, Diuretics Concomitant with , @DRUG$ , may a possible of @DRUG$	DDI-effect
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, @DRUG$ or @DRUG$).	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
@DRUG$: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-false
The possibility hypotensive effects with @DRUG$ be minimized by or the salt one week treatment with captopril ( @DRUG$ , therapy with doses ( .	DDI-false
Psychoactive Drugs Hallucinations reported @DRUG$ was in patients taking psychoactive ( @DRUG$ , .	DDI-effect
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.	DDI-mechanism
@DRUG$ : causes slight ( about 10 % steady-state @DRUG$	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
drugs which the neuromuscular blocking of agents such @DRUG$ include certain antibiotics e. , aminoglycosides tetracyclines , polymyxins , colistin , and ) , magnesium , local and @DRUG$.	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Drug-Drug Interactions Keppra   @DRUG$ @DRUG$ ( daily no on pharmacokinetic in patients refractory epilepsy	DDI-false
Dosage adjustment may be warranted when @DRUG$ is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic @DRUG$ levels may rise resulting in toxicity.	DDI-false
been reported following @DRUG$ with aminoglycoside diuretics as @DRUG$.	DDI-effect
drugs which may the such as NUROMAX ( g. , tetracyclines , , @DRUG$ clindamycin colistin sodium colistimethate ) , magnesium @DRUG$ , , procainamide , and quinidine	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Monitoring measurement @DRUG$ serum during @DRUG$ therapy be	DDI-advise
Other enhance the of nondepolarizing agents such as NUROMAX ( , , @DRUG$ , @DRUG$ and sodium colistimethate magnesium salts , lithium , local , and .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
Important Interactions To @DRUG$ does not important pharmacokinetic @DRUG$ , felodipine , digoxin , warfarin isosorbide mononitrate , ethanol itraconazole	DDI-false
: @DRUG$ injection benzodiazepines , of central system administered @DRUG$ , phenothiazines , barbiturates MAO and . When scopolamine is used with increased incidence sedation , , behavior been .	DDI-effect
Antacids clinical pharmacology study coadministration of an @DRUG$ ( hydroxide , magnesium hydroxide with fosinopril serum levels and urinary as suggesting @DRUG$ may absorption fosinopril	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
clarithromycin Didanosine @DRUG$ , , Phenytoin , Phenobarbitol , carbamazepine , @DRUG$ Saquinavir .	DDI-false
@DRUG$     @DRUG$ antagonism	DDI-false
Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
: of single doses @DRUG$ 20 and @DRUG$ mg produced additive effects on decreased alertness impaired psychomotor for 2 .	DDI-effect
@DRUG$: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.	DDI-false
Tagamet effect certain enzyme been reported to reduce the metabolism @DRUG$ propranolol , @DRUG$ , , certain antidepressants lidocaine theophylline and elimination and levels these .	DDI-false
possible between @DRUG$ and a has reported in potentiation of the action of @DRUG$.	DDI-false
the doses of naloxone required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of @DRUG$.	DDI-false
drug interactions between Keppra   other @DRUG$ ( , gabapentin , phenobarbital , , @DRUG$ and valproate were also assessed by evaluating the serum concentrations of levetiracetam these during placebo-controlled clinical .	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
The action of the be by anticonvulsants , antihistamines , barbiturates monoamine inhibitors @DRUG$ , @DRUG$ , or that CNS depression .	DDI-false
Therapeutic @DRUG$ , , piroxicam , , phenytoin @DRUG$ protein binding .	DDI-false
that been peripheral @DRUG$ , chloramphenicol , gold hydralazine , isoniazid , @DRUG$ , nitrofurantoin , ribavirin and .	DDI-false
The majority patients RA clinical studies received or more of the following medications with : NSAIDs , @DRUG$ , chloroquine @DRUG$ , leflunomide ,	DDI-false
@DRUG$ : ( pentazocine , butorphanol @DRUG$ should NOT be administered who or is receiving course therapy with a pure Levo-Dromoran	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Skeletal muscle relaxants, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the @DRUG$.	DDI-false
studies maintenance doses of @DRUG$ , or @DRUG$ effect on the warfarin pharmacokinetics .	DDI-false
Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antiarrhythmics Other antiarrhythmic drugs such , , @DRUG$ @DRUG$ have used with	DDI-false
@DRUG$: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	DDI-false
Co-administration @DRUG$ did the pharmacokinetics @DRUG$.	DDI-false
Delayed Reactions to @DRUG$ review of literature revealed 12.6 % range 11 - 28 % ) treated with containing regimens who subsequently administered @DRUG$ , atypical .	DDI-false
Other may enhance the blocking @DRUG$ @DRUG$ ( g. aminoglycosides , bacitracin , lincomycin , clindamycin , and sodium , salts lithium anesthetics procainamide and quinidine .	DDI-effect
Effects of @DRUG$ on Drug Enzymes Drug Systems @DRUG$ inhibits CYP3A4 relevant	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
of studies in patients taking TYSABRI and AVONEX ) @DRUG$ inconclusive with to need for adjustment the @DRUG$ acetate .	DDI-false
( @DRUG$ ): Steady state exposure ) @DRUG$ mg BID 12 days was decreased % with 300 mg for 12 days phenytoin ( a CYP inducer ) .	DDI-false
@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds.	DDI-effect
Because @DRUG$ has been additional beyond that obtained with aspirin and because aspirin the , the concomitant use of Nalfon and @DRUG$ is .	DDI-false
For example, when @DRUG$ are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
@DRUG$ a agonist , is possible antagonists as the neuroleptics ( butyrophenones @DRUG$ , effectiveness .	DDI-false
@DRUG$ Plasma @DRUG$ levels and clearance at not affected mg cerivastatin sodium	DDI-false
In these drugs that similar bepridil , including @DRUG$ such procainamide , glycosides and @DRUG$.	DDI-false
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with @DRUG$, @DRUG$ should be employed with caution.	DDI-false
Other Cardiovascular Agents : and have been used concomitantly agents , methyldopa , calcium-blocking agents @DRUG$ @DRUG$ of clinically	DDI-false
Magnesium- aluminum-containing antacids , containing sulfate ( iron ) , @DRUG$ cations or @DRUG$ didanosine ) or pediatric powder for oral not be taken hours 2 hours after FACTIVE	DDI-false
The pressor effects of catecholamines such as dopamine or @DRUG$ are enhanced by @DRUG$.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
structurally currently available inhibitors @DRUG$ @DRUG$ ) leading biopharmaceutical properties relative to the other this .	DDI-false
Since @DRUG$ a CYP3A4 , there is the potential that of St. s Wort patients @DRUG$ could reduced levels	DDI-false
Indinavir : Coadministration @DRUG$ 83 % increase @DRUG$ plasma AUC a % indinavir plasma A.C.	DDI-false
specific not been coadministration ( eg calcium channel disopyramide , @DRUG$ , @DRUG$ quinidine warfarin , , cyclosporine derivatives , , fentanyl , alfentanyl , triazolam ) elevated plasma when coadministered saquinavir	DDI-false
Thus, @DRUG$ should not be administered concurrently with @DRUG$.	DDI-advise
12-week study conducted no difference in the incidence gastroduodenal ulcers low-dose 81 mg ) enteric aspirin plus @DRUG$ 25 taking @DRUG$ 2400 mg	DDI-false
Administration of epinephrine patients receiving cyclopropane @DRUG$ @DRUG$ sensitize the myocardium	DDI-false
Because theoretical basis , use of ergot-type ( @DRUG$ or @DRUG$ ) 24 hours each should .	DDI-false
The increase the @DRUG$ AUC @DRUG$ % : to .	DDI-mechanism
Clinical studies of @DRUG$ alone or in combination with @DRUG$ did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.	DDI-false
The intake of @DRUG$ does not the either @DRUG$.	DDI-false
In presence these @DRUG$ , of @DRUG$ may be or adenosine not	DDI-advise
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, @DRUG$, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ @DRUG$ interact orally anticoagulant the not clinically significant .	DDI-false
In a study which patients with RA to 24 weeks @DRUG$ and anakinra therapy 7 % rate of serious infections , than that observed @DRUG$   alone 0 % .	DDI-false
@DRUG$ : Potentiation of ( and substrate ) @DRUG$ always can result in serious or fatal bleeding .	DDI-false
Cyclosporine , Digoxin like other , through effects prostaglandins , cause elimination of drugs to elevated of @DRUG$ , , @DRUG$ .	DDI-false
phenobarbital , , @DRUG$ both therapeutic @DRUG$ at three different concentrations .	DDI-false
has the adverse effects of exposure the interaction @DRUG$ congeners and @DRUG$ , coexisting the contents alcoholic beverages	DDI-false
With @DRUG$ Antiarrhythmics : , : @DRUG$ Antimigraine : ergot derivatives Antimycobacterial Benzodiazepines midazolam , GI agents :	DDI-advise
Binding In , diclofenac interferes minimally at with binding @DRUG$ ( 20 % binding @DRUG$ 10 in binding ) warfarin .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
@DRUG$ and @DRUG$ may additive hypotensite due to of other metabolism	DDI-mechanism
Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
specific have been performed coadministration with drugs that are mainly metabolized channel , dapsone , , , , , @DRUG$ , , @DRUG$ alprazolam , triazolam may have elevated concentrations coadministered	DDI-false
drugs which may the neuromuscular blocking action such as NUROMAX certain e. g. , , bacitracin @DRUG$ lincomycin , clindamycin , colistin , and salts , local anesthetics , and	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
monkeys , @DRUG$ about times more (+)-NANM decreasing , whereas pigeons @DRUG$ with (+)-NANM .	DDI-false
@DRUG$ : , such , @DRUG$ and phenytoin	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Compounds warfarin , @DRUG$ phenytoin , @DRUG$ antipyrine .	DDI-false
@DRUG$ ( with potential must be administered together @DRUG$ retard .	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other concomitant therapy specific interaction were not performed doses of mg used clinical with , acetylsalicylic acid a-blockers analgesics @DRUG$ , @DRUG$ , cardiac nitrates diuretics , H2 , synthetase ( also to without of clinically adverse interactions	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Warfarin: @DRUG$ enhances the effect of @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
No important interactions when @DRUG$ was used concomitantly or @DRUG$.	DDI-false
@DRUG$ @DRUG$ increase autonomic irritability sensitize the to the of certain administered , dopamine .	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
addition @DRUG$ induce a of 3A CYP3A5 ) responsible for the dihydropyridine antagonists and oral @DRUG$ , resulting in plasma concentration of drugs	DDI-false
Acetaminophen lidocaine @DRUG$ quinidine , @DRUG$ , valproic pooled at therapeutic .	DDI-false
@DRUG$ : Plasma concentrations atorvastatin decreased @DRUG$ atorvastatin coadministered	DDI-false
@DRUG$ : Co- administration warfarin and cerivastatin to healthy not in or when compared to @DRUG$ and	DDI-false
No Interactions To Date Levosimendan not have clinically pharmacokinetic interactions with @DRUG$ , beta-blockers , felodipine , warfarin @DRUG$.	DDI-false
that the effect hypoglycemia : oral antidiabetic ACE , disopyramide @DRUG$ , fluoxetine monoamine ( MAO inhibitors , , @DRUG$ ( , ) sulfonamide antibiotics .	DDI-false
@DRUG$ healthy subjects @DRUG$ a inhibitor , at twice daily for 7 days ( AUC to was to 3.6-fold control and half-life 1.7-fold of	DDI-false
Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Other Contraceptives ( twice did not influence @DRUG$ containing 0.03 mg @DRUG$ of , indicating that impairment contraceptive is unlikely .	DDI-false
Drugs that have neuropathy @DRUG$ chloramphenicol , , dapsone , ethionamide , , @DRUG$ , nitrofurantoin , , and vincristine .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Serial plasma and urine samples for measurement of amprenavir, @DRUG$, and rifampin and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
This time window for other @DRUG$ , which are usually administered 2 or after @DRUG$.	DDI-advise
Bacteriostatic Antibiotics: @DRUG$, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
@DRUG$ altered hypo-prothrombinemic effect ) , barbiturates , rifampin microsomal enzyme system decreased effect of diethylstilbestrol , @DRUG$ ( increased effect of .	DDI-false
Concurrent administration of drugs nephrotoxic ( e.g. aminoglycosides , ) , , cytotoxic ) ( e.g. ) or ( , @DRUG$ @DRUG$ ) effects with PROLEUKIN may increase systems .	DDI-false
A study eight healthy volunteers shown a % increase in mean @DRUG$ plasma concentrations and a 90 % in after one week cimetidine mg/day and @DRUG$ at 90 mg/day .	DDI-false
agents : Gastrointestinal acidifying guanethidine , @DRUG$ @DRUG$ , acid , fruit etc . absorption of amphetamines .	DDI-false
However , is risk of bleeding @DRUG$ , should employed when @DRUG$ is that affect	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ apparently through an effect systems has reported reduce the anticoagulants , propranolol , nifedipine diazepam , antidepressants @DRUG$ and elimination blood these drugs .	DDI-mechanism
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, @DRUG$, and phenobarbital.	DDI-false
@DRUG$ Angiotensin II Antagonists ( Congestive Failure Post-Myocardial Infarction)- EPHESUS 3020 91 % receiving 25 to 50 also received @DRUG$ or angiotensin II receptor ( ACEI/ARB	DDI-false
Verapamil: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
Ephedrine : @DRUG$ may enhance the clearance of , decreased blood levels physiologic , thus an in @DRUG$ dosage	DDI-false
In results from regression of pharmacokinetic suggest that of other inducers clearance ( nevirapine , @DRUG$ , dexamethasone or ) CANCIDAS may meaningful in @DRUG$ concentrations .	DDI-false
Rifampin significantly the of by 82 % @DRUG$ no @DRUG$ pharmacokinetics .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as propranolol and @DRUG$.	DDI-effect
@DRUG$: A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Concomitant cyclophosphamide @DRUG$ , @DRUG$ and prednisone plus active therapy in with virus-related lymphoma .	DDI-false
of @DRUG$ Drugs : of cimetidine ( 800 mg/day ) to @DRUG$ chronically had effect .	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine.	DDI-effect
@DRUG$: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Dexamethasone : Steady-state trough of were about 56 higher when mg @DRUG$ coadministered with @DRUG$ ( 15 ) neurocysticercosis	DDI-mechanism
other narcotic analgesics general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic depressants @DRUG$ concomitantly with @DRUG$ may exhibit an additive depression	DDI-effect
In interactions ( 2 weeks oral Cordarone of @DRUG$ @DRUG$ .	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
from when antimuscarinics , @DRUG$ haloperidol , @DRUG$ , monoamine oxidase MAO inhibitors antidepressants or some antihistamines	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-false
hypoglycemic action @DRUG$ may anti-inflammatory other that are highly protein bound , salicylates @DRUG$ chloramphenicol probenecid , , oxidase and adrenergic agents	DDI-effect
interact with ( levothyroxine , @DRUG$-containing products , , e.g. , , , and pump inhibitors e.g. , lansoprazole @DRUG$ ) .	DDI-false
Concomitant @DRUG$, @DRUG$, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Antidepressants, tricyclic: @DRUG$ may enhance the activity of tricyclic or @DRUG$;	DDI-effect
- Methotrexate (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	DDI-false
@DRUG$ as 1.0 subcutaneous q12h for four doses did alter the pharmacokinetics of @DRUG$ or of healthy adults .	DDI-false
@DRUG$ , @DRUG$ , quinine , can cause respiratory	DDI-false
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly.	DDI-false
@DRUG$ Because does not affect the pharmacokinetics @DRUG$ interactions with other same isozymes are not expected .	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or @DRUG$ with the addition of tiagabine given as a single dose.	DDI-false
Central Nervous The use of   transdermal ) @DRUG$ including not , , hypnotics e.g. , benzodiazepines , general @DRUG$ skeletal muscle relaxants , hypotension profound sedation , or potentially coma or death .	DDI-false
@DRUG$ dose @DRUG$ did not affect pharmacokinetics state .	DDI-false
Antiarrhythmics : Other antiarrhythmic , such @DRUG$ , , disopyramide and phenytoin , used @DRUG$.	DDI-false
When other potent parental @DRUG$, such as @DRUG$, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-effect
- Oral @DRUG$ (birth control pills) containing @DRUG$ or	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, @DRUG$ and phenobarbital.	DDI-false
Antibiotics : In and/or vivo data that erythromycin troleandomycin markedly inhibit of @DRUG$ , which can in an @DRUG$ and QT interval .	DDI-false
@DRUG$: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
Rifampin: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
@DRUG$ therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.	DDI-false
The action of potentiated by @DRUG$ alcohol , oxidase , @DRUG$ drugs depression	DDI-false
Nervous System : The concomitant use of   ( @DRUG$ transdermal system ) other central nervous to , sedatives , tranquilizers e.g. benzodiazepines , general , , @DRUG$ , alcohol , may respiratory , hypotension , profound , or result in coma death	DDI-effect
@DRUG$ : Increased activity of both and @DRUG$ may occur used concurrently	DDI-false
In addition, @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
inhibitors CYP3A4 activity ( eg , @DRUG$ and itraconazole ) decrease gefitinib and increase @DRUG$ plasma	DDI-mechanism
Antacids : In clinical pharmacology study , coadministration of aluminum hydroxide , magnesium hydroxide , @DRUG$ reduced serum and urinary as with antacids may	DDI-false
Additive may occur when @DRUG$ is with antimuscarinics , amantadine @DRUG$ tricyclic antidepressants or .	DDI-effect
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or phenobarbital.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
, drugs low @DRUG$ @DRUG$ , and theophylline , could delayed increases serum leading to a	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In the these methylxanthines , larger doses of @DRUG$ be required @DRUG$ may not effective	DDI-false
Potential   and other @DRUG$ @DRUG$ , phenobarbital , , primidone also evaluating the concentrations of levetiracetam and these clinical studies .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The in RA clinical received ORENCIA : MTX NSAIDs , , TNF , azathioprine , @DRUG$ , gold @DRUG$ leflunomide , sulfasalazine and	DDI-false
Central Nervous : The fentanyl ) with system but not opioids , tranquilizers e.g. , general @DRUG$ , @DRUG$ cause hypotension profound potentially in or death	DDI-false
Products : Concurrent a quinolone including multivalent such as magnesium or @DRUG$ sucralfate , tablets or , @DRUG$ , , decrease the ciprofloxacin , in serum and than	DDI-false
concomitant therapy Although interaction were not , finasteride of 1 mg in clinical studies acetaminophen , acetylsalicylic analgesics angiotensin-converting enzyme ACE anticonvulsants @DRUG$ , calcium-channel blockers , cardiac H2 @DRUG$ prostaglandin inhibitors also referred to as NSAIDs and evidence of clinically significant	DDI-false
@DRUG$ should at least before conducting an stress	DDI-advise
availability of potent reverse inhibitor (NNRTI)-based @DRUG$ therapy concerns metabolic disturbances have to in HIV .	DDI-false
with IV @DRUG$ such nitroglycerin , or IV @DRUG$ has not were not trials )	DDI-false
concomitant Although specific studies performed , 1 more concomitantly used acetaminophen acetylsalicylic , analgesics ) blockers , , H2 antagonists , HMG-CoA , @DRUG$ ( also referred to NSAIDs , and @DRUG$ evidence of clinically significant adverse interactions	DDI-false
Oral @DRUG$: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, @DRUG$ or fluconazole.	DDI-false
@DRUG$ have any on the pharmacokinetics of @DRUG$	DDI-false
@DRUG$ @DRUG$ should	DDI-advise
Coadministration of @DRUG$ @DRUG$ latter drugs .	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Example include @DRUG$ , , diclofenac , doxycycline , imatinib isoniazid , @DRUG$ , nicardipine propofol , protease , quinidine , and verapamil	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
peripheral caused by doses @DRUG$ is by	DDI-effect
Coingestion of with @DRUG$ @DRUG$ acetaminophen and phenobarbital to concentrations decreases the binding of target .	DDI-false
Serotonin Reuptake Inhibitors ( ): SSRIs , @DRUG$ , , sertraline ) have been to cause weakness , hyperreflexia incoordination	DDI-effect
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
Potential pharmacokinetic in clinical pharmacokinetic studies ( @DRUG$ oral @DRUG$ warfarin , the placebo-controlled clinical in patients .	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
plasmaconcentration metabolized ( , dihydropyridine @DRUG$ etc ) .	DDI-false
The pharmacokinetics @DRUG$ unaltered in the presence of @DRUG$ vice .	DDI-false
nevirapine therapy with @DRUG$ 48 initial observed and observed with	DDI-false
Higher concentrations 10(-8 @DRUG$ ( 3 X 10(-8 ) 10(-7 M ) activity	DDI-effect
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Therefore, concurrent use of @DRUG$ with hormonal contraceptives may render these @DRUG$ less effective.	DDI-false
Interactions interact some drugs like Monoamine oxidase inhibitors @DRUG$ flupenthixol - Ethanol Flupenthixol @DRUG$ depression Tricyclic antidepressants Flupenthixol the Tricyclic	DDI-false
@DRUG$ : Amphetamines of @DRUG$ ;	DDI-false
Antagonists : of and consciousness when administered @DRUG$ , the use of drugs @DRUG$ ( for , , , dolasetron , palonosetron and ) contraindicated .	DDI-false
Other with @DRUG$ @DRUG$ substrate combination amiodarone may cause and .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
addition , results of pharmacokinetic data suggest that of of clearance efavirenz , nevirapine , , @DRUG$ or may in @DRUG$ .	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
( @DRUG$ [ , ] , oxandrolone e.g. Anavar ] e.g. , @DRUG$ ] stanozolol e.g. Winstrol or	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Although been performed , coadministration , channel blockers , @DRUG$ , cyclosporine , @DRUG$ , , carbamazepine , fentanyl , alprazolam , triazolam ) may elevated plasma concentrations when with saquinavir ;	DDI-false
: inhibit metabolism @DRUG$ that metabolized by atorvastatin @DRUG$ simvastatin ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
BACKGROUND The of bombesin and hydrochloride ( @DRUG$ a @DRUG$ on the peritoneal metastasis intestinal ( and the index cancers in male Wistar	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
other @DRUG$ concurrent administration @DRUG$ with theophylline to serum concentrations and of its .	DDI-false
@DRUG$ ampicillin , oxacillin doxycycline , , , @DRUG$ vitro of diclofenac in human serum .	DDI-false
interactions occur with concomitant of and drugs that inhibit cytochrome P450 system e.g. , @DRUG$ @DRUG$ , ) , though been studied	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
include antifungals , @DRUG$ @DRUG$ , isoniazid , nicardipine propofol protease inhibitors , quinidine and	DDI-false
Valdecoxib BID ) not combination oral @DRUG$ estradiol mg , 1/35	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
have been isolated of experiencing increases their @DRUG$ was to @DRUG$	DDI-effect
Close supervision and careful adjustment dosage required when Anafranil is administered @DRUG$ or	DDI-false
Methylxanthines @DRUG$ Concomitant treatment with derivatives , steroids or @DRUG$ may possible hypokalemic   .	DDI-false
@DRUG$ @DRUG$ , lidocaine	DDI-false
Although specific with drugs systemic in IOPIDINE of additive effect CNS depressants alcohol barbiturates @DRUG$ , sedatives @DRUG$ considered .	DDI-false
ECG changes result the administration of non-potassium sparing diuretics thiazide can acutely worsened by @DRUG$ , dose the @DRUG$ exceeded .	DDI-false
@DRUG$ , Methylxanthines Concomitant xanthine @DRUG$ or diuretics potentiate a   beta2-agonists .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Conversely, the administration of @DRUG$ (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	DDI-false
Co-administration : use @DRUG$ with @DRUG$ , anticoagulants may the bleeding .	DDI-effect
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$ a substrate both @DRUG$ and	DDI-false
@DRUG$ show a significant effect plasma exposure or renal clearance	DDI-false
@DRUG$ : Since possible that dopamine , @DRUG$ ( phenothiazines , butyrophenones , ) metoclopramide , APOKYN	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
@DRUG$, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
: excretion of @DRUG$ increased and efficacy by in @DRUG$ .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, @DRUG$, or lamotrigine.	DDI-false
Drugs In ( - 10/interaction study the concomitant , gold , chloroquine , @DRUG$ , prednisolone @DRUG$ or significantly peak .	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-int
chains of N-methylthiotetrazole ( cefmenoxime , @DRUG$ , cefamandole , latamoxef ( @DRUG$ can cause vitamin deficiency hypoprothrombinemia .	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
similar association , though less , has suggested , phenylbutazone , @DRUG$ , , @DRUG$ , and possibly with ampicillin tetracyclines	DDI-false
However, LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone.	DDI-effect
@DRUG$ other medications anticholinergic - anticholinergic may be potentiated when medications are with @DRUG$ ;	DDI-false
Although there is documentation a similar @DRUG$ @DRUG$ may	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Aspirin : of @DRUG$ aspirin is not because diclofenac from its binding sites the of @DRUG$ resulting lower concentrations , peak and AUC	DDI-false
to avoid severe reactions all treated @DRUG$ should @DRUG$ ( dexamethasone , diphen-hydramine H2 antagonists ( such )	DDI-false
Potential a substrate of CYP3A4 @DRUG$ , @DRUG$ indinavir are substrates and/or , have evaluated in clinical	DDI-false
taken concomitantly with @DRUG$ for less than days increases plasma @DRUG$ and procainamide 55 % 33 respectively .	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
Acidifying agents Gastrointestinal ( guanethidine @DRUG$ glutamic HCl acid , etc . of @DRUG$.	DDI-mechanism
@DRUG$: @DRUG$ 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-false
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ : The use of ( transdermal with other depressants , including not limited opioids @DRUG$ , tranquilizers e.g. , benzodiazepines ) , anesthetics , muscle , alcohol respiratory depression , sedation , potentially result or death .	DDI-false
administration of ( e.g. , @DRUG$ , indomethacin ) , ( e.g. ) , cardiotoxic , doxorubicin or ( @DRUG$ effects PROLEUKIN toxicity in systems .	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, methotrexate and @DRUG$.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
High-dose @DRUG$ resulting in concentrations 2000 ng/mL oral led to 80 % increase in @DRUG$ a decrease in body clearance etoposide etoposide alone .	DDI-false
In patients @DRUG$/@DRUG$/leucovorin ( with or without AVASTIN	DDI-false
Nitrates: The concomitant use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
After multiple @DRUG$ @DRUG$   mcg IM weekly ) reduced TYSABRI   clearance by approximately 30	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Other : as @DRUG$ , procainamide @DRUG$ , may be QT-interval and risk of ventricular .	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, @DRUG$, simvastatin).	DDI-false
The co-administration of IV such as nitroglycerin @DRUG$ or IV @DRUG$ been these were not with Natrecor in .	DDI-false
@DRUG$, and to a lesser extent, @DRUG$, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.	DDI-false
@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Short-term studies that concomitant administration and @DRUG$ ( @DRUG$ and ) binding of was no in clearance warfarin .	DDI-false
@DRUG$ Coadministration of doses @DRUG$ have relevant of	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
No Interactions not clinically important pharmacokinetic captopril , beta-blockers , , , @DRUG$ , @DRUG$ or .	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ @DRUG$ : Amphetamines activity tricyclic or ;	DDI-false
action of the may potentiated , alcohol , @DRUG$ , narcotics , @DRUG$ , psychotropic medications , or that produce .	DDI-false
the profile in subjects @DRUG$ concomitantly with hypnotics @DRUG$ ( including non-opioid analgesics similar to that subjects these medications .	DDI-false
The following eight target drug/added drug combinations were studied: @DRUG$/@DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Antihypertensives be used with in patients receiving -receptor blocking e.g. , , a CYP3A4 or channel antagonists , verapamil , @DRUG$ , diltiazem , @DRUG$ inhibitor ) because of bradycardia , sinus arrest and	DDI-false
Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Lithium: @DRUG$ decreases lithium renal clearance and increases @DRUG$ plasma levels.	DDI-mechanism
is that @DRUG$ started in patients coumarin , prothrombin should monitored adjustment of the @DRUG$ dose necessary .	DDI-advise
may with alcohol blood , allergy cold sinus ) , diabetic drugs lithium @DRUG$ @DRUG$ like Aleve or Ibuprofen medications	DDI-false
@DRUG$ may serum concentrations and @DRUG$ increase .	DDI-mechanism
Drug : No @DRUG$ following : , @DRUG$ , Maalox	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine.	DDI-false
@DRUG$ increase plasmaconcentration of other CYP3A4 drugs e.g. , triazolo-benzodiazepines , dihydropyridine , certain @DRUG$ etc . .	DDI-mechanism
following are examples of substances may the blood-glucose-lowering effect and hypoglycemia oral @DRUG$ inhibitors fibrates , @DRUG$ , monoamine oxidase ) , propoxyphene , salicylates analog , octreotide ) , .	DDI-false
higher expected @DRUG$ levels when they are begun patients	DDI-mechanism
of GABITRIL other ( @DRUG$ ) : Phenytoin : Tiagabine had the plasma concentrations of @DRUG$ in	DDI-false
majority of in RA clinical one or of concomitant @DRUG$ MTX NSAIDs , corticosteroids , blocking agents , , @DRUG$ , , hydroxychloroquine , sulfasalazine ,	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
ibogaine ( mg/kg mg/kg ) decreases the self-administration of morphine and @DRUG$ and ethanol and @DRUG$ in	DDI-false
@DRUG$ reduced AUC0 - 12 by approximately 20 % , peak blood concentration Cmax ) 16 % , blood concentration ( C12hr in tacrolimus ( 2 doses 12 administered on the of @DRUG$ 70 mg , compared to from control	DDI-false
adjustment is had , @DRUG$.	DDI-false
( , @DRUG$ carbamazepine , @DRUG$ or St.	DDI-false
Dopamine Since dopamine agonist possible dopamine antagonists , the @DRUG$ @DRUG$ , butyrophenones thioxanthenes or metoclopramide , diminish effectiveness of APOKYN .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
@DRUG$: Since both acitretin and @DRUG$ can cause increased intracranial pressure, their combined use is contraindicated.	DDI-false
Drugs Should Not VIRACEPT , : , terfenadine Antimigraine ergot : rifampin Benzodiazepines @DRUG$ @DRUG$ motility cisapride	DDI-false
The are examples of substances the and to hypoglycemia antidiabetic @DRUG$ , disopyramide , fibrates , fluoxetine monoamine ) inhibitors , @DRUG$ , somatostatin ( e.g. , , sulfonamide antibiotics	DDI-false
has with @DRUG$ and depressants hypnotics @DRUG$ , ) .	DDI-false
@DRUG$ : Coadministration of and resulted a 24 % increase concentrations of	DDI-false
majority patients clinical studies received or of medications ORENCIA : MTX @DRUG$ , corticosteroids , @DRUG$ azathioprine chloroquine , , , sulfasalazine .	DDI-false
Prednisone/@DRUG$ Rofecoxib have any clinically effect the @DRUG$ .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ or within taking @DRUG$ central depression may severe blood pressure .	DDI-effect
Nervous System The use of   system with central system but not to @DRUG$ sedatives @DRUG$ ( e.g. , benzodiazepines anesthetics phenothiazines , muscle relaxants and alcohol hypotension , profound potentially	DDI-false
- Mephenytoin (e.g., @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	DDI-false
Multivalent administration @DRUG$ , with multivalent products @DRUG$ or aluminum or products containing , or may substantially the of , resulting and levels lower .	DDI-mechanism
There is no pharmacokinetic interaction between @DRUG$ and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ Antimycobacterial agents: @DRUG$	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
No To Date Levosimendan pharmacokinetic with captopril , @DRUG$ , felodipine digoxin , mononitrate @DRUG$ or	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
The effectiveness of @DRUG$-only is by enzyme-inducing drugs such anticonvulsants @DRUG$ and barbiturates and the antituberculosis .	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
In addition interaction , this novel between ( @DRUG$ @DRUG$ acidic conditions similar to those found resulting a	DDI-false
following are examples of blood-glucose-lowering @DRUG$ niacin danazol sympathomimetic agents ( epinephrine salbutamol , ) , , derivatives , @DRUG$ thyroid , estrogens ( in contraceptives .	DDI-false
@DRUG$ : is to slow metabolism carbamazepine increase its serum levels should be determined prior to administration with @DRUG$ , and toxicity be monitored , adjustment should made .	DDI-false
, drugs that have more activities similar to including @DRUG$ @DRUG$ and procainamide cardiac glycosides and anti-depressants	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Diuretics: @DRUG$ and other @DRUG$ can inhibit the activity of diuretics.	DDI-false
In monkeys, @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with @DRUG$.	DDI-false
Furthermore it has been proposed that @DRUG$ resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested @DRUG$ being converted to the toxic metabolites.	DDI-mechanism
Caution is therefore advised when administering @DRUG$ to patients receiving @DRUG$.	DDI-advise
@DRUG$ : of @DRUG$ by lithium carbonate .	DDI-false
clinical in healthy male volunteers ( demonstrated with @DRUG$ immediately injection some attenuation the that the and the bioavailability of @DRUG$ significantly	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
: have been agents , , @DRUG$ , agents , @DRUG$ without evidence clinically significant interactions	DDI-false
studies not been performed that by CYP3A4 ( eg , calcium blockers disopyramide , , , warfarin , derivatives @DRUG$ , , alprazolam , and triazolam ) plasma when with @DRUG$ ;	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
on metabolic profiles , significant interactions and dapsone trimethoprim/sulfamethoxazole clarithromycin , , @DRUG$	DDI-false
: study of rheumatoid patients , @DRUG$ not have significant effect on pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	DDI-false
Oral @DRUG$ @DRUG$ mg not induce the metabolism of the oral norethindrone/ethinyl ( 1 mg /35 mcg , Ortho-Novum .	DDI-false
Acidifying agents : Gastrointestinal @DRUG$ , , ) absorption @DRUG$.	DDI-mechanism
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Not Be Coadministered @DRUG$ Antiarrhythmics : quinidine Antimigraine : Antimycobacterial : @DRUG$ Benzodiazepines triazolam motility : cisapride	DDI-advise
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	DDI-advise
@DRUG$ effects are potentiated by @DRUG$.	DDI-effect
Although been coadministration drugs that are mainly metabolized by CYP3A4 ( eg , calcium blockers dapsone , quinine amiodarone , @DRUG$ , @DRUG$ , tacrolimus , ergot derivatives pimozide , , alfentanyl , and ) concentrations when coadministered saquinavir ;	DDI-false
Specific studies these sevoflurane , @DRUG$ , @DRUG$	DDI-false
@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.	DDI-false
The pharmacokinetics @DRUG$ and its major @DRUG$ were following co-administration Acamprosate .	DDI-false
In pigeons, naloxone did not systematically alter the effects of @DRUG$, (+)-NANM or @DRUG$.	DDI-false
@DRUG$: TORADOL IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
Although studies performed coadministration with drugs that mainly by CYP3A4 ( eg channel blockers dapsone , , amiodarone quinidine warfarin , tacrolimus cyclosporine , @DRUG$ , , , and @DRUG$ have plasma when with saquinavir	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
: not in who received @DRUG$ within 14 because and potentiation by MAO been with @DRUG$	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
May interact thyroid medication ( , ) , products antacids H2-antagonists ( e.g. @DRUG$ , , and proton inhibitors ( @DRUG$ , omeprazole ) .	DDI-false
Other drug interactions @DRUG$, @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of MHD.	DDI-false
The examples of that may increase the blood-glucose-lowering and hypoglycemia oral inhibitors @DRUG$ , fibrates , MAO inhibitors salicylates , somatostatin analog e.g. octreotide ) , @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
absorption @DRUG$ is significantly by the concomitant of containing aluminum and	DDI-mechanism
Estrogens, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-mechanism
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/lidocaine theophylline/acetaminophen @DRUG$/phenobarbital .	DDI-false
@DRUG$ , @DRUG$ theophylline , and valproic acid were added to human serum therapeutic	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before @DRUG$).	DDI-false
serum levels cyclosporine reported with concomitant @DRUG$	DDI-mechanism
@DRUG$ should   blocking agents ( e.g. , CYP3A4 ) @DRUG$ antagonists ( e.g. , CYP3A4 and diltiazem a CYP3A4 inhibitor ) the possible potentiation of bradycardia arrest , and AV block	DDI-false
Analysis of concentration ultracentrifugation there rapid equilibration @DRUG$ the @DRUG$ and aqueous .	DDI-false
@DRUG$ , opioids @DRUG$ have additive or potentiating .	DDI-false
following are examples of may reduce the : @DRUG$ niacin @DRUG$ , agents ( salbutamol terbutaline ) , isoniazid phenothiazine derivatives , , , ( e.g. in oral contraceptives .	DDI-false
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-int
However patients digoxin elevations @DRUG$ after initiation of @DRUG$ significant to digoxin toxicity	DDI-false
Therapeutic concentrations of digoxin warfarin , ibuprofen , @DRUG$ , piroxicam @DRUG$ andtolbutamide did not tromethamine binding .	DDI-false
Although specific drug topical glaucoma systemic were studies 0.5 % Ophthalmic possibility an or effect with CNS depressants ( alcohol , barbiturates opiates , @DRUG$ , @DRUG$ .	DDI-false
Patients other general @DRUG$ , @DRUG$ , tricyclic other CNS alcohol ) concomitantly may exhibit an CNS	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Serotonin Reuptake SSRIs SSRIs ( e.g. @DRUG$ @DRUG$ sertraline ) have been reported , , and incoordination when	DDI-false
@DRUG$ , including oral @DRUG$ : Estrogens may of certain , increasing effect .	DDI-false
@DRUG$ @DRUG$ has pharmacokinetic digoxin and , and losartan has effect on levels of bosentan .	DDI-false
5HT3 Antagonists Based reports hypotension loss when administered ondansetron , apomorphine the 5HT3 ( , for example , @DRUG$ , granisetron @DRUG$ , and is contraindicated	DDI-false
Other drugs which the neuromuscular blocking nondepolarizing agents as NUROMAX include @DRUG$ ( aminoglycosides , bacitracin , lincomycin clindamycin , and sodium salts , , anesthetics @DRUG$ , and	DDI-false
@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Cation-Containing : Concurrent administration a @DRUG$ , with cation-containing magnesium aluminum , chewable/buffered or pediatric powder or products containing @DRUG$ , , or may the absorption ciprofloxacin .	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or amoxicillin.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit of reductase that are by ( i.e. cerivastatin @DRUG$ @DRUG$ .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-false
While no were conducted between and of CYP3A , compounds that potent inducers ( such as @DRUG$ , , @DRUG$ , estazolam concentrations	DDI-false
Aspirin: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of @DRUG$.	DDI-effect
There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral @DRUG$ in the presence of diclofenac that necessitated changes in the doses of such agents.	DDI-false
clinical , FLOLAN with , diuretics , anticoagulants oral vasodilators , substudy with congestive heart failure furosemide or @DRUG$ @DRUG$ oral values furosemide n 23 digoxin n = ) by 13 % 15 respectively the second day therapy baseline values by day .	DDI-mechanism
Omeprazole rate extent of ciprofloxacin was bioequivalent when @DRUG$ was given alone given hours @DRUG$ at maximally acid .	DDI-false
major disorders , with @DRUG$ , should be treated with @DRUG$ the benefits the .	DDI-advise
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
This study demonstrated that the potent cytochrome P450 enzyme-inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$ of Drugs : @DRUG$ not to of carbamazepine , or phenobarbital .	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
lidocaine , @DRUG$ , @DRUG$ were added to pooled human concentrations	DDI-false
Ritonavir: Coadministration of @DRUG$ with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
agents class @DRUG$ , , or quinidine ): concurrent @DRUG$ may proarrhythmic effect .	DDI-false
cyclosporin A resulting 2000 with @DRUG$ has to an % increase in etoposide 38 in total clearance to @DRUG$ .	DDI-false
Administration of @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ When doses atorvastatin @DRUG$ were coadministered , % .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
Digoxin: Digoxin concentrations are increased by about 15% when @DRUG$ and @DRUG$ are administered concomitantly.	DDI-mechanism
In in 2 mg orally and without an the tract healthy AUC of @DRUG$ 10 and the of % when orally disintegrating tablet given with @DRUG$ compared when was	DDI-false
agents : of VISTIDE and agents with potential [ e.g. , @DRUG$ , @DRUG$ , foscarnet non-steroidal agents .	DDI-false
In of healthy no significant when @DRUG$ and @DRUG$ concomitantly for 6 .	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and cyclosporine (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
acidifying These agents @DRUG$ , acid phosphate ) increase the the ionized species the @DRUG$ , thereby increasing excretion .	DDI-mechanism
BOTOX and @DRUG$ other agents ( , @DRUG$ ) should only with caution the effect the may be	DDI-false
Antihypertensives : should used agents e.g. , @DRUG$ , a CYP3A4 ) calcium ( e.g. @DRUG$ , a CYP3A4 , CYP3A4 ) of possible potentiation bradycardia ,	DDI-false
Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
@DRUG$ generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of lithium toxicity.	DDI-advise
@DRUG$ @DRUG$ may result in an additive pressor .	DDI-false
- @DRUG$ : Lithium generally be given ( as ) because reduce clearance add high of @DRUG$ .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Products Absorption of ) magnesium/@DRUG$-containing @DRUG$.	DDI-false
drugs the @DRUG$ and diuretics , , thyroid , estrogens , phenytoin , , sympathomimetics , calcium drugs and	DDI-false
known to slow the metabolism @DRUG$ its serum levels should determined to administration with isoniazid signs of carbamazepine toxicity appropriate of the @DRUG$ should .	DDI-false
cases involving @DRUG$ reported to or the have involved either of large doses too frequent doses of drug to nonopioid tolerant , @DRUG$ other drugs affecting respiration	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Antagonists Since is dopamine agonist that antagonists such as @DRUG$ butyrophenones , ) @DRUG$ may diminish the of APOKYN	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Compounds have tested man include @DRUG$ , , and @DRUG$ and no were .	DDI-false
Interactions with Opioid Analgesics : analgesics pentazocine @DRUG$ , dezocine ) should administered a patient who is receiving of therapy with @DRUG$ such as	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
related presumably through nefazodone , cimetidine @DRUG$ , @DRUG$ , some	DDI-false
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, simvastatin).	DDI-false
alkalinizing @DRUG$ @DRUG$ the of the species of amphetamine , excretion	DDI-false
Pharmacokinetic studies demonstrated that @DRUG$ increased the exposure of @DRUG$ and/or its major	DDI-mechanism
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	DDI-mechanism
Therefore @DRUG$ and @DRUG$ are used the patient be observed closely to the desired effect the is obtained .	DDI-advise
These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
Similarly dialyzed were , @DRUG$ and theophylline alone concentrations serum with @DRUG$ three different	DDI-false
Multivalent Cation-Containing Products : Concurrent of , including @DRUG$ cation-containing magnesium or @DRUG$ VIDEX chewable/buffered tablets or products containing calcium substantially decrease absorption , resulting in urine considerably desired .	DDI-mechanism
, interfere absorption drugs gastric pH an important determinant of bioavailability ( , @DRUG$ , @DRUG$ salts and ) .	DDI-false
@DRUG$ Amphetamines the sedative effect of @DRUG$.	DDI-false
Anticoagulants : warfarin-type CYP2C9 substrate @DRUG$ almost always in @DRUG$ in serious or bleeding	DDI-false
@DRUG$ e.g. @DRUG$ ) or	DDI-false
Concurrent a with @DRUG$ been increased risk of efficacy use the @DRUG$ alone .	DDI-false
ACE and II Receptor ( Congestive Heart Failure Infarction)- , 3020 ( @DRUG$ to 50 @DRUG$ or angiotensin receptor ) .	DDI-false
Other of ( , , @DRUG$ , @DRUG$ , would behave similarly .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
following examples of substances that increase and susceptibility to hypoglycemia : products , @DRUG$ , disopyramide fibrates monoamine ( MAO inhibitors propoxyphene , salicylates , @DRUG$ ( e.g. , octreotide antibiotics .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Concomitant use of agents in the tricyclic antidepressant class (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
interactions Keppra   and AEDs @DRUG$ gabapentin lamotrigine , phenobarbital , phenytoin primidone and assessed evaluating the serum of @DRUG$ AEDs during .	DDI-false
Coadministration compounds are potent CYP3A4 @DRUG$ @DRUG$ , carbamazepine ) may decreased plasma saquinavir	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
- Vitamin K (e.g., @DRUG$, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
morning @DRUG$ , each single intravenous infusion @DRUG$ ( .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In addition , from regression analyses patient pharmacokinetic data that of inducers clearance , @DRUG$ , @DRUG$ ) with CANCIDAS may in clinically in caspofungin	DDI-false
been associated @DRUG$ , , dapsone , disulfiram @DRUG$ , gold hydralazine iodoquinol , metronidazole , phenytoin , ribavirin , vincristine	DDI-false
@DRUG$ to reduce PROLEUKIN-induced side effects fever renal , , confusion , and administration may antitumor of 12 other @DRUG$ may the hypotension seen PROLEUKIN	DDI-false
Lithium carbonate: The stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
These effects were not observed when @DRUG$ 20 mg was taken 24 hours before the @DRUG$.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Oral : Agents may blood-sugar-reducing @DRUG$ oral @DRUG$.	DDI-false
hypoglycemic sulfonylurea be potentiated certain including nonsteroidal anti-inflammatory and other that highly , , @DRUG$ , coumarins , @DRUG$ , and beta blocking .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
@DRUG$ Trileptal with an oral contraceptive shown the plasma concentrations hormonal , @DRUG$ ( LNG .	DDI-false
Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
studies have not with by ( channel blockers , dapsone , , , amiodarone @DRUG$ , cyclosporine ergot derivatives , , fentanyl @DRUG$ , triazolam ) have elevated plasma coadministered with ;	DDI-false
Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-@DRUG$ interaction could be found.	DDI-false
Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
drugs include and other diuretics , thyroid estrogens @DRUG$ nicotinic sympathomimet-ics @DRUG$ isoniazid .	DDI-false
of @DRUG$ 25 when @DRUG$ coadministered	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$ As with b-lactam antibiotics , renal excretion @DRUG$ inhibited by and resulted in 80 AUC for loracarbef .	DDI-false
, , theophylline/acetaminophen acid/phenobarbital	DDI-false
Both efavirenz @DRUG$ been to triple therapy with indinavir over 48 initial , similar observed regimens and superiority observed	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
@DRUG$/@DRUG$-containing Products : Absorption of is moderately reduced ( approximately 25 ) with magnesium/aluminum-containing products	DDI-false
Potential drug interactions Keppra   and other ( , , , @DRUG$ and valproate ) were assessed by of @DRUG$ these AEDs during	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Drugs : does alter pharmacokinetics @DRUG$ , @DRUG$ , .	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
levels anti-factor and @DRUG$ , @DRUG$ activity	DDI-false
significantly of @DRUG$ % , but no @DRUG$ pharmacokinetics .	DDI-false
This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.	DDI-false
Hepatic Enzyme Inducers Substrates : Drugs which induce cytochrome P450 3A4 CYP enzyme activity ( e.g. barbiturates , @DRUG$ , @DRUG$ ) may enhance metabolism of the dosage of the	DDI-false
@DRUG$ inhibits the ERMBT, and @DRUG$ and rifabutin are equipotent inducers of the ERMBT.	DDI-false
@DRUG$, @DRUG$, or narcotics: potentiation of orthostatic hypotension may occur.	DDI-false
Antiarrhythmic agents class such as flecainide , @DRUG$ @DRUG$ with a proarrhythmic effect	DDI-false
HIV Protease Indinavir mg t.i.d . ) co-administered @DRUG$ 10 resulted 16-fold in AUC a 7-fold increase in vardenafil and increase @DRUG$	DDI-false
Patients receiving both indomethacin and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	DDI-false
@DRUG$ , disopyramide @DRUG$	DDI-false
hydrate and @DRUG$ @DRUG$ , but the is not significant	DDI-int
@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
using this medication tell your or of all prescription and nonprescription use especially of ( , amikacin ) , @DRUG$ @DRUG$ , non-steroidal drugs ( e.g. , ibuprofen , vancomycin .	DDI-false
Multivitamins, or other products containing iron or @DRUG$, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
, @DRUG$ may the activity of tricyclic antidepressants @DRUG$ ;	DDI-effect
Depressants concomitant use of   fentanyl ) with other @DRUG$ , including limited to other opioids sedatives @DRUG$ e.g. , benzodiazepines , general , skeletal muscle relaxants and , may respiratory depression hypotension , and , or potentially result in or	DDI-false
drugs which enhance the nondepolarizing NUROMAX include certain antibiotics e. g. , aminoglycosides , @DRUG$ , clindamycin colistin colistimethate ) salts @DRUG$ local anesthetics procainamide , and	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving Fentanyl.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
structurally distinct the other reductase inhibitors ( @DRUG$ @DRUG$ and , to unique properties relative the agents this class	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
@DRUG$ : The concomitant administration @DRUG$ with the sulfonylurea glyburide has , on rare resulted severe .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
lidocaine/@DRUG$ phenobarbital/@DRUG$ phenobarbital/valproic acid quinidine/lidocaine , and valproic acid/phenobarbital .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
pharmacokinetic @DRUG$ or @DRUG$.	DDI-false
that have with neuropathy antiretroviral analogues , , dapsone , ethionamide , @DRUG$ hydralazine , , , metronidazole , nitrofurantoin , @DRUG$ , and .	DDI-false
In addition , influenced the , acid @DRUG$ the pharmacokinetics of @DRUG$ at	DDI-false
However, high doses of @DRUG$ may reduce the efficacy of intrathecally administered @DRUG$.	DDI-effect
Drugs that have with neuropathy include antiretroviral nucleoside chloramphenicol cisplatin , @DRUG$ disulfiram , ethionamide , , gold hydralazine , metronidazole , nitrofurantoin , , and	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
both @DRUG$ , (+)-NANM , the effects of @DRUG$ on and FR .	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
HMG-CoA Reductase Inhibitors: Simvastatin (@DRUG$ substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
of epinephrine receiving @DRUG$ or general as @DRUG$ which the myocardium cardiac	DDI-false
@DRUG$ and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
In clinical with Fondaparinux , use of ( ) , platelet inhibitors ( acetylsalicylic ) , @DRUG$ ( @DRUG$ did affect fondaparinux .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-effect
@DRUG$ such @DRUG$ and sulfinpyrazone inhibit renal tubular secretion of nitrofurantoin	DDI-false
: of VISTIDE and [ e.g. , e.g. , , ) , B @DRUG$ , intravenous pentamidine , and @DRUG$	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The of @DRUG$ or @DRUG$ by .	DDI-false
@DRUG$: Coadministration of a single dose of zaleplon and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-false
@DRUG$ Reports NSAIDs may the @DRUG$.	DDI-false
In vitro binding studies serum indicate that @DRUG$ differently not interact with @DRUG$ or dicumarol	DDI-false
@DRUG$ is an @DRUG$ it may strong affinity for other acids .	DDI-false
concomitant therapy specific interaction were or were used in clinical with acetylsalicylic , , @DRUG$ , anticonvulsants , benzodiazepines @DRUG$ , blockers , cardiac diuretics , inhibitors prostaglandin also referred to as ) and without evidence clinically adverse interactions .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ mg BID ) % @DRUG$ 40 mg BID 12 , while exposure valdecoxib ( 40 BID was not administration ( 10 BID days	DDI-mechanism
- Antihypertensives: @DRUG$ may potentiate the effect of various @DRUG$, necessitating a reduction in the dosage of these drugs.	DDI-effect
@DRUG$ may interfere the @DRUG$.	DDI-mechanism
@DRUG$ may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex.	DDI-int
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
The treatment with drugs is concurrent administration , derivatives , ( @DRUG$ , @DRUG$.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the @DRUG$ be increased.	DDI-false
is concurrently @DRUG$ @DRUG$ ) , of at least hours should maintained the two medicines , the of retard impaired	DDI-false
@DRUG$ @DRUG$ : like toxicity of drugs .	DDI-false
acetaminophen/theophylline phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/@DRUG$ , theophylline/acetaminophen , and valproic	DDI-false
These thiazides other diuretics phenothiazines , , oral @DRUG$ , @DRUG$ , calcium channel drugs and .	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
could concomitant administration of @DRUG$ ( , @DRUG$ , , antiemetics sedatives , )	DDI-false
concomitant interaction were not , finasteride doses or were concomitantly used in clinical with acetaminophen , acid , @DRUG$ enzyme , anticonvulsants benzodiazepines , blockers , blockers , diuretics H2 antagonists HMG-CoA , inhibitors also NSAIDs , @DRUG$ evidence of clinically adverse	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
1000 twice ) did not influence the @DRUG-DRUG$.	DDI-false
agents Concomitant VISTIDE and with potential e.g. ( @DRUG$ , amikacin , B , foscarnet , intravenous @DRUG$ vancomycin and ] is	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The effect @DRUG$ on plasma lithium not cases of increased lithium plasma levels during @DRUG$ therapy	DDI-false
addition oxcarbazepine and MHD induce subgroup the cytochrome P450 family ) responsible for the of @DRUG$ oral @DRUG$ resulting in of	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Nimodipine : significant and @DRUG$ @DRUG$ plasma of	DDI-false
study demonstrates that concurrent administration @DRUG$ permits increase in and total exposure to @DRUG$.	DDI-mechanism
Two percent of patients treated concurrently with @DRUG$ and @DRUG$ developed neutropenia (ANC  1 x 109/L).	DDI-effect
: Because @DRUG$ the pharmacokinetics of @DRUG$ , other drugs metabolized via same isozymes are not .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Due high inter-patient and limited sampling the extent of the @DRUG$ levels receiving concurrent @DRUG$ AVASTIN .	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-false
Before medication prescription you use especially of aminoglycosides ( e.g. , @DRUG$ amikacin ) , B cyclosporine @DRUG$ drugs e.g. tacrolimus ,	DDI-false
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
@DRUG$ be with caution   -receptor blocking agents , , a CYP3A4 inhibitor ) or calcium antagonists e.g. , , substrate , @DRUG$ inhibitor of the possible of , sinus and ;	DDI-false
@DRUG$ concentrations	DDI-mechanism
may imatinib plasma concentrations imatinib concentrations Caution is when Gleevec CYP3A4 ( e.g. , @DRUG$ @DRUG$ )	DDI-false
@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other depressant drugs ( @DRUG$ , tranquilizers opioids anesthetics additive effects with	DDI-effect
aBased on of narcotic syndrome in patients with @DRUG$ @DRUG$ concurrently , and decreased plasma concentrations of .	DDI-effect
@DRUG$ : significant steady-state pharmacokinetics R-warfarin or S-warfarin the of @DRUG$ given as dose	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Clinical interaction studies with @DRUG$ and warfarin indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	DDI-false
drug between @DRUG$ and ( phenytoin , primidone and valproate ) were assessed by evaluating the serum levetiracetam and @DRUG$ placebo-controlled	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, @DRUG$, and @DRUG$ have been demonstrated.	DDI-false
@DRUG$ and moclobemide increased blood @DRUG$ at different times after the glucose overload.	DDI-false
@DRUG$ of @DRUG$ and 7 days produced pharmacokinetic or interaction .	DDI-false
@DRUG$/@DRUG$ , , phenobarbital/acetaminophen , phenobarbital/valproic acid quinidine/lidocaine , and valproic	DDI-false
: As with other @DRUG$ , of @DRUG$ inhibited probenecid and resulted in an approximate % increase in the .	DDI-false
specific studies have not performed drugs that are mainly metabolized by eg , channel blockers , , quinine , quinidine , , , @DRUG$ , alfentanyl @DRUG$ , and triazolam ) have concentrations when with saquinavir ;	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
These drugs thiazides other diuretics , , phenothiazines thyroid , estrogens , oral contraceptives @DRUG$ , acid sympathomimetics calcium blocking ,	DDI-false
Inhibitors @DRUG$ ): e.g. , ) have reported cause , hyperreflexia , @DRUG$.	DDI-false
@DRUG$ : with @DRUG$ concurrent administration of ciprofloxacin theophylline may lead concentrations theophylline prolongation of its .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Hypersensitivity reactions reported in containing sequential PROLEUKIN and @DRUG$ , @DRUG$ cis-platinum , and .	DDI-false
The are substances may blood-glucose-lowering : , niacin , @DRUG$ @DRUG$ , ) , phenothiazine , , thyroid , estrogens progestogens contraceptives	DDI-false
Cyclopentolate may interfere with the anti-glaucoma action of @DRUG$ or @DRUG$;	DDI-false
include thiazides and other corticosteroids , thyroid products , estrogens , oral contraceptives phenytoin , nicotinic acid , @DRUG$ ,	DDI-false
The @DRUG$ @DRUG$ is clinically .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
may with , @DRUG$ allergy and medicines ) diabetic , , norepinephrine @DRUG$ like Aleve Ibuprofen high medications .	DDI-false
Steady-state serum concentrations of @DRUG$ are reported to fluctuate significantly when @DRUG$ is either added or deleted from the drug regimen.	DDI-mechanism
@DRUG$ and @DRUG$ may decrease effects of .	DDI-false
@DRUG$ counteract @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
( - 24 hrs @DRUG$ descarboethoxyloratadine were observed of of these drugs normal study ) there were clinically relevant the profile @DRUG$ , laboratory , vital , adverse .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
However , concomitant use @DRUG$ and @DRUG$ 5 - mg initial oral followed - mg/day orally 10 days ) results in of prothrombin time and International Normalized ( INR ) .	DDI-effect
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including @DRUG$, tranquilizers, and alcohol.	DDI-false
Methylxanthines : Concomitant with @DRUG$ , diuretics potentiate effect of   @DRUG$	DDI-effect
Because changes in glucose concentrations with @DRUG$ coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with @DRUG$ coadministration (up to 40 mg QD) is not indicated.	DDI-false
@DRUG$ or hydrocarbon increase cardiac sensitize the myocardium certain intravenously @DRUG$ dopamine	DDI-effect
The following may reduce the blood-glucose-lowering effect , , @DRUG$ , sympathomimetic agents ( e.g. , salbutamol , terbutaline , , derivatives , @DRUG$ , thyroid hormones estrogens progestogens e.g. oral contraceptives	DDI-false
When @DRUG$ is concurrently with @DRUG$ , of be	DDI-effect
Other Interactions pharmacokinetic were @DRUG$ drugs , , digoxin @DRUG$ ranitidine	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of @DRUG$	DDI-false
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by flumazenil.	DDI-effect
In clinical trials @DRUG$ was digoxin , , oral , @DRUG$.In a substudy patients heart failure receiving furosemide whom with FLOLAN was initiated , values furosemide ( = 23 = ) by 13 % , on the day of had returned to baseline	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
@DRUG$ concomitantly with seven plasma concentrations of @DRUG$ n-acetyl 55 % 33 % respectively	DDI-false
Mixed Opioid Agonist/antagonist ( , @DRUG$ butorphanol , dezocine buprenorphine ) administered a patient who or receiving course of with a pure	DDI-advise
The following of substances increase the and susceptibility hypoglycemia oral products , @DRUG$ , disopyramide fibrates fluoxetine , oxidase ) inhibitors , , salicylates , somatostatin e.g.	DDI-false
Prednisone/@DRUG$ : @DRUG$ did not have any clinically important on the of or	DDI-false
@DRUG$ zalcitabine reduced ( % ) coadministered @DRUG$.	DDI-false
Other reported : @DRUG$ @DRUG$ substrate combination with may hypotension , .	DDI-false
- of @DRUG$ enhanced Bezalip or @DRUG$.	DDI-effect
@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
A possible interaction @DRUG$ and @DRUG$ has been reported , resulting in hypoglycemic glyburide	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Histamine H2-receptor antagonists: @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
glucocorticoids have PROLEUKIN-induced , hyperbilirubinemia dyspnea agents @DRUG$ may the effectiveness PROLEUKIN and thus avoided . 12 Beta-blockers @DRUG$ the PROLEUKIN .	DDI-false
Imidazoles @DRUG$ , clotrimazole , fluconazole , etc . in and studies with amphotericin imidazoles that @DRUG$ induce resistance to	DDI-false
@DRUG$ : @DRUG$ been to enhance effects of the oral anticoagulant or its derivatives	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
controlled included @DRUG$ doses of 15 mcg , twice daily and 50 54 of subjects received @DRUG$ entry	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Cardiovascular @DRUG$ and enalapril have with @DRUG$ , methyldopa , and evidence clinically significant adverse interactions	DDI-false
Patients other narcotic analgesics , anesthetics , @DRUG$ , , @DRUG$ or ( including alcohol ) with may additive .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ affect @DRUG$ levels	DDI-false
@DRUG$ enterohepatic elimination and may levels and	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
levels @DRUG$ have to in the presence @DRUG$ ;	DDI-false
administration of @DRUG$ @DRUG$ may severe persistent hypertension or cerebrovascular accidents	DDI-false
@DRUG$ , Cyclosporine @DRUG$ , like , affect renal prostaglandins increase the toxicity of .	DDI-false
@DRUG$, including @DRUG$, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration of @DRUG$ and @DRUG$ 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.	DDI-mechanism
The results of the ERMBT after 2 weeks of @DRUG$ and @DRUG$ therapy were increased 187 and 156%, respectively.	DDI-false
Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of cisapride.	DDI-mechanism
animal suggest that the action barbiturates may be prolonged therapy with @DRUG$ @DRUG$ be employed with caution	DDI-false
It recommended if is started in receiving @DRUG$ , closely monitored of the @DRUG$ be	DDI-false
Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
: administration of , including , cation-containing products such as magnesium or , @DRUG$ powder , containing calcium , iron or may decrease the absorption of @DRUG$ in levels lower desired	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	DDI-false
In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and @DRUG$.	DDI-false
Administration of @DRUG$ has been reported to increase the plasma levels of @DRUG$, if given concomitantly.	DDI-mechanism
Caution should also taken in or use of other @DRUG$ and @DRUG$ because enhance nephrotoxicity ototoxicity neomycin sulfate blocking .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ ( medicine mouth ) of oral @DRUG$ with increase side effects blood the side or oral antidiabetics	DDI-false
@DRUG$ : ritonavir with @DRUG$ in a 152 % increase nelfinavir plasma change in ritonavir	DDI-false
@DRUG$ and agents with , intravenous ( e.g. , gentamicin and , B @DRUG$ , intravenous vancomycin , anti-inflammatory agents ] contraindicated .	DDI-advise
because of this, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly.	DDI-false
Concurrent administration of a @DRUG$ with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	DDI-false
In a study with @DRUG$ in healthy volunteers subjects dosed Vardenafil mg and @DRUG$ 0.4 separated hours standing systolic 85 mm Hg	DDI-false
Concurrent administration HEXALEN @DRUG$ may cause severe an a rat model	DDI-false
@DRUG$ : @DRUG$ potentiate of various , drugs .	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
that have been with neuropathy , , , @DRUG$ , , ethionamide , gold , isoniazid , @DRUG$ , , and vincristine	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	DDI-false
Urinary acidifying agents These agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Specific @DRUG$ propofol , alfentanil	DDI-false
Potassium Diuretics : @DRUG$ can attenuate potassium loss	DDI-effect
Metformin : In healthy subjects given single 500 mg doses of @DRUG$ metformin plasma @DRUG$ mean cmax and AUC increased by of 34 % , mean clearance decreased by % .	DDI-false
Isoflurane potentiates the muscle relaxant effect of all @DRUG$, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-false
that alter imatinib plasma increase concentrations : Caution recommended when administering of CYP3A4 e.g. , @DRUG$ @DRUG$ , erythromycin	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	DDI-effect
No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
It therefore necessary to acquainted the paraclinical pattern of @DRUG$ between magnesium deficiency due to an insufficient magnesium which only requires oral physiological supplementation and @DRUG$ depletion a of the control which regulation its causal dysregulation	DDI-false
MAO Inhibitors @DRUG$   not recommended in patients have received @DRUG$ within severe unpredictable potentiation by MAO has opioid analgesics	DDI-advise
@DRUG$ @DRUG$   ( 1000 twice ) not pharmacokinetics and ) given as a 0.25	DDI-false
In bioavailability studies with normal subjects, the concurrent administration of @DRUG$ at therapeutic levels did not significantly influence the bioavailability of @DRUG$ tablets.	DDI-false
drug between Keppra AEDs , gabapentin , , phenobarbital , phenytoin primidone @DRUG$ ) were also evaluating serum of levetiracetam @DRUG$	DDI-false
Potential interactions between , substrate of CYP3A4 and @DRUG$ ritonavir saquinavir , @DRUG$ ) which are of CYP3A4 have evaluated in .	DDI-false
It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing @DRUG$ for at least 4 hours following ethambutol administration.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
Although these results do not @DRUG$ and warfarin or , administration of patients taking @DRUG$ should extremely cautiously and should be closely monitored .	DDI-false
concomitant interaction were not doses of 1 or more concomitantly used clinical with acetaminophen acetylsalicylic , , @DRUG$ ( ) inhibitors , , @DRUG$ , calcium-channel blockers , nitrates , diuretics H2 antagonists , HMG-CoA reductase , prostaglandin synthetase inhibitors to as anti-infectives evidence clinically significant interactions	DDI-false
were daily treatment with synthetic hydroalcoholic solutions , @DRUG$ , alcohols and @DRUG$ in the proportions common distilled and alcoholic beverages ;	DDI-false
@DRUG$ with doses higher than mg @DRUG$ ( e.g. , BID ) studied	DDI-false
of , , @DRUG$ , and @DRUG$ was significantly given simultaneously with colestipol	DDI-false
following are of substances that increase the blood-glucose-lowering susceptibility to : , inhibitors , , , @DRUG$ , oxidase ) , , somatostatin ( e.g. , octreotide ) , @DRUG$.	DDI-false
There who developed serum creatinine , and weight gain @DRUG$ used in conjunction @DRUG$.	DDI-effect
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
lithium levels and @DRUG$ toxicity been reported patients receiving @DRUG$ therapy	DDI-false
Lithium generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
of the increased of adverse patients who have been @DRUG$ a regular basis , is particularly query their guardians carefully about alcohol @DRUG$ part prior any procedure in the use of	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
in clinical studies received one or of the following concomitant with ORENCIA : MTX @DRUG$ , TNF , @DRUG$ chloroquine , , , sulfasalazine , and .	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
of @DRUG$ with @DRUG$ 4 hours ethambutol administration	DDI-advise
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
determine whether injection thiosulfate doses be administered fixed 9.9-g/m2 of @DRUG$ intravenously three hours escalating doses of	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ be cautiously in @DRUG$ hypoprothrombinemia	DDI-advise
@DRUG$ , Including Injectable Transdermal , : An interaction that co-administration @DRUG$ the contraceptive Ortho-Novum produced average decreases norethindrone ethinyl levels 31 ,	DDI-false
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist.	DDI-false
apparently through effect microsomal has reported the anticoagulants , phenytoin , , , antidepressants , @DRUG$ @DRUG$ and , thereby elimination and levels these drugs	DDI-false
@DRUG$ : @DRUG$ IV/IM reduced in normovolemic subjects approximately 20 % ( mean output decreased 17	DDI-false
@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Central Nervous System Depressants : of DURAGESIC   ( fentanyl transdermal ) with central nervous depressants including limited opioids , , @DRUG$ , tranquilizers ( e.g. , ) , general , @DRUG$ , skeletal muscle , and alcohol cause depression , profound sedation or potentially result coma death	DDI-false
In @DRUG$-dependent patients, @DRUG$ may precipitate withdrawal symptoms.	DDI-false
been reported receiving sequential dose antineoplastic agents specifically dacarbazine @DRUG$ , @DRUG$ interferon-alfa .	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or @DRUG$.	DDI-false
In monkeys, the effects of @DRUG$, but not (+)-NANM or PCP, were antagonized by @DRUG$;	DDI-effect
therapy interaction not performed of 1 or more were concomitantly in clinical studies with acetaminophen , acetylsalicylic , , , @DRUG$ anticonvulsants benzodiazepines , beta blockers , cardiac nitrates , antagonists @DRUG$ also as NSAIDs and clinically adverse interactions .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
Potentiation occurs with @DRUG-DRUG$.	DDI-false
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	DDI-false
Data in studies @DRUG$ suggest a possible alprazolam following sertraline and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
therefore, close monitoring of prothrombin time is recommended, and adjustment of the @DRUG$ dose may be necessary when @DRUG$ is administered concomitantly.	DDI-advise
After multiple , @DRUG$ ( mcg IM once weekly ) reduced @DRUG$ by approximately % .	DDI-mechanism
OBJECTIVE : Our objective to steady-state pharmacokinetics of @DRUG$ @DRUG$ INN ciclosporin ) in novo first year transplantation .	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).	DDI-effect
Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and epinephrine may occur.	DDI-false
@DRUG$ generally not be with diuretics renal high risk of lithium toxicity .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Because of its effects @DRUG$ substitute for @DRUG$ prophylaxis	DDI-false
drug @DRUG$ @DRUG$ and dextropropoxyphene no effect the pharmacokinetics MHD	DDI-false
@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-false
Other therapy specific studies were not performed , or more were concomitantly studies with @DRUG$ , acetylsalicylic acid a-blockers analgesics , angiotensin-converting enzyme ( ACE ) inhibitors anticonvulsants benzodiazepines , calcium-channel blockers , cardiac , H2 antagonists , @DRUG$ , synthetase also referred to NSAIDs , and anti-infectives evidence of clinically significant adverse .	DDI-false
@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	DDI-false
@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	DDI-false
, @DRUG$ , increase anticholinergic of @DRUG$.	DDI-effect
However, since there is an increased risk of bleeding with @DRUG$, caution should be employed when @DRUG$ is used with other drugs that affect hemostasis.	DDI-false
Quetiapine fumarate ' @DRUG$ ' ) is a newly @DRUG$ in the treatment of positive symptoms of	DDI-false
@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics analgesics ( pentazocine nalbuphine , , dezocine @DRUG$ NOT administered to patient who a course therapy a @DRUG$ such .	DDI-false
The majority patients RA clinical one or medications MTX , NSAIDs , @DRUG$ agents , , @DRUG$ , leflunomide , sulfasalazine , and .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
@DRUG$ significant impact the Cmax @DRUG$ , although it the 44 zidovudine 110	DDI-false
reduce the blood-glucose-lowering corticosteroids niacin , @DRUG$ diuretics agents ( , epinephrine salbutamol @DRUG$ ) , phenothiazine derivatives , thyroid , , progestogens , contraceptives	DDI-false
This antagonistic effect of probenecid on @DRUG$ natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
that associated chloramphenicol , @DRUG$ , , iodoquinol , isoniazid , , nitrofurantoin ,	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-false
trials FLOLAN used with digoxin , anticoagulants , oral patients congestive heart receiving furosemide whom FLOLAN was initiated , apparent values ( ) @DRUG$ = ) were decreased by and % , respectively on the of had values day 87	DDI-false
No dose adjustment of @DRUG$ is necessary, but increased effects of @DRUG$ should be considered.	DDI-false
No are available for of @DRUG$/ritonavir FORTOVASE/@DRUG$ and garlic .	DDI-false
@DRUG$ study pharmacokinetic interaction .	DDI-false
include the @DRUG$ corticosteroids thyroid estrogens , oral @DRUG$ , acid , calcium channel blocking .	DDI-false
specific studies not performed , mg concomitantly in clinical studies with , @DRUG$ , a-blockers angiotensin-converting enzyme , , benzodiazepines beta blockers , nitrates , diuretics , @DRUG$ , HMG-CoA reductase , also referred to as NSAIDs ) quinolone anti-infectives without .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
that @DRUG$ its pharmacologically active 10-monohydroxy @DRUG$ ) have no inhibitors for most of the human cytochrome enzymes evaluated ( , , , CYP2E1 CYP4A9 with the exception CYP2C19 .	DDI-false
@DRUG$ , bepridil , sparfloxacin @DRUG$.	DDI-false
As with agents , should that potentiating @DRUG$ as opiates , and	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).	DDI-false
The pharmacokinetics of @DRUG$ and were unaffected with	DDI-false
@DRUG$ may decrease the effect , @DRUG$ can increase the effect of	DDI-false
in studies ( , valproate , @DRUG$ , digoxin , @DRUG$ ) pharmacokinetic screening in clinical patients .	DDI-false
agents administration @DRUG$ potential [ e.g. aminoglycosides ( e.g. tobramycin , @DRUG$ , ) foscarnet intravenous pentamidine , , and anti-inflammatory is .	DDI-advise
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.	DDI-effect
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
use inhibitors as @DRUG$ and with transdermal @DRUG$ also in increase plasma concentrations could increase or prolong adverse drug effects cause	DDI-mechanism
Coadministration @DRUG$ diazepam a CYP2C19 substrate , in a % decrease	DDI-false
@DRUG$ : @DRUG$ a CYP 2C9	DDI-false
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The majority of in received or medications with ORENCIA @DRUG$ , NSAIDs , , blocking , azathioprine , , @DRUG$ , and anakinra .	DDI-false
Antifungals In vitro vivo data that , @DRUG$ , and ketoconazole markedly inhibit the of @DRUG$ result increase levels of the QT ECG	DDI-mechanism
astemizole, @DRUG$, sparfloxacin, and @DRUG$.	DDI-false
associated peripheral include antiretroviral nucleoside @DRUG$ , , glutethimide , @DRUG$ isoniazid , nitrofurantoin ribavirin , and	DDI-false
@DRUG$ nandrolone [ ] oxandrolone [ , Anavar , , , @DRUG$ [ e.g. Winstrol ] or	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
toxicity has been reported occurred on chronic @DRUG$ treatment following the initiation of @DRUG$ .	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Magnesium- antacids containing ferrous iron ) multivitamin zinc cations or Videx ( ) chewable/buffered tablets or powder for oral solution be within hours before or 2 after	DDI-advise
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ : In some the a non-steroidal anti-inflammatory agent the diuretic natriuretic and antihypertensive of @DRUG$.	DDI-false
In general these have one more pharmacologic to @DRUG$ , agents as quinidine and procainamide @DRUG$ tricyclic	DDI-false
poor of : with inhibitors CYP2D6 ( as quinidine @DRUG$ , @DRUG$ , ) not been studied drugs expected to increase levels enantiomer of carvedilol .	DDI-false
The of pills by hepatic enzyme-inducing such anticonvulsants @DRUG$ carbamazepine , and , antituberculosis drug	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Acidifying : ( @DRUG$ reserpine , @DRUG$ acid , juices ) absorption of	DDI-false
It recommended that serum @DRUG$ levels monitored if is administered with @DRUG$.	DDI-false
steady-state @DRUG$ , procainamide , and during with	DDI-false
@DRUG$ : is known to slow the metabolism its levels should be determined to concurrent administration with , signs and symptoms @DRUG$ toxicity should monitored , and appropriate dosage of the should .	DDI-false
specific studies have been with drugs that CYP3A4 ( eg , calcium , dapsone , , , quinidine , @DRUG$ , tacrolimus cyclosporine , ergot @DRUG$ , fentanyl , alfentanyl alprazolam and have elevated when coadministered saquinavir	DDI-false
Although specific , coadministration with mainly metabolized by ( eg calcium channel , dapsone , , quinine , amiodarone tacrolimus , cyclosporine , ergot derivatives , , carbamazepine , fentanyl , alprazolam , @DRUG$ may have elevated concentrations when with @DRUG$	DDI-mechanism
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Lorazepam like other , the administered ethyl alcohol MAO inhibitors , @DRUG$.When scopolamine used with @DRUG$ increased of sedation hallucinations , and irrational been observed .	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-false
@DRUG$ may enhance or @DRUG$ ;	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
No significant difference was found between the mean values of the volume of distribution of @DRUG$ with and without @DRUG$ (13.0 and 12.6 liters, respectively).	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or @DRUG$ than with pentobarbital.	DDI-false
and @DRUG$ morphine-induced release in nucleus	DDI-effect
Drugs been associated peripheral include chloramphenicol , , disulfiram , ethionamide glutethimide , , @DRUG$ isoniazid , , @DRUG$ and vincristine	DDI-false
with some nondepolarizing neuromuscular blocking , time of of block induced by NUROMAX lengthened and in @DRUG$	DDI-false
@DRUG$ and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
No Important Interactions To Date does not clinically important pharmacokinetic with captopril , beta-blockers , felodipine , , warfarin , @DRUG$ , carvedilol ethanol @DRUG$.	DDI-false
Patients should be advised against the simultaneous use of other @DRUG$, and cautioned that the effect of @DRUG$ may be increased.	DDI-false
Depressants : The use   fentanyl transdermal with other @DRUG$ limited other opioids , , hypnotics , ( e.g. ) , general anesthetics , , @DRUG$ , alcohol respiratory hypotension , profound sedation , coma or death .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
) and many are for many antidepressants phenothiazines the @DRUG$ and @DRUG$ .	DDI-false
@DRUG$: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$ may enhance alcohol @DRUG$ , and other CNS depressants	DDI-effect
Drugs have with peripheral neuropathy include nucleoside analogues , chloramphenicol , cisplatin , dapsone , ethionamide , , @DRUG$ , metronidazole nitrofurantoin , ribavirin ,	DDI-false
@DRUG$ : In vitro data clarithromycin erythromycin , and @DRUG$ markedly inhibit the , in an increase in plasma cisapride and prolongation of the ECG .	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Compounds have been in man @DRUG$ , digoxin , propranolol , @DRUG$ , warfarin no meaningful were found	DDI-false
@DRUG$ : In have been a between @DRUG$ resulted .	DDI-false
of Clonazepam the Pharmacokinetics Other : does not to of , @DRUG$ or @DRUG$.	DDI-false
Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-effect
Injection: @DRUG$ injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Corticosteroids Methylxanthines and @DRUG$ : Concomitant treatment @DRUG$ , steroids , or diuretics may .	DDI-false
The effects of adenosine are by @DRUG$ @DRUG$ .	DDI-false
Cation-Containing of a quinolone , including @DRUG$ , with multivalent cation-containing such as or @DRUG$ antacids , sucralfate , or pediatric powder , or calcium , iron or the absorption , and considerably lower than	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Central Nervous System concomitant @DRUG$   fentanyl transdermal system nervous including not limited to sedatives hypnotics @DRUG$ e.g. , ) , general muscle , may cause , and profound potentially in death .	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
: should receiving ( e.g. , a CYP3A4 inhibitor ) or channel , verapamil , a CYP3A4 substrate @DRUG$ @DRUG$ inhibitor ) the possible bradycardia AV block	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when @DRUG$ and @DRUG$ are used in combination.	DDI-mechanism
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, metoclopramide, @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Interaction of @DRUG$ with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , diclofenac doxycycline , erythromycin , imatinib , nefazodone , nicardipine , , @DRUG$ , and	DDI-false
@DRUG$ , including norfloxacin , may enhance effects of @DRUG$ including its derivatives similar	DDI-effect
In patients receiving @DRUG$, the addition of @DRUG$ to therapy could prolong the prothrombin time.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
of Natrecor with such @DRUG$ , @DRUG$ ACE been ( these were not trials	DDI-false
@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
There were transient increases in liver ALT and AST when @DRUG$ and @DRUG$ were co-administered.	DDI-effect
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or @DRUG$.	DDI-false
containing side of @DRUG$ , @DRUG$ ) or methylthiadiazole ( cefazolin can cause vitamin K and hypoprothrombinemia .	DDI-false
Anticholinesterases (neostgmine, physostigmine), @DRUG$, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Nephrotoxic agents Concomitant administration agents with potential [ , e.g. @DRUG$ , , amikacin amphotericin B @DRUG$ , intravenous pentamidine , ] is .	DDI-false
with to moderate hypertension administration of the @DRUG$ benazepril , 10 to 4 weeks , associated with an increase arterial pressure of about 3 mm Hg compared to @DRUG$ .	DDI-false
@DRUG$ ( eg ) drugs , including ether , succinylcholine , and sodium citrate potentiate blocking effect should be used with extreme caution in being treated with @DRUG$ Parenteral .	DDI-effect
The of the TYSABRI -associated event between ( and 2 ( with co-administered @DRUG$ this does not necessitate the @DRUG$   dose to safety General	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
CYP2C9 response is receiving @DRUG$ can serious or fatal bleeding	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
Nervous System : The use of   system ) system @DRUG$ , @DRUG$ , , tranquilizers ( e.g. , general anesthetics , phenothiazines , muscle relaxants , and , may profound sedation , potentially result or .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
: In normal volunteers , a small decrease in @DRUG$ observed of @DRUG$ aspirin administered	DDI-false
Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Because increased of in taking a basis , important that physicians query or guardians carefully about benzodiazepine , @DRUG$ as of the history prior to any which of @DRUG$ is planned	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Thus agents likely to be concomitantly administered with @DRUG$ that are metabolized by this isoenzyme family may potentially interact with @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
administration of and @DRUG$ orthostatic drug , half-life and in a .	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other @DRUG$ or sympathomimetic drugs.	DDI-advise
This appears to be the only with Mefloquine , although theoretically coadministration of other known to alter conduction ( beta-adrenergic blocking agents calcium antihistamines or @DRUG$ antidepressants @DRUG$ ) might also contribute of the interval	DDI-false
@DRUG$ @DRUG$ are amphetamines .	DDI-false
comparison digitalis tolerance in anesthetized ketamine , @DRUG$ , dosage @DRUG$ cause ventricular higher , as was ouabain , or	DDI-effect
@DRUG$ caused a increase in ( 15 , pharmacodynamic prothrombin time as	DDI-effect
The study dosed 1200 of @DRUG$ 7 ) ( changed 600 [ n ] ) for Days 8 21 21-day course 100 times/day @DRUG$.	DDI-false
For dose of should - the start of treatment @DRUG$ @DRUG$ according to the blood clotting parameters	DDI-false
hypoglycemic of sulfonylureas may be by certain nonsteroidal anti-inflammatory and other drugs that highly protein salicylates @DRUG$ , @DRUG$ , probenecid coumarins , monoamine , adrenergic blocking agents	DDI-false
Blood glucose concentrations should be carefully monitored when @DRUG$ and oral @DRUG$ are coadministered.	DDI-advise
In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
@DRUG$/theophylline , @DRUG$/quinidine , phenobarbital/valproic , theophylline/acetaminophen , and acid/phenobarbital	DDI-false
interaction have does clinically interactions , @DRUG$ quinidine , @DRUG$ or amoxicillin	DDI-false
@DRUG$ co-administered with of drug as efavirenz , nevirapine , phenytoin or @DRUG$ , a of of be	DDI-advise
interactions : @DRUG$ no effect and insulin and @DRUG$ ( or other pharmacodynamic )	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
similar , less marked , been with barbiturates , @DRUG$ , carbamazepine @DRUG$ , , with ampicillin tetracyclines	DDI-false
The authors investigated the a similar interaction @DRUG$ and	DDI-false
: low-dose @DRUG$ with @DRUG$ may in an increased rate GI or other complications , compared of VIOXX .	DDI-effect
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Tagamet apparently through an effect certain microsomal enzyme systems , has the hepatic metabolism of warfarin-type phenytoin @DRUG$ @DRUG$ diazepam certain tricyclic antidepressants , , , delaying blood of drugs	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
@DRUG$ serum concentrations should be monitored closely when initiating or changing therapy with @DRUG$ in patients receiving lithium.	DDI-false
following are examples to inhibit of related benzodiazepines , presumably through CYP3A : @DRUG$ @DRUG$ ,	DDI-false
Other interactions: @DRUG$ had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	DDI-false
Patients be advised against simultaneous of @DRUG$ and cautioned the @DRUG$	DDI-false
Caution is advised in patients receiving concomitant high-dose @DRUG$ and @DRUG$, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.	DDI-advise
(1968, 1970), the higher serum concentrations of @DRUG$ and @DRUG$ reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-false
@DRUG$ been reduce side fever , renal insufficiency hyperbilirubinemia confusion dyspnea , concomitant the effectiveness of and be . 12 Beta-blockers and may with	DDI-false
The patients in RA following concomitant medications with ORENCIA : @DRUG$ , blocking azathioprine , hydroxychloroquine ,	DDI-false
Administration of epinephrine to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
Hormonal contraceptives Co-administration @DRUG$ with an contraceptive has shown to plasma concentrations of hormonal @DRUG$ EE levonorgestrel	DDI-false
Therapeutic concentrations , warfarin @DRUG$ naproxen , @DRUG$ phenytoin andtolbutamide did not alter protein binding .	DDI-false
when @DRUG$ @DRUG$ their dosage be	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., reserpine and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-effect
@DRUG$: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ : cyclosporine can with in clearance in serum creatinine and because renal excretion elimination of @DRUG$ TRICOR is an interaction will deterioration .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
@DRUG$ overdose recognized by a @DRUG$ assay.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$ : Concomitant administration of @DRUG$ with agents with potentiate blood-pressure- heart-rate-lowering effects .	DDI-false
all the selective serotonin reuptake inhibitors ( ) e.g. @DRUG$ , fluoxetine , @DRUG$ P450 , vary the extent of	DDI-false
There are , experiences in effects @DRUG$ oral @DRUG$ in of that necessitated changes such agents	DDI-false
No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with @DRUG$ or @DRUG$.	DDI-false
Estradiol and Norethindrone of @DRUG$ with resulted 47 % @DRUG$ and an % in plasma concentrations	DDI-false
phenobarbital/acetaminophen phenobarbital/valproic acid , valproic	DDI-false
There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable @DRUG$ therapy were treated concurrently with @DRUG$ (4 mg/kg once every 24 hours) for 14 days.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
, , acid quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The effectiveness reduced by drugs as anticonvulsants , , and @DRUG$ and @DRUG$ rifampin .	DDI-false
Anticoagulant inhibition during the of @DRUG$ secobarbital @DRUG$ ;	DDI-false
High-dose in concentrations administered led 80 increase @DRUG$ 38 % decrease of compared to @DRUG$ alone .	DDI-false
Ritonavir : Coadministration of ritonavir with @DRUG$ 152 % increase AUC and little in @DRUG$ plasma A.C.	DDI-false
The following of may reduce , @DRUG$ , danazol @DRUG$ , sympathomimetic ( , salbutamol terbutaline , , derivatives , , thyroid , , progestogens ( e.g. , contraceptives	DDI-false
However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$.	DDI-effect
interact @DRUG$ altered hypo-prothrombinemic , barbiturates , @DRUG$ of enzyme oxidation system decreased effect diethylstilbestrol corticosteroids effect of corticosteroids .	DDI-false
@DRUG$ 30 minutes the sumatriptan of @DRUG$ and Cmax decreased	DDI-false
suggest that dexamethasone and , and other @DRUG$ and regulate of prostate epithelium a dose-dependent modification of insulin and	DDI-effect
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
@DRUG$ plasma concentrations of atorvastatin increased 40 coadministration @DRUG$ erythromycin , known of 3A4	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, @DRUG$, clarithromycin or amoxicillin.	DDI-false
addition results analyses of pharmacokinetic data suggest co-administration other drug clearance ( @DRUG$ , , @DRUG$ , dexamethasone or CANCIDAS result meaningful reductions	DDI-false
Although BETAGAN used little or effect pupil size , mydriasis concomitant with @DRUG$ and @DRUG$ .	DDI-effect
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
@DRUG$ : Reports NSAIDs diminish of @DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be certain drugs drugs salicylates @DRUG$ , chloramphenicol , , @DRUG$ monoamine inhibitors , beta adrenergic blocking	DDI-false
Oral @DRUG$ : ( 40 mg BID ) ( 1 mcg .	DDI-false
@DRUG$ ( @DRUG$ ) or	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Because prostaglandins an important , and platelet function as well , concurrent with all NSAIDs including and @DRUG$ requires monitoring of patients certain in their @DRUG$ required .	DDI-false
While the serotonin inhibitors @DRUG$ , e.g. , , @DRUG$ , , , and paroxetine , inhibit may the of inhibition	DDI-false
@DRUG$ also increased rate of dissolution manner @DRUG$.	DDI-false
@DRUG$: The effect of @DRUG$ on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
a Narrow Therapeutic Index @DRUG$ : Sonata ( mg not the or of @DRUG$ ( mg q24h for days )	DDI-false
, lidocaine/quinidine , , quinidine/lidocaine @DRUG$/acetaminophen , .	DDI-false
LDL-C reduction when @DRUG$ and @DRUG$ than when either drug given .	DDI-effect
Patients receiving these drugs in combination with @DRUG$ should be monitored for signs of toxicity and the dose of @DRUG$ reduced if warranted.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
Concomitant oral administration @DRUG$ ( a known inhibitor CYP3A4 the in the mucosa ) caused an eight-fold of the systemic to oral	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other Drugs In ( 7 - , the concomitant administration @DRUG$ , , chloroquine , doxycycline , @DRUG$ did significantly affect the levels and AUC of .	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Studies in humans show that the absorption of @DRUG$ as reflected in urinary excretion is markedly decreased even when administered one hour before @DRUG$.	DDI-mechanism
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Drugs that have been neuropathy , dapsone @DRUG$ , ethionamide glutethimide hydralazine , iodoquinol , , phenytoin @DRUG$ and .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
@DRUG$ has been tolazoline , , @DRUG$ , steroids , surfactant , ventilation .	DDI-false
@DRUG$ effects of @DRUG$ and NSAIDs , such that drugs together risk of serious higher that of either drug alone .	DDI-false
Important Interactions To not pharmacokinetic interactions with , beta-blockers @DRUG$ warfarin isosorbide mononitrate , @DRUG$ , .	DDI-false
@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ and to potentiate its toxicity.	DDI-mechanism
Carbamazepine Isoniazid is to the @DRUG$ and levels levels should to concurrent administration with , signs symptoms @DRUG$ toxicity closely , appropriate of the anticonvulsant should .	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
Compounds man @DRUG$ , @DRUG$ , .	DDI-false
@DRUG$ healthy individuals , plasma approximately % with coadministration of @DRUG$ , a inhibitor of P450 3A4 .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
These drugs include the @DRUG$ and diuretics , phe-nothiazines products estrogens , oral phenytoin , sympathomimet-ics , @DRUG$ and isoniazid .	DDI-false
@DRUG$: Inhibition of renal lithium clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
These drugs include the thiazides , @DRUG$ , thyroid products , estrogens phenytoin , nicotinic acid , @DRUG$ channel blocking , isoniazid .	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
drugs thiazides and other diuretics corticosteroids , , thyroid , @DRUG$ phenytoin acid @DRUG$ ,	DDI-false
Contraceptives and @DRUG$ increased @DRUG$ by 30 20 .	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, @DRUG$, and @DRUG$.	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
@DRUG$ a substrate	DDI-false
Seizure, associated with increased @DRUG$ concentrations, has been reported with concomitant administration of intravenous @DRUG$.	DDI-false
@DRUG$ coadministered @DRUG$ rifampin or H2antagonists reduced plasma itraconazole reported	DDI-mechanism
Nephrotoxic Concomitant administration of VISTIDE and with nephrotoxic e.g. , ( e.g. , @DRUG$ , @DRUG$ ) amphotericin B , pentamidine , , and anti-inflammatory agents ]	DDI-false
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and @DRUG$ After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	DDI-false
@DRUG$ ( , ketoconazole , miconazole clotrimazole ): in vitro studies of and that imidazoles fungal	DDI-false
@DRUG$: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
Antacids : a , coadministration an ( aluminum hydroxide hydroxide and @DRUG$ with fosinopril serum excretion @DRUG$ as with fosinopril alone suggesting impair absorption of fosinopril .	DDI-false
@DRUG$ ( as lidocaine @DRUG$ ): with arbutamine have a proarrhythmic effect	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Suppression by @DRUG$ of bombesin-enhanced peritoneal intestinal adenocarcinomas induced @DRUG$ .	DDI-false
concomitant specific not performed finasteride of more in with acetaminophen , acetylsalicylic acid , a-blockers , analgesics ACE ) , , , , , H2 , HMG-CoA reductase inhibitors , @DRUG$ also as @DRUG$ ) , and anti-infectives without evidence .	DDI-false
blood AUC0 - 12 @DRUG$ by approximately 20 concentration ( Cmax ) by and 12-hour ( ) by 26 subjects @DRUG$ ( 2 doses of 0.1 12 hours apart was administered on of CANCIDAS 70 as tacrolimus was .	DDI-false
Imidazoles e. , ketoconazole @DRUG$ fluconazole , etc . ): in vitro studies with the of B @DRUG$ suggest that imidazoles induce fungal to B.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Adenocard @DRUG$ been in the presence of drugs , quinidine blocking agents , @DRUG$ and angiotensin enzyme inhibitors any the adverse reaction profile	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-mechanism
@DRUG$ (@DRUG$): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
For example , when @DRUG$ nilutamide , prothrombin should carefully monitored if necessary the dosage @DRUG$ reduced .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral @DRUG$).	DDI-false
some patients , anti-inflammatory reduce the diuretic , and effects @DRUG-DRUG$.	DDI-false
May interact thyroid e.g. ) , antacids , @DRUG$ ( e.g. @DRUG$ , ranitidine ) , and proton pump inhibitors e.g. lansoprazole , )	DDI-false
Cation-Containing Concurrent @DRUG$ including with products magnesium aluminum sucralfate VIDEX tablets pediatric powder , or or @DRUG$ may substantially decrease absorption of resulting in and urine levels desired	DDI-mechanism
Potential differences in @DRUG$ dosing and pharmacokinetics at different levels of @DRUG$ exposure were assessed in the context of ANOVA.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, nevirapine or @DRUG$).	DDI-false
specific studies not been performed with are metabolized , channel , dapsone @DRUG$ , quinine amiodarone quinidine , cyclosporine , , pimozide , carbamazepine @DRUG$ triazolam ) may have elevated plasma concentrations coadministered ;	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Ingestion of diclofenac may increase serum concentrations of @DRUG$ and @DRUG$ and increase cyclosporine s nephrotoxicity.	DDI-false
Suppression by @DRUG$ of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.	DDI-effect
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Other concomitant Although specific interaction studies not mg were concomitantly in studies , acetylsalicylic acid , a-blockers , @DRUG$ ACE , beta blockers calcium-channel blockers cardiac , , antagonists HMG-CoA reductase , prostaglandin to as @DRUG$ and of adverse interactions	DDI-false
If of CYP3A4 such as @DRUG$ intraconazole indinavir , saquinavir , erythromycin , . ) is indicated , reduction of @DRUG$ be .	DDI-advise
drug interactions between @DRUG$ other , , @DRUG$ , phenobarbital , , primidone valproate ) were also assessed evaluating serum of placebo-controlled clinical	DDI-false
, @DRUG$ influenced warfarin acetylsalicylic , @DRUG$ digoxin steady .	DDI-false
in studies other than @DRUG$ a possible drug interaction for the ergotamine cyclosporine , @DRUG$ , , and	DDI-int
In patients who have received @DRUG$, @DRUG$ may temporarily mask the residual effects of muscle relaxant drugs.	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	DDI-effect
, careful monitoring dose of @DRUG$ is concomitantly @DRUG$ and	DDI-false
tested include , @DRUG$ , aminopyrine and	DDI-false
which may blocking action of nondepolarizing agents such as @DRUG$ ( g. aminoglycosides , tetracyclines , @DRUG$ lincomycin , , , and sodium ) , , lithium , anesthetics , .	DDI-effect
no specific with systemic medications were identified in clinical studies @DRUG$ 0.5 % the possibility an effect CNS alcohol @DRUG$ , sedatives should considered .	DDI-advise
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
acetaminophen/theophylline , , phenobarbital/@DRUG$ , , ,	DDI-false
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
Compounds tested man @DRUG$ , @DRUG$ , , , aminopyrine and .	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Drug Interactions @DRUG$ may with some drugs like Monoamine ): MAOI theoretically @DRUG$ pharmacodynamics - Eproxindine Ethanol : Ethanol cause additive Flupenthixol effect Tricyclic antidepressants	DDI-false
@DRUG$ @DRUG$ produced a % increase AUC a 33 % increase in the Cmax	DDI-mechanism
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Interactions EPA supplements and aspirin @DRUG$ and herbs as garlic ( Allium sativum ginkgo @DRUG$	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Compounds tested in man include warfarin, @DRUG$, @DRUG$, diazepam, aminopyrine and antipyrine.	DDI-false
of @DRUG$ other antiarrhythmic reserved patients with life-threatening arrhythmias who are responsive	DDI-false
Interactions No pharmacokinetic interactions were between vardenafil following , @DRUG$ @DRUG$ Maalox ,	DDI-false
plasma of closely related tricyclic antidepressants have reported by administration of @DRUG$ hepatic enzyme inhibitors ( e.g. @DRUG$ fluoxetine concomitant e.g. , barbiturates , ) and an effect may be anticipated .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	DDI-false
: and enalapril have been used concomitantly beta agents , @DRUG$ , agents hydralazine , prazosin and @DRUG$ without of clinically significant .	DDI-false
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and @DRUG$.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
However because some @DRUG$ have to the or derivatives in , the time or other suitable coagulation test closely monitored if @DRUG$ is with warfarin or derivatives .	DDI-false
HIV Protease : @DRUG$ 800 t.i.d ) co-administered mg a @DRUG$ AUC , 7-fold increase in 2-fold increase in vardenafil	DDI-false
Antiarrhythmics : such procainamide @DRUG$ and have used with	DDI-false
No Important Levosimendan not have clinically interactions with , @DRUG$ , digoxin @DRUG$ , isosorbide carvedilol , ethanol	DDI-false
occur antihistamines are concomitantly with @DRUG$ including @DRUG$ tranquilizers , alcohol .	DDI-false
Repeated doses of colestipol hydrochloride given prior to a single dose of @DRUG$ in human trials have been reported to decrease @DRUG$ absorption.	DDI-false
The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	DDI-false
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Although these do not interaction @DRUG$ and @DRUG$ , administration to patients taking done extremely , patients should closely monitored	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
administration @DRUG$ 10 mg and cimetidine ( ) the mean and @DRUG$.	DDI-false
The of effects minimized by the @DRUG$ or increasing the intake approximately prior of @DRUG$ ( ) or initiating or	DDI-false
Although clinical studies not been based involvement of cytochrome P-450 3A family @DRUG$ of system , @DRUG$ should cautiously patients receiving clonazepam	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex.	DDI-false
between Keppra   and ( gabapentin @DRUG$ phenobarbital , phenytoin and @DRUG$ ) were also evaluating concentrations of and these studies	DDI-false
, on microsomal enzyme has been reported the hepatic @DRUG$ phenytoin propranolol , antidepressants , , @DRUG$ and thereby delaying elimination increasing blood these	DDI-false
In separate studies receiving doses , @DRUG$ , @DRUG$ , irbesartan administration for effect pharmacodynamics	DDI-false
Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-mechanism
@DRUG$ : pharmacology an antacid ( , simethicone ) fosinopril levels and urinary excretion fosinoprilat as alone suggesting that antacids may absorption	DDI-false
In a 12-week there no difference incidence endoscopic patients ( 81 mg enteric @DRUG$ @DRUG$ mg ibuprofen 2400 daily	DDI-false
@DRUG$ (beta-blockers) and @DRUG$ may interfere with the effect of each other when administered concurrently.	DDI-effect
@DRUG$ (NSAIDs)-A interaction study of @DRUG$ not conducted	DDI-false
@DRUG$ (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
@DRUG$ not effects @DRUG$ , but bronchospasm in	DDI-effect
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
In patients who have received @DRUG$, doxapram may temporarily mask the residual effects of @DRUG$.	DDI-false
Cardiac effects are antagonized @DRUG$ @DRUG$ metoprolol .	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, @DRUG$ treatment did not affect ribavirin distribution or clearance.	DDI-false
The extent to which @DRUG$-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
@DRUG$ In a clinical pharmacology coadministration of an , magnesium hydroxide , and ) with @DRUG$ and urinary excretion of fosinoprilat as compared with fosinopril administered alone , that antacids impair	DDI-false
may occur EPA @DRUG$ and @DRUG$ herbs garlic sativum and ginkgo biloba )	DDI-false
@DRUG$ , oxacillin doxycycline @DRUG$ , erythromycin , sulfamethoxazole have the protein binding of diclofenac human serum	DDI-false
other related compounds ( @DRUG$ quinidine @DRUG$ may of convulsions .	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Based , drug interactions VIRACEPT , @DRUG$ , @DRUG$ , itraconazole fluconazole .	DDI-false
Digoxin @DRUG$ : @DRUG$ , renal prostaglandins and toxicity of certain drugs	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
, like injectable , produces the central when with alcohol , phenothiazines @DRUG$ inhibitors and When scopolamine is used concomitantly with injectable @DRUG$ , increased sedation , hallucinations , behavior has observed .	DDI-false
Previous studies have reduction the bioavailability of @DRUG$ ciprofloxacin @DRUG$	DDI-mechanism
agents Concomitant of VISTIDE and agents nephrotoxic potential e.g. intravenous aminoglycosides ( , tobramycin @DRUG$ , , B , @DRUG$ intravenous pentamidine , vancomycin , non-steroidal agents	DDI-false
@DRUG$ : Lithium has been in patients receiving @DRUG$ cause , ACE inhibitors	DDI-false
@DRUG$/theophylline lidocaine/quinidine phenobarbital/acetaminophen , phenobarbital/valproic acid , and	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ for 10 days, and cohort 2 received amprenavir plus @DRUG$ for 4 days.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or @DRUG$.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and CYP3A such as @DRUG$ @DRUG$ barbiturates would be decrease concentrations	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Nervous System Depressants : concomitant of DURAGESIC   transdermal with central nervous including not other sedatives hypnotics , @DRUG$ , , , phenothiazines , muscle relaxants @DRUG$ cause depression , hypotension sedation , or potentially result death .	DDI-false
@DRUG$ in have shown @DRUG$ to no on warfarin metabolism on prothrombin activity .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
On of oral @DRUG$ , for @DRUG$ therapy be reviewed dose reduced by approximately or discontinued .	DDI-advise
administration @DRUG$ equivalent 145 mg @DRUG$ ) ( mg ) daily for 10 days been shown to the mean values by % range 69 decrease to % increase and % ( from 54 to 128 respectively by 55 % range from 32 decrease 314 % 39 ( % decrease to 261 ) , in healthy .	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
The concomitant use of such as @DRUG$ and @DRUG$ with transdermal also increase in concentrations which or prolong adverse drug and may serious depression .	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
coadministration @DRUG$ decreases the biologic of increase metabolic that greater of @DRUG$	DDI-false
Cardiac @DRUG$ blocking and @DRUG$.	DDI-effect
The majority of studies received one the following concomitant : NSAIDs , TNF blocking , @DRUG$ , , , hydroxychloroquine leflunomide ,	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
In clinical , @DRUG$ ( one 4 mg/kg dose or two 3 ) increased @DRUG$ .	DDI-mechanism
It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping disulfiram. since @DRUG$ may prolong prothrombin time.	DDI-false
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, @DRUG$, and @DRUG$).	DDI-false
@DRUG$ interact : Acetaminophen e.g. , @DRUG$ with long-term ) or	DDI-int
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ study healthy , mean lithium approximately receiving @DRUG$ 450 mg BID as compared subjects receiving lithium alone	DDI-false
Tolazamide : A of severe hypoglycemia in a diabetic patient on @DRUG$ ( 1 ) days addition of @DRUG$ ( 75 mg/day .	DDI-effect
@DRUG$ Caution should used if is administered concomitantly	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
CANCIDAS the AUC0 of @DRUG$ approximately % , peak concentration ( ) , 12-hour concentration ( ) by in healthy when 2 12 ) was administered 10th day of @DRUG$ , compared to results from a control tacrolimus was administered alone .	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
During transfer to oral @DRUG$, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral @DRUG$.	DDI-false
Patients receiving general @DRUG$ , tranquilizers , @DRUG$ or other depressants including alcohol ) DILAUDID an CNS depression	DDI-false
Although studies examine interactions not been done @DRUG$ for up to administered receiving @DRUG$.	DDI-false
Beta-adrenergic receptor antagonists (@DRUG$) and @DRUG$ may interfere with the effect of each other when administered concurrently.	DDI-effect
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
The @DRUG$-only pills is reduced such as anticonvulsants , and barbiturates and the drug	DDI-effect
@DRUG$: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and metoclopramide are coadministered.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Pretreatment of volunteers with doses of @DRUG$ a single dose of @DRUG$ Gleevec oral-dose clearance , ( p 0.05 ) decreased and - 8)	DDI-mechanism
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$ ( but not @DRUG$ drugs in combination high doses have shown to provoke in .	DDI-false
Supplements and @DRUG$ @DRUG$ can attenuate potassium caused by thiazide .	DDI-false
specific interaction were not performed finasteride 1 more were concomitantly clinical , @DRUG$ a-blockers analgesics @DRUG$ beta , blockers , cardiac nitrates , , reductase , synthetase inhibitors ( referred as ) , quinolone without evidence clinically significant	DDI-false
@DRUG$, disopyramide, @DRUG$	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
@DRUG$: @DRUG$ (Valium) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
drugs the thiazides diuretics , thyroid estrogens @DRUG$ , nicotinic acid @DRUG$ channel blocking drugs and	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
In Fondaparinux influenced the pharmacodynamics of @DRUG$ , piroxicam , pharmacokinetics of @DRUG$ steady	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Clinical @DRUG$ indicated @DRUG$ with does in significant	DDI-false
Hepatic , : induce cytochrome P450 3A4 3A4 ) enzyme activity ( e.g. @DRUG$ , carbamazepine , ) the @DRUG$ that the dosage of the corticosteroid	DDI-mechanism
In studies of patients receiving maintenance hydrochlorothiazide , digoxin @DRUG$ administration for days had no on pharmacokinetics @DRUG$.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, simvastatin).	DDI-false
In patients with renal function treated with @DRUG$ , co-administration @DRUG$ a further of renal .	DDI-effect
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, @DRUG$ and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
groups SH/DA SH/FA submitted with synthetic hydroalcoholic solutions containing @DRUG$ @DRUG$ , in proportions as those most common distilled alcoholic	DDI-false
data indicate that oral @DRUG$ markedly inhibits the metabolism @DRUG$ , a mean eight-fold increase of cisapride	DDI-mechanism
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
of peritoneal metastasis intestinal adenocarcinomas induced @DRUG$ in rats .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
apomorphine - prior diphenidol may decrease the @DRUG$ response @DRUG$ in the treatment of .	DDI-false
Serial urine samples of amprenavir rifabutin @DRUG$ and their @DRUG$ measured by liquid	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Clinical implications of @DRUG$ interactions with five @DRUG$.	DDI-int
exercised @DRUG$ drugs may decrease the or endogenous steroid as @DRUG$ , , and	DDI-advise
Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	DDI-false
Notably , systemic ( - 12 ) ( DHA than of @DRUG$/@DRUG$.	DDI-false
@DRUG$: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
interaction be given in @DRUG$ @DRUG$.	DDI-advise
drug Keppra and carbamazepine @DRUG$ lamotrigine phenobarbital @DRUG$ , and ) were also evaluating the serum levetiracetam during placebo-controlled clinical studies .	DDI-false
Amiodarone @DRUG$ @DRUG$ , quinidine CONTRAINDICATED to for and/or life-threatening .	DDI-false
@DRUG$ excretion @DRUG$ increased and , acidifying in methenamine .	DDI-false
in RA clinical of the following medications MTX NSAIDs , corticosteroids , TNF agents , , @DRUG$ gold , hydroxychloroquine @DRUG$ , and anakinra	DDI-false
Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-effect
@DRUG$: The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$, @DRUG$, alfentanil, and midazolam.	DDI-false
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
In the case that you are taking @DRUG$ while taking @DRUG$, higher doses of digoxin may be needed.	DDI-advise
Cytochrome P-450 inducers , such @DRUG$ @DRUG$ and phenobarbital induce an in levels .	DDI-false
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants.	DDI-false
Other therapy studies were not performed , finasteride doses 1 or used studies acetaminophen , acid @DRUG$ , angiotensin-converting enzyme inhibitors benzodiazepines beta blockers cardiac diuretics @DRUG$ reductase inhibitors , prostaglandin synthetase inhibitors ( referred as ) , and evidence of clinically adverse interactions .	DDI-false
These drugs include and other , phe-nothiazines , @DRUG$ @DRUG$ oral , phenytoin nicotinic , channel drugs isoniazid .	DDI-false
- @DRUG$ Lithium not be with @DRUG$ ( as because its renal clearance add of toxicity .	DDI-false
@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-mechanism
@DRUG$ may potentiate @DRUG$ toxicity	DDI-false
@DRUG$ : Concomitant administration of at 200 mg increase @DRUG$	DDI-false
Serial plasma and urine samples for measurement of @DRUG$, rifabutin, and @DRUG$ and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
In clinical trials was with digoxin , diuretics , oral vasodilators and supplemental oxygen In patients with failure receiving @DRUG$ @DRUG$ therapy with apparent oral values furosemide n = 23 ) ( = were 13 % , the second day had values by day 87 .	DDI-false
Digoxin and Losartan : Bosentan no pharmacokinetic interactions with @DRUG$ nimodipine , and losartan effect of @DRUG$.	DDI-false
@DRUG$ has been administered with @DRUG$, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
drugs and other diuretics corticosteroids estrogens oral phenytoin , @DRUG$ , sympathomimetics , @DRUG$ , .	DDI-false
The following substances that may effect corticosteroids , , @DRUG$ , sympathomimetic ( e.g. , salbutamol , terbutaline , isoniazid phenothiazine , @DRUG$ , thyroid hormones estrogens , progestogens ( contraceptives )	DDI-false
If it is necessary to continue the @DRUG$, initiate therapy with @DRUG$ at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.	DDI-advise
examples known the metabolism other benzodiazepines presumably inhibition of : @DRUG$ , cimetidine @DRUG$ and antibiotics	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
@DRUG$ clonidine salts , and alcohol either or effect	DDI-effect
intensity course of @DRUG$ phenobarbital @DRUG$ and in 16 receiving .	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
@DRUG$ effects @DRUG$ other depressants ( hypnotics , etc .	DDI-effect
Repeated doses of @DRUG$ given prior to a single dose of @DRUG$ in human trials have been reported to decrease propranolol absorption.	DDI-mechanism
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Benzylpenicillin @DRUG$ , oxacillin chlortetracycline doxycycline , cephalothin , @DRUG$ , sulfamethoxazole have no influence protein binding diclofenac .	DDI-false
Antidepressants tricyclic ) , @DRUG$ anticholinergic , glycosides : concurrent use @DRUG$ may additive inotropic and/or chronotropic	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$ and paroxetine.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
The @DRUG$ strong completely the @DRUG$-induced .	DDI-effect
Both @DRUG$ @DRUG$ levels dopamine nucleus accumbens but only increases levels serotonin in accumbens	DDI-false
Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
@DRUG$ apparently through an on certain microsomal systems , reported metabolism of warfarin-type , phenytoin propranolol @DRUG$ chlordiazepoxide certain tricyclic , and metronidazole elimination and increasing drugs	DDI-mechanism
Non-steroidal Anti-inflammatory Agents with compromised renal function who being with @DRUG$ , the of @DRUG$ may in a	DDI-effect
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
interactions were assessed pharmacokinetic , contraceptive @DRUG$ , warfarin @DRUG$ ) and through in placebo-controlled studies in epilepsy	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
The hypoglycemic of sulfonylureas may be by including nonsteroidal agents and other drugs are protein bound , salicylates , , @DRUG$ , , @DRUG$ , oxidase inhibitors beta .	DDI-false
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
Sulindac : The administration of @DRUG$ and @DRUG$ normal resulted in lowering of the plasma the sulindac sulfide by approximately .	DDI-mechanism
Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
specific studies not performed , with drugs mainly metabolized CYP3A4 , @DRUG$ dapsone disopyramide amiodarone quinidine @DRUG$ tacrolimus derivatives , carbamazepine , , alprazolam ) may have elevated when coadministered with ;	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
of digoxin , ibuprofen , naproxen , @DRUG$ , @DRUG$ did ketorolac binding .	DDI-false
@DRUG$ and are for P450 2D6 phenothiazines , and 1C antiarrhythmics @DRUG$ and flecainide .	DDI-false
@DRUG$ : of terfenadine @DRUG$ terfenadine in plasma	DDI-false
been reports side effects in therapy with @DRUG$	DDI-effect
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
debrisoquin Interactions carvedilol with CYP2D6 ( such @DRUG$ , @DRUG$ , propafenone ) not been studied , would blood levels of ) of carvedilol .	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
The hypoglycemic sulfonylureas by including anti-inflammatory and other drugs highly , @DRUG$ @DRUG$ , , probenecid , , oxidase inhibitors , and adrenergic blocking	DDI-false
Cholestyramine-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
: In , concomitant administration @DRUG$ and in an increase in levels	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
action sulfonylureas potentiated nonsteroidal anti-inflammatory other drugs are highly protein bound @DRUG$ sulfonamides chloramphenicol probenecid coumarins monoamine and	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/@DRUG$ acid , , valproic	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : such , procainamide , disopyramide , have @DRUG$.	DDI-false
Selective @DRUG$ ): SSRIs ( @DRUG$ , fluvoxamine , , sertraline ) have weakness , hyperreflexia , when with 5-HT1 agonists	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and @DRUG$ for injection concentrate) should not be treated with TAXOL.	DDI-false
@DRUG$ may certain CYP450 , @DRUG$ , , CYP2D6 , and CYP3A4 .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : concomitant administration ciprofloxacin @DRUG$ has , on occasions , in severe	DDI-false
@DRUG$ Coadministration rifabutin and @DRUG$ resulted plasma and % in plasma	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
The following are of substances blood-glucose-lowering susceptibility hypoglycemia ACE , @DRUG$ oxidase ( MAO ) , somatostatin , @DRUG$ ,	DDI-false
@DRUG$ may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-effect
Ethanol : Sonata mg the CNS-impairing effects @DRUG$ g/kg testing time for after @DRUG$ and on symbol test ( ) symbol copying and component the attention test 2.5 hours after ethanol	DDI-false
drugs include , thyroid , oral @DRUG$ , @DRUG$ , nicotinic acid drugs and isoniazid	DDI-false
Multivalent Products Concurrent of quinolone , with multivalent products such as magnesium or antacids @DRUG$ tablets or pediatric powder , or containing calcium @DRUG$ , or zinc substantially decrease the absorption , in and considerably than desired .	DDI-false
As agents , should noted that HALDOL of depressants as @DRUG$ , @DRUG$ , alcohol	DDI-false
In clinical trials, the concomitant administration of @DRUG$ and @DRUG$ did not alter the adverse reaction profile.	DDI-false
Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
ACE Angiotensin II (Hypertension)- In clinical studies patients with hypertension addition @DRUG$ 50 to 100 to @DRUG$ and receptor antagonists serum potassium ( about 0.09 - .	DDI-effect
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.	DDI-false
No ( or in interaction hydrochlorothiazide @DRUG$ , and	DDI-false
Plasma @DRUG$ concentration be when isoniazid and valproate administered dosage of @DRUG$ should made	DDI-false
ACE-inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: sertraline and @DRUG$.	DDI-int
of @DRUG$ may serum concentrations of digoxin and methotrexate and @DRUG$ .	DDI-effect
To evaluate chemotherapy HAART on clinical of patients with HIV-related systemic non-Hodgkin HIV-NHL the compared retrospectively group 24 patients with were treated with @DRUG$ , vincristine , ) chemotherapy plus HAART a patients who were treated CHOP or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin @DRUG$ prednisone with vincristine without antiretroviral therapy .	DDI-false
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
Concurrent administration of @DRUG$ and of @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-false
@DRUG$ tricyclic : @DRUG$ enhance of tricyclic sympathomimetic ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
specific with drugs or systemic medications were IOPIDINE 0.5 , the additive effect @DRUG$ ( alcohol , @DRUG$ , opiates sedatives anesthetics be considered .	DDI-false
@DRUG$: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
The of @DRUG$ (NNRTI)-based for therapy and @DRUG$ disturbances have led significant shifts practices .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
have antiretroviral analogues , , , ethionamide glutethimide , @DRUG$ , iodoquinol , isoniazid metronidazole @DRUG$ ribavirin and .	DDI-false
In clinical trials , FLOLAN used @DRUG$ , diuretics vasodilators , and oxygen . In pharmacokinetic substudy in @DRUG$ or digoxin in whom with was initiated , oral clearance values for furosemide ( n = 23 and n = ) decreased by 13 and 15 respectively on day and returned values by .	DDI-false
@DRUG$ of @DRUG$ anticoagulant effect of warfarin ( - 8 ) studied in healthy subjects of BEXTRA 40 for days .	DDI-false
40 , 40 intravenous self-administration morphine and and the of @DRUG$ @DRUG$ in ;	DDI-false
have not been with that are metabolized ( channel blockers dapsone , @DRUG$ amiodarone , @DRUG$ tacrolimus , cyclosporine , , carbamazepine , fentanyl alfentanyl , alprazolam and triazolam have concentrations when ;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
ketoconazole inhibits the metabolism of @DRUG$ , in elevated astemizole its @DRUG$ which may .	DDI-false
Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
In study volunteers , TORADOLORAL coadministered single @DRUG$ , causing in or pharmacodynamics @DRUG$.	DDI-false
Drugs that been associated peripheral , cisplatin , , , ethionamide glutethimide @DRUG$ hydralazine , @DRUG$ , phenytoin , ,	DDI-false
Serotonin SSRIs ): @DRUG$ ( e.g. , @DRUG$ , sertraline ) been to weakness hyperreflexia , incoordination coadministered with 5-HT1 agonists .	DDI-false
In , TORADOLIV/IM with two of @DRUG$ to volunteers , resulting a mean template bleeding ( 3.2 to min compared to mean 6.0 ( 3.4 7.5 @DRUG$ alone and 5.1 minutes ( 3.5 8.5 placebo	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free @DRUG$.	DDI-false
Before this medication , your all and products you may , of : @DRUG$ e.g. , , , B , , anti-inflammatory drugs ( e.g. , ibuprofen , @DRUG$ , vancomycin .	DDI-false
The physician is advised to monitor the plasma concentrations of @DRUG$ when any of these drugs is taken concurrently, and to increase the dose of @DRUG$ if necessary.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some @DRUG$.	DDI-false
No significant drug-drug pharmacokinetic or ) interactions found in with hydrochlorothiazide digoxin , @DRUG$ @DRUG$.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
In studies performed the concomitant of oral anticoagulants ( warfarin @DRUG$ ( acetylsalicylic ) , NSAIDs @DRUG$ ) digoxin did the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
a 12-month that included a 50 mcg once daily @DRUG$ dose of the 528 -treated subjects concomitant @DRUG$ study entry	DDI-false
@DRUG$ had no @DRUG$ .	DDI-false
cytochrome P450 enzymes ( i.e. carbamazepine , @DRUG$ @DRUG$ ) shown to decrease the plasma MHD % )	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
The of @DRUG$ are antagonized by methylxanthines such caffeine and	DDI-effect
System The concomitant @DRUG$   fentanyl transdermal system ) with other including but limited to @DRUG$ sedatives , , ( e.g. benzodiazepines , general anesthetics , phenothiazines , skeletal , and alcohol , respiratory depression , and , potentially result coma death .	DDI-effect
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-effect
@DRUG$ @DRUG$ Absorption of hydrochlorothiazide is impaired in presence anionic exchange resins	DDI-false
@DRUG$ should not be administered concomitantly with other sympathomimetic drugs (such as @DRUG$) because of possible additive effects and increased toxicity.	DDI-advise
no specific with topical clinical % Solution the additive or effect with @DRUG$ ( @DRUG$ , barbiturates , , sedatives anesthetics .	DDI-false
Therefore it would a @DRUG$ bedtime and @DRUG$ given before would not in a significant in clinical of	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Tetracyclines treatment and @DRUG$ should avoided @DRUG$ been associated a cases pseudotumor cerebri ( hypertension some of which involved use of	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
@DRUG$ Upon of 5 mg of @DRUG$ ritonavir , Cmax of were approximately 20 % .	DDI-false
Drugs : In groups patients - ) the concomitant of , @DRUG$ , D-penicillamine , , , @DRUG$ not affect the AUC diclofenac .	DDI-false
Products a ciprofloxacin products as @DRUG$ antacids , @DRUG$ VIDEX chewable/buffered tablets pediatric or products calcium or may decrease the absorption of , in serum and levels considerably desired	DDI-false
inhibits @DRUG$ , oral , methotrexate and	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., @DRUG$, omeprazole).	DDI-false
be @DRUG$ the of endogenous steroid hormones , ketoconazole ,	DDI-advise
Nephrotoxic agents Concomitant of @DRUG$ and agents potential , intravenous e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , , pentamidine , @DRUG$ , anti-inflammatory ] is .	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Prednisone/prednisolone : not have clinically important effect the pharmacokinetics @DRUG$ or @DRUG$.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Both @DRUG$ and @DRUG$ slow AV conduction.	DDI-effect
In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ other containing @DRUG$ or zinc , or sucralfate not concomitantly with within 2 hours , of because may with absorption resulting serum and urine levels of	DDI-false
Probenecid: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity.	DDI-false
The concurrent use intravenously administered @DRUG$ ( aminophylline theophylline ) by @DRUG$ has completely evaluated	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$: Diazepam (@DRUG$) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
Studies to evaluate possible interactions between @DRUG$ and drugs other than @DRUG$ have not been performed.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as @DRUG$ or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
Other Although interaction studies performed , of mg were in clinical studies with @DRUG$ acetylsalicylic acid , analgesics , ( , beta , nitrates antagonists , synthetase inhibitors ( also referred as NSAIDs @DRUG$ of significant adverse interactions .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ ( e. , @DRUG$ fluconazole etc ): and studies combination amphotericin B and imidazoles suggest that imidazoles may fungal	DDI-false
, diethylpropion interfere with ( i.e. @DRUG$ @DRUG$ ) .	DDI-false
@DRUG$ ( mg daily been with therapeutic doses of @DRUG$ cimetidine ketoconazole in studies adult volunteers	DDI-false
of @DRUG$ and @DRUG$ is contraindicated .	DDI-advise
@DRUG$ May decrease tubular secretion of in increased blood levels @DRUG$	DDI-false
@DRUG$ reversible upon discontinuation @DRUG$ and inhibitor .	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with salicylate or @DRUG$.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Antiarrhythmics Other @DRUG$ drugs such as quinidine procainamide disopyramide , and @DRUG$ , been .	DDI-false
This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Acetaminophen @DRUG$ @DRUG$ quinidine , theophylline , valproic added human serum at concentrations .	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
studies performed with Fondaparinux , concomitant anticoagulants warfarin ) platelet ( acid ) , @DRUG$ piroxicam ) and @DRUG$ did not affect the of fondaparinux	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
Although specific have not been performed with are metabolized channel @DRUG$ , amiodarone , @DRUG$ , ergot derivatives , pimozide , carbamazepine fentanyl alfentanyl , , have plasma coadministered	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Valdecoxib significant in exposures @DRUG$ @DRUG$ ( 12 , respectively ) , and pharmacodynamic prothrombin INR ) of warfarin	DDI-false
that have with neuropathy @DRUG$ dapsone gold , hydralazine @DRUG$ , isoniazid , nitrofurantoin , phenytoin , ribavirin , and	DDI-false
vitro studies indicate , concentrations of @DRUG$ ( g/mL ) , the of ketorolac from approximately % 97.5 % a twofold increase @DRUG$ .	DDI-false
interactions between and @DRUG$ ( @DRUG$ gabapentin , , phenobarbital phenytoin , and were assessed by evaluating serum of levetiracetam and AEDs clinical studies	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to desbutyl levobupivacaine and @DRUG$, respectively.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	DDI-mechanism
In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-false
Oxidase and Antidepressants @DRUG$ be with caution in patients being treated @DRUG$ or antidepressants because the action formoterol may potentiated by these agents .	DDI-advise
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (@DRUG$, sedatives, tranquilizers, etc).	DDI-false
The and efficacy of concomitant @DRUG$ and @DRUG$ is unknown , concomitant use two medications is ordinarily recommended unless probable benefits outweigh known	DDI-effect
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
this paper to study the @DRUG$ both analogue @DRUG$ , or tuftsin , on antinonciceptive effect these peptides after .	DDI-false
The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
: volunteers small decrease diflunisal levels was when doses of @DRUG$ @DRUG$ administered	DDI-mechanism
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal @DRUG$ may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
were increases liver and when @DRUG$ and @DRUG$ .	DDI-effect
The hypoglycemic sulfonylureas certain including anti-inflammatory agents and other drugs that highly , salicylates , sulfonamides @DRUG$ , probenecid coumarins inhibitors , and	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To determine whether of @DRUG$ permit doses of administered fixed 9.9-g/m2 dose @DRUG$ three concurrently with cisplatin .	DDI-false
Aspirin : @DRUG$ in an increased rate GI or complications , compared of @DRUG$ alone .	DDI-false
drugs and other , corticosteroids phenothiazines , estrogens , oral contraceptives @DRUG$ nicotinic @DRUG$ , calcium channel drugs isoniazid	DDI-false
These drugs include @DRUG$ @DRUG$ , , oral , , acid , sympathomimet-ics blocking isoniazid .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
patients , non-steroidal anti-inflammatory agent reduce diuretic , natriuretic , effects of	DDI-false
A interaction glyburide @DRUG$ , a @DRUG$ , been reported resulting the hypoglycemic of .	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Colestipol-Concomitant intake @DRUG$ K may the of	DDI-false
The effects of mixing @DRUG$ with @DRUG$ of animal source or insulin preparations produced by other manufacturers have not been studied .	DDI-false
concentrations of warfarin , , @DRUG$ piroxicam @DRUG$ phenytoin not ketorolac binding .	DDI-false
@DRUG$ : of a 27 % in @DRUG$ clearance and an increase %	DDI-false
Drugs amiodarone , quinidine : @DRUG$ : ergot derivatives rifampin @DRUG$ GI	DDI-false
efavirenz and nevirapine have compared the PI @DRUG$ 48 as initial , responses being with and observed @DRUG$.	DDI-false
TABLE 1 Effects ( of Loratadine and @DRUG$ After of Coadministration @DRUG$ Normal	DDI-false
Other drugs which may enhance action of such as NUROMAX include aminoglycosides , , bacitracin , , @DRUG$ @DRUG$ , sodium colistimethate , magnesium , , , procainamide , and	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, @DRUG$, ketoconazole), though this has not been studied	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
drugs @DRUG$ and diuretics , corticosteroids , thyroid products , @DRUG$ , oral , nicotinic sympathomimetics calcium blocking drugs .	DDI-false
@DRUG$ not affect	DDI-false
Oral @DRUG$ ( BID did not induce metabolism the combination oral @DRUG$ norethindrone/ethinyl ( mg /35 mcg Ortho-Novum .	DDI-false
which may enhance blocking nondepolarizing such as include certain ( e. g. , , tetracyclines , , lincomycin , , colistin and sodium salts @DRUG$ , , and	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
, ampicillin @DRUG$ doxycycline , @DRUG$ and have no influence in on the protein of diclofenac serum .	DDI-false
related @DRUG$ reported be administration methylphenidate or enzyme inhibitors ( e.g. , , fluoxetine ) and decreased by of hepatic enzyme inducers e.g. , barbiturates , @DRUG$ , an effect anticipated CMI	DDI-mechanism
TORADOL IV/IM reduced the @DRUG$ @DRUG$ in normovolemic healthy subjects by % sodium and urinary output 17 ) .	DDI-false
inhibitors antifungals , , , doxycycline , erythromycin , imatinib , @DRUG$ , nefazodone @DRUG$ inhibitors quinidine , and verapamil	DDI-false
metabolizers of debrisoquin : carvedilol with inhibitors CYP2D6 ( such @DRUG$ , fluoxetine , @DRUG$ ) been studied but would be expected to blood levels enantiomer	DDI-false
conversely , @DRUG$ interfere ( , @DRUG$	DDI-int
Treatment with @DRUG$ can directly interfere with levels or may with @DRUG$.	DDI-int
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
additional @DRUG$ are be any route they used with sympathetic effects @DRUG$ be .	DDI-advise
In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
: Amiodarone should be used caution in receiving blocking agents e.g. , @DRUG$ , a CYP3A4 ) or calcium antagonists ( , verapamil , a CYP3A4 substrate , and diltiazem a @DRUG$ ) of the of , sinus ;	DDI-false
Should Coadministered : , astemizole , @DRUG$ Antimigraine derivatives @DRUG$ rifampin midazolam	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
In a study in the 2 clonazepam orally tablet with without ( an agent effects on the tract ) to the of @DRUG$ Cmax @DRUG$ 20 % lower when the disintegrating tablet compared when it alone	DDI-false
@DRUG$ , clotrimazole , , animal studies amphotericin B imidazoles imidazoles may induce resistance to @DRUG$.	DDI-false
above ng/mL with oral @DRUG$ has led to an % increase in etoposide exposure a 38 decrease in total body of @DRUG$ etoposide .	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
No interactions @DRUG$ , @DRUG$ demonstrated .	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
@DRUG$ administered to receiving	DDI-advise
Potential drug AEDs carbamazepine @DRUG$ , phenobarbital phenytoin , and valproate were also assessed by evaluating serum concentrations @DRUG$ these AEDs during clinical studies	DDI-false
Antidepressants, tricyclic @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
ethanolysis @DRUG$ in @DRUG$ solutions .	DDI-mechanism
@DRUG$-A of @DRUG$ with lithium has not conducted .	DDI-false
@DRUG$ caused statistically increase exposures of @DRUG$ ( % and 15 , , and in ( , measured as ) warfarin	DDI-mechanism
- The action of sulphonylureas and @DRUG$ may be enhanced by @DRUG$ or Bezalip retard.	DDI-effect
Digoxin: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	DDI-effect
Example inhibitors include azole , , , , , imatinib , isoniazid , @DRUG$ propofol inhibitors , @DRUG$ ,	DDI-false
In addition , results regression analyses of pharmacokinetic suggest co-administration other inducers drug ( efavirenz , @DRUG$ @DRUG$ , or carbamazepine CANCIDAS may result reductions .	DDI-false
Drug Interactions : may interact with drugs @DRUG$ ( MAOI MAOI Arecoline - Eproxindine - : Ethanol cause CNS depression - @DRUG$ : increases the Tricyclic antidepressants	DDI-false
Moreover additional interaction with niacin propranolol on @DRUG$ plasma , patient digoxin resulted in no in the bioavailability of @DRUG$ relative data .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	DDI-false
not with drugs that mainly by CYP3A4 ( , blockers dapsone @DRUG$ quinine , amiodarone quinidine warfarin , tacrolimus cyclosporine @DRUG$ pimozide fentanyl , alfentanyl alprazolam , and triazolam may elevated concentrations saquinavir	DDI-false
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.	DDI-effect
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-advise
The possibility of effects with or enalaprilat be minimized discontinuing or increasing the prior to treatment @DRUG$ or @DRUG$.	DDI-false
Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
, additional studies demonstrated any @DRUG$ plasma levels to a population chronically receiving @DRUG$ resulted in difference of of to control .	DDI-false
: @DRUG$ , erythromycins , tetracyclines with effect @DRUG$.	DDI-effect
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
Micro-dosed @DRUG$ Preparations @DRUG$ preparations ( minipills that not contain may be method .	DDI-false
No @DRUG$ not have pharmacokinetic interactions captopril , felodipine , warfarin , carvedilol or @DRUG$.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
The in RA clinical studies or more of the medications ORENCIA MTX NSAIDs corticosteroids , TNF , @DRUG$ , chloroquine , gold @DRUG$ , leflunomide , anakinra	DDI-false
studies not been coadministration with are mainly by eg channel blockers , dapsone , , , quinidine , warfarin , @DRUG$ , , ergot pimozide , @DRUG$ , elevated plasma concentrations saquinavir	DDI-false
Coadministration of valdecoxib and @DRUG$ 1/35  increased the exposure of @DRUG$ and ethinyl estradiol by 20% and 34%, respectively.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	DDI-mechanism
Concomitant administration of low-dose @DRUG$ with VIOXX may in increased of GI or other complications , compared to @DRUG$	DDI-false
Injection : injection , benzodiazepines depression the nervous when with @DRUG$ phenothiazines barbiturates , MAO inhibitors and is injectable , an incidence sedation , hallucinations irrational been	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
administration of containing @DRUG$ or to monoamine oxidase inhibitors , antidepressants @DRUG$ may , or	DDI-effect
Agents @DRUG$ and been used with beta @DRUG$ nitrates , calcium-blocking agents prazosin and without of significant adverse interactions .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$ : Potentiation of @DRUG$-type ( and ) is always in amiodarone in serious	DDI-false
concentrations of @DRUG$ ( 10(-8 ) - ) M or @DRUG$ ( X 10(-8 M .	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Other specific were @DRUG$ doses mg or were concomitantly used in clinical studies with acid a-blockers , analgesics , ACE anticonvulsants , @DRUG$ , blockers calcium-channel blockers diuretics , , reductase inhibitors prostaglandin inhibitors ( referred as , and quinolone anti-infectives evidence adverse interactions .	DDI-false
Although neither @DRUG$ nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
: @DRUG$ IV concomitantly with adrenergic-blocking agents methyldopa @DRUG$ calcium-blocking agents hydralazine ,	DDI-false
concomitant Although specific interaction studies performed , finasteride doses 1 or used in studies acetaminophen , acetylsalicylic , a-blockers , @DRUG$ enzyme ( ) , , @DRUG$ blockers , nitrates diuretics , H2 antagonists HMG-CoA inhibitors prostaglandin referred ) , without of interactions .	DDI-false
In addition, higher-than expected steady-state serum concentrations of @DRUG$ have been observed when therapy is initiated in patients already taking @DRUG$.	DDI-mechanism
High-dose A concentrations ng/mL administered with oral has led increase in etoposide exposure with a % decrease in @DRUG$ @DRUG$ .	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
@DRUG$-induced and vasodilation is not either @DRUG$.	DDI-false
Benzylpenicillin @DRUG$ , chlortetracycline , @DRUG$ cephalothin erythromycin and sulfamethoxazole no influence in vitro the	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists Congestive In EPHESUS , ( patients 25 50 @DRUG$ or @DRUG$ ( ) .	DDI-false
Aminosalicylic acid may the amount of @DRUG$ ( @DRUG$ ) gets absorbed into your	DDI-false
following examples substances blood-glucose-lowering and susceptibility : antidiabetic products inhibitors , , , fluoxetine @DRUG$ , salicylates , ( @DRUG$ , antibiotics .	DDI-false
These the and diuretics , , phe-nothiazines products @DRUG$ oral contraceptives @DRUG$ , , channel blocking , isoniazid .	DDI-false
concomitant : In clinical safety profile treated anxiolytics @DRUG$ , @DRUG$ was to that of subjects taking placebo these .	DDI-false
healthy with doses rifampin followed by single @DRUG$ , increased @DRUG$ clearance , which cmax and -	DDI-false
@DRUG$ ( tricyclic , atropine or anticholinergic , or @DRUG$ concurrent with arbutamine inotropic and/or chronotropic effects	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with diltiazem.	DDI-false
Hypersensitivity Reactions with a history of products   ( eg , @DRUG$ for injection and @DRUG$ for ) be TAXOL	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
In a study of an @DRUG$ , hydroxide and with @DRUG$ reduced urinary excretion of fosinoprilat as compared fosinopril administered alone may absorption .	DDI-mechanism
Phenothiazines - Taking @DRUG$ and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-effect
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.	DDI-false
Urinary acidifying agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the @DRUG$ rifampin.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ : @DRUG$ , , potential and reactions such acute ergot toxicity peripheral vasospasm other	DDI-false
similar association though , has been suggested with @DRUG$ , phenytoin , possibly with @DRUG$ , and tetracyclines 72	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Since @DRUG$ are potentiated @DRUG$ they used in the treatment	DDI-advise
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
In addition , regression pharmacokinetic suggest co-administration of other inducers clearance efavirenz dexamethasone , or @DRUG$ with @DRUG$ may result in clinically meaningful	DDI-mechanism
@DRUG$: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).	DDI-false
Diphenhydramine hydrochloride effects with alcohol @DRUG$ hypnotics , sedatives @DRUG$ etc )	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Coadministration of @DRUG$ and Ortho-Novum 1/35  increased the exposure of norethindrone and @DRUG$ by 20% and 34%, respectively.	DDI-false
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
: Interactions carvedilol with strong of CYP2D6 ( such @DRUG$ , paroxetine ) have been but these drugs would expected increase levels of the R(+ ) enantiomer @DRUG$ .	DDI-effect
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of @DRUG$.	DDI-effect
Antidepressants, tricyclic Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	DDI-false
The effect of orally ingested @DRUG$ or @DRUG$ from breast milk on the nursing infant has not been evaluated.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Based known profiles , clinically interactions are expected between dapsone , @DRUG$/sulfamethoxazole , @DRUG$ erythromycin	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Because a similar interaction is likely, @DRUG$ should also not be administered concurrently with @DRUG$.	DDI-advise
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
which enhance the of nondepolarizing agents such @DRUG$ include certain antibiotics ( g. @DRUG$ tetracyclines bacitracin lincomycin , , ) , magnesium , lithium , local anesthetics procainamide	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
, @DRUG$ , , chlortetracycline doxycycline @DRUG$ erythromycin and sulfamethoxazole have influence vitro the protein binding of human serum .	DDI-false
@DRUG$   ( 1000 mg daily did not influence the pharmacokinetics and ( ECG @DRUG$ given as a 0.25 day .	DDI-false
@DRUG$ did not alter the plasma levels of @DRUG$ when taken in combination.	DDI-false
Lithium: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Nervous : concomitant   ( @DRUG$ transdermal ) with depressants limited other , sedatives , ( e.g. @DRUG$ ) general anesthetics phenothiazines , , alcohol , may depression , and sedation or potentially result in coma death	DDI-effect
@DRUG$ and should not beadministered concomitantly in @DRUG$ may the efficacy ofthe .	DDI-false
Other @DRUG$ Concomitant use of other @DRUG$ within 24 hours of treatment with AXERT is contraindicated.	DDI-false
no in drug-drug interaction were @DRUG$ and of CYP3A inducers ( carbamazepine , phenytoin @DRUG$ and barbiturates would be expected to	DDI-mechanism
Concomitant administration of Sonata (10 mg) and @DRUG$ (800 mg) produced an 85% increase in the mean Cmax and AUC of @DRUG$.	DDI-false
@DRUG$: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.	DDI-false
@DRUG$ by oxidase ( ) , inhibition this enzyme potentiates	DDI-false
Warfarin : @DRUG$ 3 daily for 5 days did the or (S)-warfarin were there changes pharmacodynamic ( prothrombin a oral of @DRUG$	DDI-false
To impact of chemotherapy plus HAART on of patients HIV-related ( the a group of 24 with were with , @DRUG$ , vincristine , prednisone ( CHOP chemotherapy regimen plus HAART of 80 patients who were treated with CHOP or CHOP-like ( cyclophosphamide doxorubicin , and prednisone @DRUG$ ) antiretroviral	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
agents Concomitant of VISTIDE and with nephrotoxic ( e.g. , tobramycin and amikacin , amphotericin @DRUG$ , @DRUG$ and non-steroidal is .	DDI-false
May with thyroid medication ) , antacids @DRUG$ ( e.g. , famotidine ranitidine ) and pump ( , @DRUG$ , omeprazole	DDI-false
effect the of to be maximal 5 to 7 days the @DRUG$ a similar of @DRUG$ withdrawal .	DDI-false
Multivalent Products : Concurrent of quinolone including ciprofloxacin , products @DRUG$ @DRUG$ , , , or calcium iron , or may absorption of ciprofloxacin resulting urine levels lower than desired	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
Potential interactions were in studies phenytoin , oral , @DRUG$ @DRUG$ , probenecid screening clinical studies in epilepsy	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
@DRUG$ ( Hydroxide Cerivastatin plasma concentrations by co-administration of @DRUG$.	DDI-false
agents agents nephrotoxic potential , @DRUG$ ( e.g. , , and ) , B intravenous @DRUG$ , agents	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
The may reduce blood-glucose-lowering : @DRUG$ diuretics , sympathomimetic , epinephrine , ) isoniazid , phenothiazine somatropin , @DRUG$	DDI-false
@DRUG$: The concomitant use of Bepridil and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
: or pharmacodynamic drug-drug interactions @DRUG$ and concomitantly aspirin ( 162.5 mg orally 26 and hours prior initiation of Argatroban 1   g/kg/min @DRUG$ ( mg orally , 0 prior to , 6 subsequent to , g/kg/min . 18 hours )	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
drug @DRUG$   other AEDs , gabapentin , phenobarbital , phenytoin , @DRUG$ valproate ) were also evaluating serum concentrations of these AEDs placebo-controlled	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
concentrations , warfarin , , piroxicam @DRUG$ @DRUG$ protein binding	DDI-false
agents : Gastrointestinal acidifying agents @DRUG$ , , glutamic acid , @DRUG$ juices , ) absorption of amphetamines .	DDI-false
@DRUG$ doses eszopiclone 3 @DRUG$ daily 7 produced or pharmacodynamic interaction	DDI-false
In pigeons, @DRUG$ did not systematically alter the effects of (-)-NANM, @DRUG$ or PCP.	DDI-false
Lithium : In study in subjects , lithium approximately % in subjects @DRUG$ 450 mg BID @DRUG$ mg BID alone .	DDI-mechanism
@DRUG$ : Gastrointestinal reserpine glutamic acid , acid , juices etc . ) of	DDI-false
@DRUG$ : @DRUG$ concentrations cystic fluid increased ( about 2-fold in patients treated mg/kg/day ) n=7 ) with albendazole 20 mg/kg/day ) ( n=12 ) .	DDI-false
this all prescription nonprescription you may use especially aminoglycosides , gentamicin @DRUG$ ) @DRUG$ , cyclosporine , anti-inflammatory drugs ,	DDI-false
Monoamine Oxidase Inhibitors: Coadministration of @DRUG$ resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	DDI-mechanism
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
: Concurrent administration of a quinolone ciprofloxacin , multivalent cation-containing magnesium or , tablets pediatric powder or products containing @DRUG$ , @DRUG$ , or may decrease the absorption of resulting in serum urine lower than	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and @DRUG$ (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone.	DDI-false
Other which may the neuromuscular action of nondepolarizing such include antibiotics ( g. aminoglycosides , , @DRUG$ @DRUG$ and sodium ) magnesium salts , anesthetics , quinidine .	DDI-false
- @DRUG$ Anabolin @DRUG$ e.g. , [ e.g. ] [ e.g. , Winstrol or	DDI-false
The pressor effects of @DRUG$ such as dopamine or @DRUG$ are enhanced by Bretylium Tosylate.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Oral @DRUG$ dose administration of @DRUG$ ( 8 mg/day ) pharmacokinetics oral contraceptives in of childbearing age .	DDI-false
: The of @DRUG$ @DRUG$ , severe hypoglycemia	DDI-effect
poor : with strong inhibitors of ( such , fluoxetine , paroxetine @DRUG$ ) have not been studied expected to blood levels of the enantiomer of @DRUG$	DDI-effect
Methotrexate : interaction arthritis @DRUG$ , CELEBREX did have a effect on the pharmacokinetics	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
number of disorders has been observed concurrent @DRUG$ @DRUG$ , crescentic , oculo-bulbar myasthenia , thyroiditis , bullous and Stevens-Johnson syndrome .	DDI-effect
Promethazine: Coadministration of a single dose of zaleplon and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
In the presence of these @DRUG$, larger doses of adenosine may be required or @DRUG$ may not be effective.	DDI-advise
@DRUG$ (e. g., @DRUG$, etc.) should be given concomitantly only with great caution.	DDI-false
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
While the @DRUG$ SSRIs ) , e.g. @DRUG$ escitalopram , sertraline , paroxetine inhibit 2D6 , they may the extent .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Products of @DRUG$ reduced ( 25 % when coadministered products	DDI-false
Zidovudine : between @DRUG$ @DRUG$ been	DDI-false
interact with medication ( , iodine-containing products antacids , H2-antagonists ( e.g. , famotidine , ranitidine and @DRUG$ ( e.g. , , @DRUG$ .	DDI-false
Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-advise
@DRUG$ interact with alcohol thinners @DRUG$ cold and sinus medicines ) diabetic drugs lithium , norepinephrine NSAIDs like or Ibuprofen , and blood pressure .	DDI-int
A dose of liquid @DRUG$ not affect C AUC @DRUG$	DDI-false
Lithium Lithium been in @DRUG$ concomitantly drugs sodium @DRUG$.	DDI-effect
Therefore, when MIDAMOR and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
Antihypertensives Amiodarone should with caution in   -receptor blocking propranolol ) calcium channel , @DRUG$ @DRUG$ substrate , and diltiazem , inhibitor ) because of potentiation of bradycardia , arrest and AV block ;	DDI-false
@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
The may reduce corticosteroids @DRUG$ , , diuretics @DRUG$ ( e.g. epinephrine salbutamol terbutaline , , , thyroid hormones estrogens e.g. , in oral contraceptives .	DDI-false
Results from existing clinical trials suggest no significant interactions between @DRUG$  and other therapies commonly used in MS patients, including the concurrent use of @DRUG$ for up to 28 days.	DDI-false
Although @DRUG$ effective have reports pregnancy from @DRUG$ , well topical/injectable/implantable/insertable birth	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ @DRUG$ should be use a the potential pancreatitis is required	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
While drug-drug interaction between estazolam and compounds CYP3A inducers such as @DRUG$ , , rifampin , and barbiturates ) be to decrease @DRUG$	DDI-false
Although specific studies have not been performed , coadministration with that metabolized by CYP3A4 , calcium channel , dapsone , , @DRUG$ cyclosporine , derivatives @DRUG$ , carbamazepine fentanyl have plasma	DDI-false
Concurrent administration of a @DRUG$ with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-false
Phenylbutazone: @DRUG$ causes increase (by about 80%) in the free fraction of @DRUG$.	DDI-mechanism
Serial plasma and urine samples for measurement of @DRUG$, rifabutin, and rifampin and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
@DRUG$ : Population pharmacokinetic analyses @DRUG$ is in with or without	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Hemodynamic and electrophysiologic interactions been @DRUG$ @DRUG$	DDI-false
@DRUG$: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or ampicillin toxicity.	DDI-mechanism
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
patients hypertension was controlled @DRUG$ @DRUG$ mean additional supine systolic/diastolic reductions 6/5 placebo	DDI-effect
, @DRUG$ should patients and @DRUG$ which potent CYP3A .	DDI-advise
@DRUG$ ) has been administered presence other drugs such @DRUG$ , calcium agents , and enzyme inhibitors without any change the adverse reaction	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Enzyme Inducers , : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ( e.g. @DRUG$ phenytoin , of corticosteroids and of the @DRUG$ be increased	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
If NovoLog is mixed with @DRUG$, @DRUG$ should be drawn into the syringe first.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
In clinical , FLOLAN used diuretics , anticoagulants , oral @DRUG$ oxygen in with congestive heart failure furosemide or in therapy FLOLAN was apparent clearance @DRUG$ n ) digoxin n 30 ) were decreased by 15 , respectively on the of therapy and had values day 87	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
receiving narcotic analgesics general anesthetics , phenothiazines , tranquilizers , @DRUG$ , tricyclic antidepressants or other depressants ( concomitantly @DRUG$ may exhibit additive CNS depression .	DDI-effect
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : decreases @DRUG$ renal clearance lithium .	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Other reported interactions with amiodarone: Fentanyl (@DRUG$ substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
clinical was used @DRUG$ @DRUG$ anticoagulants , , and supplemental . In a in congestive heart furosemide in whom with was , oral clearance n = = 30 by 13 % 15 % , , of therapy and had to values 87	DDI-false
appears be the relevant of this @DRUG$ although theoretically coadministration other drugs known to cardiac conduction eg , or @DRUG$ , , agents tricyclic antidepressants and might a prolongation QTc .	DDI-effect
Standard therapy includes @DRUG$, such as @DRUG$ and gentamicin;	DDI-false
drugs include the @DRUG$ other diuretics , , , , oral , phenytoin , acid , calcium channel drugs @DRUG$.	DDI-false
Tetracyclines: Since both @DRUG$ and @DRUG$ can cause increased intracranial pressure, their combined use is contraindicated.	DDI-effect
- Lithium: @DRUG$ should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
An non-CYP3A4 agent may patients taking inducers rifampin , phenytoin @DRUG$ , and @DRUG$.	DDI-false
Psychoactive : been reported when TORADOL was used patients @DRUG$ @DRUG$ thiothixene , ) .	DDI-false
appears to be only clinically interaction , although theoretically other drugs known alter cardiac ( , anti-arrhythmic or beta-adrenergic agents @DRUG$ antihistamines or H1-blocking , @DRUG$ and might a of the QTc .	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
Vasodilators The following commonly concomitant @DRUG$ or vasodilators ( n 94 ) not concomitant n = 456 ): 10 vs % infarction vs % serious pneumonia 5 vs 3 , serious 9 % 3 , and 6 vs %	DDI-false
Although no interaction between MAO inhibitors and @DRUG$ has been observed, it is not recommended for use with @DRUG$.	DDI-advise
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of @DRUG$.	DDI-false
Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with @DRUG$.	DDI-effect
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, @DRUG$, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Lithium carbonate : and @DRUG$ may be by	DDI-effect
@DRUG$ : with Accutane be because Accutane use has associated with a of ( intracranial hypertension ) some of which use @DRUG$	DDI-false
@DRUG$ the muscle relaxant of @DRUG$ , most notably nondepolarizing , MAC minimum reduced by concomitant administration of 2O	DDI-effect
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
In individuals @DRUG$ , of to 8-fold Css , max about 3- to 4-fold @DRUG$	DDI-false
with inhibitors activity ( such ketoconazole , @DRUG$ , @DRUG$ , indinavir , saquinavir , ) is indicated , of the dose should considered	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ containing @DRUG$, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Contraceptives , Including , Injectable and : An interaction study demonstrated co-administration bosentan oral hormonal contraceptive average @DRUG$ @DRUG$ levels 14 % and 31 % respectively	DDI-false
: addition tiagabine to @DRUG$ pharmacokinetics significantly @DRUG$ binding in 96.3 % , which resulted in increase of approximately in	DDI-false
@DRUG$ ( @DRUG$ plasma exposure ) of valdecoxib ( mg for 12 days was decreased by % co-administered doses ( mg for 12 days ) ( a CYP 3A4 inducer	DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-false
@DRUG$ While studies have not shown diclofenac @DRUG$ be exercised , nonetheless , interactions NSAIDs	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
No Date @DRUG$ have clinically important with , , @DRUG$ , digoxin warfarin mononitrate , carvedilol or itraconazole	DDI-false
the between @DRUG$ CYP3A4 inhibitors ( , @DRUG$ erythromycin ) has been increased exposures to almotriptan expected is used concomitantly these .	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
Death due to fulminant pancreatitis possibly related to intravenous @DRUG$ and @DRUG$ has been reported.	DDI-effect
from in vitro of other than suggest a possible drug interaction for the : @DRUG$ @DRUG$ , nicardipine , and nifedipine .	DDI-false
- @DRUG$: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
These diuretics , corticosteroids , , @DRUG$ , estrogens , , @DRUG$ , acid sympathomimet-ics , calcium drugs , and .	DDI-false
Curariform relaxants eg , tubocurarine and including ether , @DRUG$ @DRUG$ and sodium the blocking effect be used with caution in Parenteral .	DDI-false
An alternative substrate agent may be considered patients inducers as @DRUG$ , , carbamazepine , @DRUG$.	DDI-false
reactions been receiving regimens containing high dose PROLEUKIN @DRUG$ , dacarbazine , tamoxifen	DDI-false
Potentiation warfarin-type ( and @DRUG$ ) anticoagulant response almost always seen in patients receiving @DRUG$ can serious or fatal .	DDI-false
@DRUG$ and @DRUG$ concomitantly should reduction of , 1/3 the	DDI-advise
The following are examples of that may reduce blood-glucose-lowering effect : @DRUG$ , , diuretics sympathomimetic e.g. @DRUG$ ) , derivatives , , , estrogens , oral contraceptives .	DDI-false
In drugs are by this isoenzyme , many antidepressants @DRUG$ @DRUG$ , inhibit activity of this , thus resemble poor metabolizers to concomitant therapy with other metabolized enzyme system drug	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus VIOXX 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	DDI-false
When the STADOL NS was administered 30 minutes after the @DRUG$ nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.	DDI-false
Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with norfloxacin.	DDI-false
in multiple taking TYSABRI and interferon ( @DRUG$ 30 mcg IM weekly ) glatiramer were to the for dose adjustment of the beta-interferon or	DDI-false
The of the @DRUG$ may be potentiated by @DRUG$ alcohol , oxidase inhibitors , psychotropic medications or other that produce depression .	DDI-effect
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , theophylline/acetaminophen valproic acid/@DRUG$.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/@DRUG$).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
on known metabolic interactions not expected VIRACEPT @DRUG$ , clarithromycin @DRUG$ , fluconazole .	DDI-false
@DRUG$ and with administered @DRUG$ , but the effect is significant	DDI-int
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or @DRUG$.	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
@DRUG$ generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Haloperidol : @DRUG$ receptors thus inhibiting the central stimulant effects	DDI-effect
interaction does have clinically @DRUG$ , @DRUG$	DDI-false
Antiarrhythmics , bepridil , @DRUG$ @DRUG$ due potential for	DDI-false
Additive adverse effects may occur concomitantly , @DRUG$ , phenothiazines ( , tricyclic antidepressants or @DRUG$.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, @DRUG$, and nifedipine.	DDI-false
@DRUG$ and @DRUG$ amphotericin B- which may predispose patient to cardiac dysfunction	DDI-false
Curariform @DRUG$ ) , succinylcholine @DRUG$ decamethonium citrate neuromuscular blocking should with caution patients being M Parenteral .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ @DRUG$ saquinavir and ZDV as triple ) .	DDI-false
evaluate the chemotherapy HAART on the clinical of patients non-Hodgkin HIV-NHL , compared retrospectively group patients HIV-NHL who were treated with @DRUG$ , doxorubicin , prednisone ( CHOP chemotherapy regimen HAART 80 patients who treated CHOP chemotherapy a regimen ( i.e. @DRUG$ , doxorubicin , teniposide bleomycin ) without receiving antiretroviral therapy	DDI-false
@DRUG$, such as verapamil, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Magnesium- aluminum-containing , @DRUG$ ( , @DRUG$ containing zinc other metal Videx ( or powder for solution should not taken within 3 hours or .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Although studies have not been , with drugs that are mainly CYP3A4 ( calcium channel , dapsone , disopyramide amiodarone @DRUG$ , cyclosporine pimozide @DRUG$ , fentanyl , ) when coadministered with ;	DDI-false
@DRUG$ : and absorption of when or Proquin XR was given 2 after @DRUG$ suppresses acid .	DDI-false
@DRUG$: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-effect
However, concomitant administration of @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.	DDI-effect
Drugs Should Not Coadministered @DRUG$ quinidine Antihistamines : astemizole , terfenadine Antimigraine Antimycobacterial agents rifampin triazolam motility agents : @DRUG$	DDI-advise
with thyroid e.g. @DRUG$ iodine-containing @DRUG$ , ( , famotidine ) , and proton inhibitors .	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
atorvastatin does @DRUG$ @DRUG$ via the same cytochrome .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Cholestyramine and colestipol @DRUG$: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
Interaction @DRUG$ and @DRUG$ the development of motility in chick	DDI-effect
Patients these who are @DRUG$ or any other @DRUG$ , particularly those with altered should be observed of the specific these drugs	DDI-false
no interaction @DRUG$ and @DRUG$ has been recommended use with .	DDI-false
use @DRUG$ other significantly eliminated by increased concentrations of	DDI-mechanism
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
therapy studies were performed finasteride doses 1 or concomitantly studies with acetylsalicylic acid analgesics , enzyme ) beta , blockers , @DRUG$ H2 , prostaglandin synthetase ( referred to as NSAIDs , and @DRUG$ without evidence of clinically adverse	DDI-false
@DRUG$ augment activity of @DRUG$.	DDI-effect
These include and other diuretics @DRUG$ thyroid oral contraceptives @DRUG$ , nicotinic , sympathomimetics calcium channel blocking , and isoniazid	DDI-false
inhibitors include antifungals ciprofloxacin clarithromycin diclofenac doxycycline , , , @DRUG$ , , @DRUG$ , protease inhibitors , and .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antiacid , , , @DRUG$ , , @DRUG$ Phenobarbitol carbamazepine , Rifampin Ritanovir , Saquinavir .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
, @DRUG$ may interfere with absorption of drugs where gastric pH is an important ( eg @DRUG$ , iron digoxin ) .	DDI-mechanism
effects @DRUG$ @DRUG$ was but under .	DDI-false
Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole @DRUG$ due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Both @DRUG$ and nevirapine been to therapy with @DRUG$ 48 weeks as therapy responses being with nevirapine regimens superiority observed	DDI-false
Coadministration @DRUG$ inhibitor ketoconazole q.d days ) resulted an approximately the and maximal plasma	DDI-false
all the @DRUG$ SSRIs ) , citalopram , fluoxetine @DRUG$ , inhibit P450 they vary the of	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
studies performed , use of anticoagulants ( warfarin inhibitors ( , NSAIDs @DRUG$ digoxin did affect of	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
which enhance action of nondepolarizing such certain antibiotics e. g. , , tetracyclines bacitracin @DRUG$ , , , colistin and @DRUG$ ) , magnesium , procainamide , .	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
Presumably , @DRUG$ as of @DRUG$ metabolism and has to cause decreased serum coumarin increased prothrombin-proconvertin .	DDI-mechanism
a comparison digitalis in @DRUG$ Innovar Vet , of ouabain needed cause was significantly as was the of , ketamine or @DRUG$ than with pentobarbital .	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-false
Beta-blockers, clonidine, @DRUG$ salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Inhibitors and @DRUG$ ( Failure Infarction)- EPHESUS ( 91 % receiving @DRUG$ 25 to mg also received ACE inhibitors angiotensin ACEI/ARB	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with @DRUG$.	DDI-false
Warfarin effects of @DRUG$ and @DRUG$ GI are synergistic , that users of both have a than that of users either	DDI-effect
Oral @DRUG$ : drug-drug interactions between Argatroban and @DRUG$ mg single oral dose have been	DDI-false
MAO DURAGESIC not in have received @DRUG$ within because unpredictable potentiation @DRUG$ has been reported opioid analgesics	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Although glucocorticoids been to reduce including fever , , hyperbilirubinemia confusion and dyspnea concomitant administration these @DRUG$ may reduce the of PROLEUKIN thus should be avoided 12 Beta-blockers antihypertensives may the seen PROLEUKIN .	DDI-false
Antidepressants , @DRUG$ : @DRUG$ enhance of or agents	DDI-false
@DRUG$: Concomitant administration of @DRUG$ with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-false
This time window is different than for other oral formulations of @DRUG$, which are usually administered 2 hours before or 6 hours after @DRUG$.	DDI-advise
Agents Enalapril IV been concomitantly adrenergic-blocking agents @DRUG$ , @DRUG$ hydralazine prazosin and of significant adverse interactions	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Although no interaction between @DRUG$ and Levo-Dromoran has been observed, it is not recommended for use with @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ : indicate clearance is 60 % in patients with without enzyme- inducing @DRUG$.	DDI-false
This drug may interact or @DRUG$ may potentiate the depressant of either these or antihistamines , anticholinergics or other medications with activity anticholinergic be potentiated these medications are concurrently antihistamines ) oxidase MAO ) inhibitors with may prolong depressant of @DRUG$	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Haemodynamic of @DRUG$ additive when @DRUG$ was co-administered but not conditions .	DDI-false
following the effect corticosteroids , , diuretics @DRUG$ e.g. epinephrine , salbutamol , , , @DRUG$ , thyroid , e.g. in oral .	DDI-false
@DRUG$: Increased activity of both @DRUG$ and corticosteroids may occur when the two are used concurrently.	DDI-false
In studies performed with Fondaparinux the of warfarin ) @DRUG$ acid ) , NSAIDs piroxicam @DRUG$ significantly of fondaparinux sodium	DDI-false
Phenytoin: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
Other enhance nondepolarizing agents as antibiotics ( , , tetracyclines , polymyxins , clindamycin and , , local @DRUG$ , and	DDI-false
and many are P450 2D6 many @DRUG$ , phenothiazines the @DRUG$ )	DDI-false
@DRUG$ , as probenecid and can secretion of @DRUG$.	DDI-mechanism
Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-mechanism
Drugs : Drugs such disopyramide @DRUG$ , phenothiazines @DRUG$ and increased ventricular .	DDI-false
The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex.	DDI-false
Tagamet , an certain microsomal enzyme been reported to reduce the @DRUG$ @DRUG$ chlordiazepoxide , certain , lidocaine , theophylline metronidazole , delaying elimination these .	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
@DRUG$ and other diuretics , , , thyroid estrogens oral contraceptives , @DRUG$ , acid , sympathomimetics , calcium blocking drugs and .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
@DRUG$ As with , the of @DRUG$ is inhibited by probenecid .	DDI-false
Drugs small groups of - 10/interaction ) the concomitant administration of @DRUG$ chloroquine , @DRUG$ , digitoxin did not the peak levels and values diclofenac .	DDI-false
Vaccines @DRUG$ to toxoids and @DRUG$ due to of antibody response .	DDI-effect
Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Coadministration with that are potent of CYP3A4 ( eg , phenobarbital @DRUG$ , , @DRUG$ ) may in decreased of	DDI-false
@DRUG$: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-effect
Acidifying agents: @DRUG$ (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
, apparently through effect microsomal enzyme systems has reported to reduce the warfarin-type phenytoin , propranolol nifedipine @DRUG$ , certain tricyclic , lidocaine theophylline @DRUG$ increasing levels drugs	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Since indomethacin and @DRUG$, including @DRUG$, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
Protein Binding diclofenac minimally at with the binding of @DRUG$ ( in binding , tolbutamide , % decrease in ) @DRUG$.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Chronic administration of @DRUG$, a known enzyme inducer, may be associated with a decrease in the plasma half-life of @DRUG$.	DDI-mechanism
Rifabutin Coadministration @DRUG$ and in decrease AUC and % in @DRUG$ plasma	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), @DRUG$ (increased effect of corticosteroids).	DDI-false
@DRUG$ (neostgmine, physostigmine), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Moreover, the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
The absorption of @DRUG$, furosemide, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
is co-administered with drug , such @DRUG$ , @DRUG$ , dexamethasone , carbamazepine daily dose of	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, @DRUG$ or fluconazole.	DDI-false
comparison digitalis tolerance in dogs anesthetized with ketamine , @DRUG$ , pentobarbital , of ouabain needed to was significantly , as was the , @DRUG$ or Innovar .	DDI-false
Aspirin: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, @DRUG$, alfentanil, and midazolam have been demonstrated.	DDI-false
formal studies conducted to interactive effect on bone between @DRUG$	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	DDI-mechanism
In the present study, the @DRUG$ @DRUG$ was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
@DRUG$ , , diazoxide or preanesthetic agents in @DRUG$ , nondepolarizing	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ Steady-state concentrations of sulfoxide were about mg dexamethasone was coadministered of @DRUG$ mg/kg/day ) eight neurocysticercosis	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
thyroid medication e.g. @DRUG$ ) , products antacids , @DRUG$ ( e.g. ranitidine pump inhibitors ( e.g. lansoprazole .	DDI-false
The alcohol and @DRUG$ not affect of alcohol or	DDI-false
Imidazoles ( e. , ketoconazole @DRUG$ , clotrimazole , fluconazole ): in vitro animal studies with combination of @DRUG$ suggest that may to amphotericin B.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	DDI-false
Drugs that have been with neuropathy include @DRUG$ , , cisplatin , glutethimide , , , , isoniazid metronidazole nitrofurantoin , @DRUG$ , ribavirin vincristine	DDI-false
@DRUG$ and @DRUG$: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
well-controlled patients concurrent @DRUG$ , a decrease in the steady-state of @DRUG$ cime-tidine therapy is	DDI-mechanism
@DRUG$ potentiates the muscle relaxant effect of all @DRUG$, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-effect
INOmax has been administered with tolazoline, @DRUG$, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
Reported examples include the following: @DRUG$: @DRUG$ are known to inhibit CYP3A4 to varying degrees.	DDI-false
Drugs That Antiarrhythmics Antihistamines @DRUG$ Antimigraine @DRUG$ agents rifampin , GI motility agents :	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and @DRUG$.	DDI-false
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Drugs peripheral include analogues , cisplatin , , disulfiram ethionamide glutethimide gold @DRUG$ metronidazole @DRUG$ , phenytoin	DDI-false
Cation-Containing Products : Concurrent administration , with multivalent products or @DRUG$ @DRUG$ , tablets or or containing , iron , zinc may substantially absorption ciprofloxacin , serum and than desired .	DDI-false
@DRUG$ @DRUG$ 40 BID for 7 days lithium serum clearance ( ) clearance ( 30 % ) with a % higher compared alone .	DDI-false
- @DRUG$ ( AquaMEPHYTON , @DRUG$ ) sulfapyridine these the affecting the	DDI-false
: Since a is as the neuroleptics ( phenothiazines @DRUG$ , thioxanthenes ) or , diminish effectiveness	DDI-effect
Tagamet , enzyme has hepatic metabolism of anticoagulants , phenytoin , propranolol nifedipine , diazepam , @DRUG$ , lidocaine , theophylline and @DRUG$ , increasing these drugs .	DDI-false
Digoxin Cyclosporine @DRUG$ , other @DRUG$ may affect renal prostaglandins toxicity drugs .	DDI-false
Patients receiving @DRUG$s general , , @DRUG$ sedative-hypnotics , antidepressants or other CNS ( including alcohol ) concomitantly with exhibit additive depression	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
@DRUG$, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
In , @DRUG$ was used with , , , vasodilators oxygen a pharmacokinetic with congestive failure receiving furosemide or in whom with was initiated , apparent for n = and @DRUG$ n were decreased 13 15 % respectively , second therapy and had to day 87 .	DDI-false
Aminosalicylic acid may decrease the amount of @DRUG$ (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-false
administration local anesthetic containing epinephrine norepinephrine patients @DRUG$ @DRUG$ , hypertension .	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, @DRUG$, and midazolam have been demonstrated.	DDI-false
: be used caution patients -@DRUG$ ( , , a CYP3A4 inhibitor ) ( e.g. , @DRUG$ , a , and a inhibitor ) potentiation , sinus arrest , and block ;	DDI-false
@DRUG$ should given with @DRUG$ because they clearance and high lithium .	DDI-advise
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ @DRUG$.	DDI-false
patients may elevations of @DRUG$ after therapy FLOLAN may be clinically patients @DRUG$ toxicity .	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, @DRUG$, and @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
drug-drug interaction evaluated of @DRUG$ % , combination double strength ( 160 mg/800 mg ( TMP/SMX )	DDI-false
Contraceptives Oral , Injectable , , and @DRUG$ : An study of and the hormonal contraceptive Ortho-Novum decreases of @DRUG$ of 14 31	DDI-false
@DRUG$ : Increased serum lithium levels of @DRUG$ have in concomitant lithium and inhibitor therapy	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or lamotrigine.	DDI-false
g. , ketoconazole , miconazole , in and animal with imidazoles suggest @DRUG$ to	DDI-effect
studies , coadministration with are mainly metabolized by ( disopyramide quinine , tacrolimus cyclosporine pimozide , @DRUG$ and triazolam elevated @DRUG$	DDI-mechanism
@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	DDI-false
Nalfon not been shown any additional obtained aspirin and because @DRUG$ increases the rate of excretion of Nalfon use of @DRUG$ and salicylates not .	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
@DRUG$ : with some quinolones concurrent administration of ciprofloxacin with @DRUG$ of prolongation elimination half-life .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
In , simultaneous of disulfiram the 78 cause has @DRUG$ may with @DRUG$ in the stomach to a nitrosamine tumorigenic .	DDI-effect
appears to be of this although theoretically , coadministration drugs to alter cardiac conduction ( eg @DRUG$ blocking agents , calcium blockers , @DRUG$ H1-blocking tricyclic antidepressants phenothiazines contribute a of interval .	DDI-false
The pressor effects of catecholamines such as @DRUG$ or @DRUG$ are enhanced by Bretylium Tosylate.	DDI-false
@DRUG$ studies to interact anticoagulants the type , caution should be nonetheless interactions seen	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, @DRUG$, and midazolam.	DDI-false
of treatment with of this of cyclosporine @DRUG$ nicotinic acid , @DRUG$ azole antifungals	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Coadministration of moclobemide resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	DDI-false
however , deleterious were when ROMAZICON administered after @DRUG$ , @DRUG$ muscle in with sedation .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Compounds a efficacy of @DRUG$ : phenothiazines , haloperidol , @DRUG$ .	DDI-effect
The action of @DRUG$ including and other are highly protein @DRUG$ , probenecid , coumarins oxidase , and beta	DDI-effect
@DRUG$: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
@DRUG$ , @DRUG$ Diclofenac like , may affect renal the toxicity of drugs .	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus @DRUG$ 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
using this tell your pharmacist all prescription and nonprescription may : , @DRUG$ ) amphotericin , non-steroidal anti-inflammatory e.g. ibuprofen , @DRUG$ , vancomycin .	DDI-false
enhance the neuromuscular blocking nondepolarizing NUROMAX certain @DRUG$ , , @DRUG$ clindamycin colistin , and sodium colistimethate ) , magnesium , lithium , anesthetics , and quinidine .	DDI-false
- @DRUG$ (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Plasma @DRUG$ ( 10 mg ) was increased % administration 40 mg BID ) for 12 while plasma valdecoxib ( mg was substantially following of @DRUG$ ( 10 )	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Reciprocal with of drugs that or cytochrome P450 e.g. phenytoin , @DRUG$ @DRUG$ ketoconazole ) , been	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : @DRUG$ with in receiving   -receptor ( e.g. , inhibitor ) calcium ( e.g. , verapamil a , a CYP3A4 the potentiation bradycardia sinus arrest ,	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
Sinus reported with oral @DRUG$ in substrate local @DRUG$.	DDI-false
@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$: Potential interactions between Trileptal and other @DRUG$ were assessed in clinical studies.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$ , a @DRUG$ enhanced translocating action of oleate and increased its effectiveness in from the soluble microsomal fraction	DDI-false
known slow metabolism of carbamazepine levels @DRUG$ levels should prior administration @DRUG$ signs and symptoms of carbamazepine should be closely and appropriate the be	DDI-advise
@DRUG$ significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on @DRUG$ pharmacokinetics.	DDI-false
Monoamine Inhibitors and @DRUG$ : FORADIL be with extreme caution in patients with monoamine oxidase inhibitors tricyclic because action @DRUG$ system be	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users.	DDI-false
In to interactions noted ( weeks ) oral @DRUG$ impairs of @DRUG$ dextromethorphan methotrexate	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Agents Affecting Cytochrome P450 3A4 Isoenzyme System @DRUG$ is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when @DRUG$  is given concurrently with agents that affect CYP3A4 activity.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
lidocaine/quinidine , phenobarbital/@DRUG$ acid theophylline/acetaminophen valproic	DDI-false
@DRUG$ also other drugs ( digitalis the myocardium the actions of @DRUG$.	DDI-false
However , patients on @DRUG$ show elevations of digoxin after , which be significant @DRUG$ toxicity .	DDI-false
@DRUG$ tricyclic : the activity of tricyclic or @DRUG$ ;	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, ketoconazole), though this has not been studied	DDI-mechanism
Magnesium- and/or antacids containing @DRUG$ ( @DRUG$ ) , multivitamin preparations or other metal , or Videx ) chewable/buffered tablets the pediatric for oral solution be within before 2 hours FACTIVE .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with @DRUG$ or sympathomimetic drugs.	DDI-advise
examples that blood-glucose-lowering effect and susceptibility hypoglycemia : oral antidiabetic , inhibitors @DRUG$ fibrates , @DRUG$ , ( ) , , ( e.g. , .	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
A less marked has been suggested @DRUG$ , @DRUG$ carbamazepine and possibly , ampicillin and tetracyclines ( )	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, dextromethorphan, and @DRUG$.	DDI-false
Other Drugs patients 10/interaction ) , the @DRUG$ D-penicillamine , @DRUG$ , doxycycline not the levels AUC of diclofenac	DDI-false
Interactions @DRUG$ : eg @DRUG$ butorphanol , buprenorphine should administered to has received of agonist opioid .	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
of cholestyramine and @DRUG$ may reduce the vitamin K.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: The combination of HIVID, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Coadministration of esomeprazole 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
No data are for of @DRUG$/@DRUG$ garlic .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
addition @DRUG$ a number patients three well-controlled studies no systematic changes in @DRUG$ primidone concentrations when compared to placebo .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
Drug Interactions : with like Monoamine @DRUG$ ): MAOI affect - - : cause additive depression @DRUG$ Flupenthixol of Tricyclic antidepressants	DDI-false
the of @DRUG$ required to (-)-NANM more than times than to antagonize effects of @DRUG$.	DDI-effect
: dissolution of of in @DRUG$ @DRUG$.	DDI-false
These drugs include the @DRUG$ diuretics , phenothiazines estrogens , oral @DRUG$ , , .	DDI-false
administration @DRUG$ epinephrine norepinephrine to patients @DRUG$ , antidepressants produce severe , prolonged hypertension	DDI-false
known if the effects @DRUG$ are by medications that affect hepatic drugs ( @DRUG$ , etc . ) but physicians should to possibility that a smaller and longer be .	DDI-advise
@DRUG$ Adrenergic inhibited by @DRUG$.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-mechanism
@DRUG$ Cimetidine leads increased concentration and AUC there no on when it coadministered with @DRUG$.	DDI-false
@DRUG$- and/or aluminum-containing antacids products iron ) multivitamin preparations containing @DRUG$ other , or ( didanosine ) chewable/buffered or the for oral should be taken 3 hours hours .	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
May interact with thyroid medication ( , ) , iodine-containing products , @DRUG$ H2-antagonists e.g. famotidine ranitidine , ( , lansoprazole @DRUG$	DDI-false
@DRUG$ including , phenelzine , @DRUG$ : use of and MAO inhibitors .	DDI-false
@DRUG$: @DRUG$, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
thiazides and other , @DRUG$ , phenothiazines thyroid , oral phenytoin , @DRUG$ , calcium blocking and isoniazid .	DDI-false
antagonists : @DRUG$ appear have no effect on the bioavailability of @DRUG$.	DDI-false
Furosemide: TORADOL IV/IM reduced the @DRUG$ response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue @DRUG$ and @DRUG$ treatment.	DDI-false
@DRUG$ : In a pharmacology antacid ( aluminum hydroxide , magnesium , @DRUG$ fosinopril reduced serum urinary of as compared that antacids impair absorption	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$ : The administration @DRUG$ and naproxen normal volunteers had plasma , significantly the urinary excretion naproxen glucuronide metabolite	DDI-false
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Other concomitant therapy Although interaction not , finasteride were concomitantly clinical studies acetaminophen @DRUG$ , , angiotensin-converting enzyme ( ) , anticonvulsants benzodiazepines blockers @DRUG$ , nitrates , diuretics , , reductase inhibitors prostaglandin synthetase inhibitors also , evidence adverse .	DDI-false
@DRUG$ are not for	DDI-advise
Multivalent Products of , cation-containing products such magnesium or @DRUG$ , @DRUG$ chewable/buffered tablets or pediatric powder iron or zinc substantially the absorption of ciprofloxacin resulting in serum and levels considerably lower .	DDI-false
@DRUG$ been with @DRUG$ , high-frequency ventilation	DDI-false
Drugs Should Be Coadministered With Antiarrhythmics quinidine Antihistamines astemizole @DRUG$ Antimigraine : ergot derivatives Benzodiazepines @DRUG$ , triazolam cisapride	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Benzylpenicillin , oxacillin @DRUG$ , , cephalothin @DRUG$ , and sulfamethoxazole have no in on the of diclofenac in human .	DDI-false
These drugs include thiazides diuretics @DRUG$ , , , @DRUG$ oral , phenytoin , acid , , isoniazid .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
@DRUG$ ( ' ' a newly introduced @DRUG$ with demonstrated in the positive and negative symptoms of .	DDI-false
Patients who begin taking @DRUG$ or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
concomitant therapy Although studies were performed , doses of 1 mg in studies acetaminophen @DRUG$ a-blockers , @DRUG$ , angiotensin-converting enzyme ( anticonvulsants , blockers cardiac , HMG-CoA inhibitors , prostaglandin synthetase referred to as NSAIDs , and of clinically	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
In monkeys, the effects of (-)-NANM, but not @DRUG$ or PCP, were antagonized by @DRUG$;	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Other : such @DRUG$ , disopyramide , @DRUG$ , phenothiazines , , may associated with QT-interval prolongation and increased ventricular arrhythmia	DDI-false
@DRUG$ oral diabetes medicine you take by mouth ) of antidiabetics sulfapyridine may increase chance of side effects blood the side oral @DRUG$	DDI-false
The should be in mind in although do bear on the use @DRUG$	DDI-advise
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Acetaminophen , lidocaine phenobarbital @DRUG$ , @DRUG$ , valproic added to pooled human at therapeutic	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and @DRUG$).	DDI-false
Aspirin: When @DRUG$ is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-mechanism
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
acetaminophen @DRUG$ , phenobarbital acid with @DRUG$ at to toxic the binding of the target drug	DDI-false
@DRUG$ administration to over a range of to led to inhibition elimination.14 The of administration 0.25 mg of @DRUG$ drug metabolism MS is	DDI-false
Limited patients with loads treated @DRUG$- @DRUG$-based currently exist	DDI-false
THERAPY : interaction studies were not performed studies used concomitantly with @DRUG$ betablockers , , @DRUG$ and anti-inflammatory drugs ( NSAIDs without of significant interactions .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Other drug @DRUG$ @DRUG$ had effect the of .	DDI-false
@DRUG$ significantly by % amprenavir had no effect @DRUG$ .	DDI-false
@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$: Increased activity of both cyclosporine and @DRUG$ may occur when the two are used concurrently.	DDI-false
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
Although glucocorticoids have been to effects including fever , , confusion , and dyspnea , concomitant of these agents with PROLEUKIN may reduce antitumor of @DRUG$ thus should . Beta-blockers and other antihypertensives potentiate hypotension seen PROLEUKIN	DDI-false
this , your doctor pharmacist nonprescription you may use especially : e.g. , @DRUG$ ) amphotericin @DRUG$ drugs ( e.g. , vancomycin	DDI-false
@DRUG$: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
drug interactions between Keppra and carbamazepine @DRUG$ , lamotrigine , , phenytoin , @DRUG$ valproate ) evaluating the and these AEDs during placebo-controlled clinical .	DDI-false
@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
is avoid of @DRUG$ aluminum containing at least hours @DRUG$ .	DDI-false
For information on the pharmacokinetics of @DRUG$ and @DRUG$ in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.	DDI-false
Therefore , could occur following concomitant psychotropic drugs ( e.g. , narcotics @DRUG$ , @DRUG$ , ) .	DDI-false
@DRUG$ may also decrease the absorption of @DRUG$, which can lead to a deficiency.	DDI-mechanism
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
anesthetics , , sedative-hypnotics , @DRUG$ other depressants ) CNS .	DDI-false
on Drugs : Phenytoin : @DRUG$ had no on the plasma concentrations of @DRUG$ in epilepsy .	DDI-false
Antibiotics In and/or vivo data @DRUG$ , , markedly inhibit metabolism of @DRUG$ , which can result in plasma levels and QT ECG .	DDI-mechanism
, @DRUG$ and has no significant @DRUG$ nimodipine , and losartan has significant effect bosentan	DDI-false
While all selective serotonin inhibitors @DRUG$ e.g. , @DRUG$ , fluoxetine , and inhibit P450 , they may vary in the of .	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
Coadministration potent eg , phenobarbital , dexamethasone @DRUG$ may result decreased plasma levels of	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats;	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
Data in vitro studies benzodiazepines other suggest a possible drug for the following @DRUG$ @DRUG$ nifedipine	DDI-false
: of @DRUG$ effect warfarin 1 - 8 studied in healthy subjects by of @DRUG$ 40 mg for 7 days	DDI-false
In vitro studies have shown @DRUG$ can displace coumarin anticoagulants, such as @DRUG$, from their protein-binding sites.	DDI-mechanism
In a comparison of @DRUG$ dogs , Innovar Vet , , of needed to ventricular tachycardia was higher as was the of @DRUG$ with	DDI-false
@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
Drugs alter that increase @DRUG$ plasma : Caution Gleevec inhibitors of the CYP3A4 e.g. @DRUG$ , itraconazole , erythromycin , ) .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Antagonists : is dopamine agonist , possible that dopamine such @DRUG$ ( phenothiazines , thioxanthenes ) or diminish effectiveness	DDI-false
@DRUG$ and butyrophenones may reduce or the pressor effect	DDI-effect
When other antiplatelet agents or @DRUG$ are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	DDI-effect
Beta-blockers @DRUG$ , @DRUG$ and effects	DDI-false
When used in external subcutaneous infusion pumps for @DRUG$, NovoLog should not be mixed with any other @DRUG$ or diluent.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Since apomorphine @DRUG$ possible dopamine antagonists , such as the @DRUG$ , , thioxanthenes or , may diminish the of APOKYN .	DDI-false
Drugs Should Not Coadministered VIRACEPT @DRUG$ @DRUG$ : astemizole : ergot derivatives Antimycobacterial : GI motility agents	DDI-false
inhibitors including @DRUG$ , phenelzine sulfate pargyline HC1 of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
, , acid , quinidine/lidocaine , @DRUG$/acetaminophen @DRUG$/phenobarbital	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Similarly dialyzed were , @DRUG$ and @DRUG$ both therapeutic concentrations with at three .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Reciprocal may Antizol drugs or inhibit cytochrome e.g. , @DRUG$ @DRUG$ ketoconazole ) , though this not been studied	DDI-false
bradycardia has reported with oral amiodarone with lidocaine ( @DRUG$ substrate ) given for local @DRUG$.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat @DRUG$ poisoning.	DDI-false
The majority of patients studies received one the following concomitant @DRUG$ : NSAIDs , , TNF blocking azathioprine chloroquine , gold , hydroxychloroquine , @DRUG$ , and anakinra	DDI-false
Due to high inter-patient variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent irinotecan and @DRUG$ is uncertain.	DDI-false
Further in @DRUG$ ( @DRUG$ , mg ) used older have benign prostatic hyperplasia BPH ) PSA levels are decreased 50 .	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Agents Patients both @DRUG$ and can deplete catecholamines , @DRUG$ and monoamine oxidase be closely signs of hypotension and/or	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ : of @DRUG$ volunteers indomethacin decreased renal significantly the levels indomethacin	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
That Should Not Be , quinidine : astemizole @DRUG$ @DRUG$ : rifampin : cisapride	DDI-false
in the study administration cholestyramine before evening meal and 0.3 @DRUG$ 4 after same resulted in a cerivastatin AUC of less % and a of about 30 % when to dosing @DRUG$ alone .	DDI-false
Additionally , @DRUG$ did not alter the of absence role CYP2D6 @DRUG$ metabolism	DDI-false
: administration of ciprofloxacin @DRUG$ may lead to serum @DRUG$ its elimination .	DDI-false
In two clinical studies, @DRUG$ (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of @DRUG$ by approximately 35%.	DDI-mechanism
@DRUG$ ( 10 mg mg ) the caused @DRUG$ two 81 ) .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Drugs as , @DRUG$ @DRUG$ , and tricyclic be with QT-interval an arrhythmia .	DDI-false
Antacids study , ( aluminum hydroxide hydroxide and ) with @DRUG$ reduced levels and urinary excretion of as with administered suggesting @DRUG$ of	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-advise
To impact of chemotherapy plus the clinical course of patients with systemic non-Hodgkin authors compared retrospectively group of 24 patients HIV-NHL cyclophosphamide , CHOP ) plus of who treated with CHOP chemotherapy or a ( i.e. , @DRUG$ , doxorubicin , teniposide and @DRUG$ vincristine plus bleomycin without receiving antiretroviral .	DDI-false
Ketoconazole not conversion losartan after intravenous of @DRUG$ , @DRUG$ no significant effect after administration .	DDI-false
@DRUG$ and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Concurrent @DRUG$ @DRUG$ in elevated serum of .	DDI-mechanism
The steady state plasma concentrations of @DRUG$ and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
Compounds that in , @DRUG$ , @DRUG$ theophylline and and no clinically meaningful were found	DDI-false
substances increase the blood-glucose-lowering susceptibility : oral antidiabetic , @DRUG$ , , @DRUG$ , , oxidase ) inhibitors propoxyphene salicylates somatostatin analog octreotide )	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
@DRUG$ Inhibitors Felodipine is metabolized by @DRUG$.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
@DRUG$, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$/Aluminum-containing @DRUG$ Absorption of reduced approximately 25 with antacid products .	DDI-false
@DRUG$ , @DRUG$ ): responsiveness the muscle relaxant	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
used drugs , @DRUG$ be the dose the of dosing reduced as much as concomitantly drugs the @DRUG$.	DDI-false
The possibility of hypotensive @DRUG$ either @DRUG$ increasing the intake initiation of treatment	DDI-false
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-advise
adverse resulting may LEVSIN concomitantly with antimuscarinics , @DRUG$ , , monoamine oxidase MAO inhibitors @DRUG$ some	DDI-false
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving @DRUG$.	DDI-advise
Experience with co-administration of @DRUG$ and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
@DRUG$ for days produced decreases lithium 25 ) and renal ( % % serum @DRUG$	DDI-false
@DRUG$ : single of @DRUG$ 20 and imipramine 75 mg effects alertness and psychomotor 4 after .	DDI-false
It advisable coagulation time within the few the start discontinuation of @DRUG$ @DRUG$ dose , if	DDI-advise
@DRUG$ Inhibitors Felodipine @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
These thiazides other diuretics @DRUG$ estrogens , oral phenytoin @DRUG$ calcium channel blocking drugs and isoniazid .	DDI-false
( g. ketoconazole miconazole clotrimazole , ): studies with @DRUG$ and imidazoles suggest that @DRUG$ may induce fungal amphotericin	DDI-false
Lorazepam: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, and nifedipine.	DDI-false
Magnesium- and/or antacids , containing sulfate iron , multivitamin preparations @DRUG$ metal , or Videx ( chewable/buffered pediatric powder for oral solution not before .	DDI-false
Other therapy Although specific studies not performed , finasteride mg or more clinical with acetaminophen acetylsalicylic , , @DRUG$ @DRUG$ blockers , blockers , cardiac nitrates , diuretics , antagonists HMG-CoA reductase inhibitors prostaglandin synthetase inhibitors also referred to as NSAIDs , and anti-infectives of interactions	DDI-false
Results of studies multiple taking TYSABRI and beta-1a ( 30 mcg weekly ) or were inconclusive with the adjustment @DRUG$ @DRUG$.	DDI-false
As the primary effect of @DRUG$ is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of @DRUG$.	DDI-effect
then received amprenavir plus @DRUG$ for days and cohort 2 received @DRUG$ plus rifampin .	DDI-false
@DRUG$ with @DRUG$ thinners , ( cold sinus , , like Aleve pressure medications .	DDI-int
@DRUG$ may decrease to as @DRUG$.	DDI-effect
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
@DRUG$ ( @DRUG$ )	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Pyrantel Antiminth ) piperazine and @DRUG$ the effects @DRUG$.	DDI-false
Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
: Flupenthixol interact some drugs like Monoamine inhibitors ): MAOI @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Ethanol cause depression : Flupenthixol the of antidepressants	DDI-false
: of @DRUG$ on the effect of @DRUG$ studied in a of healthy receiving doses 2 of	DDI-false
of weeks @DRUG$ @DRUG$ therapy increased 187 and % .	DDI-false
While @DRUG$ @DRUG$ ) , , fluoxetine , paroxetine , and fluvoxamine P450 they vary of inhibition .	DDI-false
normal volunteers , administration of diflunisal and @DRUG$ resulted in an % plasma @DRUG$.	DDI-false
If treatment inhibitors as ketoconazole , intraconazole , @DRUG$ , @DRUG$ , erythromycin , etc budesonide dose should considered .	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
@DRUG$ , and Implantable Contraceptives interaction study that co-administration bosentan the hormonal contraceptive @DRUG$ produced average decreases ethinyl levels 14 and 31 % respectively .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	DDI-false
using this medication , tell your or prescription and nonprescription products may use , especially aminoglycosides ( e.g. , gentamicin @DRUG$ ) , @DRUG$ non-steroidal ( e.g. , ibuprofen ) tacrolimus vancomycin	DDI-false
May interact with the : cholestyramine colestipol ( use @DRUG$ prevent @DRUG$ working	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
, , @DRUG$ , ): and animal studies combination and imidazoles @DRUG$ induce fungal to B.	DDI-false
the same study it shown that @DRUG$ @DRUG$ had no significant the phosphorylation of zalcitabine mononuclear cells .	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
The intensity , uniformity and interference by @DRUG$ were systematically investigated in patients receiving @DRUG$ .	DDI-false
No significant interactions been found @DRUG$ , , @DRUG$.	DDI-false
Macrolide inhibit reductase inhibitors that metabolized ( @DRUG$ , @DRUG$ .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
acetaminophen theophylline phenobarbital @DRUG$ , @DRUG$ to decreases the the drug .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ decreased @DRUG$ by %	DDI-mechanism
The action of the @DRUG$ may be by anticonvulsants alcohol , @DRUG$ , monoamine , narcotics psychotropic medications or other drugs produce .	DDI-effect
include the thiazides and diuretics , @DRUG$ oral contraceptives , phenytoin , nicotinic acid , calcium and @DRUG$.	DDI-false
should not administered with @DRUG$ such @DRUG$ ) because additive and	DDI-false
drug Keppra   and AEDs , , @DRUG$ , @DRUG$ ) assessed by evaluating the serum concentrations of these AEDs .	DDI-false
mg . ) no on @DRUG$ maximum concentration ( Cmax of when with 20 mg @DRUG$ in healthy volunteers .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
@DRUG$ ( 10 - significantly reduced the of @DRUG$ ) moderate doses	DDI-mechanism
Although specific have not coadministration with mainly by ( , channel blockers dapsone , disopyramide , quinine , , quinidine , warfarin cyclosporine ergot derivatives , @DRUG$ , carbamazepine @DRUG$ alfentanyl , alprazolam triazolam may have elevated saquinavir	DDI-false
Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE inhibitors, including @DRUG$.	DDI-effect
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high @DRUG$ doses In vivo, the plasma levels of phenytoin increased by up to 40%, when @DRUG$ was given at doses above 1200 mg/day.	DDI-false
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and @DRUG$ against HIV.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
@DRUG$ @DRUG$ , administered , both the extent of	DDI-false
These the @DRUG$ and diuretics , , products , @DRUG$ contraceptives , nicotinic acid , , blocking drugs	DDI-false
@DRUG$: @DRUG$ may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.	DDI-false
@DRUG$ ( @DRUG$ may potentiate B- which may patient	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	DDI-false
While all reuptake inhibitors @DRUG$ , e.g. @DRUG$ , , and fluvoxamine , 2D6 , they vary in extent of .	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
possible interaction between @DRUG$ and @DRUG$ , a antibiotic , been a potentiation of glyburide	DDI-int
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
however , of @DRUG$ q12h the @DRUG$ max 23 % and ceftibuten by %	DDI-mechanism
several closely @DRUG$ reported be the concomitant administration of @DRUG$ or ( e.g. cimetidine , concomitant administration hepatic enzyme inducers ( , barbiturates , and such anticipated as well .	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, @DRUG$, niacin (nicotinic acid), erythromycin, azole antifungals.	DDI-false
Other concomitant therapy Although specific of or more concomitantly used clinical studies with acetaminophen , , a-blockers angiotensin-converting ( ACE ) , benzodiazepines , blockers blockers , cardiac @DRUG$ diuretics antagonists HMG-CoA inhibitors , prostaglandin inhibitors also as @DRUG$ , and anti-infectives of adverse .	DDI-false
It recommended avoid administration of ethambutol with aluminum hydroxide containing @DRUG$ at least following @DRUG$ administration	DDI-false
@DRUG$: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
inhibitors include azole clarithromycin diclofenac , erythromycin @DRUG$ , @DRUG$ , , nicardipine , propofol protease , quinidine	DDI-false
Anticoagulants including coumarin , @DRUG$ as NSAIDs , @DRUG$ may increase the when concomitantly with	DDI-false
Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
@DRUG$ prothrombin time , with clinical reported @DRUG$ .	DDI-effect
@DRUG$ mg twice modify the rate @DRUG$ absorption its plasma clearance or urinary .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that associated peripheral neuropathy include antiretroviral nucleoside , chloramphenicol , , disulfiram ethionamide glutethimide , @DRUG$ @DRUG$ iodoquinol metronidazole phenytoin ribavirin and .	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral @DRUG$, should be used cautiously in patients receiving @DRUG$.	DDI-advise
No drug-drug pharmacokinetic ( or pharmacodynamic interactions have in interaction studies @DRUG$ , @DRUG$ and .	DDI-false
@DRUG$ In some with renal who are treated with non-steroidal anti-inflammatory drugs , the of @DRUG$ result in	DDI-false
In a comparison of Innovar , or pentobarbital , dosage to higher the LD50 , ketamine or @DRUG$ @DRUG$.	DDI-false
Patients receiving narcotic general @DRUG$ , , tranquilizers tricyclic or other depressants ( ) with @DRUG$ exhibit additive CNS depression	DDI-effect
In Study 1, patients with colorectal cancer were given @DRUG$/5-FU/@DRUG$ (bolus-IFL) with or without AVASTIN.	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-advise
Acidifying : agents @DRUG$ , reserpine HCl ascorbic fruit juices etc . lower absorption of	DDI-mechanism
@DRUG$: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.	DDI-false
In general these are that pharmacologic similar to hydrochloride , including anti-arrhythmic agents such @DRUG$ and procainamide and	DDI-false
@DRUG$ reduce the renal clearance of @DRUG$ and add a high risk of lithium toxicity.	DDI-mechanism
@DRUG$ @DRUG$ inhibits the metabolism of astemizole in plasma of astemizole and metabolite QT intervals .	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, @DRUG$, and methotrexate.	DDI-false
Potassium and @DRUG$ : sodium attenuate potassium	DDI-false
with thyroid medication @DRUG$ ) iodine-containing e.g. , ranitidine ) , and inhibitors e.g. , @DRUG$	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Administration of repeat of FACTIVE had effect on repeat of , digoxin or @DRUG$/levonorgestrol @DRUG$ in healthy .	DDI-false
@DRUG$ with vasodilators @DRUG$ , IV ACE not these drugs were co-administered clinical trials )	DDI-false
Although there are study oxide including @DRUG$ @DRUG$ , may an effect with of developing .	DDI-false
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
the present study @DRUG$ clozapine was dose @DRUG$ two-lever signalled-unsignalled ( ) procedures	DDI-false
Erythromycin Co-administration of @DRUG$ (@DRUG$) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
effects @DRUG$ administration steady-state pharmacokinetics @DRUG$.	DDI-false
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-advise
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
@DRUG$: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Refer to the package insert for @DRUG$ preparations before use of such preparations with @DRUG$.	DDI-advise
@DRUG$: Coadministration of single doses of Sonata 20 mg and @DRUG$ 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
( @DRUG$ [ e.g. , ] oxandrolone [ e.g. , Anavar ] [ , Anadrol ] @DRUG$ [ Winstrol ) or	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
NSAIDs have produced an plasma @DRUG$ levels and reduction renal @DRUG$	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Based results , is concluded azithromycin be coadministered @DRUG$ and @DRUG$.	DDI-false
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., @DRUG$, @DRUG$).	DDI-false
Patients other general anesthetics , , , antidepressants other including @DRUG$ an CNS depression	DDI-effect
, , Injectable Transdermal @DRUG$ An interaction study that co-administration of bosentan and the oral @DRUG$ average of norethindrone and of % and 31 respectively .	DDI-false
The risk of treatment with drugs class with concurrent cyclosporine , @DRUG$ , niacin ( @DRUG$ , azole	DDI-false
Drugs that cause significant elevation ( @DRUG$ as @DRUG$ or cimetidine ) may reduce therefore potentially reduce efficacy	DDI-false
When Itraconazole was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
Clinical interaction with @DRUG$ @DRUG$ the of with in clinically- drug interactions	DDI-false
Nephrotoxic : Concomitant and agents with potential e.g. , @DRUG$ e.g. , @DRUG$ amikacin ) , B , pentamidine , vancomycin non-steroidal anti-inflammatory is contraindicated	DDI-false
Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
Prostatic epithelium proliferates in defined medium of basal medium @DRUG$ 1 ) EGF ( 10 @DRUG$ ( micrograms/ml or )	DDI-false
of N-methylthiotetrazole , cefotetan , @DRUG$ latamoxef ) or methylthiadiazole ( cause K deficiency and	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
@DRUG$ @DRUG$ AUC of atomoxetine approximately 6- Css max is about atomoxetine .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
: Other @DRUG$ as quinidine , procainamide @DRUG$ and phenytoin , have	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ DURAGESIC   recommended for use in patients who have received MAOI within unpredictable potentiation by MAO @DRUG$	DDI-false
- @DRUG$ e.g. , Anabolin , oxandrolone [ Anavar , @DRUG$ [ e.g. , ] stanozolol e.g. Winstrol ] ) or	DDI-false
- @DRUG$: Interaction studies in humans have shown bumetanide to have no effect on @DRUG$ metabolism or on plasma prothrombin activity.	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Oral Contraceptives dose administration of @DRUG$ ( mg/day monotherapy pharmacokinetics of oral @DRUG$ in childbearing .	DDI-false
Interactions The urine of who @DRUG$ can a false-positive for urobilin due presence of phenolic	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
AUC(ss ) @DRUG$ , @DRUG$ had no effect on rifampin .	DDI-false
@DRUG$ with ketamine Vet , , dosage of ouabain needed to ventricular was , as of ketamine @DRUG$ pentobarbital	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
impact chemotherapy HAART course patients with HIV-related systemic , non-Hodgkin lymphoma , the retrospectively group patients with HIV-NHL who were the cyclophosphamide , doxorubicin @DRUG$ , and prednisone ( chemotherapy a group patients were with CHOP a ( , @DRUG$ , , prednisone plus receiving antiretroviral therapy	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with Adenocard.	DDI-false
@DRUG$ : Amphetamines the effect	DDI-false
@DRUG$ no interactions with digoxin @DRUG$ , has no on plasma levels of .	DDI-false
The raise that the may in of consume @DRUG$ and @DRUG$ regular basis	DDI-mechanism
Nephrotoxic agents : administration of VISTIDE and with nephrotoxic e.g. intravenous aminoglycosides ( e.g. , , , , amphotericin B , intravenous @DRUG$ , @DRUG$ ] is .	DDI-false
Benzylpenicillin , oxacillin , @DRUG$ , cephalothin , erythromycin and have influence in on the binding @DRUG$ in human .	DDI-false
Other Drugs : patients study ) the administration , @DRUG$ , chloroquine , @DRUG$ prednisolone , or digitoxin did not affect the levels and AUC	DDI-false
Consequently the of @DRUG$ with @DRUG$ also .	DDI-advise
@DRUG$ Coadministration of a zaleplon @DRUG$ ( and mg , ) resulted in a decrease maximal plasma concentrations zaleplon , but no in area plasma curve .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
5HT3 Antagonists reports profound and loss of when was administered with @DRUG$ , use of of antagonist ( for example ondansetron , @DRUG$ dolasetron ) contraindicated	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
While selective inhibitors SSRIs ) e.g. citalopram @DRUG$ , fluoxetine , @DRUG$ , and , inhibit , they vary in extent of .	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
progestin-only pills is by hepatic enzyme-inducing drugs as the @DRUG$ phenytoin , , and , the @DRUG$ .	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	DDI-false
@DRUG$ : @DRUG$ , or with the effect .	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
who @DRUG$ or any other NSAID taking digoxin , , @DRUG$ develop characteristics for .	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
concomitant : In trials , the safety profile in treated with concomitantly , hypnotics and @DRUG$ ) or @DRUG$ subjects taking these concomitant medications	DDI-false
We the of an with by @DRUG$ overdose positive antidepressant level to alert cross-reactivity @DRUG$ a toxicology for tricyclic .	DDI-false
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Drug Interactions may interact some drugs Monoamine MAOI ): flupenthixol Eproxindine - @DRUG$ : CNS depression - Tricyclic @DRUG$ increases the effect of antidepressants	DDI-false
Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with @DRUG$ including cyclosporine.	DDI-effect
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with lamivudine or @DRUG$.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$-@DRUG$ may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-mechanism
enhance the neuromuscular action of NUROMAX include certain @DRUG$ ( e. , aminoglycosides tetracyclines , , , lincomycin clindamycin , , and sodium ) , salts lithium , local @DRUG$ quinidine .	DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
Patients other , general @DRUG$ , tranquilizers , tricyclic antidepressants other depressants alcohol ) DILAUDID may CNS .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
mild 25 with the @DRUG$ @DRUG$ , 10 to 4 , in mean pressure of mm ACE inhibitor alone .	DDI-false
- ( e.g. , e.g. Anavar ] , @DRUG$ [ e.g. , Anadrol ] , @DRUG$ [ e.g. )	DDI-false
@DRUG$ may in taking inducers as rifampin phenytoin @DRUG$ , and .	DDI-false
@DRUG$s @DRUG$ The following events were experienced commonly patients or vasodilators ( = compared to not receiving these concomitant ( n 456 hypotension 10 vs 4 % infarction vs 1 % serious 5 vs 3 % serious falls 9 3 , joint injuries % vs	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
The hypotensive with can be minimized by either discontinuing the diuretic or increasing the intake one prior to initiation of treatment @DRUG$ @DRUG$ tablets , ) initiating therapy small doses ( or )	DDI-false
Additive from blockade may when LEVSIN is administered other antimuscarinics amantadine haloperidol phenothiazines , @DRUG$ , tricyclic antidepressants @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Coadministration of this oral @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
plasma of related tricyclic have reported to increased methylphenidate hepatic inhibitors ( @DRUG$ fluoxetine and decreased by the administration of @DRUG$ and effect may with well .	DDI-false
The following that may reduce : corticosteroids , sympathomimetic agents @DRUG$ terbutaline ) isoniazid , @DRUG$ , , contraceptives ) .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (@DRUG$), erythromycin, azole antifungals.	DDI-false
reductions in blood when FLOLAN administered with @DRUG$ @DRUG$	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
The pressor effects of catecholamines such as @DRUG$ or norepinephrine are enhanced by @DRUG$.	DDI-effect
@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-false
Coadministration of @DRUG$ and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Drugs that have associated peripheral antiretroviral nucleoside analogues , , dapsone , glutethimide gold , @DRUG$ , @DRUG$ , isoniazid , , nitrofurantoin phenytoin ribavirin , vincristine .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, @DRUG$, and verapamil.	DDI-false
@DRUG$ toxicity was and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-effect
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of @DRUG$ and @DRUG$.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for @DRUG$.	DDI-false
) many are substrates for 2D6 other antidepressants , @DRUG$ and 1C @DRUG$	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
depressant drugs ( e.g. @DRUG$ , opioids and @DRUG$ ) have effects with .	DDI-false
, interactions , and @DRUG$ NOT be in with @DRUG$.	DDI-advise
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
@DRUG$ : Absorption of zalcitabine is approximately 25 % ) antacid	DDI-false
The of progestin-only is reduced by drugs @DRUG$ , and , and the @DRUG$.	DDI-false
chains ( cefmenoxime , cefamandole , @DRUG$ @DRUG$ ) can cause vitamin K and .	DDI-false
Before using medication , tell your doctor or pharmacist prescription you may use , aminoglycosides ( gentamicin , ) amphotericin , cyclosporine , non-steroidal anti-inflammatory ( , @DRUG$ ) @DRUG$ vancomycin .	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other anticholinergic drugs or @DRUG$.	DDI-advise
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
It is that cardiovascular action other @DRUG$ enhanced the addition of @DRUG$	DDI-effect
@DRUG$ : is reduced ( ) when and @DRUG$ .	DDI-false
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
There was no apparent pharmacokinetic interaction between @DRUG$ and @DRUG$ following single dose administration (10 mg and 600 mg, respectively) of each drug.	DDI-false
Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-effect
Concurrent of drugs ( , aminoglycosides , @DRUG$ ) , cytotoxic ) ( @DRUG$ ) or hepatotoxic e.g. , asparaginase effects may increase toxicity in these	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
Drugs CYP Inhibitors Clinical the Clinical ( caution during coadministration with @DRUG$ Coadministration of @DRUG$ maximum concentration 46 % decreased % , by , decreased .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or @DRUG$.	DDI-false
@DRUG$ : concentrations are increased about 15 when digoxin @DRUG$	DDI-false
@DRUG$ not have any important effect on @DRUG$.	DDI-false
Particular when using ROMAZICON of mixed drug overdosage ( as convulsions and dysrhythmias of taken in overdose especially @DRUG$ ) emerge with reversal @DRUG$ flumazenil	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), @DRUG$ (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
@DRUG$ should be used caution patients receiving blocking agents ( e.g. , @DRUG$ or channel antagonists e.g. verapamil CYP3A4 , and diltiazem a ) because possible of bradycardia , sinus arrest AV block	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, @DRUG$ or amoxicillin.	DDI-false
Intravenous adenosine effectively in presence of cardioactive , such as @DRUG$ , @DRUG$ , channel blocking , enzyme inhibitors without any the adverse reaction profile	DDI-false
assessment @DRUG$ in de novo renal transplant recipients the first pharmacokinetics , influence	DDI-false
In some patients , the steroidal anti-inflammatory agent the diuretic , effects @DRUG-DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
It is to @DRUG$ a in	DDI-advise
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	DDI-false
@DRUG$ should not be concurrently D2-antagonists , such butyrophenones or @DRUG$.	DDI-advise
tested in include @DRUG$ , @DRUG$ , diazepam and .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ may enhance the effects of alcohol, barbiturates, and other @DRUG$.	DDI-effect
@DRUG$ MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-false
Consequently, drugs with a low therapeutic margin, such as @DRUG$, @DRUG$, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
plasma closely related antidepressants have reported to be increased by the concomitant administration of @DRUG$ or inhibitors ( cimetidine , fluoxetine ) decreased by concomitant inducers e.g. , , @DRUG$ ) , may as well	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
adverse resulting from occur when @DRUG$ is amantadine @DRUG$ oxidase ) , tricyclic antidepressants or .	DDI-effect
therapy Although specific studies , doses of 1 mg were concomitantly used in clinical studies @DRUG$ enzyme ( ) inhibitors , @DRUG$ benzodiazepines blockers blockers , cardiac , antagonists reductase inhibitors prostaglandin also to NSAIDs , without significant interactions	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
1- denotes of less than 10 2- Pediatrics 3- Mean increase high In plasma @DRUG$ by up to 40 @DRUG$ was at doses	DDI-mechanism
@DRUG$ with @DRUG$ not .	DDI-false
@DRUG$: @DRUG$ is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
@DRUG$, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the muscle relaxant.	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
When @DRUG$ was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
, @DRUG$ Indanavir Ketoconazole , Phenobarbitol , , @DRUG$ Ritanovir ,	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
, ingestion of @DRUG$ the weeks to cause tumors , it has that @DRUG$ may with nitrites the rat stomach , which is tumorigenic	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, @DRUG$, and @DRUG$.	DDI-false
is increase exposure @DRUG$ @DRUG$ is with ketoconazole ( inhibitor .	DDI-false
@DRUG$ : with Other Drugs that Metabolized CYP ): At clinically , vitro indicate that @DRUG$ ( 0.6 M ) was towards major isoforms , , CYP2C9 CYP2C19 , CYP2E1 , and CYP3A	DDI-false
Benzylpenicillin , , , , cephalothin @DRUG$ , and @DRUG$ influence in vitro on the binding of human	DDI-false
of @DRUG$ has observed in comparative a of patients loads	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Rifampin: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, @DRUG$, and midazolam have been demonstrated.	DDI-false
Example include azole antifungals , , , diclofenac , erythromycin , imatinib , , nefazodone , @DRUG$ propofol , inhibitors , and @DRUG$.	DDI-false
plasma of several closely related to the concomitant methylphenidate hepatic enzyme inhibitors ( e.g. @DRUG$ ) administration of ( e.g. phenytoin ) such effect be anticipated @DRUG$ well	DDI-mechanism
apomorphine a agonist it is possible dopamine antagonists , such as neuroleptics phenothiazines , , @DRUG$ ) or of	DDI-effect
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other In safety in subjects with Acamprosate anxiolytics , @DRUG$ and @DRUG$ or non-opioid analgesics was similar to of subjects taking placebo with concomitant medications .	DDI-false
These drugs include and other @DRUG$ products phenytoin , nicotinic , calcium channel ,	DDI-false
@DRUG$ including @DRUG$ and pargyline HC1 : L-tyrosine non-selective may cause	DDI-false
Although interaction MAO and @DRUG$ observed is recommended for use with	DDI-advise
Therefore, the concomitant administration of @DRUG$ and @DRUG$ is contraindicated, and alternative hypoglycemic agents should be considered.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : studies in healthy volunteers @DRUG$ either had effect ( or associated modest , 30 ( in steady-state serum .	DDI-false
Drug interaction studies have that not have any @DRUG$ @DRUG$ or .	DDI-false
been to effects including renal insufficiency , hyperbilirubinemia confusion dyspnea administration these with @DRUG$ may reduce of @DRUG$ and should 12 Beta-blockers and antihypertensives potentiate hypotension with PROLEUKIN	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or @DRUG$).	DDI-false
agents to be @DRUG$ that are metabolized by this isoenzyme potentially interact with @DRUG$.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-effect
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, @DRUG$) and @DRUG$.	DDI-false
The majority patients clinical studies received one of the following medications ORENCIA MTX NSAIDs , @DRUG$ , @DRUG$ azathioprine chloroquine , hydroxychloroquine , , sulfasalazine , and anakinra	DDI-false
These include thiazides and diuretics , , thyroid products , oral contraceptives , @DRUG$ nicotinic acid drugs	DDI-false
@DRUG$ : The effect valdecoxib anticoagulant of ( ) in subjects @DRUG$ 40 BID for .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
Although studies not with that mainly metabolized by ( , blockers dapsone disopyramide , amiodarone , warfarin tacrolimus @DRUG$ pimozide , @DRUG$ , alfentanyl , alprazolam and triazolam may have elevated plasma when coadministered with saquinavir ;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Therefore, agents affecting sympathetic activity (e.g., @DRUG$ or @DRUG$) should be used with caution.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
because of this , dosage of @DRUG$ be when @DRUG$ administered concomitantly	DDI-false
The following are examples substances that the blood-glucose-lowering : , , danazol diuretics agents ( e.g. , epinephrine , , terbutaline ) isoniazid , @DRUG$ , thyroid hormones , estrogens progestogens ( in oral @DRUG$	DDI-false
Example inhibitors include antifungals , ciprofloxacin , clarithromycin , doxycycline , erythromycin , imatinib , isoniazid @DRUG$ nicardipine @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
Although no conducted @DRUG$ and @DRUG$ ;	DDI-false
@DRUG$/@DRUG$ : did have any the of or .	DDI-false
pharmacokinetic demonstrated concomitant and @DRUG$ ( etodolac capsules and reduced protein binding of @DRUG$ but was no change in of warfarin .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Based on profiles clinically drug not expected between and @DRUG$ , @DRUG$ erythromycin ,	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
: Anticoagulant activity be in the or @DRUG$ therapy patients @DRUG$ similar agents , these are at increased risk of bleeding complications	DDI-advise
@DRUG$ may enhance the seizure @DRUG$	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ single @DRUG$ mg and on decreased for 2 hours after administration .	DDI-false
CYP3A4 @DRUG$ ) CYP3A4 is major elimination @DRUG$.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
During co-administration, systemic levels of @DRUG$ and @DRUG$ were essentially unchanged.	DDI-false
@DRUG$ Altered serum of ( decreased ) in patients receiving	DDI-false
Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.	DDI-mechanism
Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
clinical studies with the use of ( @DRUG$ ) platelet inhibitors ( acid ) ( @DRUG$ ) , significantly affect the	DDI-false
Other Although not finasteride of 1 more studies acetaminophen , @DRUG$ a-blockers , angiotensin-converting enzyme ( inhibitors , blockers , calcium-channel cardiac H2 , reductase prostaglandin to as @DRUG$ and anti-infectives adverse interactions	DDI-false
@DRUG$, bepridil, sparfloxacin, and @DRUG$.	DDI-false
@DRUG$ antidepressants , as well as a of @DRUG$ ,	DDI-false
To of chemotherapy plus HAART on the clinical of systemic non-Hodgkin lymphoma ( compared 24 patients who were treated the cyclophosphamide , vincristine , CHOP ) chemotherapy regimen plus with of 80 were treated chemotherapy a i.e. , and @DRUG$ with @DRUG$ plus bleomycin therapy	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
studies of patients maintenance warfarin , hydrochlorothiazide , @DRUG$ irbesartan had no pharmacodynamics warfarin time ) pharmacokinetics	DDI-false
Drugs Not Be Coadministered amiodarone quinidine : ergot @DRUG$ : @DRUG$ Benzodiazepines , motility agents : cisapride	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Antacids clinical of an @DRUG$ , and simethicone ) fosinopril levels and urinary excretion @DRUG$ administered alone suggesting may absorption of .	DDI-false
@DRUG$ @DRUG$ was co-administered but	DDI-false
@DRUG$ The concomitant use of DURAGESIC   fentanyl transdermal with central including not to other sedatives , @DRUG$ , ( , benzodiazepines , general , phenothiazines , muscle , alcohol , may , hypotension , sedation or potentially in coma death .	DDI-false
@DRUG$: @DRUG$ and other NSAIDs can inhibit the activity of diuretics.	DDI-false
@DRUG$ did not the conversion losartan to the intravenous administration of losartan , and @DRUG$ had no significant effect administration .	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-mechanism
Other specific performed of mg concomitantly used in clinical studies acetaminophen acetylsalicylic a-blockers , analgesics , angiotensin-converting ACE inhibitors @DRUG$ , , , blockers , cardiac , , H2 antagonists , reductase prostaglandin inhibitors referred @DRUG$ ) , and without evidence clinically significant .	DDI-false
In general , are drugs or more activities similar bepridil , including @DRUG$ such and procainamide @DRUG$ tricyclic anti-depressants .	DDI-false
That : , quinidine Antihistamines : terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : midazolam @DRUG$ agents	DDI-false
@DRUG$ : @DRUG$-induced hypokalemia potentiate digitalis	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
BACKGROUND effects combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) a calcium , the metastasis intestinal adenocarcinomas ( @DRUG$ and the labeling intestinal cancers were in male rats	DDI-false
Catecholamine-depleting Patients taking both @DRUG$ and drug that can catecholamines , @DRUG$ ) should be observed closely signs hypotension severe bradycardia	DDI-effect
Antagonists reports profound loss of when apomorphine was , concomitant use apomorphine with drugs of antagonist class ( , example , ondansetron , @DRUG$ , @DRUG$ palonosetron and contraindicated .	DDI-false
Co-administration of felodipine ( @DRUG$ ) with @DRUG$ in approximately 2.5- AUC and and about prolongation in felodipine .	DDI-false
- Anabolic steroids (@DRUG$ [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ and @DRUG$ (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
therefore, nitroglycerin or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	DDI-advise
WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The increase of @DRUG$ level , however , is ( ) given @DRUG$.	DDI-mechanism
@DRUG$ of Trileptal with an oral @DRUG$ been shown influence plasma concentrations two components , ethinylestradiol EE and levonorgestrel LNG ) .	DDI-false
tell your all nonprescription products you use , especially of ( e.g. @DRUG$ , @DRUG$ cyclosporine anti-inflammatory drugs ( e.g. ibuprofen ) tacrolimus ,	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-false
Lithium Increased serum @DRUG$ levels and symptoms lithium been in receiving lithium and @DRUG$ therapy .	DDI-false
Drugs drug interaction of @DRUG$ with an NSAID has not been conducted	DDI-false
That Should Not Be Coadministered Antiarrhythmics : , @DRUG$ Antimigraine : @DRUG$ Antimycobacterial agents rifampin motility agents : cisapride	DDI-false
Cimetidine: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
appears interaction this kind with Mefloquine , although coadministration of other drugs alter conduction ( eg , anti-arrhythmic agents @DRUG$ , or H1-blocking , tricyclic @DRUG$ ) might also to a prolongation the interval .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In addition several AED s are cytochrome P450 inducers can decrease concentrations of @DRUG$	DDI-false
the specific interaction not clinical trial , have been more than of concomitant use of therapies i.e. , @DRUG$ )	DDI-false
Other , @DRUG$ , nefazodone , troleandomycin ritonavir , @DRUG$ would expected to .	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to @DRUG$ and @DRUG$, respectively.	DDI-false
@DRUG$ Ribavirin can in vitro antiviral activity @DRUG$ zidovudine against	DDI-false
and ii ) of @DRUG$ efficiently by added cholesterol , membrane in human cells , whereas the effects @DRUG$ were more efficiently inhibited ergosterol the in yeast	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
interaction and other potent CYP3A4 itraconazole , erythromycin ) not been to @DRUG$ may @DRUG$ concomitantly with medications	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
The sulfonylureas be potentiated certain drugs @DRUG$ other drugs that are highly @DRUG$ sulfonamides , chloramphenicol , coumarins monoamine beta adrenergic agents	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
In monkeys , @DRUG$ was than @DRUG$ responding pigeons (-)-NANM (+)-NANM .	DDI-false
Antagonists : Based on reports of hypotension loss of when ondansetron the use of apomorphine of the 5HT3 class including , for , @DRUG$ granisetron dolasetron , @DRUG$ and alosetron is contraindicated	DDI-false
Methenamine therapy Urinary excretion @DRUG$ increased , is by @DRUG$ used methenamine therapy	DDI-mechanism
concomitant administration @DRUG$ with @DRUG$	DDI-advise
Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$ @DRUG$ and pargyline HC1 Concomitant use and non-selective inhibitors may	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Concomitant use of @DRUG$ with other @DRUG$ is not recommended.	DDI-advise
These drugs include the and , phe-nothiazines , , estrogens , @DRUG$ , phenytoin nicotinic , calcium blocking and @DRUG$.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.	DDI-false
pharmacokinetic @DRUG$ NSAIDs , @DRUG$ , TNF did influence clearance	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Compounds that have been tested in man include @DRUG$, @DRUG$, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
Cation-Containing administration a @DRUG$ including ciprofloxacin , multivalent products such as @DRUG$ antacids , tablets or , or , or may substantially the ciprofloxacin resulting serum levels lower than .	DDI-mechanism
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
and been used with adrenergic-blocking , methyldopa , nitrates , agents , @DRUG$ , prazosin and @DRUG$ evidence significant adverse	DDI-false
there are no data to evaluate possibility @DRUG$ including @DRUG$ and nitroglycerin , may INOmax on risk of developing methemoglobinemia	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
The following are examples of that may reduce blood-glucose-lowering : corticosteroids niacin , danazol e.g. , @DRUG$ , salbutamol , terbutaline ) isoniazid , derivatives , @DRUG$ , thyroid hormones estrogens , ( e.g. in oral contraceptives	DDI-false
These include @DRUG$ other diuretics , contraceptives , nicotinic acid , channel and	DDI-false
@DRUG$ can interact with chlorpromazine, increasing the metabolism of @DRUG$.	DDI-false
however , ROMAZICON after @DRUG$ , @DRUG$ in or anesthesia .	DDI-false
- steroids [ e.g. ] , @DRUG$ [ ] [ e.g. Anadrol , [ @DRUG$ ) or	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
addition of @DRUG$ limited patients in well-controlled no systematic in or @DRUG$ when	DDI-false
with , blood thinners drugs , sinus , drugs @DRUG$ , like or @DRUG$ , high .	DDI-false
   on on @DRUG$ and therapy , as well those on dietary restriction dialysis occasionally experience of pressure the receiving of	DDI-effect
substances may reduce the blood-glucose-lowering : , , , agents e.g. , epinephrine , salbutamol , terbutaline ) @DRUG$ , , @DRUG$ thyroid , , progestogens ( e.g. in oral contraceptives ) .	DDI-false
exercised when administering @DRUG$ drugs that are known to inhibit @DRUG$ ) .	DDI-advise
alternative hypnotic agent in patients such , @DRUG$ carbamazepine , @DRUG$.	DDI-false
Limited clinical data in angina @DRUG$ and @DRUG$ discernible changes digoxin .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug-drug interactions In vitro studies using human liver microsomes indicate that @DRUG$ and @DRUG$ are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.	DDI-false
The concurrent use of intravenously or orally e.g. @DRUG$ ) patients @DRUG$ has been	DDI-false
- steroids ( @DRUG$ ] , e.g. , Anavar @DRUG$ e.g. , stanozolol e.g. ) or	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$ @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
be exercised PEGANONE is administered with @DRUG$ @DRUG$ ) since paranoid symptoms have been reported during therapy combination .	DDI-false
neuropathy include antiretroviral chloramphenicol , , , disulfiram , , @DRUG$ , gold , , @DRUG$ , metronidazole , nitrofurantoin ribavirin and .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
It is believed that the toxicity may have resulted from a previously unrecognized interaction between @DRUG$ and @DRUG$ and a molecular basis for this interaction has been proposed.	DDI-effect
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-effect
May interact thyroid medication ( e.g. , @DRUG$ ) , products , e.g. famotidine , , and proton inhibitors , @DRUG$ , .	DDI-false
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
majority clinical studies received or more concomitant with ORENCIA , NSAIDs , blocking azathioprine , , @DRUG$ leflunomide @DRUG$ , and	DDI-false
Therefore, if @DRUG$ is administered with VAPRISOL, the clinician should be alert to the possibility of increases in @DRUG$ levels.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, @DRUG$, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
Furosemide : studies , marketing shown @DRUG$ the of @DRUG$ and thiazides in some patients	DDI-effect
and agents with nephrotoxic potential e.g. , e.g. , and ) B , @DRUG$ , @DRUG$ , , anti-inflammatory ] is contraindicated	DDI-false
similar , , has been suggested with barbiturates , phenylbutazone , @DRUG$ carbamazepine topiramate , with ampicillin and @DRUG$ 72	DDI-false
The @DRUG$ @DRUG$ have increased average % and 20 % , , by concomitant administration alprazolam tablets in .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ binding of @DRUG$ serum a net change of 5.7 ( in drug fraction ] 11.0 % ) at by a net 7.1 ( increase in FDF , 13.7 % ) at 1324	DDI-mechanism
To Date Levosimendan not have important pharmacokinetic , @DRUG$ , , , @DRUG$ ethanol itraconazole .	DDI-false
Moreover , the development of dependence may similar @DRUG$	DDI-false
The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	DDI-mechanism
@DRUG$ : @DRUG$ other activity diuretics .	DDI-false
THE ADMINISTRATION OF THESE DRUGS TO PHENYTOIN PRIOR TO ADMINISTERING @DRUG$ ON PHENYTOIN A BASELINE @DRUG$ .	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Compounds tested in man include warfarin, @DRUG$, phenytoin, @DRUG$, aminopyrine and antipyrine.	DDI-false
and nevirapine have been @DRUG$ @DRUG$ over weeks , with being nevirapine regimens observed with efavirenz .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Vitamin A : of the of A patients be advised taking @DRUG$ containing @DRUG$ to effects	DDI-false
include the thiazides and other @DRUG$ , corticosteroids , @DRUG$ , , nicotinic , sympathomimetics , channel blocking drugs , isoniazid	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
@DRUG$ may be effective the presence of	DDI-effect
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	DDI-false
Interactions with @DRUG$ : Agonist/antagonist , , @DRUG$ and buprenorphine should administered who has is receiving a of with a agonist opioid such as Levo-Dromoran	DDI-false
basis that effects be , or @DRUG$ ( dihydroergotamine or AXERT 24 hours of be avoided .	DDI-false
Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of @DRUG$ and @DRUG$ by 20% and 34%, respectively.	DDI-false
that have been tested in include antipyrine digoxin @DRUG$ , @DRUG$ clinically meaningful interactions	DDI-false
@DRUG$ : In healthy given single 500 mg doses plasma cmax by an average of 34 and , respectively , @DRUG$ clearance decreased 14 .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: @DRUG$	DDI-false
No interactions between dexmedetomidine @DRUG$ alfentanil , @DRUG$ have .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
there is a these effects additive ergotamine-containing @DRUG$ @DRUG$ and AXERT within hours of be avoided .	DDI-false
a comparison dogs , Innovar , or pentobarbital the of @DRUG$ to was significantly higher , was the of , with or @DRUG$ with pentobarbital	DDI-false
have not been performed , with that are by , calcium , @DRUG$ quinidine warfarin cyclosporine , derivatives , , fentanyl , @DRUG$ , alprazolam , ) elevated plasma when coadministered with ;	DDI-false
It is possible that the cardiovascular action of other @DRUG$ could be enhanced by the addition of @DRUG$ .	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Additive CNS may when antihistamines concomitantly with other @DRUG$ , and @DRUG$.	DDI-false
like other injectable , produces depression of the central nervous system when administered ethyl phenothiazines , MAO and other @DRUG$ used injectable an of , and irrational been observed	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-mechanism
Other nephrotoxic : @DRUG$ cyclosporine , @DRUG$ may enhance the drug-induced renal should be	DDI-false
@DRUG$: The pharmacokinetics of @DRUG$ (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
Other Cardiovascular Agents enalapril have been used concomitantly with , methyldopa , nitrates , , @DRUG$ @DRUG$ and evidence of adverse	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
@DRUG$ and concomitantly reduction in @DRUG$ should gradual order to possible of steroid .	DDI-false
@DRUG$/theophylline phenobarbital/acetaminophen , , and acid/phenobarbital .	DDI-false
Ethopropazine can interact with @DRUG$, increasing the metabolism of @DRUG$.	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen acid , quinidine/@DRUG$ , .	DDI-false
Because of its lack of anti-platelet effect @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
is recommended @DRUG$ may of @DRUG$ urinary tract .	DDI-effect
Both the toxicity of @DRUG$ and the therapeutic value B rationalized and molecular level following observations ( i these @DRUG$ showed differential effects	DDI-false
@DRUG$ , , procainamide , phenothiazines antihistamines , @DRUG$ may be associated QT-interval risk of .	DDI-false
Drugs may alter Drugs imatinib plasma : Caution recommended when administering inhibitors ( e.g. @DRUG$ , itraconazole , erythromycin @DRUG$ .	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
@DRUG$ @DRUG$ possibly tricyclics striking and sustained in the concentration of in ;	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
inhibitors of ( @DRUG$ , @DRUG$ nefazodone , nelfinavir would expected similarly	DDI-false
Haloperidol : @DRUG$ blocks dopamine reuptake , thus central stimulant of @DRUG$.	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
of be potentiated by @DRUG$ @DRUG$ , oxidase inhibitors , medications , drugs CNS .	DDI-false
The results of assays using red cells from healthy subjects to determine whether @DRUG$ would cause direct Coombs reactions in vitro showed no positive reaction at @DRUG$ concentrations as high as 40  g/mL.	DDI-false
Diuretics Diclofenac and @DRUG$ can of	DDI-effect
Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
drugs which enhance the blocking action of nondepolarizing agents such as NUROMAX certain g. bacitracin , @DRUG$ clindamycin colistin @DRUG$ , anesthetics and quinidine	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of @DRUG$ and @DRUG$.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Coadministration of @DRUG$ (10 mg BID for 7 days) with @DRUG$ (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
- The action of @DRUG$ and insulin may be enhanced by Bezalip or @DRUG$.	DDI-effect
@DRUG$ : Altered serum levels @DRUG$ ( and ) have been reported in receiving concomitant .	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Ethopropazine with @DRUG$ the metabolism of	DDI-false
are examples known the metabolism related @DRUG$ through nefazodone , @DRUG$ cimetidine , diltiazem , isoniazide macrolide	DDI-mechanism
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Anticholinesterases neostgmine @DRUG$ ) , @DRUG$ quinine can toxicity and cause respiratory depression .	DDI-false
poor of : carvedilol strong inhibitors of CYP2D6 ( quinidine , @DRUG$ , propafenone have been , these drugs to blood levels R(+ ) enantiomer @DRUG$ .	DDI-effect
in liver , inhibition of @DRUG$ @DRUG$ 200 m M ) was - 28 %	DDI-mechanism
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
other drugs that metabolized 3A4 @DRUG$ , @DRUG$ may resulting in .	DDI-false
The of may by drugs nonsteroidal anti-inflammatory agents other that are highly , , sulfonamides , @DRUG$ , , @DRUG$ oxidase inhibitors and beta agents .	DDI-false
@DRUG$ increases @DRUG$s serum concentrations.	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These include the thiazides and diuretics corticosteroids @DRUG$ thyroid products oral @DRUG$ , , calcium channel drugs , and	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
inhibitors antifungals , diclofenac , @DRUG$ imatinib isoniazid propofol , protease , @DRUG$.	DDI-false
@DRUG$ In vitro and/or data troleandomycin inhibit the @DRUG$ , can in cisapride prolongation of the interval the .	DDI-false
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
No significant were between nisoldipine @DRUG$ or	DDI-false
@DRUG$ , @DRUG$ , or potentiation of hypotension may occur .	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
drugs may enhance the blocking of nondepolarizing such as @DRUG$ include certain antibiotics , aminoglycosides tetracyclines bacitracin , polymyxins , lincomycin , and colistimethate magnesium salts , @DRUG$ procainamide , and	DDI-effect
In oxcarbazepine @DRUG$ induce a subgroup of cytochrome P450 3A CYP3A5 ) the of dihydropyridine @DRUG$ resulting a lower of .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of @DRUG$ between the @DRUG$ and aqueous phase.	DDI-false
In monkeys , times more potent than @DRUG$ whereas (-)-NANM was about with	DDI-false
hypoglycemic may be potentiated by certain drugs including anti-inflammatory agents other drugs are highly protein bound , sulfonamides chloramphenicol , probenecid , @DRUG$ , inhibitors , and	DDI-false
Because in glucose with @DRUG$ normal variability glucose were near dose @DRUG$ 5 10 mg valdecoxib up QD ) is indicated	DDI-false
These drugs thiazides and diuretics , corticosteroids , , thyroid products , oral @DRUG$ , nicotinic acid , @DRUG$ isoniazid .	DDI-false
, , @DRUG$ @DRUG$ therapy with immunodeficiency , non-Hodgkin lymphoma .	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
Specific @DRUG$ , isoflurane , @DRUG$ , , and .	DDI-false
HIV Inhibitors @DRUG$ 800 t.i.d . ) co-administered with 10 resulted in 16-fold increase Cmax and a 2-fold in @DRUG$	DDI-false
Tagamet , apparently effect certain microsomal systems been hepatic , phenytoin , @DRUG$ chlordiazepoxide diazepam certain tricyclic lidocaine @DRUG$ and metronidazole delaying elimination and	DDI-false
@DRUG$ , Methylxanthines and @DRUG$ : Concomitant treatment with xanthine derivatives , steroids , may a of   beta2-agonists .	DDI-false
studies designed to have not been @DRUG$ or @DRUG$ treatment relapses periods to has been administered ) Betaseron .	DDI-false
healthy individuals , concentrations @DRUG$ approximately with of atorvastatin and @DRUG$ known P450 .	DDI-false
evaluate the impact of plus HAART clinical of patients with , ( , the authors 24 patients with treated with the , prednisone HAART a group of 80 who were treated CHOP chemotherapy or a CHOP-like regimen ( i.e. cyclophosphamide , doxorubicin @DRUG$ and prednisone @DRUG$ bleomycin ) without receiving therapy .	DDI-false
Central Depressants concomitant use DURAGESIC   transdermal system with other depressants , but limited other opioids , sedatives , @DRUG$ , benzodiazepines ) , general , @DRUG$ and , may , hypotension , and profound or potentially in coma .	DDI-false
tested in include , @DRUG$ phenytoin , aminopyrine @DRUG$.	DDI-false
@DRUG$ : reports of hypotension loss consciousness when apomorphine @DRUG$ , the use of apomorphine with 5HT3 class including , , dolasetron , , and alosetron is .	DDI-false
The absorption oral reduced by concomitant administration an @DRUG$	DDI-false
@DRUG$ 500 mg twice daily did not modify the rate or extent of @DRUG$ absorption or its plasma clearance or urinary excretion.	DDI-false
of @DRUG$ and potent @DRUG$ ( 400 mg q.d . days ) resulted an % increase in the area plasma concentration-time of	DDI-mechanism
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	DDI-effect
There have been isolated reports of patients experiencing increases in their prothrombin times when @DRUG$ was added to @DRUG$ therapy.	DDI-effect
Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing antacids.	DDI-advise
may alcohol @DRUG$s , drugs cold and medicines ) , drugs , norepinephrine NSAIDs like Aleve @DRUG$ , and blood	DDI-false
, , @DRUG$ Diclofenac like @DRUG$ , affect prostaglandins of	DDI-false
@DRUG$ as flecainide , lidocaine , or quinidine concurrent use with @DRUG$ may proarrhythmic effect .	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
Administration @DRUG$ to receiving or general anesthetics @DRUG$ which sensitize myocardium ,	DDI-effect
@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited zalcitabine phosphorylation in a dose dependent manner.	DDI-false
specific studies have are mainly metabolized CYP3A4 ( channel blockers dapsone @DRUG$ quinine , @DRUG$ quinidine , , tacrolimus , ergot , pimozide carbamazepine fentanyl , alprazolam , triazolam ) elevated when coadministered ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ with @DRUG$	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-advise
@DRUG$ : Co- administration of @DRUG$ and cerivastatin to healthy not changes or compared to .	DDI-false
receiving , phenothiazines , tranquilizers @DRUG$ , or @DRUG$ ( concomitantly exhibit an additive .	DDI-false
In patients taking @DRUG$ and lithium concomitantly, @DRUG$ toxicity may develop.	DDI-false
@DRUG$ (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of antacid.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
- Taking @DRUG$ and a @DRUG$ together the ( )	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
concomitant administration @DRUG$ and @DRUG$ contraindicated , alternative agents should be	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of doxepin (75 mg/day).	DDI-false
Concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Central : The concomitant use of fentanyl transdermal system with nervous system depressants not other opioids , sedatives hypnotics @DRUG$ ( , benzodiazepines ) @DRUG$ phenothiazines skeletal muscle relaxants and alcohol , may cause depression , or result death .	DDI-false
cimetidine and substrates 2D6 many @DRUG$ and the Type 1C antiarrhythmics propafenone and @DRUG$	DDI-false
Reciprocal interactions concomitant use of drugs that or inhibit system , @DRUG$ , carbamazepine , cimetidine @DRUG$ , though not been studied	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
However study healthy subjects either mg q.i.d . or 800 concomitantly with 300 b.i.d dosage @DRUG$ ( , Key , demonstrated less alteration in @DRUG$ with the 800 mg h.s particularly subjects 54 .	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$: (oral agents and @DRUG$) - dosage adjustment of the antidiabetic drug may be required.	DDI-false
Particular caution recommended when administering @DRUG$ with a narrow therapeutic window ( e.g. @DRUG$	DDI-advise
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-false
When is co-administered with inducers drug clearance , such @DRUG$ @DRUG$ , , use of a daily of 70 mg CANCIDAS should	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: @DRUG$	DDI-false
These drugs include thiazides @DRUG$ , corticosteroids @DRUG$ thyroid , estrogens , contraceptives , phenytoin , acid sympathomimetics , blocking ,	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Increasing : @DRUG$ attenuates by	DDI-effect
@DRUG$ , @DRUG$ opioids or potentiating effects INAPSINE .	DDI-false
Although glucocorticoids have been shown reduce PROLEUKIN-induced side effects fever , , , and dyspnea these reduce the antitumor effectiveness of PROLEUKIN and thus should . @DRUG$ antihypertensives may potentiate	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
With dosing of @DRUG$ and @DRUG$ 10 mg 2 subjects a pressure of less 85 mm Hg .	DDI-effect
similarly inhibit and @DRUG$- @DRUG$-induced proliferation prostatic epithelium	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Antidepressants @DRUG$ ) , atropine or other @DRUG$ digitalis glycosides concurrent use arbutamine may inotropic effects	DDI-false
@DRUG$ and and dopamine ;	DDI-effect
@DRUG$ : Increased serum lithium and symptoms lithium been reported in patients concomitant @DRUG$	DDI-false
of oral @DRUG$ is significantly reduced by concomitant administration of @DRUG$ containing and	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : A reported patient receiving	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-advise
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
therapy interaction studies performed , 1 or in clinical with acetaminophen , a-blockers , , angiotensin-converting ( ACE inhibitors anticonvulsants , beta blockers , blockers , cardiac nitrates , @DRUG$ @DRUG$ , synthetase inhibitors to ) , quinolone anti-infectives without of clinically	DDI-false
The following are of substances that corticosteroids , niacin danazol , @DRUG$ , agents ( , salbutamol , ) @DRUG$ derivatives somatropin , hormones , , ( e.g. oral )	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Valproate @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	DDI-false
Based metabolic , significant drug not expected between @DRUG$ , erythromycin itraconazole or	DDI-false
However, concomitant administration of @DRUG$ with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
reactions reported patients receiving regimens @DRUG$ agents , @DRUG$ , cis-platinum tamoxifen interferon-alfa	DDI-effect
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
The gastrointestinal @DRUG$ @DRUG$ is when they .	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-mechanism
@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or metoclopramide.	DDI-advise
CYP 3A of Significance on Basis of @DRUG$ caution recommended during Coadministration of @DRUG$ alprazolam increased plasma concentration of clearance by % , by 17 , and measured performance	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
@DRUG$ mg once daily ) AUC and 4-fold Cmax when co-administered @DRUG$ mg .	DDI-false
: @DRUG$ the analgesic effect of	DDI-effect
- ( of @DRUG$ @DRUG$ increase the chance affecting the liver the	DDI-effect
that inhibitors CYP3A4 ( eg , ketoconazole @DRUG$ @DRUG$ plasma concentrations .	DDI-false
Beta-blockers, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
The effectiveness of progestin-only pills enzyme-inducing drugs such as @DRUG$ , @DRUG$ antituberculosis rifampin .	DDI-false
have not performed coadministration with drugs that are mainly metabolized CYP3A4 eg , calcium @DRUG$ disopyramide amiodarone quinidine warfarin tacrolimus , cyclosporine , , @DRUG$ , , alprazolam , triazolam ) coadministered saquinavir ;	DDI-false
@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
with @DRUG$ , @DRUG$ use with thiazide diuretics may diuretic	DDI-false
Longitudinal assessment of @DRUG$ in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on @DRUG$.	DDI-false
: Dihydroergotamine , @DRUG$ ergotamine methylergonovine to and life-threatening reactions such @DRUG$ toxicity by and of the extremities other .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and @DRUG$.	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
The interaction is a consequence of blocking hepatic metabolism of @DRUG$ by @DRUG$, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.	DDI-mechanism
Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.	DDI-mechanism
plasma levels of several closely related tricyclic reported by of methylphenidate or hepatic enzyme , fluoxetine of hepatic enzyme ( @DRUG$ , and effect be anticipated with @DRUG$ as well .	DDI-mechanism
Although studies have not , drugs are mainly ( eg calcium blockers , disopyramide , quinine amiodarone , , warfarin , , @DRUG$ derivatives carbamazepine , , @DRUG$ , and triazolam have concentrations coadministered with ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cohort 1 then received @DRUG$ plus rifabutin for 10 days, and cohort 2 received @DRUG$ plus rifampin for 4 days.	DDI-false
@DRUG$ , ergotamine , @DRUG$ CONTRAINDICATED due to potential for life-threatening reactions such as acute ergot by peripheral and of extremities .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and @DRUG$.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drugs peripheral neuropathy include antiretroviral analogues , , cisplatin dapsone , @DRUG$ glutethimide @DRUG$ , iodoquinol isoniazid , , , ribavirin , and	DDI-false
Concomitant administration of @DRUG$ and other related compounds (eg, @DRUG$, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
@DRUG$: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
of @DRUG$ may be by drugs anti-inflammatory that highly bound , sulfonamides coumarins , @DRUG$	DDI-effect
In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg @DRUG$, causing no significant changes in pharmacokinetics or pharmacodynamics of @DRUG$.	DDI-false
@DRUG$ plus @DRUG$ was well tolerated.	DDI-false
Inhibitors and II Receptor Antagonists ( Congestive In 3020 ( 91 ) patients 25 to mg received @DRUG$ or antagonists (	DDI-false
- @DRUG$ (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Interactions Oral Contraceptives @DRUG$ ( 500 mg daily did pharmacokinetics an contraceptive containing mg @DRUG$ and 0.15 , or of luteinizing and of is	DDI-false
The benzodiazepines family @DRUG$ and	DDI-false
increased @DRUG$ high binding sites for @DRUG$ on and serotonin2-receptors the antipsychotic action of after .	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
@DRUG$ @DRUG$ blocks dopamine norepinephrine thus inhibiting central of	DDI-false
with @DRUG$ , chloramphenicol cisplatin dapsone , @DRUG$ , , , metronidazole nitrofurantoin phenytoin ribavirin .	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, @DRUG$).	DDI-mechanism
Concurrent administration of possessing e.g. , aminoglycosides indomethacin ) , myelotoxic ( e.g. , @DRUG$ , ( doxorubicin ) or hepatotoxic ( e.g. , effects with @DRUG$ may increase in .	DDI-effect
bioavailability of the capsule formulation @DRUG$ was not when minutes @DRUG$.	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
A drug-drug interaction study with @DRUG$ in healthy volunteers has shown a 30% decrease in @DRUG$ trough concentrations.	DDI-mechanism
OTHER CONCOMITANT specific interaction were performed , studies , was used concomitantly angiotensin- converting enzyme ) betablockers calcium-channel blockers @DRUG$ @DRUG$ clinically interactions .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
specific were not doses were concomitantly used in with acetaminophen , @DRUG$ , a-blockers , angiotensin-converting enzyme inhibitors , anticonvulsants , benzodiazepines , , calcium-channel cardiac nitrates @DRUG$ H2 antagonists , HMG-CoA reductase inhibitors referred ) and anti-infectives without significant adverse .	DDI-false
- When @DRUG$ is used with anion-exchange resins ( e.g. cholestryramine , of at maintained two , the absorption Bezalip or @DRUG$	DDI-false
@DRUG$ does not affect the pharmacokinetics of @DRUG$.	DDI-false
To evaluate impact of chemotherapy plus on the clinical course HIV-related , HIV-NHL ) compared retrospectively a 24 HIV-NHL who were treated the doxorubicin and prednisone ( CHOP regimen group 80 patients with or a CHOP-like regimen ( i.e. , @DRUG$ doxorubicin , and prednisone without @DRUG$ .	DDI-false
@DRUG$ reduced or eliminated the in FI responding by intermediate doses in not antagonize the responding produced high doses PCP either @DRUG$.	DDI-false
Injection Lorazepam other injectable @DRUG$ produces of the nervous when with , phenothiazines @DRUG$ MAO inhibitors , When concomitantly injectable , increased of hallucinations , irrational behavior has been	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
similar association , , been , @DRUG$ , carbamazepine , topiramate , with and @DRUG$ .	DDI-false
@DRUG$ : Patients on may diminished response or @DRUG$ due inhibition antibody response	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Enalapril @DRUG$ IV , @DRUG$ hydralazine , prazosin digoxin of adverse interactions	DDI-false
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
@DRUG$: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
of and @DRUG$ increase @DRUG$	DDI-false
These drugs and other diuretics , , @DRUG$ @DRUG$ contraceptives , acid , channel drugs , and isoniazid .	DDI-false
pharmacokinetics data that @DRUG$ of resulting increase the of @DRUG$.	DDI-false
alter imatinib concentrations @DRUG$ plasma concentrations : Caution is when administering Gleevec with the CYP3A4 , ketoconazole , itraconazole erythromycin , @DRUG$	DDI-false
Cation-Containing Concurrent administration a quinolone , including ciprofloxacin , with cation-containing products such as magnesium or , sucralfate chewable/buffered or pediatric , products , iron @DRUG$ may decrease the @DRUG$ serum urine levels considerably than .	DDI-false
Like 40 mg/kg , 40 of @DRUG$ and @DRUG$ the oral self-administration of	DDI-false
The are examples of substances that effect : @DRUG$ diuretics , sympathomimetic e.g. , salbutamol ) @DRUG$ , , thyroid , estrogens ( e.g. , contraceptives .	DDI-false
Drugs That Should Be With VIRACEPT Antiarrhythmics amiodarone , @DRUG$ Antihistamines : , terfenadine : ergot : @DRUG$ midazolam , triazolam GI motility :	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
concomitant Although specific interaction performed , finasteride 1 more were used clinical studies acetaminophen @DRUG$ , ( inhibitors anticonvulsants , calcium-channel , @DRUG$ diuretics H2 antagonists inhibitors , referred to NSAIDs ) , quinolone anti-infectives significant adverse .	DDI-false
effects from blockade may occur concomitantly @DRUG$ , amantadine , @DRUG$ , MAO tricyclic antidepressants	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, @DRUG$, and phenobarbital.	DDI-false
poor @DRUG$ : of carvedilol with strong inhibitors of CYP2D6 ( such as , @DRUG$ , propafenone studied but these drugs be to blood the ) enantiomer of carvedilol	DDI-false
hydrochloride has additive effects with alcohol and other @DRUG$ @DRUG$ tranquilizers .	DDI-false
clinical , was used with @DRUG$ , , oral vasodilators and . in patients heart failure furosemide @DRUG$ therapy FLOLAN , apparent oral clearance digoxin ( 30 decreased by and , respectively on second of therapy to values by	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ may the @DRUG$.	DDI-false
Drugs have been associated neuropathy antiretroviral dapsone disulfiram glutethimide , gold hydralazine @DRUG$ @DRUG$ phenytoin , .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and @DRUG$ (72)	DDI-false
As some other @DRUG$ , the time of onset of block by NUROMAX and duration block is receiving @DRUG$.	DDI-effect
Several drug interaction studies have completed @DRUG$	DDI-false
Hydrochlorothiazide : normal administration of @DRUG$ and @DRUG$ resulted increased levels of	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Pyrantel ( e.g. @DRUG$ - Taking pyrantel together may decrease the effects of @DRUG$.	DDI-false
That Coadministered With VIRACEPT @DRUG$ , @DRUG$ Antimigraine ergot derivatives agents : GI motility agents :	DDI-false
Terfenadine: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
The effect of TORADOL on @DRUG$ has not studied , of @DRUG$ during TORADOL been reported	DDI-false
@DRUG$, including norfloxacin, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ @DRUG$ : The effect increased on the bioavailability of ceftibuten evaluated adult volunteers .	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
specific not performed coadministration that mainly metabolized by CYP3A4 ( eg channel dapsone , disopyramide , amiodarone , , cyclosporine , derivatives , @DRUG$ , @DRUG$ , triazolam have elevated concentrations when	DDI-false
Antacids containing @DRUG$, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	DDI-mechanism
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
CNS depressant drugs e.g. tranquilizers , @DRUG$ have or potentiating effects with	DDI-effect
: a study in mean steady-state @DRUG$ plasma % in subjects receiving lithium with @DRUG$ 200 BID as receiving lithium alone	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
CNS-Active Drugs @DRUG$ Sonata mg the CNS-impairing ethanol and for hour after @DRUG$ administration substitution test ) , test variability the test for 2.5 after ethanol	DDI-false
Anticholinesterases (neostgmine, @DRUG$), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Psychoactive Drugs : have TORADOL was @DRUG$ , @DRUG$ ) .	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
receiving steroid concomitantly reduction @DRUG$ gradual order avoid sudden @DRUG$ withdrawal .	DDI-false
@DRUG$: Diclofenac and other @DRUG$ can inhibit the activity of diuretics.	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
of @DRUG$ on the volume and of	DDI-false
( In , @DRUG$ can antihypertensive effects of , @DRUG$.	DDI-effect
Cimetidine : @DRUG$ concentrations altered coadministration	DDI-false
Oral doses of @DRUG$ (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of @DRUG$ (by approximately 40%) given to healthy volunteers in moderate doses.	DDI-mechanism
Coadministration of @DRUG$ and @DRUG$, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
Anabolic ( e.g. , Anabolin @DRUG$ [ e.g. @DRUG$ [ e.g. Anadrol ,	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
@DRUG$ may augment the activity of other @DRUG$.	DDI-effect
The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	DDI-false
@DRUG$ Angiotensin Antagonists ( Congestive Failure Post-Myocardial Infarction)- EPHESUS , ( % ) patients to 50 received ACE or II receptor antagonists ( .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Drugs that been with neuropathy include analogues , chloramphenicol cisplatin , @DRUG$ , @DRUG$ glutethimide hydralazine isoniazid metronidazole , phenytoin , , .	DDI-false
hypoglycemic sulfonylureas may be potentiated drugs @DRUG$ and drugs protein bound , , @DRUG$ , , monoamine inhibitors , beta blocking agents .	DDI-false
are of substances may blood-glucose-lowering , diuretics , agents , salbutamol , , @DRUG$ , thyroid , progestogens ( e.g. in oral @DRUG$	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
In general , these are that have one pharmacologic activities similar to bepridil @DRUG$ such and @DRUG$ cardiac glycosides and anti-depressants .	DDI-false
, @DRUG$ @DRUG$ had no effect on the pharmacokinetics of .	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Cephalosporins-Cephalosporins containing N-methylthiotetrazole ( , , @DRUG$ , @DRUG$ ) or methylthiadiazole ( cefazolin can cause deficiency and .	DDI-false
Serotonin Reuptake Inhibitors ): SSRIs e.g. , @DRUG$ , fluvoxamine paroxetine @DRUG$ have been rarely to hyperreflexia , when coadministered with agonists	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of @DRUG$ with an @DRUG$ has not been conducted.	DDI-false
@DRUG$ : Bioavailability mildly ( approximately 10 % @DRUG$ coadministered .	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, @DRUG$, simvastatin).	DDI-false
Monoamine Inhibitors @DRUG$ administered treated with or antidepressants action of @DRUG$ on the system potentiated agents .	DDI-false
therapies not be used @DRUG$ as may its pharmacologic	DDI-advise
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
in in a efficacy of @DRUG$ : , @DRUG$ ,	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other Drugs In small groups ( 7 10/interaction study ) , administration of gold , @DRUG$ D-penicillamine , @DRUG$ , or digitoxin not the peak levels and AUC values diclofenac	DDI-false
Pediatric Use The safety and effectiveness of @DRUG$, alone or in combination with @DRUG$ in patients below the age of 18 years have not been established.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
and/or , containing ) multivitamin preparations containing @DRUG$ or cations or chewable/buffered tablets or the solution should not or 2 after @DRUG$.	DDI-advise
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, @DRUG$, or other @DRUG$.	DDI-false
Antagonists Since apomorphine a @DRUG$ is possible that dopamine ( , , @DRUG$ ) or may diminish the of APOKYN .	DDI-false
specific have performed , coadministration with metabolized ( eg channel dapsone , quinidine warfarin , tacrolimus , @DRUG$ derivatives @DRUG$ , , and triazolam ) have plasma when coadministered with	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The that reduce blood-glucose-lowering effect , niacin danazol ( e.g. , salbutamol , ) , isoniazid , @DRUG$ , @DRUG$ , ) .	DDI-false
diuretics ( , spironolactone , triamterene or @DRUG$ ) , @DRUG$ supplements , lead to increases in potassium .	DDI-false
Anti-inflammatory : patients the of a @DRUG$ can reduce the diuretic natriuretic , antihypertensive effects	DDI-effect
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Patients using CYP3A4 @DRUG$ have cholesterol levels after is initiated to @DRUG$ dose needs .	DDI-false
drugs include the @DRUG$ other , corticosteroids , products phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and	DDI-false
@DRUG$: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that @DRUG$ (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.	DDI-false
Caution should be if HMG-CoA reductase administered may levels or of endogenous steroid hormones , as @DRUG$ spironolactone and @DRUG$.	DDI-false
coadministration of @DRUG$ the biologic of @DRUG$ because in that in a amount hydroxylated fenoprofen in	DDI-mechanism
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Antagonists Based on of hypotension and of when apomorphine was with ondansetron , the use apomorphine of @DRUG$ example ondansetron granisetron , @DRUG$ )	DDI-false
Other @DRUG$ ( and have additive with	DDI-effect
@DRUG$ : significant differences were in the @DRUG$ or S-warfarin with addition tiagabine dose .	DDI-false
, @DRUG$ did not alter the @DRUG$ (+)-NANM	DDI-false
The majority patients clinical or more of following medications @DRUG$ , corticosteroids , @DRUG$ , azathioprine , chloroquine , gold hydroxychloroquine , leflunomide , sulfasalazine , and .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
Aspirin : of and aspirin is not recommended @DRUG$ is displaced its binding sites during the administration @DRUG$ , lower plasma levels , AUC	DDI-mechanism
Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ (CYP3A4 substrate) given for local anesthesia.	DDI-false
Antidepressants ( @DRUG$ @DRUG$ other agents , use with arbutamine produce additive .	DDI-false
Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, alfentanil, and @DRUG$.	DDI-false
effectiveness @DRUG$-only pills reduced enzyme-inducing drugs such as the anticonvulsants , carbamazepine , and barbiturates , the @DRUG$ .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
have found interaction with hydrochlorothiazide @DRUG$ , @DRUG$ , phenobarbital	DDI-false
may enhance neuromuscular action of NUROMAX ( e. g. , aminoglycosides , @DRUG$ , , , , colistin and colistimethate magnesium salts , , local anesthetics and @DRUG$.	DDI-false
These the other , corticosteroids phenothiazines thyroid estrogens oral , @DRUG$ blocking and	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Bacteriostatic Antibiotics @DRUG$ , or interfere with the effect	DDI-effect
@DRUG$ decrease the effect phenothiazines @DRUG$ ketoconazole	DDI-effect
Other of CYP3A4 ( e.g. , , @DRUG$ , @DRUG$ , troleandomycin , , would expected similarly	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-mechanism
@DRUG$ or MAO-inhibitors potential ) be	DDI-advise
Interactions Between Keppra Drugs AEDs @DRUG$ @DRUG$   mg daily had effect on pharmacokinetic of patients with refractory	DDI-false
Although not observed in this study, adverse effects could potentially arise from co-administration of @DRUG$ and @DRUG$ by inhibition of tubular secretion via organic cationic transporter systems.	DDI-mechanism
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-effect
Based on resemblance of ketoconazole coadministration of @DRUG$ @DRUG$ is contraindicated .	DDI-advise
Beta-blockers clonidine , @DRUG$ salts , or the effect of @DRUG$.	DDI-effect
@DRUG$: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing @DRUG$.	DDI-false
@DRUG$: Phenylbutazone causes increase (by about 80%) in the free fraction of @DRUG$.	DDI-false
that imatinib Drugs may increase imatinib administering Gleevec with CYP3A4 family ( e.g. , @DRUG$ itraconazole @DRUG$ clarithromycin .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
glucocorticoids have to side effects renal , , concomitant administration agents PROLEUKIN reduce of @DRUG$ thus . 12 other @DRUG$ the hypotension PROLEUKIN .	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Anti-Inflammatory Drugs of eplerenone an @DRUG$ has been conducted	DDI-false
HIV Protease : ( 800 t.i.d co-administered mg in , increase @DRUG$ 2-fold @DRUG$	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$ @DRUG$ is not .	DDI-advise
@DRUG$: Valdecoxib 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-false
and Upon concomitant of 600 @DRUG$ , @DRUG$ by approximately 20 % .	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (CYP3A4 substrate) given for local @DRUG$.	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
No difference the of distribution @DRUG$ @DRUG$ and .	DDI-false
Similarly, @DRUG$ decreased the rate of elimination of @DRUG$ (by approximately 50%) by the same mechanism.	DDI-mechanism
BACKGROUND: The effects of combined administration of @DRUG$ and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
- @DRUG$ (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
Caution should be @DRUG$	DDI-advise
@DRUG$: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Since @DRUG$ and @DRUG$, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-effect
Although there is little published information on concomitant administration of @DRUG$ and @DRUG$, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.	DDI-false
Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking @DRUG$ and @DRUG$.	DDI-advise
Concomitant use of calcium supplements and @DRUG$ may increase @DRUG$ absorption	DDI-false
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and metoprolol.	DDI-effect
Estrogens oral contraceptives @DRUG$ decrease metabolism @DRUG$ , thereby effect .	DDI-mechanism
and @DRUG$ use may be when with	DDI-effect
Micro-dosed Preparations @DRUG$ preparations ( minipills that not contain estrogen contraception @DRUG$ .	DDI-effect
Lithium-A drug interaction study of @DRUG$ with @DRUG$ has not been conducted.	DDI-false
between @DRUG$ potent inhibitors ( e.g. ritonavir @DRUG$ ) not been studied , increased exposures to be when almotriptan concomitantly with medications	DDI-false
@DRUG$ @DRUG$ ( 1500 daily the pharmacokinetics of healthy .	DDI-false
@DRUG$ had no on the anticoagulant @DRUG$ in subjects therapy .	DDI-false
Anticholinesterases (neostgmine, @DRUG$), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
In performed with Fondaparinux the concomitant anticoagulants ( @DRUG$ ) , @DRUG$ ( acetylsalicylic acid , piroxicam ) , and digoxin did not the of fondaparinux sodium	DDI-false
Based on hypotension loss of consciousness when @DRUG$ with concomitant use of @DRUG$ drugs of the 5HT3 class ( including , example , , alosetron ) is contraindicated	DDI-false
drugs @DRUG$ other @DRUG$ corticosteroids , phe-nothiazines , products estrogens , contraceptives phenytoin nicotinic acid , sympathomimet-ics , channel drugs , and isoniazid	DDI-false
@DRUG$ Coadministration VIRACEPT resulted an in @DRUG$	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
intake alcohol and @DRUG$ the pharmacokinetics of @DRUG$ acamprosate	DDI-false
Example inhibitors antifungals , @DRUG$ , doxycycline , imatinib isoniazid , nefazodone nicardipine @DRUG$ , quinidine and	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Concomitant cyclophosphamide doxorubicin , @DRUG$ , @DRUG$ in patients human ,	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
: or pharmacodynamic drug-drug have been demonstrated between Argatroban and @DRUG$ mg given prior Argatroban 1 . over hours ) @DRUG$ ( 1000 orally given , 6 prior to and 6 and 12 subsequent , initiation of   18 hours	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ : Indinavir co-administered with @DRUG$ 10 resulted in 16-fold in vardenafil , a 7-fold a vardenafil	DDI-false
In addition, @DRUG$ and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
The concentrations of @DRUG$, the active metabolite of @DRUG$, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ may the effect phenobarbital , phenytoin @DRUG$ , and the of susceptible pediatric .	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
have neuropathy antiretroviral , , cisplatin , disulfiram ethionamide glutethimide , gold , iodoquinol , , @DRUG$ nitrofurantoin , , @DRUG$ , vincristine	DDI-false
Example antifungals @DRUG$ , clarithromycin diclofenac doxycycline @DRUG$ isoniazid , , , protease inhibitors ,	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Therefore you may need to take a @DRUG$ supplement while taking @DRUG$.	DDI-advise
@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
should not with D2-antagonists , as @DRUG$ @DRUG$ or metoclopramide	DDI-false
@DRUG$- aluminum-containing antacids containing ferrous iron ) preparations metal or @DRUG$ tablets the powder for oral should not within 3 hours before hours after FACTIVE	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of diclofenac therapy.	DDI-false
@DRUG$: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, @DRUG$, and midazolam.	DDI-false
majority of patients in clinical received or of the following medications @DRUG$ , corticosteroids , TNF , azathioprine , @DRUG$ , , , , and anakinra .	DDI-false
: @DRUG$ : In digoxin , administration of @DRUG$ regularly in increase in serum that may reach levels resultant clinical toxicity	DDI-false
- retard is used @DRUG$ cholestryramine interval of at should be maintained the two medicines , since of @DRUG$ or Bezalip	DDI-false
Warfarin No were in pharmacokinetics @DRUG$ S-warfarin the addition @DRUG$ single dose	DDI-false
Although specific studies have not with are eg , disopyramide quinine , amiodarone @DRUG$ , warfarin , , cyclosporine @DRUG$ pimozide carbamazepine , , , and may have plasma concentrations coadministered	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
to monitor plasma of @DRUG$ when of these taken and @DRUG$ if necessary .	DDI-false
These , @DRUG$ , thyroid , @DRUG$ phenytoin nicotinic calcium blocking and	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
@DRUG$ , other , especially @DRUG$ and anesthetic used in surgery or skeletal-muscle relaxants , nondepolarizing	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
: Concomitant use Argatroban with @DRUG$ , and other @DRUG$ risk of bleeding	DDI-false
of with amiodarone has been to decreases serum concentrations @DRUG$	DDI-false
Example inhibitors include antifungals ciprofloxacin , clarithromycin diclofenac @DRUG$ erythromycin @DRUG$ , propofol , verapamil .	DDI-false
Anabolic nandrolone e.g. Anabolin ] oxandrolone [ e.g. , Anavar , @DRUG$ Anadrol ] stanozolol e.g. @DRUG$ ] ) or	DDI-false
@DRUG$ @DRUG$ ) effectively administered such as calcium angiotensin enzyme inhibitors , in the adverse .	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ coumarin , indandione , and platelet as nonsteroidal drugs ) , @DRUG$ the risk bleeding when with	DDI-false
It is not known if the effects of @DRUG$ are altered by concomitant medications that affect hepatic metabolism of drugs (@DRUG$, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.	DDI-advise
These and other , , @DRUG$ , estrogens , oral @DRUG$ phenytoin nicotinic acid , , calcium	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/SMX).	DDI-false
No effects on plasma concentrations of @DRUG$ or @DRUG$ were observed.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Natrecor with vasodilators such , @DRUG$ , or IV been ( drugs co-administered with @DRUG$ in	DDI-false
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
results of using healthy subjects to @DRUG$ would reactions vitro showed reaction at @DRUG$ as   g/mL.	DDI-false
- Lithium: Lithium should generally not be given with @DRUG$ (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Although studies have coadministration with mainly by CYP3A4 , channel , , quinidine warfarin , tacrolimus derivatives , @DRUG$ @DRUG$ fentanyl alfentanyl , alprazolam , and triazolam ) have concentrations coadministered saquinavir ;	DDI-false
These drugs and diuretics , , phenothiazines , products , , contraceptives @DRUG$ , sympathomimetics , calcium	DDI-false
Although studies that metabolized ( eg , calcium blockers dapsone , disopyramide quinine , , warfarin , @DRUG$ , cyclosporine ergot derivatives , @DRUG$ , , fentanyl , , alprazolam , triazolam may have elevated plasma concentrations coadministered saquinavir ;	DDI-false
significant increase exposure to imatinib @DRUG$ is coadministered @DRUG$ ( .	DDI-mechanism
Coingestion acetaminophen with @DRUG$ @DRUG$ acid phenobarbital high to toxic the of the target drug	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.	DDI-effect
These drugs include the and other diuretics , , @DRUG$ , estrogens , phenytoin nicotinic acid sympathomimetics , channel drugs and @DRUG$.	DDI-false
CNS-Active @DRUG$ @DRUG$ 10 mg CNS-impairing of 0.75 g/kg balance testing reaction time for 1 hour after ethanol on symbol ( DSST ) symbol copying test the variability of test administration	DDI-false
Saquinavir Coadministration @DRUG$ ( capsule formulation @DRUG$ mg ) in increase plasma and in saquinavir A.C.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
cimetidine and many that are substrates for P450 many other @DRUG$ phenothiazines and @DRUG$ propafenone and flecainide	DDI-false
Combination of amiodarone with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
of CYP3A4 ( @DRUG$ , @DRUG$ , , to behave similarly	DDI-false
Ephedrine @DRUG$ the metabolic clearance @DRUG$ , in decreased levels and lessened thus an corticosteroid dosage .	DDI-mechanism
Concomitant administration of @DRUG$ (10 mg) and @DRUG$ (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.	DDI-mechanism
concomitant therapy Although interaction were performed finasteride 1 mg or more used in clinical with , acid , a-blockers angiotensin-converting enzyme ACE @DRUG$ benzodiazepines , cardiac @DRUG$ , , reductase prostaglandin ( NSAIDs ) anti-infectives evidence of significant adverse .	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Since @DRUG$ and @DRUG$ , including may each increased levels the effects kinetics function be considered agents are concurrently .	DDI-effect
Antiarrhythmics @DRUG$ flecainide @DRUG$ serious life-threatening reactions	DDI-false
These indicate that not influence the plasma concentration of other AEDs and these @DRUG$ do not pharmacokinetics @DRUG$.	DDI-false
When co-administered with inducers drug clearance such , @DRUG$ , or @DRUG$ , use dose of	DDI-false
blood @DRUG$ tended to be greater in patients @DRUG$ than on no other antihypertensive .	DDI-effect
Example antifungals ciprofloxacin , clarithromycin diclofenac , @DRUG$ isoniazid , , nicardipine , , @DRUG$ , quinidine verapamil	DDI-false
- @DRUG$ ( nandrolone , ] , e.g. , @DRUG$ ] , oxymetholone e.g. , stanozolol ,	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
, as postmarketing observations have Lodine reduce the @DRUG$ and @DRUG$ patients .	DDI-false
Interaction between @DRUG$ and @DRUG$ in the development of spontaneous motility in chick embryos.	DDI-effect
@DRUG$ ) and that substrates 2D6 ( many other , phenothiazines and the @DRUG$ propafenone and flecainide	DDI-false
of @DRUG$-only pills is hepatic drugs such as phenytoin carbamazepine , @DRUG$ , and the	DDI-effect
These and other , , thyroid oral contraceptives @DRUG$ acid , sympathomimetics @DRUG$ and isoniazid	DDI-false
Standard therapy includes antibiotics, such as @DRUG$ and @DRUG$;	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
The the benzodiazepines may potentiated by , , @DRUG$ inhibitors narcotics phenothiazines @DRUG$ other drugs that .	DDI-false
The examples that reduce the effect : corticosteroids , sympathomimetic ( e.g. , , @DRUG$ terbutaline ) , phenothiazine , progestogens , oral @DRUG$	DDI-false
The of clinical received of following concomitant , , corticosteroids , TNF agents , azathioprine , @DRUG$ , @DRUG$ , sulfasalazine	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
following are that may the effect hypoglycemia oral antidiabetic , ACE inhibitors , , fibrates @DRUG$ monoamine ( ) inhibitors @DRUG$ , somatostatin analog e.g. sulfonamide .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Oxidase Inhibitors and @DRUG$ : @DRUG$ should be administered with patients being monoamine the action formoterol on the system potentiated these agents .	DDI-false
@DRUG$: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Potential between @DRUG$   and carbamazepine , lamotrigine , @DRUG$ primidone valproate by the serum concentrations of levetiracetam and AEDs during placebo-controlled studies	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Potential interactions @DRUG$ substrate CYP3A4 protease ( ritonavir @DRUG$ , indinavir , and nelfinavir ) which substrates inhibitors of CYP3A4 not been evaluated in trials	DDI-false
Omeprazole The rate and extent of of ciprofloxacin bioequivalent Proquin XR was given @DRUG$ was given after @DRUG$ the that suppresses acid secretion .	DDI-false
is not Levetiracetam no effect on concentrations @DRUG$ @DRUG$ , lamotrigine	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of @DRUG$).	DDI-false
Other Although interaction not finasteride of 1 mg or more used in studies with acetaminophen acid , a-blockers , analgesics ( ACE inhibitors , anticonvulsants benzodiazepines , blockers , calcium-channel blockers cardiac nitrates , H2 , @DRUG$ , @DRUG$ ( also referred to as ) quinolone anti-infectives without evidence of clinically interactions .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
action be potentiated by anticonvulsants , , , @DRUG$ , monoamine inhibitors @DRUG$ phenothiazines , psychotropic or CNS depression .	DDI-false
To evaluate HAART the clinical course with non-Hodgkin ( HIV-NHL ) the compared a 24 patients with HIV-NHL who were treated with cyclophosphamide doxorubicin prednisone ) chemotherapy plus HAART a group of 80 who chemotherapy or CHOP-like ( , cyclophosphamide , @DRUG$ and with vincristine plus @DRUG$ antiretroviral therapy .	DDI-false
Urinary acidifying agents @DRUG$ @DRUG$ etc ) increase the species of amphetamine molecule increasing	DDI-false
Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	DDI-effect
@DRUG$: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
Diuretics : Patients @DRUG$ , those intravascular depletion an reduction blood pressure initiation therapy with @DRUG$.	DDI-effect
@DRUG$: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
poor metabolizers : of with strong inhibitors of CYP2D6 quinidine , @DRUG$ paroxetine @DRUG$ ) not been studied these of ) enantiomer of .	DDI-false
Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
@DRUG$ : the , , at mg twice for 3 days and mg for , systemic ( to @DRUG$ approximately 72	DDI-false
( , levothyroxine @DRUG$ , famotidine , ) , pump inhibitors e.g. , @DRUG$ ) .	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
These suggest that dexamethasone retinyl and possibly other @DRUG$ and @DRUG$ , may regulate the proliferation of epithelium by a dose-dependent insulin EGF	DDI-false
Colestipol Plasma concentrations of atorvastatin 25 @DRUG$ @DRUG$ were	DDI-mechanism
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
Warfarin and @DRUG$: Increased prothrombin time, with or without clinical bleeding, has been reported when @DRUG$ is administered concomitantly.	DDI-effect
, apparently on enzyme systems , the metabolism of @DRUG$ , phenytoin , propranolol nifedipine @DRUG$ , , certain antidepressants , , theophylline delaying and blood drugs .	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Interactions Analgesics Agonist/antagonist analgesics nalbuphine , butorphanol @DRUG$ buprenorphine should NOT be to a received receiving therapy with agonist opioid such @DRUG$.	DDI-advise
However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.	DDI-false
The potentiated @DRUG$ and other drugs highly , sulfonamides , and @DRUG$.	DDI-false
Including , , Transdermal , and Contraceptives : interaction @DRUG$ oral contraceptive Ortho-Novum @DRUG$ estradiol of 14 % , .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-mechanism
While all the @DRUG$ (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ , @DRUG$ , sparfloxacin ,	DDI-false
Digoxin, Methotrexate, @DRUG$: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
@DRUG$ (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
In patients chronic with @DRUG$ COPEGUS PEGASYS treatment did affect @DRUG$ or clearance	DDI-false
@DRUG$, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Administration of @DRUG$ to patients who are receiving sympathomimetic or @DRUG$ may result in an additive pressor effect .	DDI-effect
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Injection @DRUG$ injection , like injectable benzodiazepines produces depression the central when administered with ethyl , phenothiazines , @DRUG$ , MAO inhibitors other antidepressants When used injectable lorazepam , an incidence sedation , and behavior has been observed	DDI-effect
Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-effect
Glyburide: The concomitant administration of @DRUG$ with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Adequate monitoring @DRUG$ considered with VIOXX is initiated patients receiving @DRUG$.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with NPH human insulin immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
Administration of @DRUG$ no pharmacokinetics @DRUG$ digoxin an ethinylestradiol/levonorgestrol healthy subjects .	DDI-false
No clinical currently exist comparing the agents ( , @DRUG$ @DRUG$ .	DDI-false
The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The examples of that increase blood-glucose-lowering and susceptibility to hypoglycemia oral antidiabetic products inhibitors disopyramide , fluoxetine , @DRUG$ @DRUG$ , somatostatin ( , octreotide sulfonamide .	DDI-false
Data from vitro @DRUG$ suggest a possible with for the following @DRUG$	DDI-false
use @DRUG$ in receiving @DRUG$ rarely with ventricular .	DDI-effect
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
Lithium : In study in healthy levels 17 in receiving @DRUG$ mg with CELEBREX BID compared subjects receiving @DRUG$	DDI-false
with Opioid Analgesics @DRUG$ ( @DRUG$ butorphanol , dezocine and buprenorphine ) administered to a who received or receiving a course of with a pure analgesic	DDI-false
Cation-Containing Products Concurrent administration @DRUG$ including @DRUG$ , multivalent cation-containing magnesium , , chewable/buffered or powder , zinc substantially absorption , urine	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
, , Fluoxetine , Ketoconazole , Phenobarbitol , @DRUG$ Rifampin Ritanovir @DRUG$.	DDI-false
The of in studies received one or of the following concomitant medications with : corticosteroids TNF blocking agents , chloroquine @DRUG$ , sulfasalazine , @DRUG$.	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-false
To evaluate the impact of chemotherapy on the clinical course of patients with HIV-related systemic ) , authors a group of patients with HIV-NHL @DRUG$ , doxorubicin and chemotherapy regimen HAART with of who were treated with chemotherapy CHOP-like regimen ( i.e. cyclophosphamide doxorubicin , and plus ) @DRUG$ therapy .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Drugs : , @DRUG$ astemizole , terfenadine Antimigraine derivatives @DRUG$ : midazolam , triazolam cisapride	DDI-false
Other Oral Contraceptives 500 mg twice ) did not the contraceptive containing 0.03 mg @DRUG$ and 0.15 mg @DRUG$ , or of the luteinizing hormone and progesterone , indicating of unlikely .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
If with CYP3A4 ( @DRUG$ @DRUG$ ritonavir , saquinavir , ) is indicated reduction the budesonide should	DDI-false
@DRUG$ g. ketoconazole , clotrimazole , @DRUG$ etc . ): in animal the of amphotericin and may amphotericin B.	DDI-false
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-mechanism
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
That Induce ( @DRUG$ Racemic was 80 by useof @DRUG$ ,	DDI-false
Non-selective tranylcypromine sulfate sulfate @DRUG$ : use of and @DRUG$ .	DDI-false
@DRUG$/prednisolone Rofecoxib did not clinically important effect the pharmacokinetics @DRUG$ .	DDI-false
Aminoglutethimide: @DRUG$ may diminish adrenal suppression by @DRUG$.	DDI-effect
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, @DRUG$, lovastatin, simvastatin).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The risk using @DRUG$ in with other drugs systematically may potentiate side @DRUG$.	DDI-false
of @DRUG$ or agents interfering neuromuscular ( should be performed as of the @DRUG$ be potentiated	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$ block @DRUG$-induced dopamine in the ;	DDI-effect
@DRUG$: Amiodarone, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Drug-Drug Interactions @DRUG$ Other @DRUG$ AEDs ) Keppra 3000 ) had effect the pharmacokinetic disposition phenytoin in patients with refractory	DDI-false
BACKGROUND The of combined administration of @DRUG$ and verapamil ( ) , a calcium channel blocker on the incidence peritoneal metastasis of adenocarcinomas induced @DRUG$ ) the of intestinal cancers were investigated male Wistar rats .	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
not been Argatroban @DRUG$ or @DRUG$.	DDI-false
Central Nervous System Depressants of   system with central nervous system , but opioids , , ( e.g. ) , @DRUG$ @DRUG$ , cause respiratory depression hypotension profound sedation , or potentially coma .	DDI-false
Because there is theoretical that effects may be additive , or @DRUG$ @DRUG$ of other be avoided .	DDI-advise
@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
Antidepressants (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
a clinical study , of @DRUG$ , magnesium and ) @DRUG$ serum urinary as compared alone , suggesting that may impair absorption of fosinopril	DDI-mechanism
@DRUG$ : @DRUG$ ( ) combination amiodarone associated with reports	DDI-false
@DRUG$ : In conducted , approximately 17 in subjects with @DRUG$ 200 receiving alone .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Example azole antifungals ciprofloxacin , diclofenac , doxycycline , erythromycin , , isoniazid nefazodone , nicardipine , @DRUG$ protease , @DRUG$ and verapamil .	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The of SULAR in on @DRUG$ than patients on other @DRUG$ therapy .	DDI-false
: In , of atorvastatin 40 with coadministration of @DRUG$ and @DRUG$ known of cytochrome P450 3A4 .	DDI-mechanism
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
@DRUG$ ampicillin , @DRUG$ , doxycycline cephalothin erythromycin and in vitro protein of diclofenac in human .	DDI-false
Cyclosporine , Digoxin , Methotrexate Lodine other @DRUG$ , renal , may changes in the elimination of these drugs to elevated @DRUG$ and toxicity .	DDI-mechanism
In ingestion @DRUG$ and the diet to cause , and been that @DRUG$ rat stomach to nitrosamine is .	DDI-false
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by @DRUG$.	DDI-false
, , @DRUG$ @DRUG$	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
@DRUG$ or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of @DRUG$ was evaluated in 18 healthy adult volunteers.	DDI-false
clinical studies with Fondaparinux the concomitant use oral @DRUG$ warfarin ) @DRUG$ acetylsalicylic acid NSAIDs ( piroxicam ) , and digoxin not the sodium	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus @DRUG$ 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.	DDI-false
with Agonist/Antagonist Opioid Analgesics Agonist/antagonist eg , , nalbuphine butorphanol @DRUG$ and @DRUG$ ) should be administered to a who received or is receiving of a pure agonist opioid Levo-Dromoran .	DDI-false
: be in patients receiving   -receptor agents , , CYP3A4 channel antagonists e.g. , @DRUG$ a CYP3A4 , and diltiazem a @DRUG$ inhibitor possible potentiation , arrest , and AV block ;	DDI-false
Profound hypotensive episodes may occur when @DRUG$ infection and @DRUG$ are used concomitantly.	DDI-effect
Cohort 1 then received @DRUG$ plus rifabutin for 10 days, and cohort 2 received amprenavir plus @DRUG$ for 4 days.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine @DRUG$/acetaminophen , theophylline/acetaminophen , and acid/phenobarbital .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
from drug interaction studies with @DRUG$ may predictive	DDI-false
treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole @DRUG$ , indinavir saquinavir @DRUG$ etc . is , the dose .	DDI-false
@DRUG$ : As with other b-lactam antibiotics , loracarbef is @DRUG$ and an approximate % increase AUC for	DDI-false
, when is given a patient @DRUG$ , the dosage of @DRUG$ reduced to prevent excessive prolongation of .	DDI-false
were not affected of @DRUG$ or @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ the effect @DRUG$.	DDI-false
g. , ketoconazole , miconazole clotrimazole , , etc ): vitro animal studies the @DRUG$ @DRUG$ suggest that imidazoles may to B.	DDI-false
Administration of no effect on the pharmacokinetics of @DRUG$ , digoxin ethinylestradiol/levonorgestrol oral @DRUG$ in subjects .	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
Example inhibitors azole antifungals , clarithromycin @DRUG$ , erythromycin , imatinib , isoniazid @DRUG$ , nicardipine , protease inhibitors , quinidine and verapamil	DDI-false
@DRUG$ co-administered with inducers , such efavirenz phenytoin @DRUG$ , use a daily CANCIDAS should considered	DDI-advise
studies have not been performed , coadministration with mainly CYP3A4 ( , calcium , , disopyramide , quinine quinidine , @DRUG$ , , derivatives , , fentanyl @DRUG$ alprazolam , and triazolam ) have plasma concentrations when coadministered with ;	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Corticosteroids and @DRUG$ (@DRUG$): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the @DRUG$ has been titrated to a maintenance level while the patient was taking @DRUG$.	DDI-false
: Concurrent of @DRUG$ , multivalent as or antacids , @DRUG$ , chewable/buffered tablets or pediatric or products , , or substantially decrease ciprofloxacin , resulting in and lower than desired	DDI-mechanism
Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and @DRUG$ did not influence abatacept clearance.	DDI-false
majority patients in RA clinical studies or more of concomitant with @DRUG$ , NSAIDs , , blocking agents , @DRUG$ , chloroquine , , hydroxychloroquine , and .	DDI-false
, reports that @DRUG$ may diminish the	DDI-effect
Clonidine : administration of @DRUG$ with @DRUG$ may blood-pressure- and heart-rate-lowering effects .	DDI-effect
@DRUG$: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
Concurrent administration of oxyphenbutazone @DRUG$ may result elevated levels of	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
studies have not performed coadministration with drugs that are ( , dapsone , amiodarone quinidine warfarin @DRUG$ ergot derivatives @DRUG$ , carbamazepine , , ) may have elevated plasma coadministered	DDI-false
Similarly dialyzed were @DRUG$, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
@DRUG$ significantly decreased the AUC(ss) of @DRUG$ by 82%, but amprenavir had no effect on rifampin pharmacokinetics.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Warfarin differences were observed of R-warfarin @DRUG$ addition of @DRUG$ single .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
In general that have more @DRUG$ anti-arrhythmic as and @DRUG$ , cardiac glycosides tricyclic anti-depressants .	DDI-false
The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	DDI-mechanism
therefore necessary clinical and paraclinical pattern deficit and to discriminate @DRUG$ to an intake which requires oral physiological supplementation depletion to dysregulation of of @DRUG$ status which more or regulation its dysregulation	DDI-false
( In the @DRUG$ reduce the , , effects	DDI-effect
5-HT1B/1D use @DRUG$ 24 hours of treatment @DRUG$ .	DDI-advise
(Concurrent use with @DRUG$ may enhance the possibility of @DRUG$ toxicity associated with hypokalemia.)	DDI-effect
It is not known if @DRUG$ differ in their effectiveness when used with @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Selective Reuptake ( ): @DRUG$ ( e.g. , , , @DRUG$ , sertraline ) been rarely reported to cause weakness hyperreflexia and with 5-HT1 agonists	DDI-false
The of during with this increased administration @DRUG$ derivatives , @DRUG$ ( nicotinic , azole antifungals	DDI-false
@DRUG$ : on reports of profound loss of apomorphine was administered , use @DRUG$ drugs the 5HT3 ( , ondansetron , , palonosetron and ) is .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$, @DRUG$, lidocaine	DDI-false
MAO inhibitors @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
However , of cholestyramine before the meal @DRUG$ approximately hours same evening meal in a decrease in @DRUG$ than of about 30 % when compared	DDI-false
clinical used with @DRUG$ oral supplemental In a pharmacokinetic with failure receiving furosemide in FLOLAN initiated , values for furosemide ( 23 and @DRUG$ = ) decreased by 13 and % , , the second of and values by day .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
THERAPY Although specific studies not performed in clinical studies , was used with angiotensin- converting ( ACE inhibitors betablockers @DRUG$ , diuretics and anti-inflammatory drugs ( @DRUG$ without evidence of significant adverse interactions	DDI-false
specific studies have not coadministration that are metabolized by CYP3A4 eg , , , @DRUG$ warfarin , tacrolimus , , , pimozide , , fentanyl , alfentanyl , and @DRUG$ may have elevated plasma saquinavir ;	DDI-false
No Interactions Date Levosimendan not important pharmacokinetic interactions with captopril beta-blockers , @DRUG$ digoxin @DRUG$ , carvedilol itraconazole	DDI-false
While all the @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ : As some quinolones concurrent administration ciprofloxacin with lead of @DRUG$ half-life .	DDI-false
A possible between and @DRUG$ , a fluoroquinolone has been , a of action of	DDI-false
Other Drugs : small patients ( 10/interaction , administration azathioprine , @DRUG$ , chloroquine , D-penicillamine , prednisolone , @DRUG$ , or digitoxin did not significantly affect levels AUC values of diclofenac .	DDI-false
@DRUG$ inhibitor , metabolite @DRUG$ .	DDI-mechanism
@DRUG$ @DRUG$ , sulfate pargyline Concomitant use of L-tyrosine MAO may cause hypertension	DDI-false
The of @DRUG$ does the either @DRUG$ or acamprosate	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Interactions Flupenthixol with some like oxidase inhibitors @DRUG$ could affect flupenthixol pharmacodynamics @DRUG$ Ethanol : Flupenthixol cause CNS - Flupenthixol of Tricyclic	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
which neuromuscular action agents as @DRUG$ include antibiotics , tetracyclines bacitracin , lincomycin sodium ) @DRUG$ , local , procainamide , quinidine	DDI-effect
determine has direct effect on distribution of @DRUG$ , elimination and distribution @DRUG$ was studied in patients , five lacking kidney function one with partially impaired function , absence .	DDI-false
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-false
@DRUG$ : Amphetamines absorption	DDI-false
These would seem dictate the clinical use methotrexate with @DRUG$ or during @DRUG$ therapy levels	DDI-false
@DRUG$ : a volunteers significant pharmacokinetic interaction when captopril @DRUG$ administered concomitantly	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Coadministration of @DRUG$ and a 24 in plasma concentrations of	DDI-false
@DRUG$ mg ( ) and 40 mg QD ( 2 ) glyburide 10 glyburide BID ) in % increase in - 12 @DRUG$ Cmax leading AUC0	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
higher doses of @DRUG$ 400 mg may increases in and AUC a mg Vardenafil be in period when used in combination with @DRUG$ mg	DDI-false
@DRUG$ : Concomitant @DRUG$ is recommended is displaced from sites during the of , resulting lower plasma concentrations , peak levels and AUC values .	DDI-false
successive application of or weight . ) @DRUG$ ( 15 interval significantly increased the of spontaneous motility of chick embryos comparison of @DRUG$ alone	DDI-false
@DRUG$ @DRUG$	DDI-effect
, through an on certain microsomal , has been reported the hepatic metabolism warfarin-type anticoagulants , phenytoin @DRUG$ , diazepam , tricyclic @DRUG$ , thereby levels these drugs	DDI-false
: @DRUG$ , ergotamine , @DRUG$ due to potential and life-threatening such as characterized peripheral vasospasm of extremities and	DDI-false
Medications and @DRUG$ following adverse events were receiving antihypertensive medications or @DRUG$ ( = ) to receiving concomitant drugs hypotension 10 4 % myocardial % vs serious pneumonia 5 % vs 3 , serious 9 , and bone 2	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
@DRUG$: TORADOL IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	DDI-false
study on established therapy with @DRUG$ to was added to develop mild in neutrophil in comparison to treated with @DRUG$	DDI-false
@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, @DRUG$, clarithromycin or amoxicillin.	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-@DRUG$ interaction could be found.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The effect of TORADOL on plasma not been studied but @DRUG$ @DRUG$ .	DDI-mechanism
An considered taking @DRUG$ @DRUG$ , carbamazepine , and phenobarbital	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
@DRUG$ : interaction of rheumatoid arthritis methotrexate , @DRUG$ did not have a effect on of	DDI-false
Because a theoretical basis these may be ergotamine-containing or @DRUG$ or @DRUG$ ) and AXERT hours each be avoided	DDI-false
Both @DRUG$ and its major metabolite @DRUG$ are of P450 enzyme system	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
Potential drug   ( carbamazepine , gabapentin , lamotrigine , @DRUG$ @DRUG$ and valproate ) assessed by evaluating the concentrations of these AEDs placebo-controlled	DDI-false
In monkeys, (-)-NANM was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with (+)-NANM.	DDI-false
found between @DRUG$ warfarin @DRUG$.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and cimetidine.	DDI-advise
These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
The gastrointestinal absorption of @DRUG$ and @DRUG$ is accelerated when they are coadministered with cisapride.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, @DRUG$ treatment did not affect @DRUG$ distribution or clearance.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
no with drugs identified in studies 0.5 Ophthalmic Solution , possibility of an additive or potentiating CNS ( @DRUG$ , barbiturates , @DRUG$ should be .	DDI-false
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Consequently with therapeutic margin , as @DRUG$ phenytoin and @DRUG$ could have delayed elimination and in to toxic level	DDI-false
Due high inter-patient variability limited the of the increase in @DRUG$ in patients receiving concurrent @DRUG$ uncertain	DDI-false
Interactions : may with some drugs , like oxidase inhibitors ( MAOI ): MAOI theoretically @DRUG$ pharmacodynamics - : Flupenthixol and @DRUG$ additive CNS Tricyclic antidepressants : Flupenthixol Tricyclic	DDI-false
While selective reuptake inhibitors ( @DRUG$ ) e.g. @DRUG$ , may in the extent	DDI-false
@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	DDI-false
In analyses of patient data suggest that co-administration other inducers @DRUG$ , @DRUG$ , ) with CANCIDAS in caspofungin .	DDI-false
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
Compounds in these categories result in a decreased efficacy of @DRUG$: @DRUG$, haloperidol, metoclopramide, pimozide.	DDI-effect
The effects of mixing NovoLog with @DRUG$ of animal source or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
do not indicate a interaction @DRUG$ warfarin heparin administration @DRUG$ to patients taking anticoagulants should done cautiously , should be monitored .	DDI-false
Anabolic ( @DRUG$ [ e.g. , Anabolin oxandrolone e.g. , Anavar ] oxymetholone [ , Anadrol [ e.g. , @DRUG$ ) or	DDI-false
Additive CNS depression antihistamines are concomitantly with depressants including @DRUG$ tranquilizers , and @DRUG$.	DDI-false
As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	DDI-effect
@DRUG$ generally should not be given with @DRUG$ because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
, neither @DRUG$ nor @DRUG$ appears .	DDI-false
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
: @DRUG$ may with drugs , like ( @DRUG$ ): could theoretically affect pharmacodynamics Arecoline - - Flupenthixol and Ethanol cause additive depression antidepressants Flupenthixol increases effect antidepressants	DDI-int
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
of digoxin , , @DRUG$ @DRUG$ acetaminophen phenytoin did not ketorolac tromethamine protein binding .	DDI-false
Coadministration with @DRUG$ increased exposure of @DRUG$ (AUC) by 46%.	DDI-mechanism
( @DRUG$ @DRUG$ etc the concentration of ionized species the amphetamine , thereby increasing urinary .	DDI-false
patients chronic hepatitis C with @DRUG$ did affect @DRUG$ or clearance .	DDI-false
High-dose @DRUG$ resulting concentrations administered to an % increase a 38 % total body @DRUG$ to etoposide	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	DDI-false
Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
and/or aluminum-containing , products containing ferrous sulfate ( iron multivitamin , @DRUG$ ( didanosine chewable/buffered tablets or the powder for oral taken 3 or FACTIVE .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
clinical studies performed with Fondaparinux , use of anticoagulants ( warfarin ) acid @DRUG$ ( piroxicam ) , and digoxin not significantly pharmacokinetics/pharmacodynamics @DRUG$.	DDI-false
, was , anticoagulants , oral , and supplemental a in patients congestive heart failure receiving or with @DRUG$ was , oral clearance for furosemide ( = 23 ) digoxin ( n ) decreased by % respectively , the therapy and had returned to baseline day 87	DDI-false
: some the a @DRUG$ can reduce the diuretic , , and antihypertensive loop , @DRUG$.	DDI-effect
Standard monitoring of @DRUG$-related toxicity should be continued if VIOXX and @DRUG$ are administered concomitantly.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and @DRUG$.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
Antiarrhythmics : antiarrhythmic drugs , such @DRUG$ , disopyramide , @DRUG$ been concurrently	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, cimetidine and phenobarbital.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
concomitant Although interaction studies were , finasteride of 1 mg or were concomitantly acetaminophen , , angiotensin-converting ) @DRUG$ blockers @DRUG$ , HMG-CoA reductase synthetase inhibitors also referred to ) and evidence clinically .	DDI-false
In , ingestion of @DRUG$ the 78 been tumors and it has been suggested may @DRUG$ in the rat a nitrosamine tumorigenic	DDI-false
@DRUG$/theophylline , phenobarbital/acetaminophen phenobarbital/valproic acid , , and	DDI-false
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by flumazenil.	DDI-false
, phenobarbital/valproic quinidine/lidocaine , @DRUG$/@DRUG$	DDI-false
The may nonsteroidal agents drugs highly , @DRUG$ @DRUG$ chloramphenicol , probenecid coumarins , monoamine adrenergic	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
: effects of combined administration @DRUG$ ) , calcium , the incidence of intestinal by @DRUG$ index of intestinal were investigated in male Wistar rats	DDI-false
@DRUG$ ( e.g. @DRUG$ or	DDI-false
Coadministration of @DRUG$ (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of @DRUG$.	DDI-false
Drugs that have been with include chloramphenicol @DRUG$ , ethionamide glutethimide , hydralazine , , isoniazid , metronidazole @DRUG$ , vincristine .	DDI-false
@DRUG$ @DRUG$	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
5HT3 on profound hypotension and loss apomorphine was administered ondansetron the concomitant apomorphine of the @DRUG$ ( , example , , @DRUG$ palonosetron , alosetron contraindicated .	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other Drug Interactions : pharmacokinetic interactions were between @DRUG$ and drugs : warfarin , , ,	DDI-false
It necessary to acquainted with the clinical and pattern @DRUG$ deficit and between deficiency due @DRUG$ intake which requires physiological supplementation and magnesium depletion to a the control mechanisms more or of its dysregulation .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Coadministration of @DRUG$ led to plasma concentrations of @DRUG$ , rare of life- cardiac dysrhythmias one	DDI-false
order the occurrence of hypersensitivity all patients with TAXOL be with corticosteroids such as @DRUG$ @DRUG$ such as cimetidine ranitidine )	DDI-false
Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
Patients receiving high doses of @DRUG$ concomitantly with @DRUG$, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.	DDI-effect
Although @DRUG$ reduce effects including renal , hyperbilirubinemia , confusion dyspnea concomitant of agents PROLEUKIN reduce antitumor @DRUG$ and be avoided Beta-blockers and antihypertensives PROLEUKIN .	DDI-false
The @DRUG$ significantly affected @DRUG$	DDI-false
, such @DRUG$ , @DRUG$ , disopyramide and phenytoin	DDI-false
The effect of @DRUG$ on @DRUG$ clearance has not been studied.	DDI-false
Plasma should monitored when @DRUG$ valproate are and dosage adjustments @DRUG$ be made	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33% after two days.	DDI-false
Poor higher concentrations of @DRUG$ @DRUG$ ) when doses	DDI-false
is therefore to be well acquainted the pattern of deficit between @DRUG$ deficiency an intake which only oral @DRUG$ depletion related to dysregulation of the magnesium which requires more or specific regulation of its causal .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
@DRUG$ shown to any additional effect beyond obtained with @DRUG$ increases the rate of of Nalfon the use of and salicylates is not .	DDI-false
Example include antifungals @DRUG$ diclofenac , @DRUG$ , , nicardipine , , and verapamil .	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$ ('Seroquel') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, @DRUG$.	DDI-false
Although specific studies not performed , drugs that mainly metabolized by CYP3A4 ( calcium channel , @DRUG$ , , amiodarone @DRUG$ warfarin , tacrolimus cyclosporine , derivatives , pimozide fentanyl , alprazolam , triazolam may have elevated concentrations with saquinavir	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
@DRUG$ of statins metabolism by CYP3A4 , such @DRUG$ atorvastatin .	DDI-mechanism
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
Although with @DRUG$ , nephrotoxicity been reported of @DRUG$ aminoglycosides	DDI-false
FLEXERIL may enhance the effects of alcohol, @DRUG$, and other @DRUG$.	DDI-false
Based known metabolic , significant not between @DRUG$ , trimethoprim/@DRUG$ fluconazole .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Therefore should be used administering @DRUG$ with other highly protein-bound with for binding e.g. , @DRUG$ ) .	DDI-mechanism
certain @DRUG$ (such as @DRUG$);	DDI-false
following known to inhibit metabolism of benzodiazepines inhibition of nefazodone fluvoxamine , cimetidine @DRUG$ , some	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ rifabutin and in a % in plasma a % increase @DRUG$ plasma A.C.	DDI-false
Probenecid: As with other @DRUG$, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
Coadministration of @DRUG$ and cyclosporine, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
In mg @DRUG$ and g cholestyramine resulted decreases of 22 % for and 40 for Cmax to @DRUG$	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
that been associated nucleoside @DRUG$ , cisplatin , , disulfiram @DRUG$ , , , isoniazid , nitrofurantoin phenytoin , ribavirin vincristine	DDI-false
plasma protein is altered by @DRUG$ ,	DDI-false
Hypotension Diuretic Therapy : on @DRUG$ especially in whom diuretic was recently may occasionally an excessive pressure initiation of therapy enalapril or	DDI-effect
Benzthiazide may interact with blood , @DRUG$ ( allergy , cold , sinus ) , diabetic NSAIDs like Aleve or @DRUG$ blood medications .	DDI-false
Antihypertensive medications , especially @DRUG$ agents used surgery skeletal-muscle , nondepolarizing in surgery	DDI-false
the , corticosteroids phenothiazines , , @DRUG$ , contraceptives , @DRUG$ , acid sympathomimetics , calcium blocking , and isoniazid .	DDI-false
Bacteriostatic Antibiotics : Chloramphenicol , erythromycins @DRUG$ @DRUG$ may with effect .	DDI-false
@DRUG$ (neostgmine, physostigmine), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-effect
In both species, @DRUG$, but not @DRUG$, antagonized the rate-decreasing effects of morphine on FI and FR responding.	DDI-false
Although clinical studies have been likely the @DRUG$ be the inducers ( such @DRUG$ , , rifampin ) azole e.g.	DDI-mechanism
may alter plasma concentrations Drugs may @DRUG$ plasma concentrations : Caution is when @DRUG$ with inhibitors of CYP3A4 e.g. , ketoconazole , erythromycin )	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
@DRUG$ : indinavir with % in and a 51 @DRUG$ plasma	DDI-false
Although the occurrence has not been reported with @DRUG$, nephrotoxicity has been reported following concomitant administration of other @DRUG$ and aminoglycosides.	DDI-false
Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
which may enhance the action of nondepolarizing NUROMAX include certain e. , aminoglycosides , @DRUG$ polymyxins , @DRUG$ colistin sodium ) salts lithium anesthetics , procainamide , and quinidine .	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic drug-drug interactions between @DRUG$ concomitantly 162.5 mg given 26 and hours prior Argatroban 1 . over or ( 1000 given and 0 hours and and 12 subsequent to , initiation of @DRUG$ 1.5   g/kg/min . hours )	DDI-false
May interact @DRUG$ hypo-prothrombinemic effect , rifampin microsomal oxidation decreased of diethylstilbestrol corticosteroids ( effect of @DRUG$ ) .	DDI-false
Cyclosporine Because @DRUG$ can creatinine clearance and rises and renal is primary elimination route of @DRUG$ TRICOR , is risk that an interaction	DDI-effect
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example inhibitors ciprofloxacin clarithromycin @DRUG$ doxycycline imatinib @DRUG$ , , protease , , and	DDI-false
Coadministration of Itraconazole and @DRUG$ @DRUG$ has led increased plasma latter three	DDI-false
In addition , analyses patient pharmacokinetic data suggest co-administration other @DRUG$ @DRUG$ phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result clinically reductions concentrations	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
@DRUG$ of and loss of consciousness when ondansetron , concomitant use of drugs @DRUG$ including example , granisetron , dolasetron palonosetron , alosetron )	DDI-false
@DRUG$ may enhance the effects of alcohol, @DRUG$, and other CNS depressants.	DDI-effect
In receiving @DRUG$ in @DRUG$ be gradual in to the possible complications of sudden steroid .	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or @DRUG$.	DDI-advise
Antifungals In and/or data indicate that fluconazole , oral ketoconazole markedly inhibit the metabolism of @DRUG$ , result increase in plasma @DRUG$ and of QT interval on the .	DDI-false
@DRUG$ Supplements @DRUG$ : Fosinopril sodium thiazide .	DDI-false
In , diclofenac interferes minimally or not at the binding of @DRUG$ 20 % binding , @DRUG$ , prednisolone ( 10 % in binding ) , or warfarin	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
@DRUG$ a possible that dopamine antagonists , such the , @DRUG$ , APOKYN	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other concomitant therapies : In trials , the profile in with @DRUG$ concomitantly anxiolytics , hypnotics and sedatives ( benzodiazepines ) , @DRUG$ was to of subjects taking with concomitant .	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
drug interactions between   and AEDs carbamazepine , gabapentin , and were serum concentrations @DRUG$ these @DRUG$ during clinical .	DDI-false
Coingestion @DRUG$ with @DRUG$ acetaminophen , and valproic acid with phenobarbital high to concentrations the the target .	DDI-effect
Nephrotoxicity has reported concomitant of with or @DRUG$ such as	DDI-false
@DRUG$ Doxorubicin in @DRUG$ phosphorylation 50 phosphate formation ) in U937/Molt 4 .	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
Another oral @DRUG$ inhibits metabolism of @DRUG$ resulting in of its active metabolite desmethylastermizole may QT intervals	DDI-mechanism
In monkeys, the effects of @DRUG$, but not (+)-NANM or @DRUG$, were antagonized by naloxone;	DDI-false
@DRUG$ @DRUG$ in decreased antihypertensive and requiring increased of latter	DDI-effect
@DRUG$ @DRUG$ , propranolol serum concentrations effects be increased .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Oral Contraceptives mg BID ) not the combination oral contraceptive norethindrone/@DRUG$ 1 mg /35 mcg , @DRUG$ 1/35 )	DDI-false
These drugs the thiazides other @DRUG$ , corticosteroids , phenothiazines , @DRUG$ , contraceptives phenytoin nicotinic sympathomimetics , drugs , isoniazid .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
Antagonists : on profound hypotension when with ondansetron concomitant use @DRUG$ with drugs of 5HT3 antagonist class including for @DRUG$ , , dolasetron palonosetron , and contraindicated .	DDI-advise
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, @DRUG$), though this has not been studied	DDI-false
interactions could occur following psychotropic drugs ( , @DRUG$ , analgesics , antiemetics , @DRUG$ ) .	DDI-false
Antihypertensives should with caution patients receiving -receptor agents ( e.g. @DRUG$ a CYP3A4 or @DRUG$ ( e.g. , , a , , because of of bradycardia , sinus , and AV ;	DDI-false
Although specific not , are mainly metabolized by eg , calcium channel , @DRUG$ amiodarone , warfarin tacrolimus cyclosporine , pimozide , fentanyl @DRUG$ , and ) may elevated plasma when coadministered saquinavir	DDI-false
Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-mechanism
@DRUG$ retinyl acetate stimulate or @DRUG$-induced proliferation of .	DDI-effect
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-mechanism
, phenobarbital @DRUG$ appears affect @DRUG$	DDI-false
In order avoid the of severe reactions , patients treated with as dexamethasone ) diphen-hydramine @DRUG$ such as @DRUG$ .	DDI-false
@DRUG$ pathway of is inhibited by	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other : , profile in with concomitantly @DRUG$ and @DRUG$ including benzodiazepines or analgesics was that of subjects taking placebo with concomitant medications .	DDI-false
@DRUG$ Amiodarone bepridil , @DRUG$ , propafenone quinidine CONTRAINDICATED due serious	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
All subjects received @DRUG$ (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either @DRUG$ (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.	DDI-false
@DRUG$ Vardenafil 20 , with @DRUG$ or 60 mg once daily , affect the bioavailability ) or maximum concentration Cmax of a drug that metabolized	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and @DRUG$ with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
Metformin : subjects given single @DRUG$ and @DRUG$ , plasma metformin AUC increased an average of 34 % , mean renal decreased by 14 %	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Compounds tested in man include @DRUG$, @DRUG$, phenytoin, diazepam, aminopyrine and antipyrine.	DDI-false
Antihypertensives : be used caution in receiving   agents e.g. , propranolol @DRUG$ inhibitor ) channel e.g. , a substrate , and @DRUG$ a CYP3A4 ) of the possible potentiation of bradycardia , , AV block	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
been prolongation or TdP , in patients taking @DRUG$ @DRUG$ azoles administered	DDI-false
a study who were established to , noted a mean treated @DRUG$ CI @DRUG$ alone .	DDI-false
Imidazoles e. g. , ketoconazole miconazole , fluconazole , etc in vitro and animal combination of @DRUG$ suggest that may induce fungal resistance to @DRUG$.	DDI-false
@DRUG$ is inducers , as @DRUG$ , , phenytoin dexamethasone or , use of daily 70 CANCIDAS should be	DDI-advise
@DRUG$ @DRUG$ has pharmacokinetic interaction when administered with	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
, clarithromycin @DRUG$ Fluoxetine , Indanavir Ketoconazole , Phenytoin , carbamazepine , @DRUG$ , Rifampin , ,	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ : drug-drug interactions between @DRUG$ agents has not been	DDI-false
Co-administration @DRUG$ with @DRUG$ has mean and the the curve .	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
The following of that may blood-glucose-lowering oral antidiabetic products inhibitors fibrates fluoxetine @DRUG$ propoxyphene salicylates , @DRUG$ ( e.g. , sulfonamide	DDI-false
Adverse reactions , such as CNS , and ( eg flu-like effects be more severe in the elderly and caution should in the use of @DRUG$ .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ Coadministration @DRUG$ in an increase in and increase in indinavir plasma A.C.	DDI-false
@DRUG$: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
on of zidovudine , although significantly decreased the @DRUG$ tmax and increased the intracellular exposure phosphorylated @DRUG$ by 110 % .	DDI-false
, @DRUG$ @DRUG$ , and abatacept	DDI-false
In patients taking @DRUG$ and @DRUG$ concomitantly, lithium toxicity may develop.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing @DRUG$ for at least 4 hours following @DRUG$ administration.	DDI-false
- When @DRUG$ or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-false
: administration a quinolone including , multivalent products magnesium or aluminum , @DRUG$ or calcium , iron @DRUG$ substantially the absorption , in urine levels lower desired	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
has a tendency to muscle relaxing effect of @DRUG$ potentiate the @DRUG$.	DDI-false
apomorphine - @DRUG$ emetic response to @DRUG$ treatment of poisoning .	DDI-effect
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
These drugs @DRUG$ , , thyroid estrogens , contraceptives , phenytoin , @DRUG$ , , calcium channel drugs ,	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Although specific studies not been , coadministration with that are by CYP3A4 , calcium channel blockers dapsone , , , , , tacrolimus @DRUG$ , @DRUG$ , , carbamazepine fentanyl , , triazolam ) have plasma when	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Drugs Should Not With @DRUG$ amiodarone Antihistamines , terfenadine : ergot @DRUG$ : rifampin Benzodiazepines triazolam agents :	DDI-advise
Carbamazepine : @DRUG$ to the metabolism @DRUG$ increase serum levels Carbamazepine concurrent administration , signs and symptoms carbamazepine should closely and appropriate dosage of should made	DDI-mechanism
Flucytosine: while a synergistic relationship with @DRUG$ has been reported, concomitant use may increase the toxicity of @DRUG$ by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-effect
Drugs That Induce CYP3A4 (@DRUG$) Racemic zopiclone exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
suggest @DRUG$ , when @DRUG$ , has pronounced on the biotransformation responsible the metabolism of astemizole .	DDI-false
been of effects therapy with @DRUG$ and .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, @DRUG$, etc).	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or @DRUG$.	DDI-false
@DRUG$ : @DRUG$ for use patients who have and unpredictable potentiation MAO inhibitors with opioid	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and @DRUG$.	DDI-advise
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
lidocaine/quinidine , , @DRUG$/lidocaine , and .	DDI-false
of @DRUG$ with such nitroglycerin milrinone , @DRUG$ has not evaluated ( were co-administered with Natrecor trials .	DDI-false
In results of pharmacokinetic suggest of other inducers drug clearance efavirenz , @DRUG$ @DRUG$ may in concentrations	DDI-mechanism
contrast @DRUG$ 1 mM ) and @DRUG$ ( no significant on the translocation added alone .	DDI-false
post-marketing bleeding events have been reported predominantly in the elderly , in with increases in prothrombin @DRUG$ @DRUG$.	DDI-effect
@DRUG$/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid quinidine/lidocaine , and acid/phenobarbital .	DDI-false
In clinical Fondaparinux , oral @DRUG$ ( platelet ( acid ( piroxicam , and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics fondaparinux sodium	DDI-false
drugs which may action of agents such as NUROMAX certain @DRUG$ ( aminoglycosides , tetracyclines , , polymyxins , lincomycin @DRUG$ , and colistimethate ) local , , and .	DDI-false
The concomitant administration of @DRUG$ and other @DRUG$ have resulted in previous reports of rhabdomyolysis.	DDI-effect
Central Nervous System Depressants: The concomitant use of @DRUG$  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ : be with caution patients -receptor ( @DRUG$ , a CYP3A4 inhibitor ) channel e.g. verapamil , , CYP3A4 inhibitor because of the possible arrest AV	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	DDI-effect
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	DDI-mechanism
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
muscle relaxants ( eg , @DRUG$ ) and other ether succinylcholine , gallamine and @DRUG$ , neuromuscular and should with extreme caution in patients M Parenteral	DDI-false
@DRUG$ caused a plasma exposures @DRUG$ and ( and , respectively ) and pharmacodynamic effects time measured as INR of warfarin .	DDI-mechanism
acetaminophen , @DRUG$ @DRUG$ and valproic with at high to binding drug .	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
the toxicity filipin the @DRUG$ can rationalized at and level by following observations ( i ) these @DRUG$ showed differential on ;	DDI-false
all @DRUG$ ) fluoxetine , @DRUG$ fluvoxamine , inhibit 2D6 vary in the extent inhibition	DDI-false
Interactions of @DRUG$ with inhibitors of CYP2D6 ( quinidine , @DRUG$ , drugs blood levels of the ) enantiomer of .	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, @DRUG$).	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
Based on the chemical resemblance of @DRUG$ and @DRUG$, coadministration of astemizole with itraconazole is contraindicated.	DDI-false
Doxorubicin @DRUG$ decrease @DRUG$ inhibition total in U937/Molt 4 .	DDI-effect
@DRUG$ , , , chlortetracycline , @DRUG$ erythromycin and sulfamethoxazole no vitro the protein binding serum	DDI-false
AUC - 24 hrs ) of erythromycin 15 % with coadministration of @DRUG$ to observed with @DRUG$ .	DDI-false
A association , has been with phenyl-butazone , sodium @DRUG$ and possibly @DRUG$ ( )	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of @DRUG$.	DDI-false
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	DDI-false
Protein , @DRUG$ interferes minimally or at all protein binding of @DRUG$ 20 , tolbutamide , prednisolone ( % in ) , or warfarin	DDI-mechanism
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
The absorption of tetracycline, @DRUG$, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
@DRUG$ The the sulfonylurea @DRUG$ has on occasions , resulted in hypoglycemia	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	DDI-false
Warfarin : @DRUG$ been reported to enhance the of anticoagulant @DRUG$ or its derivatives .	DDI-effect
These data indicate that @DRUG$ does not the concentration of AEDs that @DRUG$ not the pharmacokinetics	DDI-false
Additionally, @DRUG$ did not alter the pharmacokinetics of @DRUG$, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Concomitant use of @DRUG$ and corticosteroids may produce severe weakness in patients with myasthenia gravis.	DDI-false
@DRUG$, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
To determine whether probenecid has a direct effect on the distribution of @DRUG$, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
, oxacillin @DRUG$ , cephalothin , erythromycin @DRUG$ have influence in vitro on the binding diclofenac human serum .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
A similar association though less , has suggested with , phenylbutazone @DRUG$ @DRUG$ , tetracyclines 72	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Clinical studies with celecoxib have identified potentially significant interactions with @DRUG$ and @DRUG$.	DDI-false
Bosentan is also plasma of other statins have significant metabolism by as @DRUG$ and @DRUG$.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
- @DRUG$ Bumetanide may potentiate effect of @DRUG$ , necessitating reduction in the of drugs	DDI-false
Other drugs may the neuromuscular blocking action nondepolarizing agents such aminoglycosides , @DRUG$ , lincomycin clindamycin , colistin , and sodium , magnesium salts , @DRUG$ anesthetics procainamide , .	DDI-false
ANTACID (@DRUG$): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
with @DRUG$ @DRUG$ furosemide	DDI-false
These the @DRUG$ and , corticosteroids @DRUG$ thyroid products , , oral nicotinic acid calcium channel drugs ,	DDI-false
Effects of GABITRIL other Antiepilepsy Drugs ( AEDs ) : @DRUG$ Tiagabine no effect on the plasma @DRUG$ patients with epilepsy .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ addition of tiagabine to chronically had no , @DRUG$ significantly tiagabine vitro from 96.3 to resulted approximately % the free concentration .	DDI-false
Patients with major psychotic disorders, treated with @DRUG$, should be treated with @DRUG$ only if the potential benefits outweigh the risks.	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
hypoglycemic action @DRUG$ may potentiated by including nonsteroidal other drugs that highly @DRUG$ chloramphenicol , probenecid , , monoamine inhibitors and beta adrenergic blocking .	DDI-effect
Anticoagulants coumarin indandione derivatives and aggregation such @DRUG$ NSAIDs and aspirin may the risk of bleeding when administered	DDI-effect
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
- @DRUG$: Lithium should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
@DRUG$: @DRUG$ is a CYP 2C9 substrate.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$ , , and @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drugs that have associated with neuropathy include @DRUG$ , chloramphenicol , dapsone , , , , @DRUG$ , iodoquinol metronidazole , nitrofurantoin phenytoin , ribavirin , .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: @DRUG$ causes a slight decrease (about 10%) in steady-state valproate concentrations.	DDI-false
@DRUG$ @DRUG$ in zalcitabine phosphorylation ( 50 % inhibition formation ) U937/Molt cells	DDI-false
@DRUG$: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
interaction with following @DRUG$ @DRUG$.	DDI-false
@DRUG$ concomitantly with @DRUG$ increases quinidine serum % after two days	DDI-false
Antiacid @DRUG$ , Didanosine , Fluoxetine , Indanavir , @DRUG$ , carbamazepine , Rifampin Saquinavir	DDI-false
not given with @DRUG$ because reduce clearance add a high lithium toxicity .	DDI-false
may occur concomitant use of @DRUG$ and or system ( @DRUG$ , , ketoconazole , this has been	DDI-mechanism
Drugs have been peripheral include antiretroviral nucleoside chloramphenicol , @DRUG$ disulfiram , ethionamide , @DRUG$ , , phenytoin , and	DDI-false
effectiveness of reduced by hepatic enzyme-inducing drugs the @DRUG$ , and the @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Potential interactions were assessed in pharmacokinetic @DRUG$ @DRUG$ digoxin , warfarin ) through pharmacokinetic screening in the placebo-controlled epilepsy patients .	DDI-false
@DRUG$ should be administered concomitantly @DRUG$ isoproterenol ) of possible effects increased toxicity .	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Compounds tested in man include @DRUG$, theophylline, phenytoin, @DRUG$, aminopyrine and antipyrine.	DDI-false
@DRUG$ - Taking @DRUG$ and a phenothiazine may of ( seizures .	DDI-false
This may occur @DRUG$ competitively @DRUG$ binding .	DDI-mechanism
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
@DRUG$/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
Although specific not coadministration metabolized by ( , dapsone disopyramide , @DRUG$ , , warfarin , tacrolimus , cyclosporine ergot , pimozide , fentanyl , alfentanyl and triazolam concentrations @DRUG$ ;	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In I escalating doses @DRUG$ - 200 mg/m2 cisplatin 50 75 mg/m2 ) sequential was more profound when TAXOL given after cisplatin than with the sequence ie before @DRUG$ .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ significantly increased the area under the curve at steady state (AUC(ss)) of @DRUG$ by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.	DDI-mechanism
Lithium toxicity was usually reversible upon discontinuation of @DRUG$ and the @DRUG$.	DDI-effect
medications other , @DRUG$ , and used in or @DRUG$	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
Coadministration @DRUG$ drugs that induce CYP3A may @DRUG$ plasma concentrations reduce therapeutic	DDI-false
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	DDI-advise
Although have not been performed , with are by CYP3A4 eg , channel blockers dapsone disopyramide quinine , amiodarone , quinidine warfarin , , , pimozide , carbamazepine fentanyl alfentanyl @DRUG$ , @DRUG$ may have elevated plasma concentrations saquinavir ;	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
the @DRUG$ , many like @DRUG$ can clinically because they are toxic	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$ There is between ZDV and @DRUG$ which clinically	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Nephrotoxic : Concomitant agents , intravenous @DRUG$ ( tobramycin gentamicin , and amphotericin B , foscarnet pentamidine , , @DRUG$ ] is contraindicated .	DDI-false
Hepatic Inducers , Inhibitors : Drugs induce cytochrome 3A4 ( CYP ) enzyme e.g. barbiturates , phenytoin carbamazepine @DRUG$ metabolism of the @DRUG$ be increased	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
A drug-drug use , combination double strength ( 160 @DRUG$/@DRUG$ ) .	DDI-false
adjustment be when with CYP2D6 inhibitors , e.g. @DRUG$ @DRUG$ , quinidine .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
If treatment of CYP3A4 such as @DRUG$ , , ritonavir , indinavir @DRUG$ . indicated , reduction the be considered .	DDI-false
Numerous drug interactions are possible with some anticonvulsant agents, such as @DRUG$ and @DRUG$, which affect hepatic microsomal enzyme systems.	DDI-false
Although , of @DRUG$ @DRUG$ may metabolism ;	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
- Methotrexate (e.g., @DRUG$) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
addition , Fondaparinux , @DRUG$ and @DRUG$ , the pharmacokinetics of digoxin at	DDI-false
ACE Inhibitors ( Congestive In EPHESUS , 3020 ( % patients receiving 25 to 50 also @DRUG$ @DRUG$/ARB ) .	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
The of patients RA studies received or more ORENCIA : MTX NSAIDs blocking azathioprine , @DRUG$ , @DRUG$ , hydroxychloroquine , leflunomide , and anakinra .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
This interaction be in patients @DRUG$ concomitantly @DRUG$.	DDI-advise
If with of CYP3A4 activity such as ketoconazole @DRUG$ , indinavir @DRUG$ indicated , reduction the budesonide .	DDI-false
- Lithium: Lithium should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Erythromycin Co-administration of @DRUG$ (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
Drug : @DRUG$ with some drugs Monoamine oxidase theoretically flupenthixol - Ethanol : @DRUG$ and Ethanol CNS depression Tricyclic increases the effect of antidepressants	DDI-false
It may excretion @DRUG$ , and ASA and increase @DRUG$.	DDI-false
These results that and @DRUG$ , and other glucocorticoids and @DRUG$ the proliferation prostate epithelium dose-dependent of of insulin and EGF .	DDI-false
dopamine by @DRUG$ , such	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
blockade when is antimuscarinics @DRUG$ , phenothiazines inhibitors , @DRUG$ or some antihistamines	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Coadministration with @DRUG$ (40 mg BID for 7 days) resulted in a significant increase in @DRUG$ plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.	DDI-mechanism
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, @DRUG$, and ranitidine.	DDI-false
The examples increase blood-glucose-lowering effect to hypoglycemia : oral , @DRUG$ , disopyramide fibrates , , @DRUG$ , propoxyphene salicylates analog e.g. , octreotide ) ,	DDI-false
@DRUG$ @DRUG$ causes a decrease about ) valproate concentrations .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
@DRUG$ @DRUG$ , inhibit tubular secretion .	DDI-false
@DRUG$ : rifampin since the of this product with saquinavir an @DRUG$ regimen reduces the concentrations of	DDI-false
@DRUG$ decreased approximately and @DRUG$ were coadministered .	DDI-false
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	DDI-false
Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	DDI-advise
, @DRUG$ , Fluoxetine , , Phenytoin , , carbamazepine , @DRUG$ , Rifampin , Ritanovir Saquinavir	DDI-false
Acetaminophen , @DRUG$ , @DRUG$ , theophylline , and pooled serum	DDI-false
Folic acid in large may of @DRUG$ , phenytoin @DRUG$ increase frequency seizures susceptible pediatric patients	DDI-false
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
In some patients, a @DRUG$-like reaction may be produced by the ingestion of @DRUG$.	DDI-false
clarithromycin Didanosine Fluconazole , @DRUG$ , , Ketoconazole , Phenytoin Phenobarbitol carbamazepine Rifabutin , , @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
When in subcutaneous pumps for @DRUG$ @DRUG$ not be mixed any other insulins diluent .	DDI-false
Drugs been associated include antiretroviral , chloramphenicol , dapsone , gold , hydralazine iodoquinol isoniazid , nitrofurantoin , phenytoin @DRUG$	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Release : of @DRUG$ @DRUG$ IV by antihypertensive agents that cause renin e.g. , ) .	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
that have been with include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , @DRUG$ , disulfiram , ethionamide , glutethimide gold , iodoquinol nitrofurantoin , , , and vincristine .	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
@DRUG$: @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$ are family and @DRUG$.	DDI-false
Two of 16 subjects dosed simultaneously with @DRUG$ 10 mg and @DRUG$ 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.	DDI-effect
@DRUG$-Concomitant intake @DRUG$ and K may the of vitamin	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-effect
Because there are no @DRUG$ crystalline zinc insulin , @DRUG$ should be mixed with preparations .	DDI-false
Since @DRUG$ substrate for @DRUG$ , there is potential that the of Wort in receiving amiodarone result in reduced amiodarone levels .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
your doctor all and products you : @DRUG$ e.g. @DRUG$ amikacin , non-steroidal anti-inflammatory drugs ) , , vancomycin .	DDI-false
Drugs That ( @DRUG$ Racemic @DRUG$ exposure decreased 80 , CYP3A4 .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ to single @DRUG$ in human trials reported	DDI-mechanism
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
In patients receiving @DRUG$ and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-advise
@DRUG$ Valdecoxib 40 BID induce metabolism the oral contraceptive ( 1 combination , Ortho-Novum 1/35	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
In vitro studies have shown CASODEX can displace @DRUG$s, such as @DRUG$, from their protein-binding sites.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
been peripheral include nucleoside analogues , cisplatin , @DRUG$ , , @DRUG$ , iodoquinol , isoniazid , , nitrofurantoin , ribavirin and vincristine	DDI-false
@DRUG$ , @DRUG$ , lithium , and potentiate weaken the blood-glucose-lowering insulin .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other drugs which may enhance the neuromuscular blocking of such as NUROMAX antibiotics ( g. , , @DRUG$ , polymyxins , lincomycin clindamycin , colistin , and magnesium , , @DRUG$ , quinidine	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Monoamine Oxidase Antidepressants : FORADIL should be extreme caution patients being treated with @DRUG$ @DRUG$ because the of formoterol on cardiovascular may be potentiated by these agents .	DDI-false
clinical , was digoxin @DRUG$ , , vasodilators supplemental oxygen a with furosemide in therapy with @DRUG$ initiated oral clearance ( n and digoxin ( n 30 ) were 13 , second day therapy and returned baseline values by day	DDI-false
Tagamet , through on microsomal enzyme systems has reported to reduce the hepatic of warfarin-type anticoagulants , phenytoin , propranolol @DRUG$ , chlordiazepoxide , , certain @DRUG$ lidocaine thereby delaying increasing levels drugs	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and @DRUG$, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
Magnesium- and/or , products ferrous sulfate ( @DRUG$ ) zinc @DRUG$ ( didanosine ) chewable/buffered tablets powder oral not taken 3 before or hours .	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of @DRUG$/@DRUG$.	DDI-false
Quinolones @DRUG$ , enhance the anticoagulants , including @DRUG$ its derivatives or similar agents .	DDI-effect
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-false
that been associated with peripheral neuropathy include antiretroviral analogues , @DRUG$ , @DRUG$ , disulfiram , gold , , isoniazid , metronidazole , ribavirin	DDI-false
Therefore , @DRUG$ may @DRUG$ effective	DDI-false
Contraceptives : @DRUG$ ( 40 mg BID ) not metabolism oral @DRUG$/ethinyl ( mg /35 combination , 1/35	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
is recommended Levetiracetam on concentrations , valproate , @DRUG$ , @DRUG$.	DDI-false
@DRUG$: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Reuptake Inhibitors ( SSRIs ): SSRIs , fluoxetine @DRUG$ , @DRUG$ , sertraline ) rarely reported to cause , hyperreflexia , and incoordination agonists	DDI-false
Non-selective including @DRUG$ , phenelzine pargyline : use of @DRUG$ and non-selective inhibitors hypertension .	DDI-false
Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, @DRUG$ and antipyrine.	DDI-false
following examples of may increase the effect and to : oral @DRUG$ ACE inhibitors , disopyramide fibrates fluoxetine , monoamine MAO ) , @DRUG$ , salicylates , analog ( antibiotics .	DDI-false
Erythromycin Co-administration of felodipine (@DRUG$) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
Uricosuric drugs, such as @DRUG$ and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
There was no significant difference in the pharmacodynamic effect of warfarin administered alone and @DRUG$ administered with @DRUG$ as measured by prothrombin time.	DDI-false
@DRUG$ and @DRUG$ exert additive ocular and renal vasodilator effects on healthy humans.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Concomitant @DRUG$ , @DRUG$ chemotherapy active with human immunodeficiency non-Hodgkin	DDI-false
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-false
In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-false
valdecoxib ( mg BID for days @DRUG$ 5 mg or 10 mg BID ) affect the pharmacokinetics ( of	DDI-false
@DRUG$ : Quinolones have been reported effects of oral @DRUG$ warfarin .	DDI-false
Most cases of serious or fatal adverse events involving @DRUG$ reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of @DRUG$ with other drugs affecting respiration.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ , barbiturates @DRUG$ : potentiation of may .	DDI-false
In vitro when to @DRUG$ a less on responsible the metabolism	DDI-false
@DRUG$ : Coadministration of almotriptan and @DRUG$ a 24 % in plasma	DDI-false
Nursing Mothers It is not known whether @DRUG$ or @DRUG$ or its components are excreted in human milk.	DDI-false
Anticoagulants : of @DRUG$ and ) response is almost always seen in patients receiving @DRUG$ and can result serious .	DDI-false
Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The , uniformity time anticoagulant interference , @DRUG$ , chloral hydrate and @DRUG$ were systematically investigated 16 patients receiving therapy	DDI-false
interactions between a substrate of , and protease ritonavir , saquinavir , @DRUG$ , @DRUG$ which are and/or inhibitors , evaluated clinical .	DDI-false
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
specific been coadministration that mainly metabolized CYP3A4 ( calcium blockers , dapsone disopyramide quinine , , , warfarin @DRUG$ , , @DRUG$ and triazolam may elevated concentrations ;	DDI-false
Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	DDI-int
Potential between and other @DRUG$ ( gabapentin , , , and ) by serum concentrations of @DRUG$ placebo-controlled clinical studies	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
It distinct from the @DRUG$ ( , @DRUG$ ) to biopharmaceutical properties relative to other agents this .	DDI-false
interactions Keppra and other AEDs ( carbamazepine , lamotrigine @DRUG$ and valproate by evaluating concentrations of @DRUG$ placebo-controlled .	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Acidifying agents : @DRUG$ , reserpine @DRUG$ , acid , , . lower .	DDI-false
Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	DDI-effect
acetaminophen/theophylline , , acid quinidine/@DRUG$ , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Tagamet apparently on certain microsomal enzyme has been to reduce the of , propranolol , @DRUG$ , chlordiazepoxide certain lidocaine theophylline and @DRUG$ , and increasing these drugs .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Although been with drugs that mainly metabolized by ( eg calcium channel , , amiodarone quinidine , warfarin tacrolimus , , , @DRUG$ , , fentanyl , , , @DRUG$ ) have elevated coadministered with saquinavir	DDI-false
@DRUG$ studies have shown to have no @DRUG$ on plasma prothrombin	DDI-false
drugs include thiazides and , @DRUG$ , phe-nothiazines , contraceptives , channel blocking drugs	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$-related deaths is far greater the number of deaths @DRUG$ heroin	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
That Should With VIRACEPT : , @DRUG$ Antihistamines : @DRUG$ terfenadine Antimigraine : ergot derivatives Antimycobacterial : Benzodiazepines , triazolam motility : cisapride	DDI-false
Therefore, if @DRUG$ is administered with @DRUG$, the clinician should be alert to the possibility of increases in digoxin levels.	DDI-mechanism
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, @DRUG$, and increased toxicity.	DDI-false
@DRUG$ : may the hypotensive	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Similarly dialyzed @DRUG$ and @DRUG$ , alone at serum at three different concentrations in serum .	DDI-false
plasma several closely tricyclic have be increased by concomitant or enzyme ( e.g. , @DRUG$ ) and decreased by the administration hepatic inducers ( barbiturates @DRUG$ ) with CMI as .	DDI-false
- Bezalip or retard is used concurrently anion-exchange resins ) , an interval hours should maintained between the , since the of @DRUG$ @DRUG$	DDI-false
@DRUG$ not @DRUG$ the metabolite losartan , and had no after administration	DDI-false
Antiacid , clarithromycin Fluconazole , Fluoxetine , @DRUG$ , Phenobarbitol @DRUG$ , Rifampin Ritanovir , .	DDI-false
Slow-channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Ingestion @DRUG$ increase serum @DRUG$ and and nephrotoxicity	DDI-mechanism
: Vardenafil mg , co-administered with slow-release @DRUG$ mg mg once affect the ) or maximum concentration ( Cmax ) of @DRUG$ a drug that is metabolized via .	DDI-false
Agents been concomitantly @DRUG$ , @DRUG$ , calcium-blocking hydralazine and without evidence of clinically significant adverse interactions	DDI-false
@DRUG$ : terfenadine VIRACEPT resulted the of unchanged @DRUG$ in	DDI-false
using medication your doctor of and , : amikacin ) amphotericin @DRUG$ , non-steroidal drugs ( e.g. , , , @DRUG$.	DDI-false
Since @DRUG$ is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	DDI-false
Tagamet , apparently through effect microsomal enzyme reported to reduce hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , , nifedipine chlordiazepoxide certain tricyclic @DRUG$ and , thereby delaying increasing blood levels these	DDI-false
: @DRUG$ should with patients   -receptor agents ( , , CYP3A4 ) or calcium channel antagonists ( , @DRUG$ substrate and diltiazem , inhibitor because the possible bradycardia sinus arrest ,	DDI-false
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Other such quinidine @DRUG$ @DRUG$ phenothiazines , antihistamines , and tricyclic with prolongation and an increased risk ventricular arrhythmia	DDI-false
studies not been , coadministration with drugs that mainly by , calcium channel dapsone , , @DRUG$ quinidine cyclosporine ergot derivatives , pimozide , @DRUG$ alprazolam , and triazolam may plasma concentrations when ;	DDI-false
These drugs thiazides and , @DRUG$ , phenothiazines @DRUG$ , oral nicotinic acid , calcium drugs , and .	DDI-false
acetaminophen/theophylline , , phenobarbital/acetaminophen , acid , quinidine/lidocaine valproic acid/phenobarbital	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$ Other , , @DRUG$ , disopyramide , amiodarone	DDI-false
@DRUG$ , through effect enzyme systems , been reduce of warfarin-type anticoagulants propranolol , chlordiazepoxide , @DRUG$ certain lidocaine , and , increasing levels of these drugs .	DDI-mechanism
Urinary acidifying agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
The extent to which @DRUG$-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
Oral @DRUG$: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	DDI-false
include azole antifungals @DRUG$ , , imatinib , nefazodone , , propofol , protease inhibitors quinidine	DDI-false
- ( , @DRUG$ ) Use @DRUG$ may increase of side effects of these	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, cimetidine and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and @DRUG$.	DDI-false
Coadministration of @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
These include thiazides other diuretics , corticosteroids @DRUG$ , @DRUG$ , oral contraceptives , phenytoin nicotinic acid , calcium drugs .	DDI-false
Nephrotoxicity has reported concomitant administration of @DRUG$ @DRUG$.	DDI-effect
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of @DRUG$.	DDI-false
In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Drugs have been associated neuropathy antiretroviral nucleoside chloramphenicol , dapsone , , ethionamide glutethimide , @DRUG$ , iodoquinol isoniazid , , , phenytoin @DRUG$ , vincristine	DDI-false
is recommended for who have within severe and potentiation @DRUG$ has been with @DRUG$	DDI-advise
@DRUG$: Digoxin concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	DDI-false
The DCG-IV and @DRUG$ upon phencyclidine behavioral in	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ levels be if INSPRA administered	DDI-false
@DRUG$ ( 40 mg/kg , ( 40 mg/kg of morphine and and the oral self-administration of @DRUG$ in rats ;	DDI-false
- @DRUG$ ( , @DRUG$ of sulfapyridine with these increase the of affecting the blood	DDI-false
Other concomitant studies performed finasteride 1 in with acetaminophen acid a-blockers , ( anticonvulsants , benzodiazepines , blockers calcium-channel blockers nitrates @DRUG$ , H2 antagonists @DRUG$ prostaglandin synthetase ( also as NSAIDs ) and anti-infectives without significant adverse interactions .	DDI-false
Diphenhydramine additive effects @DRUG$ and other ( hypnotics , @DRUG$ tranquilizers etc .	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
Potential interactions assessed clinical phenytoin @DRUG$ @DRUG$ , probenecid ) and pharmacokinetic screening in the placebo-controlled studies patients	DDI-false
@DRUG$ should be used cautiously in conjunction with @DRUG$ in hypoprothrombinemia.	DDI-advise
@DRUG$ delay of @DRUG$.	DDI-false
impact of chemotherapy plus clinical with , , non-Hodgkin lymphoma ( , authors compared 24 the cyclophosphamide , @DRUG$ vincristine , prednisone ( CHOP ) chemotherapy of patients treated with CHOP chemotherapy regimen ( cyclophosphamide , teniposide @DRUG$ vincristine antiretroviral therapy .	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after @DRUG$, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
in result efficacy bromocriptine @DRUG$ haloperidol , @DRUG$.	DDI-false
Therefore, when @DRUG$ and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	DDI-false
@DRUG$ with produced increase a 33 the	DDI-false
trials , was @DRUG$ , , anticoagulants , oral vasodilators , and oxygen In pharmacokinetic substudy with congestive heart failure receiving @DRUG$ in therapy with FLOLAN was initiated apparent values for = 23 ) digoxin 30 decreased 13 % and on the day therapy had returned values by 87 .	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, Maalox, and @DRUG$.	DDI-false
@DRUG$ may enhance the seizure risk in patients taking @DRUG$	DDI-effect
Phenytoin Population pharmacokinetic indicate that tiagabine % greater taking @DRUG$ enzyme- @DRUG$.	DDI-false
@DRUG$ @DRUG$ not been studied , cases of lithium therapy been reported	DDI-false
While the inhibitors ( SSRIs e.g. , @DRUG$ , @DRUG$ paroxetine and P450 , they may the inhibition	DDI-false
: is a agonist , is that such the @DRUG$ ( , @DRUG$ ) or metoclopramide effectiveness of	DDI-false
Vitamin A : the @DRUG$ should against taking @DRUG$ containing A to toxic	DDI-false
For when vitamin administered @DRUG$ , should be carefully monitored and if necessary the @DRUG$ be reduced	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Drugs have been with neuropathy antiretroviral analogues chloramphenicol , , disulfiram , gold @DRUG$ , @DRUG$ , metronidazole nitrofurantoin , , , vincristine .	DDI-false
That Should Coadministered VIRACEPT Antiarrhythmics : @DRUG$ , Antihistamines : @DRUG$ Antimigraine derivatives agents : midazolam triazolam GI agents	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
As some other nondepolarizing neuromuscular the time of of block induced by @DRUG$ is lengthened the duration of block shortened patients receiving @DRUG$ carbamazepine .	DDI-effect
and/or @DRUG$ , products containing ferrous sulfate ( iron ) , @DRUG$ zinc metal cations or ) solution not be taken hours before or after FACTIVE .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Interactions : Flupenthixol may some drugs Monoamine oxidase ( MAOI ): pharmacodynamics @DRUG$ - @DRUG$ cause - Tricyclic antidepressants : Flupenthixol effect of Tricyclic antidepressants	DDI-false
these that have one or pharmacologic similar bepridil , anti-arrhythmic as and @DRUG$ cardiac @DRUG$.	DDI-false
